data_2jm2_residue save_MolProbity _Software.Sf_category software _Software.Sf_framecode MolProbity _Software.Entry_ID ? _Software.ID 1 _Software.Name MolProbity _Software.Version 4.0 _Software.Details . save_ save_CYRANGE _Software.Sf_category software _Software.Sf_framecode CYRANGE _Software.Entry_ID ? _Software.ID 2 _Software.Name CYRANGE _Software.Version 2.0 _Software.Details . save_ save_Structure_validation_residue _Structure_validation_residue.Sf_category structure_validation _Structure_validation_residue.Sf_framecode Structure_validation_residue _Structure_validation_residue.Entry_ID ? _Structure_validation_residue.List_ID 1 _Structure_validation_residue.PDB_accession_code 2jm2 _Structure_validation_residue.Date_analyzed 2016-10-07 loop_ _Residue_analysis_software.Software_ID _Residue_analysis_software.Software_label _Residue_analysis_software.Method_ID _Residue_analysis_software.Method_label _Residue_analysis_software.Entry_ID _Residue_analysis_software.Structure_validation_oneline_list_ID 1 MolProbity . . ? 1 2 CYRANGE . . ? 1 stop_ loop_ _Residue_analysis.ID _Residue_analysis.PDB_model_num _Residue_analysis.Hydrogen_positions _Residue_analysis.MolProbity_flips _Residue_analysis.Cyrange_core_flag _Residue_analysis.Two_letter_chain_ID _Residue_analysis.PDB_strand_ID _Residue_analysis.PDB_residue_no _Residue_analysis.PDB_ins_code _Residue_analysis.PDB_residue_name _Residue_analysis.Assembly_ID _Residue_analysis.Entity_assembly_ID _Residue_analysis.Entity_ID _Residue_analysis.Comp_ID _Residue_analysis.Comp_index_ID _Residue_analysis.Clash_value _Residue_analysis.Clash_source_PDB_atom_name _Residue_analysis.Clash_destination_PDB_atom_name _Residue_analysis.Clash_destination_PDB_strand_ID _Residue_analysis.Clash_destination_PDB_residue_no _Residue_analysis.Clash_destination_PDB_ins_code _Residue_analysis.Clash_destination_PDB_residue_name _Residue_analysis.Cbeta_deviation_value _Residue_analysis.Rotamer_score _Residue_analysis.Rotamer_name _Residue_analysis.Ramachandran_phi _Residue_analysis.Ramachandran_psi _Residue_analysis.Ramachandran_score _Residue_analysis.Ramachandran_evaluation _Residue_analysis.Ramachandran_type _Residue_analysis.Bond_outlier_count _Residue_analysis.Worst_bond _Residue_analysis.Worst_bond_value _Residue_analysis.Worst_bond_sigma _Residue_analysis.Angle_outlier_count _Residue_analysis.Worst_angle _Residue_analysis.Worst_angle_value _Residue_analysis.Worst_angle_sigma _Residue_analysis.RNA_phosphate_perpendicular_outlier _Residue_analysis.RNA_suitness_score _Residue_analysis.RNA_suite_conformer _Residue_analysis.RNA_suite_triage _Residue_analysis.Max_b_factor _Residue_analysis.Tau_angle _Residue_analysis.Omega_dihedral _Residue_analysis.Disulfide_chi1 _Residue_analysis.Disulfide_chi2 _Residue_analysis.Disulfide_chi3 _Residue_analysis.Disulfide_ss_angle _Residue_analysis.Disulfide_ss _Residue_analysis.Disulfide_ss_angle_prime _Residue_analysis.Disulfide_chi2prime _Residue_analysis.Disulfide_chi1prime _Residue_analysis.Outlier_count_separate_geometry _Residue_analysis.Outlier_count _Residue_analysis.Entry_ID _Residue_analysis.Structure_validation_residue_list_ID . 001 nuclear orig core ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER . . . . . 0 N--CA 1.495 1.807 0 N-CA-C 109.878 -0.416 . . . . 0.0 109.878 . . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 6' ' ' PRO . . . . . . . . . . . . . 49.5 Cg_endo -82.23 150.34 15.49 Favored 'Trans proline' 0 C--N 1.313 -1.307 0 O-C-N 123.716 1.377 . . . . 0.0 110.647 -179.822 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 88.32 -46.54 3.38 Favored Glycine 0 N--CA 1.497 2.761 0 N-CA-C 110.342 -1.103 . . . . 0.0 110.342 179.43 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 20.0 p -79.66 -174.29 4.24 Favored 'General case' 0 N--CA 1.496 1.839 0 O-C-N 121.035 -1.274 . . . . 0.0 110.493 -179.601 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 129.26 -114.43 1.73 Allowed Glycine 0 N--CA 1.494 2.545 0 N-CA-C 108.854 -1.699 . . . . 0.0 108.854 -179.433 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 10' ' ' GLN . . . . . . . . . . . . . 14.0 tp60 -164.39 -75.47 0.04 OUTLIER 'General case' 0 N--CA 1.494 1.748 0 O-C-N 121.421 -1.047 . . . . 0.0 110.542 179.222 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -56.13 -26.1 48.64 Favored Glycine 0 N--CA 1.498 2.786 0 O-C-N 121.252 -0.905 . . . . 0.0 110.986 -179.54 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 25.2 t -88.88 -53.88 8.75 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.813 0 O-C-N 121.185 -1.185 . . . . 0.0 110.241 -179.882 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 13' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -67.04 -32.08 73.04 Favored 'General case' 0 N--CA 1.501 2.113 0 O-C-N 121.375 -0.828 . . . . 0.0 112.008 -179.245 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -141.26 52.23 1.57 Allowed 'General case' 0 N--CA 1.496 1.852 0 O-C-N 120.948 -1.095 . . . . 0.0 110.615 -179.645 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -151.76 -85.36 0.05 OUTLIER Glycine 0 N--CA 1.493 2.469 0 N-CA-C 109.845 -1.302 . . . . 0.0 109.845 179.881 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 57.9 m -110.08 97.58 30.68 Favored Pre-proline 0 N--CA 1.496 1.836 0 O-C-N 121.221 -1.164 . . . . 0.0 110.442 -179.898 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 46.7 Cg_endo -72.54 66.53 3.74 Favored 'Trans proline' 0 N--CA 1.491 1.378 0 O-C-N 124.284 1.676 . . . . 0.0 110.409 179.723 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 123.29 -49.97 0.87 Allowed Glycine 0 N--CA 1.495 2.589 0 N-CA-C 109.267 -1.533 . . . . 0.0 109.267 -179.557 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 178.41 134.28 2.06 Favored Glycine 0 N--CA 1.489 2.229 0 N-CA-C 108.971 -1.652 . . . . 0.0 108.971 179.976 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 1.5 m -92.11 33.06 1.09 Allowed 'General case' 0 N--CA 1.5 2.041 0 O-C-N 121.301 -1.117 . . . . 0.0 110.634 -179.911 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 6.4 t -139.87 55.88 0.22 Allowed 'Isoleucine or valine' 0 N--CA 1.496 1.874 0 O-C-N 120.928 -1.107 . . . . 0.0 110.599 -179.89 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 5.2 tt0 -88.88 49.17 1.74 Allowed 'General case' 0 N--CA 1.496 1.863 0 O-C-N 121.135 -0.978 . . . . 0.0 109.266 178.968 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 11.1 mt-10 58.65 -168.03 0.14 Allowed 'General case' 0 N--CA 1.501 2.08 0 O-C-N 121.756 -0.59 . . . . 0.0 110.451 -179.515 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 73.0 mm-40 -69.58 -22.2 63.54 Favored 'General case' 0 N--CA 1.497 1.923 0 O-C-N 120.991 -1.068 . . . . 0.0 111.277 -179.131 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 2.8 t70 -144.34 -61.44 0.38 Allowed 'General case' 0 N--CA 1.496 1.875 0 O-C-N 121.217 -0.927 . . . . 0.0 109.807 179.879 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 172.39 82.86 0.05 OUTLIER Glycine 0 N--CA 1.495 2.567 0 N-CA-C 109.955 -1.258 . . . . 0.0 109.955 179.681 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 66.09 27.69 73.09 Favored Glycine 0 N--CA 1.496 2.658 0 N-CA-C 109.855 -1.298 . . . . 0.0 109.855 179.923 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -102.37 99.59 13.35 Favored Pre-proline 0 N--CA 1.493 1.701 0 O-C-N 121.521 -0.987 . . . . 0.0 110.068 -179.699 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 45.0 Cg_endo -70.87 66.28 2.43 Favored 'Trans proline' 0 N--CA 1.489 1.225 0 O-C-N 123.744 1.391 . . . . 0.0 110.915 -179.577 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -131.28 66.58 1.54 Allowed 'General case' 0 N--CA 1.486 1.371 0 O-C-N 121.337 -0.852 . . . . 0.0 109.974 179.664 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 8.9 tt0 -110.58 -68.75 0.91 Allowed 'General case' 0 N--CA 1.485 1.313 0 O-C-N 121.397 -0.814 . . . . 0.0 110.531 -179.539 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . -72.87 -42.71 44.55 Favored Glycine 0 N--CA 1.496 2.678 0 N-CA-C 110.088 -1.205 . . . . 0.0 110.088 -179.674 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 33' ' ' CYS . . . . . . . . . . . . . 1.7 t -113.77 79.28 1.23 Allowed 'General case' 0 N--CA 1.492 1.646 0 O-C-N 121.141 -1.211 . . . . 0.0 109.661 -179.843 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -125.23 -46.09 1.81 Allowed 'General case' 0 N--CA 1.495 1.812 0 O-C-N 121.111 -0.993 . . . . 0.0 110.992 -179.403 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 0.8 OUTLIER -97.03 -176.48 3.56 Favored 'General case' 0 N--CA 1.498 1.926 0 O-C-N 121.494 -0.754 . . . . 0.0 110.934 -179.414 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 36' ' ' ALA . . . . . 0.539 ' O ' ' HB3' ' A' ' 40' ' ' LEU . . . -79.13 -34.19 43.55 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.26 -0.9 . . . . 0.0 110.189 179.805 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -78.41 2.31 19.21 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.247 -0.908 . . . . 0.0 110.903 179.865 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -92.66 -43.81 4.12 Favored Glycine 0 N--CA 1.492 2.411 0 N-CA-C 109.432 -1.467 . . . . 0.0 109.432 179.951 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 39' ' ' CYS . . . . . . . . . . . . . 1.3 p -161.06 50.34 0.24 Allowed 'General case' 0 N--CA 1.498 1.968 0 O-C-N 121.358 -1.084 . . . . 0.0 111.215 -179.391 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 40' ' ' LEU . . . . . 0.539 ' HB3' ' O ' ' A' ' 36' ' ' ALA . 1.7 pt? . . . . . 0 N--CA 1.504 2.234 0 O-C-N 120.801 -1.187 . . . . 0.0 112.047 -179.599 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 0.3 OUTLIER . . . . . 0 N--CA 1.497 1.924 0 N-CA-C 110.277 -0.268 . . . . 0.0 110.277 . . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 6' ' ' PRO . . . . . . . . . . . . . 45.6 Cg_endo -72.82 -86.18 0.0 OUTLIER 'Trans proline' 0 C--N 1.307 -1.656 0 O-C-N 123.944 1.497 . . . . 0.0 112.062 -179.039 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -105.6 55.8 0.54 Allowed Glycine 0 N--CA 1.49 2.246 0 N-CA-C 109.893 -1.283 . . . . 0.0 109.893 -178.99 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 0.4 OUTLIER -135.34 151.54 50.61 Favored 'General case' 0 N--CA 1.498 1.96 0 O-C-N 121.335 -1.097 . . . . 0.0 110.33 179.611 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 175.98 154.1 11.19 Favored Glycine 0 N--CA 1.495 2.605 0 N-CA-C 109.655 -1.378 . . . . 0.0 109.655 -179.809 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 10' ' ' GLN . . . . . . . . . . . . . 0.3 OUTLIER -129.89 70.56 1.43 Allowed 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.283 -1.128 . . . . 0.0 109.756 179.921 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -79.45 -61.15 2.37 Favored Glycine 0 N--CA 1.495 2.591 0 N-CA-C 110.006 -1.238 . . . . 0.0 110.006 -179.491 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 24.0 m -120.58 -31.65 1.54 Allowed 'Isoleucine or valine' 0 N--CA 1.503 2.213 0 O-C-N 121.427 -1.043 . . . . 0.0 111.491 -179.493 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 13' ' ' GLN . . . . . . . . . . . . . 1.2 tt0 56.33 50.53 13.08 Favored 'General case' 0 N--CA 1.499 1.992 0 O-C-N 121.408 -0.807 . . . . 0.0 110.616 179.93 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -104.68 -60.62 1.57 Allowed 'General case' 0 N--CA 1.495 1.815 0 O-C-N 121.269 -0.894 . . . . 0.0 110.536 179.887 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -152.12 -83.43 0.04 OUTLIER Glycine 0 N--CA 1.494 2.536 0 N-CA-C 109.876 -1.29 . . . . 0.0 109.876 179.942 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 16' ' ' CYS . . . . . 0.46 ' HB2' ' HB2' ' A' ' 20' ' ' CYS . 1.1 m -86.36 136.2 35.73 Favored Pre-proline 0 N--CA 1.496 1.831 0 O-C-N 121.338 -1.096 . . . . 0.0 109.985 179.679 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 45.3 Cg_endo -72.62 72.04 3.13 Favored 'Trans proline' 0 C--N 1.312 -1.361 0 O-C-N 123.656 1.345 . . . . 0.0 109.617 178.931 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 91.52 -49.49 2.9 Favored Glycine 0 N--CA 1.493 2.447 0 N-CA-C 109.702 -1.359 . . . . 0.0 109.702 -179.254 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -74.65 67.14 1.98 Allowed Glycine 0 N--CA 1.497 2.738 0 O-C-N 121.009 -1.289 . . . . 0.0 110.831 -179.727 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 20' ' ' CYS . . . . . 0.46 ' HB2' ' HB2' ' A' ' 16' ' ' CYS . 0.4 OUTLIER -127.77 73.14 1.43 Allowed 'General case' 0 N--CA 1.496 1.83 0 O-C-N 121.24 -1.153 . . . . 0.0 109.174 179.38 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 14.6 p -126.14 -19.66 2.68 Favored 'Isoleucine or valine' 0 N--CA 1.499 2.018 0 O-C-N 121.739 -0.601 . . . . 0.0 111.506 -179.039 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 17.7 mt-10 -79.96 50.18 1.17 Allowed 'General case' 0 N--CA 1.491 1.598 0 O-C-N 120.673 -1.267 . . . . 0.0 110.231 179.831 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 2.3 mt-10 -89.21 -172.91 3.82 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 120.864 -1.147 . . . . 0.0 110.138 -179.794 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER 56.39 59.25 3.73 Favored 'General case' 0 N--CA 1.493 1.677 0 CA-C-O 121.343 0.592 . . . . 0.0 110.4 179.976 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 1.9 p-10 -101.89 -174.45 2.59 Favored 'General case' 0 N--CA 1.496 1.83 0 O-C-N 121.223 -0.923 . . . . 0.0 109.907 179.561 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 79.35 -69.95 2.89 Favored Glycine 0 N--CA 1.495 2.628 0 N-CA-C 109.559 -1.416 . . . . 0.0 109.559 -179.807 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 144.71 115.04 0.97 Allowed Glycine 0 N--CA 1.494 2.561 0 N-CA-C 109.635 -1.386 . . . . 0.0 109.635 179.789 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 73.5 m -81.91 143.63 50.21 Favored Pre-proline 0 N--CA 1.5 2.032 0 O-C-N 121.385 -1.067 . . . . 0.0 110.187 -179.973 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 45.5 Cg_endo -73.46 91.25 0.88 Allowed 'Trans proline' 0 C--N 1.315 -1.188 0 O-C-N 123.729 1.384 . . . . 0.0 111.115 -179.078 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -94.55 -55.2 3.23 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.315 -0.865 . . . . 0.0 110.59 179.883 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 36.2 tt0 -79.05 -7.26 57.97 Favored 'General case' 0 N--CA 1.496 1.858 0 O-C-N 121.513 -0.742 . . . . 0.0 110.911 -179.8 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 90.41 -10.34 74.71 Favored Glycine 0 N--CA 1.494 2.51 0 O-C-N 120.792 -1.192 . . . . 0.0 110.182 -179.515 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 33' ' ' CYS . . . . . . . . . . . . . 59.1 m -79.73 65.71 4.97 Favored 'General case' 0 N--CA 1.494 1.741 0 O-C-N 120.925 -1.338 . . . . 0.0 110.282 -179.803 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -79.2 -38.95 34.52 Favored 'General case' 0 N--CA 1.494 1.742 0 O-C-N 121.456 -0.778 . . . . 0.0 109.573 179.576 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 47.9 mt-10 -89.91 162.59 15.36 Favored 'General case' 0 N--CA 1.493 1.716 0 O-C-N 121.381 -0.825 . . . . 0.0 109.594 179.235 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 36' ' ' ALA . . . . . . . . . . . . . . . -79.35 -46.33 17.86 Favored 'General case' 0 N--CA 1.493 1.683 0 O-C-N 121.123 -0.985 . . . . 0.0 110.412 -179.221 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 1.5 tt0 -95.3 62.41 2.47 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.191 -0.943 . . . . 0.0 110.315 -179.834 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -148.68 17.49 1.26 Allowed Glycine 0 N--CA 1.496 2.673 0 C-N-CA 119.945 -1.121 . . . . 0.0 110.958 -179.984 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 39' ' ' CYS . . . . . . . . . . . . . 57.1 m -144.23 26.87 1.45 Allowed 'General case' 0 N--CA 1.502 2.135 0 O-C-N 120.663 -1.492 . . . . 0.0 111.274 -179.837 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 40' ' ' LEU . . . . . 0.44 ' O ' HD22 ' A' ' 40' ' ' LEU . 0.9 OUTLIER . . . . . 0 N--CA 1.501 2.082 0 O-C-N 121.68 -0.638 . . . . 0.0 111.647 179.886 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 9.5 t . . . . . 0 N--CA 1.497 1.897 0 N-CA-C 109.506 -0.553 . . . . 0.0 109.506 . . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' A' A ' 6' ' ' PRO . . . . . . . . . . . . . 48.9 Cg_endo -73.42 -21.13 20.08 Favored 'Trans proline' 0 C--N 1.312 -1.39 0 O-C-N 124.089 1.573 . . . . 0.0 111.949 -179.508 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -74.58 -40.21 39.2 Favored Glycine 0 N--CA 1.496 2.636 0 N-CA-C 110.386 -1.086 . . . . 0.0 110.386 -179.169 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 31.1 p -85.95 -174.61 5.19 Favored 'General case' 0 N--CA 1.498 1.943 0 O-C-N 121.168 -1.195 . . . . 0.0 110.881 -179.599 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -142.26 -135.11 3.05 Favored Glycine 0 N--CA 1.495 2.603 0 N-CA-C 109.854 -1.299 . . . . 0.0 109.854 -179.587 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 10' ' ' GLN . . . . . . . . . . . . . 4.2 mt-30 -80.62 41.37 0.55 Allowed 'General case' 0 N--CA 1.499 2.013 0 O-C-N 121.14 -1.212 . . . . 0.0 111.665 -179.566 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 80.49 -34.42 2.26 Favored Glycine 0 N--CA 1.497 2.714 0 O-C-N 120.718 -1.239 . . . . 0.0 111.224 179.445 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 16.9 m -130.66 60.98 0.3 Allowed 'Isoleucine or valine' 0 N--CA 1.498 1.933 0 O-C-N 121.056 -1.261 . . . . 0.0 110.867 -179.354 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 13' ' ' GLN . . . . . . . . . . . . . 0.6 OUTLIER -124.06 94.64 4.28 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.323 -0.86 . . . . 0.0 109.607 179.754 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -150.84 161.85 41.88 Favored 'General case' 0 N--CA 1.495 1.814 0 CA-C-O 121.539 0.685 . . . . 0.0 111.3 -179.553 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -144.61 -57.68 0.02 OUTLIER Glycine 0 N--CA 1.498 2.801 0 N-CA-C 108.427 -1.869 . . . . 0.0 108.427 179.378 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 0.8 OUTLIER -121.78 79.0 39.98 Favored Pre-proline 0 N--CA 1.499 1.988 0 N-CA-C 108.602 -0.888 . . . . 0.0 108.602 178.482 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 40.6 Cg_endo -66.89 -24.29 46.43 Favored 'Trans proline' 0 N--CA 1.49 1.319 0 C-N-CA 121.288 1.325 . . . . 0.0 112.246 -178.359 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . -96.06 19.43 54.5 Favored Glycine 0 N--CA 1.496 2.666 0 N-CA-C 109.973 -1.251 . . . . 0.0 109.973 179.821 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 114.94 141.56 7.55 Favored Glycine 0 N--CA 1.487 2.064 0 N-CA-C 108.528 -1.829 . . . . 0.0 108.528 179.842 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 36.3 m -109.39 167.48 10.09 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.28 -1.13 . . . . 0.0 109.792 179.889 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . 0.401 HG12 ' CB ' ' A' ' 25' ' ' ASP . 14.5 t -79.18 65.0 0.31 Allowed 'Isoleucine or valine' 0 N--CA 1.494 1.77 0 O-C-N 121.28 -0.887 . . . . 0.0 110.296 -179.801 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -96.14 -31.98 12.72 Favored 'General case' 0 N--CA 1.489 1.494 0 O-C-N 121.21 -0.931 . . . . 0.0 110.099 179.299 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 4.9 mm-40 -94.49 55.22 1.93 Allowed 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.184 -0.948 . . . . 0.0 110.437 -179.49 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 3.0 mm-40 39.09 68.36 0.36 Allowed 'General case' 0 N--CA 1.496 1.837 0 CA-C-O 121.616 0.722 . . . . 0.0 112.026 179.498 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 25' ' ' ASP . . . . . 0.401 ' CB ' HG12 ' A' ' 21' ' ' VAL . 0.7 OUTLIER -89.88 -9.94 47.12 Favored 'General case' 0 N--CA 1.497 1.909 0 O-C-N 121.155 -0.966 . . . . 0.0 110.276 178.85 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 90.25 -67.08 2.63 Favored Glycine 0 N--CA 1.494 2.51 0 N-CA-C 109.068 -1.613 . . . . 0.0 109.068 -179.053 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 67.91 176.55 10.28 Favored Glycine 0 N--CA 1.496 2.681 0 N-CA-C 110.234 -1.146 . . . . 0.0 110.234 179.516 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 1.9 t -111.37 94.41 22.19 Favored Pre-proline 0 N--CA 1.496 1.836 0 O-C-N 121.315 -1.109 . . . . 0.0 109.773 179.655 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 44.4 Cg_endo -71.91 110.1 2.83 Favored 'Trans proline' 0 C--N 1.315 -1.229 0 O-C-N 123.832 1.438 . . . . 0.0 110.728 -179.583 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -79.26 -54.15 6.25 Favored 'General case' 0 N--CA 1.492 1.646 0 O-C-N 121.264 -0.897 . . . . 0.0 110.364 -179.985 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 6.8 tt0 -90.24 16.52 8.47 Favored 'General case' 0 N--CA 1.492 1.665 0 O-C-N 121.073 -1.017 . . . . 0.0 111.002 179.702 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . -87.17 35.96 3.37 Favored Glycine 0 N--CA 1.492 2.431 0 N-CA-C 109.502 -1.439 . . . . 0.0 109.502 179.555 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 33' ' ' CYS . . . . . 0.417 ' HA ' ' O ' ' A' ' 38' ' ' GLY . 0.5 OUTLIER -114.28 22.08 14.08 Favored 'General case' 0 N--CA 1.494 1.746 0 O-C-N 121.497 -1.001 . . . . 0.0 110.646 179.328 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -152.24 46.48 0.75 Allowed 'General case' 0 N--CA 1.498 1.965 0 O-C-N 121.058 -1.026 . . . . 0.0 110.604 -179.722 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 7.6 pt-20 -128.73 -157.44 0.82 Allowed 'General case' 0 N--CA 1.499 2.002 0 O-C-N 121.51 -0.744 . . . . 0.0 110.253 179.856 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 36' ' ' ALA . . . . . . . . . . . . . . . -77.83 -23.64 48.9 Favored 'General case' 0 N--CA 1.499 1.985 0 O-C-N 121.242 -0.911 . . . . 0.0 110.448 -179.652 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER -79.5 -33.74 41.87 Favored 'General case' 0 N--CA 1.492 1.654 0 O-C-N 121.16 -0.962 . . . . 0.0 109.819 179.547 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 38' ' ' GLY . . . . . 0.417 ' O ' ' HA ' ' A' ' 33' ' ' CYS . . . 107.88 -97.09 1.1 Allowed Glycine 0 N--CA 1.492 2.421 0 N-CA-C 109.113 -1.595 . . . . 0.0 109.113 179.847 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 39' ' ' CYS . . . . . . . . . . . . . 1.8 t -160.81 115.04 2.1 Favored 'General case' 0 N--CA 1.498 1.957 0 O-C-N 121.637 -0.919 . . . . 0.0 109.687 179.435 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 40' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER . . . . . 0 N--CA 1.49 1.55 0 O-C-N 121.152 -0.968 . . . . 0.0 110.908 -179.334 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 N--CA 1.496 1.854 0 N-CA-C 110.074 -0.343 . . . . 0.0 110.074 . . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 6' ' ' PRO . . . . . . . . . . . . . 44.6 Cg_endo -74.74 -50.99 0.13 Allowed 'Trans proline' 0 C--N 1.314 -1.268 0 O-C-N 123.665 1.35 . . . . 0.0 111.102 -179.64 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -78.03 58.38 3.94 Favored Glycine 0 N--CA 1.494 2.559 0 N-CA-C 109.736 -1.346 . . . . 0.0 109.736 179.992 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 1.1 m -114.49 3.22 14.85 Favored 'General case' 0 N--CA 1.492 1.672 0 O-C-N 121.271 -1.135 . . . . 0.0 111.349 -179.938 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 9' ' ' GLY . . . . . 0.425 ' O ' ' HB2' ' A' ' 10' ' ' GLN . . . -80.18 57.36 4.63 Favored Glycine 0 N--CA 1.494 2.534 0 N-CA-C 109.894 -1.282 . . . . 0.0 109.894 179.598 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 10' ' ' GLN . . . . . 0.425 ' HB2' ' O ' ' A' ' 9' ' ' GLY . 5.6 tt0 -178.56 -63.4 0.01 OUTLIER 'General case' 0 N--CA 1.494 1.769 0 O-C-N 121.466 -1.02 . . . . 0.0 109.994 179.787 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -85.07 62.97 4.45 Favored Glycine 0 N--CA 1.491 2.346 0 N-CA-C 110.018 -1.233 . . . . 0.0 110.018 -179.867 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 7.5 p -146.37 -47.24 0.11 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.652 0 O-C-N 121.467 -1.019 . . . . 0.0 110.413 179.602 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 13' ' ' GLN . . . . . . . . . . . . . 20.4 tt0 -175.04 -55.07 0.01 OUTLIER 'General case' 0 N--CA 1.497 1.9 0 O-C-N 121.36 -0.838 . . . . 0.0 109.6 179.521 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -117.04 -178.26 3.4 Favored 'General case' 0 N--CA 1.496 1.825 0 O-C-N 121.788 -0.57 . . . . 0.0 110.216 179.789 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -85.03 -35.21 12.87 Favored Glycine 0 N--CA 1.496 2.65 0 N-CA-C 110.378 -1.089 . . . . 0.0 110.378 -179.581 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 0.0 OUTLIER -113.45 132.85 22.31 Favored Pre-proline 0 N--CA 1.5 2.027 0 O-C-N 121.332 -1.099 . . . . 0.0 109.67 179.702 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 47.4 Cg_endo -74.29 58.67 4.44 Favored 'Trans proline' 0 C--N 1.31 -1.488 0 O-C-N 123.72 1.379 . . . . 0.0 111.072 -179.731 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 92.9 92.85 1.48 Allowed Glycine 0 N--CA 1.495 2.579 0 N-CA-C 110.167 -1.173 . . . . 0.0 110.167 179.336 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 106.71 113.1 3.75 Favored Glycine 0 N--CA 1.49 2.298 0 N-CA-C 110.128 -1.189 . . . . 0.0 110.128 179.345 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 20' ' ' CYS . . . . . 0.47 ' O ' ' HB3' ' A' ' 25' ' ' ASP . 36.9 m -122.27 -12.99 8.18 Favored 'General case' 0 N--CA 1.502 2.166 0 O-C-N 121.521 -0.988 . . . . 0.0 111.285 179.818 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 18.5 m -80.36 18.91 0.18 Allowed 'Isoleucine or valine' 0 N--CA 1.504 2.239 0 O-C-N 120.865 -1.147 . . . . 0.0 111.848 -179.562 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 5.0 mm-40 -79.67 -19.88 47.97 Favored 'General case' 0 N--CA 1.486 1.357 0 O-C-N 120.84 -1.163 . . . . 0.0 110.884 179.836 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -139.18 55.35 1.7 Allowed 'General case' 0 N--CA 1.491 1.591 0 O-C-N 120.891 -1.131 . . . . 0.0 110.259 179.956 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 24' ' ' GLU . . . . . 0.535 ' HG3' ' HB2' ' A' ' 28' ' ' SER . 0.8 OUTLIER 53.09 31.15 10.75 Favored 'General case' 0 N--CA 1.506 2.362 0 O-C-N 121.92 -0.487 . . . . 0.0 112.013 179.473 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 25' ' ' ASP . . . . . 0.47 ' HB3' ' O ' ' A' ' 20' ' ' CYS . 21.2 t70 -106.27 115.38 30.12 Favored 'General case' 0 N--CA 1.496 1.834 0 O-C-N 120.866 -1.146 . . . . 0.0 109.661 179.715 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 77.22 -56.07 3.63 Favored Glycine 0 N--CA 1.492 2.382 0 N-CA-C 110.559 -1.016 . . . . 0.0 110.559 179.594 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -55.97 -54.34 35.97 Favored Glycine 0 N--CA 1.494 2.56 0 N-CA-C 110.27 -1.132 . . . . 0.0 110.27 -178.964 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 28' ' ' SER . . . . . 0.535 ' HB2' ' HG3' ' A' ' 24' ' ' GLU . 1.4 m -113.83 77.3 3.52 Favored Pre-proline 0 N--CA 1.497 1.893 0 O-C-N 121.742 -0.858 . . . . 0.0 110.696 -179.368 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 54.7 Cg_endo -79.86 114.32 3.15 Favored 'Trans proline' 0 C--N 1.314 -1.282 0 O-C-N 123.234 1.123 . . . . 0.0 110.028 179.602 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -77.2 -26.81 53.2 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 120.974 -1.079 . . . . 0.0 109.904 179.937 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 1.2 mt-10 -78.95 1.99 21.82 Favored 'General case' 0 N--CA 1.494 1.771 0 O-C-N 121.312 -0.867 . . . . 0.0 110.685 179.137 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . -99.28 35.8 4.46 Favored Glycine 0 N--CA 1.492 2.379 0 N-CA-C 110.04 -1.224 . . . . 0.0 110.04 179.904 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 33' ' ' CYS . . . . . . . . . . . . . 1.7 t -160.67 64.69 0.31 Allowed 'General case' 0 N--CA 1.494 1.764 0 O-C-N 121.268 -1.137 . . . . 0.0 110.3 179.739 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -78.64 -53.45 7.16 Favored 'General case' 0 N--CA 1.499 1.983 0 O-C-N 121.073 -1.017 . . . . 0.0 109.417 179.06 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 8.0 mt-10 -85.16 169.56 13.74 Favored 'General case' 0 N--CA 1.495 1.784 0 O-C-N 121.461 -0.774 . . . . 0.0 109.519 178.466 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 36' ' ' ALA . . . . . . . . . . . . . . . -78.18 -43.52 28.4 Favored 'General case' 0 N--CA 1.493 1.718 0 O-C-N 120.908 -1.12 . . . . 0.0 109.505 179.826 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 6.5 pt-20 -81.33 -28.22 34.64 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.309 -0.87 . . . . 0.0 110.194 179.458 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -74.3 71.17 1.53 Allowed Glycine 0 N--CA 1.491 2.324 0 N-CA-C 109.92 -1.272 . . . . 0.0 109.92 -179.881 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 39' ' ' CYS . . . . . . . . . . . . . 0.6 OUTLIER -160.04 -47.76 0.05 Allowed 'General case' 0 C--N 1.296 -1.742 0 O-C-N 121.678 -0.895 . . . . 0.0 110.021 179.495 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 40' ' ' LEU . . . . . . . . . . . . . 17.0 mt . . . . . 0 N--CA 1.5 2.061 0 O-C-N 121.6 -0.687 . . . . 0.0 110.595 179.368 . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 2.2 t . . . . . 0 N--CA 1.497 1.906 0 CA-C-O 120.875 0.369 . . . . 0.0 110.049 . . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' A' A ' 6' ' ' PRO . . . . . . . . . . . . . 50.5 Cg_endo -75.42 75.92 3.73 Favored 'Trans proline' 0 C--N 1.313 -1.326 0 O-C-N 123.964 1.507 . . . . 0.0 110.425 179.928 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 73.89 38.7 48.61 Favored Glycine 0 N--CA 1.498 2.798 0 N-CA-C 110.118 -1.193 . . . . 0.0 110.118 179.987 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 5.4 p -92.04 -159.84 0.69 Allowed 'General case' 0 N--CA 1.498 1.927 0 O-C-N 121.28 -1.13 . . . . 0.0 109.858 179.498 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -76.93 -93.89 0.21 Allowed Glycine 0 N--CA 1.495 2.579 0 N-CA-C 109.599 -1.4 . . . . 0.0 109.599 -179.978 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 10' ' ' GLN . . . . . . . . . . . . . 2.3 pt20 -169.58 85.72 0.14 Allowed 'General case' 0 N--CA 1.493 1.722 0 O-C-N 121.221 -1.164 . . . . 0.0 109.885 179.656 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -75.64 60.01 2.92 Favored Glycine 0 N--CA 1.497 2.7 0 N-CA-C 109.932 -1.267 . . . . 0.0 109.932 -179.809 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 14.2 p -146.26 52.57 0.11 Allowed 'Isoleucine or valine' 0 N--CA 1.495 1.783 0 O-C-N 121.537 -0.978 . . . . 0.0 109.537 -179.933 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 13' ' ' GLN . . . . . . . . . . . . . 4.5 tt0 -58.93 -55.4 35.57 Favored 'General case' 0 N--CA 1.5 2.027 0 O-C-N 121.125 -0.984 . . . . 0.0 110.851 -179.733 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -83.54 66.44 8.93 Favored 'General case' 0 N--CA 1.498 1.939 0 O-C-N 121.143 -0.973 . . . . 0.0 110.185 -179.775 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -72.58 -67.1 1.9 Allowed Glycine 0 N--CA 1.494 2.534 0 N-CA-C 109.78 -1.328 . . . . 0.0 109.78 -179.748 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 1.2 p -127.89 74.51 78.69 Favored Pre-proline 0 N--CA 1.497 1.88 0 O-C-N 121.788 -0.83 . . . . 0.0 110.45 179.608 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 43.8 Cg_endo -68.72 131.01 21.75 Favored 'Trans proline' 0 C--N 1.309 -1.523 0 O-C-N 123.462 1.243 . . . . 0.0 110.36 -179.978 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 100.89 -24.36 32.28 Favored Glycine 0 N--CA 1.493 2.453 0 N-CA-C 110.54 -1.024 . . . . 0.0 110.54 179.916 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 165.81 138.52 2.44 Favored Glycine 0 N--CA 1.489 2.177 0 N-CA-C 108.943 -1.663 . . . . 0.0 108.943 179.599 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 71.6 m -118.36 112.74 20.4 Favored 'General case' 0 N--CA 1.492 1.672 0 O-C-N 121.492 -1.005 . . . . 0.0 110.009 179.788 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 7.2 p -92.89 43.63 0.08 OUTLIER 'Isoleucine or valine' 0 N--CA 1.504 2.232 0 O-C-N 121.282 -0.886 . . . . 0.0 110.481 -179.608 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 2.1 mm-40 -79.45 -28.08 41.62 Favored 'General case' 0 N--CA 1.488 1.457 0 O-C-N 121.029 -1.044 . . . . 0.0 110.931 -179.908 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 1.3 tp10 -162.29 110.87 1.4 Allowed 'General case' 0 N--CA 1.493 1.685 0 O-C-N 121.018 -1.052 . . . . 0.0 110.328 179.852 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 2.3 tt0 -148.23 153.29 38.54 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 121.487 -0.758 . . . . 0.0 110.165 179.104 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -96.67 -54.41 3.24 Favored 'General case' 0 N--CA 1.497 1.888 0 O-C-N 121.75 -0.594 . . . . 0.0 110.183 -179.677 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -156.25 94.34 0.14 Allowed Glycine 0 N--CA 1.494 2.549 0 N-CA-C 108.723 -1.751 . . . . 0.0 108.723 -179.891 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -55.81 96.72 0.04 OUTLIER Glycine 0 N--CA 1.498 2.826 0 N-CA-C 110.567 -1.013 . . . . 0.0 110.567 -179.422 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 28' ' ' SER . . . . . 0.514 ' CB ' ' HD3' ' A' ' 29' ' ' PRO . 1.6 t -160.75 -65.51 0.02 OUTLIER Pre-proline 0 N--CA 1.496 1.849 0 O-C-N 121.334 -1.098 . . . . 0.0 109.586 179.615 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 29' ' ' PRO . . . . . 0.514 ' HD3' ' CB ' ' A' ' 28' ' ' SER . 51.8 Cg_endo -78.26 72.14 6.41 Favored 'Trans proline' 0 N--CA 1.486 1.048 0 O-C-N 123.205 1.108 . . . . 0.0 109.863 178.742 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 30' ' ' ALA . . . . . 0.411 ' O ' ' HB1' ' A' ' 34' ' ' ALA . . . -79.64 -64.26 1.23 Allowed 'General case' 0 N--CA 1.493 1.701 0 O-C-N 121.349 -0.844 . . . . 0.0 111.212 -179.065 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 3.5 tt0 -117.78 -22.99 7.73 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.038 -1.039 . . . . 0.0 111.381 -179.224 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . -52.04 -41.57 53.08 Favored Glycine 0 N--CA 1.498 2.821 0 O-C-N 120.99 -1.069 . . . . 0.0 110.915 -179.193 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 33' ' ' CYS . . . . . . . . . . . . . 0.8 OUTLIER -149.59 62.69 1.01 Allowed 'General case' 0 N--CA 1.496 1.858 0 O-C-N 121.159 -1.2 . . . . 0.0 110.381 179.78 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 34' ' ' ALA . . . . . 0.411 ' HB1' ' O ' ' A' ' 30' ' ' ALA . . . -141.5 34.06 1.65 Allowed 'General case' 0 N--CA 1.498 1.952 0 O-C-N 121.257 -0.902 . . . . 0.0 110.367 179.882 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -111.15 -168.7 1.34 Allowed 'General case' 0 N--CA 1.496 1.863 0 O-C-N 121.376 -0.827 . . . . 0.0 109.776 179.693 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 36' ' ' ALA . . . . . . . . . . . . . . . -78.66 -24.65 45.06 Favored 'General case' 0 N--CA 1.5 2.037 0 O-C-N 121.508 -0.745 . . . . 0.0 110.324 179.985 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 4.9 tt0 -80.06 -46.83 15.84 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.519 -0.738 . . . . 0.0 109.697 179.769 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 106.42 -112.71 3.92 Favored Glycine 0 N--CA 1.489 2.184 0 N-CA-C 109.688 -1.365 . . . . 0.0 109.688 179.792 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 39' ' ' CYS . . . . . . . . . . . . . 1.6 m -144.81 -47.14 0.24 Allowed 'General case' 0 N--CA 1.501 2.114 0 O-C-N 121.408 -1.054 . . . . 0.0 110.715 -179.633 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 40' ' ' LEU . . . . . . . . . . . . . 0.7 OUTLIER . . . . . 0 N--CA 1.505 2.311 0 O-C-N 121.518 -0.739 . . . . 0.0 111.892 179.731 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 5' ' ' CYS . . . . . 0.468 ' HB2' ' HB3' ' A' ' 8' ' ' CYS . 22.9 p . . . . . 0 N--CA 1.494 1.763 0 N-CA-C 109.376 -0.601 . . . . 0.0 109.376 . . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 6' ' ' PRO . . . . . . . . . . . . . 42.0 Cg_endo -70.97 -53.26 0.2 Allowed 'Trans proline' 0 C--N 1.311 -1.412 0 O-C-N 123.685 1.36 . . . . 0.0 111.778 -178.988 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -108.89 59.45 0.36 Allowed Glycine 0 N--CA 1.492 2.371 0 O-C-N 120.917 -1.114 . . . . 0.0 110.859 -179.045 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 8' ' ' CYS . . . . . 0.468 ' HB3' ' HB2' ' A' ' 5' ' ' CYS . 10.5 p -110.02 -35.68 6.06 Favored 'General case' 0 N--CA 1.5 2.034 0 O-C-N 121.264 -1.139 . . . . 0.0 110.693 179.355 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 49.4 32.19 14.57 Favored Glycine 0 N--CA 1.502 3.056 0 O-C-N 121.337 -0.852 . . . . 0.0 111.478 179.441 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 10' ' ' GLN . . . . . . . . . . . . . 69.8 mt-30 49.63 43.72 24.27 Favored 'General case' 0 N--CA 1.501 2.08 0 O-C-N 121.304 -1.115 . . . . 0.0 110.904 179.691 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -48.27 -50.06 23.88 Favored Glycine 0 N--CA 1.503 3.155 0 N-CA-C 110.619 -0.992 . . . . 0.0 110.619 -179.707 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 11.2 p -127.82 53.75 0.37 Allowed 'Isoleucine or valine' 0 N--CA 1.494 1.728 0 O-C-N 121.312 -1.111 . . . . 0.0 109.759 179.81 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 13' ' ' GLN . . . . . . . . . . . . . 1.6 pt20 -71.02 142.76 50.91 Favored 'General case' 0 N--CA 1.495 1.795 0 O-C-N 121.01 -1.057 . . . . 0.0 110.321 -179.891 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -122.75 131.89 53.98 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.321 -0.862 . . . . 0.0 109.858 179.805 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -73.36 -54.15 7.05 Favored Glycine 0 N--CA 1.491 2.314 0 N-CA-C 109.662 -1.375 . . . . 0.0 109.662 -179.976 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 12.2 m -114.3 122.0 35.18 Favored Pre-proline 0 N--CA 1.499 1.992 0 O-C-N 121.295 -1.12 . . . . 0.0 109.996 -179.94 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 43.6 Cg_endo -72.11 75.38 2.3 Favored 'Trans proline' 0 N--CA 1.497 1.692 0 O-C-N 123.611 1.322 . . . . 0.0 110.789 -179.69 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 127.14 -46.02 1.11 Allowed Glycine 0 N--CA 1.495 2.571 0 N-CA-C 109.659 -1.376 . . . . 0.0 109.659 179.879 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 161.5 147.33 4.94 Favored Glycine 0 N--CA 1.484 1.884 0 N-CA-C 109.321 -1.512 . . . . 0.0 109.321 -179.318 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 0.9 OUTLIER -106.22 172.2 6.94 Favored 'General case' 0 C--N 1.296 -1.746 0 O-C-N 121.534 -0.98 . . . . 0.0 109.647 -179.811 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 10.5 t -78.71 61.33 0.17 Allowed 'Isoleucine or valine' 0 N--CA 1.498 1.936 0 O-C-N 121.35 -0.844 . . . . 0.0 109.781 179.527 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 3.0 mm-40 -131.24 37.49 3.72 Favored 'General case' 0 C--N 1.306 -1.305 0 O-C-N 121.585 -0.697 . . . . 0.0 109.661 -179.717 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 48.2 mt-10 -68.5 167.11 15.54 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.308 -0.87 . . . . 0.0 110.874 -179.236 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 2.8 pm0 -70.91 158.9 35.65 Favored 'General case' 0 N--CA 1.495 1.794 0 O-C-N 121.733 -0.605 . . . . 0.0 111.18 -179.014 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -80.3 -65.46 1.0 Allowed 'General case' 0 N--CA 1.491 1.597 0 N-CA-C 109.376 -0.602 . . . . 0.0 109.376 179.212 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 174.74 84.57 0.06 OUTLIER Glycine 0 N--CA 1.494 2.507 0 N-CA-C 109.535 -1.426 . . . . 0.0 109.535 179.853 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 149.16 128.3 1.66 Allowed Glycine 0 N--CA 1.493 2.464 0 N-CA-C 109.268 -1.533 . . . . 0.0 109.268 179.944 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -93.39 150.73 39.47 Favored Pre-proline 0 N--CA 1.495 1.818 0 O-C-N 121.559 -0.965 . . . . 0.0 110.444 -179.507 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 29' ' ' PRO . . . . . 0.486 ' HA ' ' HB3' ' A' ' 33' ' ' CYS . 52.4 Cg_endo -79.55 14.19 1.89 Allowed 'Trans proline' 0 N--CA 1.486 1.083 0 O-C-N 123.833 1.439 . . . . 0.0 111.784 179.81 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -127.55 15.18 7.08 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.049 -1.032 . . . . 0.0 110.394 179.585 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -159.84 -75.58 0.07 Allowed 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.458 -0.776 . . . . 0.0 109.613 -179.638 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . -66.97 -56.51 12.27 Favored Glycine 0 N--CA 1.496 2.646 0 N-CA-C 109.284 -1.526 . . . . 0.0 109.284 179.699 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 33' ' ' CYS . . . . . 0.486 ' HB3' ' HA ' ' A' ' 29' ' ' PRO . 5.5 t -87.24 73.83 9.63 Favored 'General case' 0 N--CA 1.497 1.895 0 O-C-N 121.358 -1.084 . . . . 0.0 109.891 179.766 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -147.86 49.24 1.07 Allowed 'General case' 0 N--CA 1.495 1.793 0 O-C-N 121.495 -0.753 . . . . 0.0 110.063 179.831 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 12.0 mt-10 -108.51 -174.35 2.5 Favored 'General case' 0 N--CA 1.494 1.762 0 O-C-N 121.467 -0.771 . . . . 0.0 110.69 -179.862 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 36' ' ' ALA . . . . . . . . . . . . . . . -89.97 -1.96 58.07 Favored 'General case' 0 N--CA 1.499 2.006 0 O-C-N 121.294 -0.879 . . . . 0.0 111.501 179.89 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -117.81 31.89 6.45 Favored 'General case' 0 N--CA 1.493 1.689 0 O-C-N 121.297 -0.877 . . . . 0.0 110.856 179.922 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 67.3 -118.1 9.75 Favored Glycine 0 N--CA 1.49 2.252 0 N-CA-C 109.661 -1.376 . . . . 0.0 109.661 179.607 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 39' ' ' CYS . . . . . 0.428 ' C ' HD12 ' A' ' 40' ' ' LEU . 0.1 OUTLIER -153.7 24.51 0.51 Allowed 'General case' 0 N--CA 1.499 2.006 0 O-C-N 121.522 -0.987 . . . . 0.0 111.292 -179.969 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 40' ' ' LEU . . . . . 0.555 ' C ' HD23 ' A' ' 40' ' ' LEU . 0.0 OUTLIER . . . . . 0 N--CA 1.493 1.715 0 O-C-N 120.888 -1.132 . . . . 0.0 110.496 179.083 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 0.8 OUTLIER . . . . . 0 N--CA 1.492 1.659 0 CA-C-O 121.016 0.436 . . . . 0.0 110.013 . . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 6' ' ' PRO . . . . . . . . . . . . . 39.3 Cg_endo -66.93 96.46 0.37 Allowed 'Trans proline' 0 C--N 1.303 -1.823 0 O-C-N 124.835 1.966 . . . . 0.0 111.241 -179.78 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 90.35 13.17 60.44 Favored Glycine 0 N--CA 1.493 2.499 0 C-N-CA 120.292 -0.956 . . . . 0.0 111.123 179.187 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 3.7 p -143.72 171.66 13.89 Favored 'General case' 0 N--CA 1.495 1.802 0 O-C-N 120.425 -1.633 . . . . 0.0 110.134 179.614 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 97.55 122.27 4.4 Favored Glycine 0 N--CA 1.494 2.511 0 N-CA-C 108.847 -1.701 . . . . 0.0 108.847 -179.147 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 10' ' ' GLN . . . . . . . . . . . . . 2.2 mt-30 -81.7 49.44 1.34 Allowed 'General case' 0 N--CA 1.494 1.743 0 O-C-N 121.156 -1.202 . . . . 0.0 110.922 -179.483 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -92.67 58.34 2.58 Favored Glycine 0 N--CA 1.495 2.599 0 N-CA-C 108.947 -1.661 . . . . 0.0 108.947 179.453 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 10.7 t -130.21 63.08 0.3 Allowed 'Isoleucine or valine' 0 N--CA 1.496 1.873 0 O-C-N 121.551 -0.97 . . . . 0.0 109.734 -179.674 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 13' ' ' GLN . . . . . . . . . . . . . 2.2 tt0 -121.01 102.95 8.67 Favored 'General case' 0 N--CA 1.487 1.408 0 O-C-N 121.245 -0.909 . . . . 0.0 109.748 179.816 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -134.7 -73.81 0.47 Allowed 'General case' 0 N--CA 1.492 1.675 0 O-C-N 121.941 -0.475 . . . . 0.0 109.826 179.993 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 136.46 -58.47 0.66 Allowed Glycine 0 N--CA 1.495 2.608 0 N-CA-C 109.537 -1.425 . . . . 0.0 109.537 179.966 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 10.1 m -79.49 148.63 70.37 Favored Pre-proline 0 N--CA 1.5 2.043 0 O-C-N 121.387 -1.067 . . . . 0.0 109.651 179.848 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 41.1 Cg_endo -66.69 -26.57 45.68 Favored 'Trans proline' 0 N--CA 1.492 1.435 0 O-C-N 123.896 1.471 . . . . 0.0 111.414 -179.636 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 174.66 85.29 0.06 OUTLIER Glycine 0 N--CA 1.494 2.5 0 N-CA-C 109.436 -1.466 . . . . 0.0 109.436 179.802 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 94.76 142.29 12.49 Favored Glycine 0 N--CA 1.488 2.147 0 N-CA-C 109.529 -1.428 . . . . 0.0 109.529 -179.834 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 0.0 OUTLIER -142.4 110.24 5.85 Favored 'General case' 0 N--CA 1.497 1.901 0 O-C-N 121.645 -0.915 . . . . 0.0 109.62 179.602 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 3.7 t -98.51 46.7 0.11 Allowed 'Isoleucine or valine' 0 N--CA 1.497 1.901 0 O-C-N 121.645 -0.659 . . . . 0.0 110.214 -179.635 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 8.6 mt-10 -87.99 -25.62 23.05 Favored 'General case' 0 N--CA 1.488 1.459 0 O-C-N 121.307 -0.871 . . . . 0.0 110.501 179.671 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 0.9 OUTLIER 60.02 -159.96 0.3 Allowed 'General case' 0 N--CA 1.501 2.09 0 O-C-N 121.751 -0.593 . . . . 0.0 110.976 179.924 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -124.44 -154.1 0.59 Allowed 'General case' 0 N--CA 1.488 1.439 0 O-C-N 121.537 -0.727 . . . . 0.0 110.169 -179.558 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -84.96 143.98 28.62 Favored 'General case' 0 N--CA 1.494 1.765 0 O-C-N 121.282 -0.886 . . . . 0.0 110.233 -179.971 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -69.69 -16.64 72.26 Favored Glycine 0 N--CA 1.493 2.472 0 N-CA-C 109.986 -1.246 . . . . 0.0 109.986 178.926 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 115.96 -107.7 1.72 Allowed Glycine 0 N--CA 1.49 2.285 0 N-CA-C 109.286 -1.526 . . . . 0.0 109.286 179.843 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -113.01 91.7 19.04 Favored Pre-proline 0 N--CA 1.497 1.88 0 O-C-N 121.327 -1.102 . . . . 0.0 109.63 179.375 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 44.2 Cg_endo -73.42 118.22 5.41 Favored 'Trans proline' 0 N--CA 1.49 1.318 0 O-C-N 123.692 1.364 . . . . 0.0 110.955 179.959 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -121.34 34.19 5.28 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.164 -0.96 . . . . 0.0 110.716 179.664 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 31' ' ' GLU . . . . . 0.502 ' HG3' ' N ' ' A' ' 32' ' ' GLY . 0.1 OUTLIER -86.85 -32.02 20.49 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.025 -1.047 . . . . 0.0 110.168 179.873 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 32' ' ' GLY . . . . . 0.502 ' N ' ' HG3' ' A' ' 31' ' ' GLU . . . 137.41 -47.42 0.95 Allowed Glycine 0 N--CA 1.493 2.464 0 N-CA-C 110.22 -1.152 . . . . 0.0 110.22 179.623 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 33' ' ' CYS . . . . . . . . . . . . . 0.9 OUTLIER -113.72 92.21 3.9 Favored 'General case' 0 N--CA 1.493 1.675 0 O-C-N 121.582 -0.952 . . . . 0.0 110.881 -179.398 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -96.9 37.32 1.31 Allowed 'General case' 0 N--CA 1.499 1.976 0 O-C-N 121.138 -0.976 . . . . 0.0 109.863 179.211 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 10.8 mt-10 -137.48 -178.1 5.08 Favored 'General case' 0 N--CA 1.497 1.902 0 O-C-N 121.747 -0.596 . . . . 0.0 109.867 179.812 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 36' ' ' ALA . . . . . . . . . . . . . . . -88.75 35.69 0.79 Allowed 'General case' 0 N--CA 1.493 1.717 0 O-C-N 120.993 -1.067 . . . . 0.0 110.594 -179.819 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 5.6 tt0 -78.5 -26.91 46.04 Favored 'General case' 0 N--CA 1.486 1.347 0 O-C-N 121.39 -0.819 . . . . 0.0 110.076 179.666 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 70.22 70.83 1.1 Allowed Glycine 0 N--CA 1.492 2.379 0 N-CA-C 109.137 -1.585 . . . . 0.0 109.137 179.689 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 39' ' ' CYS . . . . . . . . . . . . . 1.8 m -100.89 110.08 22.11 Favored 'General case' 0 C--N 1.298 -1.665 0 O-C-N 121.733 -0.863 . . . . 0.0 109.793 -179.768 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 40' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER . . . . . 0 N--CA 1.49 1.555 0 O-C-N 121.425 -0.797 . . . . 0.0 110.961 -179.794 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 19.8 t . . . . . 0 N--CA 1.494 1.751 0 N-CA-C 109.579 -0.526 . . . . 0.0 109.579 . . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' A' A ' 6' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -80.57 -35.63 0.55 Allowed 'Trans proline' 0 C--N 1.308 -1.57 0 O-C-N 124.09 1.573 . . . . 0.0 112.171 -179.325 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -90.45 53.22 3.45 Favored Glycine 0 N--CA 1.496 2.637 0 O-C-N 120.361 -1.462 . . . . 0.0 112.007 -178.009 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 21.7 p -161.15 163.7 31.08 Favored 'General case' 0 N--CA 1.498 1.933 0 O-C-N 120.657 -1.496 . . . . 0.0 110.655 178.854 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 70.91 63.94 2.98 Favored Glycine 0 N--CA 1.494 2.535 0 N-CA-C 109.759 -1.336 . . . . 0.0 109.759 -179.951 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 10' ' ' GLN . . . . . . . . . . . . . 3.1 pt20 -145.04 27.5 1.29 Allowed 'General case' 0 N--CA 1.493 1.698 0 O-C-N 121.619 -0.93 . . . . 0.0 111.113 -179.639 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -140.53 63.31 0.53 Allowed Glycine 0 N--CA 1.491 2.35 0 N-CA-C 109.439 -1.464 . . . . 0.0 109.439 179.839 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 28.9 m -113.79 2.06 8.39 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.834 0 O-C-N 121.568 -0.96 . . . . 0.0 111.627 -179.955 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 13' ' ' GLN . . . . . . . . . . . . . 25.6 tt0 -51.41 -45.73 62.64 Favored 'General case' 0 N--CA 1.499 2.01 0 O-C-N 120.984 -1.072 . . . . 0.0 110.613 179.815 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -111.04 26.6 10.53 Favored 'General case' 0 N--CA 1.494 1.729 0 O-C-N 121.624 -0.673 . . . . 0.0 110.272 179.714 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -128.33 68.19 0.54 Allowed Glycine 0 N--CA 1.489 2.19 0 N-CA-C 108.97 -1.652 . . . . 0.0 108.97 179.753 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 17.9 m -96.0 150.27 37.06 Favored Pre-proline 0 N--CA 1.488 1.437 0 O-C-N 121.44 -1.035 . . . . 0.0 110.497 -179.745 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 43.7 Cg_endo -74.17 -39.85 1.48 Allowed 'Trans proline' 0 N--CA 1.491 1.368 0 O-C-N 123.822 1.433 . . . . 0.0 110.648 179.426 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . -167.12 59.36 0.22 Allowed Glycine 0 N--CA 1.493 2.461 0 N-CA-C 109.163 -1.575 . . . . 0.0 109.163 179.589 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 141.18 132.56 2.82 Favored Glycine 0 N--CA 1.493 2.496 0 N-CA-C 108.625 -1.79 . . . . 0.0 108.625 -179.557 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -134.32 169.38 17.31 Favored 'General case' 0 N--CA 1.496 1.851 0 O-C-N 121.512 -0.993 . . . . 0.0 109.301 -179.665 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 11.7 p -80.06 50.89 0.07 OUTLIER 'Isoleucine or valine' 0 N--CA 1.502 2.155 0 O-C-N 121.319 -0.863 . . . . 0.0 111.254 -179.736 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 2.8 mt-10 -108.58 51.76 0.73 Allowed 'General case' 0 C--N 1.305 -1.326 0 O-C-N 121.014 -1.053 . . . . 0.0 108.436 178.419 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 0.8 OUTLIER 52.55 59.41 4.52 Favored 'General case' 0 N--CA 1.495 1.806 0 CA-C-O 121.93 0.871 . . . . 0.0 109.222 -177.995 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 1.7 pm0 -61.0 -5.46 1.4 Allowed 'General case' 0 N--CA 1.5 2.034 0 O-C-N 121.432 -0.793 . . . . 0.0 112.228 -179.105 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 15.7 m-20 -77.17 -24.18 51.49 Favored 'General case' 0 N--CA 1.497 1.924 0 O-C-N 120.737 -1.227 . . . . 0.0 110.431 179.641 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 88.39 -51.96 3.99 Favored Glycine 0 N--CA 1.495 2.589 0 N-CA-C 109.726 -1.35 . . . . 0.0 109.726 -179.921 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -177.29 -140.05 3.53 Favored Glycine 0 N--CA 1.493 2.472 0 N-CA-C 109.798 -1.321 . . . . 0.0 109.798 -179.696 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 28' ' ' SER . . . . . 0.46 ' CB ' ' CD ' ' A' ' 29' ' ' PRO . 2.6 t -154.92 -64.07 0.02 OUTLIER Pre-proline 0 N--CA 1.494 1.744 0 O-C-N 121.163 -1.198 . . . . 0.0 110.665 179.835 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 29' ' ' PRO . . . . . 0.46 ' CD ' ' CB ' ' A' ' 28' ' ' SER . 41.4 Cg_endo -68.89 -31.23 25.09 Favored 'Trans proline' 0 N--CA 1.488 1.188 0 O-C-N 122.979 0.989 . . . . 0.0 111.133 -179.562 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -99.12 54.29 0.98 Allowed 'General case' 0 N--CA 1.493 1.704 0 O-C-N 121.376 -0.827 . . . . 0.0 110.827 -179.633 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 2.8 tp10 -84.48 -42.41 15.6 Favored 'General case' 0 N--CA 1.493 1.717 0 O-C-N 121.379 -0.826 . . . . 0.0 110.217 179.603 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 96.47 52.43 1.57 Allowed Glycine 0 N--CA 1.501 2.995 0 N-CA-C 109.634 -1.386 . . . . 0.0 109.634 -179.804 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 33' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -79.62 118.64 21.64 Favored 'General case' 0 N--CA 1.495 1.814 0 O-C-N 121.157 -1.202 . . . . 0.0 109.735 179.903 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -79.49 -28.5 41.47 Favored 'General case' 0 N--CA 1.497 1.918 0 O-C-N 121.259 -0.9 . . . . 0.0 110.721 -179.851 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 24.5 mp0 -78.19 153.53 31.92 Favored 'General case' 0 N--CA 1.492 1.658 0 CA-C-O 121.491 0.662 . . . . 0.0 110.556 -179.762 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 36' ' ' ALA . . . . . . . . . . . . . . . -91.88 -42.18 10.2 Favored 'General case' 0 N--CA 1.496 1.825 0 O-C-N 121.415 -0.803 . . . . 0.0 110.999 -179.668 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 16.2 tt0 -77.18 -26.12 52.57 Favored 'General case' 0 N--CA 1.494 1.757 0 O-C-N 120.796 -1.19 . . . . 0.0 111.197 -179.006 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -70.26 -32.72 68.66 Favored Glycine 0 N--CA 1.497 2.705 0 C-N-CA 120.386 -0.911 . . . . 0.0 111.203 -178.942 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 39' ' ' CYS . . . . . . . . . . . . . 90.1 m -135.36 -32.32 0.94 Allowed 'General case' 0 N--CA 1.506 2.344 0 O-C-N 120.709 -1.466 . . . . 0.0 112.872 -178.697 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 40' ' ' LEU . . . . . . . . . . . . . 1.0 OUTLIER . . . . . 0 N--CA 1.497 1.879 0 O-C-N 120.697 -1.252 . . . . 0.0 111.606 -178.371 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 31.6 p . . . . . 0 N--CA 1.493 1.686 0 CA-C-O 120.469 0.176 . . . . 0.0 110.599 . . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' A' A ' 6' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -78.26 110.59 2.9 Favored 'Trans proline' 0 N--CA 1.487 1.136 0 O-C-N 123.938 1.494 . . . . 0.0 111.516 -179.416 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 47.44 54.69 10.14 Favored Glycine 0 N--CA 1.497 2.707 0 O-C-N 121.337 -0.852 . . . . 0.0 110.983 179.147 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -112.84 -171.95 1.96 Allowed 'General case' 0 N--CA 1.495 1.784 0 O-C-N 121.342 -1.093 . . . . 0.0 109.822 179.24 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 9' ' ' GLY . . . . . 0.489 ' O ' ' HG2' ' A' ' 10' ' ' GLN . . . 95.54 36.34 5.39 Favored Glycine 0 N--CA 1.495 2.608 0 N-CA-C 109.452 -1.459 . . . . 0.0 109.452 179.973 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 10' ' ' GLN . . . . . 0.489 ' HG2' ' O ' ' A' ' 9' ' ' GLY . 0.0 OUTLIER 26.87 54.81 0.05 Allowed 'General case' 0 N--CA 1.506 2.351 0 CA-C-N 117.379 0.59 . . . . 0.0 112.055 179.679 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -135.95 52.37 0.79 Allowed Glycine 0 N--CA 1.496 2.662 0 N-CA-C 109.511 -1.436 . . . . 0.0 109.511 179.586 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 6.3 p -107.97 -2.49 10.06 Favored 'Isoleucine or valine' 0 N--CA 1.499 2.017 0 O-C-N 121.12 -1.223 . . . . 0.0 110.877 -179.331 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 13' ' ' GLN . . . . . . . . . . . . . 7.0 mt-30 -76.11 79.3 2.94 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 120.884 -1.135 . . . . 0.0 110.444 -179.491 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -119.02 174.75 6.12 Favored 'General case' 0 N--CA 1.498 1.972 0 O-C-N 121.673 -0.642 . . . . 0.0 110.29 179.662 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -143.25 -94.62 0.2 Allowed Glycine 0 N--CA 1.494 2.54 0 N-CA-C 109.544 -1.422 . . . . 0.0 109.544 179.895 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 4.7 m -89.07 151.09 46.43 Favored Pre-proline 0 N--CA 1.492 1.648 0 O-C-N 121.34 -1.094 . . . . 0.0 109.975 179.655 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 50.0 Cg_endo -75.14 59.01 5.17 Favored 'Trans proline' 0 C--N 1.315 -1.205 0 O-C-N 123.847 1.446 . . . . 0.0 111.052 -179.953 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 69.93 11.3 66.3 Favored Glycine 0 N--CA 1.494 2.56 0 N-CA-C 110.609 -0.996 . . . . 0.0 110.609 179.887 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -147.74 114.52 0.7 Allowed Glycine 0 N--CA 1.488 2.141 0 N-CA-C 109.064 -1.615 . . . . 0.0 109.064 -179.507 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -153.67 142.87 21.43 Favored 'General case' 0 N--CA 1.494 1.775 0 O-C-N 121.483 -1.01 . . . . 0.0 110.125 -179.85 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . 0.415 ' O ' HG23 ' A' ' 21' ' ' VAL . 11.5 p -150.35 44.67 0.08 OUTLIER 'Isoleucine or valine' 0 N--CA 1.499 1.99 0 CA-C-O 121.559 0.695 . . . . 0.0 110.164 -179.681 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 1.8 mt-10 -112.31 -13.57 13.43 Favored 'General case' 0 N--CA 1.487 1.418 0 O-C-N 121.191 -0.943 . . . . 0.0 110.758 179.654 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 1.4 tp10 58.73 85.95 0.09 Allowed 'General case' 0 N--CA 1.504 2.253 0 O-C-N 121.355 -0.84 . . . . 0.0 110.526 179.855 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 26.1 mt-10 -79.24 50.01 1.03 Allowed 'General case' 0 N--CA 1.496 1.854 0 O-C-N 120.858 -1.151 . . . . 0.0 111.286 -179.883 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 2.5 t70 -113.97 68.98 0.7 Allowed 'General case' 0 N--CA 1.495 1.788 0 O-C-N 121.211 -0.931 . . . . 0.0 109.979 179.706 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 159.87 -87.62 0.11 Allowed Glycine 0 N--CA 1.495 2.627 0 N-CA-C 109.638 -1.385 . . . . 0.0 109.638 179.838 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 121.47 -56.92 0.61 Allowed Glycine 0 N--CA 1.494 2.526 0 N-CA-C 109.533 -1.427 . . . . 0.0 109.533 -179.853 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 58.3 m -125.42 159.75 58.71 Favored Pre-proline 0 N--CA 1.498 1.953 0 O-C-N 121.762 -0.846 . . . . 0.0 110.157 179.964 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 42.4 Cg_endo -65.76 -29.13 51.15 Favored 'Trans proline' 0 N--CA 1.492 1.411 0 O-C-N 123.883 1.465 . . . . 0.0 111.076 179.736 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -96.15 15.81 19.83 Favored 'General case' 0 N--CA 1.487 1.384 0 O-C-N 120.822 -1.174 . . . . 0.0 110.224 178.965 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 37.0 tp10 -79.65 -50.71 10.24 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.089 -1.007 . . . . 0.0 110.818 -179.103 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 131.64 88.27 0.43 Allowed Glycine 0 N--CA 1.487 2.088 0 N-CA-C 108.771 -1.732 . . . . 0.0 108.771 -179.384 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 33' ' ' CYS . . . . . . . . . . . . . 17.9 m -78.22 125.59 29.57 Favored 'General case' 0 N--CA 1.502 2.131 0 O-C-N 121.279 -1.13 . . . . 0.0 110.307 -179.811 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -79.09 -17.21 55.56 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.363 -0.836 . . . . 0.0 109.839 179.15 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 1.1 tm-20 -103.74 165.24 11.16 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.391 -0.818 . . . . 0.0 109.999 179.581 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 36' ' ' ALA . . . . . . . . . . . . . . . -102.04 -26.92 13.22 Favored 'General case' 0 N--CA 1.498 1.955 0 O-C-N 121.335 -0.853 . . . . 0.0 110.903 179.58 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 1.5 mt-10 -79.58 -31.93 41.92 Favored 'General case' 0 N--CA 1.494 1.775 0 O-C-N 120.942 -1.099 . . . . 0.0 110.604 -179.195 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -75.22 -36.96 43.76 Favored Glycine 0 N--CA 1.493 2.459 0 N-CA-C 110.392 -1.083 . . . . 0.0 110.392 -179.91 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 39' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -96.47 -27.85 14.69 Favored 'General case' 0 N--CA 1.499 2.005 0 O-C-N 120.868 -1.372 . . . . 0.0 111.477 -179.865 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 40' ' ' LEU . . . . . . . . . . . . . 0.8 OUTLIER . . . . . 0 N--CA 1.502 2.133 0 O-C-N 121.297 -0.877 . . . . 0.0 110.657 -179.417 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 5.8 p . . . . . 0 N--CA 1.497 1.923 0 N-CA-C 110.394 -0.224 . . . . 0.0 110.394 . . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' A' A ' 6' ' ' PRO . . . . . . . . . . . . . 44.1 Cg_endo -75.09 -53.49 0.1 OUTLIER 'Trans proline' 0 C--N 1.311 -1.443 0 O-C-N 123.559 1.294 . . . . 0.0 111.351 -179.577 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -85.97 59.87 4.68 Favored Glycine 0 N--CA 1.492 2.373 0 N-CA-C 110.238 -1.145 . . . . 0.0 110.238 -179.426 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 0.7 OUTLIER -106.02 18.38 22.16 Favored 'General case' 0 N--CA 1.501 2.084 0 O-C-N 121.281 -1.129 . . . . 0.0 110.56 179.325 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 106.17 55.73 0.67 Allowed Glycine 0 N--CA 1.496 2.676 0 N-CA-C 109.975 -1.25 . . . . 0.0 109.975 179.729 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 10' ' ' GLN . . . . . . . . . . . . . 3.8 pt20 -161.79 48.35 0.19 Allowed 'General case' 0 N--CA 1.492 1.633 0 O-C-N 121.383 -1.069 . . . . 0.0 110.361 179.777 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -94.79 66.36 1.37 Allowed Glycine 0 N--CA 1.495 2.588 0 N-CA-C 109.599 -1.4 . . . . 0.0 109.599 179.901 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 24.6 t -122.3 -20.06 4.05 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.029 0 O-C-N 121.393 -1.063 . . . . 0.0 111.079 -179.483 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 13' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -81.38 -144.38 0.05 Allowed 'General case' 0 N--CA 1.492 1.646 0 O-C-N 121.053 -1.029 . . . . 0.0 110.393 -179.854 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . 59.07 -155.62 0.35 Allowed 'General case' 0 N--CA 1.498 1.966 0 O-C-N 121.647 -0.658 . . . . 0.0 109.821 -179.727 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -91.28 42.93 2.81 Favored Glycine 0 N--CA 1.49 2.262 0 N-CA-C 109.371 -1.492 . . . . 0.0 109.371 179.916 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 81.1 m -119.38 67.09 9.37 Favored Pre-proline 0 N--CA 1.493 1.709 0 O-C-N 121.295 -1.12 . . . . 0.0 110.801 -179.5 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 46.6 Cg_endo -71.83 69.01 3.0 Favored 'Trans proline' 0 C--N 1.313 -1.319 0 O-C-N 123.385 1.202 . . . . 0.0 110.504 -179.892 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 105.73 -14.71 45.73 Favored Glycine 0 N--CA 1.498 2.786 0 N-CA-C 110.134 -1.186 . . . . 0.0 110.134 -179.603 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -154.2 123.95 1.47 Allowed Glycine 0 N--CA 1.489 2.213 0 N-CA-C 109.152 -1.579 . . . . 0.0 109.152 179.87 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -108.05 47.13 0.91 Allowed 'General case' 0 N--CA 1.497 1.904 0 O-C-N 121.399 -1.059 . . . . 0.0 109.699 179.706 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 9.9 p -136.4 20.97 0.9 Allowed 'Isoleucine or valine' 0 N--CA 1.502 2.167 0 O-C-N 120.915 -1.116 . . . . 0.0 111.29 -179.444 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 22' ' ' GLU . . . . . 0.405 ' C ' ' HG3' ' A' ' 23' ' ' GLU . 1.5 tp10 -101.21 -12.06 19.03 Favored 'General case' 0 C--N 1.305 -1.339 0 O-C-N 121.179 -0.951 . . . . 0.0 109.993 179.098 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 23' ' ' GLU . . . . . 0.405 ' HG3' ' C ' ' A' ' 22' ' ' GLU . 0.0 OUTLIER -146.06 74.86 1.39 Allowed 'General case' 0 N--CA 1.488 1.446 0 O-C-N 121.429 -0.794 . . . . 0.0 109.436 -179.582 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER -56.05 -58.54 7.47 Favored 'General case' 0 N--CA 1.5 2.037 0 O-C-N 121.207 -0.933 . . . . 0.0 110.79 -179.421 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -149.28 -61.86 0.22 Allowed 'General case' 0 N--CA 1.495 1.811 0 O-C-N 121.332 -0.855 . . . . 0.0 110.06 179.964 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 134.04 86.03 0.25 Allowed Glycine 0 N--CA 1.497 2.708 0 N-CA-C 109.504 -1.438 . . . . 0.0 109.504 -179.716 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 165.45 95.95 0.11 Allowed Glycine 0 N--CA 1.494 2.557 0 N-CA-C 109.147 -1.581 . . . . 0.0 109.147 -179.702 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 28' ' ' SER . . . . . 0.506 ' HB2' ' HD3' ' A' ' 29' ' ' PRO . 0.0 OUTLIER -154.72 -62.6 0.02 OUTLIER Pre-proline 0 N--CA 1.497 1.909 0 O-C-N 121.263 -1.14 . . . . 0.0 110.777 179.85 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 29' ' ' PRO . . . . . 0.506 ' HD3' ' HB2' ' A' ' 28' ' ' SER . 44.8 Cg_endo -75.44 123.82 7.91 Favored 'Trans proline' 0 C--N 1.318 -1.062 0 O-C-N 122.922 0.959 . . . . 0.0 110.405 -179.744 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -78.54 -9.39 59.32 Favored 'General case' 0 N--CA 1.498 1.943 0 O-C-N 121.148 -0.97 . . . . 0.0 111.154 -179.665 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 4.1 tp10 -79.76 -56.92 3.94 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.253 -0.905 . . . . 0.0 109.556 179.742 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 171.88 -64.85 0.14 Allowed Glycine 0 N--CA 1.492 2.418 0 N-CA-C 109.181 -1.568 . . . . 0.0 109.181 -179.999 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 33' ' ' CYS . . . . . . . . . . . . . 12.7 p -148.29 88.33 1.64 Allowed 'General case' 0 N--CA 1.493 1.715 0 O-C-N 121.495 -1.003 . . . . 0.0 109.521 179.648 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -86.28 39.42 0.82 Allowed 'General case' 0 N--CA 1.495 1.808 0 O-C-N 121.342 -0.849 . . . . 0.0 110.82 -179.479 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER -113.8 163.26 15.28 Favored 'General case' 0 N--CA 1.495 1.793 0 O-C-N 121.218 -0.926 . . . . 0.0 110.214 179.812 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 36' ' ' ALA . . . . . 0.524 ' HA ' ' HB2' ' A' ' 40' ' ' LEU . . . -102.61 0.1 32.78 Favored 'General case' 0 N--CA 1.498 1.97 0 O-C-N 121.515 -0.741 . . . . 0.0 112.148 -178.706 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 2.7 pm0 -79.59 -27.24 41.13 Favored 'General case' 0 N--CA 1.498 1.94 0 O-C-N 120.582 -1.324 . . . . 0.0 111.556 -179.132 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -133.34 -47.41 0.1 Allowed Glycine 0 N--CA 1.498 2.799 0 C-N-CA 118.894 -1.622 . . . . 0.0 111.825 -178.77 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 39' ' ' CYS . . . . . . . . . . . . . 4.3 m -79.53 0.94 27.68 Favored 'General case' 0 N--CA 1.499 2.022 0 O-C-N 120.889 -1.359 . . . . 0.0 112.304 -178.451 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 40' ' ' LEU . . . . . 0.524 ' HB2' ' HA ' ' A' ' 36' ' ' ALA . 0.5 OUTLIER . . . . . 0 N--CA 1.497 1.923 0 O-C-N 120.851 -1.156 . . . . 0.0 109.797 179.07 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER . . . . . 0 N--CA 1.491 1.614 0 N-CA-C 110.264 -0.273 . . . . 0.0 110.264 . . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 6' ' ' PRO . . . . . . . . . . . . . 43.6 Cg_endo -75.11 -53.21 0.1 OUTLIER 'Trans proline' 0 C--N 1.315 -1.233 0 O-C-N 123.691 1.364 . . . . 0.0 110.619 179.608 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -85.17 60.73 4.74 Favored Glycine 0 N--CA 1.496 2.654 0 N-CA-C 109.465 -1.454 . . . . 0.0 109.465 179.522 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 1.5 m -96.74 24.31 6.19 Favored 'General case' 0 N--CA 1.497 1.923 0 O-C-N 121.271 -1.135 . . . . 0.0 110.678 -179.952 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -144.02 -144.46 4.22 Favored Glycine 0 N--CA 1.495 2.579 0 N-CA-C 109.354 -1.498 . . . . 0.0 109.354 179.841 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 10' ' ' GLN . . . . . . . . . . . . . 3.5 mt-30 -54.12 -49.02 70.12 Favored 'General case' 0 N--CA 1.499 2.006 0 O-C-N 121.423 -1.045 . . . . 0.0 110.959 179.953 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 109.15 -25.17 19.19 Favored Glycine 0 N--CA 1.494 2.539 0 N-CA-C 109.874 -1.29 . . . . 0.0 109.874 -179.654 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 27.4 m -95.9 46.76 0.1 OUTLIER 'Isoleucine or valine' 0 N--CA 1.497 1.908 0 O-C-N 121.015 -1.285 . . . . 0.0 110.26 179.879 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 13' ' ' GLN . . . . . . . . . . . . . 1.1 mt-30 52.11 49.38 20.76 Favored 'General case' 0 N--CA 1.498 1.93 0 O-C-N 121.705 -0.622 . . . . 0.0 111.006 179.779 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -103.87 161.65 13.78 Favored 'General case' 0 N--CA 1.497 1.917 0 O-C-N 121.263 -0.898 . . . . 0.0 110.137 179.512 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 75.58 72.06 1.1 Allowed Glycine 0 N--CA 1.495 2.625 0 N-CA-C 109.461 -1.455 . . . . 0.0 109.461 179.908 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 16' ' ' CYS . . . . . 0.433 ' HB2' ' HD2' ' A' ' 17' ' ' PRO . 17.7 p -79.8 167.23 35.42 Favored Pre-proline 0 N--CA 1.497 1.924 0 O-C-N 121.428 -1.042 . . . . 0.0 110.215 -179.922 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 17' ' ' PRO . . . . . 0.433 ' HD2' ' HB2' ' A' ' 16' ' ' CYS . 49.7 Cg_endo -77.33 53.19 4.17 Favored 'Trans proline' 0 C--N 1.311 -1.437 0 O-C-N 123.499 1.263 . . . . 0.0 110.217 178.927 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 92.7 -43.09 2.63 Favored Glycine 0 N--CA 1.496 2.64 0 N-CA-C 110.392 -1.083 . . . . 0.0 110.392 -179.89 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -74.89 83.38 0.82 Allowed Glycine 0 N--CA 1.492 2.376 0 O-C-N 121.189 -1.183 . . . . 0.0 110.495 -179.176 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 1.3 m -117.45 118.93 33.54 Favored 'General case' 0 N--CA 1.497 1.9 0 O-C-N 121.407 -1.054 . . . . 0.0 109.974 179.427 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 14.0 t -83.33 75.36 1.03 Allowed 'Isoleucine or valine' 0 N--CA 1.497 1.876 0 O-C-N 121.639 -0.663 . . . . 0.0 109.573 179.851 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 31.4 mt-10 -95.34 40.96 1.1 Allowed 'General case' 0 C--N 1.304 -1.391 0 O-C-N 121.356 -0.84 . . . . 0.0 110.115 -179.587 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 3.4 pt-20 -157.52 60.03 0.49 Allowed 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.372 -0.83 . . . . 0.0 110.164 -179.801 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -112.27 147.53 36.07 Favored 'General case' 0 N--CA 1.493 1.718 0 O-C-N 121.224 -0.922 . . . . 0.0 110.281 -179.574 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 3.1 p-10 -96.78 176.73 5.88 Favored 'General case' 0 N--CA 1.495 1.801 0 O-C-N 121.37 -0.831 . . . . 0.0 109.538 178.99 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -126.36 27.86 4.91 Favored Glycine 0 N--CA 1.493 2.487 0 N-CA-C 110.134 -1.186 . . . . 0.0 110.134 179.921 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 71.75 -68.77 1.0 Allowed Glycine 0 N--CA 1.499 2.88 0 N-CA-C 109.782 -1.327 . . . . 0.0 109.782 -179.934 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 64.4 m -83.5 116.9 66.87 Favored Pre-proline 0 N--CA 1.499 1.992 0 O-C-N 121.273 -1.134 . . . . 0.0 110.378 179.788 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 44.1 Cg_endo -71.16 154.39 62.07 Favored 'Trans proline' 0 N--CA 1.491 1.333 0 O-C-N 124.016 1.535 . . . . 0.0 111.485 -179.493 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -112.43 -50.26 2.91 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.398 -0.814 . . . . 0.0 110.625 179.84 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -102.54 -63.84 1.12 Allowed 'General case' 0 N--CA 1.495 1.79 0 O-C-N 121.485 -0.759 . . . . 0.0 110.233 -179.956 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 152.96 -59.2 0.41 Allowed Glycine 0 N--CA 1.495 2.587 0 N-CA-C 109.626 -1.39 . . . . 0.0 109.626 -179.907 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 33' ' ' CYS . . . . . . . . . . . . . 17.3 m -133.17 61.24 1.68 Allowed 'General case' 0 N--CA 1.496 1.87 0 O-C-N 121.32 -1.106 . . . . 0.0 110.075 179.87 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -122.62 26.63 8.2 Favored 'General case' 0 N--CA 1.497 1.911 0 O-C-N 121.274 -0.891 . . . . 0.0 109.876 179.528 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 22.7 mp0 -116.5 -171.88 2.09 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.732 -0.605 . . . . 0.0 110.612 -179.186 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 36' ' ' ALA . . . . . . . . . . . . . . . -92.07 -24.97 18.99 Favored 'General case' 0 N--CA 1.499 2.022 0 O-C-N 121.244 -0.91 . . . . 0.0 111.151 -179.597 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER -79.71 52.46 1.45 Allowed 'General case' 0 N--CA 1.499 2.006 0 O-C-N 120.836 -1.165 . . . . 0.0 110.739 -179.608 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 47.42 -111.5 0.79 Allowed Glycine 0 N--CA 1.501 3.013 0 N-CA-C 110.126 -1.189 . . . . 0.0 110.126 179.5 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 39' ' ' CYS . . . . . . . . . . . . . 90.0 m -143.4 141.4 30.86 Favored 'General case' 0 N--CA 1.495 1.794 0 O-C-N 121.485 -1.009 . . . . 0.0 109.26 179.462 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 40' ' ' LEU . . . . . . . . . . . . . 2.9 mt . . . . . 0 N--CA 1.495 1.778 0 O-C-N 121.351 -0.843 . . . . 0.0 110.938 -179.499 . . . . . . . . 0 0 . 1 . 012 nuclear orig core ' A' A ' 5' ' ' CYS . . . . . 0.507 ' SG ' ' N ' ' A' ' 8' ' ' CYS . 0.8 OUTLIER . . . . . 0 N--CA 1.496 1.858 0 N-CA-C 109.716 -0.475 . . . . 0.0 109.716 . . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 6' ' ' PRO . . . . . . . . . . . . . 51.6 Cg_endo -81.0 45.36 1.98 Allowed 'Trans proline' 0 C--N 1.314 -1.271 0 O-C-N 123.755 1.397 . . . . 0.0 111.627 -179.092 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 165.1 41.73 0.02 OUTLIER Glycine 0 N--CA 1.497 2.702 0 N-CA-C 109.925 -1.27 . . . . 0.0 109.925 179.838 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 8' ' ' CYS . . . . . 0.507 ' N ' ' SG ' ' A' ' 5' ' ' CYS . 14.3 m -79.84 -177.2 5.82 Favored 'General case' 0 N--CA 1.499 1.993 0 O-C-N 121.404 -1.056 . . . . 0.0 110.132 -179.842 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -86.5 -79.72 1.19 Allowed Glycine 0 N--CA 1.495 2.631 0 N-CA-C 109.886 -1.286 . . . . 0.0 109.886 -179.885 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 10' ' ' GLN . . . . . . . . . . . . . 0.1 OUTLIER -67.05 -71.73 0.19 Allowed 'General case' 0 N--CA 1.496 1.868 0 O-C-N 121.434 -1.039 . . . . 0.0 110.648 -179.677 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 72.05 8.35 69.06 Favored Glycine 0 N--CA 1.497 2.758 0 N-CA-C 110.426 -1.07 . . . . 0.0 110.426 -179.595 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 12' ' ' VAL . . . . . 0.402 HG13 ' O ' ' A' ' 12' ' ' VAL . 4.3 p -160.64 82.41 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.493 1.675 0 O-C-N 121.209 -1.171 . . . . 0.0 108.767 179.954 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 13' ' ' GLN . . . . . . . . . . . . . 1.3 tt0 -53.22 101.16 0.04 OUTLIER 'General case' 0 N--CA 1.498 1.953 0 O-C-N 121.567 -0.708 . . . . 0.0 111.089 -178.897 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -108.72 31.55 5.56 Favored 'General case' 0 N--CA 1.497 1.894 0 O-C-N 121.643 -0.661 . . . . 0.0 109.547 179.209 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 143.95 -86.24 0.18 Allowed Glycine 0 N--CA 1.49 2.278 0 N-CA-C 108.548 -1.821 . . . . 0.0 108.548 -179.45 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 28.4 m -106.93 100.66 33.11 Favored Pre-proline 0 N--CA 1.494 1.764 0 O-C-N 121.331 -1.099 . . . . 0.0 109.544 179.133 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 47.2 Cg_endo -72.66 55.4 2.66 Favored 'Trans proline' 0 C--N 1.312 -1.382 0 O-C-N 123.817 1.43 . . . . 0.0 111.826 -178.955 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 152.62 36.56 0.03 OUTLIER Glycine 0 N--CA 1.496 2.684 0 O-C-N 120.836 -1.165 . . . . 0.0 111.097 179.444 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 82.38 137.24 2.6 Favored Glycine 0 N--CA 1.492 2.37 0 O-C-N 121.013 -1.287 . . . . 0.0 109.909 179.46 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -116.37 27.36 9.27 Favored 'General case' 0 N--CA 1.5 2.035 0 O-C-N 121.265 -1.138 . . . . 0.0 110.323 179.671 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 8.4 p -132.26 8.45 1.63 Allowed 'Isoleucine or valine' 0 N--CA 1.494 1.765 0 O-C-N 121.01 -1.056 . . . . 0.0 110.926 179.945 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 8.3 mm-40 -98.81 14.99 26.88 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 120.657 -1.277 . . . . 0.0 111.145 179.965 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 4.6 tt0 -146.4 -54.92 0.26 Allowed 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.202 -0.936 . . . . 0.0 109.507 179.404 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER -124.41 101.77 7.32 Favored 'General case' 0 C--N 1.307 -1.24 0 O-C-N 121.443 -0.785 . . . . 0.0 110.129 179.61 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 3.5 p-10 -115.43 23.76 12.15 Favored 'General case' 0 N--CA 1.496 1.841 0 O-C-N 121.236 -0.915 . . . . 0.0 110.542 179.926 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 129.52 -95.69 0.37 Allowed Glycine 0 N--CA 1.493 2.451 0 N-CA-C 109.209 -1.556 . . . . 0.0 109.209 179.914 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 80.29 -95.52 1.56 Allowed Glycine 0 N--CA 1.495 2.573 0 N-CA-C 109.701 -1.36 . . . . 0.0 109.701 179.752 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -79.29 165.77 46.2 Favored Pre-proline 0 N--CA 1.5 2.062 0 O-C-N 121.39 -1.065 . . . . 0.0 110.267 -179.919 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 45.6 Cg_endo -73.68 64.73 4.79 Favored 'Trans proline' 0 C--N 1.317 -1.116 0 O-C-N 123.868 1.457 . . . . 0.0 110.579 -179.975 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -127.63 76.62 1.69 Allowed 'General case' 0 N--CA 1.485 1.314 0 O-C-N 121.449 -0.782 . . . . 0.0 110.388 179.935 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 12.9 pt-20 -79.2 -43.22 24.3 Favored 'General case' 0 N--CA 1.494 1.744 0 O-C-N 121.152 -0.967 . . . . 0.0 110.243 -179.797 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 111.54 80.15 1.06 Allowed Glycine 0 N--CA 1.492 2.433 0 N-CA-C 109.582 -1.407 . . . . 0.0 109.582 179.739 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 33' ' ' CYS . . . . . . . . . . . . . 0.7 OUTLIER -79.68 133.22 36.37 Favored 'General case' 0 N--CA 1.497 1.894 0 O-C-N 121.264 -1.139 . . . . 0.0 109.362 179.66 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -78.5 -22.48 47.37 Favored 'General case' 0 N--CA 1.501 2.096 0 O-C-N 121.325 -0.859 . . . . 0.0 110.445 179.886 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 0.8 OUTLIER -130.68 165.51 22.7 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.381 -0.824 . . . . 0.0 109.814 179.554 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 36' ' ' ALA . . . . . . . . . . . . . . . -93.28 -39.91 10.72 Favored 'General case' 0 N--CA 1.493 1.679 0 O-C-N 121.462 -0.774 . . . . 0.0 109.644 179.403 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 6.2 tt0 -79.27 -53.85 6.54 Favored 'General case' 0 N--CA 1.495 1.81 0 O-C-N 121.525 -0.735 . . . . 0.0 109.844 179.713 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -75.87 63.09 2.8 Favored Glycine 0 N--CA 1.498 2.792 0 N-CA-C 109.557 -1.417 . . . . 0.0 109.557 179.887 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 39' ' ' CYS . . . . . . . . . . . . . 2.6 t -122.4 -63.49 1.28 Allowed 'General case' 0 N--CA 1.496 1.831 0 O-C-N 121.549 -0.971 . . . . 0.0 110.181 179.497 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 40' ' ' LEU . . . . . . . . . . . . . 1.9 pt? . . . . . 0 N--CA 1.497 1.898 0 O-C-N 121.196 -0.94 . . . . 0.0 110.547 179.139 . . . . . . . . 0 0 . 1 . 013 nuclear orig core ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 9.3 t . . . . . 0 N--CA 1.497 1.925 0 N-CA-C 110.023 -0.362 . . . . 0.0 110.023 . . . . . . . . . 0 0 . 1 . 013 nuclear orig core ' A' A ' 6' ' ' PRO . . . . . . . . . . . . . 52.7 Cg_endo -77.57 155.0 31.5 Favored 'Trans proline' 0 C--N 1.314 -1.28 0 O-C-N 123.666 1.351 . . . . 0.0 110.335 179.796 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 82.82 -50.47 4.39 Favored Glycine 0 N--CA 1.497 2.762 0 C-N-CA 120.118 -1.039 . . . . 0.0 110.601 179.717 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 8' ' ' CYS . . . . . 0.443 ' SG ' ' N ' ' A' ' 9' ' ' GLY . 12.0 p -78.71 -33.09 47.07 Favored 'General case' 0 N--CA 1.497 1.905 0 O-C-N 120.967 -1.314 . . . . 0.0 111.062 -179.36 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 9' ' ' GLY . . . . . 0.443 ' N ' ' SG ' ' A' ' 8' ' ' CYS . . . -79.76 -60.63 2.42 Favored Glycine 0 N--CA 1.497 2.708 0 N-CA-C 109.631 -1.387 . . . . 0.0 109.631 -179.486 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 10' ' ' GLN . . . . . . . . . . . . . 34.2 mt-30 -143.91 -62.6 0.39 Allowed 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.438 -1.037 . . . . 0.0 110.754 -179.813 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 89.25 -68.56 2.7 Favored Glycine 0 N--CA 1.495 2.598 0 N-CA-C 108.962 -1.655 . . . . 0.0 108.962 -179.271 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 41.0 t -136.51 -94.06 0.04 OUTLIER 'Isoleucine or valine' 0 N--CA 1.496 1.85 0 O-C-N 121.657 -0.908 . . . . 0.0 109.715 179.287 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 13' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -166.86 30.76 0.04 OUTLIER 'General case' 0 N--CA 1.499 1.977 0 O-C-N 120.825 -1.172 . . . . 0.0 110.875 179.824 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -154.02 136.44 15.01 Favored 'General case' 0 N--CA 1.496 1.843 0 O-C-N 121.107 -0.996 . . . . 0.0 110.459 179.986 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -108.2 65.52 0.25 Allowed Glycine 0 N--CA 1.495 2.592 0 N-CA-C 109.788 -1.325 . . . . 0.0 109.788 179.881 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 60.6 m -80.51 114.01 44.12 Favored Pre-proline 0 N--CA 1.499 2.019 0 O-C-N 121.719 -0.871 . . . . 0.0 109.975 179.641 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 45.0 Cg_endo -70.07 89.22 0.56 Allowed 'Trans proline' 0 N--CA 1.49 1.318 0 O-C-N 123.722 1.38 . . . . 0.0 110.767 -179.931 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 108.58 -16.83 34.03 Favored Glycine 0 N--CA 1.495 2.582 0 N-CA-C 110.361 -1.096 . . . . 0.0 110.361 179.886 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 117.92 138.41 5.99 Favored Glycine 0 N--CA 1.489 2.231 0 N-CA-C 108.675 -1.77 . . . . 0.0 108.675 -179.314 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 6.0 p -124.65 -2.66 7.86 Favored 'General case' 0 N--CA 1.497 1.911 0 O-C-N 121.435 -1.038 . . . . 0.0 112.076 -179.622 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 12.1 p -160.07 39.81 0.02 OUTLIER 'Isoleucine or valine' 0 N--CA 1.497 1.894 0 O-C-N 120.581 -1.324 . . . . 0.0 110.353 -179.803 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 13.4 mm-40 -98.94 46.23 0.99 Allowed 'General case' 0 N--CA 1.487 1.408 0 O-C-N 120.84 -1.162 . . . . 0.0 111.089 -179.621 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER 43.02 68.4 0.51 Allowed 'General case' 0 N--CA 1.505 2.294 0 CA-C-O 121.409 0.623 . . . . 0.0 111.528 179.617 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 2.7 tt0 -80.6 -57.38 3.6 Favored 'General case' 0 N--CA 1.494 1.761 0 O-C-N 120.983 -1.073 . . . . 0.0 109.904 179.987 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 3.1 t70 -160.25 176.72 11.41 Favored 'General case' 0 N--CA 1.489 1.522 0 N-CA-C 108.838 -0.801 . . . . 0.0 108.838 179.136 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 62.06 39.75 98.02 Favored Glycine 0 N--CA 1.493 2.484 0 N-CA-C 109.658 -1.377 . . . . 0.0 109.658 179.683 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -58.16 -29.96 63.39 Favored Glycine 0 N--CA 1.497 2.738 0 N-CA-C 110.076 -1.21 . . . . 0.0 110.076 179.962 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 1.1 m -79.19 163.58 59.0 Favored Pre-proline 0 N--CA 1.5 2.035 0 O-C-N 121.338 -1.096 . . . . 0.0 109.515 179.467 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 44.1 Cg_endo -69.89 68.88 1.75 Allowed 'Trans proline' 0 C--N 1.308 -1.578 0 O-C-N 123.268 1.141 . . . . 0.0 110.937 -179.747 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -99.5 -40.25 7.94 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.245 -0.909 . . . . 0.0 110.537 -179.958 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 4.4 tt0 -78.98 -9.61 59.58 Favored 'General case' 0 N--CA 1.494 1.74 0 O-C-N 121.503 -0.748 . . . . 0.0 111.12 -179.754 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . -73.23 -38.59 53.87 Favored Glycine 0 N--CA 1.497 2.76 0 N-CA-C 110.198 -1.161 . . . . 0.0 110.198 -179.839 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 33' ' ' CYS . . . . . 0.406 ' HB2' ' O ' ' A' ' 38' ' ' GLY . 0.8 OUTLIER -127.22 94.0 3.89 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.544 -0.974 . . . . 0.0 109.976 179.684 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -123.04 35.29 4.91 Favored 'General case' 0 N--CA 1.495 1.78 0 O-C-N 121.699 -0.626 . . . . 0.0 109.681 179.552 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 2.2 mp0 -78.5 -144.57 0.03 OUTLIER 'General case' 0 N--CA 1.502 2.126 0 O-C-N 121.814 -0.554 . . . . 0.0 109.824 -179.782 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 36' ' ' ALA . . . . . . . . . . . . . . . -76.95 -25.89 53.37 Favored 'General case' 0 N--CA 1.492 1.634 0 O-C-N 121.022 -1.048 . . . . 0.0 109.795 -179.822 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 6.0 tt0 -99.81 -40.04 7.92 Favored 'General case' 0 N--CA 1.497 1.884 0 O-C-N 121.321 -0.862 . . . . 0.0 110.131 179.111 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 38' ' ' GLY . . . . . 0.406 ' O ' ' HB2' ' A' ' 33' ' ' CYS . . . 81.37 -119.5 4.88 Favored Glycine 0 N--CA 1.487 2.079 0 N-CA-C 109.355 -1.498 . . . . 0.0 109.355 -179.881 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 39' ' ' CYS . . . . . . . . . . . . . 1.0 OUTLIER -152.67 43.81 0.66 Allowed 'General case' 0 N--CA 1.495 1.804 0 O-C-N 121.548 -0.972 . . . . 0.0 110.23 179.605 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 40' ' ' LEU . . . . . . . . . . . . . 71.4 mt . . . . . 0 N--CA 1.493 1.684 0 O-C-N 121.085 -1.01 . . . . 0.0 110.735 -179.502 . . . . . . . . 0 0 . 1 . 014 nuclear orig core ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 8.7 t . . . . . 0 N--CA 1.492 1.668 0 N-CA-C 109.472 -0.566 . . . . 0.0 109.472 . . . . . . . . . 0 0 . 1 . 014 nuclear orig core ' A' A ' 6' ' ' PRO . . . . . . . . . . . . . 44.2 Cg_endo -75.97 -58.27 0.05 OUTLIER 'Trans proline' 0 C--N 1.314 -1.284 0 O-C-N 124.195 1.629 . . . . 0.0 111.161 -179.704 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -76.02 57.02 3.15 Favored Glycine 0 N--CA 1.498 2.811 0 N-CA-C 110.111 -1.196 . . . . 0.0 110.111 -179.77 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 0.8 OUTLIER -113.91 12.66 18.17 Favored 'General case' 0 N--CA 1.495 1.794 0 O-C-N 121.11 -1.229 . . . . 0.0 110.335 179.131 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -116.61 160.37 13.47 Favored Glycine 0 N--CA 1.494 2.534 0 N-CA-C 108.26 -1.936 . . . . 0.0 108.26 179.195 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 10' ' ' GLN . . . . . . . . . . . . . 4.8 mt-30 55.05 31.43 16.17 Favored 'General case' 0 N--CA 1.502 2.16 0 O-C-N 121.574 -0.957 . . . . 0.0 110.639 -179.635 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -76.58 53.04 3.2 Favored Glycine 0 N--CA 1.496 2.699 0 N-CA-C 110.064 -1.214 . . . . 0.0 110.064 -179.822 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 10.0 p -98.89 36.11 0.18 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.722 0 O-C-N 121.351 -1.088 . . . . 0.0 110.32 -179.8 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 13' ' ' GLN . . . . . . . . . . . . . 2.0 tt0 56.48 15.42 2.03 Favored 'General case' 0 N--CA 1.502 2.174 0 O-C-N 121.316 -0.865 . . . . 0.0 111.796 179.814 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . 46.15 36.26 3.08 Favored 'General case' 0 N--CA 1.502 2.172 0 O-C-N 121.274 -0.891 . . . . 0.0 110.663 -179.496 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -95.46 -50.22 2.05 Favored Glycine 0 N--CA 1.493 2.463 0 N-CA-C 109.961 -1.256 . . . . 0.0 109.961 -179.353 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 96.6 m -111.57 80.83 2.93 Favored Pre-proline 0 N--CA 1.497 1.922 0 O-C-N 121.126 -1.22 . . . . 0.0 110.406 -179.629 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 43.5 Cg_endo -74.48 100.9 1.37 Allowed 'Trans proline' 0 C--N 1.312 -1.358 0 O-C-N 123.769 1.405 . . . . 0.0 109.993 179.808 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 114.94 -38.68 3.04 Favored Glycine 0 N--CA 1.496 2.663 0 N-CA-C 110.184 -1.167 . . . . 0.0 110.184 -179.798 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 179.07 144.92 5.95 Favored Glycine 0 N--CA 1.487 2.055 0 N-CA-C 108.973 -1.651 . . . . 0.0 108.973 -179.742 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -108.64 43.58 1.23 Allowed 'General case' 0 N--CA 1.496 1.86 0 O-C-N 121.625 -0.927 . . . . 0.0 110.125 -179.935 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 0.1 OUTLIER -146.09 52.8 0.12 Allowed 'Isoleucine or valine' 0 N--CA 1.496 1.869 0 O-C-N 121.547 -0.721 . . . . 0.0 109.19 179.656 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 2.2 mp0 -79.32 -30.07 42.66 Favored 'General case' 0 N--CA 1.488 1.472 0 O-C-N 121.602 -0.686 . . . . 0.0 111.233 -178.842 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 10.9 tt0 -161.44 108.8 1.44 Allowed 'General case' 0 N--CA 1.493 1.693 0 O-C-N 121.178 -0.951 . . . . 0.0 110.51 -179.709 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 0.8 OUTLIER -89.73 155.26 19.32 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.223 -0.923 . . . . 0.0 109.909 179.438 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 8.8 p-10 -79.05 -33.95 44.24 Favored 'General case' 0 N--CA 1.498 1.96 0 O-C-N 121.359 -0.838 . . . . 0.0 110.7 -179.953 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -55.19 -46.87 77.32 Favored Glycine 0 N--CA 1.495 2.632 0 N-CA-C 110.36 -1.096 . . . . 0.0 110.36 -179.91 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -98.47 61.79 0.86 Allowed Glycine 0 N--CA 1.495 2.619 0 N-CA-C 109.904 -1.279 . . . . 0.0 109.904 -179.743 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 1.6 m -112.57 92.63 20.4 Favored Pre-proline 0 N--CA 1.497 1.918 0 O-C-N 121.318 -1.107 . . . . 0.0 110.578 179.998 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 52.1 Cg_endo -78.8 133.92 11.7 Favored 'Trans proline' 0 C--N 1.316 -1.181 0 O-C-N 123.817 1.43 . . . . 0.0 110.475 179.723 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -127.11 56.99 1.49 Allowed 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.357 -0.84 . . . . 0.0 110.436 179.761 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 10.0 tt0 -160.75 -48.55 0.05 OUTLIER 'General case' 0 N--CA 1.495 1.808 0 O-C-N 121.338 -0.851 . . . . 0.0 110.733 179.557 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . -59.23 -27.15 62.43 Favored Glycine 0 N--CA 1.497 2.713 0 O-C-N 121.514 -0.741 . . . . 0.0 111.524 -179.394 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 33' ' ' CYS . . . . . 0.41 ' O ' ' HB3' ' A' ' 39' ' ' CYS . 26.0 p -79.12 68.55 5.12 Favored 'General case' 0 N--CA 1.498 1.961 0 O-C-N 120.821 -1.399 . . . . 0.0 110.315 -179.556 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -92.39 33.28 1.11 Allowed 'General case' 0 N--CA 1.496 1.855 0 O-C-N 120.888 -1.133 . . . . 0.0 110.626 179.771 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 4.8 mp0 -97.4 -178.5 4.17 Favored 'General case' 0 N--CA 1.492 1.648 0 O-C-N 121.16 -0.963 . . . . 0.0 110.351 -179.968 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 36' ' ' ALA . . . . . . . . . . . . . . . -87.86 28.66 1.0 Allowed 'General case' 0 N--CA 1.498 1.957 0 O-C-N 121.045 -1.034 . . . . 0.0 111.227 -179.807 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 13.6 pt-20 -78.91 -17.57 55.31 Favored 'General case' 0 N--CA 1.493 1.721 0 O-C-N 121.046 -1.033 . . . . 0.0 110.895 179.329 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 122.45 10.22 6.14 Favored Glycine 0 N--CA 1.496 2.673 0 N-CA-C 110.148 -1.181 . . . . 0.0 110.148 -179.533 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 39' ' ' CYS . . . . . 0.41 ' HB3' ' O ' ' A' ' 33' ' ' CYS . 0.1 OUTLIER -79.35 -25.26 42.3 Favored 'General case' 0 N--CA 1.501 2.08 0 O-C-N 120.876 -1.367 . . . . 0.0 110.369 179.78 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 40' ' ' LEU . . . . . . . . . . . . . 0.9 OUTLIER . . . . . 0 N--CA 1.491 1.578 0 O-C-N 121.024 -1.047 . . . . 0.0 110.851 -179.721 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 31.2 p . . . . . 0 N--CA 1.494 1.763 0 CA-C-O 120.385 0.136 . . . . 0.0 110.652 . . . . . . . . . 0 0 . 1 . 015 nuclear orig core ' A' A ' 6' ' ' PRO . . . . . . . . . . . . . 47.3 Cg_endo -77.95 121.49 5.43 Favored 'Trans proline' 0 C--N 1.315 -1.189 0 O-C-N 123.899 1.473 . . . . 0.0 110.903 -179.549 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 96.64 12.64 50.06 Favored Glycine 0 N--CA 1.496 2.68 0 N-CA-C 110.734 -0.946 . . . . 0.0 110.734 179.536 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 0.8 OUTLIER -160.5 172.32 17.42 Favored 'General case' 0 N--CA 1.496 1.852 0 O-C-N 120.75 -1.441 . . . . 0.0 110.171 -179.47 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 115.75 -173.26 14.64 Favored Glycine 0 N--CA 1.494 2.55 0 N-CA-C 109.599 -1.4 . . . . 0.0 109.599 -179.871 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 10' ' ' GLN . . . . . . . . . . . . . 4.4 mt-30 -89.14 50.29 1.92 Allowed 'General case' 0 N--CA 1.492 1.659 0 O-C-N 121.279 -1.13 . . . . 0.0 110.381 179.939 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -83.19 60.66 4.87 Favored Glycine 0 N--CA 1.495 2.573 0 N-CA-C 109.744 -1.342 . . . . 0.0 109.744 179.974 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 9.0 p -135.43 25.33 0.93 Allowed 'Isoleucine or valine' 0 N--CA 1.496 1.851 0 O-C-N 121.334 -1.097 . . . . 0.0 110.805 179.904 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 13' ' ' GLN . . . . . . . . . . . . . 0.2 OUTLIER -71.73 -14.64 62.07 Favored 'General case' 0 N--CA 1.498 1.96 0 O-C-N 120.938 -1.101 . . . . 0.0 111.461 -179.782 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . 59.63 82.85 0.14 Allowed 'General case' 0 N--CA 1.502 2.165 0 O-C-N 121.17 -0.957 . . . . 0.0 110.583 -179.915 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -125.36 75.95 0.4 Allowed Glycine 0 N--CA 1.492 2.424 0 N-CA-C 109.045 -1.622 . . . . 0.0 109.045 179.665 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 10.7 m -78.4 118.32 71.62 Favored Pre-proline 0 N--CA 1.496 1.866 0 O-C-N 121.29 -1.124 . . . . 0.0 109.709 -179.863 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 40.7 Cg_endo -68.25 -41.2 7.3 Favored 'Trans proline' 0 C--N 1.316 -1.139 0 O-C-N 123.855 1.45 . . . . 0.0 111.32 -179.498 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . -176.22 60.87 0.1 Allowed Glycine 0 N--CA 1.496 2.66 0 N-CA-C 109.796 -1.322 . . . . 0.0 109.796 179.994 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 162.61 75.19 0.02 OUTLIER Glycine 0 N--CA 1.493 2.495 0 N-CA-C 109.539 -1.424 . . . . 0.0 109.539 179.72 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 0.3 OUTLIER -105.86 -40.09 5.82 Favored 'General case' 0 N--CA 1.495 1.803 0 O-C-N 121.191 -1.182 . . . . 0.0 110.647 -179.516 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 3.6 t -107.7 56.27 0.14 Allowed 'Isoleucine or valine' 0 N--CA 1.497 1.903 0 O-C-N 121.319 -0.863 . . . . 0.0 110.186 179.923 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER -79.72 46.2 0.75 Allowed 'General case' 0 N--CA 1.495 1.823 0 O-C-N 120.979 -1.075 . . . . 0.0 110.479 179.827 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 23' ' ' GLU . . . . . 0.474 ' HG3' ' N ' ' A' ' 24' ' ' GLU . 6.7 pt-20 -128.0 -29.41 2.55 Favored 'General case' 0 N--CA 1.493 1.676 0 O-C-N 121.06 -1.025 . . . . 0.0 110.964 179.318 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 24' ' ' GLU . . . . . 0.474 ' N ' ' HG3' ' A' ' 23' ' ' GLU . 10.7 mt-10 57.76 177.38 0.05 Allowed 'General case' 0 N--CA 1.498 1.952 0 O-C-N 121.513 -0.742 . . . . 0.0 111.8 179.401 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 1.2 p-10 -102.81 -36.53 8.23 Favored 'General case' 0 N--CA 1.495 1.802 0 O-C-N 121.122 -0.986 . . . . 0.0 110.433 -179.302 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 118.55 92.03 1.47 Allowed Glycine 0 N--CA 1.49 2.27 0 N-CA-C 108.891 -1.684 . . . . 0.0 108.891 -179.484 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -59.01 105.85 0.77 Allowed Glycine 0 N--CA 1.494 2.545 0 N-CA-C 109.636 -1.386 . . . . 0.0 109.636 -179.564 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 28' ' ' SER . . . . . 0.492 ' N ' ' HD2' ' A' ' 29' ' ' PRO . 0.0 OUTLIER -79.5 -49.3 1.4 Allowed Pre-proline 0 N--CA 1.496 1.837 0 O-C-N 121.536 -0.979 . . . . 0.0 111.769 -179.007 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 29' ' ' PRO . . . . . 0.492 ' HD2' ' N ' ' A' ' 28' ' ' SER . 44.2 Cg_endo -72.21 60.83 3.24 Favored 'Trans proline' 0 N--CA 1.49 1.292 0 O-C-N 123.159 1.083 . . . . 0.0 111.478 -179.197 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -121.74 47.62 1.84 Allowed 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.148 -0.97 . . . . 0.0 110.096 179.421 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 1.2 tp10 -80.46 -68.65 0.66 Allowed 'General case' 0 N--CA 1.493 1.706 0 O-C-N 121.494 -0.754 . . . . 0.0 109.885 -179.664 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 116.56 76.2 0.6 Allowed Glycine 0 N--CA 1.494 2.53 0 N-CA-C 109.766 -1.334 . . . . 0.0 109.766 179.943 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 33' ' ' CYS . . . . . . . . . . . . . 10.4 p -79.09 127.5 32.09 Favored 'General case' 0 N--CA 1.496 1.85 0 O-C-N 121.632 -0.922 . . . . 0.0 109.687 179.462 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -144.77 17.72 1.63 Allowed 'General case' 0 N--CA 1.499 1.989 0 O-C-N 121.385 -0.822 . . . . 0.0 110.543 -179.904 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 1.5 mp0 -90.8 -163.8 1.08 Allowed 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.395 -0.816 . . . . 0.0 110.472 -179.566 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 36' ' ' ALA . . . . . . . . . . . . . . . -88.15 43.05 1.1 Allowed 'General case' 0 N--CA 1.499 1.988 0 O-C-N 121.123 -0.986 . . . . 0.0 111.44 -179.275 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 1.9 pt-20 -138.39 9.73 2.71 Favored 'General case' 0 N--CA 1.494 1.759 0 O-C-N 121.261 -0.9 . . . . 0.0 110.956 179.254 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 68.39 -108.63 2.53 Favored Glycine 0 N--CA 1.495 2.615 0 N-CA-C 108.869 -1.692 . . . . 0.0 108.869 -179.657 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 39' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -160.64 -54.86 0.05 Allowed 'General case' 0 N--CA 1.498 1.96 0 O-C-N 121.154 -1.204 . . . . 0.0 110.376 179.321 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 40' ' ' LEU . . . . . . . . . . . . . 6.3 tt . . . . . 0 N--CA 1.494 1.764 0 O-C-N 121.271 -0.893 . . . . 0.0 111.104 -179.888 . . . . . . . . 0 0 . 1 . 016 nuclear orig core ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 8.5 t . . . . . 0 N--CA 1.496 1.828 0 N-CA-C 109.475 -0.565 . . . . 0.0 109.475 . . . . . . . . . 0 0 . 1 . 016 nuclear orig core ' A' A ' 6' ' ' PRO . . . . . . . . . . . . . 44.1 Cg_endo -73.14 106.86 2.24 Favored 'Trans proline' 0 C--N 1.312 -1.356 0 O-C-N 123.891 1.469 . . . . 0.0 111.162 -179.267 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 66.69 49.07 58.0 Favored Glycine 0 N--CA 1.496 2.659 0 N-CA-C 110.515 -1.034 . . . . 0.0 110.515 179.154 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -84.93 178.57 7.55 Favored 'General case' 0 N--CA 1.5 2.038 0 O-C-N 121.212 -1.17 . . . . 0.0 110.47 179.676 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -74.34 150.97 42.83 Favored Glycine 0 N--CA 1.491 2.311 0 N-CA-C 109.763 -1.335 . . . . 0.0 109.763 179.961 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 10' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -79.23 50.08 1.03 Allowed 'General case' 0 N--CA 1.496 1.875 0 O-C-N 121.591 -0.946 . . . . 0.0 110.773 -179.953 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -79.7 -57.06 3.17 Favored Glycine 0 N--CA 1.492 2.41 0 N-CA-C 109.612 -1.395 . . . . 0.0 109.612 179.929 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 12' ' ' VAL . . . . . 0.406 HG12 ' O ' ' A' ' 12' ' ' VAL . 7.4 p -137.17 65.69 0.25 Allowed 'Isoleucine or valine' 0 N--CA 1.496 1.85 0 O-C-N 121.466 -1.02 . . . . 0.0 110.35 -179.99 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 13' ' ' GLN . . . . . . . . . . . . . 2.6 tp-100 -80.22 -36.87 34.16 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.226 -0.921 . . . . 0.0 110.404 179.712 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -94.83 167.07 11.66 Favored 'General case' 0 N--CA 1.494 1.75 0 O-C-N 121.593 -0.692 . . . . 0.0 110.256 179.976 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -60.12 -34.19 82.92 Favored Glycine 0 N--CA 1.497 2.76 0 N-CA-C 110.228 -1.149 . . . . 0.0 110.228 179.608 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 16' ' ' CYS . . . . . 0.443 ' HB2' ' HB2' ' A' ' 20' ' ' CYS . 0.0 OUTLIER -110.01 96.86 26.98 Favored Pre-proline 0 N--CA 1.496 1.851 0 O-C-N 120.714 -1.462 . . . . 0.0 109.614 179.403 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 41.2 Cg_endo -68.43 111.26 2.48 Favored 'Trans proline' 0 C--N 1.311 -1.424 0 O-C-N 123.837 1.44 . . . . 0.0 111.079 -179.59 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 62.68 20.02 61.26 Favored Glycine 0 N--CA 1.496 2.685 0 N-CA-C 110.654 -0.978 . . . . 0.0 110.654 179.857 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -157.93 54.2 0.38 Allowed Glycine 0 N--CA 1.498 2.771 0 N-CA-C 109.741 -1.344 . . . . 0.0 109.741 -179.808 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 20' ' ' CYS . . . . . 0.443 ' HB2' ' HB2' ' A' ' 16' ' ' CYS . 0.8 OUTLIER -125.95 93.87 3.95 Favored 'General case' 0 N--CA 1.497 1.914 0 O-C-N 121.362 -1.081 . . . . 0.0 109.527 179.686 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 22.5 m -122.27 41.04 0.77 Allowed 'Isoleucine or valine' 0 N--CA 1.494 1.745 0 CA-C-O 121.268 0.556 . . . . 0.0 110.879 -179.211 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 2.8 mt-10 -110.6 44.99 1.18 Allowed 'General case' 0 C--N 1.307 -1.275 0 O-C-N 121.371 -0.83 . . . . 0.0 109.865 179.374 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 1.3 tp10 -101.2 -57.3 2.12 Favored 'General case' 0 N--CA 1.492 1.671 0 O-C-N 121.32 -0.863 . . . . 0.0 110.225 -179.824 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 1.0 OUTLIER -72.77 154.4 40.67 Favored 'General case' 0 N--CA 1.499 1.99 0 O-C-N 121.523 -0.735 . . . . 0.0 110.466 -179.744 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 4.1 p-10 -95.25 36.84 1.2 Allowed 'General case' 0 N--CA 1.502 2.134 0 O-C-N 121.353 -0.842 . . . . 0.0 111.357 179.956 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 154.96 -90.47 0.12 Allowed Glycine 0 N--CA 1.492 2.426 0 N-CA-C 109.719 -1.353 . . . . 0.0 109.719 178.922 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -138.15 141.81 12.51 Favored Glycine 0 N--CA 1.498 2.817 0 N-CA-C 109.799 -1.32 . . . . 0.0 109.799 -179.803 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 28' ' ' SER . . . . . 0.452 ' OG ' ' HD2' ' A' ' 29' ' ' PRO . 23.0 t -84.94 154.43 60.92 Favored Pre-proline 0 C--N 1.301 -1.535 0 O-C-N 121.285 -1.126 . . . . 0.0 109.854 179.759 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 29' ' ' PRO . . . . . 0.452 ' HD2' ' OG ' ' A' ' 28' ' ' SER . 37.9 Cg_endo -65.51 -26.87 54.41 Favored 'Trans proline' 0 C--N 1.308 -1.584 0 O-C-N 123.353 1.186 . . . . 0.0 109.819 179.03 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -93.59 24.2 4.19 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.592 -0.693 . . . . 0.0 110.446 179.182 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 1.7 tp10 -83.26 -7.99 59.52 Favored 'General case' 0 N--CA 1.495 1.822 0 O-C-N 121.376 -0.827 . . . . 0.0 111.106 -179.883 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 77.62 29.0 56.28 Favored Glycine 0 N--CA 1.494 2.542 0 N-CA-C 109.404 -1.478 . . . . 0.0 109.404 -179.481 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 33' ' ' CYS . . . . . . . . . . . . . 0.0 OUTLIER -161.64 43.86 0.16 Allowed 'General case' 0 N--CA 1.498 1.929 0 O-C-N 121.411 -1.052 . . . . 0.0 109.861 179.842 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -109.39 -49.44 3.11 Favored 'General case' 0 N--CA 1.498 1.943 0 O-C-N 120.919 -1.113 . . . . 0.0 111.21 -179.342 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 35.1 mt-10 -95.02 -167.45 1.63 Allowed 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.051 -1.031 . . . . 0.0 110.369 -179.217 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 36' ' ' ALA . . . . . . . . . . . . . . . -82.27 44.07 0.84 Allowed 'General case' 0 N--CA 1.497 1.89 0 O-C-N 121.299 -0.876 . . . . 0.0 110.316 179.563 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 3.2 pt-20 -79.67 -13.29 59.58 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.43 -0.794 . . . . 0.0 110.327 179.297 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 132.34 38.12 0.26 Allowed Glycine 0 N--CA 1.502 3.074 0 C-N-CA 120.159 -1.02 . . . . 0.0 111.103 179.389 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 39' ' ' CYS . . . . . . . . . . . . . 13.5 t -93.51 -47.41 6.86 Favored 'General case' 0 N--CA 1.493 1.715 0 O-C-N 121.357 -1.084 . . . . 0.0 110.196 179.76 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 40' ' ' LEU . . . . . . . . . . . . . 7.9 mt . . . . . 0 N--CA 1.488 1.465 0 O-C-N 121.136 -0.977 . . . . 0.0 110.314 179.952 . . . . . . . . 0 0 . 1 . 017 nuclear orig core ' A' A ' 5' ' ' CYS . . . . . 0.487 ' O ' ' SG ' ' A' ' 8' ' ' CYS . 1.3 p . . . . . 0 N--CA 1.496 1.859 0 CA-C-O 120.572 0.225 . . . . 0.0 110.41 . . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 6' ' ' PRO . . . . . . . . . . . . . 49.6 Cg_endo -77.54 -50.43 0.09 OUTLIER 'Trans proline' 0 C--N 1.311 -1.396 0 O-C-N 123.552 1.29 . . . . 0.0 111.173 179.488 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -105.2 67.31 0.27 Allowed Glycine 0 N--CA 1.494 2.54 0 N-CA-C 110.239 -1.144 . . . . 0.0 110.239 -179.545 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 8' ' ' CYS . . . . . 0.487 ' SG ' ' O ' ' A' ' 5' ' ' CYS . 3.5 m -86.56 138.04 32.03 Favored 'General case' 0 N--CA 1.494 1.766 0 O-C-N 121.308 -1.113 . . . . 0.0 109.404 179.107 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 114.18 88.51 1.62 Allowed Glycine 0 N--CA 1.492 2.416 0 N-CA-C 109.165 -1.574 . . . . 0.0 109.165 -179.486 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 10' ' ' GLN . . . . . . . . . . . . . 4.1 mt-30 51.62 33.38 10.65 Favored 'General case' 0 N--CA 1.507 2.383 0 O-C-N 121.647 -0.913 . . . . 0.0 111.161 -179.558 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -110.27 -40.36 1.39 Allowed Glycine 0 N--CA 1.496 2.693 0 N-CA-C 109.659 -1.377 . . . . 0.0 109.659 179.761 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 43.6 t -79.16 -47.71 22.23 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.822 0 O-C-N 121.39 -1.065 . . . . 0.0 110.485 179.905 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 13' ' ' GLN . . . . . . . . . . . . . 7.1 tt0 -72.86 133.84 44.59 Favored 'General case' 0 N--CA 1.494 1.735 0 O-C-N 121.054 -1.029 . . . . 0.0 110.244 179.887 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -102.76 -164.08 1.05 Allowed 'General case' 0 N--CA 1.495 1.784 0 O-C-N 121.524 -0.735 . . . . 0.0 109.697 179.602 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -168.71 -105.33 0.18 Allowed Glycine 0 N--CA 1.496 2.649 0 N-CA-C 109.348 -1.501 . . . . 0.0 109.348 179.886 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 16' ' ' CYS . . . . . 0.52 ' SG ' ' N ' ' A' ' 20' ' ' CYS . 0.0 OUTLIER -115.03 98.26 49.91 Favored Pre-proline 0 N--CA 1.49 1.538 0 O-C-N 121.328 -1.101 . . . . 0.0 109.8 179.855 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 48.0 Cg_endo -77.36 60.92 7.2 Favored 'Trans proline' 0 C--N 1.31 -1.458 0 O-C-N 123.572 1.301 . . . . 0.0 109.559 179.251 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 91.4 -20.61 39.87 Favored Glycine 0 N--CA 1.493 2.447 0 N-CA-C 109.605 -1.398 . . . . 0.0 109.605 -178.471 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -99.24 68.8 0.58 Allowed Glycine 0 N--CA 1.496 2.636 0 O-C-N 120.606 -1.526 . . . . 0.0 109.677 -179.901 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 20' ' ' CYS . . . . . 0.52 ' N ' ' SG ' ' A' ' 16' ' ' CYS . 16.3 m -82.17 143.35 31.48 Favored 'General case' 0 N--CA 1.488 1.473 0 O-C-N 121.308 -1.113 . . . . 0.0 109.262 179.803 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 35.7 m -77.88 -21.18 13.72 Favored 'Isoleucine or valine' 0 N--CA 1.503 2.176 0 O-C-N 121.888 -0.508 . . . . 0.0 111.685 -179.137 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 4.1 pt-20 -88.36 15.09 8.26 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.127 -0.983 . . . . 0.0 111.141 179.494 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 3.0 mm-40 -134.21 24.63 3.85 Favored 'General case' 0 N--CA 1.494 1.744 0 O-C-N 120.975 -1.078 . . . . 0.0 110.549 179.482 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 13.9 mm-40 -85.38 -2.83 58.52 Favored 'General case' 0 N--CA 1.494 1.759 0 O-C-N 121.093 -1.004 . . . . 0.0 111.563 -179.717 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 3.8 p-10 -104.98 19.69 20.15 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 120.68 -1.263 . . . . 0.0 109.999 179.972 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -72.45 56.28 1.6 Allowed Glycine 0 N--CA 1.489 2.174 0 N-CA-C 109.31 -1.516 . . . . 0.0 109.31 179.386 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 115.98 9.37 12.25 Favored Glycine 0 N--CA 1.501 3.004 0 O-C-N 121.32 -1.106 . . . . 0.0 110.378 -179.61 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -108.47 92.89 10.66 Favored Pre-proline 0 N--CA 1.493 1.718 0 O-C-N 120.899 -1.354 . . . . 0.0 109.822 179.683 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 43.9 Cg_endo -72.87 71.5 3.38 Favored 'Trans proline' 0 N--CA 1.489 1.238 0 O-C-N 123.472 1.249 . . . . 0.0 110.483 -179.751 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -108.18 61.3 0.61 Allowed 'General case' 0 N--CA 1.488 1.437 0 O-C-N 121.272 -0.893 . . . . 0.0 110.219 -179.86 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 2.1 tt0 -78.76 -28.14 44.79 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.369 -0.832 . . . . 0.0 110.569 -179.749 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 74.57 46.9 17.38 Favored Glycine 0 N--CA 1.489 2.178 0 N-CA-C 110.377 -1.089 . . . . 0.0 110.377 179.255 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 33' ' ' CYS . . . . . . . . . . . . . 14.1 m -79.84 87.56 5.3 Favored 'General case' 0 N--CA 1.497 1.921 0 O-C-N 120.931 -1.335 . . . . 0.0 109.782 179.624 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -102.87 -61.19 1.43 Allowed 'General case' 0 N--CA 1.493 1.689 0 O-C-N 121.503 -0.748 . . . . 0.0 110.201 -179.787 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 1.3 pm0 -85.18 -169.5 2.68 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.445 -0.784 . . . . 0.0 110.533 -179.747 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 36' ' ' ALA . . . . . . . . . . . . . . . -107.93 35.5 3.1 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.013 -1.055 . . . . 0.0 110.232 179.849 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -110.64 -55.36 2.49 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.181 -0.949 . . . . 0.0 110.26 179.948 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -68.38 -41.32 85.71 Favored Glycine 0 N--CA 1.497 2.713 0 N-CA-C 109.546 -1.421 . . . . 0.0 109.546 179.859 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 39' ' ' CYS . . . . . . . . . . . . . 1.6 p -156.82 84.67 0.96 Allowed 'General case' 0 N--CA 1.497 1.915 0 O-C-N 121.412 -1.052 . . . . 0.0 110.119 -179.766 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 40' ' ' LEU . . . . . . . . . . . . . 1.4 pp . . . . . 0 N--CA 1.498 1.958 0 O-C-N 121.312 -0.868 . . . . 0.0 110.611 -179.751 . . . . . . . . 0 0 . 1 . 018 nuclear orig core ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 3.3 p . . . . . 0 N--CA 1.495 1.802 0 N-CA-C 109.475 -0.565 . . . . 0.0 109.475 . . . . . . . . . 0 0 . 1 . 018 nuclear orig core ' A' A ' 6' ' ' PRO . . . . . . . . . . . . . 42.1 Cg_endo -69.06 -43.98 2.87 Favored 'Trans proline' 0 C--N 1.312 -1.364 0 O-C-N 123.588 1.309 . . . . 0.0 111.534 -179.367 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -82.75 50.81 4.44 Favored Glycine 0 N--CA 1.495 2.624 0 N-CA-C 109.946 -1.262 . . . . 0.0 109.946 -179.975 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 1.7 m -119.06 -30.25 5.04 Favored 'General case' 0 N--CA 1.499 1.995 0 O-C-N 121.257 -1.143 . . . . 0.0 111.001 179.945 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 109.34 133.51 6.76 Favored Glycine 0 N--CA 1.493 2.483 0 N-CA-C 109.73 -1.348 . . . . 0.0 109.73 -179.802 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 10' ' ' GLN . . . . . . . . . . . . . 0.7 OUTLIER 45.39 49.71 10.33 Favored 'General case' 0 N--CA 1.501 2.125 0 O-C-N 121.953 -0.734 . . . . 0.0 111.053 179.499 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -86.93 -54.7 2.55 Favored Glycine 0 N--CA 1.496 2.675 0 N-CA-C 110.092 -1.203 . . . . 0.0 110.092 -179.848 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 9.0 p -138.03 48.08 0.35 Allowed 'Isoleucine or valine' 0 N--CA 1.495 1.784 0 O-C-N 121.275 -1.132 . . . . 0.0 110.413 179.93 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 13' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -81.82 -7.38 59.6 Favored 'General case' 0 N--CA 1.495 1.78 0 O-C-N 120.946 -1.096 . . . . 0.0 111.159 179.919 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -125.6 141.72 51.88 Favored 'General case' 0 N--CA 1.495 1.821 0 O-C-N 121.303 -0.873 . . . . 0.0 109.767 179.943 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -161.05 90.98 0.11 Allowed Glycine 0 N--CA 1.492 2.406 0 N-CA-C 109.372 -1.491 . . . . 0.0 109.372 179.697 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 13.4 m -94.69 152.71 40.02 Favored Pre-proline 0 N--CA 1.5 2.04 0 O-C-N 121.233 -1.157 . . . . 0.0 110.456 -179.95 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 48.2 Cg_endo -76.38 -147.81 0.03 OUTLIER 'Trans proline' 0 C--N 1.308 -1.554 0 O-C-N 123.779 1.41 . . . . 0.0 108.773 178.454 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . -62.92 -12.39 42.44 Favored Glycine 0 N--CA 1.498 2.767 0 O-C-N 120.878 -1.139 . . . . 0.0 110.898 179.574 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -151.18 115.4 0.7 Allowed Glycine 0 N--CA 1.494 2.536 0 N-CA-C 109.175 -1.57 . . . . 0.0 109.175 -179.705 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 4.8 t -84.56 -10.3 57.53 Favored 'General case' 0 N--CA 1.499 2.01 0 O-C-N 121.179 -1.189 . . . . 0.0 111.459 -179.834 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 8.6 p -129.36 26.21 1.9 Allowed 'Isoleucine or valine' 0 N--CA 1.499 1.997 0 O-C-N 121.045 -1.034 . . . . 0.0 111.027 -179.81 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 1.4 tp10 -105.72 -4.44 20.94 Favored 'General case' 0 N--CA 1.493 1.692 0 O-C-N 120.479 -1.388 . . . . 0.0 110.952 179.56 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 0.8 OUTLIER -138.14 -47.09 0.52 Allowed 'General case' 0 N--CA 1.492 1.673 0 O-C-N 121.064 -1.023 . . . . 0.0 110.712 179.697 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 1.1 mt-10 -59.95 115.84 3.71 Favored 'General case' 0 N--CA 1.494 1.747 0 O-C-N 121.482 -0.761 . . . . 0.0 110.079 -179.423 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 6.4 t0 -104.5 91.37 3.86 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.371 -0.831 . . . . 0.0 109.37 179.297 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -79.32 60.22 4.29 Favored Glycine 0 N--CA 1.496 2.676 0 N-CA-C 109.52 -1.432 . . . . 0.0 109.52 -179.296 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 177.45 -179.24 48.24 Favored Glycine 0 N--CA 1.493 2.49 0 N-CA-C 109.956 -1.258 . . . . 0.0 109.956 179.753 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -160.07 155.56 22.09 Favored Pre-proline 0 N--CA 1.494 1.73 0 O-C-N 121.381 -1.07 . . . . 0.0 110.187 179.854 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 40.2 Cg_endo -67.74 -40.72 9.35 Favored 'Trans proline' 0 N--CA 1.492 1.438 0 O-C-N 123.549 1.289 . . . . 0.0 110.17 179.484 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -92.97 47.95 1.31 Allowed 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.403 -0.811 . . . . 0.0 110.191 179.369 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 12.5 tt0 -77.85 -11.38 59.88 Favored 'General case' 0 N--CA 1.494 1.747 0 O-C-N 121.487 -0.758 . . . . 0.0 111.034 -179.87 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 98.16 84.44 1.76 Allowed Glycine 0 N--CA 1.489 2.22 0 N-CA-C 108.675 -1.77 . . . . 0.0 108.675 -179.668 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 33' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -79.02 65.45 4.2 Favored 'General case' 0 N--CA 1.493 1.714 0 O-C-N 121.166 -1.196 . . . . 0.0 110.051 -179.341 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -115.75 56.38 0.77 Allowed 'General case' 0 N--CA 1.496 1.832 0 O-C-N 121.469 -0.769 . . . . 0.0 109.75 179.697 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 1.1 tt0 -147.59 -162.3 1.52 Allowed 'General case' 0 N--CA 1.494 1.765 0 O-C-N 121.457 -0.777 . . . . 0.0 110.081 -179.363 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 36' ' ' ALA . . . . . . . . . . . . . . . -78.65 -30.85 46.57 Favored 'General case' 0 N--CA 1.494 1.727 0 O-C-N 121.464 -0.772 . . . . 0.0 109.108 179.029 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER -134.74 -74.32 0.47 Allowed 'General case' 0 N--CA 1.487 1.395 0 O-C-N 121.6 -0.687 . . . . 0.0 109.723 179.079 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 56.97 -99.27 0.09 OUTLIER Glycine 0 N--CA 1.496 2.685 0 N-CA-C 110.319 -1.113 . . . . 0.0 110.319 179.291 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 39' ' ' CYS . . . . . . . . . . . . . 2.5 p -99.49 6.56 45.88 Favored 'General case' 0 N--CA 1.497 1.912 0 O-C-N 121.792 -0.828 . . . . 0.0 111.612 -179.674 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 40' ' ' LEU . . . . . . . . . . . . . 1.5 mt . . . . . 0 N--CA 1.504 2.266 0 O-C-N 121.416 -0.802 . . . . 0.0 110.974 179.454 . . . . . . . . 0 0 . 1 . 019 nuclear orig core ' A' A ' 5' ' ' CYS . . . . . 0.438 ' SG ' ' N ' ' A' ' 8' ' ' CYS . 1.3 p . . . . . 0 N--CA 1.491 1.595 0 N-CA-C 109.941 -0.392 . . . . 0.0 109.941 . . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 6' ' ' PRO . . . . . . . . . . . . . 41.1 Cg_endo -68.2 -31.47 29.18 Favored 'Trans proline' 0 C--N 1.314 -1.246 0 O-C-N 123.637 1.335 . . . . 0.0 110.988 179.824 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -91.81 23.37 26.33 Favored Glycine 0 N--CA 1.494 2.547 0 N-CA-C 110.29 -1.124 . . . . 0.0 110.29 179.492 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 8' ' ' CYS . . . . . 0.438 ' N ' ' SG ' ' A' ' 5' ' ' CYS . 51.0 m -96.93 19.13 13.21 Favored 'General case' 0 N--CA 1.494 1.744 0 O-C-N 120.998 -1.295 . . . . 0.0 110.751 -179.904 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -79.28 -48.03 7.1 Favored Glycine 0 N--CA 1.492 2.415 0 N-CA-C 109.929 -1.268 . . . . 0.0 109.929 -179.653 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 10' ' ' GLN . . . . . . . . . . . . . 4.3 mt-30 -111.62 40.14 2.19 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 121.15 -1.206 . . . . 0.0 110.603 -179.62 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -84.43 63.39 4.43 Favored Glycine 0 N--CA 1.497 2.727 0 N-CA-C 109.861 -1.295 . . . . 0.0 109.861 179.883 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 13.3 m -134.98 48.61 0.41 Allowed 'Isoleucine or valine' 0 N--CA 1.501 2.087 0 O-C-N 121.393 -1.063 . . . . 0.0 110.652 179.923 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 13' ' ' GLN . . . . . . . . . . . . . 11.9 mt-30 -73.56 75.7 1.48 Allowed 'General case' 0 N--CA 1.498 1.936 0 O-C-N 121.074 -1.016 . . . . 0.0 110.454 179.944 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -110.13 -69.51 0.86 Allowed 'General case' 0 N--CA 1.498 1.939 0 O-C-N 121.288 -0.882 . . . . 0.0 110.563 -179.777 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -161.01 -105.1 0.2 Allowed Glycine 0 N--CA 1.493 2.445 0 N-CA-C 109.58 -1.408 . . . . 0.0 109.58 -179.674 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 0.0 OUTLIER -116.9 161.61 31.57 Favored Pre-proline 0 N--CA 1.501 2.101 0 O-C-N 121.253 -1.145 . . . . 0.0 109.61 179.438 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 42.2 Cg_endo -70.2 -59.27 0.08 OUTLIER 'Trans proline' 0 N--CA 1.489 1.225 0 O-C-N 123.825 1.434 . . . . 0.0 111.085 179.961 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . -108.05 -36.91 2.25 Favored Glycine 0 N--CA 1.495 2.602 0 N-CA-C 110.317 -1.113 . . . . 0.0 110.317 179.942 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 172.91 135.91 2.07 Favored Glycine 0 N--CA 1.492 2.426 0 N-CA-C 108.678 -1.769 . . . . 0.0 108.678 -179.923 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 4.1 m -78.57 64.83 3.7 Favored 'General case' 0 N--CA 1.5 2.03 0 O-C-N 121.413 -1.051 . . . . 0.0 110.506 -179.906 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 7.7 p -133.18 -46.06 0.6 Allowed 'Isoleucine or valine' 0 N--CA 1.498 1.956 0 O-C-N 121.468 -0.77 . . . . 0.0 109.759 179.088 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 23.4 mt-10 -89.18 33.86 0.8 Allowed 'General case' 0 C--N 1.306 -1.306 0 O-C-N 121.062 -1.024 . . . . 0.0 109.151 178.123 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -156.81 -75.55 0.09 Allowed 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.403 -0.81 . . . . 0.0 110.145 -179.406 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER 57.08 -165.18 0.15 Allowed 'General case' 0 N--CA 1.494 1.748 0 O-C-N 121.676 -0.64 . . . . 0.0 110.65 -179.899 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 3.3 m-20 -107.12 150.91 26.06 Favored 'General case' 0 N--CA 1.495 1.823 0 O-C-N 121.367 -0.833 . . . . 0.0 110.537 -179.666 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 88.19 -86.87 1.49 Allowed Glycine 0 N--CA 1.49 2.287 0 N-CA-C 110.194 -1.162 . . . . 0.0 110.194 179.295 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 69.86 64.16 3.04 Favored Glycine 0 N--CA 1.495 2.594 0 N-CA-C 109.127 -1.589 . . . . 0.0 109.127 -178.986 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 3.5 p -82.02 129.55 63.9 Favored Pre-proline 0 N--CA 1.499 1.987 0 O-C-N 120.859 -1.377 . . . . 0.0 110.868 -179.742 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 43.1 Cg_endo -70.42 -11.0 29.23 Favored 'Trans proline' 0 N--CA 1.489 1.238 0 O-C-N 124.086 1.571 . . . . 0.0 111.043 179.828 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -83.28 6.52 19.36 Favored 'General case' 0 N--CA 1.492 1.666 0 O-C-N 121.066 -1.022 . . . . 0.0 111.564 -179.497 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 31' ' ' GLU . . . . . 0.582 ' HG2' ' N ' ' A' ' 32' ' ' GLY . 14.6 tt0 -79.44 -75.0 0.26 Allowed 'General case' 0 N--CA 1.494 1.763 0 O-C-N 121.157 -0.965 . . . . 0.0 109.736 -179.987 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 32' ' ' GLY . . . . . 0.582 ' N ' ' HG2' ' A' ' 31' ' ' GLU . . . -136.33 22.26 3.39 Favored Glycine 0 N--CA 1.492 2.374 0 N-CA-C 109.55 -1.42 . . . . 0.0 109.55 179.563 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 33' ' ' CYS . . . . . 0.439 ' O ' ' HB2' ' A' ' 39' ' ' CYS . 0.5 OUTLIER -79.39 67.36 5.1 Favored 'General case' 0 N--CA 1.494 1.749 0 O-C-N 121.089 -1.242 . . . . 0.0 109.359 179.36 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -130.32 56.45 1.76 Allowed 'General case' 0 N--CA 1.496 1.868 0 O-C-N 121.536 -0.727 . . . . 0.0 110.319 179.763 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 5.5 mm-40 -92.88 -144.32 0.22 Allowed 'General case' 0 N--CA 1.497 1.884 0 O-C-N 121.505 -0.747 . . . . 0.0 109.74 179.713 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 36' ' ' ALA . . . . . . . . . . . . . . . -114.01 11.93 17.87 Favored 'General case' 0 N--CA 1.496 1.863 0 O-C-N 121.059 -1.026 . . . . 0.0 110.9 179.925 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 20.0 tt0 -161.2 -54.97 0.05 OUTLIER 'General case' 0 N--CA 1.496 1.862 0 O-C-N 121.261 -0.899 . . . . 0.0 110.741 179.516 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -43.6 -51.82 6.6 Favored Glycine 0 N--CA 1.5 2.938 0 N-CA-C 111.525 -0.63 . . . . 0.0 111.525 -178.74 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 39' ' ' CYS . . . . . 0.439 ' HB2' ' O ' ' A' ' 33' ' ' CYS . 56.9 m -139.94 75.68 1.52 Allowed 'General case' 0 N--CA 1.496 1.866 0 O-C-N 121.07 -1.253 . . . . 0.0 110.496 -179.234 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 40' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER . . . . . 0 N--CA 1.503 2.195 0 O-C-N 121.306 -0.872 . . . . 0.0 110.199 179.794 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 13.7 t . . . . . 0 N--CA 1.495 1.802 0 N-CA-C 109.91 -0.404 . . . . 0.0 109.91 . . . . . . . . . 0 0 . 1 . 020 nuclear orig core ' A' A ' 6' ' ' PRO . . . . . . . . . . . . . 50.8 Cg_endo -87.26 -24.06 1.34 Allowed 'Trans proline' 0 C--N 1.309 -1.508 0 O-C-N 123.904 1.476 . . . . 0.0 112.212 -179.515 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -109.85 68.32 0.22 Allowed Glycine 0 N--CA 1.497 2.759 0 O-C-N 120.829 -1.169 . . . . 0.0 111.332 -178.18 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 1.2 p -158.7 150.19 20.83 Favored 'General case' 0 N--CA 1.497 1.885 0 O-C-N 121.177 -1.19 . . . . 0.0 110.213 178.837 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 92.02 -110.46 3.88 Favored Glycine 0 N--CA 1.493 2.442 0 N-CA-C 108.893 -1.683 . . . . 0.0 108.893 -179.461 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 10' ' ' GLN . . . . . . . . . . . . . 5.5 pt20 -155.32 30.29 0.39 Allowed 'General case' 0 N--CA 1.494 1.745 0 O-C-N 121.272 -1.134 . . . . 0.0 110.698 179.379 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -86.58 62.69 4.23 Favored Glycine 0 N--CA 1.493 2.447 0 N-CA-C 109.461 -1.456 . . . . 0.0 109.461 179.614 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 60.2 t -126.94 -75.19 0.36 Allowed 'Isoleucine or valine' 0 N--CA 1.495 1.795 0 O-C-N 121.808 -0.819 . . . . 0.0 109.73 179.745 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 13' ' ' GLN . . . . . . . . . . . . . 1.6 mt-30 42.69 36.33 0.82 Allowed 'General case' 0 N--CA 1.495 1.82 0 O-C-N 121.652 -0.655 . . . . 0.0 111.779 179.736 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -71.5 -22.33 61.81 Favored 'General case' 0 N--CA 1.499 2.014 0 O-C-N 121.171 -0.956 . . . . 0.0 110.936 179.854 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 134.43 -53.34 0.79 Allowed Glycine 0 N--CA 1.493 2.499 0 N-CA-C 109.248 -1.541 . . . . 0.0 109.248 -179.69 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 2.6 p -88.68 121.52 69.91 Favored Pre-proline 0 N--CA 1.497 1.915 0 O-C-N 121.358 -1.083 . . . . 0.0 110.849 179.91 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 48.7 Cg_endo -76.06 79.5 2.89 Favored 'Trans proline' 0 C--N 1.309 -1.513 0 O-C-N 123.705 1.371 . . . . 0.0 110.046 179.606 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 85.79 -48.68 4.02 Favored Glycine 0 N--CA 1.493 2.461 0 N-CA-C 109.887 -1.285 . . . . 0.0 109.887 -179.512 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -72.38 68.8 1.16 Allowed Glycine 0 N--CA 1.495 2.617 0 N-CA-C 110.13 -1.188 . . . . 0.0 110.13 -179.604 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 73.2 m -105.2 119.07 38.14 Favored 'General case' 0 N--CA 1.498 1.957 0 O-C-N 121.482 -1.011 . . . . 0.0 109.511 179.627 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 12.7 t -106.71 -9.34 10.54 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.84 0 O-C-N 121.556 -0.715 . . . . 0.0 111.616 -178.95 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER -79.4 51.5 1.23 Allowed 'General case' 0 N--CA 1.493 1.695 0 O-C-N 120.855 -1.153 . . . . 0.0 110.566 179.718 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 3.2 tt0 -101.79 -24.29 14.08 Favored 'General case' 0 N--CA 1.489 1.477 0 O-C-N 121.095 -1.003 . . . . 0.0 110.139 179.539 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 2.1 pt-20 -79.89 -154.42 0.09 Allowed 'General case' 0 N--CA 1.494 1.736 0 O-C-N 121.274 -0.891 . . . . 0.0 110.575 -179.902 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -82.36 -49.16 10.32 Favored 'General case' 0 N--CA 1.5 2.06 0 O-C-N 121.456 -0.778 . . . . 0.0 110.164 179.947 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 144.09 46.64 0.04 OUTLIER Glycine 0 N--CA 1.498 2.772 0 N-CA-C 110.614 -0.995 . . . . 0.0 110.614 179.419 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 64.73 -130.92 37.06 Favored Glycine 0 N--CA 1.501 2.98 0 N-CA-C 109.685 -1.366 . . . . 0.0 109.685 -179.975 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -146.61 74.97 12.39 Favored Pre-proline 0 N--CA 1.495 1.787 0 O-C-N 121.294 -1.121 . . . . 0.0 109.926 179.691 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 43.4 Cg_endo -74.03 74.44 3.48 Favored 'Trans proline' 0 N--CA 1.488 1.172 0 O-C-N 123.632 1.333 . . . . 0.0 110.661 -179.908 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -89.87 64.84 6.5 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.111 -0.993 . . . . 0.0 110.571 179.887 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 14.8 tp10 -153.17 -67.92 0.15 Allowed 'General case' 0 N--CA 1.493 1.694 0 O-C-N 121.378 -0.826 . . . . 0.0 110.214 179.61 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 123.69 84.52 0.65 Allowed Glycine 0 N--CA 1.497 2.716 0 N-CA-C 109.406 -1.477 . . . . 0.0 109.406 -179.82 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 33' ' ' CYS . . . . . . . . . . . . . 0.4 OUTLIER -95.29 112.36 24.08 Favored 'General case' 0 N--CA 1.493 1.704 0 O-C-N 121.394 -1.062 . . . . 0.0 109.79 179.812 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -107.58 -46.13 3.9 Favored 'General case' 0 N--CA 1.497 1.875 0 O-C-N 121.564 -0.71 . . . . 0.0 110.103 179.886 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 21.8 mt-10 -79.59 -178.88 6.55 Favored 'General case' 0 N--CA 1.5 2.052 0 O-C-N 121.635 -0.665 . . . . 0.0 110.23 179.931 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 36' ' ' ALA . . . . . . . . . . . . . . . -78.66 -38.08 40.37 Favored 'General case' 0 N--CA 1.498 1.931 0 O-C-N 121.202 -0.936 . . . . 0.0 109.897 -179.634 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 7.3 tt0 -119.87 34.07 5.36 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.381 -0.825 . . . . 0.0 109.991 179.492 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -84.72 -9.45 81.13 Favored Glycine 0 N--CA 1.495 2.63 0 O-C-N 121.101 -0.999 . . . . 0.0 110.776 -179.909 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 39' ' ' CYS . . . . . . . . . . . . . 1.3 m -79.43 72.91 6.09 Favored 'General case' 0 N--CA 1.495 1.801 0 O-C-N 120.874 -1.368 . . . . 0.0 109.822 179.842 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 40' ' ' LEU . . . . . . . . . . . . . 1.0 OUTLIER . . . . . 0 N--CA 1.494 1.763 0 O-C-N 121.372 -0.83 . . . . 0.0 110.46 -179.474 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.494 1.755 0 CA-C-O 120.816 0.341 . . . . 0.0 110.127 . . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 17.9 mt -131.53 114.97 15.53 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.162 -0.961 . . . . 0.0 110.383 179.737 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -93.42 50.71 1.52 Allowed 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.386 -0.821 . . . . 0.0 110.546 -179.847 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 4' ' ' ARG . . . . . . . . . . . . . 26.5 ttp85 -164.24 135.59 4.5 Favored 'General case' 0 N--CA 1.493 1.68 0 O-C-N 121.269 -0.894 . . . . 0.0 110.079 179.786 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -87.74 117.77 68.91 Favored Pre-proline 0 N--CA 1.495 1.807 0 O-C-N 121.28 -0.888 . . . . 0.0 109.878 179.845 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 6' ' ' PRO . . . . . . . . . . . . . 49.5 Cg_endo -82.23 150.34 15.49 Favored 'Trans proline' 0 C--N 1.313 -1.307 0 O-C-N 123.716 1.377 . . . . 0.0 110.647 -179.822 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 88.32 -46.54 3.38 Favored Glycine 0 N--CA 1.497 2.761 0 N-CA-C 110.342 -1.103 . . . . 0.0 110.342 179.43 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 20.0 p -79.66 -174.29 4.24 Favored 'General case' 0 N--CA 1.496 1.839 0 O-C-N 121.035 -1.274 . . . . 0.0 110.493 -179.601 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 129.26 -114.43 1.73 Allowed Glycine 0 N--CA 1.494 2.545 0 N-CA-C 108.854 -1.699 . . . . 0.0 108.854 -179.433 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 10' ' ' GLN . . . . . . . . . . . . . 14.0 tp60 -164.39 -75.47 0.04 OUTLIER 'General case' 0 N--CA 1.494 1.748 0 O-C-N 121.421 -1.047 . . . . 0.0 110.542 179.222 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -56.13 -26.1 48.64 Favored Glycine 0 N--CA 1.498 2.786 0 O-C-N 121.252 -0.905 . . . . 0.0 110.986 -179.54 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 25.2 t -88.88 -53.88 8.75 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.813 0 O-C-N 121.185 -1.185 . . . . 0.0 110.241 -179.882 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 13' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -67.04 -32.08 73.04 Favored 'General case' 0 N--CA 1.501 2.113 0 O-C-N 121.375 -0.828 . . . . 0.0 112.008 -179.245 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -141.26 52.23 1.57 Allowed 'General case' 0 N--CA 1.496 1.852 0 O-C-N 120.948 -1.095 . . . . 0.0 110.615 -179.645 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -151.76 -85.36 0.05 OUTLIER Glycine 0 N--CA 1.493 2.469 0 N-CA-C 109.845 -1.302 . . . . 0.0 109.845 179.881 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 57.9 m -110.08 97.58 30.68 Favored Pre-proline 0 N--CA 1.496 1.836 0 O-C-N 121.221 -1.164 . . . . 0.0 110.442 -179.898 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 46.7 Cg_endo -72.54 66.53 3.74 Favored 'Trans proline' 0 N--CA 1.491 1.378 0 O-C-N 124.284 1.676 . . . . 0.0 110.409 179.723 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 123.29 -49.97 0.87 Allowed Glycine 0 N--CA 1.495 2.589 0 N-CA-C 109.267 -1.533 . . . . 0.0 109.267 -179.557 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 178.41 134.28 2.06 Favored Glycine 0 N--CA 1.489 2.229 0 N-CA-C 108.971 -1.652 . . . . 0.0 108.971 179.976 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 1.5 m -92.11 33.06 1.09 Allowed 'General case' 0 N--CA 1.5 2.041 0 O-C-N 121.301 -1.117 . . . . 0.0 110.634 -179.911 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 6.4 t -139.87 55.88 0.22 Allowed 'Isoleucine or valine' 0 N--CA 1.496 1.874 0 O-C-N 120.928 -1.107 . . . . 0.0 110.599 -179.89 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 5.2 tt0 -88.88 49.17 1.74 Allowed 'General case' 0 N--CA 1.496 1.863 0 O-C-N 121.135 -0.978 . . . . 0.0 109.266 178.968 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 11.1 mt-10 58.65 -168.03 0.14 Allowed 'General case' 0 N--CA 1.501 2.08 0 O-C-N 121.756 -0.59 . . . . 0.0 110.451 -179.515 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 73.0 mm-40 -69.58 -22.2 63.54 Favored 'General case' 0 N--CA 1.497 1.923 0 O-C-N 120.991 -1.068 . . . . 0.0 111.277 -179.131 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 2.8 t70 -144.34 -61.44 0.38 Allowed 'General case' 0 N--CA 1.496 1.875 0 O-C-N 121.217 -0.927 . . . . 0.0 109.807 179.879 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 172.39 82.86 0.05 OUTLIER Glycine 0 N--CA 1.495 2.567 0 N-CA-C 109.955 -1.258 . . . . 0.0 109.955 179.681 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 66.09 27.69 73.09 Favored Glycine 0 N--CA 1.496 2.658 0 N-CA-C 109.855 -1.298 . . . . 0.0 109.855 179.923 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -102.37 99.59 13.35 Favored Pre-proline 0 N--CA 1.493 1.701 0 O-C-N 121.521 -0.987 . . . . 0.0 110.068 -179.699 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 45.0 Cg_endo -70.87 66.28 2.43 Favored 'Trans proline' 0 N--CA 1.489 1.225 0 O-C-N 123.744 1.391 . . . . 0.0 110.915 -179.577 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -131.28 66.58 1.54 Allowed 'General case' 0 N--CA 1.486 1.371 0 O-C-N 121.337 -0.852 . . . . 0.0 109.974 179.664 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 8.9 tt0 -110.58 -68.75 0.91 Allowed 'General case' 0 N--CA 1.485 1.313 0 O-C-N 121.397 -0.814 . . . . 0.0 110.531 -179.539 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . -72.87 -42.71 44.55 Favored Glycine 0 N--CA 1.496 2.678 0 N-CA-C 110.088 -1.205 . . . . 0.0 110.088 -179.674 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 33' ' ' CYS . . . . . . . . . . . . . 1.7 t -113.77 79.28 1.23 Allowed 'General case' 0 N--CA 1.492 1.646 0 O-C-N 121.141 -1.211 . . . . 0.0 109.661 -179.843 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -125.23 -46.09 1.81 Allowed 'General case' 0 N--CA 1.495 1.812 0 O-C-N 121.111 -0.993 . . . . 0.0 110.992 -179.403 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 0.8 OUTLIER -97.03 -176.48 3.56 Favored 'General case' 0 N--CA 1.498 1.926 0 O-C-N 121.494 -0.754 . . . . 0.0 110.934 -179.414 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 36' ' ' ALA . . . . . 0.539 ' O ' ' HB3' ' A' ' 40' ' ' LEU . . . -79.13 -34.19 43.55 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.26 -0.9 . . . . 0.0 110.189 179.805 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -78.41 2.31 19.21 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.247 -0.908 . . . . 0.0 110.903 179.865 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -92.66 -43.81 4.12 Favored Glycine 0 N--CA 1.492 2.411 0 N-CA-C 109.432 -1.467 . . . . 0.0 109.432 179.951 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 39' ' ' CYS . . . . . . . . . . . . . 1.3 p -161.06 50.34 0.24 Allowed 'General case' 0 N--CA 1.498 1.968 0 O-C-N 121.358 -1.084 . . . . 0.0 111.215 -179.391 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 40' ' ' LEU . . . . . 0.539 ' HB3' ' O ' ' A' ' 36' ' ' ALA . 1.7 pt? -55.79 -41.09 73.6 Favored 'General case' 0 N--CA 1.504 2.234 0 O-C-N 120.801 -1.187 . . . . 0.0 112.047 -179.599 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 41' ' ' ARG . . . . . 0.454 ' N ' ' HG ' ' A' ' 40' ' ' LEU . 0.4 OUTLIER 48.04 -154.48 0.08 Allowed 'General case' 0 N--CA 1.502 2.168 0 O-C-N 121.184 -0.947 . . . . 0.0 110.525 -179.733 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 42' ' ' ARG . . . . . . . . . . . . . 21.5 ttt-85 -92.98 -56.21 3.07 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 120.885 -1.134 . . . . 0.0 109.482 179.539 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -116.03 136.46 53.01 Favored 'General case' 0 N--CA 1.489 1.48 0 O-C-N 121.655 -0.653 . . . . 0.0 109.838 179.301 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -114.17 -48.96 0.55 Allowed Glycine 0 N--CA 1.491 2.348 0 N-CA-C 109.736 -1.346 . . . . 0.0 109.736 -179.783 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 45' ' ' GLN . . . . . . . . . . . . . 38.9 mt-30 . . . . . 0 N--CA 1.499 2.014 0 O-C-N 121.573 -0.957 . . . . 0.0 110.338 179.879 . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.496 1.855 0 CA-C-O 121.175 0.512 . . . . 0.0 110.374 . . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER -137.36 20.83 2.95 Favored 'General case' 0 N--CA 1.493 1.723 0 O-C-N 120.885 -1.134 . . . . 0.0 111.177 179.832 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -76.57 85.48 3.26 Favored 'General case' 0 N--CA 1.493 1.688 0 O-C-N 121.199 -0.938 . . . . 0.0 110.443 -179.862 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 4' ' ' ARG . . . . . . . . . . . . . 0.5 OUTLIER -132.19 -167.54 1.9 Allowed 'General case' 0 N--CA 1.488 1.463 0 O-C-N 121.34 -0.85 . . . . 0.0 109.543 179.435 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 0.3 OUTLIER -79.35 125.97 82.13 Favored Pre-proline 0 N--CA 1.497 1.924 0 O-C-N 121.122 -0.986 . . . . 0.0 110.277 179.935 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 6' ' ' PRO . . . . . . . . . . . . . 45.6 Cg_endo -72.82 -86.18 0.0 OUTLIER 'Trans proline' 0 C--N 1.307 -1.656 0 O-C-N 123.944 1.497 . . . . 0.0 112.062 -179.039 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -105.6 55.8 0.54 Allowed Glycine 0 N--CA 1.49 2.246 0 N-CA-C 109.893 -1.283 . . . . 0.0 109.893 -178.99 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 0.4 OUTLIER -135.34 151.54 50.61 Favored 'General case' 0 N--CA 1.498 1.96 0 O-C-N 121.335 -1.097 . . . . 0.0 110.33 179.611 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 175.98 154.1 11.19 Favored Glycine 0 N--CA 1.495 2.605 0 N-CA-C 109.655 -1.378 . . . . 0.0 109.655 -179.809 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 10' ' ' GLN . . . . . . . . . . . . . 0.3 OUTLIER -129.89 70.56 1.43 Allowed 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.283 -1.128 . . . . 0.0 109.756 179.921 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -79.45 -61.15 2.37 Favored Glycine 0 N--CA 1.495 2.591 0 N-CA-C 110.006 -1.238 . . . . 0.0 110.006 -179.491 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 24.0 m -120.58 -31.65 1.54 Allowed 'Isoleucine or valine' 0 N--CA 1.503 2.213 0 O-C-N 121.427 -1.043 . . . . 0.0 111.491 -179.493 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 13' ' ' GLN . . . . . . . . . . . . . 1.2 tt0 56.33 50.53 13.08 Favored 'General case' 0 N--CA 1.499 1.992 0 O-C-N 121.408 -0.807 . . . . 0.0 110.616 179.93 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -104.68 -60.62 1.57 Allowed 'General case' 0 N--CA 1.495 1.815 0 O-C-N 121.269 -0.894 . . . . 0.0 110.536 179.887 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -152.12 -83.43 0.04 OUTLIER Glycine 0 N--CA 1.494 2.536 0 N-CA-C 109.876 -1.29 . . . . 0.0 109.876 179.942 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 16' ' ' CYS . . . . . 0.46 ' HB2' ' HB2' ' A' ' 20' ' ' CYS . 1.1 m -86.36 136.2 35.73 Favored Pre-proline 0 N--CA 1.496 1.831 0 O-C-N 121.338 -1.096 . . . . 0.0 109.985 179.679 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 45.3 Cg_endo -72.62 72.04 3.13 Favored 'Trans proline' 0 C--N 1.312 -1.361 0 O-C-N 123.656 1.345 . . . . 0.0 109.617 178.931 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 91.52 -49.49 2.9 Favored Glycine 0 N--CA 1.493 2.447 0 N-CA-C 109.702 -1.359 . . . . 0.0 109.702 -179.254 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -74.65 67.14 1.98 Allowed Glycine 0 N--CA 1.497 2.738 0 O-C-N 121.009 -1.289 . . . . 0.0 110.831 -179.727 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 20' ' ' CYS . . . . . 0.46 ' HB2' ' HB2' ' A' ' 16' ' ' CYS . 0.4 OUTLIER -127.77 73.14 1.43 Allowed 'General case' 0 N--CA 1.496 1.83 0 O-C-N 121.24 -1.153 . . . . 0.0 109.174 179.38 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 14.6 p -126.14 -19.66 2.68 Favored 'Isoleucine or valine' 0 N--CA 1.499 2.018 0 O-C-N 121.739 -0.601 . . . . 0.0 111.506 -179.039 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 17.7 mt-10 -79.96 50.18 1.17 Allowed 'General case' 0 N--CA 1.491 1.598 0 O-C-N 120.673 -1.267 . . . . 0.0 110.231 179.831 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 2.3 mt-10 -89.21 -172.91 3.82 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 120.864 -1.147 . . . . 0.0 110.138 -179.794 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER 56.39 59.25 3.73 Favored 'General case' 0 N--CA 1.493 1.677 0 CA-C-O 121.343 0.592 . . . . 0.0 110.4 179.976 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 1.9 p-10 -101.89 -174.45 2.59 Favored 'General case' 0 N--CA 1.496 1.83 0 O-C-N 121.223 -0.923 . . . . 0.0 109.907 179.561 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 79.35 -69.95 2.89 Favored Glycine 0 N--CA 1.495 2.628 0 N-CA-C 109.559 -1.416 . . . . 0.0 109.559 -179.807 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 144.71 115.04 0.97 Allowed Glycine 0 N--CA 1.494 2.561 0 N-CA-C 109.635 -1.386 . . . . 0.0 109.635 179.789 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 73.5 m -81.91 143.63 50.21 Favored Pre-proline 0 N--CA 1.5 2.032 0 O-C-N 121.385 -1.067 . . . . 0.0 110.187 -179.973 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 45.5 Cg_endo -73.46 91.25 0.88 Allowed 'Trans proline' 0 C--N 1.315 -1.188 0 O-C-N 123.729 1.384 . . . . 0.0 111.115 -179.078 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -94.55 -55.2 3.23 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.315 -0.865 . . . . 0.0 110.59 179.883 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 36.2 tt0 -79.05 -7.26 57.97 Favored 'General case' 0 N--CA 1.496 1.858 0 O-C-N 121.513 -0.742 . . . . 0.0 110.911 -179.8 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 90.41 -10.34 74.71 Favored Glycine 0 N--CA 1.494 2.51 0 O-C-N 120.792 -1.192 . . . . 0.0 110.182 -179.515 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 33' ' ' CYS . . . . . . . . . . . . . 59.1 m -79.73 65.71 4.97 Favored 'General case' 0 N--CA 1.494 1.741 0 O-C-N 120.925 -1.338 . . . . 0.0 110.282 -179.803 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -79.2 -38.95 34.52 Favored 'General case' 0 N--CA 1.494 1.742 0 O-C-N 121.456 -0.778 . . . . 0.0 109.573 179.576 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 47.9 mt-10 -89.91 162.59 15.36 Favored 'General case' 0 N--CA 1.493 1.716 0 O-C-N 121.381 -0.825 . . . . 0.0 109.594 179.235 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 36' ' ' ALA . . . . . . . . . . . . . . . -79.35 -46.33 17.86 Favored 'General case' 0 N--CA 1.493 1.683 0 O-C-N 121.123 -0.985 . . . . 0.0 110.412 -179.221 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 1.5 tt0 -95.3 62.41 2.47 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.191 -0.943 . . . . 0.0 110.315 -179.834 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -148.68 17.49 1.26 Allowed Glycine 0 N--CA 1.496 2.673 0 C-N-CA 119.945 -1.121 . . . . 0.0 110.958 -179.984 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 39' ' ' CYS . . . . . . . . . . . . . 57.1 m -144.23 26.87 1.45 Allowed 'General case' 0 N--CA 1.502 2.135 0 O-C-N 120.663 -1.492 . . . . 0.0 111.274 -179.837 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 40' ' ' LEU . . . . . 0.44 ' O ' HD22 ' A' ' 40' ' ' LEU . 0.9 OUTLIER 45.69 67.3 0.76 Allowed 'General case' 0 N--CA 1.501 2.082 0 O-C-N 121.68 -0.638 . . . . 0.0 111.647 179.886 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 41' ' ' ARG . . . . . . . . . . . . . 4.5 ptp180 -173.34 118.43 0.3 Allowed 'General case' 0 N--CA 1.497 1.915 0 O-C-N 121.206 -0.934 . . . . 0.0 109.768 178.66 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 42' ' ' ARG . . . . . . . . . . . . . 2.9 ttt-85 -136.01 -42.3 0.66 Allowed 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.571 -0.706 . . . . 0.0 111.247 -179.708 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 1.3 mm-40 -57.95 131.58 50.85 Favored 'General case' 0 N--CA 1.498 1.937 0 O-C-N 121.381 -0.824 . . . . 0.0 110.462 -179.707 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -142.3 -46.7 0.05 OUTLIER Glycine 0 N--CA 1.498 2.789 0 N-CA-C 110.028 -1.229 . . . . 0.0 110.028 -179.641 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 45' ' ' GLN . . . . . . . . . . . . . 5.7 mm-40 . . . . . 0 N--CA 1.496 1.862 0 O-C-N 121.261 -1.14 . . . . 0.0 110.682 -179.985 . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.494 1.73 0 N-CA-C 109.468 -0.567 . . . . 0.0 109.468 . . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 0.8 OUTLIER 60.61 93.27 0.04 OUTLIER 'General case' 0 N--CA 1.505 2.284 0 O-C-N 121.688 -0.633 . . . . 0.0 110.794 179.991 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -57.8 112.73 1.57 Allowed 'General case' 0 N--CA 1.497 1.904 0 O-C-N 121.35 -0.844 . . . . 0.0 110.302 179.903 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 4' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -161.12 -56.63 0.05 Allowed 'General case' 0 N--CA 1.492 1.654 0 O-C-N 121.424 -0.797 . . . . 0.0 110.302 -179.867 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 9.5 t -135.14 90.48 21.16 Favored Pre-proline 0 N--CA 1.497 1.897 0 O-C-N 121.462 -0.774 . . . . 0.0 109.506 179.897 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 6' ' ' PRO . . . . . . . . . . . . . 48.9 Cg_endo -73.42 -21.13 20.08 Favored 'Trans proline' 0 C--N 1.312 -1.39 0 O-C-N 124.089 1.573 . . . . 0.0 111.949 -179.508 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -74.58 -40.21 39.2 Favored Glycine 0 N--CA 1.496 2.636 0 N-CA-C 110.386 -1.086 . . . . 0.0 110.386 -179.169 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 31.1 p -85.95 -174.61 5.19 Favored 'General case' 0 N--CA 1.498 1.943 0 O-C-N 121.168 -1.195 . . . . 0.0 110.881 -179.599 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -142.26 -135.11 3.05 Favored Glycine 0 N--CA 1.495 2.603 0 N-CA-C 109.854 -1.299 . . . . 0.0 109.854 -179.587 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 10' ' ' GLN . . . . . . . . . . . . . 4.2 mt-30 -80.62 41.37 0.55 Allowed 'General case' 0 N--CA 1.499 2.013 0 O-C-N 121.14 -1.212 . . . . 0.0 111.665 -179.566 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 80.49 -34.42 2.26 Favored Glycine 0 N--CA 1.497 2.714 0 O-C-N 120.718 -1.239 . . . . 0.0 111.224 179.445 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 16.9 m -130.66 60.98 0.3 Allowed 'Isoleucine or valine' 0 N--CA 1.498 1.933 0 O-C-N 121.056 -1.261 . . . . 0.0 110.867 -179.354 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 13' ' ' GLN . . . . . . . . . . . . . 0.6 OUTLIER -124.06 94.64 4.28 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.323 -0.86 . . . . 0.0 109.607 179.754 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -150.84 161.85 41.88 Favored 'General case' 0 N--CA 1.495 1.814 0 CA-C-O 121.539 0.685 . . . . 0.0 111.3 -179.553 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -144.61 -57.68 0.02 OUTLIER Glycine 0 N--CA 1.498 2.801 0 N-CA-C 108.427 -1.869 . . . . 0.0 108.427 179.378 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 0.8 OUTLIER -121.78 79.0 39.98 Favored Pre-proline 0 N--CA 1.499 1.988 0 N-CA-C 108.602 -0.888 . . . . 0.0 108.602 178.482 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 40.6 Cg_endo -66.89 -24.29 46.43 Favored 'Trans proline' 0 N--CA 1.49 1.319 0 C-N-CA 121.288 1.325 . . . . 0.0 112.246 -178.359 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . -96.06 19.43 54.5 Favored Glycine 0 N--CA 1.496 2.666 0 N-CA-C 109.973 -1.251 . . . . 0.0 109.973 179.821 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 114.94 141.56 7.55 Favored Glycine 0 N--CA 1.487 2.064 0 N-CA-C 108.528 -1.829 . . . . 0.0 108.528 179.842 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 36.3 m -109.39 167.48 10.09 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.28 -1.13 . . . . 0.0 109.792 179.889 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . 0.401 HG12 ' CB ' ' A' ' 25' ' ' ASP . 14.5 t -79.18 65.0 0.31 Allowed 'Isoleucine or valine' 0 N--CA 1.494 1.77 0 O-C-N 121.28 -0.887 . . . . 0.0 110.296 -179.801 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -96.14 -31.98 12.72 Favored 'General case' 0 N--CA 1.489 1.494 0 O-C-N 121.21 -0.931 . . . . 0.0 110.099 179.299 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 4.9 mm-40 -94.49 55.22 1.93 Allowed 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.184 -0.948 . . . . 0.0 110.437 -179.49 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 3.0 mm-40 39.09 68.36 0.36 Allowed 'General case' 0 N--CA 1.496 1.837 0 CA-C-O 121.616 0.722 . . . . 0.0 112.026 179.498 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 25' ' ' ASP . . . . . 0.401 ' CB ' HG12 ' A' ' 21' ' ' VAL . 0.7 OUTLIER -89.88 -9.94 47.12 Favored 'General case' 0 N--CA 1.497 1.909 0 O-C-N 121.155 -0.966 . . . . 0.0 110.276 178.85 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 90.25 -67.08 2.63 Favored Glycine 0 N--CA 1.494 2.51 0 N-CA-C 109.068 -1.613 . . . . 0.0 109.068 -179.053 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 67.91 176.55 10.28 Favored Glycine 0 N--CA 1.496 2.681 0 N-CA-C 110.234 -1.146 . . . . 0.0 110.234 179.516 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 1.9 t -111.37 94.41 22.19 Favored Pre-proline 0 N--CA 1.496 1.836 0 O-C-N 121.315 -1.109 . . . . 0.0 109.773 179.655 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 44.4 Cg_endo -71.91 110.1 2.83 Favored 'Trans proline' 0 C--N 1.315 -1.229 0 O-C-N 123.832 1.438 . . . . 0.0 110.728 -179.583 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -79.26 -54.15 6.25 Favored 'General case' 0 N--CA 1.492 1.646 0 O-C-N 121.264 -0.897 . . . . 0.0 110.364 -179.985 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 6.8 tt0 -90.24 16.52 8.47 Favored 'General case' 0 N--CA 1.492 1.665 0 O-C-N 121.073 -1.017 . . . . 0.0 111.002 179.702 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . -87.17 35.96 3.37 Favored Glycine 0 N--CA 1.492 2.431 0 N-CA-C 109.502 -1.439 . . . . 0.0 109.502 179.555 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 33' ' ' CYS . . . . . 0.417 ' HA ' ' O ' ' A' ' 38' ' ' GLY . 0.5 OUTLIER -114.28 22.08 14.08 Favored 'General case' 0 N--CA 1.494 1.746 0 O-C-N 121.497 -1.001 . . . . 0.0 110.646 179.328 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -152.24 46.48 0.75 Allowed 'General case' 0 N--CA 1.498 1.965 0 O-C-N 121.058 -1.026 . . . . 0.0 110.604 -179.722 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 7.6 pt-20 -128.73 -157.44 0.82 Allowed 'General case' 0 N--CA 1.499 2.002 0 O-C-N 121.51 -0.744 . . . . 0.0 110.253 179.856 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 36' ' ' ALA . . . . . . . . . . . . . . . -77.83 -23.64 48.9 Favored 'General case' 0 N--CA 1.499 1.985 0 O-C-N 121.242 -0.911 . . . . 0.0 110.448 -179.652 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER -79.5 -33.74 41.87 Favored 'General case' 0 N--CA 1.492 1.654 0 O-C-N 121.16 -0.962 . . . . 0.0 109.819 179.547 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 38' ' ' GLY . . . . . 0.417 ' O ' ' HA ' ' A' ' 33' ' ' CYS . . . 107.88 -97.09 1.1 Allowed Glycine 0 N--CA 1.492 2.421 0 N-CA-C 109.113 -1.595 . . . . 0.0 109.113 179.847 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 39' ' ' CYS . . . . . . . . . . . . . 1.8 t -160.81 115.04 2.1 Favored 'General case' 0 N--CA 1.498 1.957 0 O-C-N 121.637 -0.919 . . . . 0.0 109.687 179.435 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 40' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -89.95 117.35 28.69 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.152 -0.968 . . . . 0.0 110.908 -179.334 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 41' ' ' ARG . . . . . . . . . . . . . 4.4 tpt85 -172.24 92.7 0.13 Allowed 'General case' 0 N--CA 1.493 1.69 0 O-C-N 121.41 -0.806 . . . . 0.0 109.438 179.488 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 42' ' ' ARG . . . . . . . . . . . . . 6.8 ttt180 -174.44 -50.88 0.01 OUTLIER 'General case' 0 N--CA 1.497 1.895 0 O-C-N 121.557 -0.714 . . . . 0.0 110.844 179.955 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 1.8 tt0 57.08 -163.8 0.17 Allowed 'General case' 0 N--CA 1.497 1.896 0 CA-C-O 121.273 0.558 . . . . 0.0 110.383 -179.582 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -123.04 27.46 5.87 Favored Glycine 0 N--CA 1.495 2.63 0 N-CA-C 108.987 -1.645 . . . . 0.0 108.987 179.65 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 45' ' ' GLN . . . . . . . . . . . . . 2.9 mt-30 . . . . . 0 N--CA 1.494 1.758 0 CA-C-O 117.851 -1.071 . . . . 0.0 109.597 -179.754 . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.493 1.705 0 N-CA-C 110.013 -0.366 . . . . 0.0 110.013 . . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER 54.74 44.43 28.53 Favored 'General case' 0 N--CA 1.504 2.261 0 O-C-N 121.683 -0.636 . . . . 0.0 110.596 -179.987 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -134.96 117.16 15.49 Favored 'General case' 0 N--CA 1.484 1.268 0 O-C-N 121.225 -0.922 . . . . 0.0 110.529 179.899 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 4' ' ' ARG . . . . . . . . . . . . . 2.3 ptp85 -163.29 140.36 7.42 Favored 'General case' 0 N--CA 1.489 1.478 0 O-C-N 121.576 -0.703 . . . . 0.0 109.719 179.307 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -146.13 118.74 5.08 Favored Pre-proline 0 N--CA 1.496 1.854 0 O-C-N 121.249 -0.907 . . . . 0.0 110.074 -179.653 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 6' ' ' PRO . . . . . . . . . . . . . 44.6 Cg_endo -74.74 -50.99 0.13 Allowed 'Trans proline' 0 C--N 1.314 -1.268 0 O-C-N 123.665 1.35 . . . . 0.0 111.102 -179.64 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -78.03 58.38 3.94 Favored Glycine 0 N--CA 1.494 2.559 0 N-CA-C 109.736 -1.346 . . . . 0.0 109.736 179.992 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 1.1 m -114.49 3.22 14.85 Favored 'General case' 0 N--CA 1.492 1.672 0 O-C-N 121.271 -1.135 . . . . 0.0 111.349 -179.938 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 9' ' ' GLY . . . . . 0.425 ' O ' ' HB2' ' A' ' 10' ' ' GLN . . . -80.18 57.36 4.63 Favored Glycine 0 N--CA 1.494 2.534 0 N-CA-C 109.894 -1.282 . . . . 0.0 109.894 179.598 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 10' ' ' GLN . . . . . 0.425 ' HB2' ' O ' ' A' ' 9' ' ' GLY . 5.6 tt0 -178.56 -63.4 0.01 OUTLIER 'General case' 0 N--CA 1.494 1.769 0 O-C-N 121.466 -1.02 . . . . 0.0 109.994 179.787 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -85.07 62.97 4.45 Favored Glycine 0 N--CA 1.491 2.346 0 N-CA-C 110.018 -1.233 . . . . 0.0 110.018 -179.867 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 7.5 p -146.37 -47.24 0.11 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.652 0 O-C-N 121.467 -1.019 . . . . 0.0 110.413 179.602 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 13' ' ' GLN . . . . . . . . . . . . . 20.4 tt0 -175.04 -55.07 0.01 OUTLIER 'General case' 0 N--CA 1.497 1.9 0 O-C-N 121.36 -0.838 . . . . 0.0 109.6 179.521 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -117.04 -178.26 3.4 Favored 'General case' 0 N--CA 1.496 1.825 0 O-C-N 121.788 -0.57 . . . . 0.0 110.216 179.789 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -85.03 -35.21 12.87 Favored Glycine 0 N--CA 1.496 2.65 0 N-CA-C 110.378 -1.089 . . . . 0.0 110.378 -179.581 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 0.0 OUTLIER -113.45 132.85 22.31 Favored Pre-proline 0 N--CA 1.5 2.027 0 O-C-N 121.332 -1.099 . . . . 0.0 109.67 179.702 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 47.4 Cg_endo -74.29 58.67 4.44 Favored 'Trans proline' 0 C--N 1.31 -1.488 0 O-C-N 123.72 1.379 . . . . 0.0 111.072 -179.731 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 92.9 92.85 1.48 Allowed Glycine 0 N--CA 1.495 2.579 0 N-CA-C 110.167 -1.173 . . . . 0.0 110.167 179.336 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 106.71 113.1 3.75 Favored Glycine 0 N--CA 1.49 2.298 0 N-CA-C 110.128 -1.189 . . . . 0.0 110.128 179.345 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 20' ' ' CYS . . . . . 0.47 ' O ' ' HB3' ' A' ' 25' ' ' ASP . 36.9 m -122.27 -12.99 8.18 Favored 'General case' 0 N--CA 1.502 2.166 0 O-C-N 121.521 -0.988 . . . . 0.0 111.285 179.818 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 18.5 m -80.36 18.91 0.18 Allowed 'Isoleucine or valine' 0 N--CA 1.504 2.239 0 O-C-N 120.865 -1.147 . . . . 0.0 111.848 -179.562 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 5.0 mm-40 -79.67 -19.88 47.97 Favored 'General case' 0 N--CA 1.486 1.357 0 O-C-N 120.84 -1.163 . . . . 0.0 110.884 179.836 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -139.18 55.35 1.7 Allowed 'General case' 0 N--CA 1.491 1.591 0 O-C-N 120.891 -1.131 . . . . 0.0 110.259 179.956 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 24' ' ' GLU . . . . . 0.535 ' HG3' ' HB2' ' A' ' 28' ' ' SER . 0.8 OUTLIER 53.09 31.15 10.75 Favored 'General case' 0 N--CA 1.506 2.362 0 O-C-N 121.92 -0.487 . . . . 0.0 112.013 179.473 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 25' ' ' ASP . . . . . 0.47 ' HB3' ' O ' ' A' ' 20' ' ' CYS . 21.2 t70 -106.27 115.38 30.12 Favored 'General case' 0 N--CA 1.496 1.834 0 O-C-N 120.866 -1.146 . . . . 0.0 109.661 179.715 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 77.22 -56.07 3.63 Favored Glycine 0 N--CA 1.492 2.382 0 N-CA-C 110.559 -1.016 . . . . 0.0 110.559 179.594 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -55.97 -54.34 35.97 Favored Glycine 0 N--CA 1.494 2.56 0 N-CA-C 110.27 -1.132 . . . . 0.0 110.27 -178.964 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 28' ' ' SER . . . . . 0.535 ' HB2' ' HG3' ' A' ' 24' ' ' GLU . 1.4 m -113.83 77.3 3.52 Favored Pre-proline 0 N--CA 1.497 1.893 0 O-C-N 121.742 -0.858 . . . . 0.0 110.696 -179.368 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 54.7 Cg_endo -79.86 114.32 3.15 Favored 'Trans proline' 0 C--N 1.314 -1.282 0 O-C-N 123.234 1.123 . . . . 0.0 110.028 179.602 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -77.2 -26.81 53.2 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 120.974 -1.079 . . . . 0.0 109.904 179.937 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 1.2 mt-10 -78.95 1.99 21.82 Favored 'General case' 0 N--CA 1.494 1.771 0 O-C-N 121.312 -0.867 . . . . 0.0 110.685 179.137 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . -99.28 35.8 4.46 Favored Glycine 0 N--CA 1.492 2.379 0 N-CA-C 110.04 -1.224 . . . . 0.0 110.04 179.904 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 33' ' ' CYS . . . . . . . . . . . . . 1.7 t -160.67 64.69 0.31 Allowed 'General case' 0 N--CA 1.494 1.764 0 O-C-N 121.268 -1.137 . . . . 0.0 110.3 179.739 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -78.64 -53.45 7.16 Favored 'General case' 0 N--CA 1.499 1.983 0 O-C-N 121.073 -1.017 . . . . 0.0 109.417 179.06 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 8.0 mt-10 -85.16 169.56 13.74 Favored 'General case' 0 N--CA 1.495 1.784 0 O-C-N 121.461 -0.774 . . . . 0.0 109.519 178.466 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 36' ' ' ALA . . . . . . . . . . . . . . . -78.18 -43.52 28.4 Favored 'General case' 0 N--CA 1.493 1.718 0 O-C-N 120.908 -1.12 . . . . 0.0 109.505 179.826 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 6.5 pt-20 -81.33 -28.22 34.64 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.309 -0.87 . . . . 0.0 110.194 179.458 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -74.3 71.17 1.53 Allowed Glycine 0 N--CA 1.491 2.324 0 N-CA-C 109.92 -1.272 . . . . 0.0 109.92 -179.881 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 39' ' ' CYS . . . . . 0.466 ' O ' ' HD3' ' A' ' 41' ' ' ARG . 0.6 OUTLIER -160.04 -47.76 0.05 Allowed 'General case' 0 C--N 1.296 -1.742 0 O-C-N 121.678 -0.895 . . . . 0.0 110.021 179.495 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 40' ' ' LEU . . . . . . . . . . . . . 17.0 mt 54.94 -124.59 2.16 Favored 'General case' 0 N--CA 1.5 2.061 0 O-C-N 121.6 -0.687 . . . . 0.0 110.595 179.368 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 41' ' ' ARG . . . . . 0.466 ' HD3' ' O ' ' A' ' 39' ' ' CYS . 2.9 mpp_? 54.44 47.73 22.17 Favored 'General case' 0 N--CA 1.501 2.119 0 O-C-N 121.408 -0.808 . . . . 0.0 110.454 -179.745 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 42' ' ' ARG . . . . . . . . . . . . . 1.2 ttp180 -160.14 41.18 0.19 Allowed 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.292 -0.88 . . . . 0.0 110.349 -179.948 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 29.7 mt-10 49.76 79.25 0.08 Allowed 'General case' 0 N--CA 1.502 2.162 0 CA-C-O 121.477 0.656 . . . . 0.0 111.172 179.841 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -122.28 78.14 0.34 Allowed Glycine 0 N--CA 1.488 2.153 0 N-CA-C 109.073 -1.611 . . . . 0.0 109.073 179.59 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 45' ' ' GLN . . . . . . . . . . . . . 4.0 mt-30 . . . . . 0 N--CA 1.503 2.186 0 CA-C-O 118.306 -0.854 . . . . 0.0 110.662 -179.333 . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.494 1.742 0 N-CA-C 109.724 -0.472 . . . . 0.0 109.724 . . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER -82.52 -162.5 0.58 Allowed 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.468 -0.77 . . . . 0.0 110.066 179.779 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -72.67 76.25 1.1 Allowed 'General case' 0 N--CA 1.492 1.643 0 O-C-N 121.272 -0.893 . . . . 0.0 110.729 -179.539 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 4' ' ' ARG . . . . . . . . . . . . . 3.6 mmm180 -83.75 -157.43 0.25 Allowed 'General case' 0 N--CA 1.494 1.746 0 O-C-N 121.406 -0.808 . . . . 0.0 109.483 179.394 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 2.2 t -113.62 85.73 9.58 Favored Pre-proline 0 N--CA 1.497 1.906 0 O-C-N 120.803 -1.186 . . . . 0.0 110.049 179.881 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 6' ' ' PRO . . . . . . . . . . . . . 50.5 Cg_endo -75.42 75.92 3.73 Favored 'Trans proline' 0 C--N 1.313 -1.326 0 O-C-N 123.964 1.507 . . . . 0.0 110.425 179.928 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 73.89 38.7 48.61 Favored Glycine 0 N--CA 1.498 2.798 0 N-CA-C 110.118 -1.193 . . . . 0.0 110.118 179.987 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 5.4 p -92.04 -159.84 0.69 Allowed 'General case' 0 N--CA 1.498 1.927 0 O-C-N 121.28 -1.13 . . . . 0.0 109.858 179.498 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -76.93 -93.89 0.21 Allowed Glycine 0 N--CA 1.495 2.579 0 N-CA-C 109.599 -1.4 . . . . 0.0 109.599 -179.978 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 10' ' ' GLN . . . . . . . . . . . . . 2.3 pt20 -169.58 85.72 0.14 Allowed 'General case' 0 N--CA 1.493 1.722 0 O-C-N 121.221 -1.164 . . . . 0.0 109.885 179.656 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -75.64 60.01 2.92 Favored Glycine 0 N--CA 1.497 2.7 0 N-CA-C 109.932 -1.267 . . . . 0.0 109.932 -179.809 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 14.2 p -146.26 52.57 0.11 Allowed 'Isoleucine or valine' 0 N--CA 1.495 1.783 0 O-C-N 121.537 -0.978 . . . . 0.0 109.537 -179.933 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 13' ' ' GLN . . . . . . . . . . . . . 4.5 tt0 -58.93 -55.4 35.57 Favored 'General case' 0 N--CA 1.5 2.027 0 O-C-N 121.125 -0.984 . . . . 0.0 110.851 -179.733 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -83.54 66.44 8.93 Favored 'General case' 0 N--CA 1.498 1.939 0 O-C-N 121.143 -0.973 . . . . 0.0 110.185 -179.775 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -72.58 -67.1 1.9 Allowed Glycine 0 N--CA 1.494 2.534 0 N-CA-C 109.78 -1.328 . . . . 0.0 109.78 -179.748 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 1.2 p -127.89 74.51 78.69 Favored Pre-proline 0 N--CA 1.497 1.88 0 O-C-N 121.788 -0.83 . . . . 0.0 110.45 179.608 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 43.8 Cg_endo -68.72 131.01 21.75 Favored 'Trans proline' 0 C--N 1.309 -1.523 0 O-C-N 123.462 1.243 . . . . 0.0 110.36 -179.978 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 100.89 -24.36 32.28 Favored Glycine 0 N--CA 1.493 2.453 0 N-CA-C 110.54 -1.024 . . . . 0.0 110.54 179.916 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 165.81 138.52 2.44 Favored Glycine 0 N--CA 1.489 2.177 0 N-CA-C 108.943 -1.663 . . . . 0.0 108.943 179.599 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 71.6 m -118.36 112.74 20.4 Favored 'General case' 0 N--CA 1.492 1.672 0 O-C-N 121.492 -1.005 . . . . 0.0 110.009 179.788 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 7.2 p -92.89 43.63 0.08 OUTLIER 'Isoleucine or valine' 0 N--CA 1.504 2.232 0 O-C-N 121.282 -0.886 . . . . 0.0 110.481 -179.608 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 2.1 mm-40 -79.45 -28.08 41.62 Favored 'General case' 0 N--CA 1.488 1.457 0 O-C-N 121.029 -1.044 . . . . 0.0 110.931 -179.908 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 1.3 tp10 -162.29 110.87 1.4 Allowed 'General case' 0 N--CA 1.493 1.685 0 O-C-N 121.018 -1.052 . . . . 0.0 110.328 179.852 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 2.3 tt0 -148.23 153.29 38.54 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 121.487 -0.758 . . . . 0.0 110.165 179.104 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -96.67 -54.41 3.24 Favored 'General case' 0 N--CA 1.497 1.888 0 O-C-N 121.75 -0.594 . . . . 0.0 110.183 -179.677 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -156.25 94.34 0.14 Allowed Glycine 0 N--CA 1.494 2.549 0 N-CA-C 108.723 -1.751 . . . . 0.0 108.723 -179.891 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -55.81 96.72 0.04 OUTLIER Glycine 0 N--CA 1.498 2.826 0 N-CA-C 110.567 -1.013 . . . . 0.0 110.567 -179.422 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 28' ' ' SER . . . . . 0.514 ' CB ' ' HD3' ' A' ' 29' ' ' PRO . 1.6 t -160.75 -65.51 0.02 OUTLIER Pre-proline 0 N--CA 1.496 1.849 0 O-C-N 121.334 -1.098 . . . . 0.0 109.586 179.615 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 29' ' ' PRO . . . . . 0.514 ' HD3' ' CB ' ' A' ' 28' ' ' SER . 51.8 Cg_endo -78.26 72.14 6.41 Favored 'Trans proline' 0 N--CA 1.486 1.048 0 O-C-N 123.205 1.108 . . . . 0.0 109.863 178.742 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 30' ' ' ALA . . . . . 0.411 ' O ' ' HB1' ' A' ' 34' ' ' ALA . . . -79.64 -64.26 1.23 Allowed 'General case' 0 N--CA 1.493 1.701 0 O-C-N 121.349 -0.844 . . . . 0.0 111.212 -179.065 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 3.5 tt0 -117.78 -22.99 7.73 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.038 -1.039 . . . . 0.0 111.381 -179.224 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . -52.04 -41.57 53.08 Favored Glycine 0 N--CA 1.498 2.821 0 O-C-N 120.99 -1.069 . . . . 0.0 110.915 -179.193 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 33' ' ' CYS . . . . . . . . . . . . . 0.8 OUTLIER -149.59 62.69 1.01 Allowed 'General case' 0 N--CA 1.496 1.858 0 O-C-N 121.159 -1.2 . . . . 0.0 110.381 179.78 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 34' ' ' ALA . . . . . 0.411 ' HB1' ' O ' ' A' ' 30' ' ' ALA . . . -141.5 34.06 1.65 Allowed 'General case' 0 N--CA 1.498 1.952 0 O-C-N 121.257 -0.902 . . . . 0.0 110.367 179.882 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -111.15 -168.7 1.34 Allowed 'General case' 0 N--CA 1.496 1.863 0 O-C-N 121.376 -0.827 . . . . 0.0 109.776 179.693 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 36' ' ' ALA . . . . . . . . . . . . . . . -78.66 -24.65 45.06 Favored 'General case' 0 N--CA 1.5 2.037 0 O-C-N 121.508 -0.745 . . . . 0.0 110.324 179.985 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 4.9 tt0 -80.06 -46.83 15.84 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.519 -0.738 . . . . 0.0 109.697 179.769 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 106.42 -112.71 3.92 Favored Glycine 0 N--CA 1.489 2.184 0 N-CA-C 109.688 -1.365 . . . . 0.0 109.688 179.792 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 39' ' ' CYS . . . . . 0.466 ' O ' ' HG3' ' A' ' 42' ' ' ARG . 1.6 m -144.81 -47.14 0.24 Allowed 'General case' 0 N--CA 1.501 2.114 0 O-C-N 121.408 -1.054 . . . . 0.0 110.715 -179.633 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 40' ' ' LEU . . . . . . . . . . . . . 0.7 OUTLIER 42.14 39.11 1.28 Allowed 'General case' 0 N--CA 1.505 2.311 0 O-C-N 121.518 -0.739 . . . . 0.0 111.892 179.731 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 41' ' ' ARG . . . . . . . . . . . . . 1.6 ttt-85 54.02 34.97 20.96 Favored 'General case' 0 N--CA 1.504 2.247 0 O-C-N 121.34 -0.85 . . . . 0.0 111.755 179.079 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 42' ' ' ARG . . . . . 0.466 ' HG3' ' O ' ' A' ' 39' ' ' CYS . 4.9 mtm180 -58.0 -33.82 69.34 Favored 'General case' 0 N--CA 1.505 2.297 0 O-C-N 121.273 -0.892 . . . . 0.0 111.01 179.845 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 1.8 tt0 63.69 -175.81 0.16 Allowed 'General case' 0 N--CA 1.499 2.021 0 O-C-N 121.712 -0.617 . . . . 0.0 110.483 -179.422 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 77.08 46.76 9.95 Favored Glycine 0 N--CA 1.498 2.777 0 N-CA-C 109.342 -1.503 . . . . 0.0 109.342 -179.577 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 45' ' ' GLN . . . . . . . . . . . . . 10.3 mt-30 . . . . . 0 N--CA 1.491 1.613 0 O-C-N 121.195 -1.179 . . . . 0.0 110.384 179.92 . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . 0.403 ' O ' ' HB2' ' A' ' 2' ' ' LEU . . . . . . . . 0 N--CA 1.491 1.583 0 N-CA-C 109.569 -0.53 . . . . 0.0 109.569 . . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 2' ' ' LEU . . . . . 0.403 ' HB2' ' O ' ' A' ' 1' ' ' ALA . 3.9 mm? 59.57 -170.72 0.13 Allowed 'General case' 0 N--CA 1.504 2.25 0 O-C-N 121.939 -0.476 . . . . 0.0 110.13 -179.815 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -152.15 -84.67 0.08 Allowed 'General case' 0 N--CA 1.489 1.482 0 O-C-N 121.148 -0.97 . . . . 0.0 110.463 179.783 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 4' ' ' ARG . . . . . . . . . . . . . 14.6 mtm-85 47.05 37.31 5.0 Favored 'General case' 0 N--CA 1.503 2.194 0 O-C-N 121.372 -0.83 . . . . 0.0 111.292 -179.748 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 5' ' ' CYS . . . . . 0.468 ' HB2' ' HB3' ' A' ' 8' ' ' CYS . 22.9 p -102.43 118.76 58.04 Favored Pre-proline 0 N--CA 1.494 1.763 0 O-C-N 121.048 -1.032 . . . . 0.0 109.376 178.868 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 6' ' ' PRO . . . . . . . . . . . . . 42.0 Cg_endo -70.97 -53.26 0.2 Allowed 'Trans proline' 0 C--N 1.311 -1.412 0 O-C-N 123.685 1.36 . . . . 0.0 111.778 -178.988 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -108.89 59.45 0.36 Allowed Glycine 0 N--CA 1.492 2.371 0 O-C-N 120.917 -1.114 . . . . 0.0 110.859 -179.045 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 8' ' ' CYS . . . . . 0.468 ' HB3' ' HB2' ' A' ' 5' ' ' CYS . 10.5 p -110.02 -35.68 6.06 Favored 'General case' 0 N--CA 1.5 2.034 0 O-C-N 121.264 -1.139 . . . . 0.0 110.693 179.355 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 49.4 32.19 14.57 Favored Glycine 0 N--CA 1.502 3.056 0 O-C-N 121.337 -0.852 . . . . 0.0 111.478 179.441 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 10' ' ' GLN . . . . . . . . . . . . . 69.8 mt-30 49.63 43.72 24.27 Favored 'General case' 0 N--CA 1.501 2.08 0 O-C-N 121.304 -1.115 . . . . 0.0 110.904 179.691 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -48.27 -50.06 23.88 Favored Glycine 0 N--CA 1.503 3.155 0 N-CA-C 110.619 -0.992 . . . . 0.0 110.619 -179.707 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 11.2 p -127.82 53.75 0.37 Allowed 'Isoleucine or valine' 0 N--CA 1.494 1.728 0 O-C-N 121.312 -1.111 . . . . 0.0 109.759 179.81 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 13' ' ' GLN . . . . . . . . . . . . . 1.6 pt20 -71.02 142.76 50.91 Favored 'General case' 0 N--CA 1.495 1.795 0 O-C-N 121.01 -1.057 . . . . 0.0 110.321 -179.891 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -122.75 131.89 53.98 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.321 -0.862 . . . . 0.0 109.858 179.805 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -73.36 -54.15 7.05 Favored Glycine 0 N--CA 1.491 2.314 0 N-CA-C 109.662 -1.375 . . . . 0.0 109.662 -179.976 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 12.2 m -114.3 122.0 35.18 Favored Pre-proline 0 N--CA 1.499 1.992 0 O-C-N 121.295 -1.12 . . . . 0.0 109.996 -179.94 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 43.6 Cg_endo -72.11 75.38 2.3 Favored 'Trans proline' 0 N--CA 1.497 1.692 0 O-C-N 123.611 1.322 . . . . 0.0 110.789 -179.69 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 127.14 -46.02 1.11 Allowed Glycine 0 N--CA 1.495 2.571 0 N-CA-C 109.659 -1.376 . . . . 0.0 109.659 179.879 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 161.5 147.33 4.94 Favored Glycine 0 N--CA 1.484 1.884 0 N-CA-C 109.321 -1.512 . . . . 0.0 109.321 -179.318 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 0.9 OUTLIER -106.22 172.2 6.94 Favored 'General case' 0 C--N 1.296 -1.746 0 O-C-N 121.534 -0.98 . . . . 0.0 109.647 -179.811 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 10.5 t -78.71 61.33 0.17 Allowed 'Isoleucine or valine' 0 N--CA 1.498 1.936 0 O-C-N 121.35 -0.844 . . . . 0.0 109.781 179.527 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 3.0 mm-40 -131.24 37.49 3.72 Favored 'General case' 0 C--N 1.306 -1.305 0 O-C-N 121.585 -0.697 . . . . 0.0 109.661 -179.717 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 48.2 mt-10 -68.5 167.11 15.54 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.308 -0.87 . . . . 0.0 110.874 -179.236 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 2.8 pm0 -70.91 158.9 35.65 Favored 'General case' 0 N--CA 1.495 1.794 0 O-C-N 121.733 -0.605 . . . . 0.0 111.18 -179.014 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -80.3 -65.46 1.0 Allowed 'General case' 0 N--CA 1.491 1.597 0 N-CA-C 109.376 -0.602 . . . . 0.0 109.376 179.212 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 174.74 84.57 0.06 OUTLIER Glycine 0 N--CA 1.494 2.507 0 N-CA-C 109.535 -1.426 . . . . 0.0 109.535 179.853 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 149.16 128.3 1.66 Allowed Glycine 0 N--CA 1.493 2.464 0 N-CA-C 109.268 -1.533 . . . . 0.0 109.268 179.944 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -93.39 150.73 39.47 Favored Pre-proline 0 N--CA 1.495 1.818 0 O-C-N 121.559 -0.965 . . . . 0.0 110.444 -179.507 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 29' ' ' PRO . . . . . 0.486 ' HA ' ' HB3' ' A' ' 33' ' ' CYS . 52.4 Cg_endo -79.55 14.19 1.89 Allowed 'Trans proline' 0 N--CA 1.486 1.083 0 O-C-N 123.833 1.439 . . . . 0.0 111.784 179.81 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -127.55 15.18 7.08 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.049 -1.032 . . . . 0.0 110.394 179.585 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -159.84 -75.58 0.07 Allowed 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.458 -0.776 . . . . 0.0 109.613 -179.638 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . -66.97 -56.51 12.27 Favored Glycine 0 N--CA 1.496 2.646 0 N-CA-C 109.284 -1.526 . . . . 0.0 109.284 179.699 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 33' ' ' CYS . . . . . 0.486 ' HB3' ' HA ' ' A' ' 29' ' ' PRO . 5.5 t -87.24 73.83 9.63 Favored 'General case' 0 N--CA 1.497 1.895 0 O-C-N 121.358 -1.084 . . . . 0.0 109.891 179.766 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -147.86 49.24 1.07 Allowed 'General case' 0 N--CA 1.495 1.793 0 O-C-N 121.495 -0.753 . . . . 0.0 110.063 179.831 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 12.0 mt-10 -108.51 -174.35 2.5 Favored 'General case' 0 N--CA 1.494 1.762 0 O-C-N 121.467 -0.771 . . . . 0.0 110.69 -179.862 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 36' ' ' ALA . . . . . . . . . . . . . . . -89.97 -1.96 58.07 Favored 'General case' 0 N--CA 1.499 2.006 0 O-C-N 121.294 -0.879 . . . . 0.0 111.501 179.89 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -117.81 31.89 6.45 Favored 'General case' 0 N--CA 1.493 1.689 0 O-C-N 121.297 -0.877 . . . . 0.0 110.856 179.922 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 67.3 -118.1 9.75 Favored Glycine 0 N--CA 1.49 2.252 0 N-CA-C 109.661 -1.376 . . . . 0.0 109.661 179.607 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 39' ' ' CYS . . . . . 0.428 ' C ' HD12 ' A' ' 40' ' ' LEU . 0.1 OUTLIER -153.7 24.51 0.51 Allowed 'General case' 0 N--CA 1.499 2.006 0 O-C-N 121.522 -0.987 . . . . 0.0 111.292 -179.969 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 40' ' ' LEU . . . . . 0.555 ' C ' HD23 ' A' ' 40' ' ' LEU . 0.0 OUTLIER -140.9 172.75 12.26 Favored 'General case' 0 N--CA 1.493 1.715 0 O-C-N 120.888 -1.132 . . . . 0.0 110.496 179.083 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 41' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER 46.72 37.03 4.2 Favored 'General case' 0 N--CA 1.503 2.205 0 O-C-N 121.428 -0.795 . . . . 0.0 110.961 -179.98 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 42' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -95.19 50.16 1.25 Allowed 'General case' 0 N--CA 1.489 1.483 0 O-C-N 120.983 -1.073 . . . . 0.0 110.102 179.634 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 0.9 OUTLIER -139.13 155.66 47.71 Favored 'General case' 0 C--N 1.305 -1.348 0 O-C-N 121.865 -0.522 . . . . 0.0 109.849 179.913 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -154.43 42.05 0.61 Allowed Glycine 0 N--CA 1.5 2.914 0 N-CA-C 109.341 -1.503 . . . . 0.0 109.341 179.437 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 45' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.495 1.8 0 O-C-N 121.467 -1.019 . . . . 0.0 109.951 179.91 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.484 1.237 0 N-CA-C 109.594 -0.521 . . . . 0.0 109.594 . . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 2.1 tp 58.96 84.01 0.12 Allowed 'General case' 0 N--CA 1.507 2.397 0 CA-C-O 121.286 0.565 . . . . 0.0 111.308 179.776 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 3' ' ' ALA . . . . . 0.412 ' O ' ' HB2' ' A' ' 4' ' ' ARG . . . 61.91 177.23 0.13 Allowed 'General case' 0 N--CA 1.503 2.187 0 O-C-N 121.668 -0.645 . . . . 0.0 111.436 179.61 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 4' ' ' ARG . . . . . 0.412 ' HB2' ' O ' ' A' ' 3' ' ' ALA . 16.9 tpt180 -177.8 -57.66 0.01 OUTLIER 'General case' 0 N--CA 1.497 1.906 0 O-C-N 121.672 -0.642 . . . . 0.0 110.056 179.373 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 0.8 OUTLIER -134.56 86.98 33.07 Favored Pre-proline 0 N--CA 1.492 1.659 0 O-C-N 120.904 -1.122 . . . . 0.0 110.013 -179.964 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 6' ' ' PRO . . . . . . . . . . . . . 39.3 Cg_endo -66.93 96.46 0.37 Allowed 'Trans proline' 0 C--N 1.303 -1.823 0 O-C-N 124.835 1.966 . . . . 0.0 111.241 -179.78 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 90.35 13.17 60.44 Favored Glycine 0 N--CA 1.493 2.499 0 C-N-CA 120.292 -0.956 . . . . 0.0 111.123 179.187 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 3.7 p -143.72 171.66 13.89 Favored 'General case' 0 N--CA 1.495 1.802 0 O-C-N 120.425 -1.633 . . . . 0.0 110.134 179.614 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 97.55 122.27 4.4 Favored Glycine 0 N--CA 1.494 2.511 0 N-CA-C 108.847 -1.701 . . . . 0.0 108.847 -179.147 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 10' ' ' GLN . . . . . . . . . . . . . 2.2 mt-30 -81.7 49.44 1.34 Allowed 'General case' 0 N--CA 1.494 1.743 0 O-C-N 121.156 -1.202 . . . . 0.0 110.922 -179.483 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -92.67 58.34 2.58 Favored Glycine 0 N--CA 1.495 2.599 0 N-CA-C 108.947 -1.661 . . . . 0.0 108.947 179.453 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 10.7 t -130.21 63.08 0.3 Allowed 'Isoleucine or valine' 0 N--CA 1.496 1.873 0 O-C-N 121.551 -0.97 . . . . 0.0 109.734 -179.674 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 13' ' ' GLN . . . . . . . . . . . . . 2.2 tt0 -121.01 102.95 8.67 Favored 'General case' 0 N--CA 1.487 1.408 0 O-C-N 121.245 -0.909 . . . . 0.0 109.748 179.816 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -134.7 -73.81 0.47 Allowed 'General case' 0 N--CA 1.492 1.675 0 O-C-N 121.941 -0.475 . . . . 0.0 109.826 179.993 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 136.46 -58.47 0.66 Allowed Glycine 0 N--CA 1.495 2.608 0 N-CA-C 109.537 -1.425 . . . . 0.0 109.537 179.966 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 10.1 m -79.49 148.63 70.37 Favored Pre-proline 0 N--CA 1.5 2.043 0 O-C-N 121.387 -1.067 . . . . 0.0 109.651 179.848 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 41.1 Cg_endo -66.69 -26.57 45.68 Favored 'Trans proline' 0 N--CA 1.492 1.435 0 O-C-N 123.896 1.471 . . . . 0.0 111.414 -179.636 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 174.66 85.29 0.06 OUTLIER Glycine 0 N--CA 1.494 2.5 0 N-CA-C 109.436 -1.466 . . . . 0.0 109.436 179.802 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 94.76 142.29 12.49 Favored Glycine 0 N--CA 1.488 2.147 0 N-CA-C 109.529 -1.428 . . . . 0.0 109.529 -179.834 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 0.0 OUTLIER -142.4 110.24 5.85 Favored 'General case' 0 N--CA 1.497 1.901 0 O-C-N 121.645 -0.915 . . . . 0.0 109.62 179.602 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 3.7 t -98.51 46.7 0.11 Allowed 'Isoleucine or valine' 0 N--CA 1.497 1.901 0 O-C-N 121.645 -0.659 . . . . 0.0 110.214 -179.635 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 8.6 mt-10 -87.99 -25.62 23.05 Favored 'General case' 0 N--CA 1.488 1.459 0 O-C-N 121.307 -0.871 . . . . 0.0 110.501 179.671 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 0.9 OUTLIER 60.02 -159.96 0.3 Allowed 'General case' 0 N--CA 1.501 2.09 0 O-C-N 121.751 -0.593 . . . . 0.0 110.976 179.924 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -124.44 -154.1 0.59 Allowed 'General case' 0 N--CA 1.488 1.439 0 O-C-N 121.537 -0.727 . . . . 0.0 110.169 -179.558 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -84.96 143.98 28.62 Favored 'General case' 0 N--CA 1.494 1.765 0 O-C-N 121.282 -0.886 . . . . 0.0 110.233 -179.971 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -69.69 -16.64 72.26 Favored Glycine 0 N--CA 1.493 2.472 0 N-CA-C 109.986 -1.246 . . . . 0.0 109.986 178.926 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 115.96 -107.7 1.72 Allowed Glycine 0 N--CA 1.49 2.285 0 N-CA-C 109.286 -1.526 . . . . 0.0 109.286 179.843 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -113.01 91.7 19.04 Favored Pre-proline 0 N--CA 1.497 1.88 0 O-C-N 121.327 -1.102 . . . . 0.0 109.63 179.375 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 44.2 Cg_endo -73.42 118.22 5.41 Favored 'Trans proline' 0 N--CA 1.49 1.318 0 O-C-N 123.692 1.364 . . . . 0.0 110.955 179.959 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -121.34 34.19 5.28 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.164 -0.96 . . . . 0.0 110.716 179.664 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 31' ' ' GLU . . . . . 0.502 ' HG3' ' N ' ' A' ' 32' ' ' GLY . 0.1 OUTLIER -86.85 -32.02 20.49 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.025 -1.047 . . . . 0.0 110.168 179.873 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 32' ' ' GLY . . . . . 0.502 ' N ' ' HG3' ' A' ' 31' ' ' GLU . . . 137.41 -47.42 0.95 Allowed Glycine 0 N--CA 1.493 2.464 0 N-CA-C 110.22 -1.152 . . . . 0.0 110.22 179.623 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 33' ' ' CYS . . . . . . . . . . . . . 0.9 OUTLIER -113.72 92.21 3.9 Favored 'General case' 0 N--CA 1.493 1.675 0 O-C-N 121.582 -0.952 . . . . 0.0 110.881 -179.398 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -96.9 37.32 1.31 Allowed 'General case' 0 N--CA 1.499 1.976 0 O-C-N 121.138 -0.976 . . . . 0.0 109.863 179.211 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 10.8 mt-10 -137.48 -178.1 5.08 Favored 'General case' 0 N--CA 1.497 1.902 0 O-C-N 121.747 -0.596 . . . . 0.0 109.867 179.812 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 36' ' ' ALA . . . . . . . . . . . . . . . -88.75 35.69 0.79 Allowed 'General case' 0 N--CA 1.493 1.717 0 O-C-N 120.993 -1.067 . . . . 0.0 110.594 -179.819 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 5.6 tt0 -78.5 -26.91 46.04 Favored 'General case' 0 N--CA 1.486 1.347 0 O-C-N 121.39 -0.819 . . . . 0.0 110.076 179.666 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 70.22 70.83 1.1 Allowed Glycine 0 N--CA 1.492 2.379 0 N-CA-C 109.137 -1.585 . . . . 0.0 109.137 179.689 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 39' ' ' CYS . . . . . . . . . . . . . 1.8 m -100.89 110.08 22.11 Favored 'General case' 0 C--N 1.298 -1.665 0 O-C-N 121.733 -0.863 . . . . 0.0 109.793 -179.768 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 40' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -128.81 -64.29 0.93 Allowed 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.425 -0.797 . . . . 0.0 110.961 -179.794 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 41' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -156.62 -143.22 0.11 Allowed 'General case' 0 N--CA 1.488 1.469 0 O-C-N 121.053 -1.029 . . . . 0.0 109.878 -179.638 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 42' ' ' ARG . . . . . . . . . . . . . 1.8 mtt180 -75.13 17.46 0.24 Allowed 'General case' 0 N--CA 1.498 1.927 0 O-C-N 120.849 -1.157 . . . . 0.0 112.336 -179.767 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 3.4 mm-40 -77.95 76.44 4.48 Favored 'General case' 0 N--CA 1.494 1.773 0 O-C-N 120.499 -1.375 . . . . 0.0 109.326 179.51 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -85.96 71.55 2.83 Favored Glycine 0 N--CA 1.495 2.598 0 N-CA-C 110.397 -1.081 . . . . 0.0 110.397 -179.155 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 45' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.498 1.943 0 O-C-N 121.674 -0.898 . . . . 0.0 110.095 179.691 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.494 1.743 0 CA-C-O 120.979 0.419 . . . . 0.0 109.975 . . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 12.4 tp -167.09 -56.57 0.03 OUTLIER 'General case' 0 N--CA 1.493 1.712 0 O-C-N 121.455 -0.778 . . . . 0.0 110.089 179.758 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -70.25 117.91 12.4 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 121.269 -0.894 . . . . 0.0 109.517 179.342 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 4' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -158.4 76.21 0.75 Allowed 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.413 -0.804 . . . . 0.0 110.304 179.921 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 19.8 t -144.4 104.71 4.68 Favored Pre-proline 0 N--CA 1.494 1.751 0 O-C-N 121.508 -0.745 . . . . 0.0 109.579 179.836 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 6' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -80.57 -35.63 0.55 Allowed 'Trans proline' 0 C--N 1.308 -1.57 0 O-C-N 124.09 1.573 . . . . 0.0 112.171 -179.325 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -90.45 53.22 3.45 Favored Glycine 0 N--CA 1.496 2.637 0 O-C-N 120.361 -1.462 . . . . 0.0 112.007 -178.009 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 21.7 p -161.15 163.7 31.08 Favored 'General case' 0 N--CA 1.498 1.933 0 O-C-N 120.657 -1.496 . . . . 0.0 110.655 178.854 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 70.91 63.94 2.98 Favored Glycine 0 N--CA 1.494 2.535 0 N-CA-C 109.759 -1.336 . . . . 0.0 109.759 -179.951 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 10' ' ' GLN . . . . . . . . . . . . . 3.1 pt20 -145.04 27.5 1.29 Allowed 'General case' 0 N--CA 1.493 1.698 0 O-C-N 121.619 -0.93 . . . . 0.0 111.113 -179.639 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -140.53 63.31 0.53 Allowed Glycine 0 N--CA 1.491 2.35 0 N-CA-C 109.439 -1.464 . . . . 0.0 109.439 179.839 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 28.9 m -113.79 2.06 8.39 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.834 0 O-C-N 121.568 -0.96 . . . . 0.0 111.627 -179.955 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 13' ' ' GLN . . . . . . . . . . . . . 25.6 tt0 -51.41 -45.73 62.64 Favored 'General case' 0 N--CA 1.499 2.01 0 O-C-N 120.984 -1.072 . . . . 0.0 110.613 179.815 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -111.04 26.6 10.53 Favored 'General case' 0 N--CA 1.494 1.729 0 O-C-N 121.624 -0.673 . . . . 0.0 110.272 179.714 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -128.33 68.19 0.54 Allowed Glycine 0 N--CA 1.489 2.19 0 N-CA-C 108.97 -1.652 . . . . 0.0 108.97 179.753 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 17.9 m -96.0 150.27 37.06 Favored Pre-proline 0 N--CA 1.488 1.437 0 O-C-N 121.44 -1.035 . . . . 0.0 110.497 -179.745 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 43.7 Cg_endo -74.17 -39.85 1.48 Allowed 'Trans proline' 0 N--CA 1.491 1.368 0 O-C-N 123.822 1.433 . . . . 0.0 110.648 179.426 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . -167.12 59.36 0.22 Allowed Glycine 0 N--CA 1.493 2.461 0 N-CA-C 109.163 -1.575 . . . . 0.0 109.163 179.589 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 141.18 132.56 2.82 Favored Glycine 0 N--CA 1.493 2.496 0 N-CA-C 108.625 -1.79 . . . . 0.0 108.625 -179.557 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -134.32 169.38 17.31 Favored 'General case' 0 N--CA 1.496 1.851 0 O-C-N 121.512 -0.993 . . . . 0.0 109.301 -179.665 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 11.7 p -80.06 50.89 0.07 OUTLIER 'Isoleucine or valine' 0 N--CA 1.502 2.155 0 O-C-N 121.319 -0.863 . . . . 0.0 111.254 -179.736 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 2.8 mt-10 -108.58 51.76 0.73 Allowed 'General case' 0 C--N 1.305 -1.326 0 O-C-N 121.014 -1.053 . . . . 0.0 108.436 178.419 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 0.8 OUTLIER 52.55 59.41 4.52 Favored 'General case' 0 N--CA 1.495 1.806 0 CA-C-O 121.93 0.871 . . . . 0.0 109.222 -177.995 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 1.7 pm0 -61.0 -5.46 1.4 Allowed 'General case' 0 N--CA 1.5 2.034 0 O-C-N 121.432 -0.793 . . . . 0.0 112.228 -179.105 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 15.7 m-20 -77.17 -24.18 51.49 Favored 'General case' 0 N--CA 1.497 1.924 0 O-C-N 120.737 -1.227 . . . . 0.0 110.431 179.641 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 88.39 -51.96 3.99 Favored Glycine 0 N--CA 1.495 2.589 0 N-CA-C 109.726 -1.35 . . . . 0.0 109.726 -179.921 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -177.29 -140.05 3.53 Favored Glycine 0 N--CA 1.493 2.472 0 N-CA-C 109.798 -1.321 . . . . 0.0 109.798 -179.696 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 28' ' ' SER . . . . . 0.46 ' CB ' ' CD ' ' A' ' 29' ' ' PRO . 2.6 t -154.92 -64.07 0.02 OUTLIER Pre-proline 0 N--CA 1.494 1.744 0 O-C-N 121.163 -1.198 . . . . 0.0 110.665 179.835 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 29' ' ' PRO . . . . . 0.46 ' CD ' ' CB ' ' A' ' 28' ' ' SER . 41.4 Cg_endo -68.89 -31.23 25.09 Favored 'Trans proline' 0 N--CA 1.488 1.188 0 O-C-N 122.979 0.989 . . . . 0.0 111.133 -179.562 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -99.12 54.29 0.98 Allowed 'General case' 0 N--CA 1.493 1.704 0 O-C-N 121.376 -0.827 . . . . 0.0 110.827 -179.633 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 2.8 tp10 -84.48 -42.41 15.6 Favored 'General case' 0 N--CA 1.493 1.717 0 O-C-N 121.379 -0.826 . . . . 0.0 110.217 179.603 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 96.47 52.43 1.57 Allowed Glycine 0 N--CA 1.501 2.995 0 N-CA-C 109.634 -1.386 . . . . 0.0 109.634 -179.804 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 33' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -79.62 118.64 21.64 Favored 'General case' 0 N--CA 1.495 1.814 0 O-C-N 121.157 -1.202 . . . . 0.0 109.735 179.903 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -79.49 -28.5 41.47 Favored 'General case' 0 N--CA 1.497 1.918 0 O-C-N 121.259 -0.9 . . . . 0.0 110.721 -179.851 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 24.5 mp0 -78.19 153.53 31.92 Favored 'General case' 0 N--CA 1.492 1.658 0 CA-C-O 121.491 0.662 . . . . 0.0 110.556 -179.762 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 36' ' ' ALA . . . . . . . . . . . . . . . -91.88 -42.18 10.2 Favored 'General case' 0 N--CA 1.496 1.825 0 O-C-N 121.415 -0.803 . . . . 0.0 110.999 -179.668 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 16.2 tt0 -77.18 -26.12 52.57 Favored 'General case' 0 N--CA 1.494 1.757 0 O-C-N 120.796 -1.19 . . . . 0.0 111.197 -179.006 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -70.26 -32.72 68.66 Favored Glycine 0 N--CA 1.497 2.705 0 C-N-CA 120.386 -0.911 . . . . 0.0 111.203 -178.942 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 39' ' ' CYS . . . . . . . . . . . . . 90.1 m -135.36 -32.32 0.94 Allowed 'General case' 0 N--CA 1.506 2.344 0 O-C-N 120.709 -1.466 . . . . 0.0 112.872 -178.697 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 40' ' ' LEU . . . . . . . . . . . . . 1.0 OUTLIER -74.39 63.73 1.08 Allowed 'General case' 0 N--CA 1.497 1.879 0 O-C-N 120.697 -1.252 . . . . 0.0 111.606 -178.371 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 41' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -115.88 67.96 0.72 Allowed 'General case' 0 N--CA 1.487 1.409 0 O-C-N 120.995 -1.066 . . . . 0.0 110.262 179.23 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 42' ' ' ARG . . . . . . . . . . . . . 9.4 mtt180 -142.43 42.92 1.63 Allowed 'General case' 0 N--CA 1.488 1.435 0 O-C-N 121.476 -0.765 . . . . 0.0 109.712 179.041 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 3.7 pm0 -69.52 145.45 52.64 Favored 'General case' 0 N--CA 1.494 1.736 0 O-C-N 121.618 -0.676 . . . . 0.0 110.495 -179.71 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -77.48 58.86 3.73 Favored Glycine 0 N--CA 1.497 2.708 0 N-CA-C 110.118 -1.193 . . . . 0.0 110.118 -179.771 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 45' ' ' GLN . . . . . . . . . . . . . 18.9 mt-30 . . . . . 0 N--CA 1.493 1.712 0 CA-C-O 117.722 -1.133 . . . . 0.0 110.059 179.47 . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.493 1.702 0 N-CA-C 110.075 -0.342 . . . . 0.0 110.075 . . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 0.0 OUTLIER -151.25 57.12 0.89 Allowed 'General case' 0 N--CA 1.493 1.71 0 O-C-N 121.44 -0.788 . . . . 0.0 110.427 180.0 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -103.38 95.65 6.23 Favored 'General case' 0 N--CA 1.488 1.438 0 O-C-N 121.218 -0.926 . . . . 0.0 110.267 -179.94 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 4' ' ' ARG . . . . . . . . . . . . . 2.5 ptp85 -57.63 105.57 0.26 Allowed 'General case' 0 N--CA 1.497 1.892 0 O-C-N 121.525 -0.734 . . . . 0.0 110.463 -179.872 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 31.6 p -126.03 141.81 40.64 Favored Pre-proline 0 N--CA 1.493 1.686 0 O-C-N 121.072 -1.018 . . . . 0.0 110.599 -179.668 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 6' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -78.26 110.59 2.9 Favored 'Trans proline' 0 N--CA 1.487 1.136 0 O-C-N 123.938 1.494 . . . . 0.0 111.516 -179.416 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 47.44 54.69 10.14 Favored Glycine 0 N--CA 1.497 2.707 0 O-C-N 121.337 -0.852 . . . . 0.0 110.983 179.147 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -112.84 -171.95 1.96 Allowed 'General case' 0 N--CA 1.495 1.784 0 O-C-N 121.342 -1.093 . . . . 0.0 109.822 179.24 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 9' ' ' GLY . . . . . 0.489 ' O ' ' HG2' ' A' ' 10' ' ' GLN . . . 95.54 36.34 5.39 Favored Glycine 0 N--CA 1.495 2.608 0 N-CA-C 109.452 -1.459 . . . . 0.0 109.452 179.973 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 10' ' ' GLN . . . . . 0.489 ' HG2' ' O ' ' A' ' 9' ' ' GLY . 0.0 OUTLIER 26.87 54.81 0.05 Allowed 'General case' 0 N--CA 1.506 2.351 0 CA-C-N 117.379 0.59 . . . . 0.0 112.055 179.679 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -135.95 52.37 0.79 Allowed Glycine 0 N--CA 1.496 2.662 0 N-CA-C 109.511 -1.436 . . . . 0.0 109.511 179.586 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 6.3 p -107.97 -2.49 10.06 Favored 'Isoleucine or valine' 0 N--CA 1.499 2.017 0 O-C-N 121.12 -1.223 . . . . 0.0 110.877 -179.331 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 13' ' ' GLN . . . . . . . . . . . . . 7.0 mt-30 -76.11 79.3 2.94 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 120.884 -1.135 . . . . 0.0 110.444 -179.491 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -119.02 174.75 6.12 Favored 'General case' 0 N--CA 1.498 1.972 0 O-C-N 121.673 -0.642 . . . . 0.0 110.29 179.662 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -143.25 -94.62 0.2 Allowed Glycine 0 N--CA 1.494 2.54 0 N-CA-C 109.544 -1.422 . . . . 0.0 109.544 179.895 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 4.7 m -89.07 151.09 46.43 Favored Pre-proline 0 N--CA 1.492 1.648 0 O-C-N 121.34 -1.094 . . . . 0.0 109.975 179.655 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 50.0 Cg_endo -75.14 59.01 5.17 Favored 'Trans proline' 0 C--N 1.315 -1.205 0 O-C-N 123.847 1.446 . . . . 0.0 111.052 -179.953 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 69.93 11.3 66.3 Favored Glycine 0 N--CA 1.494 2.56 0 N-CA-C 110.609 -0.996 . . . . 0.0 110.609 179.887 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -147.74 114.52 0.7 Allowed Glycine 0 N--CA 1.488 2.141 0 N-CA-C 109.064 -1.615 . . . . 0.0 109.064 -179.507 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -153.67 142.87 21.43 Favored 'General case' 0 N--CA 1.494 1.775 0 O-C-N 121.483 -1.01 . . . . 0.0 110.125 -179.85 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . 0.415 ' O ' HG23 ' A' ' 21' ' ' VAL . 11.5 p -150.35 44.67 0.08 OUTLIER 'Isoleucine or valine' 0 N--CA 1.499 1.99 0 CA-C-O 121.559 0.695 . . . . 0.0 110.164 -179.681 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 1.8 mt-10 -112.31 -13.57 13.43 Favored 'General case' 0 N--CA 1.487 1.418 0 O-C-N 121.191 -0.943 . . . . 0.0 110.758 179.654 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 1.4 tp10 58.73 85.95 0.09 Allowed 'General case' 0 N--CA 1.504 2.253 0 O-C-N 121.355 -0.84 . . . . 0.0 110.526 179.855 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 26.1 mt-10 -79.24 50.01 1.03 Allowed 'General case' 0 N--CA 1.496 1.854 0 O-C-N 120.858 -1.151 . . . . 0.0 111.286 -179.883 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 2.5 t70 -113.97 68.98 0.7 Allowed 'General case' 0 N--CA 1.495 1.788 0 O-C-N 121.211 -0.931 . . . . 0.0 109.979 179.706 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 159.87 -87.62 0.11 Allowed Glycine 0 N--CA 1.495 2.627 0 N-CA-C 109.638 -1.385 . . . . 0.0 109.638 179.838 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 121.47 -56.92 0.61 Allowed Glycine 0 N--CA 1.494 2.526 0 N-CA-C 109.533 -1.427 . . . . 0.0 109.533 -179.853 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 58.3 m -125.42 159.75 58.71 Favored Pre-proline 0 N--CA 1.498 1.953 0 O-C-N 121.762 -0.846 . . . . 0.0 110.157 179.964 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 42.4 Cg_endo -65.76 -29.13 51.15 Favored 'Trans proline' 0 N--CA 1.492 1.411 0 O-C-N 123.883 1.465 . . . . 0.0 111.076 179.736 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -96.15 15.81 19.83 Favored 'General case' 0 N--CA 1.487 1.384 0 O-C-N 120.822 -1.174 . . . . 0.0 110.224 178.965 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 37.0 tp10 -79.65 -50.71 10.24 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.089 -1.007 . . . . 0.0 110.818 -179.103 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 131.64 88.27 0.43 Allowed Glycine 0 N--CA 1.487 2.088 0 N-CA-C 108.771 -1.732 . . . . 0.0 108.771 -179.384 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 33' ' ' CYS . . . . . . . . . . . . . 17.9 m -78.22 125.59 29.57 Favored 'General case' 0 N--CA 1.502 2.131 0 O-C-N 121.279 -1.13 . . . . 0.0 110.307 -179.811 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -79.09 -17.21 55.56 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.363 -0.836 . . . . 0.0 109.839 179.15 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 1.1 tm-20 -103.74 165.24 11.16 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.391 -0.818 . . . . 0.0 109.999 179.581 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 36' ' ' ALA . . . . . . . . . . . . . . . -102.04 -26.92 13.22 Favored 'General case' 0 N--CA 1.498 1.955 0 O-C-N 121.335 -0.853 . . . . 0.0 110.903 179.58 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 1.5 mt-10 -79.58 -31.93 41.92 Favored 'General case' 0 N--CA 1.494 1.775 0 O-C-N 120.942 -1.099 . . . . 0.0 110.604 -179.195 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -75.22 -36.96 43.76 Favored Glycine 0 N--CA 1.493 2.459 0 N-CA-C 110.392 -1.083 . . . . 0.0 110.392 -179.91 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 39' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -96.47 -27.85 14.69 Favored 'General case' 0 N--CA 1.499 2.005 0 O-C-N 120.868 -1.372 . . . . 0.0 111.477 -179.865 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 40' ' ' LEU . . . . . . . . . . . . . 0.8 OUTLIER 60.15 -170.01 0.15 Allowed 'General case' 0 N--CA 1.502 2.133 0 O-C-N 121.297 -0.877 . . . . 0.0 110.657 -179.417 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 41' ' ' ARG . . . . . . . . . . . . . 1.2 ttt-85 -125.06 82.75 2.09 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.248 -0.907 . . . . 0.0 109.875 179.707 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 42' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -100.18 -38.41 8.53 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.357 -0.839 . . . . 0.0 110.42 -179.439 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER 56.69 -167.69 0.11 Allowed 'General case' 0 N--CA 1.498 1.964 0 CA-C-O 121.506 0.67 . . . . 0.0 110.836 -179.658 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 176.1 -58.94 0.11 Allowed Glycine 0 N--CA 1.49 2.248 0 N-CA-C 109.946 -1.262 . . . . 0.0 109.946 -179.649 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 45' ' ' GLN . . . . . . . . . . . . . 2.0 pt20 . . . . . 0 N--CA 1.503 2.194 0 O-C-N 120.869 -1.371 . . . . 0.0 110.47 179.632 . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.495 1.81 0 N-CA-C 110.103 -0.332 . . . . 0.0 110.103 . . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -162.43 30.14 0.11 Allowed 'General case' 0 N--CA 1.498 1.938 0 O-C-N 121.689 -0.632 . . . . 0.0 110.903 179.618 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . 49.87 -154.34 0.12 Allowed 'General case' 0 N--CA 1.501 2.106 0 O-C-N 121.499 -0.751 . . . . 0.0 110.759 179.856 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 4' ' ' ARG . . . . . . . . . . . . . 4.0 mmt85 53.47 -145.94 0.57 Allowed 'General case' 0 N--CA 1.496 1.865 0 O-C-N 121.538 -0.726 . . . . 0.0 110.431 179.843 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 5.8 p -131.65 133.26 24.04 Favored Pre-proline 0 N--CA 1.497 1.923 0 O-C-N 121.083 -1.011 . . . . 0.0 110.394 -179.714 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 6' ' ' PRO . . . . . . . . . . . . . 44.1 Cg_endo -75.09 -53.49 0.1 OUTLIER 'Trans proline' 0 C--N 1.311 -1.443 0 O-C-N 123.559 1.294 . . . . 0.0 111.351 -179.577 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -85.97 59.87 4.68 Favored Glycine 0 N--CA 1.492 2.373 0 N-CA-C 110.238 -1.145 . . . . 0.0 110.238 -179.426 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 0.7 OUTLIER -106.02 18.38 22.16 Favored 'General case' 0 N--CA 1.501 2.084 0 O-C-N 121.281 -1.129 . . . . 0.0 110.56 179.325 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 106.17 55.73 0.67 Allowed Glycine 0 N--CA 1.496 2.676 0 N-CA-C 109.975 -1.25 . . . . 0.0 109.975 179.729 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 10' ' ' GLN . . . . . . . . . . . . . 3.8 pt20 -161.79 48.35 0.19 Allowed 'General case' 0 N--CA 1.492 1.633 0 O-C-N 121.383 -1.069 . . . . 0.0 110.361 179.777 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -94.79 66.36 1.37 Allowed Glycine 0 N--CA 1.495 2.588 0 N-CA-C 109.599 -1.4 . . . . 0.0 109.599 179.901 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 24.6 t -122.3 -20.06 4.05 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.029 0 O-C-N 121.393 -1.063 . . . . 0.0 111.079 -179.483 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 13' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -81.38 -144.38 0.05 Allowed 'General case' 0 N--CA 1.492 1.646 0 O-C-N 121.053 -1.029 . . . . 0.0 110.393 -179.854 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . 59.07 -155.62 0.35 Allowed 'General case' 0 N--CA 1.498 1.966 0 O-C-N 121.647 -0.658 . . . . 0.0 109.821 -179.727 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -91.28 42.93 2.81 Favored Glycine 0 N--CA 1.49 2.262 0 N-CA-C 109.371 -1.492 . . . . 0.0 109.371 179.916 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 81.1 m -119.38 67.09 9.37 Favored Pre-proline 0 N--CA 1.493 1.709 0 O-C-N 121.295 -1.12 . . . . 0.0 110.801 -179.5 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 46.6 Cg_endo -71.83 69.01 3.0 Favored 'Trans proline' 0 C--N 1.313 -1.319 0 O-C-N 123.385 1.202 . . . . 0.0 110.504 -179.892 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 105.73 -14.71 45.73 Favored Glycine 0 N--CA 1.498 2.786 0 N-CA-C 110.134 -1.186 . . . . 0.0 110.134 -179.603 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -154.2 123.95 1.47 Allowed Glycine 0 N--CA 1.489 2.213 0 N-CA-C 109.152 -1.579 . . . . 0.0 109.152 179.87 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -108.05 47.13 0.91 Allowed 'General case' 0 N--CA 1.497 1.904 0 O-C-N 121.399 -1.059 . . . . 0.0 109.699 179.706 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 9.9 p -136.4 20.97 0.9 Allowed 'Isoleucine or valine' 0 N--CA 1.502 2.167 0 O-C-N 120.915 -1.116 . . . . 0.0 111.29 -179.444 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 22' ' ' GLU . . . . . 0.405 ' C ' ' HG3' ' A' ' 23' ' ' GLU . 1.5 tp10 -101.21 -12.06 19.03 Favored 'General case' 0 C--N 1.305 -1.339 0 O-C-N 121.179 -0.951 . . . . 0.0 109.993 179.098 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 23' ' ' GLU . . . . . 0.405 ' HG3' ' C ' ' A' ' 22' ' ' GLU . 0.0 OUTLIER -146.06 74.86 1.39 Allowed 'General case' 0 N--CA 1.488 1.446 0 O-C-N 121.429 -0.794 . . . . 0.0 109.436 -179.582 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER -56.05 -58.54 7.47 Favored 'General case' 0 N--CA 1.5 2.037 0 O-C-N 121.207 -0.933 . . . . 0.0 110.79 -179.421 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -149.28 -61.86 0.22 Allowed 'General case' 0 N--CA 1.495 1.811 0 O-C-N 121.332 -0.855 . . . . 0.0 110.06 179.964 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 134.04 86.03 0.25 Allowed Glycine 0 N--CA 1.497 2.708 0 N-CA-C 109.504 -1.438 . . . . 0.0 109.504 -179.716 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 165.45 95.95 0.11 Allowed Glycine 0 N--CA 1.494 2.557 0 N-CA-C 109.147 -1.581 . . . . 0.0 109.147 -179.702 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 28' ' ' SER . . . . . 0.506 ' HB2' ' HD3' ' A' ' 29' ' ' PRO . 0.0 OUTLIER -154.72 -62.6 0.02 OUTLIER Pre-proline 0 N--CA 1.497 1.909 0 O-C-N 121.263 -1.14 . . . . 0.0 110.777 179.85 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 29' ' ' PRO . . . . . 0.506 ' HD3' ' HB2' ' A' ' 28' ' ' SER . 44.8 Cg_endo -75.44 123.82 7.91 Favored 'Trans proline' 0 C--N 1.318 -1.062 0 O-C-N 122.922 0.959 . . . . 0.0 110.405 -179.744 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -78.54 -9.39 59.32 Favored 'General case' 0 N--CA 1.498 1.943 0 O-C-N 121.148 -0.97 . . . . 0.0 111.154 -179.665 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 4.1 tp10 -79.76 -56.92 3.94 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.253 -0.905 . . . . 0.0 109.556 179.742 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 171.88 -64.85 0.14 Allowed Glycine 0 N--CA 1.492 2.418 0 N-CA-C 109.181 -1.568 . . . . 0.0 109.181 -179.999 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 33' ' ' CYS . . . . . . . . . . . . . 12.7 p -148.29 88.33 1.64 Allowed 'General case' 0 N--CA 1.493 1.715 0 O-C-N 121.495 -1.003 . . . . 0.0 109.521 179.648 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -86.28 39.42 0.82 Allowed 'General case' 0 N--CA 1.495 1.808 0 O-C-N 121.342 -0.849 . . . . 0.0 110.82 -179.479 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER -113.8 163.26 15.28 Favored 'General case' 0 N--CA 1.495 1.793 0 O-C-N 121.218 -0.926 . . . . 0.0 110.214 179.812 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 36' ' ' ALA . . . . . 0.524 ' HA ' ' HB2' ' A' ' 40' ' ' LEU . . . -102.61 0.1 32.78 Favored 'General case' 0 N--CA 1.498 1.97 0 O-C-N 121.515 -0.741 . . . . 0.0 112.148 -178.706 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 2.7 pm0 -79.59 -27.24 41.13 Favored 'General case' 0 N--CA 1.498 1.94 0 O-C-N 120.582 -1.324 . . . . 0.0 111.556 -179.132 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -133.34 -47.41 0.1 Allowed Glycine 0 N--CA 1.498 2.799 0 C-N-CA 118.894 -1.622 . . . . 0.0 111.825 -178.77 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 39' ' ' CYS . . . . . . . . . . . . . 4.3 m -79.53 0.94 27.68 Favored 'General case' 0 N--CA 1.499 2.022 0 O-C-N 120.889 -1.359 . . . . 0.0 112.304 -178.451 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 40' ' ' LEU . . . . . 0.524 ' HB2' ' HA ' ' A' ' 36' ' ' ALA . 0.5 OUTLIER -75.87 56.68 0.98 Allowed 'General case' 0 N--CA 1.497 1.923 0 O-C-N 120.851 -1.156 . . . . 0.0 109.797 179.07 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 41' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -177.91 42.49 0.01 OUTLIER 'General case' 0 N--CA 1.498 1.944 0 O-C-N 121.606 -0.684 . . . . 0.0 110.873 -179.846 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 42' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -123.56 7.6 8.91 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.27 -0.894 . . . . 0.0 110.894 179.745 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER -79.99 63.79 4.63 Favored 'General case' 0 N--CA 1.493 1.709 0 O-C-N 120.63 -1.294 . . . . 0.0 109.96 179.33 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -159.65 72.03 0.23 Allowed Glycine 0 N--CA 1.489 2.193 0 N-CA-C 109.266 -1.533 . . . . 0.0 109.266 -179.908 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 45' ' ' GLN . . . . . . . . . . . . . 0.6 OUTLIER . . . . . 0 N--CA 1.495 1.786 0 CA-C-O 117.889 -1.053 . . . . 0.0 110.628 -179.708 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.494 1.726 0 CA-C-O 120.86 0.362 . . . . 0.0 110.231 . . . . . . . . . 0 0 . 1 . 011 nuclear orig full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -170.65 90.8 0.16 Allowed 'General case' 0 N--CA 1.494 1.747 0 O-C-N 121.358 -0.839 . . . . 0.0 110.131 179.828 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -163.61 121.73 1.91 Allowed 'General case' 0 N--CA 1.494 1.729 0 O-C-N 121.315 -0.866 . . . . 0.0 110.114 179.945 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 4' ' ' ARG . . . . . . . . . . . . . 1.7 tmm_? -89.25 88.42 7.51 Favored 'General case' 0 N--CA 1.492 1.633 0 O-C-N 121.502 -0.749 . . . . 0.0 110.043 -179.916 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -142.32 158.89 60.01 Favored Pre-proline 0 N--CA 1.491 1.614 0 O-C-N 121.463 -0.773 . . . . 0.0 110.264 -179.757 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 6' ' ' PRO . . . . . . . . . . . . . 43.6 Cg_endo -75.11 -53.21 0.1 OUTLIER 'Trans proline' 0 C--N 1.315 -1.233 0 O-C-N 123.691 1.364 . . . . 0.0 110.619 179.608 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -85.17 60.73 4.74 Favored Glycine 0 N--CA 1.496 2.654 0 N-CA-C 109.465 -1.454 . . . . 0.0 109.465 179.522 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 1.5 m -96.74 24.31 6.19 Favored 'General case' 0 N--CA 1.497 1.923 0 O-C-N 121.271 -1.135 . . . . 0.0 110.678 -179.952 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -144.02 -144.46 4.22 Favored Glycine 0 N--CA 1.495 2.579 0 N-CA-C 109.354 -1.498 . . . . 0.0 109.354 179.841 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 10' ' ' GLN . . . . . . . . . . . . . 3.5 mt-30 -54.12 -49.02 70.12 Favored 'General case' 0 N--CA 1.499 2.006 0 O-C-N 121.423 -1.045 . . . . 0.0 110.959 179.953 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 109.15 -25.17 19.19 Favored Glycine 0 N--CA 1.494 2.539 0 N-CA-C 109.874 -1.29 . . . . 0.0 109.874 -179.654 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 27.4 m -95.9 46.76 0.1 OUTLIER 'Isoleucine or valine' 0 N--CA 1.497 1.908 0 O-C-N 121.015 -1.285 . . . . 0.0 110.26 179.879 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 13' ' ' GLN . . . . . . . . . . . . . 1.1 mt-30 52.11 49.38 20.76 Favored 'General case' 0 N--CA 1.498 1.93 0 O-C-N 121.705 -0.622 . . . . 0.0 111.006 179.779 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -103.87 161.65 13.78 Favored 'General case' 0 N--CA 1.497 1.917 0 O-C-N 121.263 -0.898 . . . . 0.0 110.137 179.512 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 75.58 72.06 1.1 Allowed Glycine 0 N--CA 1.495 2.625 0 N-CA-C 109.461 -1.455 . . . . 0.0 109.461 179.908 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 16' ' ' CYS . . . . . 0.433 ' HB2' ' HD2' ' A' ' 17' ' ' PRO . 17.7 p -79.8 167.23 35.42 Favored Pre-proline 0 N--CA 1.497 1.924 0 O-C-N 121.428 -1.042 . . . . 0.0 110.215 -179.922 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 17' ' ' PRO . . . . . 0.433 ' HD2' ' HB2' ' A' ' 16' ' ' CYS . 49.7 Cg_endo -77.33 53.19 4.17 Favored 'Trans proline' 0 C--N 1.311 -1.437 0 O-C-N 123.499 1.263 . . . . 0.0 110.217 178.927 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 92.7 -43.09 2.63 Favored Glycine 0 N--CA 1.496 2.64 0 N-CA-C 110.392 -1.083 . . . . 0.0 110.392 -179.89 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -74.89 83.38 0.82 Allowed Glycine 0 N--CA 1.492 2.376 0 O-C-N 121.189 -1.183 . . . . 0.0 110.495 -179.176 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 1.3 m -117.45 118.93 33.54 Favored 'General case' 0 N--CA 1.497 1.9 0 O-C-N 121.407 -1.054 . . . . 0.0 109.974 179.427 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 14.0 t -83.33 75.36 1.03 Allowed 'Isoleucine or valine' 0 N--CA 1.497 1.876 0 O-C-N 121.639 -0.663 . . . . 0.0 109.573 179.851 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 31.4 mt-10 -95.34 40.96 1.1 Allowed 'General case' 0 C--N 1.304 -1.391 0 O-C-N 121.356 -0.84 . . . . 0.0 110.115 -179.587 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 3.4 pt-20 -157.52 60.03 0.49 Allowed 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.372 -0.83 . . . . 0.0 110.164 -179.801 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -112.27 147.53 36.07 Favored 'General case' 0 N--CA 1.493 1.718 0 O-C-N 121.224 -0.922 . . . . 0.0 110.281 -179.574 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 3.1 p-10 -96.78 176.73 5.88 Favored 'General case' 0 N--CA 1.495 1.801 0 O-C-N 121.37 -0.831 . . . . 0.0 109.538 178.99 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -126.36 27.86 4.91 Favored Glycine 0 N--CA 1.493 2.487 0 N-CA-C 110.134 -1.186 . . . . 0.0 110.134 179.921 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 71.75 -68.77 1.0 Allowed Glycine 0 N--CA 1.499 2.88 0 N-CA-C 109.782 -1.327 . . . . 0.0 109.782 -179.934 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 64.4 m -83.5 116.9 66.87 Favored Pre-proline 0 N--CA 1.499 1.992 0 O-C-N 121.273 -1.134 . . . . 0.0 110.378 179.788 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 44.1 Cg_endo -71.16 154.39 62.07 Favored 'Trans proline' 0 N--CA 1.491 1.333 0 O-C-N 124.016 1.535 . . . . 0.0 111.485 -179.493 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -112.43 -50.26 2.91 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.398 -0.814 . . . . 0.0 110.625 179.84 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -102.54 -63.84 1.12 Allowed 'General case' 0 N--CA 1.495 1.79 0 O-C-N 121.485 -0.759 . . . . 0.0 110.233 -179.956 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 152.96 -59.2 0.41 Allowed Glycine 0 N--CA 1.495 2.587 0 N-CA-C 109.626 -1.39 . . . . 0.0 109.626 -179.907 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 33' ' ' CYS . . . . . . . . . . . . . 17.3 m -133.17 61.24 1.68 Allowed 'General case' 0 N--CA 1.496 1.87 0 O-C-N 121.32 -1.106 . . . . 0.0 110.075 179.87 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -122.62 26.63 8.2 Favored 'General case' 0 N--CA 1.497 1.911 0 O-C-N 121.274 -0.891 . . . . 0.0 109.876 179.528 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 22.7 mp0 -116.5 -171.88 2.09 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.732 -0.605 . . . . 0.0 110.612 -179.186 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 36' ' ' ALA . . . . . . . . . . . . . . . -92.07 -24.97 18.99 Favored 'General case' 0 N--CA 1.499 2.022 0 O-C-N 121.244 -0.91 . . . . 0.0 111.151 -179.597 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER -79.71 52.46 1.45 Allowed 'General case' 0 N--CA 1.499 2.006 0 O-C-N 120.836 -1.165 . . . . 0.0 110.739 -179.608 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 47.42 -111.5 0.79 Allowed Glycine 0 N--CA 1.501 3.013 0 N-CA-C 110.126 -1.189 . . . . 0.0 110.126 179.5 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 39' ' ' CYS . . . . . . . . . . . . . 90.0 m -143.4 141.4 30.86 Favored 'General case' 0 N--CA 1.495 1.794 0 O-C-N 121.485 -1.009 . . . . 0.0 109.26 179.462 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 40' ' ' LEU . . . . . 0.543 ' HB2' ' HG3' ' A' ' 43' ' ' GLU . 2.9 mt -69.87 -172.26 0.5 Allowed 'General case' 0 N--CA 1.495 1.778 0 O-C-N 121.351 -0.843 . . . . 0.0 110.938 -179.499 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 41' ' ' ARG . . . . . . . . . . . . . 13.9 mtp180 -105.9 117.59 34.43 Favored 'General case' 0 N--CA 1.489 1.477 0 O-C-N 121.096 -1.002 . . . . 0.0 111.317 -179.098 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 42' ' ' ARG . . . . . . . . . . . . . 38.0 ttp180 60.93 52.42 4.17 Favored 'General case' 0 N--CA 1.501 2.091 0 CA-C-O 121.044 0.45 . . . . 0.0 111.789 178.885 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 43' ' ' GLU . . . . . 0.543 ' HG3' ' HB2' ' A' ' 40' ' ' LEU . 69.2 mm-40 -96.34 136.97 36.1 Favored 'General case' 0 N--CA 1.487 1.424 0 O-C-N 120.93 -1.106 . . . . 0.0 109.473 178.442 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 109.64 -46.24 1.2 Allowed Glycine 0 N--CA 1.493 2.472 0 N-CA-C 109.211 -1.555 . . . . 0.0 109.211 -179.392 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 45' ' ' GLN . . . . . . . . . . . . . 2.2 mp0 . . . . . 0 N--CA 1.497 1.915 0 O-C-N 121.726 -0.867 . . . . 0.0 110.168 179.316 . . . . . . . . 0 0 . 1 . 012 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 1.497 0 N-CA-C 109.877 -0.416 . . . . 0.0 109.877 . . . . . . . . . 0 0 . 1 . 012 nuclear orig full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 0.9 OUTLIER -75.84 -178.47 4.29 Favored 'General case' 0 N--CA 1.492 1.672 0 O-C-N 121.6 -0.687 . . . . 0.0 110.689 179.913 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -163.84 -161.98 0.67 Allowed 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.18 -0.95 . . . . 0.0 109.971 179.79 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 4' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -61.22 133.73 56.24 Favored 'General case' 0 N--CA 1.494 1.73 0 O-C-N 121.515 -0.74 . . . . 0.0 110.003 179.871 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 5' ' ' CYS . . . . . 0.507 ' SG ' ' N ' ' A' ' 8' ' ' CYS . 0.8 OUTLIER -86.35 150.89 52.74 Favored Pre-proline 0 N--CA 1.496 1.858 0 O-C-N 121.512 -0.743 . . . . 0.0 109.716 179.864 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 6' ' ' PRO . . . . . . . . . . . . . 51.6 Cg_endo -81.0 45.36 1.98 Allowed 'Trans proline' 0 C--N 1.314 -1.271 0 O-C-N 123.755 1.397 . . . . 0.0 111.627 -179.092 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 165.1 41.73 0.02 OUTLIER Glycine 0 N--CA 1.497 2.702 0 N-CA-C 109.925 -1.27 . . . . 0.0 109.925 179.838 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 8' ' ' CYS . . . . . 0.507 ' N ' ' SG ' ' A' ' 5' ' ' CYS . 14.3 m -79.84 -177.2 5.82 Favored 'General case' 0 N--CA 1.499 1.993 0 O-C-N 121.404 -1.056 . . . . 0.0 110.132 -179.842 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -86.5 -79.72 1.19 Allowed Glycine 0 N--CA 1.495 2.631 0 N-CA-C 109.886 -1.286 . . . . 0.0 109.886 -179.885 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 10' ' ' GLN . . . . . . . . . . . . . 0.1 OUTLIER -67.05 -71.73 0.19 Allowed 'General case' 0 N--CA 1.496 1.868 0 O-C-N 121.434 -1.039 . . . . 0.0 110.648 -179.677 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 72.05 8.35 69.06 Favored Glycine 0 N--CA 1.497 2.758 0 N-CA-C 110.426 -1.07 . . . . 0.0 110.426 -179.595 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 12' ' ' VAL . . . . . 0.402 HG13 ' O ' ' A' ' 12' ' ' VAL . 4.3 p -160.64 82.41 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.493 1.675 0 O-C-N 121.209 -1.171 . . . . 0.0 108.767 179.954 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 13' ' ' GLN . . . . . . . . . . . . . 1.3 tt0 -53.22 101.16 0.04 OUTLIER 'General case' 0 N--CA 1.498 1.953 0 O-C-N 121.567 -0.708 . . . . 0.0 111.089 -178.897 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -108.72 31.55 5.56 Favored 'General case' 0 N--CA 1.497 1.894 0 O-C-N 121.643 -0.661 . . . . 0.0 109.547 179.209 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 143.95 -86.24 0.18 Allowed Glycine 0 N--CA 1.49 2.278 0 N-CA-C 108.548 -1.821 . . . . 0.0 108.548 -179.45 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 28.4 m -106.93 100.66 33.11 Favored Pre-proline 0 N--CA 1.494 1.764 0 O-C-N 121.331 -1.099 . . . . 0.0 109.544 179.133 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 47.2 Cg_endo -72.66 55.4 2.66 Favored 'Trans proline' 0 C--N 1.312 -1.382 0 O-C-N 123.817 1.43 . . . . 0.0 111.826 -178.955 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 152.62 36.56 0.03 OUTLIER Glycine 0 N--CA 1.496 2.684 0 O-C-N 120.836 -1.165 . . . . 0.0 111.097 179.444 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 82.38 137.24 2.6 Favored Glycine 0 N--CA 1.492 2.37 0 O-C-N 121.013 -1.287 . . . . 0.0 109.909 179.46 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -116.37 27.36 9.27 Favored 'General case' 0 N--CA 1.5 2.035 0 O-C-N 121.265 -1.138 . . . . 0.0 110.323 179.671 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 8.4 p -132.26 8.45 1.63 Allowed 'Isoleucine or valine' 0 N--CA 1.494 1.765 0 O-C-N 121.01 -1.056 . . . . 0.0 110.926 179.945 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 8.3 mm-40 -98.81 14.99 26.88 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 120.657 -1.277 . . . . 0.0 111.145 179.965 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 4.6 tt0 -146.4 -54.92 0.26 Allowed 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.202 -0.936 . . . . 0.0 109.507 179.404 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER -124.41 101.77 7.32 Favored 'General case' 0 C--N 1.307 -1.24 0 O-C-N 121.443 -0.785 . . . . 0.0 110.129 179.61 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 3.5 p-10 -115.43 23.76 12.15 Favored 'General case' 0 N--CA 1.496 1.841 0 O-C-N 121.236 -0.915 . . . . 0.0 110.542 179.926 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 129.52 -95.69 0.37 Allowed Glycine 0 N--CA 1.493 2.451 0 N-CA-C 109.209 -1.556 . . . . 0.0 109.209 179.914 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 80.29 -95.52 1.56 Allowed Glycine 0 N--CA 1.495 2.573 0 N-CA-C 109.701 -1.36 . . . . 0.0 109.701 179.752 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -79.29 165.77 46.2 Favored Pre-proline 0 N--CA 1.5 2.062 0 O-C-N 121.39 -1.065 . . . . 0.0 110.267 -179.919 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 45.6 Cg_endo -73.68 64.73 4.79 Favored 'Trans proline' 0 C--N 1.317 -1.116 0 O-C-N 123.868 1.457 . . . . 0.0 110.579 -179.975 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -127.63 76.62 1.69 Allowed 'General case' 0 N--CA 1.485 1.314 0 O-C-N 121.449 -0.782 . . . . 0.0 110.388 179.935 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 12.9 pt-20 -79.2 -43.22 24.3 Favored 'General case' 0 N--CA 1.494 1.744 0 O-C-N 121.152 -0.967 . . . . 0.0 110.243 -179.797 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 111.54 80.15 1.06 Allowed Glycine 0 N--CA 1.492 2.433 0 N-CA-C 109.582 -1.407 . . . . 0.0 109.582 179.739 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 33' ' ' CYS . . . . . . . . . . . . . 0.7 OUTLIER -79.68 133.22 36.37 Favored 'General case' 0 N--CA 1.497 1.894 0 O-C-N 121.264 -1.139 . . . . 0.0 109.362 179.66 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -78.5 -22.48 47.37 Favored 'General case' 0 N--CA 1.501 2.096 0 O-C-N 121.325 -0.859 . . . . 0.0 110.445 179.886 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 0.8 OUTLIER -130.68 165.51 22.7 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.381 -0.824 . . . . 0.0 109.814 179.554 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 36' ' ' ALA . . . . . . . . . . . . . . . -93.28 -39.91 10.72 Favored 'General case' 0 N--CA 1.493 1.679 0 O-C-N 121.462 -0.774 . . . . 0.0 109.644 179.403 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 6.2 tt0 -79.27 -53.85 6.54 Favored 'General case' 0 N--CA 1.495 1.81 0 O-C-N 121.525 -0.735 . . . . 0.0 109.844 179.713 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -75.87 63.09 2.8 Favored Glycine 0 N--CA 1.498 2.792 0 N-CA-C 109.557 -1.417 . . . . 0.0 109.557 179.887 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 39' ' ' CYS . . . . . . . . . . . . . 2.6 t -122.4 -63.49 1.28 Allowed 'General case' 0 N--CA 1.496 1.831 0 O-C-N 121.549 -0.971 . . . . 0.0 110.181 179.497 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 40' ' ' LEU . . . . . . . . . . . . . 1.9 pt? -169.86 -164.98 0.45 Allowed 'General case' 0 N--CA 1.497 1.898 0 O-C-N 121.196 -0.94 . . . . 0.0 110.547 179.139 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 41' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER 64.14 179.95 0.17 Allowed 'General case' 0 N--CA 1.503 2.203 0 O-C-N 121.768 -0.583 . . . . 0.0 110.445 179.938 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 42' ' ' ARG . . . . . . . . . . . . . 15.4 mtm180 -131.87 -70.9 0.56 Allowed 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.111 -0.993 . . . . 0.0 109.792 179.812 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 5.9 mp0 -128.74 88.51 2.74 Favored 'General case' 0 N--CA 1.487 1.391 0 O-C-N 121.423 -0.798 . . . . 0.0 109.335 -179.861 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 157.9 65.72 0.01 OUTLIER Glycine 0 N--CA 1.492 2.373 0 N-CA-C 109.279 -1.528 . . . . 0.0 109.279 -179.589 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 45' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.493 1.695 0 O-C-N 121.441 -1.035 . . . . 0.0 110.217 179.837 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.499 1.996 0 N-CA-C 109.816 -0.438 . . . . 0.0 109.816 . . . . . . . . . 0 0 . 1 . 013 nuclear orig full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 0.7 OUTLIER -174.0 154.31 2.29 Favored 'General case' 0 N--CA 1.499 1.987 0 O-C-N 121.359 -0.838 . . . . 0.0 109.697 179.575 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -110.13 162.71 14.31 Favored 'General case' 0 N--CA 1.492 1.666 0 O-C-N 121.492 -0.755 . . . . 0.0 110.325 -179.923 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 4' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -168.05 89.51 0.27 Allowed 'General case' 0 N--CA 1.495 1.817 0 O-C-N 121.418 -0.801 . . . . 0.0 110.39 -179.992 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 9.3 t -160.43 103.4 1.35 Allowed Pre-proline 0 N--CA 1.497 1.925 0 O-C-N 120.945 -1.097 . . . . 0.0 110.023 179.955 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 6' ' ' PRO . . . . . . . . . . . . . 52.7 Cg_endo -77.57 155.0 31.5 Favored 'Trans proline' 0 C--N 1.314 -1.28 0 O-C-N 123.666 1.351 . . . . 0.0 110.335 179.796 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 82.82 -50.47 4.39 Favored Glycine 0 N--CA 1.497 2.762 0 C-N-CA 120.118 -1.039 . . . . 0.0 110.601 179.717 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 8' ' ' CYS . . . . . 0.443 ' SG ' ' N ' ' A' ' 9' ' ' GLY . 12.0 p -78.71 -33.09 47.07 Favored 'General case' 0 N--CA 1.497 1.905 0 O-C-N 120.967 -1.314 . . . . 0.0 111.062 -179.36 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 9' ' ' GLY . . . . . 0.443 ' N ' ' SG ' ' A' ' 8' ' ' CYS . . . -79.76 -60.63 2.42 Favored Glycine 0 N--CA 1.497 2.708 0 N-CA-C 109.631 -1.387 . . . . 0.0 109.631 -179.486 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 10' ' ' GLN . . . . . . . . . . . . . 34.2 mt-30 -143.91 -62.6 0.39 Allowed 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.438 -1.037 . . . . 0.0 110.754 -179.813 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 89.25 -68.56 2.7 Favored Glycine 0 N--CA 1.495 2.598 0 N-CA-C 108.962 -1.655 . . . . 0.0 108.962 -179.271 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 41.0 t -136.51 -94.06 0.04 OUTLIER 'Isoleucine or valine' 0 N--CA 1.496 1.85 0 O-C-N 121.657 -0.908 . . . . 0.0 109.715 179.287 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 13' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -166.86 30.76 0.04 OUTLIER 'General case' 0 N--CA 1.499 1.977 0 O-C-N 120.825 -1.172 . . . . 0.0 110.875 179.824 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -154.02 136.44 15.01 Favored 'General case' 0 N--CA 1.496 1.843 0 O-C-N 121.107 -0.996 . . . . 0.0 110.459 179.986 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -108.2 65.52 0.25 Allowed Glycine 0 N--CA 1.495 2.592 0 N-CA-C 109.788 -1.325 . . . . 0.0 109.788 179.881 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 60.6 m -80.51 114.01 44.12 Favored Pre-proline 0 N--CA 1.499 2.019 0 O-C-N 121.719 -0.871 . . . . 0.0 109.975 179.641 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 45.0 Cg_endo -70.07 89.22 0.56 Allowed 'Trans proline' 0 N--CA 1.49 1.318 0 O-C-N 123.722 1.38 . . . . 0.0 110.767 -179.931 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 108.58 -16.83 34.03 Favored Glycine 0 N--CA 1.495 2.582 0 N-CA-C 110.361 -1.096 . . . . 0.0 110.361 179.886 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 117.92 138.41 5.99 Favored Glycine 0 N--CA 1.489 2.231 0 N-CA-C 108.675 -1.77 . . . . 0.0 108.675 -179.314 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 6.0 p -124.65 -2.66 7.86 Favored 'General case' 0 N--CA 1.497 1.911 0 O-C-N 121.435 -1.038 . . . . 0.0 112.076 -179.622 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 12.1 p -160.07 39.81 0.02 OUTLIER 'Isoleucine or valine' 0 N--CA 1.497 1.894 0 O-C-N 120.581 -1.324 . . . . 0.0 110.353 -179.803 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 13.4 mm-40 -98.94 46.23 0.99 Allowed 'General case' 0 N--CA 1.487 1.408 0 O-C-N 120.84 -1.162 . . . . 0.0 111.089 -179.621 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER 43.02 68.4 0.51 Allowed 'General case' 0 N--CA 1.505 2.294 0 CA-C-O 121.409 0.623 . . . . 0.0 111.528 179.617 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 2.7 tt0 -80.6 -57.38 3.6 Favored 'General case' 0 N--CA 1.494 1.761 0 O-C-N 120.983 -1.073 . . . . 0.0 109.904 179.987 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 3.1 t70 -160.25 176.72 11.41 Favored 'General case' 0 N--CA 1.489 1.522 0 N-CA-C 108.838 -0.801 . . . . 0.0 108.838 179.136 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 62.06 39.75 98.02 Favored Glycine 0 N--CA 1.493 2.484 0 N-CA-C 109.658 -1.377 . . . . 0.0 109.658 179.683 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -58.16 -29.96 63.39 Favored Glycine 0 N--CA 1.497 2.738 0 N-CA-C 110.076 -1.21 . . . . 0.0 110.076 179.962 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 1.1 m -79.19 163.58 59.0 Favored Pre-proline 0 N--CA 1.5 2.035 0 O-C-N 121.338 -1.096 . . . . 0.0 109.515 179.467 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 44.1 Cg_endo -69.89 68.88 1.75 Allowed 'Trans proline' 0 C--N 1.308 -1.578 0 O-C-N 123.268 1.141 . . . . 0.0 110.937 -179.747 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -99.5 -40.25 7.94 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.245 -0.909 . . . . 0.0 110.537 -179.958 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 4.4 tt0 -78.98 -9.61 59.58 Favored 'General case' 0 N--CA 1.494 1.74 0 O-C-N 121.503 -0.748 . . . . 0.0 111.12 -179.754 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . -73.23 -38.59 53.87 Favored Glycine 0 N--CA 1.497 2.76 0 N-CA-C 110.198 -1.161 . . . . 0.0 110.198 -179.839 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 33' ' ' CYS . . . . . 0.406 ' HB2' ' O ' ' A' ' 38' ' ' GLY . 0.8 OUTLIER -127.22 94.0 3.89 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.544 -0.974 . . . . 0.0 109.976 179.684 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -123.04 35.29 4.91 Favored 'General case' 0 N--CA 1.495 1.78 0 O-C-N 121.699 -0.626 . . . . 0.0 109.681 179.552 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 2.2 mp0 -78.5 -144.57 0.03 OUTLIER 'General case' 0 N--CA 1.502 2.126 0 O-C-N 121.814 -0.554 . . . . 0.0 109.824 -179.782 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 36' ' ' ALA . . . . . . . . . . . . . . . -76.95 -25.89 53.37 Favored 'General case' 0 N--CA 1.492 1.634 0 O-C-N 121.022 -1.048 . . . . 0.0 109.795 -179.822 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 6.0 tt0 -99.81 -40.04 7.92 Favored 'General case' 0 N--CA 1.497 1.884 0 O-C-N 121.321 -0.862 . . . . 0.0 110.131 179.111 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 38' ' ' GLY . . . . . 0.406 ' O ' ' HB2' ' A' ' 33' ' ' CYS . . . 81.37 -119.5 4.88 Favored Glycine 0 N--CA 1.487 2.079 0 N-CA-C 109.355 -1.498 . . . . 0.0 109.355 -179.881 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 39' ' ' CYS . . . . . . . . . . . . . 1.0 OUTLIER -152.67 43.81 0.66 Allowed 'General case' 0 N--CA 1.495 1.804 0 O-C-N 121.548 -0.972 . . . . 0.0 110.23 179.605 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 40' ' ' LEU . . . . . . . . . . . . . 71.4 mt -92.85 138.99 31.0 Favored 'General case' 0 N--CA 1.493 1.684 0 O-C-N 121.085 -1.01 . . . . 0.0 110.735 -179.502 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 41' ' ' ARG . . . . . . . . . . . . . 29.7 mmt85 -116.23 151.99 34.67 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.515 -0.741 . . . . 0.0 109.955 179.406 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 42' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -88.27 41.58 1.02 Allowed 'General case' 0 N--CA 1.496 1.835 0 O-C-N 121.235 -0.916 . . . . 0.0 111.461 -179.381 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 10.3 mt-10 -93.05 -36.28 12.79 Favored 'General case' 0 N--CA 1.492 1.643 0 O-C-N 121.149 -0.97 . . . . 0.0 110.54 179.333 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -84.8 69.94 3.23 Favored Glycine 0 N--CA 1.496 2.684 0 N-CA-C 109.957 -1.257 . . . . 0.0 109.957 -179.674 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 45' ' ' GLN . . . . . . . . . . . . . 2.2 pt20 . . . . . 0 N--CA 1.5 2.053 0 O-C-N 121.662 -0.905 . . . . 0.0 110.187 179.714 . . . . . . . . 0 0 . 1 . 014 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.492 1.632 0 CA-C-O 120.825 0.345 . . . . 0.0 110.315 . . . . . . . . . 0 0 . 1 . 014 nuclear orig full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER 50.76 34.2 9.69 Favored 'General case' 0 N--CA 1.504 2.253 0 O-C-N 121.773 -0.579 . . . . 0.0 112.191 179.371 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -168.89 31.93 0.02 OUTLIER 'General case' 0 N--CA 1.498 1.94 0 O-C-N 120.893 -1.129 . . . . 0.0 111.426 179.52 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 4' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER 42.19 31.86 0.28 Allowed 'General case' 0 N--CA 1.506 2.332 0 O-C-N 121.229 -0.919 . . . . 0.0 111.334 -179.911 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 8.7 t -124.98 114.96 26.39 Favored Pre-proline 0 N--CA 1.492 1.668 0 O-C-N 121.02 -1.05 . . . . 0.0 109.472 -179.935 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 6' ' ' PRO . . . . . . . . . . . . . 44.2 Cg_endo -75.97 -58.27 0.05 OUTLIER 'Trans proline' 0 C--N 1.314 -1.284 0 O-C-N 124.195 1.629 . . . . 0.0 111.161 -179.704 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -76.02 57.02 3.15 Favored Glycine 0 N--CA 1.498 2.811 0 N-CA-C 110.111 -1.196 . . . . 0.0 110.111 -179.77 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 0.8 OUTLIER -113.91 12.66 18.17 Favored 'General case' 0 N--CA 1.495 1.794 0 O-C-N 121.11 -1.229 . . . . 0.0 110.335 179.131 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -116.61 160.37 13.47 Favored Glycine 0 N--CA 1.494 2.534 0 N-CA-C 108.26 -1.936 . . . . 0.0 108.26 179.195 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 10' ' ' GLN . . . . . . . . . . . . . 4.8 mt-30 55.05 31.43 16.17 Favored 'General case' 0 N--CA 1.502 2.16 0 O-C-N 121.574 -0.957 . . . . 0.0 110.639 -179.635 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -76.58 53.04 3.2 Favored Glycine 0 N--CA 1.496 2.699 0 N-CA-C 110.064 -1.214 . . . . 0.0 110.064 -179.822 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 10.0 p -98.89 36.11 0.18 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.722 0 O-C-N 121.351 -1.088 . . . . 0.0 110.32 -179.8 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 13' ' ' GLN . . . . . . . . . . . . . 2.0 tt0 56.48 15.42 2.03 Favored 'General case' 0 N--CA 1.502 2.174 0 O-C-N 121.316 -0.865 . . . . 0.0 111.796 179.814 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . 46.15 36.26 3.08 Favored 'General case' 0 N--CA 1.502 2.172 0 O-C-N 121.274 -0.891 . . . . 0.0 110.663 -179.496 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -95.46 -50.22 2.05 Favored Glycine 0 N--CA 1.493 2.463 0 N-CA-C 109.961 -1.256 . . . . 0.0 109.961 -179.353 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 96.6 m -111.57 80.83 2.93 Favored Pre-proline 0 N--CA 1.497 1.922 0 O-C-N 121.126 -1.22 . . . . 0.0 110.406 -179.629 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 43.5 Cg_endo -74.48 100.9 1.37 Allowed 'Trans proline' 0 C--N 1.312 -1.358 0 O-C-N 123.769 1.405 . . . . 0.0 109.993 179.808 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 114.94 -38.68 3.04 Favored Glycine 0 N--CA 1.496 2.663 0 N-CA-C 110.184 -1.167 . . . . 0.0 110.184 -179.798 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 179.07 144.92 5.95 Favored Glycine 0 N--CA 1.487 2.055 0 N-CA-C 108.973 -1.651 . . . . 0.0 108.973 -179.742 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -108.64 43.58 1.23 Allowed 'General case' 0 N--CA 1.496 1.86 0 O-C-N 121.625 -0.927 . . . . 0.0 110.125 -179.935 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 0.1 OUTLIER -146.09 52.8 0.12 Allowed 'Isoleucine or valine' 0 N--CA 1.496 1.869 0 O-C-N 121.547 -0.721 . . . . 0.0 109.19 179.656 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 2.2 mp0 -79.32 -30.07 42.66 Favored 'General case' 0 N--CA 1.488 1.472 0 O-C-N 121.602 -0.686 . . . . 0.0 111.233 -178.842 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 10.9 tt0 -161.44 108.8 1.44 Allowed 'General case' 0 N--CA 1.493 1.693 0 O-C-N 121.178 -0.951 . . . . 0.0 110.51 -179.709 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 0.8 OUTLIER -89.73 155.26 19.32 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.223 -0.923 . . . . 0.0 109.909 179.438 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 8.8 p-10 -79.05 -33.95 44.24 Favored 'General case' 0 N--CA 1.498 1.96 0 O-C-N 121.359 -0.838 . . . . 0.0 110.7 -179.953 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -55.19 -46.87 77.32 Favored Glycine 0 N--CA 1.495 2.632 0 N-CA-C 110.36 -1.096 . . . . 0.0 110.36 -179.91 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -98.47 61.79 0.86 Allowed Glycine 0 N--CA 1.495 2.619 0 N-CA-C 109.904 -1.279 . . . . 0.0 109.904 -179.743 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 1.6 m -112.57 92.63 20.4 Favored Pre-proline 0 N--CA 1.497 1.918 0 O-C-N 121.318 -1.107 . . . . 0.0 110.578 179.998 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 52.1 Cg_endo -78.8 133.92 11.7 Favored 'Trans proline' 0 C--N 1.316 -1.181 0 O-C-N 123.817 1.43 . . . . 0.0 110.475 179.723 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -127.11 56.99 1.49 Allowed 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.357 -0.84 . . . . 0.0 110.436 179.761 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 10.0 tt0 -160.75 -48.55 0.05 OUTLIER 'General case' 0 N--CA 1.495 1.808 0 O-C-N 121.338 -0.851 . . . . 0.0 110.733 179.557 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . -59.23 -27.15 62.43 Favored Glycine 0 N--CA 1.497 2.713 0 O-C-N 121.514 -0.741 . . . . 0.0 111.524 -179.394 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 33' ' ' CYS . . . . . 0.41 ' O ' ' HB3' ' A' ' 39' ' ' CYS . 26.0 p -79.12 68.55 5.12 Favored 'General case' 0 N--CA 1.498 1.961 0 O-C-N 120.821 -1.399 . . . . 0.0 110.315 -179.556 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -92.39 33.28 1.11 Allowed 'General case' 0 N--CA 1.496 1.855 0 O-C-N 120.888 -1.133 . . . . 0.0 110.626 179.771 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 4.8 mp0 -97.4 -178.5 4.17 Favored 'General case' 0 N--CA 1.492 1.648 0 O-C-N 121.16 -0.963 . . . . 0.0 110.351 -179.968 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 36' ' ' ALA . . . . . . . . . . . . . . . -87.86 28.66 1.0 Allowed 'General case' 0 N--CA 1.498 1.957 0 O-C-N 121.045 -1.034 . . . . 0.0 111.227 -179.807 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 13.6 pt-20 -78.91 -17.57 55.31 Favored 'General case' 0 N--CA 1.493 1.721 0 O-C-N 121.046 -1.033 . . . . 0.0 110.895 179.329 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 122.45 10.22 6.14 Favored Glycine 0 N--CA 1.496 2.673 0 N-CA-C 110.148 -1.181 . . . . 0.0 110.148 -179.533 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 39' ' ' CYS . . . . . 0.41 ' HB3' ' O ' ' A' ' 33' ' ' CYS . 0.1 OUTLIER -79.35 -25.26 42.3 Favored 'General case' 0 N--CA 1.501 2.08 0 O-C-N 120.876 -1.367 . . . . 0.0 110.369 179.78 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 40' ' ' LEU . . . . . 0.433 ' CD2' ' HB3' ' A' ' 42' ' ' ARG . 0.9 OUTLIER -86.95 -69.8 0.65 Allowed 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.024 -1.047 . . . . 0.0 110.851 -179.721 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 41' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER 53.12 67.51 0.99 Allowed 'General case' 0 N--CA 1.502 2.158 0 O-C-N 121.506 -0.746 . . . . 0.0 110.77 -179.917 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 42' ' ' ARG . . . . . 0.433 ' HB3' ' CD2' ' A' ' 40' ' ' LEU . 5.0 ptm180 -110.23 17.56 20.81 Favored 'General case' 0 N--CA 1.496 1.867 0 O-C-N 121.392 -0.818 . . . . 0.0 111.15 -179.906 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 46.2 mt-10 47.33 -123.1 1.44 Allowed 'General case' 0 N--CA 1.497 1.925 0 O-C-N 121.477 -0.764 . . . . 0.0 109.959 -179.623 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -113.45 27.81 9.11 Favored Glycine 0 N--CA 1.492 2.409 0 N-CA-C 108.547 -1.821 . . . . 0.0 108.547 179.223 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 45' ' ' GLN . . . . . . . . . . . . . 0.3 OUTLIER . . . . . 0 N--CA 1.493 1.715 0 O-C-N 121.61 -0.936 . . . . 0.0 110.237 -179.392 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.492 1.671 0 CA-C-O 120.966 0.412 . . . . 0.0 109.9 . . . . . . . . . 0 0 . 1 . 015 nuclear orig full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 28.4 mt -80.17 79.31 6.75 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.359 -0.838 . . . . 0.0 110.33 -179.748 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -142.4 173.79 11.21 Favored 'General case' 0 N--CA 1.488 1.472 0 O-C-N 121.366 -0.834 . . . . 0.0 110.431 -179.961 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 4' ' ' ARG . . . . . . . . . . . . . 1.3 mmp_? -74.11 -20.7 60.17 Favored 'General case' 0 N--CA 1.496 1.874 0 O-C-N 121.184 -0.947 . . . . 0.0 111.371 -179.701 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 31.2 p -129.56 146.17 59.98 Favored Pre-proline 0 N--CA 1.494 1.763 0 O-C-N 120.753 -1.217 . . . . 0.0 110.652 -179.914 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 6' ' ' PRO . . . . . . . . . . . . . 47.3 Cg_endo -77.95 121.49 5.43 Favored 'Trans proline' 0 C--N 1.315 -1.189 0 O-C-N 123.899 1.473 . . . . 0.0 110.903 -179.549 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 96.64 12.64 50.06 Favored Glycine 0 N--CA 1.496 2.68 0 N-CA-C 110.734 -0.946 . . . . 0.0 110.734 179.536 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 0.8 OUTLIER -160.5 172.32 17.42 Favored 'General case' 0 N--CA 1.496 1.852 0 O-C-N 120.75 -1.441 . . . . 0.0 110.171 -179.47 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 115.75 -173.26 14.64 Favored Glycine 0 N--CA 1.494 2.55 0 N-CA-C 109.599 -1.4 . . . . 0.0 109.599 -179.871 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 10' ' ' GLN . . . . . . . . . . . . . 4.4 mt-30 -89.14 50.29 1.92 Allowed 'General case' 0 N--CA 1.492 1.659 0 O-C-N 121.279 -1.13 . . . . 0.0 110.381 179.939 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -83.19 60.66 4.87 Favored Glycine 0 N--CA 1.495 2.573 0 N-CA-C 109.744 -1.342 . . . . 0.0 109.744 179.974 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 9.0 p -135.43 25.33 0.93 Allowed 'Isoleucine or valine' 0 N--CA 1.496 1.851 0 O-C-N 121.334 -1.097 . . . . 0.0 110.805 179.904 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 13' ' ' GLN . . . . . . . . . . . . . 0.2 OUTLIER -71.73 -14.64 62.07 Favored 'General case' 0 N--CA 1.498 1.96 0 O-C-N 120.938 -1.101 . . . . 0.0 111.461 -179.782 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . 59.63 82.85 0.14 Allowed 'General case' 0 N--CA 1.502 2.165 0 O-C-N 121.17 -0.957 . . . . 0.0 110.583 -179.915 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -125.36 75.95 0.4 Allowed Glycine 0 N--CA 1.492 2.424 0 N-CA-C 109.045 -1.622 . . . . 0.0 109.045 179.665 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 10.7 m -78.4 118.32 71.62 Favored Pre-proline 0 N--CA 1.496 1.866 0 O-C-N 121.29 -1.124 . . . . 0.0 109.709 -179.863 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 40.7 Cg_endo -68.25 -41.2 7.3 Favored 'Trans proline' 0 C--N 1.316 -1.139 0 O-C-N 123.855 1.45 . . . . 0.0 111.32 -179.498 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . -176.22 60.87 0.1 Allowed Glycine 0 N--CA 1.496 2.66 0 N-CA-C 109.796 -1.322 . . . . 0.0 109.796 179.994 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 162.61 75.19 0.02 OUTLIER Glycine 0 N--CA 1.493 2.495 0 N-CA-C 109.539 -1.424 . . . . 0.0 109.539 179.72 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 0.3 OUTLIER -105.86 -40.09 5.82 Favored 'General case' 0 N--CA 1.495 1.803 0 O-C-N 121.191 -1.182 . . . . 0.0 110.647 -179.516 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 3.6 t -107.7 56.27 0.14 Allowed 'Isoleucine or valine' 0 N--CA 1.497 1.903 0 O-C-N 121.319 -0.863 . . . . 0.0 110.186 179.923 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER -79.72 46.2 0.75 Allowed 'General case' 0 N--CA 1.495 1.823 0 O-C-N 120.979 -1.075 . . . . 0.0 110.479 179.827 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 23' ' ' GLU . . . . . 0.474 ' HG3' ' N ' ' A' ' 24' ' ' GLU . 6.7 pt-20 -128.0 -29.41 2.55 Favored 'General case' 0 N--CA 1.493 1.676 0 O-C-N 121.06 -1.025 . . . . 0.0 110.964 179.318 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 24' ' ' GLU . . . . . 0.474 ' N ' ' HG3' ' A' ' 23' ' ' GLU . 10.7 mt-10 57.76 177.38 0.05 Allowed 'General case' 0 N--CA 1.498 1.952 0 O-C-N 121.513 -0.742 . . . . 0.0 111.8 179.401 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 1.2 p-10 -102.81 -36.53 8.23 Favored 'General case' 0 N--CA 1.495 1.802 0 O-C-N 121.122 -0.986 . . . . 0.0 110.433 -179.302 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 118.55 92.03 1.47 Allowed Glycine 0 N--CA 1.49 2.27 0 N-CA-C 108.891 -1.684 . . . . 0.0 108.891 -179.484 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -59.01 105.85 0.77 Allowed Glycine 0 N--CA 1.494 2.545 0 N-CA-C 109.636 -1.386 . . . . 0.0 109.636 -179.564 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 28' ' ' SER . . . . . 0.492 ' N ' ' HD2' ' A' ' 29' ' ' PRO . 0.0 OUTLIER -79.5 -49.3 1.4 Allowed Pre-proline 0 N--CA 1.496 1.837 0 O-C-N 121.536 -0.979 . . . . 0.0 111.769 -179.007 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 29' ' ' PRO . . . . . 0.492 ' HD2' ' N ' ' A' ' 28' ' ' SER . 44.2 Cg_endo -72.21 60.83 3.24 Favored 'Trans proline' 0 N--CA 1.49 1.292 0 O-C-N 123.159 1.083 . . . . 0.0 111.478 -179.197 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -121.74 47.62 1.84 Allowed 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.148 -0.97 . . . . 0.0 110.096 179.421 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 1.2 tp10 -80.46 -68.65 0.66 Allowed 'General case' 0 N--CA 1.493 1.706 0 O-C-N 121.494 -0.754 . . . . 0.0 109.885 -179.664 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 116.56 76.2 0.6 Allowed Glycine 0 N--CA 1.494 2.53 0 N-CA-C 109.766 -1.334 . . . . 0.0 109.766 179.943 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 33' ' ' CYS . . . . . . . . . . . . . 10.4 p -79.09 127.5 32.09 Favored 'General case' 0 N--CA 1.496 1.85 0 O-C-N 121.632 -0.922 . . . . 0.0 109.687 179.462 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -144.77 17.72 1.63 Allowed 'General case' 0 N--CA 1.499 1.989 0 O-C-N 121.385 -0.822 . . . . 0.0 110.543 -179.904 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 1.5 mp0 -90.8 -163.8 1.08 Allowed 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.395 -0.816 . . . . 0.0 110.472 -179.566 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 36' ' ' ALA . . . . . . . . . . . . . . . -88.15 43.05 1.1 Allowed 'General case' 0 N--CA 1.499 1.988 0 O-C-N 121.123 -0.986 . . . . 0.0 111.44 -179.275 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 1.9 pt-20 -138.39 9.73 2.71 Favored 'General case' 0 N--CA 1.494 1.759 0 O-C-N 121.261 -0.9 . . . . 0.0 110.956 179.254 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 68.39 -108.63 2.53 Favored Glycine 0 N--CA 1.495 2.615 0 N-CA-C 108.869 -1.692 . . . . 0.0 108.869 -179.657 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 39' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -160.64 -54.86 0.05 Allowed 'General case' 0 N--CA 1.498 1.96 0 O-C-N 121.154 -1.204 . . . . 0.0 110.376 179.321 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 40' ' ' LEU . . . . . . . . . . . . . 6.3 tt -67.35 -17.74 64.87 Favored 'General case' 0 N--CA 1.494 1.764 0 O-C-N 121.271 -0.893 . . . . 0.0 111.104 -179.888 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 41' ' ' ARG . . . . . . . . . . . . . 6.1 mtp180 64.07 75.61 0.38 Allowed 'General case' 0 N--CA 1.499 1.98 0 CA-C-O 121.869 0.842 . . . . 0.0 110.011 -179.804 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 42' ' ' ARG . . . . . 0.657 ' HG3' ' HG3' ' A' ' 45' ' ' GLN . 10.6 ttm180 -128.46 68.45 1.37 Allowed 'General case' 0 N--CA 1.485 1.298 0 O-C-N 121.353 -0.842 . . . . 0.0 109.334 -179.951 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 8.4 mt-10 -65.18 82.67 0.05 OUTLIER 'General case' 0 N--CA 1.496 1.851 0 O-C-N 121.538 -0.726 . . . . 0.0 112.386 -178.372 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 58.07 46.89 92.08 Favored Glycine 0 N--CA 1.494 2.508 0 N-CA-C 110.566 -1.014 . . . . 0.0 110.566 179.122 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 45' ' ' GLN . . . . . 0.657 ' HG3' ' HG3' ' A' ' 42' ' ' ARG . 0.0 OUTLIER . . . . . 0 N--CA 1.497 1.917 0 CA-C-O 117.996 -1.002 . . . . 0.0 109.885 179.055 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.495 1.777 0 CA-C-O 120.991 0.424 . . . . 0.0 110.1 . . . . . . . . . 0 0 . 1 . 016 nuclear orig full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER -100.95 -3.27 29.86 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.167 -0.958 . . . . 0.0 111.918 -179.722 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -57.74 -37.97 74.52 Favored 'General case' 0 N--CA 1.5 2.051 0 O-C-N 121.117 -0.99 . . . . 0.0 111.549 -179.179 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 4' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -131.46 133.59 45.32 Favored 'General case' 0 N--CA 1.489 1.482 0 O-C-N 120.924 -1.11 . . . . 0.0 110.492 -179.64 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 8.5 t -109.09 118.66 50.76 Favored Pre-proline 0 N--CA 1.496 1.828 0 O-C-N 121.403 -0.811 . . . . 0.0 109.475 179.656 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 6' ' ' PRO . . . . . . . . . . . . . 44.1 Cg_endo -73.14 106.86 2.24 Favored 'Trans proline' 0 C--N 1.312 -1.356 0 O-C-N 123.891 1.469 . . . . 0.0 111.162 -179.267 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 66.69 49.07 58.0 Favored Glycine 0 N--CA 1.496 2.659 0 N-CA-C 110.515 -1.034 . . . . 0.0 110.515 179.154 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -84.93 178.57 7.55 Favored 'General case' 0 N--CA 1.5 2.038 0 O-C-N 121.212 -1.17 . . . . 0.0 110.47 179.676 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -74.34 150.97 42.83 Favored Glycine 0 N--CA 1.491 2.311 0 N-CA-C 109.763 -1.335 . . . . 0.0 109.763 179.961 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 10' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -79.23 50.08 1.03 Allowed 'General case' 0 N--CA 1.496 1.875 0 O-C-N 121.591 -0.946 . . . . 0.0 110.773 -179.953 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -79.7 -57.06 3.17 Favored Glycine 0 N--CA 1.492 2.41 0 N-CA-C 109.612 -1.395 . . . . 0.0 109.612 179.929 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 12' ' ' VAL . . . . . 0.406 HG12 ' O ' ' A' ' 12' ' ' VAL . 7.4 p -137.17 65.69 0.25 Allowed 'Isoleucine or valine' 0 N--CA 1.496 1.85 0 O-C-N 121.466 -1.02 . . . . 0.0 110.35 -179.99 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 13' ' ' GLN . . . . . . . . . . . . . 2.6 tp-100 -80.22 -36.87 34.16 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.226 -0.921 . . . . 0.0 110.404 179.712 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -94.83 167.07 11.66 Favored 'General case' 0 N--CA 1.494 1.75 0 O-C-N 121.593 -0.692 . . . . 0.0 110.256 179.976 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -60.12 -34.19 82.92 Favored Glycine 0 N--CA 1.497 2.76 0 N-CA-C 110.228 -1.149 . . . . 0.0 110.228 179.608 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 16' ' ' CYS . . . . . 0.443 ' HB2' ' HB2' ' A' ' 20' ' ' CYS . 0.0 OUTLIER -110.01 96.86 26.98 Favored Pre-proline 0 N--CA 1.496 1.851 0 O-C-N 120.714 -1.462 . . . . 0.0 109.614 179.403 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 41.2 Cg_endo -68.43 111.26 2.48 Favored 'Trans proline' 0 C--N 1.311 -1.424 0 O-C-N 123.837 1.44 . . . . 0.0 111.079 -179.59 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 62.68 20.02 61.26 Favored Glycine 0 N--CA 1.496 2.685 0 N-CA-C 110.654 -0.978 . . . . 0.0 110.654 179.857 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -157.93 54.2 0.38 Allowed Glycine 0 N--CA 1.498 2.771 0 N-CA-C 109.741 -1.344 . . . . 0.0 109.741 -179.808 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 20' ' ' CYS . . . . . 0.443 ' HB2' ' HB2' ' A' ' 16' ' ' CYS . 0.8 OUTLIER -125.95 93.87 3.95 Favored 'General case' 0 N--CA 1.497 1.914 0 O-C-N 121.362 -1.081 . . . . 0.0 109.527 179.686 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 22.5 m -122.27 41.04 0.77 Allowed 'Isoleucine or valine' 0 N--CA 1.494 1.745 0 CA-C-O 121.268 0.556 . . . . 0.0 110.879 -179.211 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 2.8 mt-10 -110.6 44.99 1.18 Allowed 'General case' 0 C--N 1.307 -1.275 0 O-C-N 121.371 -0.83 . . . . 0.0 109.865 179.374 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 1.3 tp10 -101.2 -57.3 2.12 Favored 'General case' 0 N--CA 1.492 1.671 0 O-C-N 121.32 -0.863 . . . . 0.0 110.225 -179.824 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 1.0 OUTLIER -72.77 154.4 40.67 Favored 'General case' 0 N--CA 1.499 1.99 0 O-C-N 121.523 -0.735 . . . . 0.0 110.466 -179.744 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 4.1 p-10 -95.25 36.84 1.2 Allowed 'General case' 0 N--CA 1.502 2.134 0 O-C-N 121.353 -0.842 . . . . 0.0 111.357 179.956 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 154.96 -90.47 0.12 Allowed Glycine 0 N--CA 1.492 2.426 0 N-CA-C 109.719 -1.353 . . . . 0.0 109.719 178.922 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -138.15 141.81 12.51 Favored Glycine 0 N--CA 1.498 2.817 0 N-CA-C 109.799 -1.32 . . . . 0.0 109.799 -179.803 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 28' ' ' SER . . . . . 0.452 ' OG ' ' HD2' ' A' ' 29' ' ' PRO . 23.0 t -84.94 154.43 60.92 Favored Pre-proline 0 C--N 1.301 -1.535 0 O-C-N 121.285 -1.126 . . . . 0.0 109.854 179.759 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 29' ' ' PRO . . . . . 0.452 ' HD2' ' OG ' ' A' ' 28' ' ' SER . 37.9 Cg_endo -65.51 -26.87 54.41 Favored 'Trans proline' 0 C--N 1.308 -1.584 0 O-C-N 123.353 1.186 . . . . 0.0 109.819 179.03 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -93.59 24.2 4.19 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.592 -0.693 . . . . 0.0 110.446 179.182 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 1.7 tp10 -83.26 -7.99 59.52 Favored 'General case' 0 N--CA 1.495 1.822 0 O-C-N 121.376 -0.827 . . . . 0.0 111.106 -179.883 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 77.62 29.0 56.28 Favored Glycine 0 N--CA 1.494 2.542 0 N-CA-C 109.404 -1.478 . . . . 0.0 109.404 -179.481 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 33' ' ' CYS . . . . . . . . . . . . . 0.0 OUTLIER -161.64 43.86 0.16 Allowed 'General case' 0 N--CA 1.498 1.929 0 O-C-N 121.411 -1.052 . . . . 0.0 109.861 179.842 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -109.39 -49.44 3.11 Favored 'General case' 0 N--CA 1.498 1.943 0 O-C-N 120.919 -1.113 . . . . 0.0 111.21 -179.342 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 35.1 mt-10 -95.02 -167.45 1.63 Allowed 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.051 -1.031 . . . . 0.0 110.369 -179.217 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 36' ' ' ALA . . . . . . . . . . . . . . . -82.27 44.07 0.84 Allowed 'General case' 0 N--CA 1.497 1.89 0 O-C-N 121.299 -0.876 . . . . 0.0 110.316 179.563 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 3.2 pt-20 -79.67 -13.29 59.58 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.43 -0.794 . . . . 0.0 110.327 179.297 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 132.34 38.12 0.26 Allowed Glycine 0 N--CA 1.502 3.074 0 C-N-CA 120.159 -1.02 . . . . 0.0 111.103 179.389 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 39' ' ' CYS . . . . . . . . . . . . . 13.5 t -93.51 -47.41 6.86 Favored 'General case' 0 N--CA 1.493 1.715 0 O-C-N 121.357 -1.084 . . . . 0.0 110.196 179.76 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 40' ' ' LEU . . . . . . . . . . . . . 7.9 mt -90.31 -100.69 0.1 Allowed 'General case' 0 N--CA 1.488 1.465 0 O-C-N 121.136 -0.977 . . . . 0.0 110.314 179.952 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 41' ' ' ARG . . . . . . . . . . . . . 25.9 ptt180 -165.58 179.87 5.82 Favored 'General case' 0 N--CA 1.494 1.765 0 O-C-N 121.061 -1.025 . . . . 0.0 110.543 179.955 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 42' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -160.92 78.66 0.6 Allowed 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.386 -0.821 . . . . 0.0 110.088 179.93 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -140.05 137.5 34.64 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.381 -0.824 . . . . 0.0 110.92 -179.857 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 91.28 29.28 12.69 Favored Glycine 0 N--CA 1.495 2.599 0 N-CA-C 110.378 -1.089 . . . . 0.0 110.378 179.216 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 45' ' ' GLN . . . . . . . . . . . . . 2.5 mt-30 . . . . . 0 N--CA 1.494 1.755 0 O-C-N 121.275 -1.132 . . . . 0.0 110.106 179.551 . . . . . . . . 0 0 . 1 . 017 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.5 2.05 0 CA-C-O 120.906 0.384 . . . . 0.0 110.257 . . . . . . . . . 0 0 . 1 . 017 nuclear orig full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -147.96 111.78 5.09 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.394 -0.816 . . . . 0.0 110.0 179.926 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -119.26 165.35 14.36 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.584 -0.697 . . . . 0.0 110.345 179.786 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 4' ' ' ARG . . . . . . . . . . . . . 17.4 ttt85 -114.93 158.29 22.2 Favored 'General case' 0 N--CA 1.489 1.481 0 O-C-N 121.251 -0.906 . . . . 0.0 109.935 179.503 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 5' ' ' CYS . . . . . 0.487 ' O ' ' SG ' ' A' ' 8' ' ' CYS . 1.3 p -127.65 163.01 45.65 Favored Pre-proline 0 N--CA 1.496 1.859 0 O-C-N 121.54 -0.725 . . . . 0.0 110.41 179.724 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 6' ' ' PRO . . . . . . . . . . . . . 49.6 Cg_endo -77.54 -50.43 0.09 OUTLIER 'Trans proline' 0 C--N 1.311 -1.396 0 O-C-N 123.552 1.29 . . . . 0.0 111.173 179.488 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -105.2 67.31 0.27 Allowed Glycine 0 N--CA 1.494 2.54 0 N-CA-C 110.239 -1.144 . . . . 0.0 110.239 -179.545 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 8' ' ' CYS . . . . . 0.487 ' SG ' ' O ' ' A' ' 5' ' ' CYS . 3.5 m -86.56 138.04 32.03 Favored 'General case' 0 N--CA 1.494 1.766 0 O-C-N 121.308 -1.113 . . . . 0.0 109.404 179.107 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 114.18 88.51 1.62 Allowed Glycine 0 N--CA 1.492 2.416 0 N-CA-C 109.165 -1.574 . . . . 0.0 109.165 -179.486 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 10' ' ' GLN . . . . . . . . . . . . . 4.1 mt-30 51.62 33.38 10.65 Favored 'General case' 0 N--CA 1.507 2.383 0 O-C-N 121.647 -0.913 . . . . 0.0 111.161 -179.558 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -110.27 -40.36 1.39 Allowed Glycine 0 N--CA 1.496 2.693 0 N-CA-C 109.659 -1.377 . . . . 0.0 109.659 179.761 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 43.6 t -79.16 -47.71 22.23 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.822 0 O-C-N 121.39 -1.065 . . . . 0.0 110.485 179.905 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 13' ' ' GLN . . . . . . . . . . . . . 7.1 tt0 -72.86 133.84 44.59 Favored 'General case' 0 N--CA 1.494 1.735 0 O-C-N 121.054 -1.029 . . . . 0.0 110.244 179.887 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -102.76 -164.08 1.05 Allowed 'General case' 0 N--CA 1.495 1.784 0 O-C-N 121.524 -0.735 . . . . 0.0 109.697 179.602 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -168.71 -105.33 0.18 Allowed Glycine 0 N--CA 1.496 2.649 0 N-CA-C 109.348 -1.501 . . . . 0.0 109.348 179.886 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 16' ' ' CYS . . . . . 0.52 ' SG ' ' N ' ' A' ' 20' ' ' CYS . 0.0 OUTLIER -115.03 98.26 49.91 Favored Pre-proline 0 N--CA 1.49 1.538 0 O-C-N 121.328 -1.101 . . . . 0.0 109.8 179.855 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 48.0 Cg_endo -77.36 60.92 7.2 Favored 'Trans proline' 0 C--N 1.31 -1.458 0 O-C-N 123.572 1.301 . . . . 0.0 109.559 179.251 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 91.4 -20.61 39.87 Favored Glycine 0 N--CA 1.493 2.447 0 N-CA-C 109.605 -1.398 . . . . 0.0 109.605 -178.471 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -99.24 68.8 0.58 Allowed Glycine 0 N--CA 1.496 2.636 0 O-C-N 120.606 -1.526 . . . . 0.0 109.677 -179.901 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 20' ' ' CYS . . . . . 0.52 ' N ' ' SG ' ' A' ' 16' ' ' CYS . 16.3 m -82.17 143.35 31.48 Favored 'General case' 0 N--CA 1.488 1.473 0 O-C-N 121.308 -1.113 . . . . 0.0 109.262 179.803 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 35.7 m -77.88 -21.18 13.72 Favored 'Isoleucine or valine' 0 N--CA 1.503 2.176 0 O-C-N 121.888 -0.508 . . . . 0.0 111.685 -179.137 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 4.1 pt-20 -88.36 15.09 8.26 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.127 -0.983 . . . . 0.0 111.141 179.494 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 3.0 mm-40 -134.21 24.63 3.85 Favored 'General case' 0 N--CA 1.494 1.744 0 O-C-N 120.975 -1.078 . . . . 0.0 110.549 179.482 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 13.9 mm-40 -85.38 -2.83 58.52 Favored 'General case' 0 N--CA 1.494 1.759 0 O-C-N 121.093 -1.004 . . . . 0.0 111.563 -179.717 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 3.8 p-10 -104.98 19.69 20.15 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 120.68 -1.263 . . . . 0.0 109.999 179.972 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -72.45 56.28 1.6 Allowed Glycine 0 N--CA 1.489 2.174 0 N-CA-C 109.31 -1.516 . . . . 0.0 109.31 179.386 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 115.98 9.37 12.25 Favored Glycine 0 N--CA 1.501 3.004 0 O-C-N 121.32 -1.106 . . . . 0.0 110.378 -179.61 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -108.47 92.89 10.66 Favored Pre-proline 0 N--CA 1.493 1.718 0 O-C-N 120.899 -1.354 . . . . 0.0 109.822 179.683 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 43.9 Cg_endo -72.87 71.5 3.38 Favored 'Trans proline' 0 N--CA 1.489 1.238 0 O-C-N 123.472 1.249 . . . . 0.0 110.483 -179.751 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -108.18 61.3 0.61 Allowed 'General case' 0 N--CA 1.488 1.437 0 O-C-N 121.272 -0.893 . . . . 0.0 110.219 -179.86 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 2.1 tt0 -78.76 -28.14 44.79 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.369 -0.832 . . . . 0.0 110.569 -179.749 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 74.57 46.9 17.38 Favored Glycine 0 N--CA 1.489 2.178 0 N-CA-C 110.377 -1.089 . . . . 0.0 110.377 179.255 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 33' ' ' CYS . . . . . . . . . . . . . 14.1 m -79.84 87.56 5.3 Favored 'General case' 0 N--CA 1.497 1.921 0 O-C-N 120.931 -1.335 . . . . 0.0 109.782 179.624 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -102.87 -61.19 1.43 Allowed 'General case' 0 N--CA 1.493 1.689 0 O-C-N 121.503 -0.748 . . . . 0.0 110.201 -179.787 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 1.3 pm0 -85.18 -169.5 2.68 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.445 -0.784 . . . . 0.0 110.533 -179.747 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 36' ' ' ALA . . . . . . . . . . . . . . . -107.93 35.5 3.1 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.013 -1.055 . . . . 0.0 110.232 179.849 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -110.64 -55.36 2.49 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.181 -0.949 . . . . 0.0 110.26 179.948 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -68.38 -41.32 85.71 Favored Glycine 0 N--CA 1.497 2.713 0 N-CA-C 109.546 -1.421 . . . . 0.0 109.546 179.859 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 39' ' ' CYS . . . . . . . . . . . . . 1.6 p -156.82 84.67 0.96 Allowed 'General case' 0 N--CA 1.497 1.915 0 O-C-N 121.412 -1.052 . . . . 0.0 110.119 -179.766 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 40' ' ' LEU . . . . . 0.438 ' CD1' ' HG3' ' A' ' 42' ' ' ARG . 1.4 pp -69.83 -156.36 0.02 OUTLIER 'General case' 0 N--CA 1.498 1.958 0 O-C-N 121.312 -0.868 . . . . 0.0 110.611 -179.751 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 41' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -165.13 -35.09 0.03 OUTLIER 'General case' 0 N--CA 1.498 1.946 0 O-C-N 120.854 -1.154 . . . . 0.0 111.93 179.85 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 42' ' ' ARG . . . . . 0.438 ' HG3' ' CD1' ' A' ' 40' ' ' LEU . 34.2 mtt-85 57.9 49.98 11.1 Favored 'General case' 0 N--CA 1.498 1.972 0 O-C-N 121.13 -0.981 . . . . 0.0 110.312 -179.231 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER 53.45 71.53 0.49 Allowed 'General case' 0 N--CA 1.499 1.993 0 O-C-N 121.518 -0.739 . . . . 0.0 110.888 179.857 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -177.83 66.77 0.08 OUTLIER Glycine 0 N--CA 1.494 2.523 0 N-CA-C 109.319 -1.512 . . . . 0.0 109.319 179.903 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 45' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.497 1.893 0 O-C-N 121.735 -0.862 . . . . 0.0 110.64 -179.918 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.497 1.918 0 N-CA-C 109.998 -0.371 . . . . 0.0 109.998 . . . . . . . . . 0 0 . 1 . 018 nuclear orig full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER 67.17 94.59 0.07 Allowed 'General case' 0 N--CA 1.505 2.297 0 CA-C-O 121.458 0.647 . . . . 0.0 110.476 -179.991 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -130.06 113.45 14.55 Favored 'General case' 0 N--CA 1.488 1.47 0 O-C-N 121.447 -0.783 . . . . 0.0 110.027 179.774 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 4' ' ' ARG . . . . . . . . . . . . . 2.9 ptm180 -153.65 75.95 1.06 Allowed 'General case' 0 N--CA 1.492 1.675 0 O-C-N 121.198 -0.939 . . . . 0.0 110.49 -179.881 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 3.3 p -131.82 128.85 21.76 Favored Pre-proline 0 N--CA 1.495 1.802 0 O-C-N 121.494 -0.754 . . . . 0.0 109.475 179.463 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 6' ' ' PRO . . . . . . . . . . . . . 42.1 Cg_endo -69.06 -43.98 2.87 Favored 'Trans proline' 0 C--N 1.312 -1.364 0 O-C-N 123.588 1.309 . . . . 0.0 111.534 -179.367 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -82.75 50.81 4.44 Favored Glycine 0 N--CA 1.495 2.624 0 N-CA-C 109.946 -1.262 . . . . 0.0 109.946 -179.975 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 1.7 m -119.06 -30.25 5.04 Favored 'General case' 0 N--CA 1.499 1.995 0 O-C-N 121.257 -1.143 . . . . 0.0 111.001 179.945 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 109.34 133.51 6.76 Favored Glycine 0 N--CA 1.493 2.483 0 N-CA-C 109.73 -1.348 . . . . 0.0 109.73 -179.802 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 10' ' ' GLN . . . . . . . . . . . . . 0.7 OUTLIER 45.39 49.71 10.33 Favored 'General case' 0 N--CA 1.501 2.125 0 O-C-N 121.953 -0.734 . . . . 0.0 111.053 179.499 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -86.93 -54.7 2.55 Favored Glycine 0 N--CA 1.496 2.675 0 N-CA-C 110.092 -1.203 . . . . 0.0 110.092 -179.848 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 9.0 p -138.03 48.08 0.35 Allowed 'Isoleucine or valine' 0 N--CA 1.495 1.784 0 O-C-N 121.275 -1.132 . . . . 0.0 110.413 179.93 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 13' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -81.82 -7.38 59.6 Favored 'General case' 0 N--CA 1.495 1.78 0 O-C-N 120.946 -1.096 . . . . 0.0 111.159 179.919 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -125.6 141.72 51.88 Favored 'General case' 0 N--CA 1.495 1.821 0 O-C-N 121.303 -0.873 . . . . 0.0 109.767 179.943 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -161.05 90.98 0.11 Allowed Glycine 0 N--CA 1.492 2.406 0 N-CA-C 109.372 -1.491 . . . . 0.0 109.372 179.697 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 13.4 m -94.69 152.71 40.02 Favored Pre-proline 0 N--CA 1.5 2.04 0 O-C-N 121.233 -1.157 . . . . 0.0 110.456 -179.95 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 48.2 Cg_endo -76.38 -147.81 0.03 OUTLIER 'Trans proline' 0 C--N 1.308 -1.554 0 O-C-N 123.779 1.41 . . . . 0.0 108.773 178.454 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . -62.92 -12.39 42.44 Favored Glycine 0 N--CA 1.498 2.767 0 O-C-N 120.878 -1.139 . . . . 0.0 110.898 179.574 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -151.18 115.4 0.7 Allowed Glycine 0 N--CA 1.494 2.536 0 N-CA-C 109.175 -1.57 . . . . 0.0 109.175 -179.705 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 4.8 t -84.56 -10.3 57.53 Favored 'General case' 0 N--CA 1.499 2.01 0 O-C-N 121.179 -1.189 . . . . 0.0 111.459 -179.834 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 8.6 p -129.36 26.21 1.9 Allowed 'Isoleucine or valine' 0 N--CA 1.499 1.997 0 O-C-N 121.045 -1.034 . . . . 0.0 111.027 -179.81 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 1.4 tp10 -105.72 -4.44 20.94 Favored 'General case' 0 N--CA 1.493 1.692 0 O-C-N 120.479 -1.388 . . . . 0.0 110.952 179.56 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 0.8 OUTLIER -138.14 -47.09 0.52 Allowed 'General case' 0 N--CA 1.492 1.673 0 O-C-N 121.064 -1.023 . . . . 0.0 110.712 179.697 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 1.1 mt-10 -59.95 115.84 3.71 Favored 'General case' 0 N--CA 1.494 1.747 0 O-C-N 121.482 -0.761 . . . . 0.0 110.079 -179.423 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 6.4 t0 -104.5 91.37 3.86 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.371 -0.831 . . . . 0.0 109.37 179.297 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -79.32 60.22 4.29 Favored Glycine 0 N--CA 1.496 2.676 0 N-CA-C 109.52 -1.432 . . . . 0.0 109.52 -179.296 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 177.45 -179.24 48.24 Favored Glycine 0 N--CA 1.493 2.49 0 N-CA-C 109.956 -1.258 . . . . 0.0 109.956 179.753 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -160.07 155.56 22.09 Favored Pre-proline 0 N--CA 1.494 1.73 0 O-C-N 121.381 -1.07 . . . . 0.0 110.187 179.854 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 40.2 Cg_endo -67.74 -40.72 9.35 Favored 'Trans proline' 0 N--CA 1.492 1.438 0 O-C-N 123.549 1.289 . . . . 0.0 110.17 179.484 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -92.97 47.95 1.31 Allowed 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.403 -0.811 . . . . 0.0 110.191 179.369 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 12.5 tt0 -77.85 -11.38 59.88 Favored 'General case' 0 N--CA 1.494 1.747 0 O-C-N 121.487 -0.758 . . . . 0.0 111.034 -179.87 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 98.16 84.44 1.76 Allowed Glycine 0 N--CA 1.489 2.22 0 N-CA-C 108.675 -1.77 . . . . 0.0 108.675 -179.668 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 33' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -79.02 65.45 4.2 Favored 'General case' 0 N--CA 1.493 1.714 0 O-C-N 121.166 -1.196 . . . . 0.0 110.051 -179.341 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -115.75 56.38 0.77 Allowed 'General case' 0 N--CA 1.496 1.832 0 O-C-N 121.469 -0.769 . . . . 0.0 109.75 179.697 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 1.1 tt0 -147.59 -162.3 1.52 Allowed 'General case' 0 N--CA 1.494 1.765 0 O-C-N 121.457 -0.777 . . . . 0.0 110.081 -179.363 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 36' ' ' ALA . . . . . . . . . . . . . . . -78.65 -30.85 46.57 Favored 'General case' 0 N--CA 1.494 1.727 0 O-C-N 121.464 -0.772 . . . . 0.0 109.108 179.029 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER -134.74 -74.32 0.47 Allowed 'General case' 0 N--CA 1.487 1.395 0 O-C-N 121.6 -0.687 . . . . 0.0 109.723 179.079 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 56.97 -99.27 0.09 OUTLIER Glycine 0 N--CA 1.496 2.685 0 N-CA-C 110.319 -1.113 . . . . 0.0 110.319 179.291 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 39' ' ' CYS . . . . . . . . . . . . . 2.5 p -99.49 6.56 45.88 Favored 'General case' 0 N--CA 1.497 1.912 0 O-C-N 121.792 -0.828 . . . . 0.0 111.612 -179.674 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 40' ' ' LEU . . . . . . . . . . . . . 1.5 mt 59.25 -165.94 0.18 Allowed 'General case' 0 N--CA 1.504 2.266 0 O-C-N 121.416 -0.802 . . . . 0.0 110.974 179.454 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 41' ' ' ARG . . . . . . . . . . . . . 2.7 mtm180 -134.0 122.16 22.64 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.423 -0.798 . . . . 0.0 109.68 -179.48 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 42' ' ' ARG . . . . . . . . . . . . . 27.8 ttp-105 -135.08 53.58 1.98 Allowed 'General case' 0 N--CA 1.497 1.92 0 O-C-N 121.387 -0.821 . . . . 0.0 110.525 -179.703 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 2.5 pm0 -77.74 76.78 4.27 Favored 'General case' 0 N--CA 1.496 1.828 0 O-C-N 121.216 -0.928 . . . . 0.0 110.944 -179.467 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 114.25 -43.15 1.76 Allowed Glycine 0 N--CA 1.494 2.518 0 N-CA-C 110.184 -1.166 . . . . 0.0 110.184 179.228 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 45' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.494 1.747 0 O-C-N 121.402 -1.057 . . . . 0.0 110.408 -179.991 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.493 1.699 0 CA-C-O 121.264 0.554 . . . . 0.0 110.013 . . . . . . . . . 0 0 . 1 . 019 nuclear orig full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 0.9 OUTLIER -85.04 -164.48 1.0 Allowed 'General case' 0 N--CA 1.494 1.742 0 O-C-N 121.099 -1.001 . . . . 0.0 110.32 179.832 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 3' ' ' ALA . . . . . 0.449 ' O ' ' HB2' ' A' ' 4' ' ' ARG . . . 66.73 9.9 7.07 Favored 'General case' 0 N--CA 1.508 2.464 0 O-C-N 121.671 -0.643 . . . . 0.0 111.618 -179.988 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 4' ' ' ARG . . . . . 0.449 ' HB2' ' O ' ' A' ' 3' ' ' ALA . 3.4 mmt180 60.85 -179.76 0.1 Allowed 'General case' 0 N--CA 1.502 2.13 0 O-C-N 121.411 -0.806 . . . . 0.0 111.141 179.734 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 5' ' ' CYS . . . . . 0.438 ' SG ' ' N ' ' A' ' 8' ' ' CYS . 1.3 p -148.13 161.76 33.24 Favored Pre-proline 0 N--CA 1.491 1.595 0 O-C-N 121.572 -0.705 . . . . 0.0 109.941 -179.627 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 6' ' ' PRO . . . . . . . . . . . . . 41.1 Cg_endo -68.2 -31.47 29.18 Favored 'Trans proline' 0 C--N 1.314 -1.246 0 O-C-N 123.637 1.335 . . . . 0.0 110.988 179.824 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -91.81 23.37 26.33 Favored Glycine 0 N--CA 1.494 2.547 0 N-CA-C 110.29 -1.124 . . . . 0.0 110.29 179.492 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 8' ' ' CYS . . . . . 0.438 ' N ' ' SG ' ' A' ' 5' ' ' CYS . 51.0 m -96.93 19.13 13.21 Favored 'General case' 0 N--CA 1.494 1.744 0 O-C-N 120.998 -1.295 . . . . 0.0 110.751 -179.904 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -79.28 -48.03 7.1 Favored Glycine 0 N--CA 1.492 2.415 0 N-CA-C 109.929 -1.268 . . . . 0.0 109.929 -179.653 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 10' ' ' GLN . . . . . . . . . . . . . 4.3 mt-30 -111.62 40.14 2.19 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 121.15 -1.206 . . . . 0.0 110.603 -179.62 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -84.43 63.39 4.43 Favored Glycine 0 N--CA 1.497 2.727 0 N-CA-C 109.861 -1.295 . . . . 0.0 109.861 179.883 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 13.3 m -134.98 48.61 0.41 Allowed 'Isoleucine or valine' 0 N--CA 1.501 2.087 0 O-C-N 121.393 -1.063 . . . . 0.0 110.652 179.923 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 13' ' ' GLN . . . . . . . . . . . . . 11.9 mt-30 -73.56 75.7 1.48 Allowed 'General case' 0 N--CA 1.498 1.936 0 O-C-N 121.074 -1.016 . . . . 0.0 110.454 179.944 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -110.13 -69.51 0.86 Allowed 'General case' 0 N--CA 1.498 1.939 0 O-C-N 121.288 -0.882 . . . . 0.0 110.563 -179.777 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -161.01 -105.1 0.2 Allowed Glycine 0 N--CA 1.493 2.445 0 N-CA-C 109.58 -1.408 . . . . 0.0 109.58 -179.674 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 0.0 OUTLIER -116.9 161.61 31.57 Favored Pre-proline 0 N--CA 1.501 2.101 0 O-C-N 121.253 -1.145 . . . . 0.0 109.61 179.438 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 42.2 Cg_endo -70.2 -59.27 0.08 OUTLIER 'Trans proline' 0 N--CA 1.489 1.225 0 O-C-N 123.825 1.434 . . . . 0.0 111.085 179.961 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . -108.05 -36.91 2.25 Favored Glycine 0 N--CA 1.495 2.602 0 N-CA-C 110.317 -1.113 . . . . 0.0 110.317 179.942 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 172.91 135.91 2.07 Favored Glycine 0 N--CA 1.492 2.426 0 N-CA-C 108.678 -1.769 . . . . 0.0 108.678 -179.923 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 4.1 m -78.57 64.83 3.7 Favored 'General case' 0 N--CA 1.5 2.03 0 O-C-N 121.413 -1.051 . . . . 0.0 110.506 -179.906 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 7.7 p -133.18 -46.06 0.6 Allowed 'Isoleucine or valine' 0 N--CA 1.498 1.956 0 O-C-N 121.468 -0.77 . . . . 0.0 109.759 179.088 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 23.4 mt-10 -89.18 33.86 0.8 Allowed 'General case' 0 C--N 1.306 -1.306 0 O-C-N 121.062 -1.024 . . . . 0.0 109.151 178.123 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -156.81 -75.55 0.09 Allowed 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.403 -0.81 . . . . 0.0 110.145 -179.406 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER 57.08 -165.18 0.15 Allowed 'General case' 0 N--CA 1.494 1.748 0 O-C-N 121.676 -0.64 . . . . 0.0 110.65 -179.899 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 3.3 m-20 -107.12 150.91 26.06 Favored 'General case' 0 N--CA 1.495 1.823 0 O-C-N 121.367 -0.833 . . . . 0.0 110.537 -179.666 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 88.19 -86.87 1.49 Allowed Glycine 0 N--CA 1.49 2.287 0 N-CA-C 110.194 -1.162 . . . . 0.0 110.194 179.295 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 69.86 64.16 3.04 Favored Glycine 0 N--CA 1.495 2.594 0 N-CA-C 109.127 -1.589 . . . . 0.0 109.127 -178.986 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 3.5 p -82.02 129.55 63.9 Favored Pre-proline 0 N--CA 1.499 1.987 0 O-C-N 120.859 -1.377 . . . . 0.0 110.868 -179.742 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 43.1 Cg_endo -70.42 -11.0 29.23 Favored 'Trans proline' 0 N--CA 1.489 1.238 0 O-C-N 124.086 1.571 . . . . 0.0 111.043 179.828 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -83.28 6.52 19.36 Favored 'General case' 0 N--CA 1.492 1.666 0 O-C-N 121.066 -1.022 . . . . 0.0 111.564 -179.497 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 31' ' ' GLU . . . . . 0.582 ' HG2' ' N ' ' A' ' 32' ' ' GLY . 14.6 tt0 -79.44 -75.0 0.26 Allowed 'General case' 0 N--CA 1.494 1.763 0 O-C-N 121.157 -0.965 . . . . 0.0 109.736 -179.987 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 32' ' ' GLY . . . . . 0.582 ' N ' ' HG2' ' A' ' 31' ' ' GLU . . . -136.33 22.26 3.39 Favored Glycine 0 N--CA 1.492 2.374 0 N-CA-C 109.55 -1.42 . . . . 0.0 109.55 179.563 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 33' ' ' CYS . . . . . 0.439 ' O ' ' HB2' ' A' ' 39' ' ' CYS . 0.5 OUTLIER -79.39 67.36 5.1 Favored 'General case' 0 N--CA 1.494 1.749 0 O-C-N 121.089 -1.242 . . . . 0.0 109.359 179.36 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -130.32 56.45 1.76 Allowed 'General case' 0 N--CA 1.496 1.868 0 O-C-N 121.536 -0.727 . . . . 0.0 110.319 179.763 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 5.5 mm-40 -92.88 -144.32 0.22 Allowed 'General case' 0 N--CA 1.497 1.884 0 O-C-N 121.505 -0.747 . . . . 0.0 109.74 179.713 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 36' ' ' ALA . . . . . . . . . . . . . . . -114.01 11.93 17.87 Favored 'General case' 0 N--CA 1.496 1.863 0 O-C-N 121.059 -1.026 . . . . 0.0 110.9 179.925 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 20.0 tt0 -161.2 -54.97 0.05 OUTLIER 'General case' 0 N--CA 1.496 1.862 0 O-C-N 121.261 -0.899 . . . . 0.0 110.741 179.516 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -43.6 -51.82 6.6 Favored Glycine 0 N--CA 1.5 2.938 0 N-CA-C 111.525 -0.63 . . . . 0.0 111.525 -178.74 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 39' ' ' CYS . . . . . 0.439 ' HB2' ' O ' ' A' ' 33' ' ' CYS . 56.9 m -139.94 75.68 1.52 Allowed 'General case' 0 N--CA 1.496 1.866 0 O-C-N 121.07 -1.253 . . . . 0.0 110.496 -179.234 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 40' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER 52.28 -148.89 0.39 Allowed 'General case' 0 N--CA 1.503 2.195 0 O-C-N 121.306 -0.872 . . . . 0.0 110.199 179.794 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 41' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -141.32 156.99 45.79 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.069 -1.019 . . . . 0.0 110.664 179.762 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 42' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -92.85 -44.48 8.46 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.27 -0.894 . . . . 0.0 110.499 179.888 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -83.86 145.06 28.84 Favored 'General case' 0 N--CA 1.487 1.425 0 O-C-N 121.476 -0.765 . . . . 0.0 110.302 179.941 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -77.58 62.51 3.49 Favored Glycine 0 N--CA 1.492 2.416 0 N-CA-C 110.033 -1.227 . . . . 0.0 110.033 -179.159 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 45' ' ' GLN . . . . . . . . . . . . . 0.4 OUTLIER . . . . . 0 N--CA 1.5 2.039 0 O-C-N 121.475 -1.015 . . . . 0.0 110.401 179.986 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 1.517 0 N-CA-C 109.936 -0.394 . . . . 0.0 109.936 . . . . . . . . . 0 0 . 1 . 020 nuclear orig full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 5.0 mp -68.85 156.19 38.87 Favored 'General case' 0 N--CA 1.492 1.652 0 O-C-N 121.404 -0.81 . . . . 0.0 110.406 -179.873 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -75.7 70.51 2.5 Favored 'General case' 0 N--CA 1.491 1.623 0 O-C-N 121.484 -0.76 . . . . 0.0 110.424 179.981 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 4' ' ' ARG . . . . . . . . . . . . . 0.3 OUTLIER -114.67 106.73 14.57 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.261 -0.9 . . . . 0.0 110.422 179.882 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 13.7 t -148.26 115.12 3.92 Favored Pre-proline 0 N--CA 1.495 1.802 0 O-C-N 121.452 -0.78 . . . . 0.0 109.91 -179.939 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 6' ' ' PRO . . . . . . . . . . . . . 50.8 Cg_endo -87.26 -24.06 1.34 Allowed 'Trans proline' 0 C--N 1.309 -1.508 0 O-C-N 123.904 1.476 . . . . 0.0 112.212 -179.515 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -109.85 68.32 0.22 Allowed Glycine 0 N--CA 1.497 2.759 0 O-C-N 120.829 -1.169 . . . . 0.0 111.332 -178.18 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 1.2 p -158.7 150.19 20.83 Favored 'General case' 0 N--CA 1.497 1.885 0 O-C-N 121.177 -1.19 . . . . 0.0 110.213 178.837 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 92.02 -110.46 3.88 Favored Glycine 0 N--CA 1.493 2.442 0 N-CA-C 108.893 -1.683 . . . . 0.0 108.893 -179.461 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 10' ' ' GLN . . . . . . . . . . . . . 5.5 pt20 -155.32 30.29 0.39 Allowed 'General case' 0 N--CA 1.494 1.745 0 O-C-N 121.272 -1.134 . . . . 0.0 110.698 179.379 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -86.58 62.69 4.23 Favored Glycine 0 N--CA 1.493 2.447 0 N-CA-C 109.461 -1.456 . . . . 0.0 109.461 179.614 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 60.2 t -126.94 -75.19 0.36 Allowed 'Isoleucine or valine' 0 N--CA 1.495 1.795 0 O-C-N 121.808 -0.819 . . . . 0.0 109.73 179.745 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 13' ' ' GLN . . . . . . . . . . . . . 1.6 mt-30 42.69 36.33 0.82 Allowed 'General case' 0 N--CA 1.495 1.82 0 O-C-N 121.652 -0.655 . . . . 0.0 111.779 179.736 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -71.5 -22.33 61.81 Favored 'General case' 0 N--CA 1.499 2.014 0 O-C-N 121.171 -0.956 . . . . 0.0 110.936 179.854 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 134.43 -53.34 0.79 Allowed Glycine 0 N--CA 1.493 2.499 0 N-CA-C 109.248 -1.541 . . . . 0.0 109.248 -179.69 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 2.6 p -88.68 121.52 69.91 Favored Pre-proline 0 N--CA 1.497 1.915 0 O-C-N 121.358 -1.083 . . . . 0.0 110.849 179.91 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 48.7 Cg_endo -76.06 79.5 2.89 Favored 'Trans proline' 0 C--N 1.309 -1.513 0 O-C-N 123.705 1.371 . . . . 0.0 110.046 179.606 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 85.79 -48.68 4.02 Favored Glycine 0 N--CA 1.493 2.461 0 N-CA-C 109.887 -1.285 . . . . 0.0 109.887 -179.512 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -72.38 68.8 1.16 Allowed Glycine 0 N--CA 1.495 2.617 0 N-CA-C 110.13 -1.188 . . . . 0.0 110.13 -179.604 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 73.2 m -105.2 119.07 38.14 Favored 'General case' 0 N--CA 1.498 1.957 0 O-C-N 121.482 -1.011 . . . . 0.0 109.511 179.627 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 12.7 t -106.71 -9.34 10.54 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.84 0 O-C-N 121.556 -0.715 . . . . 0.0 111.616 -178.95 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER -79.4 51.5 1.23 Allowed 'General case' 0 N--CA 1.493 1.695 0 O-C-N 120.855 -1.153 . . . . 0.0 110.566 179.718 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 3.2 tt0 -101.79 -24.29 14.08 Favored 'General case' 0 N--CA 1.489 1.477 0 O-C-N 121.095 -1.003 . . . . 0.0 110.139 179.539 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 2.1 pt-20 -79.89 -154.42 0.09 Allowed 'General case' 0 N--CA 1.494 1.736 0 O-C-N 121.274 -0.891 . . . . 0.0 110.575 -179.902 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -82.36 -49.16 10.32 Favored 'General case' 0 N--CA 1.5 2.06 0 O-C-N 121.456 -0.778 . . . . 0.0 110.164 179.947 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 144.09 46.64 0.04 OUTLIER Glycine 0 N--CA 1.498 2.772 0 N-CA-C 110.614 -0.995 . . . . 0.0 110.614 179.419 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 64.73 -130.92 37.06 Favored Glycine 0 N--CA 1.501 2.98 0 N-CA-C 109.685 -1.366 . . . . 0.0 109.685 -179.975 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -146.61 74.97 12.39 Favored Pre-proline 0 N--CA 1.495 1.787 0 O-C-N 121.294 -1.121 . . . . 0.0 109.926 179.691 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 43.4 Cg_endo -74.03 74.44 3.48 Favored 'Trans proline' 0 N--CA 1.488 1.172 0 O-C-N 123.632 1.333 . . . . 0.0 110.661 -179.908 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -89.87 64.84 6.5 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.111 -0.993 . . . . 0.0 110.571 179.887 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 14.8 tp10 -153.17 -67.92 0.15 Allowed 'General case' 0 N--CA 1.493 1.694 0 O-C-N 121.378 -0.826 . . . . 0.0 110.214 179.61 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 123.69 84.52 0.65 Allowed Glycine 0 N--CA 1.497 2.716 0 N-CA-C 109.406 -1.477 . . . . 0.0 109.406 -179.82 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 33' ' ' CYS . . . . . . . . . . . . . 0.4 OUTLIER -95.29 112.36 24.08 Favored 'General case' 0 N--CA 1.493 1.704 0 O-C-N 121.394 -1.062 . . . . 0.0 109.79 179.812 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -107.58 -46.13 3.9 Favored 'General case' 0 N--CA 1.497 1.875 0 O-C-N 121.564 -0.71 . . . . 0.0 110.103 179.886 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 21.8 mt-10 -79.59 -178.88 6.55 Favored 'General case' 0 N--CA 1.5 2.052 0 O-C-N 121.635 -0.665 . . . . 0.0 110.23 179.931 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 36' ' ' ALA . . . . . . . . . . . . . . . -78.66 -38.08 40.37 Favored 'General case' 0 N--CA 1.498 1.931 0 O-C-N 121.202 -0.936 . . . . 0.0 109.897 -179.634 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 7.3 tt0 -119.87 34.07 5.36 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.381 -0.825 . . . . 0.0 109.991 179.492 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -84.72 -9.45 81.13 Favored Glycine 0 N--CA 1.495 2.63 0 O-C-N 121.101 -0.999 . . . . 0.0 110.776 -179.909 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 39' ' ' CYS . . . . . . . . . . . . . 1.3 m -79.43 72.91 6.09 Favored 'General case' 0 N--CA 1.495 1.801 0 O-C-N 120.874 -1.368 . . . . 0.0 109.822 179.842 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 40' ' ' LEU . . . . . 0.484 ' C ' ' HG2' ' A' ' 41' ' ' ARG . 1.0 OUTLIER -75.5 -164.72 0.36 Allowed 'General case' 0 N--CA 1.494 1.763 0 O-C-N 121.372 -0.83 . . . . 0.0 110.46 -179.474 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 41' ' ' ARG . . . . . 0.484 ' HG2' ' C ' ' A' ' 40' ' ' LEU . 4.4 mmt180 66.47 -3.92 0.79 Allowed 'General case' 0 N--CA 1.51 2.543 0 O-C-N 121.743 -0.598 . . . . 0.0 111.933 179.656 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 42' ' ' ARG . . . . . . . . . . . . . 2.7 ttt85 56.4 22.89 6.82 Favored 'General case' 0 N--CA 1.5 2.039 0 O-C-N 120.922 -1.111 . . . . 0.0 111.53 -179.932 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 48.0 mm-40 -90.09 95.18 10.09 Favored 'General case' 0 N--CA 1.488 1.431 0 O-C-N 121.153 -0.967 . . . . 0.0 109.606 179.236 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -155.7 71.62 0.26 Allowed Glycine 0 N--CA 1.492 2.411 0 N-CA-C 109.26 -1.536 . . . . 0.0 109.26 -179.249 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 45' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.499 1.994 0 O-C-N 121.757 -0.849 . . . . 0.0 110.255 -179.822 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER . . . . . 0 N--CA 1.495 1.807 0 N-CA-C 109.878 -0.416 . . . . 0.0 109.878 . . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 6' ' ' PRO . . . . . . . . . . . . . 49.5 Cg_endo -82.23 150.34 15.49 Favored 'Trans proline' 0 C--N 1.313 -1.307 0 O-C-N 123.716 1.377 . . . . 0.0 110.647 -179.822 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 88.32 -46.54 3.38 Favored Glycine 0 N--CA 1.497 2.761 0 N-CA-C 110.342 -1.103 . . . . 0.0 110.342 179.43 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 20.0 p -79.66 -174.29 4.24 Favored 'General case' 0 N--CA 1.496 1.839 0 O-C-N 121.035 -1.274 . . . . 0.0 110.493 -179.601 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 129.26 -114.43 1.73 Allowed Glycine 0 N--CA 1.494 2.545 0 N-CA-C 108.854 -1.699 . . . . 0.0 108.854 -179.433 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 10' ' ' GLN . . . . . . . . . . . . . 14.0 tp60 -164.39 -75.47 0.04 OUTLIER 'General case' 0 N--CA 1.494 1.748 0 O-C-N 121.421 -1.047 . . . . 0.0 110.542 179.222 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -56.13 -26.1 48.64 Favored Glycine 0 N--CA 1.498 2.786 0 O-C-N 121.252 -0.905 . . . . 0.0 110.986 -179.54 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 25.2 t -88.88 -53.88 8.75 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.813 0 O-C-N 121.185 -1.185 . . . . 0.0 110.241 -179.882 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 13' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -67.04 -32.08 73.04 Favored 'General case' 0 N--CA 1.501 2.113 0 O-C-N 121.375 -0.828 . . . . 0.0 112.008 -179.245 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -141.26 52.23 1.57 Allowed 'General case' 0 N--CA 1.496 1.852 0 O-C-N 120.948 -1.095 . . . . 0.0 110.615 -179.645 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -151.76 -85.36 0.05 OUTLIER Glycine 0 N--CA 1.493 2.469 0 N-CA-C 109.845 -1.302 . . . . 0.0 109.845 179.881 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 57.9 m -110.08 97.58 30.68 Favored Pre-proline 0 N--CA 1.496 1.836 0 O-C-N 121.221 -1.164 . . . . 0.0 110.442 -179.898 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 46.7 Cg_endo -72.54 66.53 3.74 Favored 'Trans proline' 0 N--CA 1.491 1.378 0 O-C-N 124.284 1.676 . . . . 0.0 110.409 179.723 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 123.29 -49.97 0.87 Allowed Glycine 0 N--CA 1.495 2.589 0 N-CA-C 109.267 -1.533 . . . . 0.0 109.267 -179.557 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 178.41 134.28 2.06 Favored Glycine 0 N--CA 1.489 2.229 0 N-CA-C 108.971 -1.652 . . . . 0.0 108.971 179.976 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 1.5 m -92.11 33.06 1.09 Allowed 'General case' 0 N--CA 1.5 2.041 0 O-C-N 121.301 -1.117 . . . . 0.0 110.634 -179.911 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 6.4 t -139.87 55.88 0.22 Allowed 'Isoleucine or valine' 0 N--CA 1.496 1.874 0 O-C-N 120.928 -1.107 . . . . 0.0 110.599 -179.89 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 5.2 tt0 -88.88 49.17 1.74 Allowed 'General case' 0 N--CA 1.496 1.863 0 O-C-N 121.135 -0.978 . . . . 0.0 109.266 178.968 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 11.1 mt-10 58.65 -168.03 0.14 Allowed 'General case' 0 N--CA 1.501 2.08 0 O-C-N 121.756 -0.59 . . . . 0.0 110.451 -179.515 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 73.0 mm-40 -69.58 -22.2 63.54 Favored 'General case' 0 N--CA 1.497 1.923 0 O-C-N 120.991 -1.068 . . . . 0.0 111.277 -179.131 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 2.8 t70 -144.34 -61.44 0.38 Allowed 'General case' 0 N--CA 1.496 1.875 0 O-C-N 121.217 -0.927 . . . . 0.0 109.807 179.879 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 172.39 82.86 0.05 OUTLIER Glycine 0 N--CA 1.495 2.567 0 N-CA-C 109.955 -1.258 . . . . 0.0 109.955 179.681 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 66.09 27.69 73.09 Favored Glycine 0 N--CA 1.496 2.658 0 N-CA-C 109.855 -1.298 . . . . 0.0 109.855 179.923 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -102.37 99.59 13.35 Favored Pre-proline 0 N--CA 1.493 1.701 0 O-C-N 121.521 -0.987 . . . . 0.0 110.068 -179.699 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 45.0 Cg_endo -70.87 66.28 2.43 Favored 'Trans proline' 0 N--CA 1.489 1.225 0 O-C-N 123.744 1.391 . . . . 0.0 110.915 -179.577 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -131.28 66.58 1.54 Allowed 'General case' 0 N--CA 1.486 1.371 0 O-C-N 121.337 -0.852 . . . . 0.0 109.974 179.664 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 8.9 tt0 -110.58 -68.75 0.91 Allowed 'General case' 0 N--CA 1.485 1.313 0 O-C-N 121.397 -0.814 . . . . 0.0 110.531 -179.539 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . -72.87 -42.71 44.55 Favored Glycine 0 N--CA 1.496 2.678 0 N-CA-C 110.088 -1.205 . . . . 0.0 110.088 -179.674 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 33' ' ' CYS . . . . . . . . . . . . . 1.7 t -113.77 79.28 1.23 Allowed 'General case' 0 N--CA 1.492 1.646 0 O-C-N 121.141 -1.211 . . . . 0.0 109.661 -179.843 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -125.23 -46.09 1.81 Allowed 'General case' 0 N--CA 1.495 1.812 0 O-C-N 121.111 -0.993 . . . . 0.0 110.992 -179.403 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 0.8 OUTLIER -97.03 -176.48 3.56 Favored 'General case' 0 N--CA 1.498 1.926 0 O-C-N 121.494 -0.754 . . . . 0.0 110.934 -179.414 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 36' ' ' ALA . . . . . 0.548 ' O ' ' HB3' ' A' ' 40' ' ' LEU . . . -79.13 -34.19 43.55 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.26 -0.9 . . . . 0.0 110.189 179.805 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -78.41 2.31 19.21 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.247 -0.908 . . . . 0.0 110.903 179.865 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -92.66 -43.81 4.12 Favored Glycine 0 N--CA 1.492 2.411 0 N-CA-C 109.432 -1.467 . . . . 0.0 109.432 179.951 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 39' ' ' CYS . . . . . . . . . . . . . 1.3 p -161.06 50.34 0.24 Allowed 'General case' 0 N--CA 1.498 1.968 0 O-C-N 121.358 -1.084 . . . . 0.0 111.215 -179.391 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 40' ' ' LEU . . . . . 0.548 ' HB3' ' O ' ' A' ' 36' ' ' ALA . 1.7 pt? . . . . . 0 N--CA 1.504 2.234 0 O-C-N 120.801 -1.187 . . . . 0.0 112.047 -179.599 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 0.3 OUTLIER . . . . . 0 N--CA 1.497 1.924 0 N-CA-C 110.277 -0.268 . . . . 0.0 110.277 . . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 6' ' ' PRO . . . . . . . . . . . . . 45.6 Cg_endo -72.82 -86.18 0.0 OUTLIER 'Trans proline' 0 C--N 1.307 -1.656 0 O-C-N 123.944 1.497 . . . . 0.0 112.062 -179.039 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -105.6 55.8 0.54 Allowed Glycine 0 N--CA 1.49 2.246 0 N-CA-C 109.893 -1.283 . . . . 0.0 109.893 -178.99 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 0.4 OUTLIER -135.34 151.54 50.61 Favored 'General case' 0 N--CA 1.498 1.96 0 O-C-N 121.335 -1.097 . . . . 0.0 110.33 179.611 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 175.98 154.1 11.19 Favored Glycine 0 N--CA 1.495 2.605 0 N-CA-C 109.655 -1.378 . . . . 0.0 109.655 -179.809 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 10' ' ' GLN . . . . . . . . . . . . . 0.3 OUTLIER -129.89 70.56 1.43 Allowed 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.283 -1.128 . . . . 0.0 109.756 179.921 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -79.45 -61.15 2.37 Favored Glycine 0 N--CA 1.495 2.591 0 N-CA-C 110.006 -1.238 . . . . 0.0 110.006 -179.491 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 24.0 m -120.58 -31.65 1.54 Allowed 'Isoleucine or valine' 0 N--CA 1.503 2.213 0 O-C-N 121.427 -1.043 . . . . 0.0 111.491 -179.493 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 13' ' ' GLN . . . . . . . . . . . . . 1.2 tt0 56.33 50.53 13.08 Favored 'General case' 0 N--CA 1.499 1.992 0 O-C-N 121.408 -0.807 . . . . 0.0 110.616 179.93 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -104.68 -60.62 1.57 Allowed 'General case' 0 N--CA 1.495 1.815 0 O-C-N 121.269 -0.894 . . . . 0.0 110.536 179.887 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -152.12 -83.43 0.04 OUTLIER Glycine 0 N--CA 1.494 2.536 0 N-CA-C 109.876 -1.29 . . . . 0.0 109.876 179.942 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 16' ' ' CYS . . . . . 0.456 ' HB2' ' HB2' ' A' ' 20' ' ' CYS . 1.1 m -86.36 136.2 35.73 Favored Pre-proline 0 N--CA 1.496 1.831 0 O-C-N 121.338 -1.096 . . . . 0.0 109.985 179.679 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 45.3 Cg_endo -72.62 72.04 3.13 Favored 'Trans proline' 0 C--N 1.312 -1.361 0 O-C-N 123.656 1.345 . . . . 0.0 109.617 178.931 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 91.52 -49.49 2.9 Favored Glycine 0 N--CA 1.493 2.447 0 N-CA-C 109.702 -1.359 . . . . 0.0 109.702 -179.254 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -74.65 67.14 1.98 Allowed Glycine 0 N--CA 1.497 2.738 0 O-C-N 121.009 -1.289 . . . . 0.0 110.831 -179.727 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 20' ' ' CYS . . . . . 0.456 ' HB2' ' HB2' ' A' ' 16' ' ' CYS . 0.4 OUTLIER -127.77 73.14 1.43 Allowed 'General case' 0 N--CA 1.496 1.83 0 O-C-N 121.24 -1.153 . . . . 0.0 109.174 179.38 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 14.6 p -126.14 -19.66 2.68 Favored 'Isoleucine or valine' 0 N--CA 1.499 2.018 0 O-C-N 121.739 -0.601 . . . . 0.0 111.506 -179.039 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 17.7 mt-10 -79.96 50.18 1.17 Allowed 'General case' 0 N--CA 1.491 1.598 0 O-C-N 120.673 -1.267 . . . . 0.0 110.231 179.831 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 2.3 mt-10 -89.21 -172.91 3.82 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 120.864 -1.147 . . . . 0.0 110.138 -179.794 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER 56.39 59.25 3.73 Favored 'General case' 0 N--CA 1.493 1.677 0 CA-C-O 121.343 0.592 . . . . 0.0 110.4 179.976 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 1.9 p-10 -101.89 -174.45 2.59 Favored 'General case' 0 N--CA 1.496 1.83 0 O-C-N 121.223 -0.923 . . . . 0.0 109.907 179.561 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 79.35 -69.95 2.89 Favored Glycine 0 N--CA 1.495 2.628 0 N-CA-C 109.559 -1.416 . . . . 0.0 109.559 -179.807 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 144.71 115.04 0.97 Allowed Glycine 0 N--CA 1.494 2.561 0 N-CA-C 109.635 -1.386 . . . . 0.0 109.635 179.789 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 73.5 m -81.91 143.63 50.21 Favored Pre-proline 0 N--CA 1.5 2.032 0 O-C-N 121.385 -1.067 . . . . 0.0 110.187 -179.973 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 45.5 Cg_endo -73.46 91.25 0.88 Allowed 'Trans proline' 0 C--N 1.315 -1.188 0 O-C-N 123.729 1.384 . . . . 0.0 111.115 -179.078 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -94.55 -55.2 3.23 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.315 -0.865 . . . . 0.0 110.59 179.883 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 36.2 tt0 -79.05 -7.26 57.97 Favored 'General case' 0 N--CA 1.496 1.858 0 O-C-N 121.513 -0.742 . . . . 0.0 110.911 -179.8 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 90.41 -10.34 74.71 Favored Glycine 0 N--CA 1.494 2.51 0 O-C-N 120.792 -1.192 . . . . 0.0 110.182 -179.515 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 33' ' ' CYS . . . . . . . . . . . . . 59.1 m -79.73 65.71 4.97 Favored 'General case' 0 N--CA 1.494 1.741 0 O-C-N 120.925 -1.338 . . . . 0.0 110.282 -179.803 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -79.2 -38.95 34.52 Favored 'General case' 0 N--CA 1.494 1.742 0 O-C-N 121.456 -0.778 . . . . 0.0 109.573 179.576 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 47.9 mt-10 -89.91 162.59 15.36 Favored 'General case' 0 N--CA 1.493 1.716 0 O-C-N 121.381 -0.825 . . . . 0.0 109.594 179.235 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 36' ' ' ALA . . . . . . . . . . . . . . . -79.35 -46.33 17.86 Favored 'General case' 0 N--CA 1.493 1.683 0 O-C-N 121.123 -0.985 . . . . 0.0 110.412 -179.221 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 1.5 tt0 -95.3 62.41 2.47 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.191 -0.943 . . . . 0.0 110.315 -179.834 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -148.68 17.49 1.26 Allowed Glycine 0 N--CA 1.496 2.673 0 C-N-CA 119.945 -1.121 . . . . 0.0 110.958 -179.984 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 39' ' ' CYS . . . . . . . . . . . . . 57.1 m -144.23 26.87 1.45 Allowed 'General case' 0 N--CA 1.502 2.135 0 O-C-N 120.663 -1.492 . . . . 0.0 111.274 -179.837 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 40' ' ' LEU . . . . . . . . . . . . . 0.9 OUTLIER . . . . . 0 N--CA 1.501 2.082 0 O-C-N 121.68 -0.638 . . . . 0.0 111.647 179.886 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 9.5 t . . . . . 0 N--CA 1.497 1.897 0 N-CA-C 109.506 -0.553 . . . . 0.0 109.506 . . . . . . . . . 0 0 . 1 . 003 nuclear build core ' A' A ' 6' ' ' PRO . . . . . . . . . . . . . 48.9 Cg_endo -73.42 -21.13 20.08 Favored 'Trans proline' 0 C--N 1.312 -1.39 0 O-C-N 124.089 1.573 . . . . 0.0 111.949 -179.508 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -74.58 -40.21 39.2 Favored Glycine 0 N--CA 1.496 2.636 0 N-CA-C 110.386 -1.086 . . . . 0.0 110.386 -179.169 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 31.1 p -85.95 -174.61 5.19 Favored 'General case' 0 N--CA 1.498 1.943 0 O-C-N 121.168 -1.195 . . . . 0.0 110.881 -179.599 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -142.26 -135.11 3.05 Favored Glycine 0 N--CA 1.495 2.603 0 N-CA-C 109.854 -1.299 . . . . 0.0 109.854 -179.587 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 10' ' ' GLN . . . . . . . . . . . . . 4.2 mt-30 -80.62 41.37 0.55 Allowed 'General case' 0 N--CA 1.499 2.013 0 O-C-N 121.14 -1.212 . . . . 0.0 111.665 -179.566 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 80.49 -34.42 2.26 Favored Glycine 0 N--CA 1.497 2.714 0 O-C-N 120.718 -1.239 . . . . 0.0 111.224 179.445 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 16.9 m -130.66 60.98 0.3 Allowed 'Isoleucine or valine' 0 N--CA 1.498 1.933 0 O-C-N 121.056 -1.261 . . . . 0.0 110.867 -179.354 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 13' ' ' GLN . . . . . . . . . . . . . 0.6 OUTLIER -124.06 94.64 4.28 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.323 -0.86 . . . . 0.0 109.607 179.754 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -150.84 161.85 41.88 Favored 'General case' 0 N--CA 1.495 1.814 0 CA-C-O 121.539 0.685 . . . . 0.0 111.3 -179.553 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -144.61 -57.68 0.02 OUTLIER Glycine 0 N--CA 1.498 2.801 0 N-CA-C 108.427 -1.869 . . . . 0.0 108.427 179.378 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 0.8 OUTLIER -121.78 79.0 39.98 Favored Pre-proline 0 N--CA 1.499 1.988 0 N-CA-C 108.602 -0.888 . . . . 0.0 108.602 178.482 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 40.6 Cg_endo -66.89 -24.29 46.43 Favored 'Trans proline' 0 N--CA 1.49 1.319 0 C-N-CA 121.288 1.325 . . . . 0.0 112.246 -178.359 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . -96.06 19.43 54.5 Favored Glycine 0 N--CA 1.496 2.666 0 N-CA-C 109.973 -1.251 . . . . 0.0 109.973 179.821 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 114.94 141.56 7.55 Favored Glycine 0 N--CA 1.487 2.064 0 N-CA-C 108.528 -1.829 . . . . 0.0 108.528 179.842 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 36.3 m -109.39 167.48 10.09 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.28 -1.13 . . . . 0.0 109.792 179.889 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 21' ' ' VAL . . . . . 0.411 HG13 ' CB ' ' A' ' 25' ' ' ASP . 14.5 t -79.18 65.0 0.31 Allowed 'Isoleucine or valine' 0 N--CA 1.494 1.77 0 O-C-N 121.28 -0.887 . . . . 0.0 110.296 -179.801 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -96.14 -31.98 12.72 Favored 'General case' 0 N--CA 1.489 1.494 0 O-C-N 121.21 -0.931 . . . . 0.0 110.099 179.299 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 4.9 mm-40 -94.49 55.22 1.93 Allowed 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.184 -0.948 . . . . 0.0 110.437 -179.49 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 3.0 mm-40 39.09 68.36 0.36 Allowed 'General case' 0 N--CA 1.496 1.837 0 CA-C-O 121.616 0.722 . . . . 0.0 112.026 179.498 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 25' ' ' ASP . . . . . 0.411 ' CB ' HG13 ' A' ' 21' ' ' VAL . 0.7 OUTLIER -89.88 -9.94 47.12 Favored 'General case' 0 N--CA 1.497 1.909 0 O-C-N 121.155 -0.966 . . . . 0.0 110.276 178.85 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 90.25 -67.08 2.63 Favored Glycine 0 N--CA 1.494 2.51 0 N-CA-C 109.068 -1.613 . . . . 0.0 109.068 -179.053 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 67.91 176.55 10.28 Favored Glycine 0 N--CA 1.496 2.681 0 N-CA-C 110.234 -1.146 . . . . 0.0 110.234 179.516 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 1.9 t -111.37 94.41 22.19 Favored Pre-proline 0 N--CA 1.496 1.836 0 O-C-N 121.315 -1.109 . . . . 0.0 109.773 179.655 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 44.4 Cg_endo -71.91 110.1 2.83 Favored 'Trans proline' 0 C--N 1.315 -1.229 0 O-C-N 123.832 1.438 . . . . 0.0 110.728 -179.583 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -79.26 -54.15 6.25 Favored 'General case' 0 N--CA 1.492 1.646 0 O-C-N 121.264 -0.897 . . . . 0.0 110.364 -179.985 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 6.8 tt0 -90.24 16.52 8.47 Favored 'General case' 0 N--CA 1.492 1.665 0 O-C-N 121.073 -1.017 . . . . 0.0 111.002 179.702 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . -87.17 35.96 3.37 Favored Glycine 0 N--CA 1.492 2.431 0 N-CA-C 109.502 -1.439 . . . . 0.0 109.502 179.555 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 33' ' ' CYS . . . . . 0.471 ' HA ' ' O ' ' A' ' 38' ' ' GLY . 0.5 OUTLIER -114.28 22.08 14.08 Favored 'General case' 0 N--CA 1.494 1.746 0 O-C-N 121.497 -1.001 . . . . 0.0 110.646 179.328 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -152.24 46.48 0.75 Allowed 'General case' 0 N--CA 1.498 1.965 0 O-C-N 121.058 -1.026 . . . . 0.0 110.604 -179.722 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 7.6 pt-20 -128.73 -157.44 0.82 Allowed 'General case' 0 N--CA 1.499 2.002 0 O-C-N 121.51 -0.744 . . . . 0.0 110.253 179.856 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 36' ' ' ALA . . . . . . . . . . . . . . . -77.83 -23.64 48.9 Favored 'General case' 0 N--CA 1.499 1.985 0 O-C-N 121.242 -0.911 . . . . 0.0 110.448 -179.652 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER -79.5 -33.74 41.87 Favored 'General case' 0 N--CA 1.492 1.654 0 O-C-N 121.16 -0.962 . . . . 0.0 109.819 179.547 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 38' ' ' GLY . . . . . 0.471 ' O ' ' HA ' ' A' ' 33' ' ' CYS . . . 107.88 -97.09 1.1 Allowed Glycine 0 N--CA 1.492 2.421 0 N-CA-C 109.113 -1.595 . . . . 0.0 109.113 179.847 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 39' ' ' CYS . . . . . . . . . . . . . 1.8 t -160.81 115.04 2.1 Favored 'General case' 0 N--CA 1.498 1.957 0 O-C-N 121.637 -0.919 . . . . 0.0 109.687 179.435 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 40' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER . . . . . 0 N--CA 1.49 1.55 0 O-C-N 121.152 -0.968 . . . . 0.0 110.908 -179.334 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 N--CA 1.496 1.854 0 N-CA-C 110.074 -0.343 . . . . 0.0 110.074 . . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 6' ' ' PRO . . . . . . . . . . . . . 44.6 Cg_endo -74.74 -50.99 0.13 Allowed 'Trans proline' 0 C--N 1.314 -1.268 0 O-C-N 123.665 1.35 . . . . 0.0 111.102 -179.64 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -78.03 58.38 3.94 Favored Glycine 0 N--CA 1.494 2.559 0 N-CA-C 109.736 -1.346 . . . . 0.0 109.736 179.992 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 1.1 m -114.49 3.22 14.85 Favored 'General case' 0 N--CA 1.492 1.672 0 O-C-N 121.271 -1.135 . . . . 0.0 111.349 -179.938 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 9' ' ' GLY . . . . . 0.428 ' O ' ' HB2' ' A' ' 10' ' ' GLN . . . -80.18 57.36 4.63 Favored Glycine 0 N--CA 1.494 2.534 0 N-CA-C 109.894 -1.282 . . . . 0.0 109.894 179.598 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 10' ' ' GLN . . . . . 0.428 ' HB2' ' O ' ' A' ' 9' ' ' GLY . 5.6 tt0 -178.56 -63.4 0.01 OUTLIER 'General case' 0 N--CA 1.494 1.769 0 O-C-N 121.466 -1.02 . . . . 0.0 109.994 179.787 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -85.07 62.97 4.45 Favored Glycine 0 N--CA 1.491 2.346 0 N-CA-C 110.018 -1.233 . . . . 0.0 110.018 -179.867 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 12' ' ' VAL . . . . . 0.478 HG13 ' N ' ' A' ' 13' ' ' GLN . 7.5 p -146.37 -47.24 0.11 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.652 0 O-C-N 121.467 -1.019 . . . . 0.0 110.413 179.602 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 13' ' ' GLN . . . . . 0.478 ' N ' HG13 ' A' ' 12' ' ' VAL . 20.4 tt0 -175.04 -55.07 0.01 OUTLIER 'General case' 0 N--CA 1.497 1.9 0 O-C-N 121.36 -0.838 . . . . 0.0 109.6 179.521 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -117.04 -178.26 3.4 Favored 'General case' 0 N--CA 1.496 1.825 0 O-C-N 121.788 -0.57 . . . . 0.0 110.216 179.789 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -85.03 -35.21 12.87 Favored Glycine 0 N--CA 1.496 2.65 0 N-CA-C 110.378 -1.089 . . . . 0.0 110.378 -179.581 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 0.0 OUTLIER -113.45 132.85 22.31 Favored Pre-proline 0 N--CA 1.5 2.027 0 O-C-N 121.332 -1.099 . . . . 0.0 109.67 179.702 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 47.4 Cg_endo -74.29 58.67 4.44 Favored 'Trans proline' 0 C--N 1.31 -1.488 0 O-C-N 123.72 1.379 . . . . 0.0 111.072 -179.731 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 92.9 92.85 1.48 Allowed Glycine 0 N--CA 1.495 2.579 0 N-CA-C 110.167 -1.173 . . . . 0.0 110.167 179.336 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 106.71 113.1 3.75 Favored Glycine 0 N--CA 1.49 2.298 0 N-CA-C 110.128 -1.189 . . . . 0.0 110.128 179.345 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 20' ' ' CYS . . . . . 0.477 ' O ' ' HB3' ' A' ' 25' ' ' ASP . 36.9 m -122.27 -12.99 8.18 Favored 'General case' 0 N--CA 1.502 2.166 0 O-C-N 121.521 -0.988 . . . . 0.0 111.285 179.818 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 21' ' ' VAL . . . . . 0.586 HG12 ' CA ' ' A' ' 27' ' ' GLY . 18.5 m -80.36 18.91 0.18 Allowed 'Isoleucine or valine' 0 N--CA 1.504 2.239 0 O-C-N 120.865 -1.147 . . . . 0.0 111.848 -179.562 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 5.0 mm-40 -79.67 -19.88 47.97 Favored 'General case' 0 N--CA 1.486 1.357 0 O-C-N 120.84 -1.163 . . . . 0.0 110.884 179.836 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -139.18 55.35 1.7 Allowed 'General case' 0 N--CA 1.491 1.591 0 O-C-N 120.891 -1.131 . . . . 0.0 110.259 179.956 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 24' ' ' GLU . . . . . 0.545 ' HG3' ' HB2' ' A' ' 28' ' ' SER . 0.8 OUTLIER 53.09 31.15 10.75 Favored 'General case' 0 N--CA 1.506 2.362 0 O-C-N 121.92 -0.487 . . . . 0.0 112.013 179.473 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 25' ' ' ASP . . . . . 0.477 ' HB3' ' O ' ' A' ' 20' ' ' CYS . 21.2 t70 -106.27 115.38 30.12 Favored 'General case' 0 N--CA 1.496 1.834 0 O-C-N 120.866 -1.146 . . . . 0.0 109.661 179.715 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 77.22 -56.07 3.63 Favored Glycine 0 N--CA 1.492 2.382 0 N-CA-C 110.559 -1.016 . . . . 0.0 110.559 179.594 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 27' ' ' GLY . . . . . 0.586 ' CA ' HG12 ' A' ' 21' ' ' VAL . . . -55.97 -54.34 35.97 Favored Glycine 0 N--CA 1.494 2.56 0 N-CA-C 110.27 -1.132 . . . . 0.0 110.27 -178.964 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 28' ' ' SER . . . . . 0.545 ' HB2' ' HG3' ' A' ' 24' ' ' GLU . 1.4 m -113.83 77.3 3.52 Favored Pre-proline 0 N--CA 1.497 1.893 0 O-C-N 121.742 -0.858 . . . . 0.0 110.696 -179.368 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 54.7 Cg_endo -79.86 114.32 3.15 Favored 'Trans proline' 0 C--N 1.314 -1.282 0 O-C-N 123.234 1.123 . . . . 0.0 110.028 179.602 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -77.2 -26.81 53.2 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 120.974 -1.079 . . . . 0.0 109.904 179.937 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 1.2 mt-10 -78.95 1.99 21.82 Favored 'General case' 0 N--CA 1.494 1.771 0 O-C-N 121.312 -0.867 . . . . 0.0 110.685 179.137 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . -99.28 35.8 4.46 Favored Glycine 0 N--CA 1.492 2.379 0 N-CA-C 110.04 -1.224 . . . . 0.0 110.04 179.904 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 33' ' ' CYS . . . . . . . . . . . . . 1.7 t -160.67 64.69 0.31 Allowed 'General case' 0 N--CA 1.494 1.764 0 O-C-N 121.268 -1.137 . . . . 0.0 110.3 179.739 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -78.64 -53.45 7.16 Favored 'General case' 0 N--CA 1.499 1.983 0 O-C-N 121.073 -1.017 . . . . 0.0 109.417 179.06 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 8.0 mt-10 -85.16 169.56 13.74 Favored 'General case' 0 N--CA 1.495 1.784 0 O-C-N 121.461 -0.774 . . . . 0.0 109.519 178.466 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 36' ' ' ALA . . . . . . . . . . . . . . . -78.18 -43.52 28.4 Favored 'General case' 0 N--CA 1.493 1.718 0 O-C-N 120.908 -1.12 . . . . 0.0 109.505 179.826 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 6.5 pt-20 -81.33 -28.22 34.64 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.309 -0.87 . . . . 0.0 110.194 179.458 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -74.3 71.17 1.53 Allowed Glycine 0 N--CA 1.491 2.324 0 N-CA-C 109.92 -1.272 . . . . 0.0 109.92 -179.881 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 39' ' ' CYS . . . . . . . . . . . . . 0.6 OUTLIER -160.04 -47.76 0.05 Allowed 'General case' 0 C--N 1.296 -1.742 0 O-C-N 121.678 -0.895 . . . . 0.0 110.021 179.495 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 40' ' ' LEU . . . . . . . . . . . . . 17.0 mt . . . . . 0 N--CA 1.5 2.061 0 O-C-N 121.6 -0.687 . . . . 0.0 110.595 179.368 . . . . . . . . 0 0 . 1 . 005 nuclear build core ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 2.2 t . . . . . 0 N--CA 1.497 1.906 0 CA-C-O 120.875 0.369 . . . . 0.0 110.049 . . . . . . . . . 0 0 . 1 . 005 nuclear build core ' A' A ' 6' ' ' PRO . . . . . . . . . . . . . 50.5 Cg_endo -75.42 75.92 3.73 Favored 'Trans proline' 0 C--N 1.313 -1.326 0 O-C-N 123.964 1.507 . . . . 0.0 110.425 179.928 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 73.89 38.7 48.61 Favored Glycine 0 N--CA 1.498 2.798 0 N-CA-C 110.118 -1.193 . . . . 0.0 110.118 179.987 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 5.4 p -92.04 -159.84 0.69 Allowed 'General case' 0 N--CA 1.498 1.927 0 O-C-N 121.28 -1.13 . . . . 0.0 109.858 179.498 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -76.93 -93.89 0.21 Allowed Glycine 0 N--CA 1.495 2.579 0 N-CA-C 109.599 -1.4 . . . . 0.0 109.599 -179.978 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 10' ' ' GLN . . . . . . . . . . . . . 2.3 pt20 -169.58 85.72 0.14 Allowed 'General case' 0 N--CA 1.493 1.722 0 O-C-N 121.221 -1.164 . . . . 0.0 109.885 179.656 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -75.64 60.01 2.92 Favored Glycine 0 N--CA 1.497 2.7 0 N-CA-C 109.932 -1.267 . . . . 0.0 109.932 -179.809 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 12' ' ' VAL . . . . . 0.445 ' O ' HG13 ' A' ' 12' ' ' VAL . 14.2 p -146.26 52.57 0.11 Allowed 'Isoleucine or valine' 0 N--CA 1.495 1.783 0 O-C-N 121.537 -0.978 . . . . 0.0 109.537 -179.933 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 13' ' ' GLN . . . . . . . . . . . . . 4.5 tt0 -58.93 -55.4 35.57 Favored 'General case' 0 N--CA 1.5 2.027 0 O-C-N 121.125 -0.984 . . . . 0.0 110.851 -179.733 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -83.54 66.44 8.93 Favored 'General case' 0 N--CA 1.498 1.939 0 O-C-N 121.143 -0.973 . . . . 0.0 110.185 -179.775 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -72.58 -67.1 1.9 Allowed Glycine 0 N--CA 1.494 2.534 0 N-CA-C 109.78 -1.328 . . . . 0.0 109.78 -179.748 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 1.2 p -127.89 74.51 78.69 Favored Pre-proline 0 N--CA 1.497 1.88 0 O-C-N 121.788 -0.83 . . . . 0.0 110.45 179.608 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 43.8 Cg_endo -68.72 131.01 21.75 Favored 'Trans proline' 0 C--N 1.309 -1.523 0 O-C-N 123.462 1.243 . . . . 0.0 110.36 -179.978 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 100.89 -24.36 32.28 Favored Glycine 0 N--CA 1.493 2.453 0 N-CA-C 110.54 -1.024 . . . . 0.0 110.54 179.916 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 165.81 138.52 2.44 Favored Glycine 0 N--CA 1.489 2.177 0 N-CA-C 108.943 -1.663 . . . . 0.0 108.943 179.599 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 71.6 m -118.36 112.74 20.4 Favored 'General case' 0 N--CA 1.492 1.672 0 O-C-N 121.492 -1.005 . . . . 0.0 110.009 179.788 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 21' ' ' VAL . . . . . 0.423 ' O ' HG13 ' A' ' 21' ' ' VAL . 7.2 p -92.89 43.63 0.08 OUTLIER 'Isoleucine or valine' 0 N--CA 1.504 2.232 0 O-C-N 121.282 -0.886 . . . . 0.0 110.481 -179.608 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 2.1 mm-40 -79.45 -28.08 41.62 Favored 'General case' 0 N--CA 1.488 1.457 0 O-C-N 121.029 -1.044 . . . . 0.0 110.931 -179.908 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 1.3 tp10 -162.29 110.87 1.4 Allowed 'General case' 0 N--CA 1.493 1.685 0 O-C-N 121.018 -1.052 . . . . 0.0 110.328 179.852 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 2.3 tt0 -148.23 153.29 38.54 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 121.487 -0.758 . . . . 0.0 110.165 179.104 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -96.67 -54.41 3.24 Favored 'General case' 0 N--CA 1.497 1.888 0 O-C-N 121.75 -0.594 . . . . 0.0 110.183 -179.677 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -156.25 94.34 0.14 Allowed Glycine 0 N--CA 1.494 2.549 0 N-CA-C 108.723 -1.751 . . . . 0.0 108.723 -179.891 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -55.81 96.72 0.04 OUTLIER Glycine 0 N--CA 1.498 2.826 0 N-CA-C 110.567 -1.013 . . . . 0.0 110.567 -179.422 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 28' ' ' SER . . . . . 0.531 ' CB ' ' HD3' ' A' ' 29' ' ' PRO . 1.6 t -160.75 -65.51 0.02 OUTLIER Pre-proline 0 N--CA 1.496 1.849 0 O-C-N 121.334 -1.098 . . . . 0.0 109.586 179.615 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 29' ' ' PRO . . . . . 0.531 ' HD3' ' CB ' ' A' ' 28' ' ' SER . 51.8 Cg_endo -78.26 72.14 6.41 Favored 'Trans proline' 0 N--CA 1.486 1.048 0 O-C-N 123.205 1.108 . . . . 0.0 109.863 178.742 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 30' ' ' ALA . . . . . 0.406 ' O ' ' HB3' ' A' ' 34' ' ' ALA . . . -79.64 -64.26 1.23 Allowed 'General case' 0 N--CA 1.493 1.701 0 O-C-N 121.349 -0.844 . . . . 0.0 111.212 -179.065 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 3.5 tt0 -117.78 -22.99 7.73 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.038 -1.039 . . . . 0.0 111.381 -179.224 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . -52.04 -41.57 53.08 Favored Glycine 0 N--CA 1.498 2.821 0 O-C-N 120.99 -1.069 . . . . 0.0 110.915 -179.193 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 33' ' ' CYS . . . . . . . . . . . . . 0.8 OUTLIER -149.59 62.69 1.01 Allowed 'General case' 0 N--CA 1.496 1.858 0 O-C-N 121.159 -1.2 . . . . 0.0 110.381 179.78 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 34' ' ' ALA . . . . . 0.406 ' HB3' ' O ' ' A' ' 30' ' ' ALA . . . -141.5 34.06 1.65 Allowed 'General case' 0 N--CA 1.498 1.952 0 O-C-N 121.257 -0.902 . . . . 0.0 110.367 179.882 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -111.15 -168.7 1.34 Allowed 'General case' 0 N--CA 1.496 1.863 0 O-C-N 121.376 -0.827 . . . . 0.0 109.776 179.693 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 36' ' ' ALA . . . . . . . . . . . . . . . -78.66 -24.65 45.06 Favored 'General case' 0 N--CA 1.5 2.037 0 O-C-N 121.508 -0.745 . . . . 0.0 110.324 179.985 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 4.9 tt0 -80.06 -46.83 15.84 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.519 -0.738 . . . . 0.0 109.697 179.769 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 106.42 -112.71 3.92 Favored Glycine 0 N--CA 1.489 2.184 0 N-CA-C 109.688 -1.365 . . . . 0.0 109.688 179.792 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 39' ' ' CYS . . . . . . . . . . . . . 1.6 m -144.81 -47.14 0.24 Allowed 'General case' 0 N--CA 1.501 2.114 0 O-C-N 121.408 -1.054 . . . . 0.0 110.715 -179.633 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 40' ' ' LEU . . . . . . . . . . . . . 0.7 OUTLIER . . . . . 0 N--CA 1.505 2.311 0 O-C-N 121.518 -0.739 . . . . 0.0 111.892 179.731 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 22.9 p . . . . . 0 N--CA 1.494 1.763 0 N-CA-C 109.376 -0.601 . . . . 0.0 109.376 . . . . . . . . . 0 0 . 1 . 006 nuclear build core ' A' A ' 6' ' ' PRO . . . . . . . . . . . . . 42.0 Cg_endo -70.97 -53.26 0.2 Allowed 'Trans proline' 0 C--N 1.311 -1.412 0 O-C-N 123.685 1.36 . . . . 0.0 111.778 -178.988 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -108.89 59.45 0.36 Allowed Glycine 0 N--CA 1.492 2.371 0 O-C-N 120.917 -1.114 . . . . 0.0 110.859 -179.045 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 10.5 p -110.02 -35.68 6.06 Favored 'General case' 0 N--CA 1.5 2.034 0 O-C-N 121.264 -1.139 . . . . 0.0 110.693 179.355 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 49.4 32.19 14.57 Favored Glycine 0 N--CA 1.502 3.056 0 O-C-N 121.337 -0.852 . . . . 0.0 111.478 179.441 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 10' ' ' GLN . . . . . . . . . . . . . 69.8 mt-30 49.63 43.72 24.27 Favored 'General case' 0 N--CA 1.501 2.08 0 O-C-N 121.304 -1.115 . . . . 0.0 110.904 179.691 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -48.27 -50.06 23.88 Favored Glycine 0 N--CA 1.503 3.155 0 N-CA-C 110.619 -0.992 . . . . 0.0 110.619 -179.707 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 12' ' ' VAL . . . . . 0.51 ' O ' HG13 ' A' ' 12' ' ' VAL . 11.2 p -127.82 53.75 0.37 Allowed 'Isoleucine or valine' 0 N--CA 1.494 1.728 0 O-C-N 121.312 -1.111 . . . . 0.0 109.759 179.81 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 13' ' ' GLN . . . . . . . . . . . . . 1.6 pt20 -71.02 142.76 50.91 Favored 'General case' 0 N--CA 1.495 1.795 0 O-C-N 121.01 -1.057 . . . . 0.0 110.321 -179.891 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -122.75 131.89 53.98 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.321 -0.862 . . . . 0.0 109.858 179.805 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -73.36 -54.15 7.05 Favored Glycine 0 N--CA 1.491 2.314 0 N-CA-C 109.662 -1.375 . . . . 0.0 109.662 -179.976 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 12.2 m -114.3 122.0 35.18 Favored Pre-proline 0 N--CA 1.499 1.992 0 O-C-N 121.295 -1.12 . . . . 0.0 109.996 -179.94 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 43.6 Cg_endo -72.11 75.38 2.3 Favored 'Trans proline' 0 N--CA 1.497 1.692 0 O-C-N 123.611 1.322 . . . . 0.0 110.789 -179.69 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 127.14 -46.02 1.11 Allowed Glycine 0 N--CA 1.495 2.571 0 N-CA-C 109.659 -1.376 . . . . 0.0 109.659 179.879 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 161.5 147.33 4.94 Favored Glycine 0 N--CA 1.484 1.884 0 N-CA-C 109.321 -1.512 . . . . 0.0 109.321 -179.318 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 0.9 OUTLIER -106.22 172.2 6.94 Favored 'General case' 0 C--N 1.296 -1.746 0 O-C-N 121.534 -0.98 . . . . 0.0 109.647 -179.811 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 10.5 t -78.71 61.33 0.17 Allowed 'Isoleucine or valine' 0 N--CA 1.498 1.936 0 O-C-N 121.35 -0.844 . . . . 0.0 109.781 179.527 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 3.0 mm-40 -131.24 37.49 3.72 Favored 'General case' 0 C--N 1.306 -1.305 0 O-C-N 121.585 -0.697 . . . . 0.0 109.661 -179.717 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 48.2 mt-10 -68.5 167.11 15.54 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.308 -0.87 . . . . 0.0 110.874 -179.236 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 2.8 pm0 -70.91 158.9 35.65 Favored 'General case' 0 N--CA 1.495 1.794 0 O-C-N 121.733 -0.605 . . . . 0.0 111.18 -179.014 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -80.3 -65.46 1.0 Allowed 'General case' 0 N--CA 1.491 1.597 0 N-CA-C 109.376 -0.602 . . . . 0.0 109.376 179.212 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 174.74 84.57 0.06 OUTLIER Glycine 0 N--CA 1.494 2.507 0 N-CA-C 109.535 -1.426 . . . . 0.0 109.535 179.853 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 149.16 128.3 1.66 Allowed Glycine 0 N--CA 1.493 2.464 0 N-CA-C 109.268 -1.533 . . . . 0.0 109.268 179.944 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -93.39 150.73 39.47 Favored Pre-proline 0 N--CA 1.495 1.818 0 O-C-N 121.559 -0.965 . . . . 0.0 110.444 -179.507 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 29' ' ' PRO . . . . . 0.487 ' HA ' ' HB3' ' A' ' 33' ' ' CYS . 52.4 Cg_endo -79.55 14.19 1.89 Allowed 'Trans proline' 0 N--CA 1.486 1.083 0 O-C-N 123.833 1.439 . . . . 0.0 111.784 179.81 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -127.55 15.18 7.08 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.049 -1.032 . . . . 0.0 110.394 179.585 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -159.84 -75.58 0.07 Allowed 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.458 -0.776 . . . . 0.0 109.613 -179.638 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . -66.97 -56.51 12.27 Favored Glycine 0 N--CA 1.496 2.646 0 N-CA-C 109.284 -1.526 . . . . 0.0 109.284 179.699 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 33' ' ' CYS . . . . . 0.487 ' HB3' ' HA ' ' A' ' 29' ' ' PRO . 5.5 t -87.24 73.83 9.63 Favored 'General case' 0 N--CA 1.497 1.895 0 O-C-N 121.358 -1.084 . . . . 0.0 109.891 179.766 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -147.86 49.24 1.07 Allowed 'General case' 0 N--CA 1.495 1.793 0 O-C-N 121.495 -0.753 . . . . 0.0 110.063 179.831 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 12.0 mt-10 -108.51 -174.35 2.5 Favored 'General case' 0 N--CA 1.494 1.762 0 O-C-N 121.467 -0.771 . . . . 0.0 110.69 -179.862 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 36' ' ' ALA . . . . . . . . . . . . . . . -89.97 -1.96 58.07 Favored 'General case' 0 N--CA 1.499 2.006 0 O-C-N 121.294 -0.879 . . . . 0.0 111.501 179.89 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -117.81 31.89 6.45 Favored 'General case' 0 N--CA 1.493 1.689 0 O-C-N 121.297 -0.877 . . . . 0.0 110.856 179.922 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 67.3 -118.1 9.75 Favored Glycine 0 N--CA 1.49 2.252 0 N-CA-C 109.661 -1.376 . . . . 0.0 109.661 179.607 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 39' ' ' CYS . . . . . 0.539 ' C ' HD13 ' A' ' 40' ' ' LEU . 0.1 OUTLIER -153.7 24.51 0.51 Allowed 'General case' 0 N--CA 1.499 2.006 0 O-C-N 121.522 -0.987 . . . . 0.0 111.292 -179.969 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 40' ' ' LEU . . . . . 0.76 HD22 ' H ' ' A' ' 40' ' ' LEU . 0.0 OUTLIER . . . . . 0 N--CA 1.493 1.715 0 O-C-N 120.888 -1.132 . . . . 0.0 110.496 179.083 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 0.8 OUTLIER . . . . . 0 N--CA 1.492 1.659 0 CA-C-O 121.016 0.436 . . . . 0.0 110.013 . . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 6' ' ' PRO . . . . . . . . . . . . . 39.3 Cg_endo -66.93 96.46 0.37 Allowed 'Trans proline' 0 C--N 1.303 -1.823 0 O-C-N 124.835 1.966 . . . . 0.0 111.241 -179.78 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 90.35 13.17 60.44 Favored Glycine 0 N--CA 1.493 2.499 0 C-N-CA 120.292 -0.956 . . . . 0.0 111.123 179.187 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 3.7 p -143.72 171.66 13.89 Favored 'General case' 0 N--CA 1.495 1.802 0 O-C-N 120.425 -1.633 . . . . 0.0 110.134 179.614 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 97.55 122.27 4.4 Favored Glycine 0 N--CA 1.494 2.511 0 N-CA-C 108.847 -1.701 . . . . 0.0 108.847 -179.147 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 10' ' ' GLN . . . . . . . . . . . . . 2.2 mt-30 -81.7 49.44 1.34 Allowed 'General case' 0 N--CA 1.494 1.743 0 O-C-N 121.156 -1.202 . . . . 0.0 110.922 -179.483 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -92.67 58.34 2.58 Favored Glycine 0 N--CA 1.495 2.599 0 N-CA-C 108.947 -1.661 . . . . 0.0 108.947 179.453 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 10.7 t -130.21 63.08 0.3 Allowed 'Isoleucine or valine' 0 N--CA 1.496 1.873 0 O-C-N 121.551 -0.97 . . . . 0.0 109.734 -179.674 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 13' ' ' GLN . . . . . . . . . . . . . 2.2 tt0 -121.01 102.95 8.67 Favored 'General case' 0 N--CA 1.487 1.408 0 O-C-N 121.245 -0.909 . . . . 0.0 109.748 179.816 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -134.7 -73.81 0.47 Allowed 'General case' 0 N--CA 1.492 1.675 0 O-C-N 121.941 -0.475 . . . . 0.0 109.826 179.993 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 136.46 -58.47 0.66 Allowed Glycine 0 N--CA 1.495 2.608 0 N-CA-C 109.537 -1.425 . . . . 0.0 109.537 179.966 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 10.1 m -79.49 148.63 70.37 Favored Pre-proline 0 N--CA 1.5 2.043 0 O-C-N 121.387 -1.067 . . . . 0.0 109.651 179.848 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 41.1 Cg_endo -66.69 -26.57 45.68 Favored 'Trans proline' 0 N--CA 1.492 1.435 0 O-C-N 123.896 1.471 . . . . 0.0 111.414 -179.636 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 174.66 85.29 0.06 OUTLIER Glycine 0 N--CA 1.494 2.5 0 N-CA-C 109.436 -1.466 . . . . 0.0 109.436 179.802 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 94.76 142.29 12.49 Favored Glycine 0 N--CA 1.488 2.147 0 N-CA-C 109.529 -1.428 . . . . 0.0 109.529 -179.834 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 0.0 OUTLIER -142.4 110.24 5.85 Favored 'General case' 0 N--CA 1.497 1.901 0 O-C-N 121.645 -0.915 . . . . 0.0 109.62 179.602 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 3.7 t -98.51 46.7 0.11 Allowed 'Isoleucine or valine' 0 N--CA 1.497 1.901 0 O-C-N 121.645 -0.659 . . . . 0.0 110.214 -179.635 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 8.6 mt-10 -87.99 -25.62 23.05 Favored 'General case' 0 N--CA 1.488 1.459 0 O-C-N 121.307 -0.871 . . . . 0.0 110.501 179.671 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 0.9 OUTLIER 60.02 -159.96 0.3 Allowed 'General case' 0 N--CA 1.501 2.09 0 O-C-N 121.751 -0.593 . . . . 0.0 110.976 179.924 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -124.44 -154.1 0.59 Allowed 'General case' 0 N--CA 1.488 1.439 0 O-C-N 121.537 -0.727 . . . . 0.0 110.169 -179.558 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -84.96 143.98 28.62 Favored 'General case' 0 N--CA 1.494 1.765 0 O-C-N 121.282 -0.886 . . . . 0.0 110.233 -179.971 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -69.69 -16.64 72.26 Favored Glycine 0 N--CA 1.493 2.472 0 N-CA-C 109.986 -1.246 . . . . 0.0 109.986 178.926 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 115.96 -107.7 1.72 Allowed Glycine 0 N--CA 1.49 2.285 0 N-CA-C 109.286 -1.526 . . . . 0.0 109.286 179.843 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -113.01 91.7 19.04 Favored Pre-proline 0 N--CA 1.497 1.88 0 O-C-N 121.327 -1.102 . . . . 0.0 109.63 179.375 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 44.2 Cg_endo -73.42 118.22 5.41 Favored 'Trans proline' 0 N--CA 1.49 1.318 0 O-C-N 123.692 1.364 . . . . 0.0 110.955 179.959 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -121.34 34.19 5.28 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.164 -0.96 . . . . 0.0 110.716 179.664 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 31' ' ' GLU . . . . . 0.507 ' HG3' ' N ' ' A' ' 32' ' ' GLY . 0.1 OUTLIER -86.85 -32.02 20.49 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.025 -1.047 . . . . 0.0 110.168 179.873 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 32' ' ' GLY . . . . . 0.507 ' N ' ' HG3' ' A' ' 31' ' ' GLU . . . 137.41 -47.42 0.95 Allowed Glycine 0 N--CA 1.493 2.464 0 N-CA-C 110.22 -1.152 . . . . 0.0 110.22 179.623 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 33' ' ' CYS . . . . . . . . . . . . . 0.9 OUTLIER -113.72 92.21 3.9 Favored 'General case' 0 N--CA 1.493 1.675 0 O-C-N 121.582 -0.952 . . . . 0.0 110.881 -179.398 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -96.9 37.32 1.31 Allowed 'General case' 0 N--CA 1.499 1.976 0 O-C-N 121.138 -0.976 . . . . 0.0 109.863 179.211 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 10.8 mt-10 -137.48 -178.1 5.08 Favored 'General case' 0 N--CA 1.497 1.902 0 O-C-N 121.747 -0.596 . . . . 0.0 109.867 179.812 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 36' ' ' ALA . . . . . . . . . . . . . . . -88.75 35.69 0.79 Allowed 'General case' 0 N--CA 1.493 1.717 0 O-C-N 120.993 -1.067 . . . . 0.0 110.594 -179.819 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 5.6 tt0 -78.5 -26.91 46.04 Favored 'General case' 0 N--CA 1.486 1.347 0 O-C-N 121.39 -0.819 . . . . 0.0 110.076 179.666 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 70.22 70.83 1.1 Allowed Glycine 0 N--CA 1.492 2.379 0 N-CA-C 109.137 -1.585 . . . . 0.0 109.137 179.689 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 39' ' ' CYS . . . . . . . . . . . . . 1.8 m -100.89 110.08 22.11 Favored 'General case' 0 C--N 1.298 -1.665 0 O-C-N 121.733 -0.863 . . . . 0.0 109.793 -179.768 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 40' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER . . . . . 0 N--CA 1.49 1.555 0 O-C-N 121.425 -0.797 . . . . 0.0 110.961 -179.794 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 19.8 t . . . . . 0 N--CA 1.494 1.751 0 N-CA-C 109.579 -0.526 . . . . 0.0 109.579 . . . . . . . . . 0 0 . 1 . 008 nuclear build core ' A' A ' 6' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -80.57 -35.63 0.55 Allowed 'Trans proline' 0 C--N 1.308 -1.57 0 O-C-N 124.09 1.573 . . . . 0.0 112.171 -179.325 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -90.45 53.22 3.45 Favored Glycine 0 N--CA 1.496 2.637 0 O-C-N 120.361 -1.462 . . . . 0.0 112.007 -178.009 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 21.7 p -161.15 163.7 31.08 Favored 'General case' 0 N--CA 1.498 1.933 0 O-C-N 120.657 -1.496 . . . . 0.0 110.655 178.854 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 70.91 63.94 2.98 Favored Glycine 0 N--CA 1.494 2.535 0 N-CA-C 109.759 -1.336 . . . . 0.0 109.759 -179.951 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 10' ' ' GLN . . . . . . . . . . . . . 3.1 pt20 -145.04 27.5 1.29 Allowed 'General case' 0 N--CA 1.493 1.698 0 O-C-N 121.619 -0.93 . . . . 0.0 111.113 -179.639 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -140.53 63.31 0.53 Allowed Glycine 0 N--CA 1.491 2.35 0 N-CA-C 109.439 -1.464 . . . . 0.0 109.439 179.839 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 28.9 m -113.79 2.06 8.39 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.834 0 O-C-N 121.568 -0.96 . . . . 0.0 111.627 -179.955 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 13' ' ' GLN . . . . . . . . . . . . . 25.6 tt0 -51.41 -45.73 62.64 Favored 'General case' 0 N--CA 1.499 2.01 0 O-C-N 120.984 -1.072 . . . . 0.0 110.613 179.815 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -111.04 26.6 10.53 Favored 'General case' 0 N--CA 1.494 1.729 0 O-C-N 121.624 -0.673 . . . . 0.0 110.272 179.714 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -128.33 68.19 0.54 Allowed Glycine 0 N--CA 1.489 2.19 0 N-CA-C 108.97 -1.652 . . . . 0.0 108.97 179.753 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 17.9 m -96.0 150.27 37.06 Favored Pre-proline 0 N--CA 1.488 1.437 0 O-C-N 121.44 -1.035 . . . . 0.0 110.497 -179.745 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 43.7 Cg_endo -74.17 -39.85 1.48 Allowed 'Trans proline' 0 N--CA 1.491 1.368 0 O-C-N 123.822 1.433 . . . . 0.0 110.648 179.426 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . -167.12 59.36 0.22 Allowed Glycine 0 N--CA 1.493 2.461 0 N-CA-C 109.163 -1.575 . . . . 0.0 109.163 179.589 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 141.18 132.56 2.82 Favored Glycine 0 N--CA 1.493 2.496 0 N-CA-C 108.625 -1.79 . . . . 0.0 108.625 -179.557 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -134.32 169.38 17.31 Favored 'General case' 0 N--CA 1.496 1.851 0 O-C-N 121.512 -0.993 . . . . 0.0 109.301 -179.665 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 21' ' ' VAL . . . . . 0.427 HG22 ' O ' ' A' ' 21' ' ' VAL . 11.7 p -80.06 50.89 0.07 OUTLIER 'Isoleucine or valine' 0 N--CA 1.502 2.155 0 O-C-N 121.319 -0.863 . . . . 0.0 111.254 -179.736 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 2.8 mt-10 -108.58 51.76 0.73 Allowed 'General case' 0 C--N 1.305 -1.326 0 O-C-N 121.014 -1.053 . . . . 0.0 108.436 178.419 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 0.8 OUTLIER 52.55 59.41 4.52 Favored 'General case' 0 N--CA 1.495 1.806 0 CA-C-O 121.93 0.871 . . . . 0.0 109.222 -177.995 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 1.7 pm0 -61.0 -5.46 1.4 Allowed 'General case' 0 N--CA 1.5 2.034 0 O-C-N 121.432 -0.793 . . . . 0.0 112.228 -179.105 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 15.7 m-20 -77.17 -24.18 51.49 Favored 'General case' 0 N--CA 1.497 1.924 0 O-C-N 120.737 -1.227 . . . . 0.0 110.431 179.641 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 88.39 -51.96 3.99 Favored Glycine 0 N--CA 1.495 2.589 0 N-CA-C 109.726 -1.35 . . . . 0.0 109.726 -179.921 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -177.29 -140.05 3.53 Favored Glycine 0 N--CA 1.493 2.472 0 N-CA-C 109.798 -1.321 . . . . 0.0 109.798 -179.696 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 28' ' ' SER . . . . . 0.46 ' CB ' ' CD ' ' A' ' 29' ' ' PRO . 2.6 t -154.92 -64.07 0.02 OUTLIER Pre-proline 0 N--CA 1.494 1.744 0 O-C-N 121.163 -1.198 . . . . 0.0 110.665 179.835 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 29' ' ' PRO . . . . . 0.46 ' CD ' ' CB ' ' A' ' 28' ' ' SER . 41.4 Cg_endo -68.89 -31.23 25.09 Favored 'Trans proline' 0 N--CA 1.488 1.188 0 O-C-N 122.979 0.989 . . . . 0.0 111.133 -179.562 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -99.12 54.29 0.98 Allowed 'General case' 0 N--CA 1.493 1.704 0 O-C-N 121.376 -0.827 . . . . 0.0 110.827 -179.633 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 2.8 tp10 -84.48 -42.41 15.6 Favored 'General case' 0 N--CA 1.493 1.717 0 O-C-N 121.379 -0.826 . . . . 0.0 110.217 179.603 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 96.47 52.43 1.57 Allowed Glycine 0 N--CA 1.501 2.995 0 N-CA-C 109.634 -1.386 . . . . 0.0 109.634 -179.804 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 33' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -79.62 118.64 21.64 Favored 'General case' 0 N--CA 1.495 1.814 0 O-C-N 121.157 -1.202 . . . . 0.0 109.735 179.903 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -79.49 -28.5 41.47 Favored 'General case' 0 N--CA 1.497 1.918 0 O-C-N 121.259 -0.9 . . . . 0.0 110.721 -179.851 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 24.5 mp0 -78.19 153.53 31.92 Favored 'General case' 0 N--CA 1.492 1.658 0 CA-C-O 121.491 0.662 . . . . 0.0 110.556 -179.762 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 36' ' ' ALA . . . . . . . . . . . . . . . -91.88 -42.18 10.2 Favored 'General case' 0 N--CA 1.496 1.825 0 O-C-N 121.415 -0.803 . . . . 0.0 110.999 -179.668 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 16.2 tt0 -77.18 -26.12 52.57 Favored 'General case' 0 N--CA 1.494 1.757 0 O-C-N 120.796 -1.19 . . . . 0.0 111.197 -179.006 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -70.26 -32.72 68.66 Favored Glycine 0 N--CA 1.497 2.705 0 C-N-CA 120.386 -0.911 . . . . 0.0 111.203 -178.942 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 39' ' ' CYS . . . . . . . . . . . . . 90.1 m -135.36 -32.32 0.94 Allowed 'General case' 0 N--CA 1.506 2.344 0 O-C-N 120.709 -1.466 . . . . 0.0 112.872 -178.697 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 40' ' ' LEU . . . . . . . . . . . . . 1.0 OUTLIER . . . . . 0 N--CA 1.497 1.879 0 O-C-N 120.697 -1.252 . . . . 0.0 111.606 -178.371 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 31.6 p . . . . . 0 N--CA 1.493 1.686 0 CA-C-O 120.469 0.176 . . . . 0.0 110.599 . . . . . . . . . 0 0 . 1 . 009 nuclear build core ' A' A ' 6' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -78.26 110.59 2.9 Favored 'Trans proline' 0 N--CA 1.487 1.136 0 O-C-N 123.938 1.494 . . . . 0.0 111.516 -179.416 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 47.44 54.69 10.14 Favored Glycine 0 N--CA 1.497 2.707 0 O-C-N 121.337 -0.852 . . . . 0.0 110.983 179.147 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -112.84 -171.95 1.96 Allowed 'General case' 0 N--CA 1.495 1.784 0 O-C-N 121.342 -1.093 . . . . 0.0 109.822 179.24 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 9' ' ' GLY . . . . . 0.493 ' O ' ' HG2' ' A' ' 10' ' ' GLN . . . 95.54 36.34 5.39 Favored Glycine 0 N--CA 1.495 2.608 0 N-CA-C 109.452 -1.459 . . . . 0.0 109.452 179.973 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 10' ' ' GLN . . . . . 0.493 ' HG2' ' O ' ' A' ' 9' ' ' GLY . 0.0 OUTLIER 26.87 54.81 0.05 Allowed 'General case' 0 N--CA 1.506 2.351 0 CA-C-N 117.379 0.59 . . . . 0.0 112.055 179.679 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -135.95 52.37 0.79 Allowed Glycine 0 N--CA 1.496 2.662 0 N-CA-C 109.511 -1.436 . . . . 0.0 109.511 179.586 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 6.3 p -107.97 -2.49 10.06 Favored 'Isoleucine or valine' 0 N--CA 1.499 2.017 0 O-C-N 121.12 -1.223 . . . . 0.0 110.877 -179.331 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 13' ' ' GLN . . . . . . . . . . . . . 7.0 mt-30 -76.11 79.3 2.94 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 120.884 -1.135 . . . . 0.0 110.444 -179.491 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -119.02 174.75 6.12 Favored 'General case' 0 N--CA 1.498 1.972 0 O-C-N 121.673 -0.642 . . . . 0.0 110.29 179.662 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -143.25 -94.62 0.2 Allowed Glycine 0 N--CA 1.494 2.54 0 N-CA-C 109.544 -1.422 . . . . 0.0 109.544 179.895 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 4.7 m -89.07 151.09 46.43 Favored Pre-proline 0 N--CA 1.492 1.648 0 O-C-N 121.34 -1.094 . . . . 0.0 109.975 179.655 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 50.0 Cg_endo -75.14 59.01 5.17 Favored 'Trans proline' 0 C--N 1.315 -1.205 0 O-C-N 123.847 1.446 . . . . 0.0 111.052 -179.953 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 69.93 11.3 66.3 Favored Glycine 0 N--CA 1.494 2.56 0 N-CA-C 110.609 -0.996 . . . . 0.0 110.609 179.887 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -147.74 114.52 0.7 Allowed Glycine 0 N--CA 1.488 2.141 0 N-CA-C 109.064 -1.615 . . . . 0.0 109.064 -179.507 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -153.67 142.87 21.43 Favored 'General case' 0 N--CA 1.494 1.775 0 O-C-N 121.483 -1.01 . . . . 0.0 110.125 -179.85 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 11.5 p -150.35 44.67 0.08 OUTLIER 'Isoleucine or valine' 0 N--CA 1.499 1.99 0 CA-C-O 121.559 0.695 . . . . 0.0 110.164 -179.681 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 1.8 mt-10 -112.31 -13.57 13.43 Favored 'General case' 0 N--CA 1.487 1.418 0 O-C-N 121.191 -0.943 . . . . 0.0 110.758 179.654 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 1.4 tp10 58.73 85.95 0.09 Allowed 'General case' 0 N--CA 1.504 2.253 0 O-C-N 121.355 -0.84 . . . . 0.0 110.526 179.855 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 26.1 mt-10 -79.24 50.01 1.03 Allowed 'General case' 0 N--CA 1.496 1.854 0 O-C-N 120.858 -1.151 . . . . 0.0 111.286 -179.883 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 2.5 t70 -113.97 68.98 0.7 Allowed 'General case' 0 N--CA 1.495 1.788 0 O-C-N 121.211 -0.931 . . . . 0.0 109.979 179.706 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 159.87 -87.62 0.11 Allowed Glycine 0 N--CA 1.495 2.627 0 N-CA-C 109.638 -1.385 . . . . 0.0 109.638 179.838 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 121.47 -56.92 0.61 Allowed Glycine 0 N--CA 1.494 2.526 0 N-CA-C 109.533 -1.427 . . . . 0.0 109.533 -179.853 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 58.3 m -125.42 159.75 58.71 Favored Pre-proline 0 N--CA 1.498 1.953 0 O-C-N 121.762 -0.846 . . . . 0.0 110.157 179.964 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 42.4 Cg_endo -65.76 -29.13 51.15 Favored 'Trans proline' 0 N--CA 1.492 1.411 0 O-C-N 123.883 1.465 . . . . 0.0 111.076 179.736 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -96.15 15.81 19.83 Favored 'General case' 0 N--CA 1.487 1.384 0 O-C-N 120.822 -1.174 . . . . 0.0 110.224 178.965 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 37.0 tp10 -79.65 -50.71 10.24 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.089 -1.007 . . . . 0.0 110.818 -179.103 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 131.64 88.27 0.43 Allowed Glycine 0 N--CA 1.487 2.088 0 N-CA-C 108.771 -1.732 . . . . 0.0 108.771 -179.384 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 33' ' ' CYS . . . . . . . . . . . . . 17.9 m -78.22 125.59 29.57 Favored 'General case' 0 N--CA 1.502 2.131 0 O-C-N 121.279 -1.13 . . . . 0.0 110.307 -179.811 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -79.09 -17.21 55.56 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.363 -0.836 . . . . 0.0 109.839 179.15 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 1.1 tm-20 -103.74 165.24 11.16 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.391 -0.818 . . . . 0.0 109.999 179.581 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 36' ' ' ALA . . . . . . . . . . . . . . . -102.04 -26.92 13.22 Favored 'General case' 0 N--CA 1.498 1.955 0 O-C-N 121.335 -0.853 . . . . 0.0 110.903 179.58 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 1.5 mt-10 -79.58 -31.93 41.92 Favored 'General case' 0 N--CA 1.494 1.775 0 O-C-N 120.942 -1.099 . . . . 0.0 110.604 -179.195 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -75.22 -36.96 43.76 Favored Glycine 0 N--CA 1.493 2.459 0 N-CA-C 110.392 -1.083 . . . . 0.0 110.392 -179.91 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 39' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -96.47 -27.85 14.69 Favored 'General case' 0 N--CA 1.499 2.005 0 O-C-N 120.868 -1.372 . . . . 0.0 111.477 -179.865 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 40' ' ' LEU . . . . . . . . . . . . . 0.8 OUTLIER . . . . . 0 N--CA 1.502 2.133 0 O-C-N 121.297 -0.877 . . . . 0.0 110.657 -179.417 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 5.8 p . . . . . 0 N--CA 1.497 1.923 0 N-CA-C 110.394 -0.224 . . . . 0.0 110.394 . . . . . . . . . 0 0 . 1 . 010 nuclear build core ' A' A ' 6' ' ' PRO . . . . . . . . . . . . . 44.1 Cg_endo -75.09 -53.49 0.1 OUTLIER 'Trans proline' 0 C--N 1.311 -1.443 0 O-C-N 123.559 1.294 . . . . 0.0 111.351 -179.577 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -85.97 59.87 4.68 Favored Glycine 0 N--CA 1.492 2.373 0 N-CA-C 110.238 -1.145 . . . . 0.0 110.238 -179.426 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 0.7 OUTLIER -106.02 18.38 22.16 Favored 'General case' 0 N--CA 1.501 2.084 0 O-C-N 121.281 -1.129 . . . . 0.0 110.56 179.325 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 106.17 55.73 0.67 Allowed Glycine 0 N--CA 1.496 2.676 0 N-CA-C 109.975 -1.25 . . . . 0.0 109.975 179.729 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 10' ' ' GLN . . . . . . . . . . . . . 3.8 pt20 -161.79 48.35 0.19 Allowed 'General case' 0 N--CA 1.492 1.633 0 O-C-N 121.383 -1.069 . . . . 0.0 110.361 179.777 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -94.79 66.36 1.37 Allowed Glycine 0 N--CA 1.495 2.588 0 N-CA-C 109.599 -1.4 . . . . 0.0 109.599 179.901 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 24.6 t -122.3 -20.06 4.05 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.029 0 O-C-N 121.393 -1.063 . . . . 0.0 111.079 -179.483 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 13' ' ' GLN . . . . . 0.427 ' O ' ' HB3' ' A' ' 14' ' ' ALA . 0.0 OUTLIER -81.38 -144.38 0.05 Allowed 'General case' 0 N--CA 1.492 1.646 0 O-C-N 121.053 -1.029 . . . . 0.0 110.393 -179.854 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 14' ' ' ALA . . . . . 0.427 ' HB3' ' O ' ' A' ' 13' ' ' GLN . . . 59.07 -155.62 0.35 Allowed 'General case' 0 N--CA 1.498 1.966 0 O-C-N 121.647 -0.658 . . . . 0.0 109.821 -179.727 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -91.28 42.93 2.81 Favored Glycine 0 N--CA 1.49 2.262 0 N-CA-C 109.371 -1.492 . . . . 0.0 109.371 179.916 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 81.1 m -119.38 67.09 9.37 Favored Pre-proline 0 N--CA 1.493 1.709 0 O-C-N 121.295 -1.12 . . . . 0.0 110.801 -179.5 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 46.6 Cg_endo -71.83 69.01 3.0 Favored 'Trans proline' 0 C--N 1.313 -1.319 0 O-C-N 123.385 1.202 . . . . 0.0 110.504 -179.892 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 105.73 -14.71 45.73 Favored Glycine 0 N--CA 1.498 2.786 0 N-CA-C 110.134 -1.186 . . . . 0.0 110.134 -179.603 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -154.2 123.95 1.47 Allowed Glycine 0 N--CA 1.489 2.213 0 N-CA-C 109.152 -1.579 . . . . 0.0 109.152 179.87 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -108.05 47.13 0.91 Allowed 'General case' 0 N--CA 1.497 1.904 0 O-C-N 121.399 -1.059 . . . . 0.0 109.699 179.706 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 9.9 p -136.4 20.97 0.9 Allowed 'Isoleucine or valine' 0 N--CA 1.502 2.167 0 O-C-N 120.915 -1.116 . . . . 0.0 111.29 -179.444 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 22' ' ' GLU . . . . . 0.401 ' C ' ' HG3' ' A' ' 23' ' ' GLU . 1.5 tp10 -101.21 -12.06 19.03 Favored 'General case' 0 C--N 1.305 -1.339 0 O-C-N 121.179 -0.951 . . . . 0.0 109.993 179.098 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 23' ' ' GLU . . . . . 0.401 ' HG3' ' C ' ' A' ' 22' ' ' GLU . 0.0 OUTLIER -146.06 74.86 1.39 Allowed 'General case' 0 N--CA 1.488 1.446 0 O-C-N 121.429 -0.794 . . . . 0.0 109.436 -179.582 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER -56.05 -58.54 7.47 Favored 'General case' 0 N--CA 1.5 2.037 0 O-C-N 121.207 -0.933 . . . . 0.0 110.79 -179.421 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -149.28 -61.86 0.22 Allowed 'General case' 0 N--CA 1.495 1.811 0 O-C-N 121.332 -0.855 . . . . 0.0 110.06 179.964 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 134.04 86.03 0.25 Allowed Glycine 0 N--CA 1.497 2.708 0 N-CA-C 109.504 -1.438 . . . . 0.0 109.504 -179.716 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 165.45 95.95 0.11 Allowed Glycine 0 N--CA 1.494 2.557 0 N-CA-C 109.147 -1.581 . . . . 0.0 109.147 -179.702 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 28' ' ' SER . . . . . 0.484 ' HB2' ' HD3' ' A' ' 29' ' ' PRO . 0.0 OUTLIER -154.72 -62.6 0.02 OUTLIER Pre-proline 0 N--CA 1.497 1.909 0 O-C-N 121.263 -1.14 . . . . 0.0 110.777 179.85 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 29' ' ' PRO . . . . . 0.484 ' HD3' ' HB2' ' A' ' 28' ' ' SER . 44.8 Cg_endo -75.44 123.82 7.91 Favored 'Trans proline' 0 C--N 1.318 -1.062 0 O-C-N 122.922 0.959 . . . . 0.0 110.405 -179.744 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -78.54 -9.39 59.32 Favored 'General case' 0 N--CA 1.498 1.943 0 O-C-N 121.148 -0.97 . . . . 0.0 111.154 -179.665 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 4.1 tp10 -79.76 -56.92 3.94 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.253 -0.905 . . . . 0.0 109.556 179.742 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 171.88 -64.85 0.14 Allowed Glycine 0 N--CA 1.492 2.418 0 N-CA-C 109.181 -1.568 . . . . 0.0 109.181 -179.999 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 33' ' ' CYS . . . . . . . . . . . . . 12.7 p -148.29 88.33 1.64 Allowed 'General case' 0 N--CA 1.493 1.715 0 O-C-N 121.495 -1.003 . . . . 0.0 109.521 179.648 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -86.28 39.42 0.82 Allowed 'General case' 0 N--CA 1.495 1.808 0 O-C-N 121.342 -0.849 . . . . 0.0 110.82 -179.479 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER -113.8 163.26 15.28 Favored 'General case' 0 N--CA 1.495 1.793 0 O-C-N 121.218 -0.926 . . . . 0.0 110.214 179.812 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 36' ' ' ALA . . . . . 1.066 ' HB1' HD12 ' A' ' 40' ' ' LEU . . . -102.61 0.1 32.78 Favored 'General case' 0 N--CA 1.498 1.97 0 O-C-N 121.515 -0.741 . . . . 0.0 112.148 -178.706 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 2.7 pm0 -79.59 -27.24 41.13 Favored 'General case' 0 N--CA 1.498 1.94 0 O-C-N 120.582 -1.324 . . . . 0.0 111.556 -179.132 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -133.34 -47.41 0.1 Allowed Glycine 0 N--CA 1.498 2.799 0 C-N-CA 118.894 -1.622 . . . . 0.0 111.825 -178.77 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 39' ' ' CYS . . . . . . . . . . . . . 4.3 m -79.53 0.94 27.68 Favored 'General case' 0 N--CA 1.499 2.022 0 O-C-N 120.889 -1.359 . . . . 0.0 112.304 -178.451 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 40' ' ' LEU . . . . . 1.066 HD12 ' HB1' ' A' ' 36' ' ' ALA . 0.5 OUTLIER . . . . . 0 N--CA 1.497 1.923 0 O-C-N 120.851 -1.156 . . . . 0.0 109.797 179.07 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER . . . . . 0 N--CA 1.491 1.614 0 N-CA-C 110.264 -0.273 . . . . 0.0 110.264 . . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 6' ' ' PRO . . . . . . . . . . . . . 43.6 Cg_endo -75.11 -53.21 0.1 OUTLIER 'Trans proline' 0 C--N 1.315 -1.233 0 O-C-N 123.691 1.364 . . . . 0.0 110.619 179.608 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -85.17 60.73 4.74 Favored Glycine 0 N--CA 1.496 2.654 0 N-CA-C 109.465 -1.454 . . . . 0.0 109.465 179.522 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 1.5 m -96.74 24.31 6.19 Favored 'General case' 0 N--CA 1.497 1.923 0 O-C-N 121.271 -1.135 . . . . 0.0 110.678 -179.952 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -144.02 -144.46 4.22 Favored Glycine 0 N--CA 1.495 2.579 0 N-CA-C 109.354 -1.498 . . . . 0.0 109.354 179.841 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 10' ' ' GLN . . . . . 0.491 ' HB2' ' HB3' ' A' ' 14' ' ' ALA . 3.5 mt-30 -54.12 -49.02 70.12 Favored 'General case' 0 N--CA 1.499 2.006 0 O-C-N 121.423 -1.045 . . . . 0.0 110.959 179.953 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 109.15 -25.17 19.19 Favored Glycine 0 N--CA 1.494 2.539 0 N-CA-C 109.874 -1.29 . . . . 0.0 109.874 -179.654 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 12' ' ' VAL . . . . . 0.438 ' H ' HG22 ' A' ' 12' ' ' VAL . 27.4 m -95.9 46.76 0.1 OUTLIER 'Isoleucine or valine' 0 N--CA 1.497 1.908 0 O-C-N 121.015 -1.285 . . . . 0.0 110.26 179.879 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 13' ' ' GLN . . . . . . . . . . . . . 1.1 mt-30 52.11 49.38 20.76 Favored 'General case' 0 N--CA 1.498 1.93 0 O-C-N 121.705 -0.622 . . . . 0.0 111.006 179.779 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 14' ' ' ALA . . . . . 0.491 ' HB3' ' HB2' ' A' ' 10' ' ' GLN . . . -103.87 161.65 13.78 Favored 'General case' 0 N--CA 1.497 1.917 0 O-C-N 121.263 -0.898 . . . . 0.0 110.137 179.512 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 75.58 72.06 1.1 Allowed Glycine 0 N--CA 1.495 2.625 0 N-CA-C 109.461 -1.455 . . . . 0.0 109.461 179.908 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 16' ' ' CYS . . . . . 0.44 ' HB2' ' HD2' ' A' ' 17' ' ' PRO . 17.7 p -79.8 167.23 35.42 Favored Pre-proline 0 N--CA 1.497 1.924 0 O-C-N 121.428 -1.042 . . . . 0.0 110.215 -179.922 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 17' ' ' PRO . . . . . 0.44 ' HD2' ' HB2' ' A' ' 16' ' ' CYS . 49.7 Cg_endo -77.33 53.19 4.17 Favored 'Trans proline' 0 C--N 1.311 -1.437 0 O-C-N 123.499 1.263 . . . . 0.0 110.217 178.927 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 92.7 -43.09 2.63 Favored Glycine 0 N--CA 1.496 2.64 0 N-CA-C 110.392 -1.083 . . . . 0.0 110.392 -179.89 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -74.89 83.38 0.82 Allowed Glycine 0 N--CA 1.492 2.376 0 O-C-N 121.189 -1.183 . . . . 0.0 110.495 -179.176 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 1.3 m -117.45 118.93 33.54 Favored 'General case' 0 N--CA 1.497 1.9 0 O-C-N 121.407 -1.054 . . . . 0.0 109.974 179.427 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 14.0 t -83.33 75.36 1.03 Allowed 'Isoleucine or valine' 0 N--CA 1.497 1.876 0 O-C-N 121.639 -0.663 . . . . 0.0 109.573 179.851 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 31.4 mt-10 -95.34 40.96 1.1 Allowed 'General case' 0 C--N 1.304 -1.391 0 O-C-N 121.356 -0.84 . . . . 0.0 110.115 -179.587 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 3.4 pt-20 -157.52 60.03 0.49 Allowed 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.372 -0.83 . . . . 0.0 110.164 -179.801 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -112.27 147.53 36.07 Favored 'General case' 0 N--CA 1.493 1.718 0 O-C-N 121.224 -0.922 . . . . 0.0 110.281 -179.574 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 3.1 p-10 -96.78 176.73 5.88 Favored 'General case' 0 N--CA 1.495 1.801 0 O-C-N 121.37 -0.831 . . . . 0.0 109.538 178.99 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -126.36 27.86 4.91 Favored Glycine 0 N--CA 1.493 2.487 0 N-CA-C 110.134 -1.186 . . . . 0.0 110.134 179.921 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 71.75 -68.77 1.0 Allowed Glycine 0 N--CA 1.499 2.88 0 N-CA-C 109.782 -1.327 . . . . 0.0 109.782 -179.934 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 64.4 m -83.5 116.9 66.87 Favored Pre-proline 0 N--CA 1.499 1.992 0 O-C-N 121.273 -1.134 . . . . 0.0 110.378 179.788 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 44.1 Cg_endo -71.16 154.39 62.07 Favored 'Trans proline' 0 N--CA 1.491 1.333 0 O-C-N 124.016 1.535 . . . . 0.0 111.485 -179.493 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -112.43 -50.26 2.91 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.398 -0.814 . . . . 0.0 110.625 179.84 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -102.54 -63.84 1.12 Allowed 'General case' 0 N--CA 1.495 1.79 0 O-C-N 121.485 -0.759 . . . . 0.0 110.233 -179.956 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 152.96 -59.2 0.41 Allowed Glycine 0 N--CA 1.495 2.587 0 N-CA-C 109.626 -1.39 . . . . 0.0 109.626 -179.907 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 33' ' ' CYS . . . . . . . . . . . . . 17.3 m -133.17 61.24 1.68 Allowed 'General case' 0 N--CA 1.496 1.87 0 O-C-N 121.32 -1.106 . . . . 0.0 110.075 179.87 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -122.62 26.63 8.2 Favored 'General case' 0 N--CA 1.497 1.911 0 O-C-N 121.274 -0.891 . . . . 0.0 109.876 179.528 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 22.7 mp0 -116.5 -171.88 2.09 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.732 -0.605 . . . . 0.0 110.612 -179.186 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 36' ' ' ALA . . . . . . . . . . . . . . . -92.07 -24.97 18.99 Favored 'General case' 0 N--CA 1.499 2.022 0 O-C-N 121.244 -0.91 . . . . 0.0 111.151 -179.597 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER -79.71 52.46 1.45 Allowed 'General case' 0 N--CA 1.499 2.006 0 O-C-N 120.836 -1.165 . . . . 0.0 110.739 -179.608 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 47.42 -111.5 0.79 Allowed Glycine 0 N--CA 1.501 3.013 0 N-CA-C 110.126 -1.189 . . . . 0.0 110.126 179.5 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 39' ' ' CYS . . . . . . . . . . . . . 90.0 m -143.4 141.4 30.86 Favored 'General case' 0 N--CA 1.495 1.794 0 O-C-N 121.485 -1.009 . . . . 0.0 109.26 179.462 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 40' ' ' LEU . . . . . . . . . . . . . 2.9 mt . . . . . 0 N--CA 1.495 1.778 0 O-C-N 121.351 -0.843 . . . . 0.0 110.938 -179.499 . . . . . . . . 0 0 . 1 . 012 nuclear build core ' A' A ' 5' ' ' CYS . . . . . 0.507 ' SG ' ' N ' ' A' ' 8' ' ' CYS . 0.8 OUTLIER . . . . . 0 N--CA 1.496 1.858 0 N-CA-C 109.716 -0.475 . . . . 0.0 109.716 . . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 6' ' ' PRO . . . . . . . . . . . . . 51.6 Cg_endo -81.0 45.36 1.98 Allowed 'Trans proline' 0 C--N 1.314 -1.271 0 O-C-N 123.755 1.397 . . . . 0.0 111.627 -179.092 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 165.1 41.73 0.02 OUTLIER Glycine 0 N--CA 1.497 2.702 0 N-CA-C 109.925 -1.27 . . . . 0.0 109.925 179.838 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 8' ' ' CYS . . . . . 0.507 ' N ' ' SG ' ' A' ' 5' ' ' CYS . 14.3 m -79.84 -177.2 5.82 Favored 'General case' 0 N--CA 1.499 1.993 0 O-C-N 121.404 -1.056 . . . . 0.0 110.132 -179.842 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -86.5 -79.72 1.19 Allowed Glycine 0 N--CA 1.495 2.631 0 N-CA-C 109.886 -1.286 . . . . 0.0 109.886 -179.885 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 10' ' ' GLN . . . . . . . . . . . . . 0.1 OUTLIER -67.05 -71.73 0.19 Allowed 'General case' 0 N--CA 1.496 1.868 0 O-C-N 121.434 -1.039 . . . . 0.0 110.648 -179.677 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 72.05 8.35 69.06 Favored Glycine 0 N--CA 1.497 2.758 0 N-CA-C 110.426 -1.07 . . . . 0.0 110.426 -179.595 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 12' ' ' VAL . . . . . 0.451 ' O ' HG13 ' A' ' 12' ' ' VAL . 4.3 p -160.64 82.41 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.493 1.675 0 O-C-N 121.209 -1.171 . . . . 0.0 108.767 179.954 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 13' ' ' GLN . . . . . . . . . . . . . 1.3 tt0 -53.22 101.16 0.04 OUTLIER 'General case' 0 N--CA 1.498 1.953 0 O-C-N 121.567 -0.708 . . . . 0.0 111.089 -178.897 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -108.72 31.55 5.56 Favored 'General case' 0 N--CA 1.497 1.894 0 O-C-N 121.643 -0.661 . . . . 0.0 109.547 179.209 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 143.95 -86.24 0.18 Allowed Glycine 0 N--CA 1.49 2.278 0 N-CA-C 108.548 -1.821 . . . . 0.0 108.548 -179.45 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 28.4 m -106.93 100.66 33.11 Favored Pre-proline 0 N--CA 1.494 1.764 0 O-C-N 121.331 -1.099 . . . . 0.0 109.544 179.133 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 47.2 Cg_endo -72.66 55.4 2.66 Favored 'Trans proline' 0 C--N 1.312 -1.382 0 O-C-N 123.817 1.43 . . . . 0.0 111.826 -178.955 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 152.62 36.56 0.03 OUTLIER Glycine 0 N--CA 1.496 2.684 0 O-C-N 120.836 -1.165 . . . . 0.0 111.097 179.444 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 82.38 137.24 2.6 Favored Glycine 0 N--CA 1.492 2.37 0 O-C-N 121.013 -1.287 . . . . 0.0 109.909 179.46 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -116.37 27.36 9.27 Favored 'General case' 0 N--CA 1.5 2.035 0 O-C-N 121.265 -1.138 . . . . 0.0 110.323 179.671 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 8.4 p -132.26 8.45 1.63 Allowed 'Isoleucine or valine' 0 N--CA 1.494 1.765 0 O-C-N 121.01 -1.056 . . . . 0.0 110.926 179.945 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 8.3 mm-40 -98.81 14.99 26.88 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 120.657 -1.277 . . . . 0.0 111.145 179.965 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 4.6 tt0 -146.4 -54.92 0.26 Allowed 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.202 -0.936 . . . . 0.0 109.507 179.404 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER -124.41 101.77 7.32 Favored 'General case' 0 C--N 1.307 -1.24 0 O-C-N 121.443 -0.785 . . . . 0.0 110.129 179.61 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 3.5 p-10 -115.43 23.76 12.15 Favored 'General case' 0 N--CA 1.496 1.841 0 O-C-N 121.236 -0.915 . . . . 0.0 110.542 179.926 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 129.52 -95.69 0.37 Allowed Glycine 0 N--CA 1.493 2.451 0 N-CA-C 109.209 -1.556 . . . . 0.0 109.209 179.914 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 80.29 -95.52 1.56 Allowed Glycine 0 N--CA 1.495 2.573 0 N-CA-C 109.701 -1.36 . . . . 0.0 109.701 179.752 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -79.29 165.77 46.2 Favored Pre-proline 0 N--CA 1.5 2.062 0 O-C-N 121.39 -1.065 . . . . 0.0 110.267 -179.919 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 45.6 Cg_endo -73.68 64.73 4.79 Favored 'Trans proline' 0 C--N 1.317 -1.116 0 O-C-N 123.868 1.457 . . . . 0.0 110.579 -179.975 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -127.63 76.62 1.69 Allowed 'General case' 0 N--CA 1.485 1.314 0 O-C-N 121.449 -0.782 . . . . 0.0 110.388 179.935 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 31' ' ' GLU . . . . . 0.42 ' HG3' ' N ' ' A' ' 32' ' ' GLY . 12.9 pt-20 -79.2 -43.22 24.3 Favored 'General case' 0 N--CA 1.494 1.744 0 O-C-N 121.152 -0.967 . . . . 0.0 110.243 -179.797 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 32' ' ' GLY . . . . . 0.42 ' N ' ' HG3' ' A' ' 31' ' ' GLU . . . 111.54 80.15 1.06 Allowed Glycine 0 N--CA 1.492 2.433 0 N-CA-C 109.582 -1.407 . . . . 0.0 109.582 179.739 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 33' ' ' CYS . . . . . . . . . . . . . 0.7 OUTLIER -79.68 133.22 36.37 Favored 'General case' 0 N--CA 1.497 1.894 0 O-C-N 121.264 -1.139 . . . . 0.0 109.362 179.66 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -78.5 -22.48 47.37 Favored 'General case' 0 N--CA 1.501 2.096 0 O-C-N 121.325 -0.859 . . . . 0.0 110.445 179.886 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 0.8 OUTLIER -130.68 165.51 22.7 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.381 -0.824 . . . . 0.0 109.814 179.554 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 36' ' ' ALA . . . . . . . . . . . . . . . -93.28 -39.91 10.72 Favored 'General case' 0 N--CA 1.493 1.679 0 O-C-N 121.462 -0.774 . . . . 0.0 109.644 179.403 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 6.2 tt0 -79.27 -53.85 6.54 Favored 'General case' 0 N--CA 1.495 1.81 0 O-C-N 121.525 -0.735 . . . . 0.0 109.844 179.713 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -75.87 63.09 2.8 Favored Glycine 0 N--CA 1.498 2.792 0 N-CA-C 109.557 -1.417 . . . . 0.0 109.557 179.887 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 39' ' ' CYS . . . . . 0.435 ' HB3' HD23 ' A' ' 40' ' ' LEU . 2.6 t -122.4 -63.49 1.28 Allowed 'General case' 0 N--CA 1.496 1.831 0 O-C-N 121.549 -0.971 . . . . 0.0 110.181 179.497 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 40' ' ' LEU . . . . . 0.435 HD23 ' HB3' ' A' ' 39' ' ' CYS . 1.9 pt? . . . . . 0 N--CA 1.497 1.898 0 O-C-N 121.196 -0.94 . . . . 0.0 110.547 179.139 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 9.3 t . . . . . 0 N--CA 1.497 1.925 0 N-CA-C 110.023 -0.362 . . . . 0.0 110.023 . . . . . . . . . 0 0 . 1 . 013 nuclear build core ' A' A ' 6' ' ' PRO . . . . . . . . . . . . . 52.7 Cg_endo -77.57 155.0 31.5 Favored 'Trans proline' 0 C--N 1.314 -1.28 0 O-C-N 123.666 1.351 . . . . 0.0 110.335 179.796 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 82.82 -50.47 4.39 Favored Glycine 0 N--CA 1.497 2.762 0 C-N-CA 120.118 -1.039 . . . . 0.0 110.601 179.717 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 8' ' ' CYS . . . . . 0.443 ' SG ' ' N ' ' A' ' 9' ' ' GLY . 12.0 p -78.71 -33.09 47.07 Favored 'General case' 0 N--CA 1.497 1.905 0 O-C-N 120.967 -1.314 . . . . 0.0 111.062 -179.36 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 9' ' ' GLY . . . . . 0.443 ' N ' ' SG ' ' A' ' 8' ' ' CYS . . . -79.76 -60.63 2.42 Favored Glycine 0 N--CA 1.497 2.708 0 N-CA-C 109.631 -1.387 . . . . 0.0 109.631 -179.486 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 10' ' ' GLN . . . . . . . . . . . . . 34.2 mt-30 -143.91 -62.6 0.39 Allowed 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.438 -1.037 . . . . 0.0 110.754 -179.813 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 89.25 -68.56 2.7 Favored Glycine 0 N--CA 1.495 2.598 0 N-CA-C 108.962 -1.655 . . . . 0.0 108.962 -179.271 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 41.0 t -136.51 -94.06 0.04 OUTLIER 'Isoleucine or valine' 0 N--CA 1.496 1.85 0 O-C-N 121.657 -0.908 . . . . 0.0 109.715 179.287 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 13' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -166.86 30.76 0.04 OUTLIER 'General case' 0 N--CA 1.499 1.977 0 O-C-N 120.825 -1.172 . . . . 0.0 110.875 179.824 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -154.02 136.44 15.01 Favored 'General case' 0 N--CA 1.496 1.843 0 O-C-N 121.107 -0.996 . . . . 0.0 110.459 179.986 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -108.2 65.52 0.25 Allowed Glycine 0 N--CA 1.495 2.592 0 N-CA-C 109.788 -1.325 . . . . 0.0 109.788 179.881 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 60.6 m -80.51 114.01 44.12 Favored Pre-proline 0 N--CA 1.499 2.019 0 O-C-N 121.719 -0.871 . . . . 0.0 109.975 179.641 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 45.0 Cg_endo -70.07 89.22 0.56 Allowed 'Trans proline' 0 N--CA 1.49 1.318 0 O-C-N 123.722 1.38 . . . . 0.0 110.767 -179.931 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 108.58 -16.83 34.03 Favored Glycine 0 N--CA 1.495 2.582 0 N-CA-C 110.361 -1.096 . . . . 0.0 110.361 179.886 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 117.92 138.41 5.99 Favored Glycine 0 N--CA 1.489 2.231 0 N-CA-C 108.675 -1.77 . . . . 0.0 108.675 -179.314 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 6.0 p -124.65 -2.66 7.86 Favored 'General case' 0 N--CA 1.497 1.911 0 O-C-N 121.435 -1.038 . . . . 0.0 112.076 -179.622 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 21' ' ' VAL . . . . . 0.459 HG22 ' O ' ' A' ' 21' ' ' VAL . 12.1 p -160.07 39.81 0.02 OUTLIER 'Isoleucine or valine' 0 N--CA 1.497 1.894 0 O-C-N 120.581 -1.324 . . . . 0.0 110.353 -179.803 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 13.4 mm-40 -98.94 46.23 0.99 Allowed 'General case' 0 N--CA 1.487 1.408 0 O-C-N 120.84 -1.162 . . . . 0.0 111.089 -179.621 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER 43.02 68.4 0.51 Allowed 'General case' 0 N--CA 1.505 2.294 0 CA-C-O 121.409 0.623 . . . . 0.0 111.528 179.617 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 2.7 tt0 -80.6 -57.38 3.6 Favored 'General case' 0 N--CA 1.494 1.761 0 O-C-N 120.983 -1.073 . . . . 0.0 109.904 179.987 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 3.1 t70 -160.25 176.72 11.41 Favored 'General case' 0 N--CA 1.489 1.522 0 N-CA-C 108.838 -0.801 . . . . 0.0 108.838 179.136 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 62.06 39.75 98.02 Favored Glycine 0 N--CA 1.493 2.484 0 N-CA-C 109.658 -1.377 . . . . 0.0 109.658 179.683 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -58.16 -29.96 63.39 Favored Glycine 0 N--CA 1.497 2.738 0 N-CA-C 110.076 -1.21 . . . . 0.0 110.076 179.962 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 1.1 m -79.19 163.58 59.0 Favored Pre-proline 0 N--CA 1.5 2.035 0 O-C-N 121.338 -1.096 . . . . 0.0 109.515 179.467 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 44.1 Cg_endo -69.89 68.88 1.75 Allowed 'Trans proline' 0 C--N 1.308 -1.578 0 O-C-N 123.268 1.141 . . . . 0.0 110.937 -179.747 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -99.5 -40.25 7.94 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.245 -0.909 . . . . 0.0 110.537 -179.958 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 4.4 tt0 -78.98 -9.61 59.58 Favored 'General case' 0 N--CA 1.494 1.74 0 O-C-N 121.503 -0.748 . . . . 0.0 111.12 -179.754 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . -73.23 -38.59 53.87 Favored Glycine 0 N--CA 1.497 2.76 0 N-CA-C 110.198 -1.161 . . . . 0.0 110.198 -179.839 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 33' ' ' CYS . . . . . 0.421 ' HB2' ' O ' ' A' ' 38' ' ' GLY . 0.8 OUTLIER -127.22 94.0 3.89 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.544 -0.974 . . . . 0.0 109.976 179.684 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -123.04 35.29 4.91 Favored 'General case' 0 N--CA 1.495 1.78 0 O-C-N 121.699 -0.626 . . . . 0.0 109.681 179.552 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 2.2 mp0 -78.5 -144.57 0.03 OUTLIER 'General case' 0 N--CA 1.502 2.126 0 O-C-N 121.814 -0.554 . . . . 0.0 109.824 -179.782 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 36' ' ' ALA . . . . . . . . . . . . . . . -76.95 -25.89 53.37 Favored 'General case' 0 N--CA 1.492 1.634 0 O-C-N 121.022 -1.048 . . . . 0.0 109.795 -179.822 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 6.0 tt0 -99.81 -40.04 7.92 Favored 'General case' 0 N--CA 1.497 1.884 0 O-C-N 121.321 -0.862 . . . . 0.0 110.131 179.111 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 38' ' ' GLY . . . . . 0.421 ' O ' ' HB2' ' A' ' 33' ' ' CYS . . . 81.37 -119.5 4.88 Favored Glycine 0 N--CA 1.487 2.079 0 N-CA-C 109.355 -1.498 . . . . 0.0 109.355 -179.881 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 39' ' ' CYS . . . . . . . . . . . . . 1.0 OUTLIER -152.67 43.81 0.66 Allowed 'General case' 0 N--CA 1.495 1.804 0 O-C-N 121.548 -0.972 . . . . 0.0 110.23 179.605 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 40' ' ' LEU . . . . . . . . . . . . . 71.4 mt . . . . . 0 N--CA 1.493 1.684 0 O-C-N 121.085 -1.01 . . . . 0.0 110.735 -179.502 . . . . . . . . 0 0 . 1 . 014 nuclear build core ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 8.7 t . . . . . 0 N--CA 1.492 1.668 0 N-CA-C 109.472 -0.566 . . . . 0.0 109.472 . . . . . . . . . 0 0 . 1 . 014 nuclear build core ' A' A ' 6' ' ' PRO . . . . . . . . . . . . . 44.2 Cg_endo -75.97 -58.27 0.05 OUTLIER 'Trans proline' 0 C--N 1.314 -1.284 0 O-C-N 124.195 1.629 . . . . 0.0 111.161 -179.704 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -76.02 57.02 3.15 Favored Glycine 0 N--CA 1.498 2.811 0 N-CA-C 110.111 -1.196 . . . . 0.0 110.111 -179.77 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 0.8 OUTLIER -113.91 12.66 18.17 Favored 'General case' 0 N--CA 1.495 1.794 0 O-C-N 121.11 -1.229 . . . . 0.0 110.335 179.131 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -116.61 160.37 13.47 Favored Glycine 0 N--CA 1.494 2.534 0 N-CA-C 108.26 -1.936 . . . . 0.0 108.26 179.195 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 10' ' ' GLN . . . . . . . . . . . . . 4.8 mt-30 55.05 31.43 16.17 Favored 'General case' 0 N--CA 1.502 2.16 0 O-C-N 121.574 -0.957 . . . . 0.0 110.639 -179.635 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -76.58 53.04 3.2 Favored Glycine 0 N--CA 1.496 2.699 0 N-CA-C 110.064 -1.214 . . . . 0.0 110.064 -179.822 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 10.0 p -98.89 36.11 0.18 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.722 0 O-C-N 121.351 -1.088 . . . . 0.0 110.32 -179.8 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 13' ' ' GLN . . . . . . . . . . . . . 8.6 tt0 56.48 15.42 2.03 Favored 'General case' 0 N--CA 1.502 2.174 0 O-C-N 121.316 -0.865 . . . . 0.0 111.796 179.814 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . 46.15 36.26 3.08 Favored 'General case' 0 N--CA 1.502 2.172 0 O-C-N 121.274 -0.891 . . . . 0.0 110.663 -179.496 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -95.46 -50.22 2.05 Favored Glycine 0 N--CA 1.493 2.463 0 N-CA-C 109.961 -1.256 . . . . 0.0 109.961 -179.353 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 96.6 m -111.57 80.83 2.93 Favored Pre-proline 0 N--CA 1.497 1.922 0 O-C-N 121.126 -1.22 . . . . 0.0 110.406 -179.629 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 43.5 Cg_endo -74.48 100.9 1.37 Allowed 'Trans proline' 0 C--N 1.312 -1.358 0 O-C-N 123.769 1.405 . . . . 0.0 109.993 179.808 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 114.94 -38.68 3.04 Favored Glycine 0 N--CA 1.496 2.663 0 N-CA-C 110.184 -1.167 . . . . 0.0 110.184 -179.798 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 179.07 144.92 5.95 Favored Glycine 0 N--CA 1.487 2.055 0 N-CA-C 108.973 -1.651 . . . . 0.0 108.973 -179.742 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -108.64 43.58 1.23 Allowed 'General case' 0 N--CA 1.496 1.86 0 O-C-N 121.625 -0.927 . . . . 0.0 110.125 -179.935 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 0.1 OUTLIER -146.09 52.8 0.12 Allowed 'Isoleucine or valine' 0 N--CA 1.496 1.869 0 O-C-N 121.547 -0.721 . . . . 0.0 109.19 179.656 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 2.2 mp0 -79.32 -30.07 42.66 Favored 'General case' 0 N--CA 1.488 1.472 0 O-C-N 121.602 -0.686 . . . . 0.0 111.233 -178.842 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 10.9 tt0 -161.44 108.8 1.44 Allowed 'General case' 0 N--CA 1.493 1.693 0 O-C-N 121.178 -0.951 . . . . 0.0 110.51 -179.709 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 0.8 OUTLIER -89.73 155.26 19.32 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.223 -0.923 . . . . 0.0 109.909 179.438 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 8.8 p-10 -79.05 -33.95 44.24 Favored 'General case' 0 N--CA 1.498 1.96 0 O-C-N 121.359 -0.838 . . . . 0.0 110.7 -179.953 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -55.19 -46.87 77.32 Favored Glycine 0 N--CA 1.495 2.632 0 N-CA-C 110.36 -1.096 . . . . 0.0 110.36 -179.91 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -98.47 61.79 0.86 Allowed Glycine 0 N--CA 1.495 2.619 0 N-CA-C 109.904 -1.279 . . . . 0.0 109.904 -179.743 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 1.6 m -112.57 92.63 20.4 Favored Pre-proline 0 N--CA 1.497 1.918 0 O-C-N 121.318 -1.107 . . . . 0.0 110.578 179.998 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 52.1 Cg_endo -78.8 133.92 11.7 Favored 'Trans proline' 0 C--N 1.316 -1.181 0 O-C-N 123.817 1.43 . . . . 0.0 110.475 179.723 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -127.11 56.99 1.49 Allowed 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.357 -0.84 . . . . 0.0 110.436 179.761 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 10.0 tt0 -160.75 -48.55 0.05 OUTLIER 'General case' 0 N--CA 1.495 1.808 0 O-C-N 121.338 -0.851 . . . . 0.0 110.733 179.557 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . -59.23 -27.15 62.43 Favored Glycine 0 N--CA 1.497 2.713 0 O-C-N 121.514 -0.741 . . . . 0.0 111.524 -179.394 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 33' ' ' CYS . . . . . 0.43 ' O ' ' HB3' ' A' ' 39' ' ' CYS . 26.0 p -79.12 68.55 5.12 Favored 'General case' 0 N--CA 1.498 1.961 0 O-C-N 120.821 -1.399 . . . . 0.0 110.315 -179.556 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -92.39 33.28 1.11 Allowed 'General case' 0 N--CA 1.496 1.855 0 O-C-N 120.888 -1.133 . . . . 0.0 110.626 179.771 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 4.8 mp0 -97.4 -178.5 4.17 Favored 'General case' 0 N--CA 1.492 1.648 0 O-C-N 121.16 -0.963 . . . . 0.0 110.351 -179.968 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 36' ' ' ALA . . . . . . . . . . . . . . . -87.86 28.66 1.0 Allowed 'General case' 0 N--CA 1.498 1.957 0 O-C-N 121.045 -1.034 . . . . 0.0 111.227 -179.807 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 13.6 pt-20 -78.91 -17.57 55.31 Favored 'General case' 0 N--CA 1.493 1.721 0 O-C-N 121.046 -1.033 . . . . 0.0 110.895 179.329 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 122.45 10.22 6.14 Favored Glycine 0 N--CA 1.496 2.673 0 N-CA-C 110.148 -1.181 . . . . 0.0 110.148 -179.533 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 39' ' ' CYS . . . . . 0.43 ' HB3' ' O ' ' A' ' 33' ' ' CYS . 0.1 OUTLIER -79.35 -25.26 42.3 Favored 'General case' 0 N--CA 1.501 2.08 0 O-C-N 120.876 -1.367 . . . . 0.0 110.369 179.78 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 40' ' ' LEU . . . . . . . . . . . . . 0.9 OUTLIER . . . . . 0 N--CA 1.491 1.578 0 O-C-N 121.024 -1.047 . . . . 0.0 110.851 -179.721 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 31.2 p . . . . . 0 N--CA 1.494 1.763 0 CA-C-O 120.385 0.136 . . . . 0.0 110.652 . . . . . . . . . 0 0 . 1 . 015 nuclear build core ' A' A ' 6' ' ' PRO . . . . . . . . . . . . . 47.3 Cg_endo -77.95 121.49 5.43 Favored 'Trans proline' 0 C--N 1.315 -1.189 0 O-C-N 123.899 1.473 . . . . 0.0 110.903 -179.549 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 96.64 12.64 50.06 Favored Glycine 0 N--CA 1.496 2.68 0 N-CA-C 110.734 -0.946 . . . . 0.0 110.734 179.536 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 0.8 OUTLIER -160.5 172.32 17.42 Favored 'General case' 0 N--CA 1.496 1.852 0 O-C-N 120.75 -1.441 . . . . 0.0 110.171 -179.47 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 115.75 -173.26 14.64 Favored Glycine 0 N--CA 1.494 2.55 0 N-CA-C 109.599 -1.4 . . . . 0.0 109.599 -179.871 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 10' ' ' GLN . . . . . . . . . . . . . 4.4 mt-30 -89.14 50.29 1.92 Allowed 'General case' 0 N--CA 1.492 1.659 0 O-C-N 121.279 -1.13 . . . . 0.0 110.381 179.939 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -83.19 60.66 4.87 Favored Glycine 0 N--CA 1.495 2.573 0 N-CA-C 109.744 -1.342 . . . . 0.0 109.744 179.974 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 9.0 p -135.43 25.33 0.93 Allowed 'Isoleucine or valine' 0 N--CA 1.496 1.851 0 O-C-N 121.334 -1.097 . . . . 0.0 110.805 179.904 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 13' ' ' GLN . . . . . 0.45 ' O ' ' HB3' ' A' ' 14' ' ' ALA . 0.2 OUTLIER -71.73 -14.64 62.07 Favored 'General case' 0 N--CA 1.498 1.96 0 O-C-N 120.938 -1.101 . . . . 0.0 111.461 -179.782 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 14' ' ' ALA . . . . . 0.45 ' HB3' ' O ' ' A' ' 13' ' ' GLN . . . 59.63 82.85 0.14 Allowed 'General case' 0 N--CA 1.502 2.165 0 O-C-N 121.17 -0.957 . . . . 0.0 110.583 -179.915 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -125.36 75.95 0.4 Allowed Glycine 0 N--CA 1.492 2.424 0 N-CA-C 109.045 -1.622 . . . . 0.0 109.045 179.665 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 10.7 m -78.4 118.32 71.62 Favored Pre-proline 0 N--CA 1.496 1.866 0 O-C-N 121.29 -1.124 . . . . 0.0 109.709 -179.863 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 40.7 Cg_endo -68.25 -41.2 7.3 Favored 'Trans proline' 0 C--N 1.316 -1.139 0 O-C-N 123.855 1.45 . . . . 0.0 111.32 -179.498 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . -176.22 60.87 0.1 Allowed Glycine 0 N--CA 1.496 2.66 0 N-CA-C 109.796 -1.322 . . . . 0.0 109.796 179.994 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 162.61 75.19 0.02 OUTLIER Glycine 0 N--CA 1.493 2.495 0 N-CA-C 109.539 -1.424 . . . . 0.0 109.539 179.72 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 0.3 OUTLIER -105.86 -40.09 5.82 Favored 'General case' 0 N--CA 1.495 1.803 0 O-C-N 121.191 -1.182 . . . . 0.0 110.647 -179.516 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 3.6 t -107.7 56.27 0.14 Allowed 'Isoleucine or valine' 0 N--CA 1.497 1.903 0 O-C-N 121.319 -0.863 . . . . 0.0 110.186 179.923 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER -79.72 46.2 0.75 Allowed 'General case' 0 N--CA 1.495 1.823 0 O-C-N 120.979 -1.075 . . . . 0.0 110.479 179.827 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 23' ' ' GLU . . . . . 0.488 ' HG3' ' N ' ' A' ' 24' ' ' GLU . 6.7 pt-20 -128.0 -29.41 2.55 Favored 'General case' 0 N--CA 1.493 1.676 0 O-C-N 121.06 -1.025 . . . . 0.0 110.964 179.318 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 24' ' ' GLU . . . . . 0.488 ' N ' ' HG3' ' A' ' 23' ' ' GLU . 10.7 mt-10 57.76 177.38 0.05 Allowed 'General case' 0 N--CA 1.498 1.952 0 O-C-N 121.513 -0.742 . . . . 0.0 111.8 179.401 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 1.2 p-10 -102.81 -36.53 8.23 Favored 'General case' 0 N--CA 1.495 1.802 0 O-C-N 121.122 -0.986 . . . . 0.0 110.433 -179.302 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 118.55 92.03 1.47 Allowed Glycine 0 N--CA 1.49 2.27 0 N-CA-C 108.891 -1.684 . . . . 0.0 108.891 -179.484 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -59.01 105.85 0.77 Allowed Glycine 0 N--CA 1.494 2.545 0 N-CA-C 109.636 -1.386 . . . . 0.0 109.636 -179.564 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 28' ' ' SER . . . . . 0.508 ' N ' ' HD2' ' A' ' 29' ' ' PRO . 0.0 OUTLIER -79.5 -49.3 1.4 Allowed Pre-proline 0 N--CA 1.496 1.837 0 O-C-N 121.536 -0.979 . . . . 0.0 111.769 -179.007 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 29' ' ' PRO . . . . . 0.508 ' HD2' ' N ' ' A' ' 28' ' ' SER . 44.2 Cg_endo -72.21 60.83 3.24 Favored 'Trans proline' 0 N--CA 1.49 1.292 0 O-C-N 123.159 1.083 . . . . 0.0 111.478 -179.197 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -121.74 47.62 1.84 Allowed 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.148 -0.97 . . . . 0.0 110.096 179.421 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 1.2 tp10 -80.46 -68.65 0.66 Allowed 'General case' 0 N--CA 1.493 1.706 0 O-C-N 121.494 -0.754 . . . . 0.0 109.885 -179.664 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 116.56 76.2 0.6 Allowed Glycine 0 N--CA 1.494 2.53 0 N-CA-C 109.766 -1.334 . . . . 0.0 109.766 179.943 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 33' ' ' CYS . . . . . . . . . . . . . 10.4 p -79.09 127.5 32.09 Favored 'General case' 0 N--CA 1.496 1.85 0 O-C-N 121.632 -0.922 . . . . 0.0 109.687 179.462 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -144.77 17.72 1.63 Allowed 'General case' 0 N--CA 1.499 1.989 0 O-C-N 121.385 -0.822 . . . . 0.0 110.543 -179.904 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 1.5 mp0 -90.8 -163.8 1.08 Allowed 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.395 -0.816 . . . . 0.0 110.472 -179.566 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 36' ' ' ALA . . . . . . . . . . . . . . . -88.15 43.05 1.1 Allowed 'General case' 0 N--CA 1.499 1.988 0 O-C-N 121.123 -0.986 . . . . 0.0 111.44 -179.275 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 1.9 pt-20 -138.39 9.73 2.71 Favored 'General case' 0 N--CA 1.494 1.759 0 O-C-N 121.261 -0.9 . . . . 0.0 110.956 179.254 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 68.39 -108.63 2.53 Favored Glycine 0 N--CA 1.495 2.615 0 N-CA-C 108.869 -1.692 . . . . 0.0 108.869 -179.657 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 39' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -160.64 -54.86 0.05 Allowed 'General case' 0 N--CA 1.498 1.96 0 O-C-N 121.154 -1.204 . . . . 0.0 110.376 179.321 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 40' ' ' LEU . . . . . . . . . . . . . 6.3 tt . . . . . 0 N--CA 1.494 1.764 0 O-C-N 121.271 -0.893 . . . . 0.0 111.104 -179.888 . . . . . . . . 0 0 . 1 . 016 nuclear build core ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 8.5 t . . . . . 0 N--CA 1.496 1.828 0 N-CA-C 109.475 -0.565 . . . . 0.0 109.475 . . . . . . . . . 0 0 . 1 . 016 nuclear build core ' A' A ' 6' ' ' PRO . . . . . . . . . . . . . 44.1 Cg_endo -73.14 106.86 2.24 Favored 'Trans proline' 0 C--N 1.312 -1.356 0 O-C-N 123.891 1.469 . . . . 0.0 111.162 -179.267 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 66.69 49.07 58.0 Favored Glycine 0 N--CA 1.496 2.659 0 N-CA-C 110.515 -1.034 . . . . 0.0 110.515 179.154 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -84.93 178.57 7.55 Favored 'General case' 0 N--CA 1.5 2.038 0 O-C-N 121.212 -1.17 . . . . 0.0 110.47 179.676 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -74.34 150.97 42.83 Favored Glycine 0 N--CA 1.491 2.311 0 N-CA-C 109.763 -1.335 . . . . 0.0 109.763 179.961 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 10' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -79.23 50.08 1.03 Allowed 'General case' 0 N--CA 1.496 1.875 0 O-C-N 121.591 -0.946 . . . . 0.0 110.773 -179.953 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -79.7 -57.06 3.17 Favored Glycine 0 N--CA 1.492 2.41 0 N-CA-C 109.612 -1.395 . . . . 0.0 109.612 179.929 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 12' ' ' VAL . . . . . 0.456 HG22 ' O ' ' A' ' 12' ' ' VAL . 7.4 p -137.17 65.69 0.25 Allowed 'Isoleucine or valine' 0 N--CA 1.496 1.85 0 O-C-N 121.466 -1.02 . . . . 0.0 110.35 -179.99 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 13' ' ' GLN . . . . . . . . . . . . . 2.6 tp-100 -80.22 -36.87 34.16 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.226 -0.921 . . . . 0.0 110.404 179.712 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -94.83 167.07 11.66 Favored 'General case' 0 N--CA 1.494 1.75 0 O-C-N 121.593 -0.692 . . . . 0.0 110.256 179.976 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -60.12 -34.19 82.92 Favored Glycine 0 N--CA 1.497 2.76 0 N-CA-C 110.228 -1.149 . . . . 0.0 110.228 179.608 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 16' ' ' CYS . . . . . 0.446 ' HB2' ' HB2' ' A' ' 20' ' ' CYS . 0.0 OUTLIER -110.01 96.86 26.98 Favored Pre-proline 0 N--CA 1.496 1.851 0 O-C-N 120.714 -1.462 . . . . 0.0 109.614 179.403 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 41.2 Cg_endo -68.43 111.26 2.48 Favored 'Trans proline' 0 C--N 1.311 -1.424 0 O-C-N 123.837 1.44 . . . . 0.0 111.079 -179.59 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 62.68 20.02 61.26 Favored Glycine 0 N--CA 1.496 2.685 0 N-CA-C 110.654 -0.978 . . . . 0.0 110.654 179.857 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -157.93 54.2 0.38 Allowed Glycine 0 N--CA 1.498 2.771 0 N-CA-C 109.741 -1.344 . . . . 0.0 109.741 -179.808 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 20' ' ' CYS . . . . . 0.446 ' HB2' ' HB2' ' A' ' 16' ' ' CYS . 0.8 OUTLIER -125.95 93.87 3.95 Favored 'General case' 0 N--CA 1.497 1.914 0 O-C-N 121.362 -1.081 . . . . 0.0 109.527 179.686 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 22.5 m -122.27 41.04 0.77 Allowed 'Isoleucine or valine' 0 N--CA 1.494 1.745 0 CA-C-O 121.268 0.556 . . . . 0.0 110.879 -179.211 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 2.8 mt-10 -110.6 44.99 1.18 Allowed 'General case' 0 C--N 1.307 -1.275 0 O-C-N 121.371 -0.83 . . . . 0.0 109.865 179.374 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 1.3 tp10 -101.2 -57.3 2.12 Favored 'General case' 0 N--CA 1.492 1.671 0 O-C-N 121.32 -0.863 . . . . 0.0 110.225 -179.824 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 1.0 OUTLIER -72.77 154.4 40.67 Favored 'General case' 0 N--CA 1.499 1.99 0 O-C-N 121.523 -0.735 . . . . 0.0 110.466 -179.744 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 4.1 p-10 -95.25 36.84 1.2 Allowed 'General case' 0 N--CA 1.502 2.134 0 O-C-N 121.353 -0.842 . . . . 0.0 111.357 179.956 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 154.96 -90.47 0.12 Allowed Glycine 0 N--CA 1.492 2.426 0 N-CA-C 109.719 -1.353 . . . . 0.0 109.719 178.922 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -138.15 141.81 12.51 Favored Glycine 0 N--CA 1.498 2.817 0 N-CA-C 109.799 -1.32 . . . . 0.0 109.799 -179.803 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 28' ' ' SER . . . . . 0.452 ' OG ' ' HD2' ' A' ' 29' ' ' PRO . 23.0 t -84.94 154.43 60.92 Favored Pre-proline 0 C--N 1.301 -1.535 0 O-C-N 121.285 -1.126 . . . . 0.0 109.854 179.759 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 29' ' ' PRO . . . . . 0.452 ' HD2' ' OG ' ' A' ' 28' ' ' SER . 37.9 Cg_endo -65.51 -26.87 54.41 Favored 'Trans proline' 0 C--N 1.308 -1.584 0 O-C-N 123.353 1.186 . . . . 0.0 109.819 179.03 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -93.59 24.2 4.19 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.592 -0.693 . . . . 0.0 110.446 179.182 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 31' ' ' GLU . . . . . 0.413 ' HB2' ' O ' ' A' ' 28' ' ' SER . 1.7 tp10 -83.26 -7.99 59.52 Favored 'General case' 0 N--CA 1.495 1.822 0 O-C-N 121.376 -0.827 . . . . 0.0 111.106 -179.883 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 77.62 29.0 56.28 Favored Glycine 0 N--CA 1.494 2.542 0 N-CA-C 109.404 -1.478 . . . . 0.0 109.404 -179.481 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 33' ' ' CYS . . . . . . . . . . . . . 0.0 OUTLIER -161.64 43.86 0.16 Allowed 'General case' 0 N--CA 1.498 1.929 0 O-C-N 121.411 -1.052 . . . . 0.0 109.861 179.842 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -109.39 -49.44 3.11 Favored 'General case' 0 N--CA 1.498 1.943 0 O-C-N 120.919 -1.113 . . . . 0.0 111.21 -179.342 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 35.1 mt-10 -95.02 -167.45 1.63 Allowed 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.051 -1.031 . . . . 0.0 110.369 -179.217 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 36' ' ' ALA . . . . . . . . . . . . . . . -82.27 44.07 0.84 Allowed 'General case' 0 N--CA 1.497 1.89 0 O-C-N 121.299 -0.876 . . . . 0.0 110.316 179.563 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 3.2 pt-20 -79.67 -13.29 59.58 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.43 -0.794 . . . . 0.0 110.327 179.297 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 132.34 38.12 0.26 Allowed Glycine 0 N--CA 1.502 3.074 0 C-N-CA 120.159 -1.02 . . . . 0.0 111.103 179.389 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 39' ' ' CYS . . . . . . . . . . . . . 13.5 t -93.51 -47.41 6.86 Favored 'General case' 0 N--CA 1.493 1.715 0 O-C-N 121.357 -1.084 . . . . 0.0 110.196 179.76 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 40' ' ' LEU . . . . . . . . . . . . . 7.9 mt . . . . . 0 N--CA 1.488 1.465 0 O-C-N 121.136 -0.977 . . . . 0.0 110.314 179.952 . . . . . . . . 0 0 . 1 . 017 nuclear build core ' A' A ' 5' ' ' CYS . . . . . 0.487 ' O ' ' SG ' ' A' ' 8' ' ' CYS . 1.3 p . . . . . 0 N--CA 1.496 1.859 0 CA-C-O 120.572 0.225 . . . . 0.0 110.41 . . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 6' ' ' PRO . . . . . . . . . . . . . 49.6 Cg_endo -77.54 -50.43 0.09 OUTLIER 'Trans proline' 0 C--N 1.311 -1.396 0 O-C-N 123.552 1.29 . . . . 0.0 111.173 179.488 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -105.2 67.31 0.27 Allowed Glycine 0 N--CA 1.494 2.54 0 N-CA-C 110.239 -1.144 . . . . 0.0 110.239 -179.545 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 8' ' ' CYS . . . . . 0.487 ' SG ' ' O ' ' A' ' 5' ' ' CYS . 3.5 m -86.56 138.04 32.03 Favored 'General case' 0 N--CA 1.494 1.766 0 O-C-N 121.308 -1.113 . . . . 0.0 109.404 179.107 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 114.18 88.51 1.62 Allowed Glycine 0 N--CA 1.492 2.416 0 N-CA-C 109.165 -1.574 . . . . 0.0 109.165 -179.486 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 10' ' ' GLN . . . . . . . . . . . . . 4.1 mt-30 51.62 33.38 10.65 Favored 'General case' 0 N--CA 1.507 2.383 0 O-C-N 121.647 -0.913 . . . . 0.0 111.161 -179.558 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -110.27 -40.36 1.39 Allowed Glycine 0 N--CA 1.496 2.693 0 N-CA-C 109.659 -1.377 . . . . 0.0 109.659 179.761 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 43.6 t -79.16 -47.71 22.23 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.822 0 O-C-N 121.39 -1.065 . . . . 0.0 110.485 179.905 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 13' ' ' GLN . . . . . . . . . . . . . 7.1 tt0 -72.86 133.84 44.59 Favored 'General case' 0 N--CA 1.494 1.735 0 O-C-N 121.054 -1.029 . . . . 0.0 110.244 179.887 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -102.76 -164.08 1.05 Allowed 'General case' 0 N--CA 1.495 1.784 0 O-C-N 121.524 -0.735 . . . . 0.0 109.697 179.602 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -168.71 -105.33 0.18 Allowed Glycine 0 N--CA 1.496 2.649 0 N-CA-C 109.348 -1.501 . . . . 0.0 109.348 179.886 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 16' ' ' CYS . . . . . 0.52 ' SG ' ' N ' ' A' ' 20' ' ' CYS . 0.0 OUTLIER -115.03 98.26 49.91 Favored Pre-proline 0 N--CA 1.49 1.538 0 O-C-N 121.328 -1.101 . . . . 0.0 109.8 179.855 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 48.0 Cg_endo -77.36 60.92 7.2 Favored 'Trans proline' 0 C--N 1.31 -1.458 0 O-C-N 123.572 1.301 . . . . 0.0 109.559 179.251 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 91.4 -20.61 39.87 Favored Glycine 0 N--CA 1.493 2.447 0 N-CA-C 109.605 -1.398 . . . . 0.0 109.605 -178.471 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -99.24 68.8 0.58 Allowed Glycine 0 N--CA 1.496 2.636 0 O-C-N 120.606 -1.526 . . . . 0.0 109.677 -179.901 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 20' ' ' CYS . . . . . 0.52 ' N ' ' SG ' ' A' ' 16' ' ' CYS . 16.3 m -82.17 143.35 31.48 Favored 'General case' 0 N--CA 1.488 1.473 0 O-C-N 121.308 -1.113 . . . . 0.0 109.262 179.803 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 35.7 m -77.88 -21.18 13.72 Favored 'Isoleucine or valine' 0 N--CA 1.503 2.176 0 O-C-N 121.888 -0.508 . . . . 0.0 111.685 -179.137 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 4.1 pt-20 -88.36 15.09 8.26 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.127 -0.983 . . . . 0.0 111.141 179.494 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 3.0 mm-40 -134.21 24.63 3.85 Favored 'General case' 0 N--CA 1.494 1.744 0 O-C-N 120.975 -1.078 . . . . 0.0 110.549 179.482 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 13.9 mm-40 -85.38 -2.83 58.52 Favored 'General case' 0 N--CA 1.494 1.759 0 O-C-N 121.093 -1.004 . . . . 0.0 111.563 -179.717 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 3.8 p-10 -104.98 19.69 20.15 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 120.68 -1.263 . . . . 0.0 109.999 179.972 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -72.45 56.28 1.6 Allowed Glycine 0 N--CA 1.489 2.174 0 N-CA-C 109.31 -1.516 . . . . 0.0 109.31 179.386 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 115.98 9.37 12.25 Favored Glycine 0 N--CA 1.501 3.004 0 O-C-N 121.32 -1.106 . . . . 0.0 110.378 -179.61 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -108.47 92.89 10.66 Favored Pre-proline 0 N--CA 1.493 1.718 0 O-C-N 120.899 -1.354 . . . . 0.0 109.822 179.683 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 43.9 Cg_endo -72.87 71.5 3.38 Favored 'Trans proline' 0 N--CA 1.489 1.238 0 O-C-N 123.472 1.249 . . . . 0.0 110.483 -179.751 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -108.18 61.3 0.61 Allowed 'General case' 0 N--CA 1.488 1.437 0 O-C-N 121.272 -0.893 . . . . 0.0 110.219 -179.86 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 2.1 tt0 -78.76 -28.14 44.79 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.369 -0.832 . . . . 0.0 110.569 -179.749 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 74.57 46.9 17.38 Favored Glycine 0 N--CA 1.489 2.178 0 N-CA-C 110.377 -1.089 . . . . 0.0 110.377 179.255 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 33' ' ' CYS . . . . . . . . . . . . . 14.1 m -79.84 87.56 5.3 Favored 'General case' 0 N--CA 1.497 1.921 0 O-C-N 120.931 -1.335 . . . . 0.0 109.782 179.624 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -102.87 -61.19 1.43 Allowed 'General case' 0 N--CA 1.493 1.689 0 O-C-N 121.503 -0.748 . . . . 0.0 110.201 -179.787 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 1.3 pm0 -85.18 -169.5 2.68 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.445 -0.784 . . . . 0.0 110.533 -179.747 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 36' ' ' ALA . . . . . . . . . . . . . . . -107.93 35.5 3.1 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.013 -1.055 . . . . 0.0 110.232 179.849 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -110.64 -55.36 2.49 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.181 -0.949 . . . . 0.0 110.26 179.948 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -68.38 -41.32 85.71 Favored Glycine 0 N--CA 1.497 2.713 0 N-CA-C 109.546 -1.421 . . . . 0.0 109.546 179.859 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 39' ' ' CYS . . . . . . . . . . . . . 1.6 p -156.82 84.67 0.96 Allowed 'General case' 0 N--CA 1.497 1.915 0 O-C-N 121.412 -1.052 . . . . 0.0 110.119 -179.766 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 40' ' ' LEU . . . . . . . . . . . . . 1.4 pp . . . . . 0 N--CA 1.498 1.958 0 O-C-N 121.312 -0.868 . . . . 0.0 110.611 -179.751 . . . . . . . . 0 0 . 1 . 018 nuclear build core ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 3.3 p . . . . . 0 N--CA 1.495 1.802 0 N-CA-C 109.475 -0.565 . . . . 0.0 109.475 . . . . . . . . . 0 0 . 1 . 018 nuclear build core ' A' A ' 6' ' ' PRO . . . . . . . . . . . . . 42.1 Cg_endo -69.06 -43.98 2.87 Favored 'Trans proline' 0 C--N 1.312 -1.364 0 O-C-N 123.588 1.309 . . . . 0.0 111.534 -179.367 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -82.75 50.81 4.44 Favored Glycine 0 N--CA 1.495 2.624 0 N-CA-C 109.946 -1.262 . . . . 0.0 109.946 -179.975 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 1.7 m -119.06 -30.25 5.04 Favored 'General case' 0 N--CA 1.499 1.995 0 O-C-N 121.257 -1.143 . . . . 0.0 111.001 179.945 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 109.34 133.51 6.76 Favored Glycine 0 N--CA 1.493 2.483 0 N-CA-C 109.73 -1.348 . . . . 0.0 109.73 -179.802 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 10' ' ' GLN . . . . . . . . . . . . . 0.7 OUTLIER 45.39 49.71 10.33 Favored 'General case' 0 N--CA 1.501 2.125 0 O-C-N 121.953 -0.734 . . . . 0.0 111.053 179.499 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -86.93 -54.7 2.55 Favored Glycine 0 N--CA 1.496 2.675 0 N-CA-C 110.092 -1.203 . . . . 0.0 110.092 -179.848 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 12' ' ' VAL . . . . . 0.458 ' O ' HG13 ' A' ' 12' ' ' VAL . 9.0 p -138.03 48.08 0.35 Allowed 'Isoleucine or valine' 0 N--CA 1.495 1.784 0 O-C-N 121.275 -1.132 . . . . 0.0 110.413 179.93 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 13' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -81.82 -7.38 59.6 Favored 'General case' 0 N--CA 1.495 1.78 0 O-C-N 120.946 -1.096 . . . . 0.0 111.159 179.919 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -125.6 141.72 51.88 Favored 'General case' 0 N--CA 1.495 1.821 0 O-C-N 121.303 -0.873 . . . . 0.0 109.767 179.943 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -161.05 90.98 0.11 Allowed Glycine 0 N--CA 1.492 2.406 0 N-CA-C 109.372 -1.491 . . . . 0.0 109.372 179.697 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 13.4 m -94.69 152.71 40.02 Favored Pre-proline 0 N--CA 1.5 2.04 0 O-C-N 121.233 -1.157 . . . . 0.0 110.456 -179.95 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 48.2 Cg_endo -76.38 -147.81 0.03 OUTLIER 'Trans proline' 0 C--N 1.308 -1.554 0 O-C-N 123.779 1.41 . . . . 0.0 108.773 178.454 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . -62.92 -12.39 42.44 Favored Glycine 0 N--CA 1.498 2.767 0 O-C-N 120.878 -1.139 . . . . 0.0 110.898 179.574 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -151.18 115.4 0.7 Allowed Glycine 0 N--CA 1.494 2.536 0 N-CA-C 109.175 -1.57 . . . . 0.0 109.175 -179.705 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 4.8 t -84.56 -10.3 57.53 Favored 'General case' 0 N--CA 1.499 2.01 0 O-C-N 121.179 -1.189 . . . . 0.0 111.459 -179.834 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 8.6 p -129.36 26.21 1.9 Allowed 'Isoleucine or valine' 0 N--CA 1.499 1.997 0 O-C-N 121.045 -1.034 . . . . 0.0 111.027 -179.81 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 1.4 tp10 -105.72 -4.44 20.94 Favored 'General case' 0 N--CA 1.493 1.692 0 O-C-N 120.479 -1.388 . . . . 0.0 110.952 179.56 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 0.8 OUTLIER -138.14 -47.09 0.52 Allowed 'General case' 0 N--CA 1.492 1.673 0 O-C-N 121.064 -1.023 . . . . 0.0 110.712 179.697 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 1.1 mt-10 -59.95 115.84 3.71 Favored 'General case' 0 N--CA 1.494 1.747 0 O-C-N 121.482 -0.761 . . . . 0.0 110.079 -179.423 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 6.4 t0 -104.5 91.37 3.86 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.371 -0.831 . . . . 0.0 109.37 179.297 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -79.32 60.22 4.29 Favored Glycine 0 N--CA 1.496 2.676 0 N-CA-C 109.52 -1.432 . . . . 0.0 109.52 -179.296 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 177.45 -179.24 48.24 Favored Glycine 0 N--CA 1.493 2.49 0 N-CA-C 109.956 -1.258 . . . . 0.0 109.956 179.753 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -160.07 155.56 22.09 Favored Pre-proline 0 N--CA 1.494 1.73 0 O-C-N 121.381 -1.07 . . . . 0.0 110.187 179.854 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 40.2 Cg_endo -67.74 -40.72 9.35 Favored 'Trans proline' 0 N--CA 1.492 1.438 0 O-C-N 123.549 1.289 . . . . 0.0 110.17 179.484 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -92.97 47.95 1.31 Allowed 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.403 -0.811 . . . . 0.0 110.191 179.369 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 12.5 tt0 -77.85 -11.38 59.88 Favored 'General case' 0 N--CA 1.494 1.747 0 O-C-N 121.487 -0.758 . . . . 0.0 111.034 -179.87 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 98.16 84.44 1.76 Allowed Glycine 0 N--CA 1.489 2.22 0 N-CA-C 108.675 -1.77 . . . . 0.0 108.675 -179.668 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 33' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -79.02 65.45 4.2 Favored 'General case' 0 N--CA 1.493 1.714 0 O-C-N 121.166 -1.196 . . . . 0.0 110.051 -179.341 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -115.75 56.38 0.77 Allowed 'General case' 0 N--CA 1.496 1.832 0 O-C-N 121.469 -0.769 . . . . 0.0 109.75 179.697 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 1.1 tt0 -147.59 -162.3 1.52 Allowed 'General case' 0 N--CA 1.494 1.765 0 O-C-N 121.457 -0.777 . . . . 0.0 110.081 -179.363 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 36' ' ' ALA . . . . . . . . . . . . . . . -78.65 -30.85 46.57 Favored 'General case' 0 N--CA 1.494 1.727 0 O-C-N 121.464 -0.772 . . . . 0.0 109.108 179.029 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER -134.74 -74.32 0.47 Allowed 'General case' 0 N--CA 1.487 1.395 0 O-C-N 121.6 -0.687 . . . . 0.0 109.723 179.079 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 56.97 -99.27 0.09 OUTLIER Glycine 0 N--CA 1.496 2.685 0 N-CA-C 110.319 -1.113 . . . . 0.0 110.319 179.291 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 39' ' ' CYS . . . . . . . . . . . . . 2.5 p -99.49 6.56 45.88 Favored 'General case' 0 N--CA 1.497 1.912 0 O-C-N 121.792 -0.828 . . . . 0.0 111.612 -179.674 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 40' ' ' LEU . . . . . . . . . . . . . 1.5 mt . . . . . 0 N--CA 1.504 2.266 0 O-C-N 121.416 -0.802 . . . . 0.0 110.974 179.454 . . . . . . . . 0 0 . 1 . 019 nuclear build core ' A' A ' 5' ' ' CYS . . . . . 0.438 ' SG ' ' N ' ' A' ' 8' ' ' CYS . 1.3 p . . . . . 0 N--CA 1.491 1.595 0 N-CA-C 109.941 -0.392 . . . . 0.0 109.941 . . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 6' ' ' PRO . . . . . . . . . . . . . 41.1 Cg_endo -68.2 -31.47 29.18 Favored 'Trans proline' 0 C--N 1.314 -1.246 0 O-C-N 123.637 1.335 . . . . 0.0 110.988 179.824 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -91.81 23.37 26.33 Favored Glycine 0 N--CA 1.494 2.547 0 N-CA-C 110.29 -1.124 . . . . 0.0 110.29 179.492 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 8' ' ' CYS . . . . . 0.438 ' N ' ' SG ' ' A' ' 5' ' ' CYS . 51.0 m -96.93 19.13 13.21 Favored 'General case' 0 N--CA 1.494 1.744 0 O-C-N 120.998 -1.295 . . . . 0.0 110.751 -179.904 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -79.28 -48.03 7.1 Favored Glycine 0 N--CA 1.492 2.415 0 N-CA-C 109.929 -1.268 . . . . 0.0 109.929 -179.653 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 10' ' ' GLN . . . . . . . . . . . . . 4.3 mt-30 -111.62 40.14 2.19 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 121.15 -1.206 . . . . 0.0 110.603 -179.62 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -84.43 63.39 4.43 Favored Glycine 0 N--CA 1.497 2.727 0 N-CA-C 109.861 -1.295 . . . . 0.0 109.861 179.883 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 13.3 m -134.98 48.61 0.41 Allowed 'Isoleucine or valine' 0 N--CA 1.501 2.087 0 O-C-N 121.393 -1.063 . . . . 0.0 110.652 179.923 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 13' ' ' GLN . . . . . . . . . . . . . 11.9 mt-30 -73.56 75.7 1.48 Allowed 'General case' 0 N--CA 1.498 1.936 0 O-C-N 121.074 -1.016 . . . . 0.0 110.454 179.944 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -110.13 -69.51 0.86 Allowed 'General case' 0 N--CA 1.498 1.939 0 O-C-N 121.288 -0.882 . . . . 0.0 110.563 -179.777 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -161.01 -105.1 0.2 Allowed Glycine 0 N--CA 1.493 2.445 0 N-CA-C 109.58 -1.408 . . . . 0.0 109.58 -179.674 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 0.0 OUTLIER -116.9 161.61 31.57 Favored Pre-proline 0 N--CA 1.501 2.101 0 O-C-N 121.253 -1.145 . . . . 0.0 109.61 179.438 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 42.2 Cg_endo -70.2 -59.27 0.08 OUTLIER 'Trans proline' 0 N--CA 1.489 1.225 0 O-C-N 123.825 1.434 . . . . 0.0 111.085 179.961 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . -108.05 -36.91 2.25 Favored Glycine 0 N--CA 1.495 2.602 0 N-CA-C 110.317 -1.113 . . . . 0.0 110.317 179.942 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 172.91 135.91 2.07 Favored Glycine 0 N--CA 1.492 2.426 0 N-CA-C 108.678 -1.769 . . . . 0.0 108.678 -179.923 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 4.1 m -78.57 64.83 3.7 Favored 'General case' 0 N--CA 1.5 2.03 0 O-C-N 121.413 -1.051 . . . . 0.0 110.506 -179.906 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 21' ' ' VAL . . . . . 0.455 HG13 ' N ' ' A' ' 22' ' ' GLU . 7.7 p -133.18 -46.06 0.6 Allowed 'Isoleucine or valine' 0 N--CA 1.498 1.956 0 O-C-N 121.468 -0.77 . . . . 0.0 109.759 179.088 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 22' ' ' GLU . . . . . 0.455 ' N ' HG13 ' A' ' 21' ' ' VAL . 23.4 mt-10 -89.18 33.86 0.8 Allowed 'General case' 0 C--N 1.306 -1.306 0 O-C-N 121.062 -1.024 . . . . 0.0 109.151 178.123 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -156.81 -75.55 0.09 Allowed 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.403 -0.81 . . . . 0.0 110.145 -179.406 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER 57.08 -165.18 0.15 Allowed 'General case' 0 N--CA 1.494 1.748 0 O-C-N 121.676 -0.64 . . . . 0.0 110.65 -179.899 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 3.3 m-20 -107.12 150.91 26.06 Favored 'General case' 0 N--CA 1.495 1.823 0 O-C-N 121.367 -0.833 . . . . 0.0 110.537 -179.666 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 88.19 -86.87 1.49 Allowed Glycine 0 N--CA 1.49 2.287 0 N-CA-C 110.194 -1.162 . . . . 0.0 110.194 179.295 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 69.86 64.16 3.04 Favored Glycine 0 N--CA 1.495 2.594 0 N-CA-C 109.127 -1.589 . . . . 0.0 109.127 -178.986 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 3.5 p -82.02 129.55 63.9 Favored Pre-proline 0 N--CA 1.499 1.987 0 O-C-N 120.859 -1.377 . . . . 0.0 110.868 -179.742 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 43.1 Cg_endo -70.42 -11.0 29.23 Favored 'Trans proline' 0 N--CA 1.489 1.238 0 O-C-N 124.086 1.571 . . . . 0.0 111.043 179.828 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -83.28 6.52 19.36 Favored 'General case' 0 N--CA 1.492 1.666 0 O-C-N 121.066 -1.022 . . . . 0.0 111.564 -179.497 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 31' ' ' GLU . . . . . 0.586 ' HG2' ' N ' ' A' ' 32' ' ' GLY . 14.6 tt0 -79.44 -75.0 0.26 Allowed 'General case' 0 N--CA 1.494 1.763 0 O-C-N 121.157 -0.965 . . . . 0.0 109.736 -179.987 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 32' ' ' GLY . . . . . 0.586 ' N ' ' HG2' ' A' ' 31' ' ' GLU . . . -136.33 22.26 3.39 Favored Glycine 0 N--CA 1.492 2.374 0 N-CA-C 109.55 -1.42 . . . . 0.0 109.55 179.563 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 33' ' ' CYS . . . . . 0.46 ' O ' ' HB2' ' A' ' 39' ' ' CYS . 0.5 OUTLIER -79.39 67.36 5.1 Favored 'General case' 0 N--CA 1.494 1.749 0 O-C-N 121.089 -1.242 . . . . 0.0 109.359 179.36 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -130.32 56.45 1.76 Allowed 'General case' 0 N--CA 1.496 1.868 0 O-C-N 121.536 -0.727 . . . . 0.0 110.319 179.763 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 5.5 mm-40 -92.88 -144.32 0.22 Allowed 'General case' 0 N--CA 1.497 1.884 0 O-C-N 121.505 -0.747 . . . . 0.0 109.74 179.713 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 36' ' ' ALA . . . . . . . . . . . . . . . -114.01 11.93 17.87 Favored 'General case' 0 N--CA 1.496 1.863 0 O-C-N 121.059 -1.026 . . . . 0.0 110.9 179.925 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 20.0 tt0 -161.2 -54.97 0.05 OUTLIER 'General case' 0 N--CA 1.496 1.862 0 O-C-N 121.261 -0.899 . . . . 0.0 110.741 179.516 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -43.6 -51.82 6.6 Favored Glycine 0 N--CA 1.5 2.938 0 N-CA-C 111.525 -0.63 . . . . 0.0 111.525 -178.74 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 39' ' ' CYS . . . . . 0.46 ' HB2' ' O ' ' A' ' 33' ' ' CYS . 56.9 m -139.94 75.68 1.52 Allowed 'General case' 0 N--CA 1.496 1.866 0 O-C-N 121.07 -1.253 . . . . 0.0 110.496 -179.234 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 40' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER . . . . . 0 N--CA 1.503 2.195 0 O-C-N 121.306 -0.872 . . . . 0.0 110.199 179.794 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 13.7 t . . . . . 0 N--CA 1.495 1.802 0 N-CA-C 109.91 -0.404 . . . . 0.0 109.91 . . . . . . . . . 0 0 . 1 . 020 nuclear build core ' A' A ' 6' ' ' PRO . . . . . . . . . . . . . 50.8 Cg_endo -87.26 -24.06 1.34 Allowed 'Trans proline' 0 C--N 1.309 -1.508 0 O-C-N 123.904 1.476 . . . . 0.0 112.212 -179.515 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -109.85 68.32 0.22 Allowed Glycine 0 N--CA 1.497 2.759 0 O-C-N 120.829 -1.169 . . . . 0.0 111.332 -178.18 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 1.2 p -158.7 150.19 20.83 Favored 'General case' 0 N--CA 1.497 1.885 0 O-C-N 121.177 -1.19 . . . . 0.0 110.213 178.837 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 92.02 -110.46 3.88 Favored Glycine 0 N--CA 1.493 2.442 0 N-CA-C 108.893 -1.683 . . . . 0.0 108.893 -179.461 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 10' ' ' GLN . . . . . . . . . . . . . 5.5 pt20 -155.32 30.29 0.39 Allowed 'General case' 0 N--CA 1.494 1.745 0 O-C-N 121.272 -1.134 . . . . 0.0 110.698 179.379 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -86.58 62.69 4.23 Favored Glycine 0 N--CA 1.493 2.447 0 N-CA-C 109.461 -1.456 . . . . 0.0 109.461 179.614 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 60.2 t -126.94 -75.19 0.36 Allowed 'Isoleucine or valine' 0 N--CA 1.495 1.795 0 O-C-N 121.808 -0.819 . . . . 0.0 109.73 179.745 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 13' ' ' GLN . . . . . . . . . . . . . 1.6 mt-30 42.69 36.33 0.82 Allowed 'General case' 0 N--CA 1.495 1.82 0 O-C-N 121.652 -0.655 . . . . 0.0 111.779 179.736 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -71.5 -22.33 61.81 Favored 'General case' 0 N--CA 1.499 2.014 0 O-C-N 121.171 -0.956 . . . . 0.0 110.936 179.854 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 134.43 -53.34 0.79 Allowed Glycine 0 N--CA 1.493 2.499 0 N-CA-C 109.248 -1.541 . . . . 0.0 109.248 -179.69 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 2.6 p -88.68 121.52 69.91 Favored Pre-proline 0 N--CA 1.497 1.915 0 O-C-N 121.358 -1.083 . . . . 0.0 110.849 179.91 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 48.7 Cg_endo -76.06 79.5 2.89 Favored 'Trans proline' 0 C--N 1.309 -1.513 0 O-C-N 123.705 1.371 . . . . 0.0 110.046 179.606 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 85.79 -48.68 4.02 Favored Glycine 0 N--CA 1.493 2.461 0 N-CA-C 109.887 -1.285 . . . . 0.0 109.887 -179.512 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -72.38 68.8 1.16 Allowed Glycine 0 N--CA 1.495 2.617 0 N-CA-C 110.13 -1.188 . . . . 0.0 110.13 -179.604 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 73.2 m -105.2 119.07 38.14 Favored 'General case' 0 N--CA 1.498 1.957 0 O-C-N 121.482 -1.011 . . . . 0.0 109.511 179.627 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 12.7 t -106.71 -9.34 10.54 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.84 0 O-C-N 121.556 -0.715 . . . . 0.0 111.616 -178.95 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER -79.4 51.5 1.23 Allowed 'General case' 0 N--CA 1.493 1.695 0 O-C-N 120.855 -1.153 . . . . 0.0 110.566 179.718 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 3.2 tt0 -101.79 -24.29 14.08 Favored 'General case' 0 N--CA 1.489 1.477 0 O-C-N 121.095 -1.003 . . . . 0.0 110.139 179.539 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 2.1 pt-20 -79.89 -154.42 0.09 Allowed 'General case' 0 N--CA 1.494 1.736 0 O-C-N 121.274 -0.891 . . . . 0.0 110.575 -179.902 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -82.36 -49.16 10.32 Favored 'General case' 0 N--CA 1.5 2.06 0 O-C-N 121.456 -0.778 . . . . 0.0 110.164 179.947 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 144.09 46.64 0.04 OUTLIER Glycine 0 N--CA 1.498 2.772 0 N-CA-C 110.614 -0.995 . . . . 0.0 110.614 179.419 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 64.73 -130.92 37.06 Favored Glycine 0 N--CA 1.501 2.98 0 N-CA-C 109.685 -1.366 . . . . 0.0 109.685 -179.975 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -146.61 74.97 12.39 Favored Pre-proline 0 N--CA 1.495 1.787 0 O-C-N 121.294 -1.121 . . . . 0.0 109.926 179.691 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 43.4 Cg_endo -74.03 74.44 3.48 Favored 'Trans proline' 0 N--CA 1.488 1.172 0 O-C-N 123.632 1.333 . . . . 0.0 110.661 -179.908 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -89.87 64.84 6.5 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.111 -0.993 . . . . 0.0 110.571 179.887 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 14.8 tp10 -153.17 -67.92 0.15 Allowed 'General case' 0 N--CA 1.493 1.694 0 O-C-N 121.378 -0.826 . . . . 0.0 110.214 179.61 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 123.69 84.52 0.65 Allowed Glycine 0 N--CA 1.497 2.716 0 N-CA-C 109.406 -1.477 . . . . 0.0 109.406 -179.82 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 33' ' ' CYS . . . . . . . . . . . . . 0.4 OUTLIER -95.29 112.36 24.08 Favored 'General case' 0 N--CA 1.493 1.704 0 O-C-N 121.394 -1.062 . . . . 0.0 109.79 179.812 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -107.58 -46.13 3.9 Favored 'General case' 0 N--CA 1.497 1.875 0 O-C-N 121.564 -0.71 . . . . 0.0 110.103 179.886 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 21.8 mt-10 -79.59 -178.88 6.55 Favored 'General case' 0 N--CA 1.5 2.052 0 O-C-N 121.635 -0.665 . . . . 0.0 110.23 179.931 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 36' ' ' ALA . . . . . . . . . . . . . . . -78.66 -38.08 40.37 Favored 'General case' 0 N--CA 1.498 1.931 0 O-C-N 121.202 -0.936 . . . . 0.0 109.897 -179.634 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 7.3 tt0 -119.87 34.07 5.36 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.381 -0.825 . . . . 0.0 109.991 179.492 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -84.72 -9.45 81.13 Favored Glycine 0 N--CA 1.495 2.63 0 O-C-N 121.101 -0.999 . . . . 0.0 110.776 -179.909 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 39' ' ' CYS . . . . . . . . . . . . . 1.3 m -79.43 72.91 6.09 Favored 'General case' 0 N--CA 1.495 1.801 0 O-C-N 120.874 -1.368 . . . . 0.0 109.822 179.842 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 40' ' ' LEU . . . . . . . . . . . . . 1.0 OUTLIER . . . . . 0 N--CA 1.494 1.763 0 O-C-N 121.372 -0.83 . . . . 0.0 110.46 -179.474 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.494 1.755 0 CA-C-O 120.816 0.341 . . . . 0.0 110.127 . . . . . . . . . 0 0 . 1 . 001 nuclear build full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 17.9 mt -131.53 114.97 15.53 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.162 -0.961 . . . . 0.0 110.383 179.737 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -93.42 50.71 1.52 Allowed 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.386 -0.821 . . . . 0.0 110.546 -179.847 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 4' ' ' ARG . . . . . . . . . . . . . 26.5 ttp85 -164.24 135.59 4.5 Favored 'General case' 0 N--CA 1.493 1.68 0 O-C-N 121.269 -0.894 . . . . 0.0 110.079 179.786 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -87.74 117.77 68.91 Favored Pre-proline 0 N--CA 1.495 1.807 0 O-C-N 121.28 -0.888 . . . . 0.0 109.878 179.845 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 6' ' ' PRO . . . . . . . . . . . . . 49.5 Cg_endo -82.23 150.34 15.49 Favored 'Trans proline' 0 C--N 1.313 -1.307 0 O-C-N 123.716 1.377 . . . . 0.0 110.647 -179.822 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 88.32 -46.54 3.38 Favored Glycine 0 N--CA 1.497 2.761 0 N-CA-C 110.342 -1.103 . . . . 0.0 110.342 179.43 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 20.0 p -79.66 -174.29 4.24 Favored 'General case' 0 N--CA 1.496 1.839 0 O-C-N 121.035 -1.274 . . . . 0.0 110.493 -179.601 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 129.26 -114.43 1.73 Allowed Glycine 0 N--CA 1.494 2.545 0 N-CA-C 108.854 -1.699 . . . . 0.0 108.854 -179.433 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 10' ' ' GLN . . . . . . . . . . . . . 14.0 tp60 -164.39 -75.47 0.04 OUTLIER 'General case' 0 N--CA 1.494 1.748 0 O-C-N 121.421 -1.047 . . . . 0.0 110.542 179.222 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -56.13 -26.1 48.64 Favored Glycine 0 N--CA 1.498 2.786 0 O-C-N 121.252 -0.905 . . . . 0.0 110.986 -179.54 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 25.2 t -88.88 -53.88 8.75 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.813 0 O-C-N 121.185 -1.185 . . . . 0.0 110.241 -179.882 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 13' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -67.04 -32.08 73.04 Favored 'General case' 0 N--CA 1.501 2.113 0 O-C-N 121.375 -0.828 . . . . 0.0 112.008 -179.245 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -141.26 52.23 1.57 Allowed 'General case' 0 N--CA 1.496 1.852 0 O-C-N 120.948 -1.095 . . . . 0.0 110.615 -179.645 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -151.76 -85.36 0.05 OUTLIER Glycine 0 N--CA 1.493 2.469 0 N-CA-C 109.845 -1.302 . . . . 0.0 109.845 179.881 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 57.9 m -110.08 97.58 30.68 Favored Pre-proline 0 N--CA 1.496 1.836 0 O-C-N 121.221 -1.164 . . . . 0.0 110.442 -179.898 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 46.7 Cg_endo -72.54 66.53 3.74 Favored 'Trans proline' 0 N--CA 1.491 1.378 0 O-C-N 124.284 1.676 . . . . 0.0 110.409 179.723 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 123.29 -49.97 0.87 Allowed Glycine 0 N--CA 1.495 2.589 0 N-CA-C 109.267 -1.533 . . . . 0.0 109.267 -179.557 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 178.41 134.28 2.06 Favored Glycine 0 N--CA 1.489 2.229 0 N-CA-C 108.971 -1.652 . . . . 0.0 108.971 179.976 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 1.5 m -92.11 33.06 1.09 Allowed 'General case' 0 N--CA 1.5 2.041 0 O-C-N 121.301 -1.117 . . . . 0.0 110.634 -179.911 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 6.4 t -139.87 55.88 0.22 Allowed 'Isoleucine or valine' 0 N--CA 1.496 1.874 0 O-C-N 120.928 -1.107 . . . . 0.0 110.599 -179.89 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 5.2 tt0 -88.88 49.17 1.74 Allowed 'General case' 0 N--CA 1.496 1.863 0 O-C-N 121.135 -0.978 . . . . 0.0 109.266 178.968 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 11.1 mt-10 58.65 -168.03 0.14 Allowed 'General case' 0 N--CA 1.501 2.08 0 O-C-N 121.756 -0.59 . . . . 0.0 110.451 -179.515 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 73.0 mm-40 -69.58 -22.2 63.54 Favored 'General case' 0 N--CA 1.497 1.923 0 O-C-N 120.991 -1.068 . . . . 0.0 111.277 -179.131 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 2.8 t70 -144.34 -61.44 0.38 Allowed 'General case' 0 N--CA 1.496 1.875 0 O-C-N 121.217 -0.927 . . . . 0.0 109.807 179.879 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 172.39 82.86 0.05 OUTLIER Glycine 0 N--CA 1.495 2.567 0 N-CA-C 109.955 -1.258 . . . . 0.0 109.955 179.681 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 66.09 27.69 73.09 Favored Glycine 0 N--CA 1.496 2.658 0 N-CA-C 109.855 -1.298 . . . . 0.0 109.855 179.923 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -102.37 99.59 13.35 Favored Pre-proline 0 N--CA 1.493 1.701 0 O-C-N 121.521 -0.987 . . . . 0.0 110.068 -179.699 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 45.0 Cg_endo -70.87 66.28 2.43 Favored 'Trans proline' 0 N--CA 1.489 1.225 0 O-C-N 123.744 1.391 . . . . 0.0 110.915 -179.577 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -131.28 66.58 1.54 Allowed 'General case' 0 N--CA 1.486 1.371 0 O-C-N 121.337 -0.852 . . . . 0.0 109.974 179.664 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 8.9 tt0 -110.58 -68.75 0.91 Allowed 'General case' 0 N--CA 1.485 1.313 0 O-C-N 121.397 -0.814 . . . . 0.0 110.531 -179.539 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . -72.87 -42.71 44.55 Favored Glycine 0 N--CA 1.496 2.678 0 N-CA-C 110.088 -1.205 . . . . 0.0 110.088 -179.674 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 33' ' ' CYS . . . . . . . . . . . . . 1.7 t -113.77 79.28 1.23 Allowed 'General case' 0 N--CA 1.492 1.646 0 O-C-N 121.141 -1.211 . . . . 0.0 109.661 -179.843 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -125.23 -46.09 1.81 Allowed 'General case' 0 N--CA 1.495 1.812 0 O-C-N 121.111 -0.993 . . . . 0.0 110.992 -179.403 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 0.8 OUTLIER -97.03 -176.48 3.56 Favored 'General case' 0 N--CA 1.498 1.926 0 O-C-N 121.494 -0.754 . . . . 0.0 110.934 -179.414 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 36' ' ' ALA . . . . . 0.548 ' O ' ' HB3' ' A' ' 40' ' ' LEU . . . -79.13 -34.19 43.55 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.26 -0.9 . . . . 0.0 110.189 179.805 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -78.41 2.31 19.21 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.247 -0.908 . . . . 0.0 110.903 179.865 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -92.66 -43.81 4.12 Favored Glycine 0 N--CA 1.492 2.411 0 N-CA-C 109.432 -1.467 . . . . 0.0 109.432 179.951 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 39' ' ' CYS . . . . . . . . . . . . . 1.3 p -161.06 50.34 0.24 Allowed 'General case' 0 N--CA 1.498 1.968 0 O-C-N 121.358 -1.084 . . . . 0.0 111.215 -179.391 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 40' ' ' LEU . . . . . 0.548 ' HB3' ' O ' ' A' ' 36' ' ' ALA . 1.7 pt? -55.79 -41.09 73.6 Favored 'General case' 0 N--CA 1.504 2.234 0 O-C-N 120.801 -1.187 . . . . 0.0 112.047 -179.599 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 41' ' ' ARG . . . . . 0.529 ' H ' HD23 ' A' ' 40' ' ' LEU . 0.4 OUTLIER 48.04 -154.48 0.08 Allowed 'General case' 0 N--CA 1.502 2.168 0 O-C-N 121.184 -0.947 . . . . 0.0 110.525 -179.733 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 42' ' ' ARG . . . . . . . . . . . . . 21.5 ttt-85 -92.98 -56.21 3.07 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 120.885 -1.134 . . . . 0.0 109.482 179.539 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -116.03 136.46 53.01 Favored 'General case' 0 N--CA 1.489 1.48 0 O-C-N 121.655 -0.653 . . . . 0.0 109.838 179.301 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -114.17 -48.96 0.55 Allowed Glycine 0 N--CA 1.491 2.348 0 N-CA-C 109.736 -1.346 . . . . 0.0 109.736 -179.783 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 45' ' ' GLN . . . . . . . . . . . . . 38.9 mt-30 . . . . . 0 N--CA 1.499 2.014 0 O-C-N 121.573 -0.957 . . . . 0.0 110.338 179.879 . . . . . . . . 0 0 . 1 . 002 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.496 1.855 0 CA-C-O 121.175 0.512 . . . . 0.0 110.374 . . . . . . . . . 0 0 . 1 . 002 nuclear build full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER -137.36 20.83 2.95 Favored 'General case' 0 N--CA 1.493 1.723 0 O-C-N 120.885 -1.134 . . . . 0.0 111.177 179.832 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -76.57 85.48 3.26 Favored 'General case' 0 N--CA 1.493 1.688 0 O-C-N 121.199 -0.938 . . . . 0.0 110.443 -179.862 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 4' ' ' ARG . . . . . . . . . . . . . 0.5 OUTLIER -132.19 -167.54 1.9 Allowed 'General case' 0 N--CA 1.488 1.463 0 O-C-N 121.34 -0.85 . . . . 0.0 109.543 179.435 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 0.3 OUTLIER -79.35 125.97 82.13 Favored Pre-proline 0 N--CA 1.497 1.924 0 O-C-N 121.122 -0.986 . . . . 0.0 110.277 179.935 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 6' ' ' PRO . . . . . . . . . . . . . 45.6 Cg_endo -72.82 -86.18 0.0 OUTLIER 'Trans proline' 0 C--N 1.307 -1.656 0 O-C-N 123.944 1.497 . . . . 0.0 112.062 -179.039 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -105.6 55.8 0.54 Allowed Glycine 0 N--CA 1.49 2.246 0 N-CA-C 109.893 -1.283 . . . . 0.0 109.893 -178.99 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 0.4 OUTLIER -135.34 151.54 50.61 Favored 'General case' 0 N--CA 1.498 1.96 0 O-C-N 121.335 -1.097 . . . . 0.0 110.33 179.611 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 175.98 154.1 11.19 Favored Glycine 0 N--CA 1.495 2.605 0 N-CA-C 109.655 -1.378 . . . . 0.0 109.655 -179.809 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 10' ' ' GLN . . . . . . . . . . . . . 0.3 OUTLIER -129.89 70.56 1.43 Allowed 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.283 -1.128 . . . . 0.0 109.756 179.921 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -79.45 -61.15 2.37 Favored Glycine 0 N--CA 1.495 2.591 0 N-CA-C 110.006 -1.238 . . . . 0.0 110.006 -179.491 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 24.0 m -120.58 -31.65 1.54 Allowed 'Isoleucine or valine' 0 N--CA 1.503 2.213 0 O-C-N 121.427 -1.043 . . . . 0.0 111.491 -179.493 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 13' ' ' GLN . . . . . . . . . . . . . 1.2 tt0 56.33 50.53 13.08 Favored 'General case' 0 N--CA 1.499 1.992 0 O-C-N 121.408 -0.807 . . . . 0.0 110.616 179.93 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -104.68 -60.62 1.57 Allowed 'General case' 0 N--CA 1.495 1.815 0 O-C-N 121.269 -0.894 . . . . 0.0 110.536 179.887 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -152.12 -83.43 0.04 OUTLIER Glycine 0 N--CA 1.494 2.536 0 N-CA-C 109.876 -1.29 . . . . 0.0 109.876 179.942 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 16' ' ' CYS . . . . . 0.456 ' HB2' ' HB2' ' A' ' 20' ' ' CYS . 1.1 m -86.36 136.2 35.73 Favored Pre-proline 0 N--CA 1.496 1.831 0 O-C-N 121.338 -1.096 . . . . 0.0 109.985 179.679 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 45.3 Cg_endo -72.62 72.04 3.13 Favored 'Trans proline' 0 C--N 1.312 -1.361 0 O-C-N 123.656 1.345 . . . . 0.0 109.617 178.931 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 91.52 -49.49 2.9 Favored Glycine 0 N--CA 1.493 2.447 0 N-CA-C 109.702 -1.359 . . . . 0.0 109.702 -179.254 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -74.65 67.14 1.98 Allowed Glycine 0 N--CA 1.497 2.738 0 O-C-N 121.009 -1.289 . . . . 0.0 110.831 -179.727 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 20' ' ' CYS . . . . . 0.456 ' HB2' ' HB2' ' A' ' 16' ' ' CYS . 0.4 OUTLIER -127.77 73.14 1.43 Allowed 'General case' 0 N--CA 1.496 1.83 0 O-C-N 121.24 -1.153 . . . . 0.0 109.174 179.38 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 14.6 p -126.14 -19.66 2.68 Favored 'Isoleucine or valine' 0 N--CA 1.499 2.018 0 O-C-N 121.739 -0.601 . . . . 0.0 111.506 -179.039 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 17.7 mt-10 -79.96 50.18 1.17 Allowed 'General case' 0 N--CA 1.491 1.598 0 O-C-N 120.673 -1.267 . . . . 0.0 110.231 179.831 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 2.3 mt-10 -89.21 -172.91 3.82 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 120.864 -1.147 . . . . 0.0 110.138 -179.794 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER 56.39 59.25 3.73 Favored 'General case' 0 N--CA 1.493 1.677 0 CA-C-O 121.343 0.592 . . . . 0.0 110.4 179.976 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 1.9 p-10 -101.89 -174.45 2.59 Favored 'General case' 0 N--CA 1.496 1.83 0 O-C-N 121.223 -0.923 . . . . 0.0 109.907 179.561 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 79.35 -69.95 2.89 Favored Glycine 0 N--CA 1.495 2.628 0 N-CA-C 109.559 -1.416 . . . . 0.0 109.559 -179.807 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 144.71 115.04 0.97 Allowed Glycine 0 N--CA 1.494 2.561 0 N-CA-C 109.635 -1.386 . . . . 0.0 109.635 179.789 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 73.5 m -81.91 143.63 50.21 Favored Pre-proline 0 N--CA 1.5 2.032 0 O-C-N 121.385 -1.067 . . . . 0.0 110.187 -179.973 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 45.5 Cg_endo -73.46 91.25 0.88 Allowed 'Trans proline' 0 C--N 1.315 -1.188 0 O-C-N 123.729 1.384 . . . . 0.0 111.115 -179.078 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -94.55 -55.2 3.23 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.315 -0.865 . . . . 0.0 110.59 179.883 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 36.2 tt0 -79.05 -7.26 57.97 Favored 'General case' 0 N--CA 1.496 1.858 0 O-C-N 121.513 -0.742 . . . . 0.0 110.911 -179.8 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 90.41 -10.34 74.71 Favored Glycine 0 N--CA 1.494 2.51 0 O-C-N 120.792 -1.192 . . . . 0.0 110.182 -179.515 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 33' ' ' CYS . . . . . . . . . . . . . 59.1 m -79.73 65.71 4.97 Favored 'General case' 0 N--CA 1.494 1.741 0 O-C-N 120.925 -1.338 . . . . 0.0 110.282 -179.803 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -79.2 -38.95 34.52 Favored 'General case' 0 N--CA 1.494 1.742 0 O-C-N 121.456 -0.778 . . . . 0.0 109.573 179.576 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 47.9 mt-10 -89.91 162.59 15.36 Favored 'General case' 0 N--CA 1.493 1.716 0 O-C-N 121.381 -0.825 . . . . 0.0 109.594 179.235 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 36' ' ' ALA . . . . . . . . . . . . . . . -79.35 -46.33 17.86 Favored 'General case' 0 N--CA 1.493 1.683 0 O-C-N 121.123 -0.985 . . . . 0.0 110.412 -179.221 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 1.5 tt0 -95.3 62.41 2.47 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.191 -0.943 . . . . 0.0 110.315 -179.834 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -148.68 17.49 1.26 Allowed Glycine 0 N--CA 1.496 2.673 0 C-N-CA 119.945 -1.121 . . . . 0.0 110.958 -179.984 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 39' ' ' CYS . . . . . . . . . . . . . 57.1 m -144.23 26.87 1.45 Allowed 'General case' 0 N--CA 1.502 2.135 0 O-C-N 120.663 -1.492 . . . . 0.0 111.274 -179.837 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 40' ' ' LEU . . . . . . . . . . . . . 0.9 OUTLIER 45.69 67.3 0.76 Allowed 'General case' 0 N--CA 1.501 2.082 0 O-C-N 121.68 -0.638 . . . . 0.0 111.647 179.886 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 41' ' ' ARG . . . . . . . . . . . . . 4.5 ptp180 -173.34 118.43 0.3 Allowed 'General case' 0 N--CA 1.497 1.915 0 O-C-N 121.206 -0.934 . . . . 0.0 109.768 178.66 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 42' ' ' ARG . . . . . . . . . . . . . 2.9 ttt-85 -136.01 -42.3 0.66 Allowed 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.571 -0.706 . . . . 0.0 111.247 -179.708 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 1.3 mm-40 -57.95 131.58 50.85 Favored 'General case' 0 N--CA 1.498 1.937 0 O-C-N 121.381 -0.824 . . . . 0.0 110.462 -179.707 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -142.3 -46.7 0.05 OUTLIER Glycine 0 N--CA 1.498 2.789 0 N-CA-C 110.028 -1.229 . . . . 0.0 110.028 -179.641 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 45' ' ' GLN . . . . . . . . . . . . . 5.7 mm-40 . . . . . 0 N--CA 1.496 1.862 0 O-C-N 121.261 -1.14 . . . . 0.0 110.682 -179.985 . . . . . . . . 0 0 . 1 . 003 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.494 1.73 0 N-CA-C 109.468 -0.567 . . . . 0.0 109.468 . . . . . . . . . 0 0 . 1 . 003 nuclear build full ' A' A ' 2' ' ' LEU . . . . . 0.482 HD13 ' HA ' ' A' ' 2' ' ' LEU . 0.8 OUTLIER 60.61 93.27 0.04 OUTLIER 'General case' 0 N--CA 1.505 2.284 0 O-C-N 121.688 -0.633 . . . . 0.0 110.794 179.991 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -57.8 112.73 1.57 Allowed 'General case' 0 N--CA 1.497 1.904 0 O-C-N 121.35 -0.844 . . . . 0.0 110.302 179.903 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 4' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -161.12 -56.63 0.05 Allowed 'General case' 0 N--CA 1.492 1.654 0 O-C-N 121.424 -0.797 . . . . 0.0 110.302 -179.867 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 9.5 t -135.14 90.48 21.16 Favored Pre-proline 0 N--CA 1.497 1.897 0 O-C-N 121.462 -0.774 . . . . 0.0 109.506 179.897 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 6' ' ' PRO . . . . . . . . . . . . . 48.9 Cg_endo -73.42 -21.13 20.08 Favored 'Trans proline' 0 C--N 1.312 -1.39 0 O-C-N 124.089 1.573 . . . . 0.0 111.949 -179.508 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -74.58 -40.21 39.2 Favored Glycine 0 N--CA 1.496 2.636 0 N-CA-C 110.386 -1.086 . . . . 0.0 110.386 -179.169 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 31.1 p -85.95 -174.61 5.19 Favored 'General case' 0 N--CA 1.498 1.943 0 O-C-N 121.168 -1.195 . . . . 0.0 110.881 -179.599 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -142.26 -135.11 3.05 Favored Glycine 0 N--CA 1.495 2.603 0 N-CA-C 109.854 -1.299 . . . . 0.0 109.854 -179.587 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 10' ' ' GLN . . . . . . . . . . . . . 4.2 mt-30 -80.62 41.37 0.55 Allowed 'General case' 0 N--CA 1.499 2.013 0 O-C-N 121.14 -1.212 . . . . 0.0 111.665 -179.566 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 80.49 -34.42 2.26 Favored Glycine 0 N--CA 1.497 2.714 0 O-C-N 120.718 -1.239 . . . . 0.0 111.224 179.445 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 16.9 m -130.66 60.98 0.3 Allowed 'Isoleucine or valine' 0 N--CA 1.498 1.933 0 O-C-N 121.056 -1.261 . . . . 0.0 110.867 -179.354 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 13' ' ' GLN . . . . . . . . . . . . . 0.6 OUTLIER -124.06 94.64 4.28 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.323 -0.86 . . . . 0.0 109.607 179.754 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -150.84 161.85 41.88 Favored 'General case' 0 N--CA 1.495 1.814 0 CA-C-O 121.539 0.685 . . . . 0.0 111.3 -179.553 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -144.61 -57.68 0.02 OUTLIER Glycine 0 N--CA 1.498 2.801 0 N-CA-C 108.427 -1.869 . . . . 0.0 108.427 179.378 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 0.8 OUTLIER -121.78 79.0 39.98 Favored Pre-proline 0 N--CA 1.499 1.988 0 N-CA-C 108.602 -0.888 . . . . 0.0 108.602 178.482 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 40.6 Cg_endo -66.89 -24.29 46.43 Favored 'Trans proline' 0 N--CA 1.49 1.319 0 C-N-CA 121.288 1.325 . . . . 0.0 112.246 -178.359 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . -96.06 19.43 54.5 Favored Glycine 0 N--CA 1.496 2.666 0 N-CA-C 109.973 -1.251 . . . . 0.0 109.973 179.821 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 114.94 141.56 7.55 Favored Glycine 0 N--CA 1.487 2.064 0 N-CA-C 108.528 -1.829 . . . . 0.0 108.528 179.842 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 36.3 m -109.39 167.48 10.09 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.28 -1.13 . . . . 0.0 109.792 179.889 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 21' ' ' VAL . . . . . 0.411 HG13 ' CB ' ' A' ' 25' ' ' ASP . 14.5 t -79.18 65.0 0.31 Allowed 'Isoleucine or valine' 0 N--CA 1.494 1.77 0 O-C-N 121.28 -0.887 . . . . 0.0 110.296 -179.801 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -96.14 -31.98 12.72 Favored 'General case' 0 N--CA 1.489 1.494 0 O-C-N 121.21 -0.931 . . . . 0.0 110.099 179.299 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 4.9 mm-40 -94.49 55.22 1.93 Allowed 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.184 -0.948 . . . . 0.0 110.437 -179.49 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 3.0 mm-40 39.09 68.36 0.36 Allowed 'General case' 0 N--CA 1.496 1.837 0 CA-C-O 121.616 0.722 . . . . 0.0 112.026 179.498 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 25' ' ' ASP . . . . . 0.411 ' CB ' HG13 ' A' ' 21' ' ' VAL . 0.7 OUTLIER -89.88 -9.94 47.12 Favored 'General case' 0 N--CA 1.497 1.909 0 O-C-N 121.155 -0.966 . . . . 0.0 110.276 178.85 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 90.25 -67.08 2.63 Favored Glycine 0 N--CA 1.494 2.51 0 N-CA-C 109.068 -1.613 . . . . 0.0 109.068 -179.053 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 67.91 176.55 10.28 Favored Glycine 0 N--CA 1.496 2.681 0 N-CA-C 110.234 -1.146 . . . . 0.0 110.234 179.516 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 1.9 t -111.37 94.41 22.19 Favored Pre-proline 0 N--CA 1.496 1.836 0 O-C-N 121.315 -1.109 . . . . 0.0 109.773 179.655 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 44.4 Cg_endo -71.91 110.1 2.83 Favored 'Trans proline' 0 C--N 1.315 -1.229 0 O-C-N 123.832 1.438 . . . . 0.0 110.728 -179.583 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -79.26 -54.15 6.25 Favored 'General case' 0 N--CA 1.492 1.646 0 O-C-N 121.264 -0.897 . . . . 0.0 110.364 -179.985 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 6.8 tt0 -90.24 16.52 8.47 Favored 'General case' 0 N--CA 1.492 1.665 0 O-C-N 121.073 -1.017 . . . . 0.0 111.002 179.702 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . -87.17 35.96 3.37 Favored Glycine 0 N--CA 1.492 2.431 0 N-CA-C 109.502 -1.439 . . . . 0.0 109.502 179.555 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 33' ' ' CYS . . . . . 0.471 ' HA ' ' O ' ' A' ' 38' ' ' GLY . 0.5 OUTLIER -114.28 22.08 14.08 Favored 'General case' 0 N--CA 1.494 1.746 0 O-C-N 121.497 -1.001 . . . . 0.0 110.646 179.328 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -152.24 46.48 0.75 Allowed 'General case' 0 N--CA 1.498 1.965 0 O-C-N 121.058 -1.026 . . . . 0.0 110.604 -179.722 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 7.6 pt-20 -128.73 -157.44 0.82 Allowed 'General case' 0 N--CA 1.499 2.002 0 O-C-N 121.51 -0.744 . . . . 0.0 110.253 179.856 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 36' ' ' ALA . . . . . . . . . . . . . . . -77.83 -23.64 48.9 Favored 'General case' 0 N--CA 1.499 1.985 0 O-C-N 121.242 -0.911 . . . . 0.0 110.448 -179.652 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER -79.5 -33.74 41.87 Favored 'General case' 0 N--CA 1.492 1.654 0 O-C-N 121.16 -0.962 . . . . 0.0 109.819 179.547 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 38' ' ' GLY . . . . . 0.471 ' O ' ' HA ' ' A' ' 33' ' ' CYS . . . 107.88 -97.09 1.1 Allowed Glycine 0 N--CA 1.492 2.421 0 N-CA-C 109.113 -1.595 . . . . 0.0 109.113 179.847 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 39' ' ' CYS . . . . . . . . . . . . . 1.8 t -160.81 115.04 2.1 Favored 'General case' 0 N--CA 1.498 1.957 0 O-C-N 121.637 -0.919 . . . . 0.0 109.687 179.435 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 40' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -89.95 117.35 28.69 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.152 -0.968 . . . . 0.0 110.908 -179.334 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 41' ' ' ARG . . . . . . . . . . . . . 4.4 tpt85 -172.24 92.7 0.13 Allowed 'General case' 0 N--CA 1.493 1.69 0 O-C-N 121.41 -0.806 . . . . 0.0 109.438 179.488 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 42' ' ' ARG . . . . . . . . . . . . . 6.8 ttt180 -174.44 -50.88 0.01 OUTLIER 'General case' 0 N--CA 1.497 1.895 0 O-C-N 121.557 -0.714 . . . . 0.0 110.844 179.955 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 1.8 tt0 57.08 -163.8 0.17 Allowed 'General case' 0 N--CA 1.497 1.896 0 CA-C-O 121.273 0.558 . . . . 0.0 110.383 -179.582 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -123.04 27.46 5.87 Favored Glycine 0 N--CA 1.495 2.63 0 N-CA-C 108.987 -1.645 . . . . 0.0 108.987 179.65 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 45' ' ' GLN . . . . . . . . . . . . . 2.9 mt-30 . . . . . 0 N--CA 1.494 1.758 0 CA-C-O 117.851 -1.071 . . . . 0.0 109.597 -179.754 . . . . . . . . 0 0 . 1 . 004 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.493 1.705 0 N-CA-C 110.013 -0.366 . . . . 0.0 110.013 . . . . . . . . . 0 0 . 1 . 004 nuclear build full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER 54.74 44.43 28.53 Favored 'General case' 0 N--CA 1.504 2.261 0 O-C-N 121.683 -0.636 . . . . 0.0 110.596 -179.987 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -134.96 117.16 15.49 Favored 'General case' 0 N--CA 1.484 1.268 0 O-C-N 121.225 -0.922 . . . . 0.0 110.529 179.899 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 4' ' ' ARG . . . . . . . . . . . . . 2.3 ptp85 -163.29 140.36 7.42 Favored 'General case' 0 N--CA 1.489 1.478 0 O-C-N 121.576 -0.703 . . . . 0.0 109.719 179.307 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -146.13 118.74 5.08 Favored Pre-proline 0 N--CA 1.496 1.854 0 O-C-N 121.249 -0.907 . . . . 0.0 110.074 -179.653 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 6' ' ' PRO . . . . . . . . . . . . . 44.6 Cg_endo -74.74 -50.99 0.13 Allowed 'Trans proline' 0 C--N 1.314 -1.268 0 O-C-N 123.665 1.35 . . . . 0.0 111.102 -179.64 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -78.03 58.38 3.94 Favored Glycine 0 N--CA 1.494 2.559 0 N-CA-C 109.736 -1.346 . . . . 0.0 109.736 179.992 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 1.1 m -114.49 3.22 14.85 Favored 'General case' 0 N--CA 1.492 1.672 0 O-C-N 121.271 -1.135 . . . . 0.0 111.349 -179.938 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 9' ' ' GLY . . . . . 0.428 ' O ' ' HB2' ' A' ' 10' ' ' GLN . . . -80.18 57.36 4.63 Favored Glycine 0 N--CA 1.494 2.534 0 N-CA-C 109.894 -1.282 . . . . 0.0 109.894 179.598 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 10' ' ' GLN . . . . . 0.428 ' HB2' ' O ' ' A' ' 9' ' ' GLY . 5.6 tt0 -178.56 -63.4 0.01 OUTLIER 'General case' 0 N--CA 1.494 1.769 0 O-C-N 121.466 -1.02 . . . . 0.0 109.994 179.787 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -85.07 62.97 4.45 Favored Glycine 0 N--CA 1.491 2.346 0 N-CA-C 110.018 -1.233 . . . . 0.0 110.018 -179.867 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 12' ' ' VAL . . . . . 0.478 HG13 ' N ' ' A' ' 13' ' ' GLN . 7.5 p -146.37 -47.24 0.11 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.652 0 O-C-N 121.467 -1.019 . . . . 0.0 110.413 179.602 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 13' ' ' GLN . . . . . 0.478 ' N ' HG13 ' A' ' 12' ' ' VAL . 20.4 tt0 -175.04 -55.07 0.01 OUTLIER 'General case' 0 N--CA 1.497 1.9 0 O-C-N 121.36 -0.838 . . . . 0.0 109.6 179.521 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -117.04 -178.26 3.4 Favored 'General case' 0 N--CA 1.496 1.825 0 O-C-N 121.788 -0.57 . . . . 0.0 110.216 179.789 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -85.03 -35.21 12.87 Favored Glycine 0 N--CA 1.496 2.65 0 N-CA-C 110.378 -1.089 . . . . 0.0 110.378 -179.581 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 0.0 OUTLIER -113.45 132.85 22.31 Favored Pre-proline 0 N--CA 1.5 2.027 0 O-C-N 121.332 -1.099 . . . . 0.0 109.67 179.702 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 47.4 Cg_endo -74.29 58.67 4.44 Favored 'Trans proline' 0 C--N 1.31 -1.488 0 O-C-N 123.72 1.379 . . . . 0.0 111.072 -179.731 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 92.9 92.85 1.48 Allowed Glycine 0 N--CA 1.495 2.579 0 N-CA-C 110.167 -1.173 . . . . 0.0 110.167 179.336 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 106.71 113.1 3.75 Favored Glycine 0 N--CA 1.49 2.298 0 N-CA-C 110.128 -1.189 . . . . 0.0 110.128 179.345 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 20' ' ' CYS . . . . . 0.477 ' O ' ' HB3' ' A' ' 25' ' ' ASP . 36.9 m -122.27 -12.99 8.18 Favored 'General case' 0 N--CA 1.502 2.166 0 O-C-N 121.521 -0.988 . . . . 0.0 111.285 179.818 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 21' ' ' VAL . . . . . 0.586 HG12 ' CA ' ' A' ' 27' ' ' GLY . 18.5 m -80.36 18.91 0.18 Allowed 'Isoleucine or valine' 0 N--CA 1.504 2.239 0 O-C-N 120.865 -1.147 . . . . 0.0 111.848 -179.562 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 5.0 mm-40 -79.67 -19.88 47.97 Favored 'General case' 0 N--CA 1.486 1.357 0 O-C-N 120.84 -1.163 . . . . 0.0 110.884 179.836 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -139.18 55.35 1.7 Allowed 'General case' 0 N--CA 1.491 1.591 0 O-C-N 120.891 -1.131 . . . . 0.0 110.259 179.956 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 24' ' ' GLU . . . . . 0.545 ' HG3' ' HB2' ' A' ' 28' ' ' SER . 0.8 OUTLIER 53.09 31.15 10.75 Favored 'General case' 0 N--CA 1.506 2.362 0 O-C-N 121.92 -0.487 . . . . 0.0 112.013 179.473 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 25' ' ' ASP . . . . . 0.477 ' HB3' ' O ' ' A' ' 20' ' ' CYS . 21.2 t70 -106.27 115.38 30.12 Favored 'General case' 0 N--CA 1.496 1.834 0 O-C-N 120.866 -1.146 . . . . 0.0 109.661 179.715 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 77.22 -56.07 3.63 Favored Glycine 0 N--CA 1.492 2.382 0 N-CA-C 110.559 -1.016 . . . . 0.0 110.559 179.594 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 27' ' ' GLY . . . . . 0.586 ' CA ' HG12 ' A' ' 21' ' ' VAL . . . -55.97 -54.34 35.97 Favored Glycine 0 N--CA 1.494 2.56 0 N-CA-C 110.27 -1.132 . . . . 0.0 110.27 -178.964 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 28' ' ' SER . . . . . 0.545 ' HB2' ' HG3' ' A' ' 24' ' ' GLU . 1.4 m -113.83 77.3 3.52 Favored Pre-proline 0 N--CA 1.497 1.893 0 O-C-N 121.742 -0.858 . . . . 0.0 110.696 -179.368 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 54.7 Cg_endo -79.86 114.32 3.15 Favored 'Trans proline' 0 C--N 1.314 -1.282 0 O-C-N 123.234 1.123 . . . . 0.0 110.028 179.602 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -77.2 -26.81 53.2 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 120.974 -1.079 . . . . 0.0 109.904 179.937 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 1.2 mt-10 -78.95 1.99 21.82 Favored 'General case' 0 N--CA 1.494 1.771 0 O-C-N 121.312 -0.867 . . . . 0.0 110.685 179.137 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . -99.28 35.8 4.46 Favored Glycine 0 N--CA 1.492 2.379 0 N-CA-C 110.04 -1.224 . . . . 0.0 110.04 179.904 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 33' ' ' CYS . . . . . . . . . . . . . 1.7 t -160.67 64.69 0.31 Allowed 'General case' 0 N--CA 1.494 1.764 0 O-C-N 121.268 -1.137 . . . . 0.0 110.3 179.739 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -78.64 -53.45 7.16 Favored 'General case' 0 N--CA 1.499 1.983 0 O-C-N 121.073 -1.017 . . . . 0.0 109.417 179.06 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 8.0 mt-10 -85.16 169.56 13.74 Favored 'General case' 0 N--CA 1.495 1.784 0 O-C-N 121.461 -0.774 . . . . 0.0 109.519 178.466 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 36' ' ' ALA . . . . . . . . . . . . . . . -78.18 -43.52 28.4 Favored 'General case' 0 N--CA 1.493 1.718 0 O-C-N 120.908 -1.12 . . . . 0.0 109.505 179.826 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 6.5 pt-20 -81.33 -28.22 34.64 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.309 -0.87 . . . . 0.0 110.194 179.458 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -74.3 71.17 1.53 Allowed Glycine 0 N--CA 1.491 2.324 0 N-CA-C 109.92 -1.272 . . . . 0.0 109.92 -179.881 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 39' ' ' CYS . . . . . 0.461 ' O ' ' HD3' ' A' ' 41' ' ' ARG . 0.6 OUTLIER -160.04 -47.76 0.05 Allowed 'General case' 0 C--N 1.296 -1.742 0 O-C-N 121.678 -0.895 . . . . 0.0 110.021 179.495 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 40' ' ' LEU . . . . . . . . . . . . . 17.0 mt 54.94 -124.59 2.16 Favored 'General case' 0 N--CA 1.5 2.061 0 O-C-N 121.6 -0.687 . . . . 0.0 110.595 179.368 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 41' ' ' ARG . . . . . 0.461 ' HD3' ' O ' ' A' ' 39' ' ' CYS . 2.9 mpp_? 54.44 47.73 22.17 Favored 'General case' 0 N--CA 1.501 2.119 0 O-C-N 121.408 -0.808 . . . . 0.0 110.454 -179.745 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 42' ' ' ARG . . . . . . . . . . . . . 1.2 ttp180 -160.14 41.18 0.19 Allowed 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.292 -0.88 . . . . 0.0 110.349 -179.948 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 29.7 mt-10 49.76 79.25 0.08 Allowed 'General case' 0 N--CA 1.502 2.162 0 CA-C-O 121.477 0.656 . . . . 0.0 111.172 179.841 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -122.28 78.14 0.34 Allowed Glycine 0 N--CA 1.488 2.153 0 N-CA-C 109.073 -1.611 . . . . 0.0 109.073 179.59 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 45' ' ' GLN . . . . . . . . . . . . . 4.0 mt-30 . . . . . 0 N--CA 1.503 2.186 0 CA-C-O 118.306 -0.854 . . . . 0.0 110.662 -179.333 . . . . . . . . 0 0 . 1 . 005 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.494 1.742 0 N-CA-C 109.724 -0.472 . . . . 0.0 109.724 . . . . . . . . . 0 0 . 1 . 005 nuclear build full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER -82.52 -162.5 0.58 Allowed 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.468 -0.77 . . . . 0.0 110.066 179.779 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -72.67 76.25 1.1 Allowed 'General case' 0 N--CA 1.492 1.643 0 O-C-N 121.272 -0.893 . . . . 0.0 110.729 -179.539 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 4' ' ' ARG . . . . . . . . . . . . . 3.6 mmm180 -83.75 -157.43 0.25 Allowed 'General case' 0 N--CA 1.494 1.746 0 O-C-N 121.406 -0.808 . . . . 0.0 109.483 179.394 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 2.2 t -113.62 85.73 9.58 Favored Pre-proline 0 N--CA 1.497 1.906 0 O-C-N 120.803 -1.186 . . . . 0.0 110.049 179.881 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 6' ' ' PRO . . . . . . . . . . . . . 50.5 Cg_endo -75.42 75.92 3.73 Favored 'Trans proline' 0 C--N 1.313 -1.326 0 O-C-N 123.964 1.507 . . . . 0.0 110.425 179.928 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 73.89 38.7 48.61 Favored Glycine 0 N--CA 1.498 2.798 0 N-CA-C 110.118 -1.193 . . . . 0.0 110.118 179.987 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 5.4 p -92.04 -159.84 0.69 Allowed 'General case' 0 N--CA 1.498 1.927 0 O-C-N 121.28 -1.13 . . . . 0.0 109.858 179.498 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -76.93 -93.89 0.21 Allowed Glycine 0 N--CA 1.495 2.579 0 N-CA-C 109.599 -1.4 . . . . 0.0 109.599 -179.978 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 10' ' ' GLN . . . . . . . . . . . . . 2.3 pt20 -169.58 85.72 0.14 Allowed 'General case' 0 N--CA 1.493 1.722 0 O-C-N 121.221 -1.164 . . . . 0.0 109.885 179.656 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -75.64 60.01 2.92 Favored Glycine 0 N--CA 1.497 2.7 0 N-CA-C 109.932 -1.267 . . . . 0.0 109.932 -179.809 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 12' ' ' VAL . . . . . 0.445 ' O ' HG13 ' A' ' 12' ' ' VAL . 14.2 p -146.26 52.57 0.11 Allowed 'Isoleucine or valine' 0 N--CA 1.495 1.783 0 O-C-N 121.537 -0.978 . . . . 0.0 109.537 -179.933 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 13' ' ' GLN . . . . . . . . . . . . . 4.5 tt0 -58.93 -55.4 35.57 Favored 'General case' 0 N--CA 1.5 2.027 0 O-C-N 121.125 -0.984 . . . . 0.0 110.851 -179.733 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -83.54 66.44 8.93 Favored 'General case' 0 N--CA 1.498 1.939 0 O-C-N 121.143 -0.973 . . . . 0.0 110.185 -179.775 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -72.58 -67.1 1.9 Allowed Glycine 0 N--CA 1.494 2.534 0 N-CA-C 109.78 -1.328 . . . . 0.0 109.78 -179.748 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 1.2 p -127.89 74.51 78.69 Favored Pre-proline 0 N--CA 1.497 1.88 0 O-C-N 121.788 -0.83 . . . . 0.0 110.45 179.608 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 43.8 Cg_endo -68.72 131.01 21.75 Favored 'Trans proline' 0 C--N 1.309 -1.523 0 O-C-N 123.462 1.243 . . . . 0.0 110.36 -179.978 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 100.89 -24.36 32.28 Favored Glycine 0 N--CA 1.493 2.453 0 N-CA-C 110.54 -1.024 . . . . 0.0 110.54 179.916 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 165.81 138.52 2.44 Favored Glycine 0 N--CA 1.489 2.177 0 N-CA-C 108.943 -1.663 . . . . 0.0 108.943 179.599 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 71.6 m -118.36 112.74 20.4 Favored 'General case' 0 N--CA 1.492 1.672 0 O-C-N 121.492 -1.005 . . . . 0.0 110.009 179.788 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 21' ' ' VAL . . . . . 0.423 ' O ' HG13 ' A' ' 21' ' ' VAL . 7.2 p -92.89 43.63 0.08 OUTLIER 'Isoleucine or valine' 0 N--CA 1.504 2.232 0 O-C-N 121.282 -0.886 . . . . 0.0 110.481 -179.608 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 2.1 mm-40 -79.45 -28.08 41.62 Favored 'General case' 0 N--CA 1.488 1.457 0 O-C-N 121.029 -1.044 . . . . 0.0 110.931 -179.908 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 1.3 tp10 -162.29 110.87 1.4 Allowed 'General case' 0 N--CA 1.493 1.685 0 O-C-N 121.018 -1.052 . . . . 0.0 110.328 179.852 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 2.3 tt0 -148.23 153.29 38.54 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 121.487 -0.758 . . . . 0.0 110.165 179.104 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -96.67 -54.41 3.24 Favored 'General case' 0 N--CA 1.497 1.888 0 O-C-N 121.75 -0.594 . . . . 0.0 110.183 -179.677 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -156.25 94.34 0.14 Allowed Glycine 0 N--CA 1.494 2.549 0 N-CA-C 108.723 -1.751 . . . . 0.0 108.723 -179.891 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -55.81 96.72 0.04 OUTLIER Glycine 0 N--CA 1.498 2.826 0 N-CA-C 110.567 -1.013 . . . . 0.0 110.567 -179.422 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 28' ' ' SER . . . . . 0.531 ' CB ' ' HD3' ' A' ' 29' ' ' PRO . 1.6 t -160.75 -65.51 0.02 OUTLIER Pre-proline 0 N--CA 1.496 1.849 0 O-C-N 121.334 -1.098 . . . . 0.0 109.586 179.615 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 29' ' ' PRO . . . . . 0.531 ' HD3' ' CB ' ' A' ' 28' ' ' SER . 51.8 Cg_endo -78.26 72.14 6.41 Favored 'Trans proline' 0 N--CA 1.486 1.048 0 O-C-N 123.205 1.108 . . . . 0.0 109.863 178.742 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 30' ' ' ALA . . . . . 0.406 ' O ' ' HB3' ' A' ' 34' ' ' ALA . . . -79.64 -64.26 1.23 Allowed 'General case' 0 N--CA 1.493 1.701 0 O-C-N 121.349 -0.844 . . . . 0.0 111.212 -179.065 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 3.5 tt0 -117.78 -22.99 7.73 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.038 -1.039 . . . . 0.0 111.381 -179.224 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . -52.04 -41.57 53.08 Favored Glycine 0 N--CA 1.498 2.821 0 O-C-N 120.99 -1.069 . . . . 0.0 110.915 -179.193 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 33' ' ' CYS . . . . . . . . . . . . . 0.8 OUTLIER -149.59 62.69 1.01 Allowed 'General case' 0 N--CA 1.496 1.858 0 O-C-N 121.159 -1.2 . . . . 0.0 110.381 179.78 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 34' ' ' ALA . . . . . 0.406 ' HB3' ' O ' ' A' ' 30' ' ' ALA . . . -141.5 34.06 1.65 Allowed 'General case' 0 N--CA 1.498 1.952 0 O-C-N 121.257 -0.902 . . . . 0.0 110.367 179.882 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -111.15 -168.7 1.34 Allowed 'General case' 0 N--CA 1.496 1.863 0 O-C-N 121.376 -0.827 . . . . 0.0 109.776 179.693 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 36' ' ' ALA . . . . . . . . . . . . . . . -78.66 -24.65 45.06 Favored 'General case' 0 N--CA 1.5 2.037 0 O-C-N 121.508 -0.745 . . . . 0.0 110.324 179.985 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 4.9 tt0 -80.06 -46.83 15.84 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.519 -0.738 . . . . 0.0 109.697 179.769 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 106.42 -112.71 3.92 Favored Glycine 0 N--CA 1.489 2.184 0 N-CA-C 109.688 -1.365 . . . . 0.0 109.688 179.792 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 39' ' ' CYS . . . . . 0.479 ' O ' ' HG3' ' A' ' 42' ' ' ARG . 1.6 m -144.81 -47.14 0.24 Allowed 'General case' 0 N--CA 1.501 2.114 0 O-C-N 121.408 -1.054 . . . . 0.0 110.715 -179.633 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 40' ' ' LEU . . . . . . . . . . . . . 0.7 OUTLIER 42.14 39.11 1.28 Allowed 'General case' 0 N--CA 1.505 2.311 0 O-C-N 121.518 -0.739 . . . . 0.0 111.892 179.731 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 41' ' ' ARG . . . . . . . . . . . . . 1.6 ttt-85 54.02 34.97 20.96 Favored 'General case' 0 N--CA 1.504 2.247 0 O-C-N 121.34 -0.85 . . . . 0.0 111.755 179.079 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 42' ' ' ARG . . . . . 0.479 ' HG3' ' O ' ' A' ' 39' ' ' CYS . 4.9 mtm180 -58.0 -33.82 69.34 Favored 'General case' 0 N--CA 1.505 2.297 0 O-C-N 121.273 -0.892 . . . . 0.0 111.01 179.845 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 1.8 tt0 63.69 -175.81 0.16 Allowed 'General case' 0 N--CA 1.499 2.021 0 O-C-N 121.712 -0.617 . . . . 0.0 110.483 -179.422 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 77.08 46.76 9.95 Favored Glycine 0 N--CA 1.498 2.777 0 N-CA-C 109.342 -1.503 . . . . 0.0 109.342 -179.577 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 45' ' ' GLN . . . . . . . . . . . . . 10.3 mt-30 . . . . . 0 N--CA 1.491 1.613 0 O-C-N 121.195 -1.179 . . . . 0.0 110.384 179.92 . . . . . . . . 0 0 . 1 . 006 nuclear build full ' A' A ' 1' ' ' ALA . . . . . 0.409 ' O ' ' HB2' ' A' ' 2' ' ' LEU . . . . . . . . 0 N--CA 1.491 1.583 0 N-CA-C 109.569 -0.53 . . . . 0.0 109.569 . . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 2' ' ' LEU . . . . . 0.467 HD13 ' HA ' ' A' ' 2' ' ' LEU . 3.9 mm? 59.57 -170.72 0.13 Allowed 'General case' 0 N--CA 1.504 2.25 0 O-C-N 121.939 -0.476 . . . . 0.0 110.13 -179.815 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -152.15 -84.67 0.08 Allowed 'General case' 0 N--CA 1.489 1.482 0 O-C-N 121.148 -0.97 . . . . 0.0 110.463 179.783 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 4' ' ' ARG . . . . . . . . . . . . . 14.6 mtm-85 47.05 37.31 5.0 Favored 'General case' 0 N--CA 1.503 2.194 0 O-C-N 121.372 -0.83 . . . . 0.0 111.292 -179.748 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 22.9 p -102.43 118.76 58.04 Favored Pre-proline 0 N--CA 1.494 1.763 0 O-C-N 121.048 -1.032 . . . . 0.0 109.376 178.868 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 6' ' ' PRO . . . . . . . . . . . . . 42.0 Cg_endo -70.97 -53.26 0.2 Allowed 'Trans proline' 0 C--N 1.311 -1.412 0 O-C-N 123.685 1.36 . . . . 0.0 111.778 -178.988 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -108.89 59.45 0.36 Allowed Glycine 0 N--CA 1.492 2.371 0 O-C-N 120.917 -1.114 . . . . 0.0 110.859 -179.045 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 10.5 p -110.02 -35.68 6.06 Favored 'General case' 0 N--CA 1.5 2.034 0 O-C-N 121.264 -1.139 . . . . 0.0 110.693 179.355 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 49.4 32.19 14.57 Favored Glycine 0 N--CA 1.502 3.056 0 O-C-N 121.337 -0.852 . . . . 0.0 111.478 179.441 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 10' ' ' GLN . . . . . . . . . . . . . 69.8 mt-30 49.63 43.72 24.27 Favored 'General case' 0 N--CA 1.501 2.08 0 O-C-N 121.304 -1.115 . . . . 0.0 110.904 179.691 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -48.27 -50.06 23.88 Favored Glycine 0 N--CA 1.503 3.155 0 N-CA-C 110.619 -0.992 . . . . 0.0 110.619 -179.707 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 12' ' ' VAL . . . . . 0.51 ' O ' HG13 ' A' ' 12' ' ' VAL . 11.2 p -127.82 53.75 0.37 Allowed 'Isoleucine or valine' 0 N--CA 1.494 1.728 0 O-C-N 121.312 -1.111 . . . . 0.0 109.759 179.81 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 13' ' ' GLN . . . . . . . . . . . . . 1.6 pt20 -71.02 142.76 50.91 Favored 'General case' 0 N--CA 1.495 1.795 0 O-C-N 121.01 -1.057 . . . . 0.0 110.321 -179.891 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -122.75 131.89 53.98 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.321 -0.862 . . . . 0.0 109.858 179.805 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -73.36 -54.15 7.05 Favored Glycine 0 N--CA 1.491 2.314 0 N-CA-C 109.662 -1.375 . . . . 0.0 109.662 -179.976 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 12.2 m -114.3 122.0 35.18 Favored Pre-proline 0 N--CA 1.499 1.992 0 O-C-N 121.295 -1.12 . . . . 0.0 109.996 -179.94 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 43.6 Cg_endo -72.11 75.38 2.3 Favored 'Trans proline' 0 N--CA 1.497 1.692 0 O-C-N 123.611 1.322 . . . . 0.0 110.789 -179.69 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 127.14 -46.02 1.11 Allowed Glycine 0 N--CA 1.495 2.571 0 N-CA-C 109.659 -1.376 . . . . 0.0 109.659 179.879 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 161.5 147.33 4.94 Favored Glycine 0 N--CA 1.484 1.884 0 N-CA-C 109.321 -1.512 . . . . 0.0 109.321 -179.318 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 0.9 OUTLIER -106.22 172.2 6.94 Favored 'General case' 0 C--N 1.296 -1.746 0 O-C-N 121.534 -0.98 . . . . 0.0 109.647 -179.811 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 10.5 t -78.71 61.33 0.17 Allowed 'Isoleucine or valine' 0 N--CA 1.498 1.936 0 O-C-N 121.35 -0.844 . . . . 0.0 109.781 179.527 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 3.0 mm-40 -131.24 37.49 3.72 Favored 'General case' 0 C--N 1.306 -1.305 0 O-C-N 121.585 -0.697 . . . . 0.0 109.661 -179.717 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 48.2 mt-10 -68.5 167.11 15.54 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.308 -0.87 . . . . 0.0 110.874 -179.236 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 2.8 pm0 -70.91 158.9 35.65 Favored 'General case' 0 N--CA 1.495 1.794 0 O-C-N 121.733 -0.605 . . . . 0.0 111.18 -179.014 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -80.3 -65.46 1.0 Allowed 'General case' 0 N--CA 1.491 1.597 0 N-CA-C 109.376 -0.602 . . . . 0.0 109.376 179.212 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 174.74 84.57 0.06 OUTLIER Glycine 0 N--CA 1.494 2.507 0 N-CA-C 109.535 -1.426 . . . . 0.0 109.535 179.853 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 149.16 128.3 1.66 Allowed Glycine 0 N--CA 1.493 2.464 0 N-CA-C 109.268 -1.533 . . . . 0.0 109.268 179.944 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -93.39 150.73 39.47 Favored Pre-proline 0 N--CA 1.495 1.818 0 O-C-N 121.559 -0.965 . . . . 0.0 110.444 -179.507 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 29' ' ' PRO . . . . . 0.487 ' HA ' ' HB3' ' A' ' 33' ' ' CYS . 52.4 Cg_endo -79.55 14.19 1.89 Allowed 'Trans proline' 0 N--CA 1.486 1.083 0 O-C-N 123.833 1.439 . . . . 0.0 111.784 179.81 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -127.55 15.18 7.08 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.049 -1.032 . . . . 0.0 110.394 179.585 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -159.84 -75.58 0.07 Allowed 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.458 -0.776 . . . . 0.0 109.613 -179.638 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . -66.97 -56.51 12.27 Favored Glycine 0 N--CA 1.496 2.646 0 N-CA-C 109.284 -1.526 . . . . 0.0 109.284 179.699 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 33' ' ' CYS . . . . . 0.487 ' HB3' ' HA ' ' A' ' 29' ' ' PRO . 5.5 t -87.24 73.83 9.63 Favored 'General case' 0 N--CA 1.497 1.895 0 O-C-N 121.358 -1.084 . . . . 0.0 109.891 179.766 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -147.86 49.24 1.07 Allowed 'General case' 0 N--CA 1.495 1.793 0 O-C-N 121.495 -0.753 . . . . 0.0 110.063 179.831 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 12.0 mt-10 -108.51 -174.35 2.5 Favored 'General case' 0 N--CA 1.494 1.762 0 O-C-N 121.467 -0.771 . . . . 0.0 110.69 -179.862 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 36' ' ' ALA . . . . . . . . . . . . . . . -89.97 -1.96 58.07 Favored 'General case' 0 N--CA 1.499 2.006 0 O-C-N 121.294 -0.879 . . . . 0.0 111.501 179.89 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -117.81 31.89 6.45 Favored 'General case' 0 N--CA 1.493 1.689 0 O-C-N 121.297 -0.877 . . . . 0.0 110.856 179.922 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 67.3 -118.1 9.75 Favored Glycine 0 N--CA 1.49 2.252 0 N-CA-C 109.661 -1.376 . . . . 0.0 109.661 179.607 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 39' ' ' CYS . . . . . 0.539 ' C ' HD13 ' A' ' 40' ' ' LEU . 0.1 OUTLIER -153.7 24.51 0.51 Allowed 'General case' 0 N--CA 1.499 2.006 0 O-C-N 121.522 -0.987 . . . . 0.0 111.292 -179.969 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 40' ' ' LEU . . . . . 0.76 HD22 ' H ' ' A' ' 40' ' ' LEU . 0.0 OUTLIER -140.9 172.75 12.26 Favored 'General case' 0 N--CA 1.493 1.715 0 O-C-N 120.888 -1.132 . . . . 0.0 110.496 179.083 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 41' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER 46.72 37.03 4.2 Favored 'General case' 0 N--CA 1.503 2.205 0 O-C-N 121.428 -0.795 . . . . 0.0 110.961 -179.98 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 42' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -95.19 50.16 1.25 Allowed 'General case' 0 N--CA 1.489 1.483 0 O-C-N 120.983 -1.073 . . . . 0.0 110.102 179.634 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 43' ' ' GLU . . . . . 0.402 ' H ' ' HG3' ' A' ' 43' ' ' GLU . 0.9 OUTLIER -139.13 155.66 47.71 Favored 'General case' 0 C--N 1.305 -1.348 0 O-C-N 121.865 -0.522 . . . . 0.0 109.849 179.913 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -154.43 42.05 0.61 Allowed Glycine 0 N--CA 1.5 2.914 0 N-CA-C 109.341 -1.503 . . . . 0.0 109.341 179.437 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 45' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.495 1.8 0 O-C-N 121.467 -1.019 . . . . 0.0 109.951 179.91 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.484 1.237 0 N-CA-C 109.594 -0.521 . . . . 0.0 109.594 . . . . . . . . . 0 0 . 1 . 007 nuclear build full ' A' A ' 2' ' ' LEU . . . . . 0.487 ' O ' ' HB3' ' A' ' 3' ' ' ALA . 2.1 tp 58.96 84.01 0.12 Allowed 'General case' 0 N--CA 1.507 2.397 0 CA-C-O 121.286 0.565 . . . . 0.0 111.308 179.776 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 3' ' ' ALA . . . . . 0.487 ' HB3' ' O ' ' A' ' 2' ' ' LEU . . . 61.91 177.23 0.13 Allowed 'General case' 0 N--CA 1.503 2.187 0 O-C-N 121.668 -0.645 . . . . 0.0 111.436 179.61 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 4' ' ' ARG . . . . . 0.407 ' HB2' ' O ' ' A' ' 3' ' ' ALA . 16.9 tpt180 -177.8 -57.66 0.01 OUTLIER 'General case' 0 N--CA 1.497 1.906 0 O-C-N 121.672 -0.642 . . . . 0.0 110.056 179.373 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 0.8 OUTLIER -134.56 86.98 33.07 Favored Pre-proline 0 N--CA 1.492 1.659 0 O-C-N 120.904 -1.122 . . . . 0.0 110.013 -179.964 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 6' ' ' PRO . . . . . . . . . . . . . 39.3 Cg_endo -66.93 96.46 0.37 Allowed 'Trans proline' 0 C--N 1.303 -1.823 0 O-C-N 124.835 1.966 . . . . 0.0 111.241 -179.78 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 90.35 13.17 60.44 Favored Glycine 0 N--CA 1.493 2.499 0 C-N-CA 120.292 -0.956 . . . . 0.0 111.123 179.187 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 3.7 p -143.72 171.66 13.89 Favored 'General case' 0 N--CA 1.495 1.802 0 O-C-N 120.425 -1.633 . . . . 0.0 110.134 179.614 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 97.55 122.27 4.4 Favored Glycine 0 N--CA 1.494 2.511 0 N-CA-C 108.847 -1.701 . . . . 0.0 108.847 -179.147 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 10' ' ' GLN . . . . . . . . . . . . . 2.2 mt-30 -81.7 49.44 1.34 Allowed 'General case' 0 N--CA 1.494 1.743 0 O-C-N 121.156 -1.202 . . . . 0.0 110.922 -179.483 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -92.67 58.34 2.58 Favored Glycine 0 N--CA 1.495 2.599 0 N-CA-C 108.947 -1.661 . . . . 0.0 108.947 179.453 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 10.7 t -130.21 63.08 0.3 Allowed 'Isoleucine or valine' 0 N--CA 1.496 1.873 0 O-C-N 121.551 -0.97 . . . . 0.0 109.734 -179.674 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 13' ' ' GLN . . . . . . . . . . . . . 2.2 tt0 -121.01 102.95 8.67 Favored 'General case' 0 N--CA 1.487 1.408 0 O-C-N 121.245 -0.909 . . . . 0.0 109.748 179.816 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -134.7 -73.81 0.47 Allowed 'General case' 0 N--CA 1.492 1.675 0 O-C-N 121.941 -0.475 . . . . 0.0 109.826 179.993 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 136.46 -58.47 0.66 Allowed Glycine 0 N--CA 1.495 2.608 0 N-CA-C 109.537 -1.425 . . . . 0.0 109.537 179.966 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 10.1 m -79.49 148.63 70.37 Favored Pre-proline 0 N--CA 1.5 2.043 0 O-C-N 121.387 -1.067 . . . . 0.0 109.651 179.848 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 41.1 Cg_endo -66.69 -26.57 45.68 Favored 'Trans proline' 0 N--CA 1.492 1.435 0 O-C-N 123.896 1.471 . . . . 0.0 111.414 -179.636 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 174.66 85.29 0.06 OUTLIER Glycine 0 N--CA 1.494 2.5 0 N-CA-C 109.436 -1.466 . . . . 0.0 109.436 179.802 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 94.76 142.29 12.49 Favored Glycine 0 N--CA 1.488 2.147 0 N-CA-C 109.529 -1.428 . . . . 0.0 109.529 -179.834 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 0.0 OUTLIER -142.4 110.24 5.85 Favored 'General case' 0 N--CA 1.497 1.901 0 O-C-N 121.645 -0.915 . . . . 0.0 109.62 179.602 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 3.7 t -98.51 46.7 0.11 Allowed 'Isoleucine or valine' 0 N--CA 1.497 1.901 0 O-C-N 121.645 -0.659 . . . . 0.0 110.214 -179.635 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 8.6 mt-10 -87.99 -25.62 23.05 Favored 'General case' 0 N--CA 1.488 1.459 0 O-C-N 121.307 -0.871 . . . . 0.0 110.501 179.671 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 0.9 OUTLIER 60.02 -159.96 0.3 Allowed 'General case' 0 N--CA 1.501 2.09 0 O-C-N 121.751 -0.593 . . . . 0.0 110.976 179.924 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -124.44 -154.1 0.59 Allowed 'General case' 0 N--CA 1.488 1.439 0 O-C-N 121.537 -0.727 . . . . 0.0 110.169 -179.558 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -84.96 143.98 28.62 Favored 'General case' 0 N--CA 1.494 1.765 0 O-C-N 121.282 -0.886 . . . . 0.0 110.233 -179.971 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -69.69 -16.64 72.26 Favored Glycine 0 N--CA 1.493 2.472 0 N-CA-C 109.986 -1.246 . . . . 0.0 109.986 178.926 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 115.96 -107.7 1.72 Allowed Glycine 0 N--CA 1.49 2.285 0 N-CA-C 109.286 -1.526 . . . . 0.0 109.286 179.843 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -113.01 91.7 19.04 Favored Pre-proline 0 N--CA 1.497 1.88 0 O-C-N 121.327 -1.102 . . . . 0.0 109.63 179.375 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 44.2 Cg_endo -73.42 118.22 5.41 Favored 'Trans proline' 0 N--CA 1.49 1.318 0 O-C-N 123.692 1.364 . . . . 0.0 110.955 179.959 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -121.34 34.19 5.28 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.164 -0.96 . . . . 0.0 110.716 179.664 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 31' ' ' GLU . . . . . 0.507 ' HG3' ' N ' ' A' ' 32' ' ' GLY . 0.1 OUTLIER -86.85 -32.02 20.49 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.025 -1.047 . . . . 0.0 110.168 179.873 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 32' ' ' GLY . . . . . 0.507 ' N ' ' HG3' ' A' ' 31' ' ' GLU . . . 137.41 -47.42 0.95 Allowed Glycine 0 N--CA 1.493 2.464 0 N-CA-C 110.22 -1.152 . . . . 0.0 110.22 179.623 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 33' ' ' CYS . . . . . . . . . . . . . 0.9 OUTLIER -113.72 92.21 3.9 Favored 'General case' 0 N--CA 1.493 1.675 0 O-C-N 121.582 -0.952 . . . . 0.0 110.881 -179.398 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -96.9 37.32 1.31 Allowed 'General case' 0 N--CA 1.499 1.976 0 O-C-N 121.138 -0.976 . . . . 0.0 109.863 179.211 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 10.8 mt-10 -137.48 -178.1 5.08 Favored 'General case' 0 N--CA 1.497 1.902 0 O-C-N 121.747 -0.596 . . . . 0.0 109.867 179.812 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 36' ' ' ALA . . . . . . . . . . . . . . . -88.75 35.69 0.79 Allowed 'General case' 0 N--CA 1.493 1.717 0 O-C-N 120.993 -1.067 . . . . 0.0 110.594 -179.819 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 5.6 tt0 -78.5 -26.91 46.04 Favored 'General case' 0 N--CA 1.486 1.347 0 O-C-N 121.39 -0.819 . . . . 0.0 110.076 179.666 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 70.22 70.83 1.1 Allowed Glycine 0 N--CA 1.492 2.379 0 N-CA-C 109.137 -1.585 . . . . 0.0 109.137 179.689 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 39' ' ' CYS . . . . . . . . . . . . . 1.8 m -100.89 110.08 22.11 Favored 'General case' 0 C--N 1.298 -1.665 0 O-C-N 121.733 -0.863 . . . . 0.0 109.793 -179.768 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 40' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -128.81 -64.29 0.93 Allowed 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.425 -0.797 . . . . 0.0 110.961 -179.794 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 41' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -156.62 -143.22 0.11 Allowed 'General case' 0 N--CA 1.488 1.469 0 O-C-N 121.053 -1.029 . . . . 0.0 109.878 -179.638 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 42' ' ' ARG . . . . . . . . . . . . . 1.8 mtt180 -75.13 17.46 0.24 Allowed 'General case' 0 N--CA 1.498 1.927 0 O-C-N 120.849 -1.157 . . . . 0.0 112.336 -179.767 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 3.4 mm-40 -77.95 76.44 4.48 Favored 'General case' 0 N--CA 1.494 1.773 0 O-C-N 120.499 -1.375 . . . . 0.0 109.326 179.51 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -85.96 71.55 2.83 Favored Glycine 0 N--CA 1.495 2.598 0 N-CA-C 110.397 -1.081 . . . . 0.0 110.397 -179.155 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 45' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.498 1.943 0 O-C-N 121.674 -0.898 . . . . 0.0 110.095 179.691 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.494 1.743 0 CA-C-O 120.979 0.419 . . . . 0.0 109.975 . . . . . . . . . 0 0 . 1 . 008 nuclear build full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 12.4 tp -167.09 -56.57 0.03 OUTLIER 'General case' 0 N--CA 1.493 1.712 0 O-C-N 121.455 -0.778 . . . . 0.0 110.089 179.758 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -70.25 117.91 12.4 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 121.269 -0.894 . . . . 0.0 109.517 179.342 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 4' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -158.4 76.21 0.75 Allowed 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.413 -0.804 . . . . 0.0 110.304 179.921 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 19.8 t -144.4 104.71 4.68 Favored Pre-proline 0 N--CA 1.494 1.751 0 O-C-N 121.508 -0.745 . . . . 0.0 109.579 179.836 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 6' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -80.57 -35.63 0.55 Allowed 'Trans proline' 0 C--N 1.308 -1.57 0 O-C-N 124.09 1.573 . . . . 0.0 112.171 -179.325 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -90.45 53.22 3.45 Favored Glycine 0 N--CA 1.496 2.637 0 O-C-N 120.361 -1.462 . . . . 0.0 112.007 -178.009 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 21.7 p -161.15 163.7 31.08 Favored 'General case' 0 N--CA 1.498 1.933 0 O-C-N 120.657 -1.496 . . . . 0.0 110.655 178.854 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 70.91 63.94 2.98 Favored Glycine 0 N--CA 1.494 2.535 0 N-CA-C 109.759 -1.336 . . . . 0.0 109.759 -179.951 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 10' ' ' GLN . . . . . . . . . . . . . 3.1 pt20 -145.04 27.5 1.29 Allowed 'General case' 0 N--CA 1.493 1.698 0 O-C-N 121.619 -0.93 . . . . 0.0 111.113 -179.639 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -140.53 63.31 0.53 Allowed Glycine 0 N--CA 1.491 2.35 0 N-CA-C 109.439 -1.464 . . . . 0.0 109.439 179.839 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 28.9 m -113.79 2.06 8.39 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.834 0 O-C-N 121.568 -0.96 . . . . 0.0 111.627 -179.955 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 13' ' ' GLN . . . . . . . . . . . . . 25.6 tt0 -51.41 -45.73 62.64 Favored 'General case' 0 N--CA 1.499 2.01 0 O-C-N 120.984 -1.072 . . . . 0.0 110.613 179.815 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -111.04 26.6 10.53 Favored 'General case' 0 N--CA 1.494 1.729 0 O-C-N 121.624 -0.673 . . . . 0.0 110.272 179.714 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -128.33 68.19 0.54 Allowed Glycine 0 N--CA 1.489 2.19 0 N-CA-C 108.97 -1.652 . . . . 0.0 108.97 179.753 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 17.9 m -96.0 150.27 37.06 Favored Pre-proline 0 N--CA 1.488 1.437 0 O-C-N 121.44 -1.035 . . . . 0.0 110.497 -179.745 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 43.7 Cg_endo -74.17 -39.85 1.48 Allowed 'Trans proline' 0 N--CA 1.491 1.368 0 O-C-N 123.822 1.433 . . . . 0.0 110.648 179.426 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . -167.12 59.36 0.22 Allowed Glycine 0 N--CA 1.493 2.461 0 N-CA-C 109.163 -1.575 . . . . 0.0 109.163 179.589 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 141.18 132.56 2.82 Favored Glycine 0 N--CA 1.493 2.496 0 N-CA-C 108.625 -1.79 . . . . 0.0 108.625 -179.557 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -134.32 169.38 17.31 Favored 'General case' 0 N--CA 1.496 1.851 0 O-C-N 121.512 -0.993 . . . . 0.0 109.301 -179.665 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 21' ' ' VAL . . . . . 0.427 HG22 ' O ' ' A' ' 21' ' ' VAL . 11.7 p -80.06 50.89 0.07 OUTLIER 'Isoleucine or valine' 0 N--CA 1.502 2.155 0 O-C-N 121.319 -0.863 . . . . 0.0 111.254 -179.736 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 2.8 mt-10 -108.58 51.76 0.73 Allowed 'General case' 0 C--N 1.305 -1.326 0 O-C-N 121.014 -1.053 . . . . 0.0 108.436 178.419 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 0.8 OUTLIER 52.55 59.41 4.52 Favored 'General case' 0 N--CA 1.495 1.806 0 CA-C-O 121.93 0.871 . . . . 0.0 109.222 -177.995 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 1.7 pm0 -61.0 -5.46 1.4 Allowed 'General case' 0 N--CA 1.5 2.034 0 O-C-N 121.432 -0.793 . . . . 0.0 112.228 -179.105 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 15.7 m-20 -77.17 -24.18 51.49 Favored 'General case' 0 N--CA 1.497 1.924 0 O-C-N 120.737 -1.227 . . . . 0.0 110.431 179.641 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 88.39 -51.96 3.99 Favored Glycine 0 N--CA 1.495 2.589 0 N-CA-C 109.726 -1.35 . . . . 0.0 109.726 -179.921 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -177.29 -140.05 3.53 Favored Glycine 0 N--CA 1.493 2.472 0 N-CA-C 109.798 -1.321 . . . . 0.0 109.798 -179.696 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 28' ' ' SER . . . . . 0.46 ' CB ' ' CD ' ' A' ' 29' ' ' PRO . 2.6 t -154.92 -64.07 0.02 OUTLIER Pre-proline 0 N--CA 1.494 1.744 0 O-C-N 121.163 -1.198 . . . . 0.0 110.665 179.835 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 29' ' ' PRO . . . . . 0.46 ' CD ' ' CB ' ' A' ' 28' ' ' SER . 41.4 Cg_endo -68.89 -31.23 25.09 Favored 'Trans proline' 0 N--CA 1.488 1.188 0 O-C-N 122.979 0.989 . . . . 0.0 111.133 -179.562 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -99.12 54.29 0.98 Allowed 'General case' 0 N--CA 1.493 1.704 0 O-C-N 121.376 -0.827 . . . . 0.0 110.827 -179.633 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 2.8 tp10 -84.48 -42.41 15.6 Favored 'General case' 0 N--CA 1.493 1.717 0 O-C-N 121.379 -0.826 . . . . 0.0 110.217 179.603 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 96.47 52.43 1.57 Allowed Glycine 0 N--CA 1.501 2.995 0 N-CA-C 109.634 -1.386 . . . . 0.0 109.634 -179.804 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 33' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -79.62 118.64 21.64 Favored 'General case' 0 N--CA 1.495 1.814 0 O-C-N 121.157 -1.202 . . . . 0.0 109.735 179.903 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -79.49 -28.5 41.47 Favored 'General case' 0 N--CA 1.497 1.918 0 O-C-N 121.259 -0.9 . . . . 0.0 110.721 -179.851 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 24.5 mp0 -78.19 153.53 31.92 Favored 'General case' 0 N--CA 1.492 1.658 0 CA-C-O 121.491 0.662 . . . . 0.0 110.556 -179.762 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 36' ' ' ALA . . . . . . . . . . . . . . . -91.88 -42.18 10.2 Favored 'General case' 0 N--CA 1.496 1.825 0 O-C-N 121.415 -0.803 . . . . 0.0 110.999 -179.668 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 16.2 tt0 -77.18 -26.12 52.57 Favored 'General case' 0 N--CA 1.494 1.757 0 O-C-N 120.796 -1.19 . . . . 0.0 111.197 -179.006 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -70.26 -32.72 68.66 Favored Glycine 0 N--CA 1.497 2.705 0 C-N-CA 120.386 -0.911 . . . . 0.0 111.203 -178.942 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 39' ' ' CYS . . . . . . . . . . . . . 90.1 m -135.36 -32.32 0.94 Allowed 'General case' 0 N--CA 1.506 2.344 0 O-C-N 120.709 -1.466 . . . . 0.0 112.872 -178.697 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 40' ' ' LEU . . . . . . . . . . . . . 1.0 OUTLIER -74.39 63.73 1.08 Allowed 'General case' 0 N--CA 1.497 1.879 0 O-C-N 120.697 -1.252 . . . . 0.0 111.606 -178.371 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 41' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -115.88 67.96 0.72 Allowed 'General case' 0 N--CA 1.487 1.409 0 O-C-N 120.995 -1.066 . . . . 0.0 110.262 179.23 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 42' ' ' ARG . . . . . . . . . . . . . 9.4 mtt180 -142.43 42.92 1.63 Allowed 'General case' 0 N--CA 1.488 1.435 0 O-C-N 121.476 -0.765 . . . . 0.0 109.712 179.041 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 3.7 pm0 -69.52 145.45 52.64 Favored 'General case' 0 N--CA 1.494 1.736 0 O-C-N 121.618 -0.676 . . . . 0.0 110.495 -179.71 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -77.48 58.86 3.73 Favored Glycine 0 N--CA 1.497 2.708 0 N-CA-C 110.118 -1.193 . . . . 0.0 110.118 -179.771 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 45' ' ' GLN . . . . . . . . . . . . . 18.9 mt-30 . . . . . 0 N--CA 1.493 1.712 0 CA-C-O 117.722 -1.133 . . . . 0.0 110.059 179.47 . . . . . . . . 0 0 . 1 . 009 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.493 1.702 0 N-CA-C 110.075 -0.342 . . . . 0.0 110.075 . . . . . . . . . 0 0 . 1 . 009 nuclear build full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 0.0 OUTLIER -151.25 57.12 0.89 Allowed 'General case' 0 N--CA 1.493 1.71 0 O-C-N 121.44 -0.788 . . . . 0.0 110.427 180.0 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -103.38 95.65 6.23 Favored 'General case' 0 N--CA 1.488 1.438 0 O-C-N 121.218 -0.926 . . . . 0.0 110.267 -179.94 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 4' ' ' ARG . . . . . . . . . . . . . 2.5 ptp85 -57.63 105.57 0.26 Allowed 'General case' 0 N--CA 1.497 1.892 0 O-C-N 121.525 -0.734 . . . . 0.0 110.463 -179.872 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 31.6 p -126.03 141.81 40.64 Favored Pre-proline 0 N--CA 1.493 1.686 0 O-C-N 121.072 -1.018 . . . . 0.0 110.599 -179.668 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 6' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -78.26 110.59 2.9 Favored 'Trans proline' 0 N--CA 1.487 1.136 0 O-C-N 123.938 1.494 . . . . 0.0 111.516 -179.416 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 47.44 54.69 10.14 Favored Glycine 0 N--CA 1.497 2.707 0 O-C-N 121.337 -0.852 . . . . 0.0 110.983 179.147 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -112.84 -171.95 1.96 Allowed 'General case' 0 N--CA 1.495 1.784 0 O-C-N 121.342 -1.093 . . . . 0.0 109.822 179.24 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 9' ' ' GLY . . . . . 0.493 ' O ' ' HG2' ' A' ' 10' ' ' GLN . . . 95.54 36.34 5.39 Favored Glycine 0 N--CA 1.495 2.608 0 N-CA-C 109.452 -1.459 . . . . 0.0 109.452 179.973 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 10' ' ' GLN . . . . . 0.493 ' HG2' ' O ' ' A' ' 9' ' ' GLY . 0.0 OUTLIER 26.87 54.81 0.05 Allowed 'General case' 0 N--CA 1.506 2.351 0 CA-C-N 117.379 0.59 . . . . 0.0 112.055 179.679 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -135.95 52.37 0.79 Allowed Glycine 0 N--CA 1.496 2.662 0 N-CA-C 109.511 -1.436 . . . . 0.0 109.511 179.586 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 6.3 p -107.97 -2.49 10.06 Favored 'Isoleucine or valine' 0 N--CA 1.499 2.017 0 O-C-N 121.12 -1.223 . . . . 0.0 110.877 -179.331 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 13' ' ' GLN . . . . . . . . . . . . . 7.0 mt-30 -76.11 79.3 2.94 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 120.884 -1.135 . . . . 0.0 110.444 -179.491 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -119.02 174.75 6.12 Favored 'General case' 0 N--CA 1.498 1.972 0 O-C-N 121.673 -0.642 . . . . 0.0 110.29 179.662 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -143.25 -94.62 0.2 Allowed Glycine 0 N--CA 1.494 2.54 0 N-CA-C 109.544 -1.422 . . . . 0.0 109.544 179.895 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 4.7 m -89.07 151.09 46.43 Favored Pre-proline 0 N--CA 1.492 1.648 0 O-C-N 121.34 -1.094 . . . . 0.0 109.975 179.655 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 50.0 Cg_endo -75.14 59.01 5.17 Favored 'Trans proline' 0 C--N 1.315 -1.205 0 O-C-N 123.847 1.446 . . . . 0.0 111.052 -179.953 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 69.93 11.3 66.3 Favored Glycine 0 N--CA 1.494 2.56 0 N-CA-C 110.609 -0.996 . . . . 0.0 110.609 179.887 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -147.74 114.52 0.7 Allowed Glycine 0 N--CA 1.488 2.141 0 N-CA-C 109.064 -1.615 . . . . 0.0 109.064 -179.507 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -153.67 142.87 21.43 Favored 'General case' 0 N--CA 1.494 1.775 0 O-C-N 121.483 -1.01 . . . . 0.0 110.125 -179.85 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 11.5 p -150.35 44.67 0.08 OUTLIER 'Isoleucine or valine' 0 N--CA 1.499 1.99 0 CA-C-O 121.559 0.695 . . . . 0.0 110.164 -179.681 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 1.8 mt-10 -112.31 -13.57 13.43 Favored 'General case' 0 N--CA 1.487 1.418 0 O-C-N 121.191 -0.943 . . . . 0.0 110.758 179.654 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 1.4 tp10 58.73 85.95 0.09 Allowed 'General case' 0 N--CA 1.504 2.253 0 O-C-N 121.355 -0.84 . . . . 0.0 110.526 179.855 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 26.1 mt-10 -79.24 50.01 1.03 Allowed 'General case' 0 N--CA 1.496 1.854 0 O-C-N 120.858 -1.151 . . . . 0.0 111.286 -179.883 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 2.5 t70 -113.97 68.98 0.7 Allowed 'General case' 0 N--CA 1.495 1.788 0 O-C-N 121.211 -0.931 . . . . 0.0 109.979 179.706 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 159.87 -87.62 0.11 Allowed Glycine 0 N--CA 1.495 2.627 0 N-CA-C 109.638 -1.385 . . . . 0.0 109.638 179.838 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 121.47 -56.92 0.61 Allowed Glycine 0 N--CA 1.494 2.526 0 N-CA-C 109.533 -1.427 . . . . 0.0 109.533 -179.853 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 58.3 m -125.42 159.75 58.71 Favored Pre-proline 0 N--CA 1.498 1.953 0 O-C-N 121.762 -0.846 . . . . 0.0 110.157 179.964 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 42.4 Cg_endo -65.76 -29.13 51.15 Favored 'Trans proline' 0 N--CA 1.492 1.411 0 O-C-N 123.883 1.465 . . . . 0.0 111.076 179.736 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -96.15 15.81 19.83 Favored 'General case' 0 N--CA 1.487 1.384 0 O-C-N 120.822 -1.174 . . . . 0.0 110.224 178.965 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 37.0 tp10 -79.65 -50.71 10.24 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.089 -1.007 . . . . 0.0 110.818 -179.103 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 131.64 88.27 0.43 Allowed Glycine 0 N--CA 1.487 2.088 0 N-CA-C 108.771 -1.732 . . . . 0.0 108.771 -179.384 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 33' ' ' CYS . . . . . . . . . . . . . 17.9 m -78.22 125.59 29.57 Favored 'General case' 0 N--CA 1.502 2.131 0 O-C-N 121.279 -1.13 . . . . 0.0 110.307 -179.811 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -79.09 -17.21 55.56 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.363 -0.836 . . . . 0.0 109.839 179.15 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 1.1 tm-20 -103.74 165.24 11.16 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.391 -0.818 . . . . 0.0 109.999 179.581 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 36' ' ' ALA . . . . . . . . . . . . . . . -102.04 -26.92 13.22 Favored 'General case' 0 N--CA 1.498 1.955 0 O-C-N 121.335 -0.853 . . . . 0.0 110.903 179.58 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 1.5 mt-10 -79.58 -31.93 41.92 Favored 'General case' 0 N--CA 1.494 1.775 0 O-C-N 120.942 -1.099 . . . . 0.0 110.604 -179.195 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -75.22 -36.96 43.76 Favored Glycine 0 N--CA 1.493 2.459 0 N-CA-C 110.392 -1.083 . . . . 0.0 110.392 -179.91 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 39' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -96.47 -27.85 14.69 Favored 'General case' 0 N--CA 1.499 2.005 0 O-C-N 120.868 -1.372 . . . . 0.0 111.477 -179.865 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 40' ' ' LEU . . . . . . . . . . . . . 0.8 OUTLIER 60.15 -170.01 0.15 Allowed 'General case' 0 N--CA 1.502 2.133 0 O-C-N 121.297 -0.877 . . . . 0.0 110.657 -179.417 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 41' ' ' ARG . . . . . . . . . . . . . 1.2 ttt-85 -125.06 82.75 2.09 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.248 -0.907 . . . . 0.0 109.875 179.707 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 42' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -100.18 -38.41 8.53 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.357 -0.839 . . . . 0.0 110.42 -179.439 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER 56.69 -167.69 0.11 Allowed 'General case' 0 N--CA 1.498 1.964 0 CA-C-O 121.506 0.67 . . . . 0.0 110.836 -179.658 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 176.1 -58.94 0.11 Allowed Glycine 0 N--CA 1.49 2.248 0 N-CA-C 109.946 -1.262 . . . . 0.0 109.946 -179.649 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 45' ' ' GLN . . . . . . . . . . . . . 2.0 pt20 . . . . . 0 N--CA 1.503 2.194 0 O-C-N 120.869 -1.371 . . . . 0.0 110.47 179.632 . . . . . . . . 0 0 . 1 . 010 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.495 1.81 0 N-CA-C 110.103 -0.332 . . . . 0.0 110.103 . . . . . . . . . 0 0 . 1 . 010 nuclear build full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -162.43 30.14 0.11 Allowed 'General case' 0 N--CA 1.498 1.938 0 O-C-N 121.689 -0.632 . . . . 0.0 110.903 179.618 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . 49.87 -154.34 0.12 Allowed 'General case' 0 N--CA 1.501 2.106 0 O-C-N 121.499 -0.751 . . . . 0.0 110.759 179.856 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 4' ' ' ARG . . . . . . . . . . . . . 4.0 mmt85 53.47 -145.94 0.57 Allowed 'General case' 0 N--CA 1.496 1.865 0 O-C-N 121.538 -0.726 . . . . 0.0 110.431 179.843 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 5.8 p -131.65 133.26 24.04 Favored Pre-proline 0 N--CA 1.497 1.923 0 O-C-N 121.083 -1.011 . . . . 0.0 110.394 -179.714 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 6' ' ' PRO . . . . . . . . . . . . . 44.1 Cg_endo -75.09 -53.49 0.1 OUTLIER 'Trans proline' 0 C--N 1.311 -1.443 0 O-C-N 123.559 1.294 . . . . 0.0 111.351 -179.577 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -85.97 59.87 4.68 Favored Glycine 0 N--CA 1.492 2.373 0 N-CA-C 110.238 -1.145 . . . . 0.0 110.238 -179.426 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 0.7 OUTLIER -106.02 18.38 22.16 Favored 'General case' 0 N--CA 1.501 2.084 0 O-C-N 121.281 -1.129 . . . . 0.0 110.56 179.325 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 106.17 55.73 0.67 Allowed Glycine 0 N--CA 1.496 2.676 0 N-CA-C 109.975 -1.25 . . . . 0.0 109.975 179.729 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 10' ' ' GLN . . . . . . . . . . . . . 3.8 pt20 -161.79 48.35 0.19 Allowed 'General case' 0 N--CA 1.492 1.633 0 O-C-N 121.383 -1.069 . . . . 0.0 110.361 179.777 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -94.79 66.36 1.37 Allowed Glycine 0 N--CA 1.495 2.588 0 N-CA-C 109.599 -1.4 . . . . 0.0 109.599 179.901 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 24.6 t -122.3 -20.06 4.05 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.029 0 O-C-N 121.393 -1.063 . . . . 0.0 111.079 -179.483 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 13' ' ' GLN . . . . . 0.427 ' O ' ' HB3' ' A' ' 14' ' ' ALA . 0.0 OUTLIER -81.38 -144.38 0.05 Allowed 'General case' 0 N--CA 1.492 1.646 0 O-C-N 121.053 -1.029 . . . . 0.0 110.393 -179.854 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 14' ' ' ALA . . . . . 0.427 ' HB3' ' O ' ' A' ' 13' ' ' GLN . . . 59.07 -155.62 0.35 Allowed 'General case' 0 N--CA 1.498 1.966 0 O-C-N 121.647 -0.658 . . . . 0.0 109.821 -179.727 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -91.28 42.93 2.81 Favored Glycine 0 N--CA 1.49 2.262 0 N-CA-C 109.371 -1.492 . . . . 0.0 109.371 179.916 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 81.1 m -119.38 67.09 9.37 Favored Pre-proline 0 N--CA 1.493 1.709 0 O-C-N 121.295 -1.12 . . . . 0.0 110.801 -179.5 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 46.6 Cg_endo -71.83 69.01 3.0 Favored 'Trans proline' 0 C--N 1.313 -1.319 0 O-C-N 123.385 1.202 . . . . 0.0 110.504 -179.892 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 105.73 -14.71 45.73 Favored Glycine 0 N--CA 1.498 2.786 0 N-CA-C 110.134 -1.186 . . . . 0.0 110.134 -179.603 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -154.2 123.95 1.47 Allowed Glycine 0 N--CA 1.489 2.213 0 N-CA-C 109.152 -1.579 . . . . 0.0 109.152 179.87 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -108.05 47.13 0.91 Allowed 'General case' 0 N--CA 1.497 1.904 0 O-C-N 121.399 -1.059 . . . . 0.0 109.699 179.706 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 9.9 p -136.4 20.97 0.9 Allowed 'Isoleucine or valine' 0 N--CA 1.502 2.167 0 O-C-N 120.915 -1.116 . . . . 0.0 111.29 -179.444 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 22' ' ' GLU . . . . . 0.401 ' C ' ' HG3' ' A' ' 23' ' ' GLU . 1.5 tp10 -101.21 -12.06 19.03 Favored 'General case' 0 C--N 1.305 -1.339 0 O-C-N 121.179 -0.951 . . . . 0.0 109.993 179.098 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 23' ' ' GLU . . . . . 0.401 ' HG3' ' C ' ' A' ' 22' ' ' GLU . 0.0 OUTLIER -146.06 74.86 1.39 Allowed 'General case' 0 N--CA 1.488 1.446 0 O-C-N 121.429 -0.794 . . . . 0.0 109.436 -179.582 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER -56.05 -58.54 7.47 Favored 'General case' 0 N--CA 1.5 2.037 0 O-C-N 121.207 -0.933 . . . . 0.0 110.79 -179.421 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -149.28 -61.86 0.22 Allowed 'General case' 0 N--CA 1.495 1.811 0 O-C-N 121.332 -0.855 . . . . 0.0 110.06 179.964 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 134.04 86.03 0.25 Allowed Glycine 0 N--CA 1.497 2.708 0 N-CA-C 109.504 -1.438 . . . . 0.0 109.504 -179.716 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 165.45 95.95 0.11 Allowed Glycine 0 N--CA 1.494 2.557 0 N-CA-C 109.147 -1.581 . . . . 0.0 109.147 -179.702 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 28' ' ' SER . . . . . 0.484 ' HB2' ' HD3' ' A' ' 29' ' ' PRO . 0.0 OUTLIER -154.72 -62.6 0.02 OUTLIER Pre-proline 0 N--CA 1.497 1.909 0 O-C-N 121.263 -1.14 . . . . 0.0 110.777 179.85 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 29' ' ' PRO . . . . . 0.484 ' HD3' ' HB2' ' A' ' 28' ' ' SER . 44.8 Cg_endo -75.44 123.82 7.91 Favored 'Trans proline' 0 C--N 1.318 -1.062 0 O-C-N 122.922 0.959 . . . . 0.0 110.405 -179.744 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -78.54 -9.39 59.32 Favored 'General case' 0 N--CA 1.498 1.943 0 O-C-N 121.148 -0.97 . . . . 0.0 111.154 -179.665 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 4.1 tp10 -79.76 -56.92 3.94 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.253 -0.905 . . . . 0.0 109.556 179.742 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 171.88 -64.85 0.14 Allowed Glycine 0 N--CA 1.492 2.418 0 N-CA-C 109.181 -1.568 . . . . 0.0 109.181 -179.999 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 33' ' ' CYS . . . . . . . . . . . . . 12.7 p -148.29 88.33 1.64 Allowed 'General case' 0 N--CA 1.493 1.715 0 O-C-N 121.495 -1.003 . . . . 0.0 109.521 179.648 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -86.28 39.42 0.82 Allowed 'General case' 0 N--CA 1.495 1.808 0 O-C-N 121.342 -0.849 . . . . 0.0 110.82 -179.479 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER -113.8 163.26 15.28 Favored 'General case' 0 N--CA 1.495 1.793 0 O-C-N 121.218 -0.926 . . . . 0.0 110.214 179.812 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 36' ' ' ALA . . . . . 1.066 ' HB1' HD12 ' A' ' 40' ' ' LEU . . . -102.61 0.1 32.78 Favored 'General case' 0 N--CA 1.498 1.97 0 O-C-N 121.515 -0.741 . . . . 0.0 112.148 -178.706 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 2.7 pm0 -79.59 -27.24 41.13 Favored 'General case' 0 N--CA 1.498 1.94 0 O-C-N 120.582 -1.324 . . . . 0.0 111.556 -179.132 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -133.34 -47.41 0.1 Allowed Glycine 0 N--CA 1.498 2.799 0 C-N-CA 118.894 -1.622 . . . . 0.0 111.825 -178.77 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 39' ' ' CYS . . . . . . . . . . . . . 4.3 m -79.53 0.94 27.68 Favored 'General case' 0 N--CA 1.499 2.022 0 O-C-N 120.889 -1.359 . . . . 0.0 112.304 -178.451 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 40' ' ' LEU . . . . . 1.066 HD12 ' HB1' ' A' ' 36' ' ' ALA . 0.5 OUTLIER -75.87 56.68 0.98 Allowed 'General case' 0 N--CA 1.497 1.923 0 O-C-N 120.851 -1.156 . . . . 0.0 109.797 179.07 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 41' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -177.91 42.49 0.01 OUTLIER 'General case' 0 N--CA 1.498 1.944 0 O-C-N 121.606 -0.684 . . . . 0.0 110.873 -179.846 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 42' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -123.56 7.6 8.91 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.27 -0.894 . . . . 0.0 110.894 179.745 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER -79.99 63.79 4.63 Favored 'General case' 0 N--CA 1.493 1.709 0 O-C-N 120.63 -1.294 . . . . 0.0 109.96 179.33 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -159.65 72.03 0.23 Allowed Glycine 0 N--CA 1.489 2.193 0 N-CA-C 109.266 -1.533 . . . . 0.0 109.266 -179.908 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 45' ' ' GLN . . . . . . . . . . . . . 0.6 OUTLIER . . . . . 0 N--CA 1.495 1.786 0 CA-C-O 117.889 -1.053 . . . . 0.0 110.628 -179.708 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.494 1.726 0 CA-C-O 120.86 0.362 . . . . 0.0 110.231 . . . . . . . . . 0 0 . 1 . 011 nuclear build full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -170.65 90.8 0.16 Allowed 'General case' 0 N--CA 1.494 1.747 0 O-C-N 121.358 -0.839 . . . . 0.0 110.131 179.828 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -163.61 121.73 1.91 Allowed 'General case' 0 N--CA 1.494 1.729 0 O-C-N 121.315 -0.866 . . . . 0.0 110.114 179.945 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 4' ' ' ARG . . . . . . . . . . . . . 1.7 tmm_? -89.25 88.42 7.51 Favored 'General case' 0 N--CA 1.492 1.633 0 O-C-N 121.502 -0.749 . . . . 0.0 110.043 -179.916 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -142.32 158.89 60.01 Favored Pre-proline 0 N--CA 1.491 1.614 0 O-C-N 121.463 -0.773 . . . . 0.0 110.264 -179.757 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 6' ' ' PRO . . . . . . . . . . . . . 43.6 Cg_endo -75.11 -53.21 0.1 OUTLIER 'Trans proline' 0 C--N 1.315 -1.233 0 O-C-N 123.691 1.364 . . . . 0.0 110.619 179.608 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -85.17 60.73 4.74 Favored Glycine 0 N--CA 1.496 2.654 0 N-CA-C 109.465 -1.454 . . . . 0.0 109.465 179.522 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 1.5 m -96.74 24.31 6.19 Favored 'General case' 0 N--CA 1.497 1.923 0 O-C-N 121.271 -1.135 . . . . 0.0 110.678 -179.952 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -144.02 -144.46 4.22 Favored Glycine 0 N--CA 1.495 2.579 0 N-CA-C 109.354 -1.498 . . . . 0.0 109.354 179.841 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 10' ' ' GLN . . . . . 0.491 ' HB2' ' HB3' ' A' ' 14' ' ' ALA . 3.5 mt-30 -54.12 -49.02 70.12 Favored 'General case' 0 N--CA 1.499 2.006 0 O-C-N 121.423 -1.045 . . . . 0.0 110.959 179.953 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 109.15 -25.17 19.19 Favored Glycine 0 N--CA 1.494 2.539 0 N-CA-C 109.874 -1.29 . . . . 0.0 109.874 -179.654 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 12' ' ' VAL . . . . . 0.438 ' H ' HG22 ' A' ' 12' ' ' VAL . 27.4 m -95.9 46.76 0.1 OUTLIER 'Isoleucine or valine' 0 N--CA 1.497 1.908 0 O-C-N 121.015 -1.285 . . . . 0.0 110.26 179.879 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 13' ' ' GLN . . . . . . . . . . . . . 1.1 mt-30 52.11 49.38 20.76 Favored 'General case' 0 N--CA 1.498 1.93 0 O-C-N 121.705 -0.622 . . . . 0.0 111.006 179.779 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 14' ' ' ALA . . . . . 0.491 ' HB3' ' HB2' ' A' ' 10' ' ' GLN . . . -103.87 161.65 13.78 Favored 'General case' 0 N--CA 1.497 1.917 0 O-C-N 121.263 -0.898 . . . . 0.0 110.137 179.512 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 75.58 72.06 1.1 Allowed Glycine 0 N--CA 1.495 2.625 0 N-CA-C 109.461 -1.455 . . . . 0.0 109.461 179.908 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 16' ' ' CYS . . . . . 0.44 ' HB2' ' HD2' ' A' ' 17' ' ' PRO . 17.7 p -79.8 167.23 35.42 Favored Pre-proline 0 N--CA 1.497 1.924 0 O-C-N 121.428 -1.042 . . . . 0.0 110.215 -179.922 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 17' ' ' PRO . . . . . 0.44 ' HD2' ' HB2' ' A' ' 16' ' ' CYS . 49.7 Cg_endo -77.33 53.19 4.17 Favored 'Trans proline' 0 C--N 1.311 -1.437 0 O-C-N 123.499 1.263 . . . . 0.0 110.217 178.927 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 92.7 -43.09 2.63 Favored Glycine 0 N--CA 1.496 2.64 0 N-CA-C 110.392 -1.083 . . . . 0.0 110.392 -179.89 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -74.89 83.38 0.82 Allowed Glycine 0 N--CA 1.492 2.376 0 O-C-N 121.189 -1.183 . . . . 0.0 110.495 -179.176 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 1.3 m -117.45 118.93 33.54 Favored 'General case' 0 N--CA 1.497 1.9 0 O-C-N 121.407 -1.054 . . . . 0.0 109.974 179.427 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 14.0 t -83.33 75.36 1.03 Allowed 'Isoleucine or valine' 0 N--CA 1.497 1.876 0 O-C-N 121.639 -0.663 . . . . 0.0 109.573 179.851 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 31.4 mt-10 -95.34 40.96 1.1 Allowed 'General case' 0 C--N 1.304 -1.391 0 O-C-N 121.356 -0.84 . . . . 0.0 110.115 -179.587 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 3.4 pt-20 -157.52 60.03 0.49 Allowed 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.372 -0.83 . . . . 0.0 110.164 -179.801 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -112.27 147.53 36.07 Favored 'General case' 0 N--CA 1.493 1.718 0 O-C-N 121.224 -0.922 . . . . 0.0 110.281 -179.574 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 3.1 p-10 -96.78 176.73 5.88 Favored 'General case' 0 N--CA 1.495 1.801 0 O-C-N 121.37 -0.831 . . . . 0.0 109.538 178.99 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -126.36 27.86 4.91 Favored Glycine 0 N--CA 1.493 2.487 0 N-CA-C 110.134 -1.186 . . . . 0.0 110.134 179.921 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 71.75 -68.77 1.0 Allowed Glycine 0 N--CA 1.499 2.88 0 N-CA-C 109.782 -1.327 . . . . 0.0 109.782 -179.934 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 64.4 m -83.5 116.9 66.87 Favored Pre-proline 0 N--CA 1.499 1.992 0 O-C-N 121.273 -1.134 . . . . 0.0 110.378 179.788 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 44.1 Cg_endo -71.16 154.39 62.07 Favored 'Trans proline' 0 N--CA 1.491 1.333 0 O-C-N 124.016 1.535 . . . . 0.0 111.485 -179.493 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -112.43 -50.26 2.91 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.398 -0.814 . . . . 0.0 110.625 179.84 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -102.54 -63.84 1.12 Allowed 'General case' 0 N--CA 1.495 1.79 0 O-C-N 121.485 -0.759 . . . . 0.0 110.233 -179.956 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 152.96 -59.2 0.41 Allowed Glycine 0 N--CA 1.495 2.587 0 N-CA-C 109.626 -1.39 . . . . 0.0 109.626 -179.907 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 33' ' ' CYS . . . . . . . . . . . . . 17.3 m -133.17 61.24 1.68 Allowed 'General case' 0 N--CA 1.496 1.87 0 O-C-N 121.32 -1.106 . . . . 0.0 110.075 179.87 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -122.62 26.63 8.2 Favored 'General case' 0 N--CA 1.497 1.911 0 O-C-N 121.274 -0.891 . . . . 0.0 109.876 179.528 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 22.7 mp0 -116.5 -171.88 2.09 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.732 -0.605 . . . . 0.0 110.612 -179.186 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 36' ' ' ALA . . . . . . . . . . . . . . . -92.07 -24.97 18.99 Favored 'General case' 0 N--CA 1.499 2.022 0 O-C-N 121.244 -0.91 . . . . 0.0 111.151 -179.597 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER -79.71 52.46 1.45 Allowed 'General case' 0 N--CA 1.499 2.006 0 O-C-N 120.836 -1.165 . . . . 0.0 110.739 -179.608 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 47.42 -111.5 0.79 Allowed Glycine 0 N--CA 1.501 3.013 0 N-CA-C 110.126 -1.189 . . . . 0.0 110.126 179.5 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 39' ' ' CYS . . . . . . . . . . . . . 90.0 m -143.4 141.4 30.86 Favored 'General case' 0 N--CA 1.495 1.794 0 O-C-N 121.485 -1.009 . . . . 0.0 109.26 179.462 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 40' ' ' LEU . . . . . 0.584 ' HB2' ' HG3' ' A' ' 43' ' ' GLU . 2.9 mt -69.87 -172.26 0.5 Allowed 'General case' 0 N--CA 1.495 1.778 0 O-C-N 121.351 -0.843 . . . . 0.0 110.938 -179.499 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 41' ' ' ARG . . . . . . . . . . . . . 13.9 mtp180 -105.9 117.59 34.43 Favored 'General case' 0 N--CA 1.489 1.477 0 O-C-N 121.096 -1.002 . . . . 0.0 111.317 -179.098 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 42' ' ' ARG . . . . . . . . . . . . . 38.0 ttp180 60.93 52.42 4.17 Favored 'General case' 0 N--CA 1.501 2.091 0 CA-C-O 121.044 0.45 . . . . 0.0 111.789 178.885 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 43' ' ' GLU . . . . . 0.584 ' HG3' ' HB2' ' A' ' 40' ' ' LEU . 69.2 mm-40 -96.34 136.97 36.1 Favored 'General case' 0 N--CA 1.487 1.424 0 O-C-N 120.93 -1.106 . . . . 0.0 109.473 178.442 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 109.64 -46.24 1.2 Allowed Glycine 0 N--CA 1.493 2.472 0 N-CA-C 109.211 -1.555 . . . . 0.0 109.211 -179.392 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 45' ' ' GLN . . . . . . . . . . . . . 2.2 mp0 . . . . . 0 N--CA 1.497 1.915 0 O-C-N 121.726 -0.867 . . . . 0.0 110.168 179.316 . . . . . . . . 0 0 . 1 . 012 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 1.497 0 N-CA-C 109.877 -0.416 . . . . 0.0 109.877 . . . . . . . . . 0 0 . 1 . 012 nuclear build full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 0.9 OUTLIER -75.84 -178.47 4.29 Favored 'General case' 0 N--CA 1.492 1.672 0 O-C-N 121.6 -0.687 . . . . 0.0 110.689 179.913 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -163.84 -161.98 0.67 Allowed 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.18 -0.95 . . . . 0.0 109.971 179.79 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 4' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -61.22 133.73 56.24 Favored 'General case' 0 N--CA 1.494 1.73 0 O-C-N 121.515 -0.74 . . . . 0.0 110.003 179.871 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 5' ' ' CYS . . . . . 0.507 ' SG ' ' N ' ' A' ' 8' ' ' CYS . 0.8 OUTLIER -86.35 150.89 52.74 Favored Pre-proline 0 N--CA 1.496 1.858 0 O-C-N 121.512 -0.743 . . . . 0.0 109.716 179.864 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 6' ' ' PRO . . . . . . . . . . . . . 51.6 Cg_endo -81.0 45.36 1.98 Allowed 'Trans proline' 0 C--N 1.314 -1.271 0 O-C-N 123.755 1.397 . . . . 0.0 111.627 -179.092 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 165.1 41.73 0.02 OUTLIER Glycine 0 N--CA 1.497 2.702 0 N-CA-C 109.925 -1.27 . . . . 0.0 109.925 179.838 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 8' ' ' CYS . . . . . 0.507 ' N ' ' SG ' ' A' ' 5' ' ' CYS . 14.3 m -79.84 -177.2 5.82 Favored 'General case' 0 N--CA 1.499 1.993 0 O-C-N 121.404 -1.056 . . . . 0.0 110.132 -179.842 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -86.5 -79.72 1.19 Allowed Glycine 0 N--CA 1.495 2.631 0 N-CA-C 109.886 -1.286 . . . . 0.0 109.886 -179.885 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 10' ' ' GLN . . . . . . . . . . . . . 0.1 OUTLIER -67.05 -71.73 0.19 Allowed 'General case' 0 N--CA 1.496 1.868 0 O-C-N 121.434 -1.039 . . . . 0.0 110.648 -179.677 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 72.05 8.35 69.06 Favored Glycine 0 N--CA 1.497 2.758 0 N-CA-C 110.426 -1.07 . . . . 0.0 110.426 -179.595 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 12' ' ' VAL . . . . . 0.451 ' O ' HG13 ' A' ' 12' ' ' VAL . 4.3 p -160.64 82.41 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.493 1.675 0 O-C-N 121.209 -1.171 . . . . 0.0 108.767 179.954 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 13' ' ' GLN . . . . . . . . . . . . . 1.3 tt0 -53.22 101.16 0.04 OUTLIER 'General case' 0 N--CA 1.498 1.953 0 O-C-N 121.567 -0.708 . . . . 0.0 111.089 -178.897 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -108.72 31.55 5.56 Favored 'General case' 0 N--CA 1.497 1.894 0 O-C-N 121.643 -0.661 . . . . 0.0 109.547 179.209 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 143.95 -86.24 0.18 Allowed Glycine 0 N--CA 1.49 2.278 0 N-CA-C 108.548 -1.821 . . . . 0.0 108.548 -179.45 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 28.4 m -106.93 100.66 33.11 Favored Pre-proline 0 N--CA 1.494 1.764 0 O-C-N 121.331 -1.099 . . . . 0.0 109.544 179.133 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 47.2 Cg_endo -72.66 55.4 2.66 Favored 'Trans proline' 0 C--N 1.312 -1.382 0 O-C-N 123.817 1.43 . . . . 0.0 111.826 -178.955 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 152.62 36.56 0.03 OUTLIER Glycine 0 N--CA 1.496 2.684 0 O-C-N 120.836 -1.165 . . . . 0.0 111.097 179.444 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 82.38 137.24 2.6 Favored Glycine 0 N--CA 1.492 2.37 0 O-C-N 121.013 -1.287 . . . . 0.0 109.909 179.46 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -116.37 27.36 9.27 Favored 'General case' 0 N--CA 1.5 2.035 0 O-C-N 121.265 -1.138 . . . . 0.0 110.323 179.671 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 8.4 p -132.26 8.45 1.63 Allowed 'Isoleucine or valine' 0 N--CA 1.494 1.765 0 O-C-N 121.01 -1.056 . . . . 0.0 110.926 179.945 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 8.3 mm-40 -98.81 14.99 26.88 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 120.657 -1.277 . . . . 0.0 111.145 179.965 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 4.6 tt0 -146.4 -54.92 0.26 Allowed 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.202 -0.936 . . . . 0.0 109.507 179.404 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER -124.41 101.77 7.32 Favored 'General case' 0 C--N 1.307 -1.24 0 O-C-N 121.443 -0.785 . . . . 0.0 110.129 179.61 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 3.5 p-10 -115.43 23.76 12.15 Favored 'General case' 0 N--CA 1.496 1.841 0 O-C-N 121.236 -0.915 . . . . 0.0 110.542 179.926 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 129.52 -95.69 0.37 Allowed Glycine 0 N--CA 1.493 2.451 0 N-CA-C 109.209 -1.556 . . . . 0.0 109.209 179.914 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 80.29 -95.52 1.56 Allowed Glycine 0 N--CA 1.495 2.573 0 N-CA-C 109.701 -1.36 . . . . 0.0 109.701 179.752 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -79.29 165.77 46.2 Favored Pre-proline 0 N--CA 1.5 2.062 0 O-C-N 121.39 -1.065 . . . . 0.0 110.267 -179.919 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 45.6 Cg_endo -73.68 64.73 4.79 Favored 'Trans proline' 0 C--N 1.317 -1.116 0 O-C-N 123.868 1.457 . . . . 0.0 110.579 -179.975 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -127.63 76.62 1.69 Allowed 'General case' 0 N--CA 1.485 1.314 0 O-C-N 121.449 -0.782 . . . . 0.0 110.388 179.935 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 31' ' ' GLU . . . . . 0.42 ' HG3' ' N ' ' A' ' 32' ' ' GLY . 12.9 pt-20 -79.2 -43.22 24.3 Favored 'General case' 0 N--CA 1.494 1.744 0 O-C-N 121.152 -0.967 . . . . 0.0 110.243 -179.797 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 32' ' ' GLY . . . . . 0.42 ' N ' ' HG3' ' A' ' 31' ' ' GLU . . . 111.54 80.15 1.06 Allowed Glycine 0 N--CA 1.492 2.433 0 N-CA-C 109.582 -1.407 . . . . 0.0 109.582 179.739 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 33' ' ' CYS . . . . . . . . . . . . . 0.7 OUTLIER -79.68 133.22 36.37 Favored 'General case' 0 N--CA 1.497 1.894 0 O-C-N 121.264 -1.139 . . . . 0.0 109.362 179.66 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -78.5 -22.48 47.37 Favored 'General case' 0 N--CA 1.501 2.096 0 O-C-N 121.325 -0.859 . . . . 0.0 110.445 179.886 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 0.8 OUTLIER -130.68 165.51 22.7 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.381 -0.824 . . . . 0.0 109.814 179.554 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 36' ' ' ALA . . . . . . . . . . . . . . . -93.28 -39.91 10.72 Favored 'General case' 0 N--CA 1.493 1.679 0 O-C-N 121.462 -0.774 . . . . 0.0 109.644 179.403 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 6.2 tt0 -79.27 -53.85 6.54 Favored 'General case' 0 N--CA 1.495 1.81 0 O-C-N 121.525 -0.735 . . . . 0.0 109.844 179.713 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -75.87 63.09 2.8 Favored Glycine 0 N--CA 1.498 2.792 0 N-CA-C 109.557 -1.417 . . . . 0.0 109.557 179.887 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 39' ' ' CYS . . . . . 0.435 ' HB3' HD23 ' A' ' 40' ' ' LEU . 2.6 t -122.4 -63.49 1.28 Allowed 'General case' 0 N--CA 1.496 1.831 0 O-C-N 121.549 -0.971 . . . . 0.0 110.181 179.497 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 40' ' ' LEU . . . . . 0.435 HD23 ' HB3' ' A' ' 39' ' ' CYS . 1.9 pt? -169.86 -164.98 0.45 Allowed 'General case' 0 N--CA 1.497 1.898 0 O-C-N 121.196 -0.94 . . . . 0.0 110.547 179.139 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 41' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER 64.14 179.95 0.17 Allowed 'General case' 0 N--CA 1.503 2.203 0 O-C-N 121.768 -0.583 . . . . 0.0 110.445 179.938 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 42' ' ' ARG . . . . . . . . . . . . . 15.4 mtm180 -131.87 -70.9 0.56 Allowed 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.111 -0.993 . . . . 0.0 109.792 179.812 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 5.9 mp0 -128.74 88.51 2.74 Favored 'General case' 0 N--CA 1.487 1.391 0 O-C-N 121.423 -0.798 . . . . 0.0 109.335 -179.861 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 157.9 65.72 0.01 OUTLIER Glycine 0 N--CA 1.492 2.373 0 N-CA-C 109.279 -1.528 . . . . 0.0 109.279 -179.589 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 45' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.493 1.695 0 O-C-N 121.441 -1.035 . . . . 0.0 110.217 179.837 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.499 1.996 0 N-CA-C 109.816 -0.438 . . . . 0.0 109.816 . . . . . . . . . 0 0 . 1 . 013 nuclear build full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 0.7 OUTLIER -174.0 154.31 2.29 Favored 'General case' 0 N--CA 1.499 1.987 0 O-C-N 121.359 -0.838 . . . . 0.0 109.697 179.575 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -110.13 162.71 14.31 Favored 'General case' 0 N--CA 1.492 1.666 0 O-C-N 121.492 -0.755 . . . . 0.0 110.325 -179.923 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 4' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -168.05 89.51 0.27 Allowed 'General case' 0 N--CA 1.495 1.817 0 O-C-N 121.418 -0.801 . . . . 0.0 110.39 -179.992 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 9.3 t -160.43 103.4 1.35 Allowed Pre-proline 0 N--CA 1.497 1.925 0 O-C-N 120.945 -1.097 . . . . 0.0 110.023 179.955 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 6' ' ' PRO . . . . . . . . . . . . . 52.7 Cg_endo -77.57 155.0 31.5 Favored 'Trans proline' 0 C--N 1.314 -1.28 0 O-C-N 123.666 1.351 . . . . 0.0 110.335 179.796 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 82.82 -50.47 4.39 Favored Glycine 0 N--CA 1.497 2.762 0 C-N-CA 120.118 -1.039 . . . . 0.0 110.601 179.717 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 8' ' ' CYS . . . . . 0.443 ' SG ' ' N ' ' A' ' 9' ' ' GLY . 12.0 p -78.71 -33.09 47.07 Favored 'General case' 0 N--CA 1.497 1.905 0 O-C-N 120.967 -1.314 . . . . 0.0 111.062 -179.36 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 9' ' ' GLY . . . . . 0.443 ' N ' ' SG ' ' A' ' 8' ' ' CYS . . . -79.76 -60.63 2.42 Favored Glycine 0 N--CA 1.497 2.708 0 N-CA-C 109.631 -1.387 . . . . 0.0 109.631 -179.486 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 10' ' ' GLN . . . . . . . . . . . . . 34.2 mt-30 -143.91 -62.6 0.39 Allowed 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.438 -1.037 . . . . 0.0 110.754 -179.813 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 89.25 -68.56 2.7 Favored Glycine 0 N--CA 1.495 2.598 0 N-CA-C 108.962 -1.655 . . . . 0.0 108.962 -179.271 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 41.0 t -136.51 -94.06 0.04 OUTLIER 'Isoleucine or valine' 0 N--CA 1.496 1.85 0 O-C-N 121.657 -0.908 . . . . 0.0 109.715 179.287 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 13' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -166.86 30.76 0.04 OUTLIER 'General case' 0 N--CA 1.499 1.977 0 O-C-N 120.825 -1.172 . . . . 0.0 110.875 179.824 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -154.02 136.44 15.01 Favored 'General case' 0 N--CA 1.496 1.843 0 O-C-N 121.107 -0.996 . . . . 0.0 110.459 179.986 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -108.2 65.52 0.25 Allowed Glycine 0 N--CA 1.495 2.592 0 N-CA-C 109.788 -1.325 . . . . 0.0 109.788 179.881 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 60.6 m -80.51 114.01 44.12 Favored Pre-proline 0 N--CA 1.499 2.019 0 O-C-N 121.719 -0.871 . . . . 0.0 109.975 179.641 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 45.0 Cg_endo -70.07 89.22 0.56 Allowed 'Trans proline' 0 N--CA 1.49 1.318 0 O-C-N 123.722 1.38 . . . . 0.0 110.767 -179.931 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 108.58 -16.83 34.03 Favored Glycine 0 N--CA 1.495 2.582 0 N-CA-C 110.361 -1.096 . . . . 0.0 110.361 179.886 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 117.92 138.41 5.99 Favored Glycine 0 N--CA 1.489 2.231 0 N-CA-C 108.675 -1.77 . . . . 0.0 108.675 -179.314 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 6.0 p -124.65 -2.66 7.86 Favored 'General case' 0 N--CA 1.497 1.911 0 O-C-N 121.435 -1.038 . . . . 0.0 112.076 -179.622 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 21' ' ' VAL . . . . . 0.459 HG22 ' O ' ' A' ' 21' ' ' VAL . 12.1 p -160.07 39.81 0.02 OUTLIER 'Isoleucine or valine' 0 N--CA 1.497 1.894 0 O-C-N 120.581 -1.324 . . . . 0.0 110.353 -179.803 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 13.4 mm-40 -98.94 46.23 0.99 Allowed 'General case' 0 N--CA 1.487 1.408 0 O-C-N 120.84 -1.162 . . . . 0.0 111.089 -179.621 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER 43.02 68.4 0.51 Allowed 'General case' 0 N--CA 1.505 2.294 0 CA-C-O 121.409 0.623 . . . . 0.0 111.528 179.617 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 2.7 tt0 -80.6 -57.38 3.6 Favored 'General case' 0 N--CA 1.494 1.761 0 O-C-N 120.983 -1.073 . . . . 0.0 109.904 179.987 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 3.1 t70 -160.25 176.72 11.41 Favored 'General case' 0 N--CA 1.489 1.522 0 N-CA-C 108.838 -0.801 . . . . 0.0 108.838 179.136 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 62.06 39.75 98.02 Favored Glycine 0 N--CA 1.493 2.484 0 N-CA-C 109.658 -1.377 . . . . 0.0 109.658 179.683 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -58.16 -29.96 63.39 Favored Glycine 0 N--CA 1.497 2.738 0 N-CA-C 110.076 -1.21 . . . . 0.0 110.076 179.962 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 1.1 m -79.19 163.58 59.0 Favored Pre-proline 0 N--CA 1.5 2.035 0 O-C-N 121.338 -1.096 . . . . 0.0 109.515 179.467 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 44.1 Cg_endo -69.89 68.88 1.75 Allowed 'Trans proline' 0 C--N 1.308 -1.578 0 O-C-N 123.268 1.141 . . . . 0.0 110.937 -179.747 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -99.5 -40.25 7.94 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.245 -0.909 . . . . 0.0 110.537 -179.958 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 4.4 tt0 -78.98 -9.61 59.58 Favored 'General case' 0 N--CA 1.494 1.74 0 O-C-N 121.503 -0.748 . . . . 0.0 111.12 -179.754 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . -73.23 -38.59 53.87 Favored Glycine 0 N--CA 1.497 2.76 0 N-CA-C 110.198 -1.161 . . . . 0.0 110.198 -179.839 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 33' ' ' CYS . . . . . 0.421 ' HB2' ' O ' ' A' ' 38' ' ' GLY . 0.8 OUTLIER -127.22 94.0 3.89 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.544 -0.974 . . . . 0.0 109.976 179.684 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -123.04 35.29 4.91 Favored 'General case' 0 N--CA 1.495 1.78 0 O-C-N 121.699 -0.626 . . . . 0.0 109.681 179.552 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 2.2 mp0 -78.5 -144.57 0.03 OUTLIER 'General case' 0 N--CA 1.502 2.126 0 O-C-N 121.814 -0.554 . . . . 0.0 109.824 -179.782 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 36' ' ' ALA . . . . . . . . . . . . . . . -76.95 -25.89 53.37 Favored 'General case' 0 N--CA 1.492 1.634 0 O-C-N 121.022 -1.048 . . . . 0.0 109.795 -179.822 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 6.0 tt0 -99.81 -40.04 7.92 Favored 'General case' 0 N--CA 1.497 1.884 0 O-C-N 121.321 -0.862 . . . . 0.0 110.131 179.111 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 38' ' ' GLY . . . . . 0.421 ' O ' ' HB2' ' A' ' 33' ' ' CYS . . . 81.37 -119.5 4.88 Favored Glycine 0 N--CA 1.487 2.079 0 N-CA-C 109.355 -1.498 . . . . 0.0 109.355 -179.881 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 39' ' ' CYS . . . . . . . . . . . . . 1.0 OUTLIER -152.67 43.81 0.66 Allowed 'General case' 0 N--CA 1.495 1.804 0 O-C-N 121.548 -0.972 . . . . 0.0 110.23 179.605 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 40' ' ' LEU . . . . . . . . . . . . . 71.4 mt -92.85 138.99 31.0 Favored 'General case' 0 N--CA 1.493 1.684 0 O-C-N 121.085 -1.01 . . . . 0.0 110.735 -179.502 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 41' ' ' ARG . . . . . . . . . . . . . 29.7 mmt85 -116.23 151.99 34.67 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.515 -0.741 . . . . 0.0 109.955 179.406 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 42' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -88.27 41.58 1.02 Allowed 'General case' 0 N--CA 1.496 1.835 0 O-C-N 121.235 -0.916 . . . . 0.0 111.461 -179.381 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 10.3 mt-10 -93.05 -36.28 12.79 Favored 'General case' 0 N--CA 1.492 1.643 0 O-C-N 121.149 -0.97 . . . . 0.0 110.54 179.333 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -84.8 69.94 3.23 Favored Glycine 0 N--CA 1.496 2.684 0 N-CA-C 109.957 -1.257 . . . . 0.0 109.957 -179.674 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 45' ' ' GLN . . . . . . . . . . . . . 2.2 pt20 . . . . . 0 N--CA 1.5 2.053 0 O-C-N 121.662 -0.905 . . . . 0.0 110.187 179.714 . . . . . . . . 0 0 . 1 . 014 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.492 1.632 0 CA-C-O 120.825 0.345 . . . . 0.0 110.315 . . . . . . . . . 0 0 . 1 . 014 nuclear build full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER 50.76 34.2 9.69 Favored 'General case' 0 N--CA 1.504 2.253 0 O-C-N 121.773 -0.579 . . . . 0.0 112.191 179.371 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -168.89 31.93 0.02 OUTLIER 'General case' 0 N--CA 1.498 1.94 0 O-C-N 120.893 -1.129 . . . . 0.0 111.426 179.52 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 4' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER 42.19 31.86 0.28 Allowed 'General case' 0 N--CA 1.506 2.332 0 O-C-N 121.229 -0.919 . . . . 0.0 111.334 -179.911 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 8.7 t -124.98 114.96 26.39 Favored Pre-proline 0 N--CA 1.492 1.668 0 O-C-N 121.02 -1.05 . . . . 0.0 109.472 -179.935 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 6' ' ' PRO . . . . . . . . . . . . . 44.2 Cg_endo -75.97 -58.27 0.05 OUTLIER 'Trans proline' 0 C--N 1.314 -1.284 0 O-C-N 124.195 1.629 . . . . 0.0 111.161 -179.704 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -76.02 57.02 3.15 Favored Glycine 0 N--CA 1.498 2.811 0 N-CA-C 110.111 -1.196 . . . . 0.0 110.111 -179.77 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 0.8 OUTLIER -113.91 12.66 18.17 Favored 'General case' 0 N--CA 1.495 1.794 0 O-C-N 121.11 -1.229 . . . . 0.0 110.335 179.131 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -116.61 160.37 13.47 Favored Glycine 0 N--CA 1.494 2.534 0 N-CA-C 108.26 -1.936 . . . . 0.0 108.26 179.195 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 10' ' ' GLN . . . . . . . . . . . . . 4.8 mt-30 55.05 31.43 16.17 Favored 'General case' 0 N--CA 1.502 2.16 0 O-C-N 121.574 -0.957 . . . . 0.0 110.639 -179.635 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -76.58 53.04 3.2 Favored Glycine 0 N--CA 1.496 2.699 0 N-CA-C 110.064 -1.214 . . . . 0.0 110.064 -179.822 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 10.0 p -98.89 36.11 0.18 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.722 0 O-C-N 121.351 -1.088 . . . . 0.0 110.32 -179.8 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 13' ' ' GLN . . . . . . . . . . . . . 8.6 tt0 56.48 15.42 2.03 Favored 'General case' 0 N--CA 1.502 2.174 0 O-C-N 121.316 -0.865 . . . . 0.0 111.796 179.814 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . 46.15 36.26 3.08 Favored 'General case' 0 N--CA 1.502 2.172 0 O-C-N 121.274 -0.891 . . . . 0.0 110.663 -179.496 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -95.46 -50.22 2.05 Favored Glycine 0 N--CA 1.493 2.463 0 N-CA-C 109.961 -1.256 . . . . 0.0 109.961 -179.353 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 96.6 m -111.57 80.83 2.93 Favored Pre-proline 0 N--CA 1.497 1.922 0 O-C-N 121.126 -1.22 . . . . 0.0 110.406 -179.629 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 43.5 Cg_endo -74.48 100.9 1.37 Allowed 'Trans proline' 0 C--N 1.312 -1.358 0 O-C-N 123.769 1.405 . . . . 0.0 109.993 179.808 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 114.94 -38.68 3.04 Favored Glycine 0 N--CA 1.496 2.663 0 N-CA-C 110.184 -1.167 . . . . 0.0 110.184 -179.798 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 179.07 144.92 5.95 Favored Glycine 0 N--CA 1.487 2.055 0 N-CA-C 108.973 -1.651 . . . . 0.0 108.973 -179.742 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -108.64 43.58 1.23 Allowed 'General case' 0 N--CA 1.496 1.86 0 O-C-N 121.625 -0.927 . . . . 0.0 110.125 -179.935 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 0.1 OUTLIER -146.09 52.8 0.12 Allowed 'Isoleucine or valine' 0 N--CA 1.496 1.869 0 O-C-N 121.547 -0.721 . . . . 0.0 109.19 179.656 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 2.2 mp0 -79.32 -30.07 42.66 Favored 'General case' 0 N--CA 1.488 1.472 0 O-C-N 121.602 -0.686 . . . . 0.0 111.233 -178.842 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 10.9 tt0 -161.44 108.8 1.44 Allowed 'General case' 0 N--CA 1.493 1.693 0 O-C-N 121.178 -0.951 . . . . 0.0 110.51 -179.709 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 0.8 OUTLIER -89.73 155.26 19.32 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.223 -0.923 . . . . 0.0 109.909 179.438 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 8.8 p-10 -79.05 -33.95 44.24 Favored 'General case' 0 N--CA 1.498 1.96 0 O-C-N 121.359 -0.838 . . . . 0.0 110.7 -179.953 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -55.19 -46.87 77.32 Favored Glycine 0 N--CA 1.495 2.632 0 N-CA-C 110.36 -1.096 . . . . 0.0 110.36 -179.91 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -98.47 61.79 0.86 Allowed Glycine 0 N--CA 1.495 2.619 0 N-CA-C 109.904 -1.279 . . . . 0.0 109.904 -179.743 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 1.6 m -112.57 92.63 20.4 Favored Pre-proline 0 N--CA 1.497 1.918 0 O-C-N 121.318 -1.107 . . . . 0.0 110.578 179.998 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 52.1 Cg_endo -78.8 133.92 11.7 Favored 'Trans proline' 0 C--N 1.316 -1.181 0 O-C-N 123.817 1.43 . . . . 0.0 110.475 179.723 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -127.11 56.99 1.49 Allowed 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.357 -0.84 . . . . 0.0 110.436 179.761 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 10.0 tt0 -160.75 -48.55 0.05 OUTLIER 'General case' 0 N--CA 1.495 1.808 0 O-C-N 121.338 -0.851 . . . . 0.0 110.733 179.557 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . -59.23 -27.15 62.43 Favored Glycine 0 N--CA 1.497 2.713 0 O-C-N 121.514 -0.741 . . . . 0.0 111.524 -179.394 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 33' ' ' CYS . . . . . 0.43 ' O ' ' HB3' ' A' ' 39' ' ' CYS . 26.0 p -79.12 68.55 5.12 Favored 'General case' 0 N--CA 1.498 1.961 0 O-C-N 120.821 -1.399 . . . . 0.0 110.315 -179.556 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -92.39 33.28 1.11 Allowed 'General case' 0 N--CA 1.496 1.855 0 O-C-N 120.888 -1.133 . . . . 0.0 110.626 179.771 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 4.8 mp0 -97.4 -178.5 4.17 Favored 'General case' 0 N--CA 1.492 1.648 0 O-C-N 121.16 -0.963 . . . . 0.0 110.351 -179.968 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 36' ' ' ALA . . . . . . . . . . . . . . . -87.86 28.66 1.0 Allowed 'General case' 0 N--CA 1.498 1.957 0 O-C-N 121.045 -1.034 . . . . 0.0 111.227 -179.807 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 13.6 pt-20 -78.91 -17.57 55.31 Favored 'General case' 0 N--CA 1.493 1.721 0 O-C-N 121.046 -1.033 . . . . 0.0 110.895 179.329 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 122.45 10.22 6.14 Favored Glycine 0 N--CA 1.496 2.673 0 N-CA-C 110.148 -1.181 . . . . 0.0 110.148 -179.533 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 39' ' ' CYS . . . . . 0.43 ' HB3' ' O ' ' A' ' 33' ' ' CYS . 0.1 OUTLIER -79.35 -25.26 42.3 Favored 'General case' 0 N--CA 1.501 2.08 0 O-C-N 120.876 -1.367 . . . . 0.0 110.369 179.78 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 40' ' ' LEU . . . . . 0.44 ' CD2' ' HB3' ' A' ' 42' ' ' ARG . 0.9 OUTLIER -86.95 -69.8 0.65 Allowed 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.024 -1.047 . . . . 0.0 110.851 -179.721 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 41' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER 53.12 67.51 0.99 Allowed 'General case' 0 N--CA 1.502 2.158 0 O-C-N 121.506 -0.746 . . . . 0.0 110.77 -179.917 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 42' ' ' ARG . . . . . 0.44 ' HB3' ' CD2' ' A' ' 40' ' ' LEU . 5.0 ptm180 -110.23 17.56 20.81 Favored 'General case' 0 N--CA 1.496 1.867 0 O-C-N 121.392 -0.818 . . . . 0.0 111.15 -179.906 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 46.2 mt-10 47.33 -123.1 1.44 Allowed 'General case' 0 N--CA 1.497 1.925 0 O-C-N 121.477 -0.764 . . . . 0.0 109.959 -179.623 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -113.45 27.81 9.11 Favored Glycine 0 N--CA 1.492 2.409 0 N-CA-C 108.547 -1.821 . . . . 0.0 108.547 179.223 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 45' ' ' GLN . . . . . . . . . . . . . 0.3 OUTLIER . . . . . 0 N--CA 1.493 1.715 0 O-C-N 121.61 -0.936 . . . . 0.0 110.237 -179.392 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.492 1.671 0 CA-C-O 120.966 0.412 . . . . 0.0 109.9 . . . . . . . . . 0 0 . 1 . 015 nuclear build full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 28.4 mt -80.17 79.31 6.75 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.359 -0.838 . . . . 0.0 110.33 -179.748 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -142.4 173.79 11.21 Favored 'General case' 0 N--CA 1.488 1.472 0 O-C-N 121.366 -0.834 . . . . 0.0 110.431 -179.961 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 4' ' ' ARG . . . . . . . . . . . . . 1.3 mmp_? -74.11 -20.7 60.17 Favored 'General case' 0 N--CA 1.496 1.874 0 O-C-N 121.184 -0.947 . . . . 0.0 111.371 -179.701 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 31.2 p -129.56 146.17 59.98 Favored Pre-proline 0 N--CA 1.494 1.763 0 O-C-N 120.753 -1.217 . . . . 0.0 110.652 -179.914 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 6' ' ' PRO . . . . . . . . . . . . . 47.3 Cg_endo -77.95 121.49 5.43 Favored 'Trans proline' 0 C--N 1.315 -1.189 0 O-C-N 123.899 1.473 . . . . 0.0 110.903 -179.549 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 96.64 12.64 50.06 Favored Glycine 0 N--CA 1.496 2.68 0 N-CA-C 110.734 -0.946 . . . . 0.0 110.734 179.536 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 0.8 OUTLIER -160.5 172.32 17.42 Favored 'General case' 0 N--CA 1.496 1.852 0 O-C-N 120.75 -1.441 . . . . 0.0 110.171 -179.47 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 115.75 -173.26 14.64 Favored Glycine 0 N--CA 1.494 2.55 0 N-CA-C 109.599 -1.4 . . . . 0.0 109.599 -179.871 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 10' ' ' GLN . . . . . . . . . . . . . 4.4 mt-30 -89.14 50.29 1.92 Allowed 'General case' 0 N--CA 1.492 1.659 0 O-C-N 121.279 -1.13 . . . . 0.0 110.381 179.939 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -83.19 60.66 4.87 Favored Glycine 0 N--CA 1.495 2.573 0 N-CA-C 109.744 -1.342 . . . . 0.0 109.744 179.974 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 9.0 p -135.43 25.33 0.93 Allowed 'Isoleucine or valine' 0 N--CA 1.496 1.851 0 O-C-N 121.334 -1.097 . . . . 0.0 110.805 179.904 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 13' ' ' GLN . . . . . 0.45 ' O ' ' HB3' ' A' ' 14' ' ' ALA . 0.2 OUTLIER -71.73 -14.64 62.07 Favored 'General case' 0 N--CA 1.498 1.96 0 O-C-N 120.938 -1.101 . . . . 0.0 111.461 -179.782 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 14' ' ' ALA . . . . . 0.45 ' HB3' ' O ' ' A' ' 13' ' ' GLN . . . 59.63 82.85 0.14 Allowed 'General case' 0 N--CA 1.502 2.165 0 O-C-N 121.17 -0.957 . . . . 0.0 110.583 -179.915 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -125.36 75.95 0.4 Allowed Glycine 0 N--CA 1.492 2.424 0 N-CA-C 109.045 -1.622 . . . . 0.0 109.045 179.665 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 10.7 m -78.4 118.32 71.62 Favored Pre-proline 0 N--CA 1.496 1.866 0 O-C-N 121.29 -1.124 . . . . 0.0 109.709 -179.863 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 40.7 Cg_endo -68.25 -41.2 7.3 Favored 'Trans proline' 0 C--N 1.316 -1.139 0 O-C-N 123.855 1.45 . . . . 0.0 111.32 -179.498 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . -176.22 60.87 0.1 Allowed Glycine 0 N--CA 1.496 2.66 0 N-CA-C 109.796 -1.322 . . . . 0.0 109.796 179.994 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 162.61 75.19 0.02 OUTLIER Glycine 0 N--CA 1.493 2.495 0 N-CA-C 109.539 -1.424 . . . . 0.0 109.539 179.72 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 0.3 OUTLIER -105.86 -40.09 5.82 Favored 'General case' 0 N--CA 1.495 1.803 0 O-C-N 121.191 -1.182 . . . . 0.0 110.647 -179.516 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 3.6 t -107.7 56.27 0.14 Allowed 'Isoleucine or valine' 0 N--CA 1.497 1.903 0 O-C-N 121.319 -0.863 . . . . 0.0 110.186 179.923 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER -79.72 46.2 0.75 Allowed 'General case' 0 N--CA 1.495 1.823 0 O-C-N 120.979 -1.075 . . . . 0.0 110.479 179.827 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 23' ' ' GLU . . . . . 0.488 ' HG3' ' N ' ' A' ' 24' ' ' GLU . 6.7 pt-20 -128.0 -29.41 2.55 Favored 'General case' 0 N--CA 1.493 1.676 0 O-C-N 121.06 -1.025 . . . . 0.0 110.964 179.318 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 24' ' ' GLU . . . . . 0.488 ' N ' ' HG3' ' A' ' 23' ' ' GLU . 10.7 mt-10 57.76 177.38 0.05 Allowed 'General case' 0 N--CA 1.498 1.952 0 O-C-N 121.513 -0.742 . . . . 0.0 111.8 179.401 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 1.2 p-10 -102.81 -36.53 8.23 Favored 'General case' 0 N--CA 1.495 1.802 0 O-C-N 121.122 -0.986 . . . . 0.0 110.433 -179.302 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 118.55 92.03 1.47 Allowed Glycine 0 N--CA 1.49 2.27 0 N-CA-C 108.891 -1.684 . . . . 0.0 108.891 -179.484 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -59.01 105.85 0.77 Allowed Glycine 0 N--CA 1.494 2.545 0 N-CA-C 109.636 -1.386 . . . . 0.0 109.636 -179.564 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 28' ' ' SER . . . . . 0.508 ' N ' ' HD2' ' A' ' 29' ' ' PRO . 0.0 OUTLIER -79.5 -49.3 1.4 Allowed Pre-proline 0 N--CA 1.496 1.837 0 O-C-N 121.536 -0.979 . . . . 0.0 111.769 -179.007 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 29' ' ' PRO . . . . . 0.508 ' HD2' ' N ' ' A' ' 28' ' ' SER . 44.2 Cg_endo -72.21 60.83 3.24 Favored 'Trans proline' 0 N--CA 1.49 1.292 0 O-C-N 123.159 1.083 . . . . 0.0 111.478 -179.197 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -121.74 47.62 1.84 Allowed 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.148 -0.97 . . . . 0.0 110.096 179.421 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 1.2 tp10 -80.46 -68.65 0.66 Allowed 'General case' 0 N--CA 1.493 1.706 0 O-C-N 121.494 -0.754 . . . . 0.0 109.885 -179.664 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 116.56 76.2 0.6 Allowed Glycine 0 N--CA 1.494 2.53 0 N-CA-C 109.766 -1.334 . . . . 0.0 109.766 179.943 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 33' ' ' CYS . . . . . . . . . . . . . 10.4 p -79.09 127.5 32.09 Favored 'General case' 0 N--CA 1.496 1.85 0 O-C-N 121.632 -0.922 . . . . 0.0 109.687 179.462 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -144.77 17.72 1.63 Allowed 'General case' 0 N--CA 1.499 1.989 0 O-C-N 121.385 -0.822 . . . . 0.0 110.543 -179.904 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 1.5 mp0 -90.8 -163.8 1.08 Allowed 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.395 -0.816 . . . . 0.0 110.472 -179.566 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 36' ' ' ALA . . . . . . . . . . . . . . . -88.15 43.05 1.1 Allowed 'General case' 0 N--CA 1.499 1.988 0 O-C-N 121.123 -0.986 . . . . 0.0 111.44 -179.275 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 1.9 pt-20 -138.39 9.73 2.71 Favored 'General case' 0 N--CA 1.494 1.759 0 O-C-N 121.261 -0.9 . . . . 0.0 110.956 179.254 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 68.39 -108.63 2.53 Favored Glycine 0 N--CA 1.495 2.615 0 N-CA-C 108.869 -1.692 . . . . 0.0 108.869 -179.657 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 39' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -160.64 -54.86 0.05 Allowed 'General case' 0 N--CA 1.498 1.96 0 O-C-N 121.154 -1.204 . . . . 0.0 110.376 179.321 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 40' ' ' LEU . . . . . . . . . . . . . 6.3 tt -67.35 -17.74 64.87 Favored 'General case' 0 N--CA 1.494 1.764 0 O-C-N 121.271 -0.893 . . . . 0.0 111.104 -179.888 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 41' ' ' ARG . . . . . . . . . . . . . 6.1 mtp180 64.07 75.61 0.38 Allowed 'General case' 0 N--CA 1.499 1.98 0 CA-C-O 121.869 0.842 . . . . 0.0 110.011 -179.804 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 42' ' ' ARG . . . . . 0.691 ' HG3' ' HG3' ' A' ' 45' ' ' GLN . 10.6 ttm180 -128.46 68.45 1.37 Allowed 'General case' 0 N--CA 1.485 1.298 0 O-C-N 121.353 -0.842 . . . . 0.0 109.334 -179.951 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 8.4 mt-10 -65.18 82.67 0.05 OUTLIER 'General case' 0 N--CA 1.496 1.851 0 O-C-N 121.538 -0.726 . . . . 0.0 112.386 -178.372 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 58.07 46.89 92.08 Favored Glycine 0 N--CA 1.494 2.508 0 N-CA-C 110.566 -1.014 . . . . 0.0 110.566 179.122 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 45' ' ' GLN . . . . . 0.691 ' HG3' ' HG3' ' A' ' 42' ' ' ARG . 0.0 OUTLIER . . . . . 0 N--CA 1.497 1.917 0 CA-C-O 117.996 -1.002 . . . . 0.0 109.885 179.055 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.495 1.777 0 CA-C-O 120.991 0.424 . . . . 0.0 110.1 . . . . . . . . . 0 0 . 1 . 016 nuclear build full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER -100.95 -3.27 29.86 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.167 -0.958 . . . . 0.0 111.918 -179.722 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -57.74 -37.97 74.52 Favored 'General case' 0 N--CA 1.5 2.051 0 O-C-N 121.117 -0.99 . . . . 0.0 111.549 -179.179 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 4' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -131.46 133.59 45.32 Favored 'General case' 0 N--CA 1.489 1.482 0 O-C-N 120.924 -1.11 . . . . 0.0 110.492 -179.64 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 8.5 t -109.09 118.66 50.76 Favored Pre-proline 0 N--CA 1.496 1.828 0 O-C-N 121.403 -0.811 . . . . 0.0 109.475 179.656 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 6' ' ' PRO . . . . . . . . . . . . . 44.1 Cg_endo -73.14 106.86 2.24 Favored 'Trans proline' 0 C--N 1.312 -1.356 0 O-C-N 123.891 1.469 . . . . 0.0 111.162 -179.267 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 66.69 49.07 58.0 Favored Glycine 0 N--CA 1.496 2.659 0 N-CA-C 110.515 -1.034 . . . . 0.0 110.515 179.154 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -84.93 178.57 7.55 Favored 'General case' 0 N--CA 1.5 2.038 0 O-C-N 121.212 -1.17 . . . . 0.0 110.47 179.676 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -74.34 150.97 42.83 Favored Glycine 0 N--CA 1.491 2.311 0 N-CA-C 109.763 -1.335 . . . . 0.0 109.763 179.961 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 10' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -79.23 50.08 1.03 Allowed 'General case' 0 N--CA 1.496 1.875 0 O-C-N 121.591 -0.946 . . . . 0.0 110.773 -179.953 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -79.7 -57.06 3.17 Favored Glycine 0 N--CA 1.492 2.41 0 N-CA-C 109.612 -1.395 . . . . 0.0 109.612 179.929 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 12' ' ' VAL . . . . . 0.456 HG22 ' O ' ' A' ' 12' ' ' VAL . 7.4 p -137.17 65.69 0.25 Allowed 'Isoleucine or valine' 0 N--CA 1.496 1.85 0 O-C-N 121.466 -1.02 . . . . 0.0 110.35 -179.99 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 13' ' ' GLN . . . . . . . . . . . . . 2.6 tp-100 -80.22 -36.87 34.16 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.226 -0.921 . . . . 0.0 110.404 179.712 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -94.83 167.07 11.66 Favored 'General case' 0 N--CA 1.494 1.75 0 O-C-N 121.593 -0.692 . . . . 0.0 110.256 179.976 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -60.12 -34.19 82.92 Favored Glycine 0 N--CA 1.497 2.76 0 N-CA-C 110.228 -1.149 . . . . 0.0 110.228 179.608 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 16' ' ' CYS . . . . . 0.446 ' HB2' ' HB2' ' A' ' 20' ' ' CYS . 0.0 OUTLIER -110.01 96.86 26.98 Favored Pre-proline 0 N--CA 1.496 1.851 0 O-C-N 120.714 -1.462 . . . . 0.0 109.614 179.403 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 41.2 Cg_endo -68.43 111.26 2.48 Favored 'Trans proline' 0 C--N 1.311 -1.424 0 O-C-N 123.837 1.44 . . . . 0.0 111.079 -179.59 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 62.68 20.02 61.26 Favored Glycine 0 N--CA 1.496 2.685 0 N-CA-C 110.654 -0.978 . . . . 0.0 110.654 179.857 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -157.93 54.2 0.38 Allowed Glycine 0 N--CA 1.498 2.771 0 N-CA-C 109.741 -1.344 . . . . 0.0 109.741 -179.808 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 20' ' ' CYS . . . . . 0.446 ' HB2' ' HB2' ' A' ' 16' ' ' CYS . 0.8 OUTLIER -125.95 93.87 3.95 Favored 'General case' 0 N--CA 1.497 1.914 0 O-C-N 121.362 -1.081 . . . . 0.0 109.527 179.686 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 22.5 m -122.27 41.04 0.77 Allowed 'Isoleucine or valine' 0 N--CA 1.494 1.745 0 CA-C-O 121.268 0.556 . . . . 0.0 110.879 -179.211 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 2.8 mt-10 -110.6 44.99 1.18 Allowed 'General case' 0 C--N 1.307 -1.275 0 O-C-N 121.371 -0.83 . . . . 0.0 109.865 179.374 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 1.3 tp10 -101.2 -57.3 2.12 Favored 'General case' 0 N--CA 1.492 1.671 0 O-C-N 121.32 -0.863 . . . . 0.0 110.225 -179.824 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 1.0 OUTLIER -72.77 154.4 40.67 Favored 'General case' 0 N--CA 1.499 1.99 0 O-C-N 121.523 -0.735 . . . . 0.0 110.466 -179.744 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 4.1 p-10 -95.25 36.84 1.2 Allowed 'General case' 0 N--CA 1.502 2.134 0 O-C-N 121.353 -0.842 . . . . 0.0 111.357 179.956 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 154.96 -90.47 0.12 Allowed Glycine 0 N--CA 1.492 2.426 0 N-CA-C 109.719 -1.353 . . . . 0.0 109.719 178.922 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -138.15 141.81 12.51 Favored Glycine 0 N--CA 1.498 2.817 0 N-CA-C 109.799 -1.32 . . . . 0.0 109.799 -179.803 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 28' ' ' SER . . . . . 0.452 ' OG ' ' HD2' ' A' ' 29' ' ' PRO . 23.0 t -84.94 154.43 60.92 Favored Pre-proline 0 C--N 1.301 -1.535 0 O-C-N 121.285 -1.126 . . . . 0.0 109.854 179.759 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 29' ' ' PRO . . . . . 0.452 ' HD2' ' OG ' ' A' ' 28' ' ' SER . 37.9 Cg_endo -65.51 -26.87 54.41 Favored 'Trans proline' 0 C--N 1.308 -1.584 0 O-C-N 123.353 1.186 . . . . 0.0 109.819 179.03 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -93.59 24.2 4.19 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.592 -0.693 . . . . 0.0 110.446 179.182 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 31' ' ' GLU . . . . . 0.413 ' HB2' ' O ' ' A' ' 28' ' ' SER . 1.7 tp10 -83.26 -7.99 59.52 Favored 'General case' 0 N--CA 1.495 1.822 0 O-C-N 121.376 -0.827 . . . . 0.0 111.106 -179.883 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 77.62 29.0 56.28 Favored Glycine 0 N--CA 1.494 2.542 0 N-CA-C 109.404 -1.478 . . . . 0.0 109.404 -179.481 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 33' ' ' CYS . . . . . . . . . . . . . 0.0 OUTLIER -161.64 43.86 0.16 Allowed 'General case' 0 N--CA 1.498 1.929 0 O-C-N 121.411 -1.052 . . . . 0.0 109.861 179.842 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -109.39 -49.44 3.11 Favored 'General case' 0 N--CA 1.498 1.943 0 O-C-N 120.919 -1.113 . . . . 0.0 111.21 -179.342 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 35.1 mt-10 -95.02 -167.45 1.63 Allowed 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.051 -1.031 . . . . 0.0 110.369 -179.217 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 36' ' ' ALA . . . . . . . . . . . . . . . -82.27 44.07 0.84 Allowed 'General case' 0 N--CA 1.497 1.89 0 O-C-N 121.299 -0.876 . . . . 0.0 110.316 179.563 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 3.2 pt-20 -79.67 -13.29 59.58 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.43 -0.794 . . . . 0.0 110.327 179.297 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 132.34 38.12 0.26 Allowed Glycine 0 N--CA 1.502 3.074 0 C-N-CA 120.159 -1.02 . . . . 0.0 111.103 179.389 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 39' ' ' CYS . . . . . . . . . . . . . 13.5 t -93.51 -47.41 6.86 Favored 'General case' 0 N--CA 1.493 1.715 0 O-C-N 121.357 -1.084 . . . . 0.0 110.196 179.76 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 40' ' ' LEU . . . . . . . . . . . . . 7.9 mt -90.31 -100.69 0.1 Allowed 'General case' 0 N--CA 1.488 1.465 0 O-C-N 121.136 -0.977 . . . . 0.0 110.314 179.952 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 41' ' ' ARG . . . . . . . . . . . . . 25.9 ptt180 -165.58 179.87 5.82 Favored 'General case' 0 N--CA 1.494 1.765 0 O-C-N 121.061 -1.025 . . . . 0.0 110.543 179.955 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 42' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -160.92 78.66 0.6 Allowed 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.386 -0.821 . . . . 0.0 110.088 179.93 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -140.05 137.5 34.64 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.381 -0.824 . . . . 0.0 110.92 -179.857 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 91.28 29.28 12.69 Favored Glycine 0 N--CA 1.495 2.599 0 N-CA-C 110.378 -1.089 . . . . 0.0 110.378 179.216 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 45' ' ' GLN . . . . . . . . . . . . . 2.5 mt-30 . . . . . 0 N--CA 1.494 1.755 0 O-C-N 121.275 -1.132 . . . . 0.0 110.106 179.551 . . . . . . . . 0 0 . 1 . 017 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.5 2.05 0 CA-C-O 120.906 0.384 . . . . 0.0 110.257 . . . . . . . . . 0 0 . 1 . 017 nuclear build full ' A' A ' 2' ' ' LEU . . . . . 0.507 HD22 ' HA ' ' A' ' 2' ' ' LEU . 0.3 OUTLIER -147.96 111.78 5.09 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.394 -0.816 . . . . 0.0 110.0 179.926 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -119.26 165.35 14.36 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.584 -0.697 . . . . 0.0 110.345 179.786 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 4' ' ' ARG . . . . . . . . . . . . . 17.4 ttt85 -114.93 158.29 22.2 Favored 'General case' 0 N--CA 1.489 1.481 0 O-C-N 121.251 -0.906 . . . . 0.0 109.935 179.503 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 5' ' ' CYS . . . . . 0.487 ' O ' ' SG ' ' A' ' 8' ' ' CYS . 1.3 p -127.65 163.01 45.65 Favored Pre-proline 0 N--CA 1.496 1.859 0 O-C-N 121.54 -0.725 . . . . 0.0 110.41 179.724 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 6' ' ' PRO . . . . . . . . . . . . . 49.6 Cg_endo -77.54 -50.43 0.09 OUTLIER 'Trans proline' 0 C--N 1.311 -1.396 0 O-C-N 123.552 1.29 . . . . 0.0 111.173 179.488 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -105.2 67.31 0.27 Allowed Glycine 0 N--CA 1.494 2.54 0 N-CA-C 110.239 -1.144 . . . . 0.0 110.239 -179.545 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 8' ' ' CYS . . . . . 0.487 ' SG ' ' O ' ' A' ' 5' ' ' CYS . 3.5 m -86.56 138.04 32.03 Favored 'General case' 0 N--CA 1.494 1.766 0 O-C-N 121.308 -1.113 . . . . 0.0 109.404 179.107 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 114.18 88.51 1.62 Allowed Glycine 0 N--CA 1.492 2.416 0 N-CA-C 109.165 -1.574 . . . . 0.0 109.165 -179.486 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 10' ' ' GLN . . . . . . . . . . . . . 4.1 mt-30 51.62 33.38 10.65 Favored 'General case' 0 N--CA 1.507 2.383 0 O-C-N 121.647 -0.913 . . . . 0.0 111.161 -179.558 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -110.27 -40.36 1.39 Allowed Glycine 0 N--CA 1.496 2.693 0 N-CA-C 109.659 -1.377 . . . . 0.0 109.659 179.761 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 43.6 t -79.16 -47.71 22.23 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.822 0 O-C-N 121.39 -1.065 . . . . 0.0 110.485 179.905 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 13' ' ' GLN . . . . . . . . . . . . . 7.1 tt0 -72.86 133.84 44.59 Favored 'General case' 0 N--CA 1.494 1.735 0 O-C-N 121.054 -1.029 . . . . 0.0 110.244 179.887 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -102.76 -164.08 1.05 Allowed 'General case' 0 N--CA 1.495 1.784 0 O-C-N 121.524 -0.735 . . . . 0.0 109.697 179.602 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -168.71 -105.33 0.18 Allowed Glycine 0 N--CA 1.496 2.649 0 N-CA-C 109.348 -1.501 . . . . 0.0 109.348 179.886 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 16' ' ' CYS . . . . . 0.52 ' SG ' ' N ' ' A' ' 20' ' ' CYS . 0.0 OUTLIER -115.03 98.26 49.91 Favored Pre-proline 0 N--CA 1.49 1.538 0 O-C-N 121.328 -1.101 . . . . 0.0 109.8 179.855 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 48.0 Cg_endo -77.36 60.92 7.2 Favored 'Trans proline' 0 C--N 1.31 -1.458 0 O-C-N 123.572 1.301 . . . . 0.0 109.559 179.251 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 91.4 -20.61 39.87 Favored Glycine 0 N--CA 1.493 2.447 0 N-CA-C 109.605 -1.398 . . . . 0.0 109.605 -178.471 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -99.24 68.8 0.58 Allowed Glycine 0 N--CA 1.496 2.636 0 O-C-N 120.606 -1.526 . . . . 0.0 109.677 -179.901 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 20' ' ' CYS . . . . . 0.52 ' N ' ' SG ' ' A' ' 16' ' ' CYS . 16.3 m -82.17 143.35 31.48 Favored 'General case' 0 N--CA 1.488 1.473 0 O-C-N 121.308 -1.113 . . . . 0.0 109.262 179.803 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 35.7 m -77.88 -21.18 13.72 Favored 'Isoleucine or valine' 0 N--CA 1.503 2.176 0 O-C-N 121.888 -0.508 . . . . 0.0 111.685 -179.137 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 4.1 pt-20 -88.36 15.09 8.26 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.127 -0.983 . . . . 0.0 111.141 179.494 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 3.0 mm-40 -134.21 24.63 3.85 Favored 'General case' 0 N--CA 1.494 1.744 0 O-C-N 120.975 -1.078 . . . . 0.0 110.549 179.482 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 13.9 mm-40 -85.38 -2.83 58.52 Favored 'General case' 0 N--CA 1.494 1.759 0 O-C-N 121.093 -1.004 . . . . 0.0 111.563 -179.717 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 3.8 p-10 -104.98 19.69 20.15 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 120.68 -1.263 . . . . 0.0 109.999 179.972 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -72.45 56.28 1.6 Allowed Glycine 0 N--CA 1.489 2.174 0 N-CA-C 109.31 -1.516 . . . . 0.0 109.31 179.386 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 115.98 9.37 12.25 Favored Glycine 0 N--CA 1.501 3.004 0 O-C-N 121.32 -1.106 . . . . 0.0 110.378 -179.61 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -108.47 92.89 10.66 Favored Pre-proline 0 N--CA 1.493 1.718 0 O-C-N 120.899 -1.354 . . . . 0.0 109.822 179.683 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 43.9 Cg_endo -72.87 71.5 3.38 Favored 'Trans proline' 0 N--CA 1.489 1.238 0 O-C-N 123.472 1.249 . . . . 0.0 110.483 -179.751 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -108.18 61.3 0.61 Allowed 'General case' 0 N--CA 1.488 1.437 0 O-C-N 121.272 -0.893 . . . . 0.0 110.219 -179.86 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 2.1 tt0 -78.76 -28.14 44.79 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.369 -0.832 . . . . 0.0 110.569 -179.749 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 74.57 46.9 17.38 Favored Glycine 0 N--CA 1.489 2.178 0 N-CA-C 110.377 -1.089 . . . . 0.0 110.377 179.255 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 33' ' ' CYS . . . . . . . . . . . . . 14.1 m -79.84 87.56 5.3 Favored 'General case' 0 N--CA 1.497 1.921 0 O-C-N 120.931 -1.335 . . . . 0.0 109.782 179.624 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -102.87 -61.19 1.43 Allowed 'General case' 0 N--CA 1.493 1.689 0 O-C-N 121.503 -0.748 . . . . 0.0 110.201 -179.787 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 1.3 pm0 -85.18 -169.5 2.68 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.445 -0.784 . . . . 0.0 110.533 -179.747 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 36' ' ' ALA . . . . . . . . . . . . . . . -107.93 35.5 3.1 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.013 -1.055 . . . . 0.0 110.232 179.849 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -110.64 -55.36 2.49 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.181 -0.949 . . . . 0.0 110.26 179.948 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -68.38 -41.32 85.71 Favored Glycine 0 N--CA 1.497 2.713 0 N-CA-C 109.546 -1.421 . . . . 0.0 109.546 179.859 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 39' ' ' CYS . . . . . . . . . . . . . 1.6 p -156.82 84.67 0.96 Allowed 'General case' 0 N--CA 1.497 1.915 0 O-C-N 121.412 -1.052 . . . . 0.0 110.119 -179.766 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 40' ' ' LEU . . . . . 0.503 HD12 ' N ' ' A' ' 41' ' ' ARG . 1.4 pp -69.83 -156.36 0.02 OUTLIER 'General case' 0 N--CA 1.498 1.958 0 O-C-N 121.312 -0.868 . . . . 0.0 110.611 -179.751 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 41' ' ' ARG . . . . . 0.503 ' N ' HD12 ' A' ' 40' ' ' LEU . 0.0 OUTLIER -165.13 -35.09 0.03 OUTLIER 'General case' 0 N--CA 1.498 1.946 0 O-C-N 120.854 -1.154 . . . . 0.0 111.93 179.85 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 42' ' ' ARG . . . . . 0.46 ' HG3' ' CD1' ' A' ' 40' ' ' LEU . 34.2 mtt-85 57.9 49.98 11.1 Favored 'General case' 0 N--CA 1.498 1.972 0 O-C-N 121.13 -0.981 . . . . 0.0 110.312 -179.231 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER 53.45 71.53 0.49 Allowed 'General case' 0 N--CA 1.499 1.993 0 O-C-N 121.518 -0.739 . . . . 0.0 110.888 179.857 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -177.83 66.77 0.08 OUTLIER Glycine 0 N--CA 1.494 2.523 0 N-CA-C 109.319 -1.512 . . . . 0.0 109.319 179.903 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 45' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.497 1.893 0 O-C-N 121.735 -0.862 . . . . 0.0 110.64 -179.918 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.497 1.918 0 N-CA-C 109.998 -0.371 . . . . 0.0 109.998 . . . . . . . . . 0 0 . 1 . 018 nuclear build full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER 67.17 94.59 0.07 Allowed 'General case' 0 N--CA 1.505 2.297 0 CA-C-O 121.458 0.647 . . . . 0.0 110.476 -179.991 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -130.06 113.45 14.55 Favored 'General case' 0 N--CA 1.488 1.47 0 O-C-N 121.447 -0.783 . . . . 0.0 110.027 179.774 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 4' ' ' ARG . . . . . . . . . . . . . 2.9 ptm180 -153.65 75.95 1.06 Allowed 'General case' 0 N--CA 1.492 1.675 0 O-C-N 121.198 -0.939 . . . . 0.0 110.49 -179.881 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 3.3 p -131.82 128.85 21.76 Favored Pre-proline 0 N--CA 1.495 1.802 0 O-C-N 121.494 -0.754 . . . . 0.0 109.475 179.463 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 6' ' ' PRO . . . . . . . . . . . . . 42.1 Cg_endo -69.06 -43.98 2.87 Favored 'Trans proline' 0 C--N 1.312 -1.364 0 O-C-N 123.588 1.309 . . . . 0.0 111.534 -179.367 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -82.75 50.81 4.44 Favored Glycine 0 N--CA 1.495 2.624 0 N-CA-C 109.946 -1.262 . . . . 0.0 109.946 -179.975 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 1.7 m -119.06 -30.25 5.04 Favored 'General case' 0 N--CA 1.499 1.995 0 O-C-N 121.257 -1.143 . . . . 0.0 111.001 179.945 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 109.34 133.51 6.76 Favored Glycine 0 N--CA 1.493 2.483 0 N-CA-C 109.73 -1.348 . . . . 0.0 109.73 -179.802 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 10' ' ' GLN . . . . . . . . . . . . . 0.7 OUTLIER 45.39 49.71 10.33 Favored 'General case' 0 N--CA 1.501 2.125 0 O-C-N 121.953 -0.734 . . . . 0.0 111.053 179.499 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -86.93 -54.7 2.55 Favored Glycine 0 N--CA 1.496 2.675 0 N-CA-C 110.092 -1.203 . . . . 0.0 110.092 -179.848 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 12' ' ' VAL . . . . . 0.458 ' O ' HG13 ' A' ' 12' ' ' VAL . 9.0 p -138.03 48.08 0.35 Allowed 'Isoleucine or valine' 0 N--CA 1.495 1.784 0 O-C-N 121.275 -1.132 . . . . 0.0 110.413 179.93 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 13' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -81.82 -7.38 59.6 Favored 'General case' 0 N--CA 1.495 1.78 0 O-C-N 120.946 -1.096 . . . . 0.0 111.159 179.919 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -125.6 141.72 51.88 Favored 'General case' 0 N--CA 1.495 1.821 0 O-C-N 121.303 -0.873 . . . . 0.0 109.767 179.943 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -161.05 90.98 0.11 Allowed Glycine 0 N--CA 1.492 2.406 0 N-CA-C 109.372 -1.491 . . . . 0.0 109.372 179.697 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 13.4 m -94.69 152.71 40.02 Favored Pre-proline 0 N--CA 1.5 2.04 0 O-C-N 121.233 -1.157 . . . . 0.0 110.456 -179.95 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 48.2 Cg_endo -76.38 -147.81 0.03 OUTLIER 'Trans proline' 0 C--N 1.308 -1.554 0 O-C-N 123.779 1.41 . . . . 0.0 108.773 178.454 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . -62.92 -12.39 42.44 Favored Glycine 0 N--CA 1.498 2.767 0 O-C-N 120.878 -1.139 . . . . 0.0 110.898 179.574 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -151.18 115.4 0.7 Allowed Glycine 0 N--CA 1.494 2.536 0 N-CA-C 109.175 -1.57 . . . . 0.0 109.175 -179.705 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 4.8 t -84.56 -10.3 57.53 Favored 'General case' 0 N--CA 1.499 2.01 0 O-C-N 121.179 -1.189 . . . . 0.0 111.459 -179.834 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 8.6 p -129.36 26.21 1.9 Allowed 'Isoleucine or valine' 0 N--CA 1.499 1.997 0 O-C-N 121.045 -1.034 . . . . 0.0 111.027 -179.81 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 1.4 tp10 -105.72 -4.44 20.94 Favored 'General case' 0 N--CA 1.493 1.692 0 O-C-N 120.479 -1.388 . . . . 0.0 110.952 179.56 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 0.8 OUTLIER -138.14 -47.09 0.52 Allowed 'General case' 0 N--CA 1.492 1.673 0 O-C-N 121.064 -1.023 . . . . 0.0 110.712 179.697 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 1.1 mt-10 -59.95 115.84 3.71 Favored 'General case' 0 N--CA 1.494 1.747 0 O-C-N 121.482 -0.761 . . . . 0.0 110.079 -179.423 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 6.4 t0 -104.5 91.37 3.86 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.371 -0.831 . . . . 0.0 109.37 179.297 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -79.32 60.22 4.29 Favored Glycine 0 N--CA 1.496 2.676 0 N-CA-C 109.52 -1.432 . . . . 0.0 109.52 -179.296 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 177.45 -179.24 48.24 Favored Glycine 0 N--CA 1.493 2.49 0 N-CA-C 109.956 -1.258 . . . . 0.0 109.956 179.753 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -160.07 155.56 22.09 Favored Pre-proline 0 N--CA 1.494 1.73 0 O-C-N 121.381 -1.07 . . . . 0.0 110.187 179.854 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 40.2 Cg_endo -67.74 -40.72 9.35 Favored 'Trans proline' 0 N--CA 1.492 1.438 0 O-C-N 123.549 1.289 . . . . 0.0 110.17 179.484 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -92.97 47.95 1.31 Allowed 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.403 -0.811 . . . . 0.0 110.191 179.369 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 12.5 tt0 -77.85 -11.38 59.88 Favored 'General case' 0 N--CA 1.494 1.747 0 O-C-N 121.487 -0.758 . . . . 0.0 111.034 -179.87 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 98.16 84.44 1.76 Allowed Glycine 0 N--CA 1.489 2.22 0 N-CA-C 108.675 -1.77 . . . . 0.0 108.675 -179.668 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 33' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -79.02 65.45 4.2 Favored 'General case' 0 N--CA 1.493 1.714 0 O-C-N 121.166 -1.196 . . . . 0.0 110.051 -179.341 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -115.75 56.38 0.77 Allowed 'General case' 0 N--CA 1.496 1.832 0 O-C-N 121.469 -0.769 . . . . 0.0 109.75 179.697 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 1.1 tt0 -147.59 -162.3 1.52 Allowed 'General case' 0 N--CA 1.494 1.765 0 O-C-N 121.457 -0.777 . . . . 0.0 110.081 -179.363 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 36' ' ' ALA . . . . . . . . . . . . . . . -78.65 -30.85 46.57 Favored 'General case' 0 N--CA 1.494 1.727 0 O-C-N 121.464 -0.772 . . . . 0.0 109.108 179.029 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER -134.74 -74.32 0.47 Allowed 'General case' 0 N--CA 1.487 1.395 0 O-C-N 121.6 -0.687 . . . . 0.0 109.723 179.079 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 56.97 -99.27 0.09 OUTLIER Glycine 0 N--CA 1.496 2.685 0 N-CA-C 110.319 -1.113 . . . . 0.0 110.319 179.291 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 39' ' ' CYS . . . . . . . . . . . . . 2.5 p -99.49 6.56 45.88 Favored 'General case' 0 N--CA 1.497 1.912 0 O-C-N 121.792 -0.828 . . . . 0.0 111.612 -179.674 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 40' ' ' LEU . . . . . . . . . . . . . 1.5 mt 59.25 -165.94 0.18 Allowed 'General case' 0 N--CA 1.504 2.266 0 O-C-N 121.416 -0.802 . . . . 0.0 110.974 179.454 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 41' ' ' ARG . . . . . . . . . . . . . 2.7 mtm180 -134.0 122.16 22.64 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.423 -0.798 . . . . 0.0 109.68 -179.48 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 42' ' ' ARG . . . . . 0.402 HH11 ' HD3' ' A' ' 42' ' ' ARG . 27.8 ttp-105 -135.08 53.58 1.98 Allowed 'General case' 0 N--CA 1.497 1.92 0 O-C-N 121.387 -0.821 . . . . 0.0 110.525 -179.703 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 2.5 pm0 -77.74 76.78 4.27 Favored 'General case' 0 N--CA 1.496 1.828 0 O-C-N 121.216 -0.928 . . . . 0.0 110.944 -179.467 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 114.25 -43.15 1.76 Allowed Glycine 0 N--CA 1.494 2.518 0 N-CA-C 110.184 -1.166 . . . . 0.0 110.184 179.228 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 45' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.494 1.747 0 O-C-N 121.402 -1.057 . . . . 0.0 110.408 -179.991 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.493 1.699 0 CA-C-O 121.264 0.554 . . . . 0.0 110.013 . . . . . . . . . 0 0 . 1 . 019 nuclear build full ' A' A ' 2' ' ' LEU . . . . . 0.548 ' O ' ' HB3' ' A' ' 3' ' ' ALA . 0.9 OUTLIER -85.04 -164.48 1.0 Allowed 'General case' 0 N--CA 1.494 1.742 0 O-C-N 121.099 -1.001 . . . . 0.0 110.32 179.832 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 3' ' ' ALA . . . . . 0.548 ' HB3' ' O ' ' A' ' 2' ' ' LEU . . . 66.73 9.9 7.07 Favored 'General case' 0 N--CA 1.508 2.464 0 O-C-N 121.671 -0.643 . . . . 0.0 111.618 -179.988 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 4' ' ' ARG . . . . . 0.435 ' HB2' ' O ' ' A' ' 3' ' ' ALA . 3.4 mmt180 60.85 -179.76 0.1 Allowed 'General case' 0 N--CA 1.502 2.13 0 O-C-N 121.411 -0.806 . . . . 0.0 111.141 179.734 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 5' ' ' CYS . . . . . 0.438 ' SG ' ' N ' ' A' ' 8' ' ' CYS . 1.3 p -148.13 161.76 33.24 Favored Pre-proline 0 N--CA 1.491 1.595 0 O-C-N 121.572 -0.705 . . . . 0.0 109.941 -179.627 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 6' ' ' PRO . . . . . . . . . . . . . 41.1 Cg_endo -68.2 -31.47 29.18 Favored 'Trans proline' 0 C--N 1.314 -1.246 0 O-C-N 123.637 1.335 . . . . 0.0 110.988 179.824 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -91.81 23.37 26.33 Favored Glycine 0 N--CA 1.494 2.547 0 N-CA-C 110.29 -1.124 . . . . 0.0 110.29 179.492 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 8' ' ' CYS . . . . . 0.438 ' N ' ' SG ' ' A' ' 5' ' ' CYS . 51.0 m -96.93 19.13 13.21 Favored 'General case' 0 N--CA 1.494 1.744 0 O-C-N 120.998 -1.295 . . . . 0.0 110.751 -179.904 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -79.28 -48.03 7.1 Favored Glycine 0 N--CA 1.492 2.415 0 N-CA-C 109.929 -1.268 . . . . 0.0 109.929 -179.653 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 10' ' ' GLN . . . . . . . . . . . . . 4.3 mt-30 -111.62 40.14 2.19 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 121.15 -1.206 . . . . 0.0 110.603 -179.62 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -84.43 63.39 4.43 Favored Glycine 0 N--CA 1.497 2.727 0 N-CA-C 109.861 -1.295 . . . . 0.0 109.861 179.883 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 13.3 m -134.98 48.61 0.41 Allowed 'Isoleucine or valine' 0 N--CA 1.501 2.087 0 O-C-N 121.393 -1.063 . . . . 0.0 110.652 179.923 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 13' ' ' GLN . . . . . . . . . . . . . 11.9 mt-30 -73.56 75.7 1.48 Allowed 'General case' 0 N--CA 1.498 1.936 0 O-C-N 121.074 -1.016 . . . . 0.0 110.454 179.944 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -110.13 -69.51 0.86 Allowed 'General case' 0 N--CA 1.498 1.939 0 O-C-N 121.288 -0.882 . . . . 0.0 110.563 -179.777 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -161.01 -105.1 0.2 Allowed Glycine 0 N--CA 1.493 2.445 0 N-CA-C 109.58 -1.408 . . . . 0.0 109.58 -179.674 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 0.0 OUTLIER -116.9 161.61 31.57 Favored Pre-proline 0 N--CA 1.501 2.101 0 O-C-N 121.253 -1.145 . . . . 0.0 109.61 179.438 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 42.2 Cg_endo -70.2 -59.27 0.08 OUTLIER 'Trans proline' 0 N--CA 1.489 1.225 0 O-C-N 123.825 1.434 . . . . 0.0 111.085 179.961 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . -108.05 -36.91 2.25 Favored Glycine 0 N--CA 1.495 2.602 0 N-CA-C 110.317 -1.113 . . . . 0.0 110.317 179.942 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 172.91 135.91 2.07 Favored Glycine 0 N--CA 1.492 2.426 0 N-CA-C 108.678 -1.769 . . . . 0.0 108.678 -179.923 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 4.1 m -78.57 64.83 3.7 Favored 'General case' 0 N--CA 1.5 2.03 0 O-C-N 121.413 -1.051 . . . . 0.0 110.506 -179.906 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 21' ' ' VAL . . . . . 0.455 HG13 ' N ' ' A' ' 22' ' ' GLU . 7.7 p -133.18 -46.06 0.6 Allowed 'Isoleucine or valine' 0 N--CA 1.498 1.956 0 O-C-N 121.468 -0.77 . . . . 0.0 109.759 179.088 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 22' ' ' GLU . . . . . 0.455 ' N ' HG13 ' A' ' 21' ' ' VAL . 23.4 mt-10 -89.18 33.86 0.8 Allowed 'General case' 0 C--N 1.306 -1.306 0 O-C-N 121.062 -1.024 . . . . 0.0 109.151 178.123 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -156.81 -75.55 0.09 Allowed 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.403 -0.81 . . . . 0.0 110.145 -179.406 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER 57.08 -165.18 0.15 Allowed 'General case' 0 N--CA 1.494 1.748 0 O-C-N 121.676 -0.64 . . . . 0.0 110.65 -179.899 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 3.3 m-20 -107.12 150.91 26.06 Favored 'General case' 0 N--CA 1.495 1.823 0 O-C-N 121.367 -0.833 . . . . 0.0 110.537 -179.666 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 88.19 -86.87 1.49 Allowed Glycine 0 N--CA 1.49 2.287 0 N-CA-C 110.194 -1.162 . . . . 0.0 110.194 179.295 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 69.86 64.16 3.04 Favored Glycine 0 N--CA 1.495 2.594 0 N-CA-C 109.127 -1.589 . . . . 0.0 109.127 -178.986 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 3.5 p -82.02 129.55 63.9 Favored Pre-proline 0 N--CA 1.499 1.987 0 O-C-N 120.859 -1.377 . . . . 0.0 110.868 -179.742 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 43.1 Cg_endo -70.42 -11.0 29.23 Favored 'Trans proline' 0 N--CA 1.489 1.238 0 O-C-N 124.086 1.571 . . . . 0.0 111.043 179.828 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -83.28 6.52 19.36 Favored 'General case' 0 N--CA 1.492 1.666 0 O-C-N 121.066 -1.022 . . . . 0.0 111.564 -179.497 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 31' ' ' GLU . . . . . 0.586 ' HG2' ' N ' ' A' ' 32' ' ' GLY . 14.6 tt0 -79.44 -75.0 0.26 Allowed 'General case' 0 N--CA 1.494 1.763 0 O-C-N 121.157 -0.965 . . . . 0.0 109.736 -179.987 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 32' ' ' GLY . . . . . 0.586 ' N ' ' HG2' ' A' ' 31' ' ' GLU . . . -136.33 22.26 3.39 Favored Glycine 0 N--CA 1.492 2.374 0 N-CA-C 109.55 -1.42 . . . . 0.0 109.55 179.563 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 33' ' ' CYS . . . . . 0.46 ' O ' ' HB2' ' A' ' 39' ' ' CYS . 0.5 OUTLIER -79.39 67.36 5.1 Favored 'General case' 0 N--CA 1.494 1.749 0 O-C-N 121.089 -1.242 . . . . 0.0 109.359 179.36 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 34' ' ' ALA . . . . . 0.498 ' HB1' ' HB2' ' A' ' 42' ' ' ARG . . . -130.32 56.45 1.76 Allowed 'General case' 0 N--CA 1.496 1.868 0 O-C-N 121.536 -0.727 . . . . 0.0 110.319 179.763 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 5.5 mm-40 -92.88 -144.32 0.22 Allowed 'General case' 0 N--CA 1.497 1.884 0 O-C-N 121.505 -0.747 . . . . 0.0 109.74 179.713 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 36' ' ' ALA . . . . . . . . . . . . . . . -114.01 11.93 17.87 Favored 'General case' 0 N--CA 1.496 1.863 0 O-C-N 121.059 -1.026 . . . . 0.0 110.9 179.925 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 20.0 tt0 -161.2 -54.97 0.05 OUTLIER 'General case' 0 N--CA 1.496 1.862 0 O-C-N 121.261 -0.899 . . . . 0.0 110.741 179.516 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -43.6 -51.82 6.6 Favored Glycine 0 N--CA 1.5 2.938 0 N-CA-C 111.525 -0.63 . . . . 0.0 111.525 -178.74 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 39' ' ' CYS . . . . . 0.46 ' HB2' ' O ' ' A' ' 33' ' ' CYS . 56.9 m -139.94 75.68 1.52 Allowed 'General case' 0 N--CA 1.496 1.866 0 O-C-N 121.07 -1.253 . . . . 0.0 110.496 -179.234 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 40' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER 52.28 -148.89 0.39 Allowed 'General case' 0 N--CA 1.503 2.195 0 O-C-N 121.306 -0.872 . . . . 0.0 110.199 179.794 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 41' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -141.32 156.99 45.79 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.069 -1.019 . . . . 0.0 110.664 179.762 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 42' ' ' ARG . . . . . 0.498 ' HB2' ' HB1' ' A' ' 34' ' ' ALA . 0.0 OUTLIER -92.85 -44.48 8.46 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.27 -0.894 . . . . 0.0 110.499 179.888 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -83.86 145.06 28.84 Favored 'General case' 0 N--CA 1.487 1.425 0 O-C-N 121.476 -0.765 . . . . 0.0 110.302 179.941 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -77.58 62.51 3.49 Favored Glycine 0 N--CA 1.492 2.416 0 N-CA-C 110.033 -1.227 . . . . 0.0 110.033 -179.159 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 45' ' ' GLN . . . . . . . . . . . . . 0.4 OUTLIER . . . . . 0 N--CA 1.5 2.039 0 O-C-N 121.475 -1.015 . . . . 0.0 110.401 179.986 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 1.517 0 N-CA-C 109.936 -0.394 . . . . 0.0 109.936 . . . . . . . . . 0 0 . 1 . 020 nuclear build full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 5.0 mp -68.85 156.19 38.87 Favored 'General case' 0 N--CA 1.492 1.652 0 O-C-N 121.404 -0.81 . . . . 0.0 110.406 -179.873 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -75.7 70.51 2.5 Favored 'General case' 0 N--CA 1.491 1.623 0 O-C-N 121.484 -0.76 . . . . 0.0 110.424 179.981 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 4' ' ' ARG . . . . . . . . . . . . . 0.3 OUTLIER -114.67 106.73 14.57 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.261 -0.9 . . . . 0.0 110.422 179.882 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 13.7 t -148.26 115.12 3.92 Favored Pre-proline 0 N--CA 1.495 1.802 0 O-C-N 121.452 -0.78 . . . . 0.0 109.91 -179.939 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 6' ' ' PRO . . . . . . . . . . . . . 50.8 Cg_endo -87.26 -24.06 1.34 Allowed 'Trans proline' 0 C--N 1.309 -1.508 0 O-C-N 123.904 1.476 . . . . 0.0 112.212 -179.515 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -109.85 68.32 0.22 Allowed Glycine 0 N--CA 1.497 2.759 0 O-C-N 120.829 -1.169 . . . . 0.0 111.332 -178.18 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 1.2 p -158.7 150.19 20.83 Favored 'General case' 0 N--CA 1.497 1.885 0 O-C-N 121.177 -1.19 . . . . 0.0 110.213 178.837 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 92.02 -110.46 3.88 Favored Glycine 0 N--CA 1.493 2.442 0 N-CA-C 108.893 -1.683 . . . . 0.0 108.893 -179.461 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 10' ' ' GLN . . . . . . . . . . . . . 5.5 pt20 -155.32 30.29 0.39 Allowed 'General case' 0 N--CA 1.494 1.745 0 O-C-N 121.272 -1.134 . . . . 0.0 110.698 179.379 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -86.58 62.69 4.23 Favored Glycine 0 N--CA 1.493 2.447 0 N-CA-C 109.461 -1.456 . . . . 0.0 109.461 179.614 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 60.2 t -126.94 -75.19 0.36 Allowed 'Isoleucine or valine' 0 N--CA 1.495 1.795 0 O-C-N 121.808 -0.819 . . . . 0.0 109.73 179.745 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 13' ' ' GLN . . . . . . . . . . . . . 1.6 mt-30 42.69 36.33 0.82 Allowed 'General case' 0 N--CA 1.495 1.82 0 O-C-N 121.652 -0.655 . . . . 0.0 111.779 179.736 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -71.5 -22.33 61.81 Favored 'General case' 0 N--CA 1.499 2.014 0 O-C-N 121.171 -0.956 . . . . 0.0 110.936 179.854 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 134.43 -53.34 0.79 Allowed Glycine 0 N--CA 1.493 2.499 0 N-CA-C 109.248 -1.541 . . . . 0.0 109.248 -179.69 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 2.6 p -88.68 121.52 69.91 Favored Pre-proline 0 N--CA 1.497 1.915 0 O-C-N 121.358 -1.083 . . . . 0.0 110.849 179.91 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 48.7 Cg_endo -76.06 79.5 2.89 Favored 'Trans proline' 0 C--N 1.309 -1.513 0 O-C-N 123.705 1.371 . . . . 0.0 110.046 179.606 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 85.79 -48.68 4.02 Favored Glycine 0 N--CA 1.493 2.461 0 N-CA-C 109.887 -1.285 . . . . 0.0 109.887 -179.512 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -72.38 68.8 1.16 Allowed Glycine 0 N--CA 1.495 2.617 0 N-CA-C 110.13 -1.188 . . . . 0.0 110.13 -179.604 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 73.2 m -105.2 119.07 38.14 Favored 'General case' 0 N--CA 1.498 1.957 0 O-C-N 121.482 -1.011 . . . . 0.0 109.511 179.627 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 12.7 t -106.71 -9.34 10.54 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.84 0 O-C-N 121.556 -0.715 . . . . 0.0 111.616 -178.95 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER -79.4 51.5 1.23 Allowed 'General case' 0 N--CA 1.493 1.695 0 O-C-N 120.855 -1.153 . . . . 0.0 110.566 179.718 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 3.2 tt0 -101.79 -24.29 14.08 Favored 'General case' 0 N--CA 1.489 1.477 0 O-C-N 121.095 -1.003 . . . . 0.0 110.139 179.539 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 2.1 pt-20 -79.89 -154.42 0.09 Allowed 'General case' 0 N--CA 1.494 1.736 0 O-C-N 121.274 -0.891 . . . . 0.0 110.575 -179.902 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -82.36 -49.16 10.32 Favored 'General case' 0 N--CA 1.5 2.06 0 O-C-N 121.456 -0.778 . . . . 0.0 110.164 179.947 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 144.09 46.64 0.04 OUTLIER Glycine 0 N--CA 1.498 2.772 0 N-CA-C 110.614 -0.995 . . . . 0.0 110.614 179.419 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 64.73 -130.92 37.06 Favored Glycine 0 N--CA 1.501 2.98 0 N-CA-C 109.685 -1.366 . . . . 0.0 109.685 -179.975 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -146.61 74.97 12.39 Favored Pre-proline 0 N--CA 1.495 1.787 0 O-C-N 121.294 -1.121 . . . . 0.0 109.926 179.691 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 43.4 Cg_endo -74.03 74.44 3.48 Favored 'Trans proline' 0 N--CA 1.488 1.172 0 O-C-N 123.632 1.333 . . . . 0.0 110.661 -179.908 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -89.87 64.84 6.5 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.111 -0.993 . . . . 0.0 110.571 179.887 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 14.8 tp10 -153.17 -67.92 0.15 Allowed 'General case' 0 N--CA 1.493 1.694 0 O-C-N 121.378 -0.826 . . . . 0.0 110.214 179.61 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 123.69 84.52 0.65 Allowed Glycine 0 N--CA 1.497 2.716 0 N-CA-C 109.406 -1.477 . . . . 0.0 109.406 -179.82 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 33' ' ' CYS . . . . . . . . . . . . . 0.4 OUTLIER -95.29 112.36 24.08 Favored 'General case' 0 N--CA 1.493 1.704 0 O-C-N 121.394 -1.062 . . . . 0.0 109.79 179.812 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -107.58 -46.13 3.9 Favored 'General case' 0 N--CA 1.497 1.875 0 O-C-N 121.564 -0.71 . . . . 0.0 110.103 179.886 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 21.8 mt-10 -79.59 -178.88 6.55 Favored 'General case' 0 N--CA 1.5 2.052 0 O-C-N 121.635 -0.665 . . . . 0.0 110.23 179.931 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 36' ' ' ALA . . . . . . . . . . . . . . . -78.66 -38.08 40.37 Favored 'General case' 0 N--CA 1.498 1.931 0 O-C-N 121.202 -0.936 . . . . 0.0 109.897 -179.634 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 7.3 tt0 -119.87 34.07 5.36 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.381 -0.825 . . . . 0.0 109.991 179.492 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -84.72 -9.45 81.13 Favored Glycine 0 N--CA 1.495 2.63 0 O-C-N 121.101 -0.999 . . . . 0.0 110.776 -179.909 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 39' ' ' CYS . . . . . . . . . . . . . 1.3 m -79.43 72.91 6.09 Favored 'General case' 0 N--CA 1.495 1.801 0 O-C-N 120.874 -1.368 . . . . 0.0 109.822 179.842 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 40' ' ' LEU . . . . . 0.489 ' C ' ' HG2' ' A' ' 41' ' ' ARG . 1.0 OUTLIER -75.5 -164.72 0.36 Allowed 'General case' 0 N--CA 1.494 1.763 0 O-C-N 121.372 -0.83 . . . . 0.0 110.46 -179.474 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 41' ' ' ARG . . . . . 0.489 ' HG2' ' C ' ' A' ' 40' ' ' LEU . 4.4 mmt180 66.47 -3.92 0.79 Allowed 'General case' 0 N--CA 1.51 2.543 0 O-C-N 121.743 -0.598 . . . . 0.0 111.933 179.656 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 42' ' ' ARG . . . . . . . . . . . . . 2.7 ttt85 56.4 22.89 6.82 Favored 'General case' 0 N--CA 1.5 2.039 0 O-C-N 120.922 -1.111 . . . . 0.0 111.53 -179.932 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 48.0 mm-40 -90.09 95.18 10.09 Favored 'General case' 0 N--CA 1.488 1.431 0 O-C-N 121.153 -0.967 . . . . 0.0 109.606 179.236 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -155.7 71.62 0.26 Allowed Glycine 0 N--CA 1.492 2.411 0 N-CA-C 109.26 -1.536 . . . . 0.0 109.26 -179.249 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 45' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.499 1.994 0 O-C-N 121.757 -0.849 . . . . 0.0 110.255 -179.822 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER . . . . . 0 N--CA 1.495 1.807 0 N-CA-C 109.878 -0.416 . . . . 0.0 109.878 . . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 6' ' ' PRO . . . . . . . . . . . . . 49.5 Cg_endo -82.23 150.34 15.49 Favored 'Trans proline' 0 C--N 1.313 -1.307 0 O-C-N 123.716 1.377 . . . . 0.0 110.647 -179.822 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 88.32 -46.54 3.38 Favored Glycine 0 N--CA 1.497 2.761 0 N-CA-C 110.342 -1.103 . . . . 0.0 110.342 179.43 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 20.0 p -79.66 -174.29 4.24 Favored 'General case' 0 N--CA 1.496 1.839 0 O-C-N 121.035 -1.274 . . . . 0.0 110.493 -179.601 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 129.26 -114.43 1.73 Allowed Glycine 0 N--CA 1.494 2.545 0 N-CA-C 108.854 -1.699 . . . . 0.0 108.854 -179.433 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 10' ' ' GLN . . . . . . . . . . . . . 14.0 tp60 -164.39 -75.47 0.04 OUTLIER 'General case' 0 N--CA 1.494 1.748 0 O-C-N 121.421 -1.047 . . . . 0.0 110.542 179.222 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -56.13 -26.1 48.64 Favored Glycine 0 N--CA 1.498 2.786 0 O-C-N 121.252 -0.905 . . . . 0.0 110.986 -179.54 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 25.2 t -88.88 -53.88 8.75 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.813 0 O-C-N 121.185 -1.185 . . . . 0.0 110.241 -179.882 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 13' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -67.04 -32.08 73.04 Favored 'General case' 0 N--CA 1.501 2.113 0 O-C-N 121.375 -0.828 . . . . 0.0 112.008 -179.245 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -141.26 52.23 1.57 Allowed 'General case' 0 N--CA 1.496 1.852 0 O-C-N 120.948 -1.095 . . . . 0.0 110.615 -179.645 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -151.76 -85.36 0.05 OUTLIER Glycine 0 N--CA 1.493 2.469 0 N-CA-C 109.845 -1.302 . . . . 0.0 109.845 179.881 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 57.9 m -110.08 97.58 30.68 Favored Pre-proline 0 N--CA 1.496 1.836 0 O-C-N 121.221 -1.164 . . . . 0.0 110.442 -179.898 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 46.7 Cg_endo -72.54 66.53 3.74 Favored 'Trans proline' 0 N--CA 1.491 1.378 0 O-C-N 124.284 1.676 . . . . 0.0 110.409 179.723 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 123.29 -49.97 0.87 Allowed Glycine 0 N--CA 1.495 2.589 0 N-CA-C 109.267 -1.533 . . . . 0.0 109.267 -179.557 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 178.41 134.28 2.06 Favored Glycine 0 N--CA 1.489 2.229 0 N-CA-C 108.971 -1.652 . . . . 0.0 108.971 179.976 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 1.5 m -92.11 33.06 1.09 Allowed 'General case' 0 N--CA 1.5 2.041 0 O-C-N 121.301 -1.117 . . . . 0.0 110.634 -179.911 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 6.4 t -139.87 55.88 0.22 Allowed 'Isoleucine or valine' 0 N--CA 1.496 1.874 0 O-C-N 120.928 -1.107 . . . . 0.0 110.599 -179.89 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 5.2 tt0 -88.88 49.17 1.74 Allowed 'General case' 0 N--CA 1.496 1.863 0 O-C-N 121.135 -0.978 . . . . 0.0 109.266 178.968 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 11.1 mt-10 58.65 -168.03 0.14 Allowed 'General case' 0 N--CA 1.501 2.08 0 O-C-N 121.756 -0.59 . . . . 0.0 110.451 -179.515 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 73.0 mm-40 -69.58 -22.2 63.54 Favored 'General case' 0 N--CA 1.497 1.923 0 O-C-N 120.991 -1.068 . . . . 0.0 111.277 -179.131 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 2.8 t70 -144.34 -61.44 0.38 Allowed 'General case' 0 N--CA 1.496 1.875 0 O-C-N 121.217 -0.927 . . . . 0.0 109.807 179.879 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 172.39 82.86 0.05 OUTLIER Glycine 0 N--CA 1.495 2.567 0 N-CA-C 109.955 -1.258 . . . . 0.0 109.955 179.681 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 66.09 27.69 73.09 Favored Glycine 0 N--CA 1.496 2.658 0 N-CA-C 109.855 -1.298 . . . . 0.0 109.855 179.923 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -102.37 99.59 13.35 Favored Pre-proline 0 N--CA 1.493 1.701 0 O-C-N 121.521 -0.987 . . . . 0.0 110.068 -179.699 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 45.0 Cg_endo -70.87 66.28 2.43 Favored 'Trans proline' 0 N--CA 1.489 1.225 0 O-C-N 123.744 1.391 . . . . 0.0 110.915 -179.577 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -131.28 66.58 1.54 Allowed 'General case' 0 N--CA 1.486 1.371 0 O-C-N 121.337 -0.852 . . . . 0.0 109.974 179.664 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 8.9 tt0 -110.58 -68.75 0.91 Allowed 'General case' 0 N--CA 1.485 1.313 0 O-C-N 121.397 -0.814 . . . . 0.0 110.531 -179.539 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . -72.87 -42.71 44.55 Favored Glycine 0 N--CA 1.496 2.678 0 N-CA-C 110.088 -1.205 . . . . 0.0 110.088 -179.674 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 33' ' ' CYS . . . . . . . . . . . . . 1.7 t -113.77 79.28 1.23 Allowed 'General case' 0 N--CA 1.492 1.646 0 O-C-N 121.141 -1.211 . . . . 0.0 109.661 -179.843 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -125.23 -46.09 1.81 Allowed 'General case' 0 N--CA 1.495 1.812 0 O-C-N 121.111 -0.993 . . . . 0.0 110.992 -179.403 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 0.8 OUTLIER -97.03 -176.48 3.56 Favored 'General case' 0 N--CA 1.498 1.926 0 O-C-N 121.494 -0.754 . . . . 0.0 110.934 -179.414 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 36' ' ' ALA . . . . . 0.548 ' O ' ' HB3' ' A' ' 40' ' ' LEU . . . -79.13 -34.19 43.55 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.26 -0.9 . . . . 0.0 110.189 179.805 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -78.41 2.31 19.21 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.247 -0.908 . . . . 0.0 110.903 179.865 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -92.66 -43.81 4.12 Favored Glycine 0 N--CA 1.492 2.411 0 N-CA-C 109.432 -1.467 . . . . 0.0 109.432 179.951 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 39' ' ' CYS . . . . . . . . . . . . . 1.3 p -161.06 50.34 0.24 Allowed 'General case' 0 N--CA 1.498 1.968 0 O-C-N 121.358 -1.084 . . . . 0.0 111.215 -179.391 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 40' ' ' LEU . . . . . 0.548 ' HB3' ' O ' ' A' ' 36' ' ' ALA . 1.7 pt? . . . . . 0 N--CA 1.504 2.234 0 O-C-N 120.801 -1.187 . . . . 0.0 112.047 -179.599 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 0.3 OUTLIER . . . . . 0 N--CA 1.497 1.924 0 N-CA-C 110.277 -0.268 . . . . 0.0 110.277 . . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 6' ' ' PRO . . . . . . . . . . . . . 45.6 Cg_endo -72.82 -86.18 0.0 OUTLIER 'Trans proline' 0 C--N 1.307 -1.656 0 O-C-N 123.944 1.497 . . . . 0.0 112.062 -179.039 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -105.6 55.8 0.54 Allowed Glycine 0 N--CA 1.49 2.246 0 N-CA-C 109.893 -1.283 . . . . 0.0 109.893 -178.99 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 0.4 OUTLIER -135.34 151.54 50.61 Favored 'General case' 0 N--CA 1.498 1.96 0 O-C-N 121.335 -1.097 . . . . 0.0 110.33 179.611 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 175.98 154.1 11.19 Favored Glycine 0 N--CA 1.495 2.605 0 N-CA-C 109.655 -1.378 . . . . 0.0 109.655 -179.809 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 10' ' ' GLN . . . . . . . . . . . . . 0.3 OUTLIER -129.89 70.56 1.43 Allowed 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.283 -1.128 . . . . 0.0 109.756 179.921 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -79.45 -61.15 2.37 Favored Glycine 0 N--CA 1.495 2.591 0 N-CA-C 110.006 -1.238 . . . . 0.0 110.006 -179.491 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 24.0 m -120.58 -31.65 1.54 Allowed 'Isoleucine or valine' 0 N--CA 1.503 2.213 0 O-C-N 121.427 -1.043 . . . . 0.0 111.491 -179.493 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 13' ' ' GLN . . . . . . . . . . . . . 1.2 tt0 56.33 50.53 13.08 Favored 'General case' 0 N--CA 1.499 1.992 0 O-C-N 121.408 -0.807 . . . . 0.0 110.616 179.93 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -104.68 -60.62 1.57 Allowed 'General case' 0 N--CA 1.495 1.815 0 O-C-N 121.269 -0.894 . . . . 0.0 110.536 179.887 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -152.12 -83.43 0.04 OUTLIER Glycine 0 N--CA 1.494 2.536 0 N-CA-C 109.876 -1.29 . . . . 0.0 109.876 179.942 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 16' ' ' CYS . . . . . 0.456 ' HB2' ' HB2' ' A' ' 20' ' ' CYS . 1.1 m -86.36 136.2 35.73 Favored Pre-proline 0 N--CA 1.496 1.831 0 O-C-N 121.338 -1.096 . . . . 0.0 109.985 179.679 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 45.3 Cg_endo -72.62 72.04 3.13 Favored 'Trans proline' 0 C--N 1.312 -1.361 0 O-C-N 123.656 1.345 . . . . 0.0 109.617 178.931 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 91.52 -49.49 2.9 Favored Glycine 0 N--CA 1.493 2.447 0 N-CA-C 109.702 -1.359 . . . . 0.0 109.702 -179.254 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -74.65 67.14 1.98 Allowed Glycine 0 N--CA 1.497 2.738 0 O-C-N 121.009 -1.289 . . . . 0.0 110.831 -179.727 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 20' ' ' CYS . . . . . 0.456 ' HB2' ' HB2' ' A' ' 16' ' ' CYS . 0.4 OUTLIER -127.77 73.14 1.43 Allowed 'General case' 0 N--CA 1.496 1.83 0 O-C-N 121.24 -1.153 . . . . 0.0 109.174 179.38 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 14.6 p -126.14 -19.66 2.68 Favored 'Isoleucine or valine' 0 N--CA 1.499 2.018 0 O-C-N 121.739 -0.601 . . . . 0.0 111.506 -179.039 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 17.7 mt-10 -79.96 50.18 1.17 Allowed 'General case' 0 N--CA 1.491 1.598 0 O-C-N 120.673 -1.267 . . . . 0.0 110.231 179.831 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 2.3 mt-10 -89.21 -172.91 3.82 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 120.864 -1.147 . . . . 0.0 110.138 -179.794 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER 56.39 59.25 3.73 Favored 'General case' 0 N--CA 1.493 1.677 0 CA-C-O 121.343 0.592 . . . . 0.0 110.4 179.976 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 1.9 p-10 -101.89 -174.45 2.59 Favored 'General case' 0 N--CA 1.496 1.83 0 O-C-N 121.223 -0.923 . . . . 0.0 109.907 179.561 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 79.35 -69.95 2.89 Favored Glycine 0 N--CA 1.495 2.628 0 N-CA-C 109.559 -1.416 . . . . 0.0 109.559 -179.807 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 144.71 115.04 0.97 Allowed Glycine 0 N--CA 1.494 2.561 0 N-CA-C 109.635 -1.386 . . . . 0.0 109.635 179.789 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 73.5 m -81.91 143.63 50.21 Favored Pre-proline 0 N--CA 1.5 2.032 0 O-C-N 121.385 -1.067 . . . . 0.0 110.187 -179.973 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 45.5 Cg_endo -73.46 91.25 0.88 Allowed 'Trans proline' 0 C--N 1.315 -1.188 0 O-C-N 123.729 1.384 . . . . 0.0 111.115 -179.078 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -94.55 -55.2 3.23 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.315 -0.865 . . . . 0.0 110.59 179.883 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 36.2 tt0 -79.05 -7.26 57.97 Favored 'General case' 0 N--CA 1.496 1.858 0 O-C-N 121.513 -0.742 . . . . 0.0 110.911 -179.8 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 90.41 -10.34 74.71 Favored Glycine 0 N--CA 1.494 2.51 0 O-C-N 120.792 -1.192 . . . . 0.0 110.182 -179.515 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 33' ' ' CYS . . . . . . . . . . . . . 59.1 m -79.73 65.71 4.97 Favored 'General case' 0 N--CA 1.494 1.741 0 O-C-N 120.925 -1.338 . . . . 0.0 110.282 -179.803 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -79.2 -38.95 34.52 Favored 'General case' 0 N--CA 1.494 1.742 0 O-C-N 121.456 -0.778 . . . . 0.0 109.573 179.576 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 47.9 mt-10 -89.91 162.59 15.36 Favored 'General case' 0 N--CA 1.493 1.716 0 O-C-N 121.381 -0.825 . . . . 0.0 109.594 179.235 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 36' ' ' ALA . . . . . . . . . . . . . . . -79.35 -46.33 17.86 Favored 'General case' 0 N--CA 1.493 1.683 0 O-C-N 121.123 -0.985 . . . . 0.0 110.412 -179.221 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 1.5 tt0 -95.3 62.41 2.47 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.191 -0.943 . . . . 0.0 110.315 -179.834 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -148.68 17.49 1.26 Allowed Glycine 0 N--CA 1.496 2.673 0 C-N-CA 119.945 -1.121 . . . . 0.0 110.958 -179.984 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 39' ' ' CYS . . . . . . . . . . . . . 57.1 m -144.23 26.87 1.45 Allowed 'General case' 0 N--CA 1.502 2.135 0 O-C-N 120.663 -1.492 . . . . 0.0 111.274 -179.837 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 40' ' ' LEU . . . . . . . . . . . . . 0.9 OUTLIER . . . . . 0 N--CA 1.501 2.082 0 O-C-N 121.68 -0.638 . . . . 0.0 111.647 179.886 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 9.5 t . . . . . 0 N--CA 1.497 1.897 0 N-CA-C 109.506 -0.553 . . . . 0.0 109.506 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' A' A ' 6' ' ' PRO . . . . . . . . . . . . . 48.9 Cg_endo -73.42 -21.13 20.08 Favored 'Trans proline' 0 C--N 1.312 -1.39 0 O-C-N 124.089 1.573 . . . . 0.0 111.949 -179.508 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -74.58 -40.21 39.2 Favored Glycine 0 N--CA 1.496 2.636 0 N-CA-C 110.386 -1.086 . . . . 0.0 110.386 -179.169 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 31.1 p -85.95 -174.61 5.19 Favored 'General case' 0 N--CA 1.498 1.943 0 O-C-N 121.168 -1.195 . . . . 0.0 110.881 -179.599 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -142.26 -135.11 3.05 Favored Glycine 0 N--CA 1.495 2.603 0 N-CA-C 109.854 -1.299 . . . . 0.0 109.854 -179.587 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 10' ' ' GLN . . . . . . . . . . . . . 4.2 mt-30 -80.62 41.37 0.55 Allowed 'General case' 0 N--CA 1.499 2.013 0 O-C-N 121.14 -1.212 . . . . 0.0 111.665 -179.566 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 80.49 -34.42 2.26 Favored Glycine 0 N--CA 1.497 2.714 0 O-C-N 120.718 -1.239 . . . . 0.0 111.224 179.445 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 16.9 m -130.66 60.98 0.3 Allowed 'Isoleucine or valine' 0 N--CA 1.498 1.933 0 O-C-N 121.056 -1.261 . . . . 0.0 110.867 -179.354 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 13' ' ' GLN . . . . . . . . . . . . . 0.6 OUTLIER -124.06 94.64 4.28 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.323 -0.86 . . . . 0.0 109.607 179.754 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -150.84 161.85 41.88 Favored 'General case' 0 N--CA 1.495 1.814 0 CA-C-O 121.539 0.685 . . . . 0.0 111.3 -179.553 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -144.61 -57.68 0.02 OUTLIER Glycine 0 N--CA 1.498 2.801 0 N-CA-C 108.427 -1.869 . . . . 0.0 108.427 179.378 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 0.8 OUTLIER -121.78 79.0 39.98 Favored Pre-proline 0 N--CA 1.499 1.988 0 N-CA-C 108.602 -0.888 . . . . 0.0 108.602 178.482 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 40.6 Cg_endo -66.89 -24.29 46.43 Favored 'Trans proline' 0 N--CA 1.49 1.319 0 C-N-CA 121.288 1.325 . . . . 0.0 112.246 -178.359 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . -96.06 19.43 54.5 Favored Glycine 0 N--CA 1.496 2.666 0 N-CA-C 109.973 -1.251 . . . . 0.0 109.973 179.821 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 114.94 141.56 7.55 Favored Glycine 0 N--CA 1.487 2.064 0 N-CA-C 108.528 -1.829 . . . . 0.0 108.528 179.842 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 36.3 m -109.39 167.48 10.09 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.28 -1.13 . . . . 0.0 109.792 179.889 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . 0.411 HG13 ' CB ' ' A' ' 25' ' ' ASP . 14.5 t -79.18 65.0 0.31 Allowed 'Isoleucine or valine' 0 N--CA 1.494 1.77 0 O-C-N 121.28 -0.887 . . . . 0.0 110.296 -179.801 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -96.14 -31.98 12.72 Favored 'General case' 0 N--CA 1.489 1.494 0 O-C-N 121.21 -0.931 . . . . 0.0 110.099 179.299 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 4.9 mm-40 -94.49 55.22 1.93 Allowed 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.184 -0.948 . . . . 0.0 110.437 -179.49 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 3.0 mm-40 39.09 68.36 0.36 Allowed 'General case' 0 N--CA 1.496 1.837 0 CA-C-O 121.616 0.722 . . . . 0.0 112.026 179.498 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 25' ' ' ASP . . . . . 0.411 ' CB ' HG13 ' A' ' 21' ' ' VAL . 0.7 OUTLIER -89.88 -9.94 47.12 Favored 'General case' 0 N--CA 1.497 1.909 0 O-C-N 121.155 -0.966 . . . . 0.0 110.276 178.85 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 90.25 -67.08 2.63 Favored Glycine 0 N--CA 1.494 2.51 0 N-CA-C 109.068 -1.613 . . . . 0.0 109.068 -179.053 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 67.91 176.55 10.28 Favored Glycine 0 N--CA 1.496 2.681 0 N-CA-C 110.234 -1.146 . . . . 0.0 110.234 179.516 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 1.9 t -111.37 94.41 22.19 Favored Pre-proline 0 N--CA 1.496 1.836 0 O-C-N 121.315 -1.109 . . . . 0.0 109.773 179.655 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 44.4 Cg_endo -71.91 110.1 2.83 Favored 'Trans proline' 0 C--N 1.315 -1.229 0 O-C-N 123.832 1.438 . . . . 0.0 110.728 -179.583 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -79.26 -54.15 6.25 Favored 'General case' 0 N--CA 1.492 1.646 0 O-C-N 121.264 -0.897 . . . . 0.0 110.364 -179.985 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 6.8 tt0 -90.24 16.52 8.47 Favored 'General case' 0 N--CA 1.492 1.665 0 O-C-N 121.073 -1.017 . . . . 0.0 111.002 179.702 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . -87.17 35.96 3.37 Favored Glycine 0 N--CA 1.492 2.431 0 N-CA-C 109.502 -1.439 . . . . 0.0 109.502 179.555 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 33' ' ' CYS . . . . . 0.471 ' HA ' ' O ' ' A' ' 38' ' ' GLY . 0.5 OUTLIER -114.28 22.08 14.08 Favored 'General case' 0 N--CA 1.494 1.746 0 O-C-N 121.497 -1.001 . . . . 0.0 110.646 179.328 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -152.24 46.48 0.75 Allowed 'General case' 0 N--CA 1.498 1.965 0 O-C-N 121.058 -1.026 . . . . 0.0 110.604 -179.722 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 7.6 pt-20 -128.73 -157.44 0.82 Allowed 'General case' 0 N--CA 1.499 2.002 0 O-C-N 121.51 -0.744 . . . . 0.0 110.253 179.856 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 36' ' ' ALA . . . . . . . . . . . . . . . -77.83 -23.64 48.9 Favored 'General case' 0 N--CA 1.499 1.985 0 O-C-N 121.242 -0.911 . . . . 0.0 110.448 -179.652 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER -79.5 -33.74 41.87 Favored 'General case' 0 N--CA 1.492 1.654 0 O-C-N 121.16 -0.962 . . . . 0.0 109.819 179.547 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 38' ' ' GLY . . . . . 0.471 ' O ' ' HA ' ' A' ' 33' ' ' CYS . . . 107.88 -97.09 1.1 Allowed Glycine 0 N--CA 1.492 2.421 0 N-CA-C 109.113 -1.595 . . . . 0.0 109.113 179.847 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 39' ' ' CYS . . . . . . . . . . . . . 1.8 t -160.81 115.04 2.1 Favored 'General case' 0 N--CA 1.498 1.957 0 O-C-N 121.637 -0.919 . . . . 0.0 109.687 179.435 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 40' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER . . . . . 0 N--CA 1.49 1.55 0 O-C-N 121.152 -0.968 . . . . 0.0 110.908 -179.334 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 N--CA 1.496 1.854 0 N-CA-C 110.074 -0.343 . . . . 0.0 110.074 . . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 6' ' ' PRO . . . . . . . . . . . . . 44.6 Cg_endo -74.74 -50.99 0.13 Allowed 'Trans proline' 0 C--N 1.314 -1.268 0 O-C-N 123.665 1.35 . . . . 0.0 111.102 -179.64 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -78.03 58.38 3.94 Favored Glycine 0 N--CA 1.494 2.559 0 N-CA-C 109.736 -1.346 . . . . 0.0 109.736 179.992 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 1.1 m -114.49 3.22 14.85 Favored 'General case' 0 N--CA 1.492 1.672 0 O-C-N 121.271 -1.135 . . . . 0.0 111.349 -179.938 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 9' ' ' GLY . . . . . 0.428 ' O ' ' HB2' ' A' ' 10' ' ' GLN . . . -80.18 57.36 4.63 Favored Glycine 0 N--CA 1.494 2.534 0 N-CA-C 109.894 -1.282 . . . . 0.0 109.894 179.598 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 10' ' ' GLN . . . . . 0.428 ' HB2' ' O ' ' A' ' 9' ' ' GLY . 5.6 tt0 -178.56 -63.4 0.01 OUTLIER 'General case' 0 N--CA 1.494 1.769 0 O-C-N 121.466 -1.02 . . . . 0.0 109.994 179.787 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -85.07 62.97 4.45 Favored Glycine 0 N--CA 1.491 2.346 0 N-CA-C 110.018 -1.233 . . . . 0.0 110.018 -179.867 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 12' ' ' VAL . . . . . 0.478 HG13 ' N ' ' A' ' 13' ' ' GLN . 7.5 p -146.37 -47.24 0.11 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.652 0 O-C-N 121.467 -1.019 . . . . 0.0 110.413 179.602 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 13' ' ' GLN . . . . . 0.478 ' N ' HG13 ' A' ' 12' ' ' VAL . 20.4 tt0 -175.04 -55.07 0.01 OUTLIER 'General case' 0 N--CA 1.497 1.9 0 O-C-N 121.36 -0.838 . . . . 0.0 109.6 179.521 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -117.04 -178.26 3.4 Favored 'General case' 0 N--CA 1.496 1.825 0 O-C-N 121.788 -0.57 . . . . 0.0 110.216 179.789 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -85.03 -35.21 12.87 Favored Glycine 0 N--CA 1.496 2.65 0 N-CA-C 110.378 -1.089 . . . . 0.0 110.378 -179.581 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 0.0 OUTLIER -113.45 132.85 22.31 Favored Pre-proline 0 N--CA 1.5 2.027 0 O-C-N 121.332 -1.099 . . . . 0.0 109.67 179.702 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 47.4 Cg_endo -74.29 58.67 4.44 Favored 'Trans proline' 0 C--N 1.31 -1.488 0 O-C-N 123.72 1.379 . . . . 0.0 111.072 -179.731 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 92.9 92.85 1.48 Allowed Glycine 0 N--CA 1.495 2.579 0 N-CA-C 110.167 -1.173 . . . . 0.0 110.167 179.336 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 106.71 113.1 3.75 Favored Glycine 0 N--CA 1.49 2.298 0 N-CA-C 110.128 -1.189 . . . . 0.0 110.128 179.345 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 20' ' ' CYS . . . . . 0.477 ' O ' ' HB3' ' A' ' 25' ' ' ASP . 36.9 m -122.27 -12.99 8.18 Favored 'General case' 0 N--CA 1.502 2.166 0 O-C-N 121.521 -0.988 . . . . 0.0 111.285 179.818 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . 0.586 HG12 ' CA ' ' A' ' 27' ' ' GLY . 18.5 m -80.36 18.91 0.18 Allowed 'Isoleucine or valine' 0 N--CA 1.504 2.239 0 O-C-N 120.865 -1.147 . . . . 0.0 111.848 -179.562 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 5.0 mm-40 -79.67 -19.88 47.97 Favored 'General case' 0 N--CA 1.486 1.357 0 O-C-N 120.84 -1.163 . . . . 0.0 110.884 179.836 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -139.18 55.35 1.7 Allowed 'General case' 0 N--CA 1.491 1.591 0 O-C-N 120.891 -1.131 . . . . 0.0 110.259 179.956 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 24' ' ' GLU . . . . . 0.545 ' HG3' ' HB2' ' A' ' 28' ' ' SER . 0.8 OUTLIER 53.09 31.15 10.75 Favored 'General case' 0 N--CA 1.506 2.362 0 O-C-N 121.92 -0.487 . . . . 0.0 112.013 179.473 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 25' ' ' ASP . . . . . 0.477 ' HB3' ' O ' ' A' ' 20' ' ' CYS . 21.2 t70 -106.27 115.38 30.12 Favored 'General case' 0 N--CA 1.496 1.834 0 O-C-N 120.866 -1.146 . . . . 0.0 109.661 179.715 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 77.22 -56.07 3.63 Favored Glycine 0 N--CA 1.492 2.382 0 N-CA-C 110.559 -1.016 . . . . 0.0 110.559 179.594 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 27' ' ' GLY . . . . . 0.586 ' CA ' HG12 ' A' ' 21' ' ' VAL . . . -55.97 -54.34 35.97 Favored Glycine 0 N--CA 1.494 2.56 0 N-CA-C 110.27 -1.132 . . . . 0.0 110.27 -178.964 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 28' ' ' SER . . . . . 0.545 ' HB2' ' HG3' ' A' ' 24' ' ' GLU . 1.4 m -113.83 77.3 3.52 Favored Pre-proline 0 N--CA 1.497 1.893 0 O-C-N 121.742 -0.858 . . . . 0.0 110.696 -179.368 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 54.7 Cg_endo -79.86 114.32 3.15 Favored 'Trans proline' 0 C--N 1.314 -1.282 0 O-C-N 123.234 1.123 . . . . 0.0 110.028 179.602 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -77.2 -26.81 53.2 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 120.974 -1.079 . . . . 0.0 109.904 179.937 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 1.2 mt-10 -78.95 1.99 21.82 Favored 'General case' 0 N--CA 1.494 1.771 0 O-C-N 121.312 -0.867 . . . . 0.0 110.685 179.137 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . -99.28 35.8 4.46 Favored Glycine 0 N--CA 1.492 2.379 0 N-CA-C 110.04 -1.224 . . . . 0.0 110.04 179.904 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 33' ' ' CYS . . . . . . . . . . . . . 1.7 t -160.67 64.69 0.31 Allowed 'General case' 0 N--CA 1.494 1.764 0 O-C-N 121.268 -1.137 . . . . 0.0 110.3 179.739 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -78.64 -53.45 7.16 Favored 'General case' 0 N--CA 1.499 1.983 0 O-C-N 121.073 -1.017 . . . . 0.0 109.417 179.06 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 8.0 mt-10 -85.16 169.56 13.74 Favored 'General case' 0 N--CA 1.495 1.784 0 O-C-N 121.461 -0.774 . . . . 0.0 109.519 178.466 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 36' ' ' ALA . . . . . . . . . . . . . . . -78.18 -43.52 28.4 Favored 'General case' 0 N--CA 1.493 1.718 0 O-C-N 120.908 -1.12 . . . . 0.0 109.505 179.826 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 6.5 pt-20 -81.33 -28.22 34.64 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.309 -0.87 . . . . 0.0 110.194 179.458 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -74.3 71.17 1.53 Allowed Glycine 0 N--CA 1.491 2.324 0 N-CA-C 109.92 -1.272 . . . . 0.0 109.92 -179.881 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 39' ' ' CYS . . . . . . . . . . . . . 0.6 OUTLIER -160.04 -47.76 0.05 Allowed 'General case' 0 C--N 1.296 -1.742 0 O-C-N 121.678 -0.895 . . . . 0.0 110.021 179.495 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 40' ' ' LEU . . . . . . . . . . . . . 17.0 mt . . . . . 0 N--CA 1.5 2.061 0 O-C-N 121.6 -0.687 . . . . 0.0 110.595 179.368 . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 2.2 t . . . . . 0 N--CA 1.497 1.906 0 CA-C-O 120.875 0.369 . . . . 0.0 110.049 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' A' A ' 6' ' ' PRO . . . . . . . . . . . . . 50.5 Cg_endo -75.42 75.92 3.73 Favored 'Trans proline' 0 C--N 1.313 -1.326 0 O-C-N 123.964 1.507 . . . . 0.0 110.425 179.928 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 73.89 38.7 48.61 Favored Glycine 0 N--CA 1.498 2.798 0 N-CA-C 110.118 -1.193 . . . . 0.0 110.118 179.987 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 5.4 p -92.04 -159.84 0.69 Allowed 'General case' 0 N--CA 1.498 1.927 0 O-C-N 121.28 -1.13 . . . . 0.0 109.858 179.498 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -76.93 -93.89 0.21 Allowed Glycine 0 N--CA 1.495 2.579 0 N-CA-C 109.599 -1.4 . . . . 0.0 109.599 -179.978 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 10' ' ' GLN . . . . . . . . . . . . . 2.3 pt20 -169.58 85.72 0.14 Allowed 'General case' 0 N--CA 1.493 1.722 0 O-C-N 121.221 -1.164 . . . . 0.0 109.885 179.656 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -75.64 60.01 2.92 Favored Glycine 0 N--CA 1.497 2.7 0 N-CA-C 109.932 -1.267 . . . . 0.0 109.932 -179.809 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 12' ' ' VAL . . . . . 0.445 ' O ' HG13 ' A' ' 12' ' ' VAL . 14.2 p -146.26 52.57 0.11 Allowed 'Isoleucine or valine' 0 N--CA 1.495 1.783 0 O-C-N 121.537 -0.978 . . . . 0.0 109.537 -179.933 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 13' ' ' GLN . . . . . . . . . . . . . 4.5 tt0 -58.93 -55.4 35.57 Favored 'General case' 0 N--CA 1.5 2.027 0 O-C-N 121.125 -0.984 . . . . 0.0 110.851 -179.733 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -83.54 66.44 8.93 Favored 'General case' 0 N--CA 1.498 1.939 0 O-C-N 121.143 -0.973 . . . . 0.0 110.185 -179.775 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -72.58 -67.1 1.9 Allowed Glycine 0 N--CA 1.494 2.534 0 N-CA-C 109.78 -1.328 . . . . 0.0 109.78 -179.748 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 1.2 p -127.89 74.51 78.69 Favored Pre-proline 0 N--CA 1.497 1.88 0 O-C-N 121.788 -0.83 . . . . 0.0 110.45 179.608 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 43.8 Cg_endo -68.72 131.01 21.75 Favored 'Trans proline' 0 C--N 1.309 -1.523 0 O-C-N 123.462 1.243 . . . . 0.0 110.36 -179.978 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 100.89 -24.36 32.28 Favored Glycine 0 N--CA 1.493 2.453 0 N-CA-C 110.54 -1.024 . . . . 0.0 110.54 179.916 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 165.81 138.52 2.44 Favored Glycine 0 N--CA 1.489 2.177 0 N-CA-C 108.943 -1.663 . . . . 0.0 108.943 179.599 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 71.6 m -118.36 112.74 20.4 Favored 'General case' 0 N--CA 1.492 1.672 0 O-C-N 121.492 -1.005 . . . . 0.0 110.009 179.788 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . 0.423 ' O ' HG13 ' A' ' 21' ' ' VAL . 7.2 p -92.89 43.63 0.08 OUTLIER 'Isoleucine or valine' 0 N--CA 1.504 2.232 0 O-C-N 121.282 -0.886 . . . . 0.0 110.481 -179.608 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 2.1 mm-40 -79.45 -28.08 41.62 Favored 'General case' 0 N--CA 1.488 1.457 0 O-C-N 121.029 -1.044 . . . . 0.0 110.931 -179.908 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 1.3 tp10 -162.29 110.87 1.4 Allowed 'General case' 0 N--CA 1.493 1.685 0 O-C-N 121.018 -1.052 . . . . 0.0 110.328 179.852 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 2.3 tt0 -148.23 153.29 38.54 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 121.487 -0.758 . . . . 0.0 110.165 179.104 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -96.67 -54.41 3.24 Favored 'General case' 0 N--CA 1.497 1.888 0 O-C-N 121.75 -0.594 . . . . 0.0 110.183 -179.677 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -156.25 94.34 0.14 Allowed Glycine 0 N--CA 1.494 2.549 0 N-CA-C 108.723 -1.751 . . . . 0.0 108.723 -179.891 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -55.81 96.72 0.04 OUTLIER Glycine 0 N--CA 1.498 2.826 0 N-CA-C 110.567 -1.013 . . . . 0.0 110.567 -179.422 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 28' ' ' SER . . . . . 0.531 ' CB ' ' HD3' ' A' ' 29' ' ' PRO . 1.6 t -160.75 -65.51 0.02 OUTLIER Pre-proline 0 N--CA 1.496 1.849 0 O-C-N 121.334 -1.098 . . . . 0.0 109.586 179.615 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 29' ' ' PRO . . . . . 0.531 ' HD3' ' CB ' ' A' ' 28' ' ' SER . 51.8 Cg_endo -78.26 72.14 6.41 Favored 'Trans proline' 0 N--CA 1.486 1.048 0 O-C-N 123.205 1.108 . . . . 0.0 109.863 178.742 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 30' ' ' ALA . . . . . 0.406 ' O ' ' HB3' ' A' ' 34' ' ' ALA . . . -79.64 -64.26 1.23 Allowed 'General case' 0 N--CA 1.493 1.701 0 O-C-N 121.349 -0.844 . . . . 0.0 111.212 -179.065 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 3.5 tt0 -117.78 -22.99 7.73 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.038 -1.039 . . . . 0.0 111.381 -179.224 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . -52.04 -41.57 53.08 Favored Glycine 0 N--CA 1.498 2.821 0 O-C-N 120.99 -1.069 . . . . 0.0 110.915 -179.193 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 33' ' ' CYS . . . . . . . . . . . . . 0.8 OUTLIER -149.59 62.69 1.01 Allowed 'General case' 0 N--CA 1.496 1.858 0 O-C-N 121.159 -1.2 . . . . 0.0 110.381 179.78 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 34' ' ' ALA . . . . . 0.406 ' HB3' ' O ' ' A' ' 30' ' ' ALA . . . -141.5 34.06 1.65 Allowed 'General case' 0 N--CA 1.498 1.952 0 O-C-N 121.257 -0.902 . . . . 0.0 110.367 179.882 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -111.15 -168.7 1.34 Allowed 'General case' 0 N--CA 1.496 1.863 0 O-C-N 121.376 -0.827 . . . . 0.0 109.776 179.693 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 36' ' ' ALA . . . . . . . . . . . . . . . -78.66 -24.65 45.06 Favored 'General case' 0 N--CA 1.5 2.037 0 O-C-N 121.508 -0.745 . . . . 0.0 110.324 179.985 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 4.9 tt0 -80.06 -46.83 15.84 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.519 -0.738 . . . . 0.0 109.697 179.769 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 106.42 -112.71 3.92 Favored Glycine 0 N--CA 1.489 2.184 0 N-CA-C 109.688 -1.365 . . . . 0.0 109.688 179.792 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 39' ' ' CYS . . . . . . . . . . . . . 1.6 m -144.81 -47.14 0.24 Allowed 'General case' 0 N--CA 1.501 2.114 0 O-C-N 121.408 -1.054 . . . . 0.0 110.715 -179.633 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 40' ' ' LEU . . . . . . . . . . . . . 0.7 OUTLIER . . . . . 0 N--CA 1.505 2.311 0 O-C-N 121.518 -0.739 . . . . 0.0 111.892 179.731 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 22.9 p . . . . . 0 N--CA 1.494 1.763 0 N-CA-C 109.376 -0.601 . . . . 0.0 109.376 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' A' A ' 6' ' ' PRO . . . . . . . . . . . . . 42.0 Cg_endo -70.97 -53.26 0.2 Allowed 'Trans proline' 0 C--N 1.311 -1.412 0 O-C-N 123.685 1.36 . . . . 0.0 111.778 -178.988 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -108.89 59.45 0.36 Allowed Glycine 0 N--CA 1.492 2.371 0 O-C-N 120.917 -1.114 . . . . 0.0 110.859 -179.045 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 10.5 p -110.02 -35.68 6.06 Favored 'General case' 0 N--CA 1.5 2.034 0 O-C-N 121.264 -1.139 . . . . 0.0 110.693 179.355 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 49.4 32.19 14.57 Favored Glycine 0 N--CA 1.502 3.056 0 O-C-N 121.337 -0.852 . . . . 0.0 111.478 179.441 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 10' ' ' GLN . . . . . . . . . . . . . 69.8 mt-30 49.63 43.72 24.27 Favored 'General case' 0 N--CA 1.501 2.08 0 O-C-N 121.304 -1.115 . . . . 0.0 110.904 179.691 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -48.27 -50.06 23.88 Favored Glycine 0 N--CA 1.503 3.155 0 N-CA-C 110.619 -0.992 . . . . 0.0 110.619 -179.707 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 12' ' ' VAL . . . . . 0.51 ' O ' HG13 ' A' ' 12' ' ' VAL . 11.2 p -127.82 53.75 0.37 Allowed 'Isoleucine or valine' 0 N--CA 1.494 1.728 0 O-C-N 121.312 -1.111 . . . . 0.0 109.759 179.81 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 13' ' ' GLN . . . . . . . . . . . . . 1.6 pt20 -71.02 142.76 50.91 Favored 'General case' 0 N--CA 1.495 1.795 0 O-C-N 121.01 -1.057 . . . . 0.0 110.321 -179.891 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -122.75 131.89 53.98 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.321 -0.862 . . . . 0.0 109.858 179.805 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -73.36 -54.15 7.05 Favored Glycine 0 N--CA 1.491 2.314 0 N-CA-C 109.662 -1.375 . . . . 0.0 109.662 -179.976 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 12.2 m -114.3 122.0 35.18 Favored Pre-proline 0 N--CA 1.499 1.992 0 O-C-N 121.295 -1.12 . . . . 0.0 109.996 -179.94 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 43.6 Cg_endo -72.11 75.38 2.3 Favored 'Trans proline' 0 N--CA 1.497 1.692 0 O-C-N 123.611 1.322 . . . . 0.0 110.789 -179.69 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 127.14 -46.02 1.11 Allowed Glycine 0 N--CA 1.495 2.571 0 N-CA-C 109.659 -1.376 . . . . 0.0 109.659 179.879 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 161.5 147.33 4.94 Favored Glycine 0 N--CA 1.484 1.884 0 N-CA-C 109.321 -1.512 . . . . 0.0 109.321 -179.318 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 0.9 OUTLIER -106.22 172.2 6.94 Favored 'General case' 0 C--N 1.296 -1.746 0 O-C-N 121.534 -0.98 . . . . 0.0 109.647 -179.811 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 10.5 t -78.71 61.33 0.17 Allowed 'Isoleucine or valine' 0 N--CA 1.498 1.936 0 O-C-N 121.35 -0.844 . . . . 0.0 109.781 179.527 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 3.0 mm-40 -131.24 37.49 3.72 Favored 'General case' 0 C--N 1.306 -1.305 0 O-C-N 121.585 -0.697 . . . . 0.0 109.661 -179.717 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 48.2 mt-10 -68.5 167.11 15.54 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.308 -0.87 . . . . 0.0 110.874 -179.236 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 2.8 pm0 -70.91 158.9 35.65 Favored 'General case' 0 N--CA 1.495 1.794 0 O-C-N 121.733 -0.605 . . . . 0.0 111.18 -179.014 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -80.3 -65.46 1.0 Allowed 'General case' 0 N--CA 1.491 1.597 0 N-CA-C 109.376 -0.602 . . . . 0.0 109.376 179.212 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 174.74 84.57 0.06 OUTLIER Glycine 0 N--CA 1.494 2.507 0 N-CA-C 109.535 -1.426 . . . . 0.0 109.535 179.853 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 149.16 128.3 1.66 Allowed Glycine 0 N--CA 1.493 2.464 0 N-CA-C 109.268 -1.533 . . . . 0.0 109.268 179.944 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -93.39 150.73 39.47 Favored Pre-proline 0 N--CA 1.495 1.818 0 O-C-N 121.559 -0.965 . . . . 0.0 110.444 -179.507 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 29' ' ' PRO . . . . . 0.487 ' HA ' ' HB3' ' A' ' 33' ' ' CYS . 52.4 Cg_endo -79.55 14.19 1.89 Allowed 'Trans proline' 0 N--CA 1.486 1.083 0 O-C-N 123.833 1.439 . . . . 0.0 111.784 179.81 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -127.55 15.18 7.08 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.049 -1.032 . . . . 0.0 110.394 179.585 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -159.84 -75.58 0.07 Allowed 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.458 -0.776 . . . . 0.0 109.613 -179.638 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . -66.97 -56.51 12.27 Favored Glycine 0 N--CA 1.496 2.646 0 N-CA-C 109.284 -1.526 . . . . 0.0 109.284 179.699 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 33' ' ' CYS . . . . . 0.487 ' HB3' ' HA ' ' A' ' 29' ' ' PRO . 5.5 t -87.24 73.83 9.63 Favored 'General case' 0 N--CA 1.497 1.895 0 O-C-N 121.358 -1.084 . . . . 0.0 109.891 179.766 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -147.86 49.24 1.07 Allowed 'General case' 0 N--CA 1.495 1.793 0 O-C-N 121.495 -0.753 . . . . 0.0 110.063 179.831 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 12.0 mt-10 -108.51 -174.35 2.5 Favored 'General case' 0 N--CA 1.494 1.762 0 O-C-N 121.467 -0.771 . . . . 0.0 110.69 -179.862 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 36' ' ' ALA . . . . . . . . . . . . . . . -89.97 -1.96 58.07 Favored 'General case' 0 N--CA 1.499 2.006 0 O-C-N 121.294 -0.879 . . . . 0.0 111.501 179.89 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -117.81 31.89 6.45 Favored 'General case' 0 N--CA 1.493 1.689 0 O-C-N 121.297 -0.877 . . . . 0.0 110.856 179.922 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 67.3 -118.1 9.75 Favored Glycine 0 N--CA 1.49 2.252 0 N-CA-C 109.661 -1.376 . . . . 0.0 109.661 179.607 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 39' ' ' CYS . . . . . 0.539 ' C ' HD13 ' A' ' 40' ' ' LEU . 0.1 OUTLIER -153.7 24.51 0.51 Allowed 'General case' 0 N--CA 1.499 2.006 0 O-C-N 121.522 -0.987 . . . . 0.0 111.292 -179.969 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 40' ' ' LEU . . . . . 0.76 HD22 ' H ' ' A' ' 40' ' ' LEU . 0.0 OUTLIER . . . . . 0 N--CA 1.493 1.715 0 O-C-N 120.888 -1.132 . . . . 0.0 110.496 179.083 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 0.8 OUTLIER . . . . . 0 N--CA 1.492 1.659 0 CA-C-O 121.016 0.436 . . . . 0.0 110.013 . . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 6' ' ' PRO . . . . . . . . . . . . . 39.3 Cg_endo -66.93 96.46 0.37 Allowed 'Trans proline' 0 C--N 1.303 -1.823 0 O-C-N 124.835 1.966 . . . . 0.0 111.241 -179.78 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 90.35 13.17 60.44 Favored Glycine 0 N--CA 1.493 2.499 0 C-N-CA 120.292 -0.956 . . . . 0.0 111.123 179.187 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 3.7 p -143.72 171.66 13.89 Favored 'General case' 0 N--CA 1.495 1.802 0 O-C-N 120.425 -1.633 . . . . 0.0 110.134 179.614 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 97.55 122.27 4.4 Favored Glycine 0 N--CA 1.494 2.511 0 N-CA-C 108.847 -1.701 . . . . 0.0 108.847 -179.147 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 10' ' ' GLN . . . . . . . . . . . . . 2.2 mt-30 -81.7 49.44 1.34 Allowed 'General case' 0 N--CA 1.494 1.743 0 O-C-N 121.156 -1.202 . . . . 0.0 110.922 -179.483 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -92.67 58.34 2.58 Favored Glycine 0 N--CA 1.495 2.599 0 N-CA-C 108.947 -1.661 . . . . 0.0 108.947 179.453 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 10.7 t -130.21 63.08 0.3 Allowed 'Isoleucine or valine' 0 N--CA 1.496 1.873 0 O-C-N 121.551 -0.97 . . . . 0.0 109.734 -179.674 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 13' ' ' GLN . . . . . . . . . . . . . 2.2 tt0 -121.01 102.95 8.67 Favored 'General case' 0 N--CA 1.487 1.408 0 O-C-N 121.245 -0.909 . . . . 0.0 109.748 179.816 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -134.7 -73.81 0.47 Allowed 'General case' 0 N--CA 1.492 1.675 0 O-C-N 121.941 -0.475 . . . . 0.0 109.826 179.993 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 136.46 -58.47 0.66 Allowed Glycine 0 N--CA 1.495 2.608 0 N-CA-C 109.537 -1.425 . . . . 0.0 109.537 179.966 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 10.1 m -79.49 148.63 70.37 Favored Pre-proline 0 N--CA 1.5 2.043 0 O-C-N 121.387 -1.067 . . . . 0.0 109.651 179.848 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 41.1 Cg_endo -66.69 -26.57 45.68 Favored 'Trans proline' 0 N--CA 1.492 1.435 0 O-C-N 123.896 1.471 . . . . 0.0 111.414 -179.636 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 174.66 85.29 0.06 OUTLIER Glycine 0 N--CA 1.494 2.5 0 N-CA-C 109.436 -1.466 . . . . 0.0 109.436 179.802 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 94.76 142.29 12.49 Favored Glycine 0 N--CA 1.488 2.147 0 N-CA-C 109.529 -1.428 . . . . 0.0 109.529 -179.834 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 0.0 OUTLIER -142.4 110.24 5.85 Favored 'General case' 0 N--CA 1.497 1.901 0 O-C-N 121.645 -0.915 . . . . 0.0 109.62 179.602 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 3.7 t -98.51 46.7 0.11 Allowed 'Isoleucine or valine' 0 N--CA 1.497 1.901 0 O-C-N 121.645 -0.659 . . . . 0.0 110.214 -179.635 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 8.6 mt-10 -87.99 -25.62 23.05 Favored 'General case' 0 N--CA 1.488 1.459 0 O-C-N 121.307 -0.871 . . . . 0.0 110.501 179.671 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 0.9 OUTLIER 60.02 -159.96 0.3 Allowed 'General case' 0 N--CA 1.501 2.09 0 O-C-N 121.751 -0.593 . . . . 0.0 110.976 179.924 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -124.44 -154.1 0.59 Allowed 'General case' 0 N--CA 1.488 1.439 0 O-C-N 121.537 -0.727 . . . . 0.0 110.169 -179.558 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -84.96 143.98 28.62 Favored 'General case' 0 N--CA 1.494 1.765 0 O-C-N 121.282 -0.886 . . . . 0.0 110.233 -179.971 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -69.69 -16.64 72.26 Favored Glycine 0 N--CA 1.493 2.472 0 N-CA-C 109.986 -1.246 . . . . 0.0 109.986 178.926 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 115.96 -107.7 1.72 Allowed Glycine 0 N--CA 1.49 2.285 0 N-CA-C 109.286 -1.526 . . . . 0.0 109.286 179.843 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -113.01 91.7 19.04 Favored Pre-proline 0 N--CA 1.497 1.88 0 O-C-N 121.327 -1.102 . . . . 0.0 109.63 179.375 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 44.2 Cg_endo -73.42 118.22 5.41 Favored 'Trans proline' 0 N--CA 1.49 1.318 0 O-C-N 123.692 1.364 . . . . 0.0 110.955 179.959 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -121.34 34.19 5.28 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.164 -0.96 . . . . 0.0 110.716 179.664 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 31' ' ' GLU . . . . . 0.507 ' HG3' ' N ' ' A' ' 32' ' ' GLY . 0.1 OUTLIER -86.85 -32.02 20.49 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.025 -1.047 . . . . 0.0 110.168 179.873 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 32' ' ' GLY . . . . . 0.507 ' N ' ' HG3' ' A' ' 31' ' ' GLU . . . 137.41 -47.42 0.95 Allowed Glycine 0 N--CA 1.493 2.464 0 N-CA-C 110.22 -1.152 . . . . 0.0 110.22 179.623 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 33' ' ' CYS . . . . . . . . . . . . . 0.9 OUTLIER -113.72 92.21 3.9 Favored 'General case' 0 N--CA 1.493 1.675 0 O-C-N 121.582 -0.952 . . . . 0.0 110.881 -179.398 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -96.9 37.32 1.31 Allowed 'General case' 0 N--CA 1.499 1.976 0 O-C-N 121.138 -0.976 . . . . 0.0 109.863 179.211 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 10.8 mt-10 -137.48 -178.1 5.08 Favored 'General case' 0 N--CA 1.497 1.902 0 O-C-N 121.747 -0.596 . . . . 0.0 109.867 179.812 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 36' ' ' ALA . . . . . . . . . . . . . . . -88.75 35.69 0.79 Allowed 'General case' 0 N--CA 1.493 1.717 0 O-C-N 120.993 -1.067 . . . . 0.0 110.594 -179.819 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 5.6 tt0 -78.5 -26.91 46.04 Favored 'General case' 0 N--CA 1.486 1.347 0 O-C-N 121.39 -0.819 . . . . 0.0 110.076 179.666 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 70.22 70.83 1.1 Allowed Glycine 0 N--CA 1.492 2.379 0 N-CA-C 109.137 -1.585 . . . . 0.0 109.137 179.689 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 39' ' ' CYS . . . . . . . . . . . . . 1.8 m -100.89 110.08 22.11 Favored 'General case' 0 C--N 1.298 -1.665 0 O-C-N 121.733 -0.863 . . . . 0.0 109.793 -179.768 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 40' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER . . . . . 0 N--CA 1.49 1.555 0 O-C-N 121.425 -0.797 . . . . 0.0 110.961 -179.794 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 19.8 t . . . . . 0 N--CA 1.494 1.751 0 N-CA-C 109.579 -0.526 . . . . 0.0 109.579 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' A' A ' 6' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -80.57 -35.63 0.55 Allowed 'Trans proline' 0 C--N 1.308 -1.57 0 O-C-N 124.09 1.573 . . . . 0.0 112.171 -179.325 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -90.45 53.22 3.45 Favored Glycine 0 N--CA 1.496 2.637 0 O-C-N 120.361 -1.462 . . . . 0.0 112.007 -178.009 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 21.7 p -161.15 163.7 31.08 Favored 'General case' 0 N--CA 1.498 1.933 0 O-C-N 120.657 -1.496 . . . . 0.0 110.655 178.854 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 70.91 63.94 2.98 Favored Glycine 0 N--CA 1.494 2.535 0 N-CA-C 109.759 -1.336 . . . . 0.0 109.759 -179.951 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 10' ' ' GLN . . . . . . . . . . . . . 3.1 pt20 -145.04 27.5 1.29 Allowed 'General case' 0 N--CA 1.493 1.698 0 O-C-N 121.619 -0.93 . . . . 0.0 111.113 -179.639 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -140.53 63.31 0.53 Allowed Glycine 0 N--CA 1.491 2.35 0 N-CA-C 109.439 -1.464 . . . . 0.0 109.439 179.839 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 28.9 m -113.79 2.06 8.39 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.834 0 O-C-N 121.568 -0.96 . . . . 0.0 111.627 -179.955 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 13' ' ' GLN . . . . . . . . . . . . . 25.6 tt0 -51.41 -45.73 62.64 Favored 'General case' 0 N--CA 1.499 2.01 0 O-C-N 120.984 -1.072 . . . . 0.0 110.613 179.815 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -111.04 26.6 10.53 Favored 'General case' 0 N--CA 1.494 1.729 0 O-C-N 121.624 -0.673 . . . . 0.0 110.272 179.714 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -128.33 68.19 0.54 Allowed Glycine 0 N--CA 1.489 2.19 0 N-CA-C 108.97 -1.652 . . . . 0.0 108.97 179.753 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 17.9 m -96.0 150.27 37.06 Favored Pre-proline 0 N--CA 1.488 1.437 0 O-C-N 121.44 -1.035 . . . . 0.0 110.497 -179.745 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 43.7 Cg_endo -74.17 -39.85 1.48 Allowed 'Trans proline' 0 N--CA 1.491 1.368 0 O-C-N 123.822 1.433 . . . . 0.0 110.648 179.426 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . -167.12 59.36 0.22 Allowed Glycine 0 N--CA 1.493 2.461 0 N-CA-C 109.163 -1.575 . . . . 0.0 109.163 179.589 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 141.18 132.56 2.82 Favored Glycine 0 N--CA 1.493 2.496 0 N-CA-C 108.625 -1.79 . . . . 0.0 108.625 -179.557 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -134.32 169.38 17.31 Favored 'General case' 0 N--CA 1.496 1.851 0 O-C-N 121.512 -0.993 . . . . 0.0 109.301 -179.665 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . 0.427 HG22 ' O ' ' A' ' 21' ' ' VAL . 11.7 p -80.06 50.89 0.07 OUTLIER 'Isoleucine or valine' 0 N--CA 1.502 2.155 0 O-C-N 121.319 -0.863 . . . . 0.0 111.254 -179.736 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 2.8 mt-10 -108.58 51.76 0.73 Allowed 'General case' 0 C--N 1.305 -1.326 0 O-C-N 121.014 -1.053 . . . . 0.0 108.436 178.419 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 0.8 OUTLIER 52.55 59.41 4.52 Favored 'General case' 0 N--CA 1.495 1.806 0 CA-C-O 121.93 0.871 . . . . 0.0 109.222 -177.995 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 1.7 pm0 -61.0 -5.46 1.4 Allowed 'General case' 0 N--CA 1.5 2.034 0 O-C-N 121.432 -0.793 . . . . 0.0 112.228 -179.105 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 15.7 m-20 -77.17 -24.18 51.49 Favored 'General case' 0 N--CA 1.497 1.924 0 O-C-N 120.737 -1.227 . . . . 0.0 110.431 179.641 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 88.39 -51.96 3.99 Favored Glycine 0 N--CA 1.495 2.589 0 N-CA-C 109.726 -1.35 . . . . 0.0 109.726 -179.921 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -177.29 -140.05 3.53 Favored Glycine 0 N--CA 1.493 2.472 0 N-CA-C 109.798 -1.321 . . . . 0.0 109.798 -179.696 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 28' ' ' SER . . . . . 0.46 ' CB ' ' CD ' ' A' ' 29' ' ' PRO . 2.6 t -154.92 -64.07 0.02 OUTLIER Pre-proline 0 N--CA 1.494 1.744 0 O-C-N 121.163 -1.198 . . . . 0.0 110.665 179.835 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 29' ' ' PRO . . . . . 0.46 ' CD ' ' CB ' ' A' ' 28' ' ' SER . 41.4 Cg_endo -68.89 -31.23 25.09 Favored 'Trans proline' 0 N--CA 1.488 1.188 0 O-C-N 122.979 0.989 . . . . 0.0 111.133 -179.562 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -99.12 54.29 0.98 Allowed 'General case' 0 N--CA 1.493 1.704 0 O-C-N 121.376 -0.827 . . . . 0.0 110.827 -179.633 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 2.8 tp10 -84.48 -42.41 15.6 Favored 'General case' 0 N--CA 1.493 1.717 0 O-C-N 121.379 -0.826 . . . . 0.0 110.217 179.603 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 96.47 52.43 1.57 Allowed Glycine 0 N--CA 1.501 2.995 0 N-CA-C 109.634 -1.386 . . . . 0.0 109.634 -179.804 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 33' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -79.62 118.64 21.64 Favored 'General case' 0 N--CA 1.495 1.814 0 O-C-N 121.157 -1.202 . . . . 0.0 109.735 179.903 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -79.49 -28.5 41.47 Favored 'General case' 0 N--CA 1.497 1.918 0 O-C-N 121.259 -0.9 . . . . 0.0 110.721 -179.851 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 24.5 mp0 -78.19 153.53 31.92 Favored 'General case' 0 N--CA 1.492 1.658 0 CA-C-O 121.491 0.662 . . . . 0.0 110.556 -179.762 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 36' ' ' ALA . . . . . . . . . . . . . . . -91.88 -42.18 10.2 Favored 'General case' 0 N--CA 1.496 1.825 0 O-C-N 121.415 -0.803 . . . . 0.0 110.999 -179.668 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 16.2 tt0 -77.18 -26.12 52.57 Favored 'General case' 0 N--CA 1.494 1.757 0 O-C-N 120.796 -1.19 . . . . 0.0 111.197 -179.006 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -70.26 -32.72 68.66 Favored Glycine 0 N--CA 1.497 2.705 0 C-N-CA 120.386 -0.911 . . . . 0.0 111.203 -178.942 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 39' ' ' CYS . . . . . . . . . . . . . 90.1 m -135.36 -32.32 0.94 Allowed 'General case' 0 N--CA 1.506 2.344 0 O-C-N 120.709 -1.466 . . . . 0.0 112.872 -178.697 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 40' ' ' LEU . . . . . . . . . . . . . 1.0 OUTLIER . . . . . 0 N--CA 1.497 1.879 0 O-C-N 120.697 -1.252 . . . . 0.0 111.606 -178.371 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 31.6 p . . . . . 0 N--CA 1.493 1.686 0 CA-C-O 120.469 0.176 . . . . 0.0 110.599 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' A' A ' 6' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -78.26 110.59 2.9 Favored 'Trans proline' 0 N--CA 1.487 1.136 0 O-C-N 123.938 1.494 . . . . 0.0 111.516 -179.416 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 47.44 54.69 10.14 Favored Glycine 0 N--CA 1.497 2.707 0 O-C-N 121.337 -0.852 . . . . 0.0 110.983 179.147 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -112.84 -171.95 1.96 Allowed 'General case' 0 N--CA 1.495 1.784 0 O-C-N 121.342 -1.093 . . . . 0.0 109.822 179.24 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 9' ' ' GLY . . . . . 0.493 ' O ' ' HG2' ' A' ' 10' ' ' GLN . . . 95.54 36.34 5.39 Favored Glycine 0 N--CA 1.495 2.608 0 N-CA-C 109.452 -1.459 . . . . 0.0 109.452 179.973 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 10' ' ' GLN . . . . . 0.493 ' HG2' ' O ' ' A' ' 9' ' ' GLY . 0.0 OUTLIER 26.87 54.81 0.05 Allowed 'General case' 0 N--CA 1.506 2.351 0 CA-C-N 117.379 0.59 . . . . 0.0 112.055 179.679 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -135.95 52.37 0.79 Allowed Glycine 0 N--CA 1.496 2.662 0 N-CA-C 109.511 -1.436 . . . . 0.0 109.511 179.586 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 6.3 p -107.97 -2.49 10.06 Favored 'Isoleucine or valine' 0 N--CA 1.499 2.017 0 O-C-N 121.12 -1.223 . . . . 0.0 110.877 -179.331 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 13' ' ' GLN . . . . . . . . . . . . . 7.0 mt-30 -76.11 79.3 2.94 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 120.884 -1.135 . . . . 0.0 110.444 -179.491 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -119.02 174.75 6.12 Favored 'General case' 0 N--CA 1.498 1.972 0 O-C-N 121.673 -0.642 . . . . 0.0 110.29 179.662 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -143.25 -94.62 0.2 Allowed Glycine 0 N--CA 1.494 2.54 0 N-CA-C 109.544 -1.422 . . . . 0.0 109.544 179.895 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 4.7 m -89.07 151.09 46.43 Favored Pre-proline 0 N--CA 1.492 1.648 0 O-C-N 121.34 -1.094 . . . . 0.0 109.975 179.655 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 50.0 Cg_endo -75.14 59.01 5.17 Favored 'Trans proline' 0 C--N 1.315 -1.205 0 O-C-N 123.847 1.446 . . . . 0.0 111.052 -179.953 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 69.93 11.3 66.3 Favored Glycine 0 N--CA 1.494 2.56 0 N-CA-C 110.609 -0.996 . . . . 0.0 110.609 179.887 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -147.74 114.52 0.7 Allowed Glycine 0 N--CA 1.488 2.141 0 N-CA-C 109.064 -1.615 . . . . 0.0 109.064 -179.507 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -153.67 142.87 21.43 Favored 'General case' 0 N--CA 1.494 1.775 0 O-C-N 121.483 -1.01 . . . . 0.0 110.125 -179.85 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 11.5 p -150.35 44.67 0.08 OUTLIER 'Isoleucine or valine' 0 N--CA 1.499 1.99 0 CA-C-O 121.559 0.695 . . . . 0.0 110.164 -179.681 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 1.8 mt-10 -112.31 -13.57 13.43 Favored 'General case' 0 N--CA 1.487 1.418 0 O-C-N 121.191 -0.943 . . . . 0.0 110.758 179.654 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 1.4 tp10 58.73 85.95 0.09 Allowed 'General case' 0 N--CA 1.504 2.253 0 O-C-N 121.355 -0.84 . . . . 0.0 110.526 179.855 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 26.1 mt-10 -79.24 50.01 1.03 Allowed 'General case' 0 N--CA 1.496 1.854 0 O-C-N 120.858 -1.151 . . . . 0.0 111.286 -179.883 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 2.5 t70 -113.97 68.98 0.7 Allowed 'General case' 0 N--CA 1.495 1.788 0 O-C-N 121.211 -0.931 . . . . 0.0 109.979 179.706 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 159.87 -87.62 0.11 Allowed Glycine 0 N--CA 1.495 2.627 0 N-CA-C 109.638 -1.385 . . . . 0.0 109.638 179.838 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 121.47 -56.92 0.61 Allowed Glycine 0 N--CA 1.494 2.526 0 N-CA-C 109.533 -1.427 . . . . 0.0 109.533 -179.853 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 58.3 m -125.42 159.75 58.71 Favored Pre-proline 0 N--CA 1.498 1.953 0 O-C-N 121.762 -0.846 . . . . 0.0 110.157 179.964 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 42.4 Cg_endo -65.76 -29.13 51.15 Favored 'Trans proline' 0 N--CA 1.492 1.411 0 O-C-N 123.883 1.465 . . . . 0.0 111.076 179.736 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -96.15 15.81 19.83 Favored 'General case' 0 N--CA 1.487 1.384 0 O-C-N 120.822 -1.174 . . . . 0.0 110.224 178.965 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 37.0 tp10 -79.65 -50.71 10.24 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.089 -1.007 . . . . 0.0 110.818 -179.103 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 131.64 88.27 0.43 Allowed Glycine 0 N--CA 1.487 2.088 0 N-CA-C 108.771 -1.732 . . . . 0.0 108.771 -179.384 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 33' ' ' CYS . . . . . . . . . . . . . 17.9 m -78.22 125.59 29.57 Favored 'General case' 0 N--CA 1.502 2.131 0 O-C-N 121.279 -1.13 . . . . 0.0 110.307 -179.811 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -79.09 -17.21 55.56 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.363 -0.836 . . . . 0.0 109.839 179.15 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 1.1 tm-20 -103.74 165.24 11.16 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.391 -0.818 . . . . 0.0 109.999 179.581 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 36' ' ' ALA . . . . . . . . . . . . . . . -102.04 -26.92 13.22 Favored 'General case' 0 N--CA 1.498 1.955 0 O-C-N 121.335 -0.853 . . . . 0.0 110.903 179.58 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 1.5 mt-10 -79.58 -31.93 41.92 Favored 'General case' 0 N--CA 1.494 1.775 0 O-C-N 120.942 -1.099 . . . . 0.0 110.604 -179.195 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -75.22 -36.96 43.76 Favored Glycine 0 N--CA 1.493 2.459 0 N-CA-C 110.392 -1.083 . . . . 0.0 110.392 -179.91 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 39' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -96.47 -27.85 14.69 Favored 'General case' 0 N--CA 1.499 2.005 0 O-C-N 120.868 -1.372 . . . . 0.0 111.477 -179.865 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 40' ' ' LEU . . . . . . . . . . . . . 0.8 OUTLIER . . . . . 0 N--CA 1.502 2.133 0 O-C-N 121.297 -0.877 . . . . 0.0 110.657 -179.417 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 5.8 p . . . . . 0 N--CA 1.497 1.923 0 N-CA-C 110.394 -0.224 . . . . 0.0 110.394 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' A' A ' 6' ' ' PRO . . . . . . . . . . . . . 44.1 Cg_endo -75.09 -53.49 0.1 OUTLIER 'Trans proline' 0 C--N 1.311 -1.443 0 O-C-N 123.559 1.294 . . . . 0.0 111.351 -179.577 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -85.97 59.87 4.68 Favored Glycine 0 N--CA 1.492 2.373 0 N-CA-C 110.238 -1.145 . . . . 0.0 110.238 -179.426 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 0.7 OUTLIER -106.02 18.38 22.16 Favored 'General case' 0 N--CA 1.501 2.084 0 O-C-N 121.281 -1.129 . . . . 0.0 110.56 179.325 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 106.17 55.73 0.67 Allowed Glycine 0 N--CA 1.496 2.676 0 N-CA-C 109.975 -1.25 . . . . 0.0 109.975 179.729 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 10' ' ' GLN . . . . . . . . . . . . . 3.8 pt20 -161.79 48.35 0.19 Allowed 'General case' 0 N--CA 1.492 1.633 0 O-C-N 121.383 -1.069 . . . . 0.0 110.361 179.777 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -94.79 66.36 1.37 Allowed Glycine 0 N--CA 1.495 2.588 0 N-CA-C 109.599 -1.4 . . . . 0.0 109.599 179.901 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 24.6 t -122.3 -20.06 4.05 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.029 0 O-C-N 121.393 -1.063 . . . . 0.0 111.079 -179.483 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 13' ' ' GLN . . . . . 0.427 ' O ' ' HB3' ' A' ' 14' ' ' ALA . 0.0 OUTLIER -81.38 -144.38 0.05 Allowed 'General case' 0 N--CA 1.492 1.646 0 O-C-N 121.053 -1.029 . . . . 0.0 110.393 -179.854 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 14' ' ' ALA . . . . . 0.427 ' HB3' ' O ' ' A' ' 13' ' ' GLN . . . 59.07 -155.62 0.35 Allowed 'General case' 0 N--CA 1.498 1.966 0 O-C-N 121.647 -0.658 . . . . 0.0 109.821 -179.727 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -91.28 42.93 2.81 Favored Glycine 0 N--CA 1.49 2.262 0 N-CA-C 109.371 -1.492 . . . . 0.0 109.371 179.916 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 81.1 m -119.38 67.09 9.37 Favored Pre-proline 0 N--CA 1.493 1.709 0 O-C-N 121.295 -1.12 . . . . 0.0 110.801 -179.5 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 46.6 Cg_endo -71.83 69.01 3.0 Favored 'Trans proline' 0 C--N 1.313 -1.319 0 O-C-N 123.385 1.202 . . . . 0.0 110.504 -179.892 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 105.73 -14.71 45.73 Favored Glycine 0 N--CA 1.498 2.786 0 N-CA-C 110.134 -1.186 . . . . 0.0 110.134 -179.603 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -154.2 123.95 1.47 Allowed Glycine 0 N--CA 1.489 2.213 0 N-CA-C 109.152 -1.579 . . . . 0.0 109.152 179.87 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -108.05 47.13 0.91 Allowed 'General case' 0 N--CA 1.497 1.904 0 O-C-N 121.399 -1.059 . . . . 0.0 109.699 179.706 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 9.9 p -136.4 20.97 0.9 Allowed 'Isoleucine or valine' 0 N--CA 1.502 2.167 0 O-C-N 120.915 -1.116 . . . . 0.0 111.29 -179.444 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 22' ' ' GLU . . . . . 0.401 ' C ' ' HG3' ' A' ' 23' ' ' GLU . 1.5 tp10 -101.21 -12.06 19.03 Favored 'General case' 0 C--N 1.305 -1.339 0 O-C-N 121.179 -0.951 . . . . 0.0 109.993 179.098 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 23' ' ' GLU . . . . . 0.401 ' HG3' ' C ' ' A' ' 22' ' ' GLU . 0.0 OUTLIER -146.06 74.86 1.39 Allowed 'General case' 0 N--CA 1.488 1.446 0 O-C-N 121.429 -0.794 . . . . 0.0 109.436 -179.582 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER -56.05 -58.54 7.47 Favored 'General case' 0 N--CA 1.5 2.037 0 O-C-N 121.207 -0.933 . . . . 0.0 110.79 -179.421 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -149.28 -61.86 0.22 Allowed 'General case' 0 N--CA 1.495 1.811 0 O-C-N 121.332 -0.855 . . . . 0.0 110.06 179.964 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 134.04 86.03 0.25 Allowed Glycine 0 N--CA 1.497 2.708 0 N-CA-C 109.504 -1.438 . . . . 0.0 109.504 -179.716 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 165.45 95.95 0.11 Allowed Glycine 0 N--CA 1.494 2.557 0 N-CA-C 109.147 -1.581 . . . . 0.0 109.147 -179.702 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 28' ' ' SER . . . . . 0.484 ' HB2' ' HD3' ' A' ' 29' ' ' PRO . 0.0 OUTLIER -154.72 -62.6 0.02 OUTLIER Pre-proline 0 N--CA 1.497 1.909 0 O-C-N 121.263 -1.14 . . . . 0.0 110.777 179.85 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 29' ' ' PRO . . . . . 0.484 ' HD3' ' HB2' ' A' ' 28' ' ' SER . 44.8 Cg_endo -75.44 123.82 7.91 Favored 'Trans proline' 0 C--N 1.318 -1.062 0 O-C-N 122.922 0.959 . . . . 0.0 110.405 -179.744 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -78.54 -9.39 59.32 Favored 'General case' 0 N--CA 1.498 1.943 0 O-C-N 121.148 -0.97 . . . . 0.0 111.154 -179.665 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 4.1 tp10 -79.76 -56.92 3.94 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.253 -0.905 . . . . 0.0 109.556 179.742 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 171.88 -64.85 0.14 Allowed Glycine 0 N--CA 1.492 2.418 0 N-CA-C 109.181 -1.568 . . . . 0.0 109.181 -179.999 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 33' ' ' CYS . . . . . . . . . . . . . 12.7 p -148.29 88.33 1.64 Allowed 'General case' 0 N--CA 1.493 1.715 0 O-C-N 121.495 -1.003 . . . . 0.0 109.521 179.648 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -86.28 39.42 0.82 Allowed 'General case' 0 N--CA 1.495 1.808 0 O-C-N 121.342 -0.849 . . . . 0.0 110.82 -179.479 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER -113.8 163.26 15.28 Favored 'General case' 0 N--CA 1.495 1.793 0 O-C-N 121.218 -0.926 . . . . 0.0 110.214 179.812 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 36' ' ' ALA . . . . . 1.066 ' HB1' HD12 ' A' ' 40' ' ' LEU . . . -102.61 0.1 32.78 Favored 'General case' 0 N--CA 1.498 1.97 0 O-C-N 121.515 -0.741 . . . . 0.0 112.148 -178.706 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 2.7 pm0 -79.59 -27.24 41.13 Favored 'General case' 0 N--CA 1.498 1.94 0 O-C-N 120.582 -1.324 . . . . 0.0 111.556 -179.132 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -133.34 -47.41 0.1 Allowed Glycine 0 N--CA 1.498 2.799 0 C-N-CA 118.894 -1.622 . . . . 0.0 111.825 -178.77 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 39' ' ' CYS . . . . . . . . . . . . . 4.3 m -79.53 0.94 27.68 Favored 'General case' 0 N--CA 1.499 2.022 0 O-C-N 120.889 -1.359 . . . . 0.0 112.304 -178.451 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 40' ' ' LEU . . . . . 1.066 HD12 ' HB1' ' A' ' 36' ' ' ALA . 0.5 OUTLIER . . . . . 0 N--CA 1.497 1.923 0 O-C-N 120.851 -1.156 . . . . 0.0 109.797 179.07 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER . . . . . 0 N--CA 1.491 1.614 0 N-CA-C 110.264 -0.273 . . . . 0.0 110.264 . . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 6' ' ' PRO . . . . . . . . . . . . . 43.6 Cg_endo -75.11 -53.21 0.1 OUTLIER 'Trans proline' 0 C--N 1.315 -1.233 0 O-C-N 123.691 1.364 . . . . 0.0 110.619 179.608 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -85.17 60.73 4.74 Favored Glycine 0 N--CA 1.496 2.654 0 N-CA-C 109.465 -1.454 . . . . 0.0 109.465 179.522 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 1.5 m -96.74 24.31 6.19 Favored 'General case' 0 N--CA 1.497 1.923 0 O-C-N 121.271 -1.135 . . . . 0.0 110.678 -179.952 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -144.02 -144.46 4.22 Favored Glycine 0 N--CA 1.495 2.579 0 N-CA-C 109.354 -1.498 . . . . 0.0 109.354 179.841 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 10' ' ' GLN . . . . . 0.491 ' HB2' ' HB3' ' A' ' 14' ' ' ALA . 3.5 mt-30 -54.12 -49.02 70.12 Favored 'General case' 0 N--CA 1.499 2.006 0 O-C-N 121.423 -1.045 . . . . 0.0 110.959 179.953 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 109.15 -25.17 19.19 Favored Glycine 0 N--CA 1.494 2.539 0 N-CA-C 109.874 -1.29 . . . . 0.0 109.874 -179.654 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 12' ' ' VAL . . . . . 0.438 ' H ' HG22 ' A' ' 12' ' ' VAL . 27.4 m -95.9 46.76 0.1 OUTLIER 'Isoleucine or valine' 0 N--CA 1.497 1.908 0 O-C-N 121.015 -1.285 . . . . 0.0 110.26 179.879 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 13' ' ' GLN . . . . . . . . . . . . . 1.1 mt-30 52.11 49.38 20.76 Favored 'General case' 0 N--CA 1.498 1.93 0 O-C-N 121.705 -0.622 . . . . 0.0 111.006 179.779 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 14' ' ' ALA . . . . . 0.491 ' HB3' ' HB2' ' A' ' 10' ' ' GLN . . . -103.87 161.65 13.78 Favored 'General case' 0 N--CA 1.497 1.917 0 O-C-N 121.263 -0.898 . . . . 0.0 110.137 179.512 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 75.58 72.06 1.1 Allowed Glycine 0 N--CA 1.495 2.625 0 N-CA-C 109.461 -1.455 . . . . 0.0 109.461 179.908 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 16' ' ' CYS . . . . . 0.44 ' HB2' ' HD2' ' A' ' 17' ' ' PRO . 17.7 p -79.8 167.23 35.42 Favored Pre-proline 0 N--CA 1.497 1.924 0 O-C-N 121.428 -1.042 . . . . 0.0 110.215 -179.922 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 17' ' ' PRO . . . . . 0.44 ' HD2' ' HB2' ' A' ' 16' ' ' CYS . 49.7 Cg_endo -77.33 53.19 4.17 Favored 'Trans proline' 0 C--N 1.311 -1.437 0 O-C-N 123.499 1.263 . . . . 0.0 110.217 178.927 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 92.7 -43.09 2.63 Favored Glycine 0 N--CA 1.496 2.64 0 N-CA-C 110.392 -1.083 . . . . 0.0 110.392 -179.89 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -74.89 83.38 0.82 Allowed Glycine 0 N--CA 1.492 2.376 0 O-C-N 121.189 -1.183 . . . . 0.0 110.495 -179.176 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 1.3 m -117.45 118.93 33.54 Favored 'General case' 0 N--CA 1.497 1.9 0 O-C-N 121.407 -1.054 . . . . 0.0 109.974 179.427 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 14.0 t -83.33 75.36 1.03 Allowed 'Isoleucine or valine' 0 N--CA 1.497 1.876 0 O-C-N 121.639 -0.663 . . . . 0.0 109.573 179.851 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 31.4 mt-10 -95.34 40.96 1.1 Allowed 'General case' 0 C--N 1.304 -1.391 0 O-C-N 121.356 -0.84 . . . . 0.0 110.115 -179.587 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 3.4 pt-20 -157.52 60.03 0.49 Allowed 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.372 -0.83 . . . . 0.0 110.164 -179.801 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -112.27 147.53 36.07 Favored 'General case' 0 N--CA 1.493 1.718 0 O-C-N 121.224 -0.922 . . . . 0.0 110.281 -179.574 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 3.1 p-10 -96.78 176.73 5.88 Favored 'General case' 0 N--CA 1.495 1.801 0 O-C-N 121.37 -0.831 . . . . 0.0 109.538 178.99 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -126.36 27.86 4.91 Favored Glycine 0 N--CA 1.493 2.487 0 N-CA-C 110.134 -1.186 . . . . 0.0 110.134 179.921 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 71.75 -68.77 1.0 Allowed Glycine 0 N--CA 1.499 2.88 0 N-CA-C 109.782 -1.327 . . . . 0.0 109.782 -179.934 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 64.4 m -83.5 116.9 66.87 Favored Pre-proline 0 N--CA 1.499 1.992 0 O-C-N 121.273 -1.134 . . . . 0.0 110.378 179.788 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 44.1 Cg_endo -71.16 154.39 62.07 Favored 'Trans proline' 0 N--CA 1.491 1.333 0 O-C-N 124.016 1.535 . . . . 0.0 111.485 -179.493 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -112.43 -50.26 2.91 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.398 -0.814 . . . . 0.0 110.625 179.84 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -102.54 -63.84 1.12 Allowed 'General case' 0 N--CA 1.495 1.79 0 O-C-N 121.485 -0.759 . . . . 0.0 110.233 -179.956 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 152.96 -59.2 0.41 Allowed Glycine 0 N--CA 1.495 2.587 0 N-CA-C 109.626 -1.39 . . . . 0.0 109.626 -179.907 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 33' ' ' CYS . . . . . . . . . . . . . 17.3 m -133.17 61.24 1.68 Allowed 'General case' 0 N--CA 1.496 1.87 0 O-C-N 121.32 -1.106 . . . . 0.0 110.075 179.87 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -122.62 26.63 8.2 Favored 'General case' 0 N--CA 1.497 1.911 0 O-C-N 121.274 -0.891 . . . . 0.0 109.876 179.528 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 22.7 mp0 -116.5 -171.88 2.09 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.732 -0.605 . . . . 0.0 110.612 -179.186 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 36' ' ' ALA . . . . . . . . . . . . . . . -92.07 -24.97 18.99 Favored 'General case' 0 N--CA 1.499 2.022 0 O-C-N 121.244 -0.91 . . . . 0.0 111.151 -179.597 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER -79.71 52.46 1.45 Allowed 'General case' 0 N--CA 1.499 2.006 0 O-C-N 120.836 -1.165 . . . . 0.0 110.739 -179.608 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 47.42 -111.5 0.79 Allowed Glycine 0 N--CA 1.501 3.013 0 N-CA-C 110.126 -1.189 . . . . 0.0 110.126 179.5 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 39' ' ' CYS . . . . . . . . . . . . . 90.0 m -143.4 141.4 30.86 Favored 'General case' 0 N--CA 1.495 1.794 0 O-C-N 121.485 -1.009 . . . . 0.0 109.26 179.462 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 40' ' ' LEU . . . . . . . . . . . . . 2.9 mt . . . . . 0 N--CA 1.495 1.778 0 O-C-N 121.351 -0.843 . . . . 0.0 110.938 -179.499 . . . . . . . . 0 0 . 1 . 012 nuclear nobuild core ' A' A ' 5' ' ' CYS . . . . . 0.507 ' SG ' ' N ' ' A' ' 8' ' ' CYS . 0.8 OUTLIER . . . . . 0 N--CA 1.496 1.858 0 N-CA-C 109.716 -0.475 . . . . 0.0 109.716 . . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 6' ' ' PRO . . . . . . . . . . . . . 51.6 Cg_endo -81.0 45.36 1.98 Allowed 'Trans proline' 0 C--N 1.314 -1.271 0 O-C-N 123.755 1.397 . . . . 0.0 111.627 -179.092 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 165.1 41.73 0.02 OUTLIER Glycine 0 N--CA 1.497 2.702 0 N-CA-C 109.925 -1.27 . . . . 0.0 109.925 179.838 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 8' ' ' CYS . . . . . 0.507 ' N ' ' SG ' ' A' ' 5' ' ' CYS . 14.3 m -79.84 -177.2 5.82 Favored 'General case' 0 N--CA 1.499 1.993 0 O-C-N 121.404 -1.056 . . . . 0.0 110.132 -179.842 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -86.5 -79.72 1.19 Allowed Glycine 0 N--CA 1.495 2.631 0 N-CA-C 109.886 -1.286 . . . . 0.0 109.886 -179.885 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 10' ' ' GLN . . . . . . . . . . . . . 0.1 OUTLIER -67.05 -71.73 0.19 Allowed 'General case' 0 N--CA 1.496 1.868 0 O-C-N 121.434 -1.039 . . . . 0.0 110.648 -179.677 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 72.05 8.35 69.06 Favored Glycine 0 N--CA 1.497 2.758 0 N-CA-C 110.426 -1.07 . . . . 0.0 110.426 -179.595 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 12' ' ' VAL . . . . . 0.451 ' O ' HG13 ' A' ' 12' ' ' VAL . 4.3 p -160.64 82.41 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.493 1.675 0 O-C-N 121.209 -1.171 . . . . 0.0 108.767 179.954 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 13' ' ' GLN . . . . . . . . . . . . . 1.3 tt0 -53.22 101.16 0.04 OUTLIER 'General case' 0 N--CA 1.498 1.953 0 O-C-N 121.567 -0.708 . . . . 0.0 111.089 -178.897 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -108.72 31.55 5.56 Favored 'General case' 0 N--CA 1.497 1.894 0 O-C-N 121.643 -0.661 . . . . 0.0 109.547 179.209 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 143.95 -86.24 0.18 Allowed Glycine 0 N--CA 1.49 2.278 0 N-CA-C 108.548 -1.821 . . . . 0.0 108.548 -179.45 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 28.4 m -106.93 100.66 33.11 Favored Pre-proline 0 N--CA 1.494 1.764 0 O-C-N 121.331 -1.099 . . . . 0.0 109.544 179.133 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 47.2 Cg_endo -72.66 55.4 2.66 Favored 'Trans proline' 0 C--N 1.312 -1.382 0 O-C-N 123.817 1.43 . . . . 0.0 111.826 -178.955 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 152.62 36.56 0.03 OUTLIER Glycine 0 N--CA 1.496 2.684 0 O-C-N 120.836 -1.165 . . . . 0.0 111.097 179.444 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 82.38 137.24 2.6 Favored Glycine 0 N--CA 1.492 2.37 0 O-C-N 121.013 -1.287 . . . . 0.0 109.909 179.46 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -116.37 27.36 9.27 Favored 'General case' 0 N--CA 1.5 2.035 0 O-C-N 121.265 -1.138 . . . . 0.0 110.323 179.671 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 8.4 p -132.26 8.45 1.63 Allowed 'Isoleucine or valine' 0 N--CA 1.494 1.765 0 O-C-N 121.01 -1.056 . . . . 0.0 110.926 179.945 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 8.3 mm-40 -98.81 14.99 26.88 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 120.657 -1.277 . . . . 0.0 111.145 179.965 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 4.6 tt0 -146.4 -54.92 0.26 Allowed 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.202 -0.936 . . . . 0.0 109.507 179.404 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER -124.41 101.77 7.32 Favored 'General case' 0 C--N 1.307 -1.24 0 O-C-N 121.443 -0.785 . . . . 0.0 110.129 179.61 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 3.5 p-10 -115.43 23.76 12.15 Favored 'General case' 0 N--CA 1.496 1.841 0 O-C-N 121.236 -0.915 . . . . 0.0 110.542 179.926 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 129.52 -95.69 0.37 Allowed Glycine 0 N--CA 1.493 2.451 0 N-CA-C 109.209 -1.556 . . . . 0.0 109.209 179.914 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 80.29 -95.52 1.56 Allowed Glycine 0 N--CA 1.495 2.573 0 N-CA-C 109.701 -1.36 . . . . 0.0 109.701 179.752 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -79.29 165.77 46.2 Favored Pre-proline 0 N--CA 1.5 2.062 0 O-C-N 121.39 -1.065 . . . . 0.0 110.267 -179.919 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 45.6 Cg_endo -73.68 64.73 4.79 Favored 'Trans proline' 0 C--N 1.317 -1.116 0 O-C-N 123.868 1.457 . . . . 0.0 110.579 -179.975 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -127.63 76.62 1.69 Allowed 'General case' 0 N--CA 1.485 1.314 0 O-C-N 121.449 -0.782 . . . . 0.0 110.388 179.935 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 31' ' ' GLU . . . . . 0.42 ' HG3' ' N ' ' A' ' 32' ' ' GLY . 12.9 pt-20 -79.2 -43.22 24.3 Favored 'General case' 0 N--CA 1.494 1.744 0 O-C-N 121.152 -0.967 . . . . 0.0 110.243 -179.797 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 32' ' ' GLY . . . . . 0.42 ' N ' ' HG3' ' A' ' 31' ' ' GLU . . . 111.54 80.15 1.06 Allowed Glycine 0 N--CA 1.492 2.433 0 N-CA-C 109.582 -1.407 . . . . 0.0 109.582 179.739 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 33' ' ' CYS . . . . . . . . . . . . . 0.7 OUTLIER -79.68 133.22 36.37 Favored 'General case' 0 N--CA 1.497 1.894 0 O-C-N 121.264 -1.139 . . . . 0.0 109.362 179.66 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -78.5 -22.48 47.37 Favored 'General case' 0 N--CA 1.501 2.096 0 O-C-N 121.325 -0.859 . . . . 0.0 110.445 179.886 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 0.8 OUTLIER -130.68 165.51 22.7 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.381 -0.824 . . . . 0.0 109.814 179.554 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 36' ' ' ALA . . . . . . . . . . . . . . . -93.28 -39.91 10.72 Favored 'General case' 0 N--CA 1.493 1.679 0 O-C-N 121.462 -0.774 . . . . 0.0 109.644 179.403 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 6.2 tt0 -79.27 -53.85 6.54 Favored 'General case' 0 N--CA 1.495 1.81 0 O-C-N 121.525 -0.735 . . . . 0.0 109.844 179.713 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -75.87 63.09 2.8 Favored Glycine 0 N--CA 1.498 2.792 0 N-CA-C 109.557 -1.417 . . . . 0.0 109.557 179.887 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 39' ' ' CYS . . . . . 0.435 ' HB3' HD23 ' A' ' 40' ' ' LEU . 2.6 t -122.4 -63.49 1.28 Allowed 'General case' 0 N--CA 1.496 1.831 0 O-C-N 121.549 -0.971 . . . . 0.0 110.181 179.497 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 40' ' ' LEU . . . . . 0.435 HD23 ' HB3' ' A' ' 39' ' ' CYS . 1.9 pt? . . . . . 0 N--CA 1.497 1.898 0 O-C-N 121.196 -0.94 . . . . 0.0 110.547 179.139 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 9.3 t . . . . . 0 N--CA 1.497 1.925 0 N-CA-C 110.023 -0.362 . . . . 0.0 110.023 . . . . . . . . . 0 0 . 1 . 013 nuclear nobuild core ' A' A ' 6' ' ' PRO . . . . . . . . . . . . . 52.7 Cg_endo -77.57 155.0 31.5 Favored 'Trans proline' 0 C--N 1.314 -1.28 0 O-C-N 123.666 1.351 . . . . 0.0 110.335 179.796 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 82.82 -50.47 4.39 Favored Glycine 0 N--CA 1.497 2.762 0 C-N-CA 120.118 -1.039 . . . . 0.0 110.601 179.717 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 8' ' ' CYS . . . . . 0.443 ' SG ' ' N ' ' A' ' 9' ' ' GLY . 12.0 p -78.71 -33.09 47.07 Favored 'General case' 0 N--CA 1.497 1.905 0 O-C-N 120.967 -1.314 . . . . 0.0 111.062 -179.36 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 9' ' ' GLY . . . . . 0.443 ' N ' ' SG ' ' A' ' 8' ' ' CYS . . . -79.76 -60.63 2.42 Favored Glycine 0 N--CA 1.497 2.708 0 N-CA-C 109.631 -1.387 . . . . 0.0 109.631 -179.486 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 10' ' ' GLN . . . . . . . . . . . . . 34.2 mt-30 -143.91 -62.6 0.39 Allowed 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.438 -1.037 . . . . 0.0 110.754 -179.813 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 89.25 -68.56 2.7 Favored Glycine 0 N--CA 1.495 2.598 0 N-CA-C 108.962 -1.655 . . . . 0.0 108.962 -179.271 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 41.0 t -136.51 -94.06 0.04 OUTLIER 'Isoleucine or valine' 0 N--CA 1.496 1.85 0 O-C-N 121.657 -0.908 . . . . 0.0 109.715 179.287 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 13' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -166.86 30.76 0.04 OUTLIER 'General case' 0 N--CA 1.499 1.977 0 O-C-N 120.825 -1.172 . . . . 0.0 110.875 179.824 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -154.02 136.44 15.01 Favored 'General case' 0 N--CA 1.496 1.843 0 O-C-N 121.107 -0.996 . . . . 0.0 110.459 179.986 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -108.2 65.52 0.25 Allowed Glycine 0 N--CA 1.495 2.592 0 N-CA-C 109.788 -1.325 . . . . 0.0 109.788 179.881 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 60.6 m -80.51 114.01 44.12 Favored Pre-proline 0 N--CA 1.499 2.019 0 O-C-N 121.719 -0.871 . . . . 0.0 109.975 179.641 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 45.0 Cg_endo -70.07 89.22 0.56 Allowed 'Trans proline' 0 N--CA 1.49 1.318 0 O-C-N 123.722 1.38 . . . . 0.0 110.767 -179.931 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 108.58 -16.83 34.03 Favored Glycine 0 N--CA 1.495 2.582 0 N-CA-C 110.361 -1.096 . . . . 0.0 110.361 179.886 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 117.92 138.41 5.99 Favored Glycine 0 N--CA 1.489 2.231 0 N-CA-C 108.675 -1.77 . . . . 0.0 108.675 -179.314 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 6.0 p -124.65 -2.66 7.86 Favored 'General case' 0 N--CA 1.497 1.911 0 O-C-N 121.435 -1.038 . . . . 0.0 112.076 -179.622 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . 0.459 HG22 ' O ' ' A' ' 21' ' ' VAL . 12.1 p -160.07 39.81 0.02 OUTLIER 'Isoleucine or valine' 0 N--CA 1.497 1.894 0 O-C-N 120.581 -1.324 . . . . 0.0 110.353 -179.803 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 13.4 mm-40 -98.94 46.23 0.99 Allowed 'General case' 0 N--CA 1.487 1.408 0 O-C-N 120.84 -1.162 . . . . 0.0 111.089 -179.621 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER 43.02 68.4 0.51 Allowed 'General case' 0 N--CA 1.505 2.294 0 CA-C-O 121.409 0.623 . . . . 0.0 111.528 179.617 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 2.7 tt0 -80.6 -57.38 3.6 Favored 'General case' 0 N--CA 1.494 1.761 0 O-C-N 120.983 -1.073 . . . . 0.0 109.904 179.987 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 3.1 t70 -160.25 176.72 11.41 Favored 'General case' 0 N--CA 1.489 1.522 0 N-CA-C 108.838 -0.801 . . . . 0.0 108.838 179.136 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 62.06 39.75 98.02 Favored Glycine 0 N--CA 1.493 2.484 0 N-CA-C 109.658 -1.377 . . . . 0.0 109.658 179.683 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -58.16 -29.96 63.39 Favored Glycine 0 N--CA 1.497 2.738 0 N-CA-C 110.076 -1.21 . . . . 0.0 110.076 179.962 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 1.1 m -79.19 163.58 59.0 Favored Pre-proline 0 N--CA 1.5 2.035 0 O-C-N 121.338 -1.096 . . . . 0.0 109.515 179.467 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 44.1 Cg_endo -69.89 68.88 1.75 Allowed 'Trans proline' 0 C--N 1.308 -1.578 0 O-C-N 123.268 1.141 . . . . 0.0 110.937 -179.747 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -99.5 -40.25 7.94 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.245 -0.909 . . . . 0.0 110.537 -179.958 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 4.4 tt0 -78.98 -9.61 59.58 Favored 'General case' 0 N--CA 1.494 1.74 0 O-C-N 121.503 -0.748 . . . . 0.0 111.12 -179.754 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . -73.23 -38.59 53.87 Favored Glycine 0 N--CA 1.497 2.76 0 N-CA-C 110.198 -1.161 . . . . 0.0 110.198 -179.839 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 33' ' ' CYS . . . . . 0.421 ' HB2' ' O ' ' A' ' 38' ' ' GLY . 0.8 OUTLIER -127.22 94.0 3.89 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.544 -0.974 . . . . 0.0 109.976 179.684 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -123.04 35.29 4.91 Favored 'General case' 0 N--CA 1.495 1.78 0 O-C-N 121.699 -0.626 . . . . 0.0 109.681 179.552 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 2.2 mp0 -78.5 -144.57 0.03 OUTLIER 'General case' 0 N--CA 1.502 2.126 0 O-C-N 121.814 -0.554 . . . . 0.0 109.824 -179.782 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 36' ' ' ALA . . . . . . . . . . . . . . . -76.95 -25.89 53.37 Favored 'General case' 0 N--CA 1.492 1.634 0 O-C-N 121.022 -1.048 . . . . 0.0 109.795 -179.822 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 6.0 tt0 -99.81 -40.04 7.92 Favored 'General case' 0 N--CA 1.497 1.884 0 O-C-N 121.321 -0.862 . . . . 0.0 110.131 179.111 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 38' ' ' GLY . . . . . 0.421 ' O ' ' HB2' ' A' ' 33' ' ' CYS . . . 81.37 -119.5 4.88 Favored Glycine 0 N--CA 1.487 2.079 0 N-CA-C 109.355 -1.498 . . . . 0.0 109.355 -179.881 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 39' ' ' CYS . . . . . . . . . . . . . 1.0 OUTLIER -152.67 43.81 0.66 Allowed 'General case' 0 N--CA 1.495 1.804 0 O-C-N 121.548 -0.972 . . . . 0.0 110.23 179.605 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 40' ' ' LEU . . . . . . . . . . . . . 71.4 mt . . . . . 0 N--CA 1.493 1.684 0 O-C-N 121.085 -1.01 . . . . 0.0 110.735 -179.502 . . . . . . . . 0 0 . 1 . 014 nuclear nobuild core ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 8.7 t . . . . . 0 N--CA 1.492 1.668 0 N-CA-C 109.472 -0.566 . . . . 0.0 109.472 . . . . . . . . . 0 0 . 1 . 014 nuclear nobuild core ' A' A ' 6' ' ' PRO . . . . . . . . . . . . . 44.2 Cg_endo -75.97 -58.27 0.05 OUTLIER 'Trans proline' 0 C--N 1.314 -1.284 0 O-C-N 124.195 1.629 . . . . 0.0 111.161 -179.704 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -76.02 57.02 3.15 Favored Glycine 0 N--CA 1.498 2.811 0 N-CA-C 110.111 -1.196 . . . . 0.0 110.111 -179.77 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 0.8 OUTLIER -113.91 12.66 18.17 Favored 'General case' 0 N--CA 1.495 1.794 0 O-C-N 121.11 -1.229 . . . . 0.0 110.335 179.131 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -116.61 160.37 13.47 Favored Glycine 0 N--CA 1.494 2.534 0 N-CA-C 108.26 -1.936 . . . . 0.0 108.26 179.195 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 10' ' ' GLN . . . . . . . . . . . . . 4.8 mt-30 55.05 31.43 16.17 Favored 'General case' 0 N--CA 1.502 2.16 0 O-C-N 121.574 -0.957 . . . . 0.0 110.639 -179.635 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -76.58 53.04 3.2 Favored Glycine 0 N--CA 1.496 2.699 0 N-CA-C 110.064 -1.214 . . . . 0.0 110.064 -179.822 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 10.0 p -98.89 36.11 0.18 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.722 0 O-C-N 121.351 -1.088 . . . . 0.0 110.32 -179.8 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 13' ' ' GLN . . . . . . . . . . . . . 2.0 tt0 56.48 15.42 2.03 Favored 'General case' 0 N--CA 1.502 2.174 0 O-C-N 121.316 -0.865 . . . . 0.0 111.796 179.814 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . 46.15 36.26 3.08 Favored 'General case' 0 N--CA 1.502 2.172 0 O-C-N 121.274 -0.891 . . . . 0.0 110.663 -179.496 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -95.46 -50.22 2.05 Favored Glycine 0 N--CA 1.493 2.463 0 N-CA-C 109.961 -1.256 . . . . 0.0 109.961 -179.353 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 96.6 m -111.57 80.83 2.93 Favored Pre-proline 0 N--CA 1.497 1.922 0 O-C-N 121.126 -1.22 . . . . 0.0 110.406 -179.629 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 43.5 Cg_endo -74.48 100.9 1.37 Allowed 'Trans proline' 0 C--N 1.312 -1.358 0 O-C-N 123.769 1.405 . . . . 0.0 109.993 179.808 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 114.94 -38.68 3.04 Favored Glycine 0 N--CA 1.496 2.663 0 N-CA-C 110.184 -1.167 . . . . 0.0 110.184 -179.798 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 179.07 144.92 5.95 Favored Glycine 0 N--CA 1.487 2.055 0 N-CA-C 108.973 -1.651 . . . . 0.0 108.973 -179.742 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -108.64 43.58 1.23 Allowed 'General case' 0 N--CA 1.496 1.86 0 O-C-N 121.625 -0.927 . . . . 0.0 110.125 -179.935 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 0.1 OUTLIER -146.09 52.8 0.12 Allowed 'Isoleucine or valine' 0 N--CA 1.496 1.869 0 O-C-N 121.547 -0.721 . . . . 0.0 109.19 179.656 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 2.2 mp0 -79.32 -30.07 42.66 Favored 'General case' 0 N--CA 1.488 1.472 0 O-C-N 121.602 -0.686 . . . . 0.0 111.233 -178.842 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 10.9 tt0 -161.44 108.8 1.44 Allowed 'General case' 0 N--CA 1.493 1.693 0 O-C-N 121.178 -0.951 . . . . 0.0 110.51 -179.709 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 0.8 OUTLIER -89.73 155.26 19.32 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.223 -0.923 . . . . 0.0 109.909 179.438 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 8.8 p-10 -79.05 -33.95 44.24 Favored 'General case' 0 N--CA 1.498 1.96 0 O-C-N 121.359 -0.838 . . . . 0.0 110.7 -179.953 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -55.19 -46.87 77.32 Favored Glycine 0 N--CA 1.495 2.632 0 N-CA-C 110.36 -1.096 . . . . 0.0 110.36 -179.91 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -98.47 61.79 0.86 Allowed Glycine 0 N--CA 1.495 2.619 0 N-CA-C 109.904 -1.279 . . . . 0.0 109.904 -179.743 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 1.6 m -112.57 92.63 20.4 Favored Pre-proline 0 N--CA 1.497 1.918 0 O-C-N 121.318 -1.107 . . . . 0.0 110.578 179.998 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 52.1 Cg_endo -78.8 133.92 11.7 Favored 'Trans proline' 0 C--N 1.316 -1.181 0 O-C-N 123.817 1.43 . . . . 0.0 110.475 179.723 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -127.11 56.99 1.49 Allowed 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.357 -0.84 . . . . 0.0 110.436 179.761 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 10.0 tt0 -160.75 -48.55 0.05 OUTLIER 'General case' 0 N--CA 1.495 1.808 0 O-C-N 121.338 -0.851 . . . . 0.0 110.733 179.557 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . -59.23 -27.15 62.43 Favored Glycine 0 N--CA 1.497 2.713 0 O-C-N 121.514 -0.741 . . . . 0.0 111.524 -179.394 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 33' ' ' CYS . . . . . 0.43 ' O ' ' HB3' ' A' ' 39' ' ' CYS . 26.0 p -79.12 68.55 5.12 Favored 'General case' 0 N--CA 1.498 1.961 0 O-C-N 120.821 -1.399 . . . . 0.0 110.315 -179.556 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -92.39 33.28 1.11 Allowed 'General case' 0 N--CA 1.496 1.855 0 O-C-N 120.888 -1.133 . . . . 0.0 110.626 179.771 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 4.8 mp0 -97.4 -178.5 4.17 Favored 'General case' 0 N--CA 1.492 1.648 0 O-C-N 121.16 -0.963 . . . . 0.0 110.351 -179.968 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 36' ' ' ALA . . . . . . . . . . . . . . . -87.86 28.66 1.0 Allowed 'General case' 0 N--CA 1.498 1.957 0 O-C-N 121.045 -1.034 . . . . 0.0 111.227 -179.807 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 13.6 pt-20 -78.91 -17.57 55.31 Favored 'General case' 0 N--CA 1.493 1.721 0 O-C-N 121.046 -1.033 . . . . 0.0 110.895 179.329 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 122.45 10.22 6.14 Favored Glycine 0 N--CA 1.496 2.673 0 N-CA-C 110.148 -1.181 . . . . 0.0 110.148 -179.533 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 39' ' ' CYS . . . . . 0.43 ' HB3' ' O ' ' A' ' 33' ' ' CYS . 0.1 OUTLIER -79.35 -25.26 42.3 Favored 'General case' 0 N--CA 1.501 2.08 0 O-C-N 120.876 -1.367 . . . . 0.0 110.369 179.78 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 40' ' ' LEU . . . . . . . . . . . . . 0.9 OUTLIER . . . . . 0 N--CA 1.491 1.578 0 O-C-N 121.024 -1.047 . . . . 0.0 110.851 -179.721 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 31.2 p . . . . . 0 N--CA 1.494 1.763 0 CA-C-O 120.385 0.136 . . . . 0.0 110.652 . . . . . . . . . 0 0 . 1 . 015 nuclear nobuild core ' A' A ' 6' ' ' PRO . . . . . . . . . . . . . 47.3 Cg_endo -77.95 121.49 5.43 Favored 'Trans proline' 0 C--N 1.315 -1.189 0 O-C-N 123.899 1.473 . . . . 0.0 110.903 -179.549 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 96.64 12.64 50.06 Favored Glycine 0 N--CA 1.496 2.68 0 N-CA-C 110.734 -0.946 . . . . 0.0 110.734 179.536 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 0.8 OUTLIER -160.5 172.32 17.42 Favored 'General case' 0 N--CA 1.496 1.852 0 O-C-N 120.75 -1.441 . . . . 0.0 110.171 -179.47 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 115.75 -173.26 14.64 Favored Glycine 0 N--CA 1.494 2.55 0 N-CA-C 109.599 -1.4 . . . . 0.0 109.599 -179.871 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 10' ' ' GLN . . . . . . . . . . . . . 4.4 mt-30 -89.14 50.29 1.92 Allowed 'General case' 0 N--CA 1.492 1.659 0 O-C-N 121.279 -1.13 . . . . 0.0 110.381 179.939 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -83.19 60.66 4.87 Favored Glycine 0 N--CA 1.495 2.573 0 N-CA-C 109.744 -1.342 . . . . 0.0 109.744 179.974 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 9.0 p -135.43 25.33 0.93 Allowed 'Isoleucine or valine' 0 N--CA 1.496 1.851 0 O-C-N 121.334 -1.097 . . . . 0.0 110.805 179.904 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 13' ' ' GLN . . . . . 0.45 ' O ' ' HB3' ' A' ' 14' ' ' ALA . 0.2 OUTLIER -71.73 -14.64 62.07 Favored 'General case' 0 N--CA 1.498 1.96 0 O-C-N 120.938 -1.101 . . . . 0.0 111.461 -179.782 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 14' ' ' ALA . . . . . 0.45 ' HB3' ' O ' ' A' ' 13' ' ' GLN . . . 59.63 82.85 0.14 Allowed 'General case' 0 N--CA 1.502 2.165 0 O-C-N 121.17 -0.957 . . . . 0.0 110.583 -179.915 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -125.36 75.95 0.4 Allowed Glycine 0 N--CA 1.492 2.424 0 N-CA-C 109.045 -1.622 . . . . 0.0 109.045 179.665 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 10.7 m -78.4 118.32 71.62 Favored Pre-proline 0 N--CA 1.496 1.866 0 O-C-N 121.29 -1.124 . . . . 0.0 109.709 -179.863 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 40.7 Cg_endo -68.25 -41.2 7.3 Favored 'Trans proline' 0 C--N 1.316 -1.139 0 O-C-N 123.855 1.45 . . . . 0.0 111.32 -179.498 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . -176.22 60.87 0.1 Allowed Glycine 0 N--CA 1.496 2.66 0 N-CA-C 109.796 -1.322 . . . . 0.0 109.796 179.994 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 162.61 75.19 0.02 OUTLIER Glycine 0 N--CA 1.493 2.495 0 N-CA-C 109.539 -1.424 . . . . 0.0 109.539 179.72 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 0.3 OUTLIER -105.86 -40.09 5.82 Favored 'General case' 0 N--CA 1.495 1.803 0 O-C-N 121.191 -1.182 . . . . 0.0 110.647 -179.516 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 3.6 t -107.7 56.27 0.14 Allowed 'Isoleucine or valine' 0 N--CA 1.497 1.903 0 O-C-N 121.319 -0.863 . . . . 0.0 110.186 179.923 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER -79.72 46.2 0.75 Allowed 'General case' 0 N--CA 1.495 1.823 0 O-C-N 120.979 -1.075 . . . . 0.0 110.479 179.827 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 23' ' ' GLU . . . . . 0.488 ' HG3' ' N ' ' A' ' 24' ' ' GLU . 6.7 pt-20 -128.0 -29.41 2.55 Favored 'General case' 0 N--CA 1.493 1.676 0 O-C-N 121.06 -1.025 . . . . 0.0 110.964 179.318 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 24' ' ' GLU . . . . . 0.488 ' N ' ' HG3' ' A' ' 23' ' ' GLU . 10.7 mt-10 57.76 177.38 0.05 Allowed 'General case' 0 N--CA 1.498 1.952 0 O-C-N 121.513 -0.742 . . . . 0.0 111.8 179.401 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 1.2 p-10 -102.81 -36.53 8.23 Favored 'General case' 0 N--CA 1.495 1.802 0 O-C-N 121.122 -0.986 . . . . 0.0 110.433 -179.302 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 118.55 92.03 1.47 Allowed Glycine 0 N--CA 1.49 2.27 0 N-CA-C 108.891 -1.684 . . . . 0.0 108.891 -179.484 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -59.01 105.85 0.77 Allowed Glycine 0 N--CA 1.494 2.545 0 N-CA-C 109.636 -1.386 . . . . 0.0 109.636 -179.564 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 28' ' ' SER . . . . . 0.508 ' N ' ' HD2' ' A' ' 29' ' ' PRO . 0.0 OUTLIER -79.5 -49.3 1.4 Allowed Pre-proline 0 N--CA 1.496 1.837 0 O-C-N 121.536 -0.979 . . . . 0.0 111.769 -179.007 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 29' ' ' PRO . . . . . 0.508 ' HD2' ' N ' ' A' ' 28' ' ' SER . 44.2 Cg_endo -72.21 60.83 3.24 Favored 'Trans proline' 0 N--CA 1.49 1.292 0 O-C-N 123.159 1.083 . . . . 0.0 111.478 -179.197 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -121.74 47.62 1.84 Allowed 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.148 -0.97 . . . . 0.0 110.096 179.421 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 1.2 tp10 -80.46 -68.65 0.66 Allowed 'General case' 0 N--CA 1.493 1.706 0 O-C-N 121.494 -0.754 . . . . 0.0 109.885 -179.664 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 116.56 76.2 0.6 Allowed Glycine 0 N--CA 1.494 2.53 0 N-CA-C 109.766 -1.334 . . . . 0.0 109.766 179.943 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 33' ' ' CYS . . . . . . . . . . . . . 10.4 p -79.09 127.5 32.09 Favored 'General case' 0 N--CA 1.496 1.85 0 O-C-N 121.632 -0.922 . . . . 0.0 109.687 179.462 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -144.77 17.72 1.63 Allowed 'General case' 0 N--CA 1.499 1.989 0 O-C-N 121.385 -0.822 . . . . 0.0 110.543 -179.904 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 1.5 mp0 -90.8 -163.8 1.08 Allowed 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.395 -0.816 . . . . 0.0 110.472 -179.566 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 36' ' ' ALA . . . . . . . . . . . . . . . -88.15 43.05 1.1 Allowed 'General case' 0 N--CA 1.499 1.988 0 O-C-N 121.123 -0.986 . . . . 0.0 111.44 -179.275 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 1.9 pt-20 -138.39 9.73 2.71 Favored 'General case' 0 N--CA 1.494 1.759 0 O-C-N 121.261 -0.9 . . . . 0.0 110.956 179.254 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 68.39 -108.63 2.53 Favored Glycine 0 N--CA 1.495 2.615 0 N-CA-C 108.869 -1.692 . . . . 0.0 108.869 -179.657 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 39' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -160.64 -54.86 0.05 Allowed 'General case' 0 N--CA 1.498 1.96 0 O-C-N 121.154 -1.204 . . . . 0.0 110.376 179.321 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 40' ' ' LEU . . . . . . . . . . . . . 6.3 tt . . . . . 0 N--CA 1.494 1.764 0 O-C-N 121.271 -0.893 . . . . 0.0 111.104 -179.888 . . . . . . . . 0 0 . 1 . 016 nuclear nobuild core ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 8.5 t . . . . . 0 N--CA 1.496 1.828 0 N-CA-C 109.475 -0.565 . . . . 0.0 109.475 . . . . . . . . . 0 0 . 1 . 016 nuclear nobuild core ' A' A ' 6' ' ' PRO . . . . . . . . . . . . . 44.1 Cg_endo -73.14 106.86 2.24 Favored 'Trans proline' 0 C--N 1.312 -1.356 0 O-C-N 123.891 1.469 . . . . 0.0 111.162 -179.267 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 66.69 49.07 58.0 Favored Glycine 0 N--CA 1.496 2.659 0 N-CA-C 110.515 -1.034 . . . . 0.0 110.515 179.154 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -84.93 178.57 7.55 Favored 'General case' 0 N--CA 1.5 2.038 0 O-C-N 121.212 -1.17 . . . . 0.0 110.47 179.676 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -74.34 150.97 42.83 Favored Glycine 0 N--CA 1.491 2.311 0 N-CA-C 109.763 -1.335 . . . . 0.0 109.763 179.961 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 10' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -79.23 50.08 1.03 Allowed 'General case' 0 N--CA 1.496 1.875 0 O-C-N 121.591 -0.946 . . . . 0.0 110.773 -179.953 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -79.7 -57.06 3.17 Favored Glycine 0 N--CA 1.492 2.41 0 N-CA-C 109.612 -1.395 . . . . 0.0 109.612 179.929 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 12' ' ' VAL . . . . . 0.456 HG22 ' O ' ' A' ' 12' ' ' VAL . 7.4 p -137.17 65.69 0.25 Allowed 'Isoleucine or valine' 0 N--CA 1.496 1.85 0 O-C-N 121.466 -1.02 . . . . 0.0 110.35 -179.99 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 13' ' ' GLN . . . . . . . . . . . . . 2.6 tp-100 -80.22 -36.87 34.16 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.226 -0.921 . . . . 0.0 110.404 179.712 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -94.83 167.07 11.66 Favored 'General case' 0 N--CA 1.494 1.75 0 O-C-N 121.593 -0.692 . . . . 0.0 110.256 179.976 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -60.12 -34.19 82.92 Favored Glycine 0 N--CA 1.497 2.76 0 N-CA-C 110.228 -1.149 . . . . 0.0 110.228 179.608 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 16' ' ' CYS . . . . . 0.446 ' HB2' ' HB2' ' A' ' 20' ' ' CYS . 0.0 OUTLIER -110.01 96.86 26.98 Favored Pre-proline 0 N--CA 1.496 1.851 0 O-C-N 120.714 -1.462 . . . . 0.0 109.614 179.403 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 41.2 Cg_endo -68.43 111.26 2.48 Favored 'Trans proline' 0 C--N 1.311 -1.424 0 O-C-N 123.837 1.44 . . . . 0.0 111.079 -179.59 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 62.68 20.02 61.26 Favored Glycine 0 N--CA 1.496 2.685 0 N-CA-C 110.654 -0.978 . . . . 0.0 110.654 179.857 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -157.93 54.2 0.38 Allowed Glycine 0 N--CA 1.498 2.771 0 N-CA-C 109.741 -1.344 . . . . 0.0 109.741 -179.808 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 20' ' ' CYS . . . . . 0.446 ' HB2' ' HB2' ' A' ' 16' ' ' CYS . 0.8 OUTLIER -125.95 93.87 3.95 Favored 'General case' 0 N--CA 1.497 1.914 0 O-C-N 121.362 -1.081 . . . . 0.0 109.527 179.686 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 22.5 m -122.27 41.04 0.77 Allowed 'Isoleucine or valine' 0 N--CA 1.494 1.745 0 CA-C-O 121.268 0.556 . . . . 0.0 110.879 -179.211 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 2.8 mt-10 -110.6 44.99 1.18 Allowed 'General case' 0 C--N 1.307 -1.275 0 O-C-N 121.371 -0.83 . . . . 0.0 109.865 179.374 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 1.3 tp10 -101.2 -57.3 2.12 Favored 'General case' 0 N--CA 1.492 1.671 0 O-C-N 121.32 -0.863 . . . . 0.0 110.225 -179.824 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 1.0 OUTLIER -72.77 154.4 40.67 Favored 'General case' 0 N--CA 1.499 1.99 0 O-C-N 121.523 -0.735 . . . . 0.0 110.466 -179.744 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 4.1 p-10 -95.25 36.84 1.2 Allowed 'General case' 0 N--CA 1.502 2.134 0 O-C-N 121.353 -0.842 . . . . 0.0 111.357 179.956 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 154.96 -90.47 0.12 Allowed Glycine 0 N--CA 1.492 2.426 0 N-CA-C 109.719 -1.353 . . . . 0.0 109.719 178.922 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -138.15 141.81 12.51 Favored Glycine 0 N--CA 1.498 2.817 0 N-CA-C 109.799 -1.32 . . . . 0.0 109.799 -179.803 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 28' ' ' SER . . . . . 0.452 ' OG ' ' HD2' ' A' ' 29' ' ' PRO . 23.0 t -84.94 154.43 60.92 Favored Pre-proline 0 C--N 1.301 -1.535 0 O-C-N 121.285 -1.126 . . . . 0.0 109.854 179.759 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 29' ' ' PRO . . . . . 0.452 ' HD2' ' OG ' ' A' ' 28' ' ' SER . 37.9 Cg_endo -65.51 -26.87 54.41 Favored 'Trans proline' 0 C--N 1.308 -1.584 0 O-C-N 123.353 1.186 . . . . 0.0 109.819 179.03 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -93.59 24.2 4.19 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.592 -0.693 . . . . 0.0 110.446 179.182 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 31' ' ' GLU . . . . . 0.413 ' HB2' ' O ' ' A' ' 28' ' ' SER . 1.7 tp10 -83.26 -7.99 59.52 Favored 'General case' 0 N--CA 1.495 1.822 0 O-C-N 121.376 -0.827 . . . . 0.0 111.106 -179.883 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 77.62 29.0 56.28 Favored Glycine 0 N--CA 1.494 2.542 0 N-CA-C 109.404 -1.478 . . . . 0.0 109.404 -179.481 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 33' ' ' CYS . . . . . . . . . . . . . 0.0 OUTLIER -161.64 43.86 0.16 Allowed 'General case' 0 N--CA 1.498 1.929 0 O-C-N 121.411 -1.052 . . . . 0.0 109.861 179.842 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -109.39 -49.44 3.11 Favored 'General case' 0 N--CA 1.498 1.943 0 O-C-N 120.919 -1.113 . . . . 0.0 111.21 -179.342 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 35.1 mt-10 -95.02 -167.45 1.63 Allowed 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.051 -1.031 . . . . 0.0 110.369 -179.217 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 36' ' ' ALA . . . . . . . . . . . . . . . -82.27 44.07 0.84 Allowed 'General case' 0 N--CA 1.497 1.89 0 O-C-N 121.299 -0.876 . . . . 0.0 110.316 179.563 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 3.2 pt-20 -79.67 -13.29 59.58 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.43 -0.794 . . . . 0.0 110.327 179.297 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 132.34 38.12 0.26 Allowed Glycine 0 N--CA 1.502 3.074 0 C-N-CA 120.159 -1.02 . . . . 0.0 111.103 179.389 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 39' ' ' CYS . . . . . . . . . . . . . 13.5 t -93.51 -47.41 6.86 Favored 'General case' 0 N--CA 1.493 1.715 0 O-C-N 121.357 -1.084 . . . . 0.0 110.196 179.76 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 40' ' ' LEU . . . . . . . . . . . . . 7.9 mt . . . . . 0 N--CA 1.488 1.465 0 O-C-N 121.136 -0.977 . . . . 0.0 110.314 179.952 . . . . . . . . 0 0 . 1 . 017 nuclear nobuild core ' A' A ' 5' ' ' CYS . . . . . 0.487 ' O ' ' SG ' ' A' ' 8' ' ' CYS . 1.3 p . . . . . 0 N--CA 1.496 1.859 0 CA-C-O 120.572 0.225 . . . . 0.0 110.41 . . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 6' ' ' PRO . . . . . . . . . . . . . 49.6 Cg_endo -77.54 -50.43 0.09 OUTLIER 'Trans proline' 0 C--N 1.311 -1.396 0 O-C-N 123.552 1.29 . . . . 0.0 111.173 179.488 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -105.2 67.31 0.27 Allowed Glycine 0 N--CA 1.494 2.54 0 N-CA-C 110.239 -1.144 . . . . 0.0 110.239 -179.545 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 8' ' ' CYS . . . . . 0.487 ' SG ' ' O ' ' A' ' 5' ' ' CYS . 3.5 m -86.56 138.04 32.03 Favored 'General case' 0 N--CA 1.494 1.766 0 O-C-N 121.308 -1.113 . . . . 0.0 109.404 179.107 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 114.18 88.51 1.62 Allowed Glycine 0 N--CA 1.492 2.416 0 N-CA-C 109.165 -1.574 . . . . 0.0 109.165 -179.486 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 10' ' ' GLN . . . . . . . . . . . . . 4.1 mt-30 51.62 33.38 10.65 Favored 'General case' 0 N--CA 1.507 2.383 0 O-C-N 121.647 -0.913 . . . . 0.0 111.161 -179.558 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -110.27 -40.36 1.39 Allowed Glycine 0 N--CA 1.496 2.693 0 N-CA-C 109.659 -1.377 . . . . 0.0 109.659 179.761 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 43.6 t -79.16 -47.71 22.23 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.822 0 O-C-N 121.39 -1.065 . . . . 0.0 110.485 179.905 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 13' ' ' GLN . . . . . . . . . . . . . 7.1 tt0 -72.86 133.84 44.59 Favored 'General case' 0 N--CA 1.494 1.735 0 O-C-N 121.054 -1.029 . . . . 0.0 110.244 179.887 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -102.76 -164.08 1.05 Allowed 'General case' 0 N--CA 1.495 1.784 0 O-C-N 121.524 -0.735 . . . . 0.0 109.697 179.602 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -168.71 -105.33 0.18 Allowed Glycine 0 N--CA 1.496 2.649 0 N-CA-C 109.348 -1.501 . . . . 0.0 109.348 179.886 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 16' ' ' CYS . . . . . 0.52 ' SG ' ' N ' ' A' ' 20' ' ' CYS . 0.0 OUTLIER -115.03 98.26 49.91 Favored Pre-proline 0 N--CA 1.49 1.538 0 O-C-N 121.328 -1.101 . . . . 0.0 109.8 179.855 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 48.0 Cg_endo -77.36 60.92 7.2 Favored 'Trans proline' 0 C--N 1.31 -1.458 0 O-C-N 123.572 1.301 . . . . 0.0 109.559 179.251 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 91.4 -20.61 39.87 Favored Glycine 0 N--CA 1.493 2.447 0 N-CA-C 109.605 -1.398 . . . . 0.0 109.605 -178.471 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -99.24 68.8 0.58 Allowed Glycine 0 N--CA 1.496 2.636 0 O-C-N 120.606 -1.526 . . . . 0.0 109.677 -179.901 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 20' ' ' CYS . . . . . 0.52 ' N ' ' SG ' ' A' ' 16' ' ' CYS . 16.3 m -82.17 143.35 31.48 Favored 'General case' 0 N--CA 1.488 1.473 0 O-C-N 121.308 -1.113 . . . . 0.0 109.262 179.803 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 35.7 m -77.88 -21.18 13.72 Favored 'Isoleucine or valine' 0 N--CA 1.503 2.176 0 O-C-N 121.888 -0.508 . . . . 0.0 111.685 -179.137 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 4.1 pt-20 -88.36 15.09 8.26 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.127 -0.983 . . . . 0.0 111.141 179.494 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 3.0 mm-40 -134.21 24.63 3.85 Favored 'General case' 0 N--CA 1.494 1.744 0 O-C-N 120.975 -1.078 . . . . 0.0 110.549 179.482 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 13.9 mm-40 -85.38 -2.83 58.52 Favored 'General case' 0 N--CA 1.494 1.759 0 O-C-N 121.093 -1.004 . . . . 0.0 111.563 -179.717 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 3.8 p-10 -104.98 19.69 20.15 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 120.68 -1.263 . . . . 0.0 109.999 179.972 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -72.45 56.28 1.6 Allowed Glycine 0 N--CA 1.489 2.174 0 N-CA-C 109.31 -1.516 . . . . 0.0 109.31 179.386 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 115.98 9.37 12.25 Favored Glycine 0 N--CA 1.501 3.004 0 O-C-N 121.32 -1.106 . . . . 0.0 110.378 -179.61 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -108.47 92.89 10.66 Favored Pre-proline 0 N--CA 1.493 1.718 0 O-C-N 120.899 -1.354 . . . . 0.0 109.822 179.683 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 43.9 Cg_endo -72.87 71.5 3.38 Favored 'Trans proline' 0 N--CA 1.489 1.238 0 O-C-N 123.472 1.249 . . . . 0.0 110.483 -179.751 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -108.18 61.3 0.61 Allowed 'General case' 0 N--CA 1.488 1.437 0 O-C-N 121.272 -0.893 . . . . 0.0 110.219 -179.86 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 2.1 tt0 -78.76 -28.14 44.79 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.369 -0.832 . . . . 0.0 110.569 -179.749 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 74.57 46.9 17.38 Favored Glycine 0 N--CA 1.489 2.178 0 N-CA-C 110.377 -1.089 . . . . 0.0 110.377 179.255 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 33' ' ' CYS . . . . . . . . . . . . . 14.1 m -79.84 87.56 5.3 Favored 'General case' 0 N--CA 1.497 1.921 0 O-C-N 120.931 -1.335 . . . . 0.0 109.782 179.624 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -102.87 -61.19 1.43 Allowed 'General case' 0 N--CA 1.493 1.689 0 O-C-N 121.503 -0.748 . . . . 0.0 110.201 -179.787 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 1.3 pm0 -85.18 -169.5 2.68 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.445 -0.784 . . . . 0.0 110.533 -179.747 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 36' ' ' ALA . . . . . . . . . . . . . . . -107.93 35.5 3.1 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.013 -1.055 . . . . 0.0 110.232 179.849 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -110.64 -55.36 2.49 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.181 -0.949 . . . . 0.0 110.26 179.948 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -68.38 -41.32 85.71 Favored Glycine 0 N--CA 1.497 2.713 0 N-CA-C 109.546 -1.421 . . . . 0.0 109.546 179.859 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 39' ' ' CYS . . . . . . . . . . . . . 1.6 p -156.82 84.67 0.96 Allowed 'General case' 0 N--CA 1.497 1.915 0 O-C-N 121.412 -1.052 . . . . 0.0 110.119 -179.766 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 40' ' ' LEU . . . . . . . . . . . . . 1.4 pp . . . . . 0 N--CA 1.498 1.958 0 O-C-N 121.312 -0.868 . . . . 0.0 110.611 -179.751 . . . . . . . . 0 0 . 1 . 018 nuclear nobuild core ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 3.3 p . . . . . 0 N--CA 1.495 1.802 0 N-CA-C 109.475 -0.565 . . . . 0.0 109.475 . . . . . . . . . 0 0 . 1 . 018 nuclear nobuild core ' A' A ' 6' ' ' PRO . . . . . . . . . . . . . 42.1 Cg_endo -69.06 -43.98 2.87 Favored 'Trans proline' 0 C--N 1.312 -1.364 0 O-C-N 123.588 1.309 . . . . 0.0 111.534 -179.367 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -82.75 50.81 4.44 Favored Glycine 0 N--CA 1.495 2.624 0 N-CA-C 109.946 -1.262 . . . . 0.0 109.946 -179.975 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 1.7 m -119.06 -30.25 5.04 Favored 'General case' 0 N--CA 1.499 1.995 0 O-C-N 121.257 -1.143 . . . . 0.0 111.001 179.945 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 109.34 133.51 6.76 Favored Glycine 0 N--CA 1.493 2.483 0 N-CA-C 109.73 -1.348 . . . . 0.0 109.73 -179.802 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 10' ' ' GLN . . . . . . . . . . . . . 0.7 OUTLIER 45.39 49.71 10.33 Favored 'General case' 0 N--CA 1.501 2.125 0 O-C-N 121.953 -0.734 . . . . 0.0 111.053 179.499 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -86.93 -54.7 2.55 Favored Glycine 0 N--CA 1.496 2.675 0 N-CA-C 110.092 -1.203 . . . . 0.0 110.092 -179.848 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 12' ' ' VAL . . . . . 0.458 ' O ' HG13 ' A' ' 12' ' ' VAL . 9.0 p -138.03 48.08 0.35 Allowed 'Isoleucine or valine' 0 N--CA 1.495 1.784 0 O-C-N 121.275 -1.132 . . . . 0.0 110.413 179.93 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 13' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -81.82 -7.38 59.6 Favored 'General case' 0 N--CA 1.495 1.78 0 O-C-N 120.946 -1.096 . . . . 0.0 111.159 179.919 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -125.6 141.72 51.88 Favored 'General case' 0 N--CA 1.495 1.821 0 O-C-N 121.303 -0.873 . . . . 0.0 109.767 179.943 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -161.05 90.98 0.11 Allowed Glycine 0 N--CA 1.492 2.406 0 N-CA-C 109.372 -1.491 . . . . 0.0 109.372 179.697 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 13.4 m -94.69 152.71 40.02 Favored Pre-proline 0 N--CA 1.5 2.04 0 O-C-N 121.233 -1.157 . . . . 0.0 110.456 -179.95 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 48.2 Cg_endo -76.38 -147.81 0.03 OUTLIER 'Trans proline' 0 C--N 1.308 -1.554 0 O-C-N 123.779 1.41 . . . . 0.0 108.773 178.454 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . -62.92 -12.39 42.44 Favored Glycine 0 N--CA 1.498 2.767 0 O-C-N 120.878 -1.139 . . . . 0.0 110.898 179.574 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -151.18 115.4 0.7 Allowed Glycine 0 N--CA 1.494 2.536 0 N-CA-C 109.175 -1.57 . . . . 0.0 109.175 -179.705 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 4.8 t -84.56 -10.3 57.53 Favored 'General case' 0 N--CA 1.499 2.01 0 O-C-N 121.179 -1.189 . . . . 0.0 111.459 -179.834 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 8.6 p -129.36 26.21 1.9 Allowed 'Isoleucine or valine' 0 N--CA 1.499 1.997 0 O-C-N 121.045 -1.034 . . . . 0.0 111.027 -179.81 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 1.4 tp10 -105.72 -4.44 20.94 Favored 'General case' 0 N--CA 1.493 1.692 0 O-C-N 120.479 -1.388 . . . . 0.0 110.952 179.56 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 0.8 OUTLIER -138.14 -47.09 0.52 Allowed 'General case' 0 N--CA 1.492 1.673 0 O-C-N 121.064 -1.023 . . . . 0.0 110.712 179.697 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 1.1 mt-10 -59.95 115.84 3.71 Favored 'General case' 0 N--CA 1.494 1.747 0 O-C-N 121.482 -0.761 . . . . 0.0 110.079 -179.423 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 6.4 t0 -104.5 91.37 3.86 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.371 -0.831 . . . . 0.0 109.37 179.297 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -79.32 60.22 4.29 Favored Glycine 0 N--CA 1.496 2.676 0 N-CA-C 109.52 -1.432 . . . . 0.0 109.52 -179.296 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 177.45 -179.24 48.24 Favored Glycine 0 N--CA 1.493 2.49 0 N-CA-C 109.956 -1.258 . . . . 0.0 109.956 179.753 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -160.07 155.56 22.09 Favored Pre-proline 0 N--CA 1.494 1.73 0 O-C-N 121.381 -1.07 . . . . 0.0 110.187 179.854 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 40.2 Cg_endo -67.74 -40.72 9.35 Favored 'Trans proline' 0 N--CA 1.492 1.438 0 O-C-N 123.549 1.289 . . . . 0.0 110.17 179.484 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -92.97 47.95 1.31 Allowed 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.403 -0.811 . . . . 0.0 110.191 179.369 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 12.5 tt0 -77.85 -11.38 59.88 Favored 'General case' 0 N--CA 1.494 1.747 0 O-C-N 121.487 -0.758 . . . . 0.0 111.034 -179.87 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 98.16 84.44 1.76 Allowed Glycine 0 N--CA 1.489 2.22 0 N-CA-C 108.675 -1.77 . . . . 0.0 108.675 -179.668 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 33' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -79.02 65.45 4.2 Favored 'General case' 0 N--CA 1.493 1.714 0 O-C-N 121.166 -1.196 . . . . 0.0 110.051 -179.341 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -115.75 56.38 0.77 Allowed 'General case' 0 N--CA 1.496 1.832 0 O-C-N 121.469 -0.769 . . . . 0.0 109.75 179.697 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 1.1 tt0 -147.59 -162.3 1.52 Allowed 'General case' 0 N--CA 1.494 1.765 0 O-C-N 121.457 -0.777 . . . . 0.0 110.081 -179.363 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 36' ' ' ALA . . . . . . . . . . . . . . . -78.65 -30.85 46.57 Favored 'General case' 0 N--CA 1.494 1.727 0 O-C-N 121.464 -0.772 . . . . 0.0 109.108 179.029 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER -134.74 -74.32 0.47 Allowed 'General case' 0 N--CA 1.487 1.395 0 O-C-N 121.6 -0.687 . . . . 0.0 109.723 179.079 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 56.97 -99.27 0.09 OUTLIER Glycine 0 N--CA 1.496 2.685 0 N-CA-C 110.319 -1.113 . . . . 0.0 110.319 179.291 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 39' ' ' CYS . . . . . . . . . . . . . 2.5 p -99.49 6.56 45.88 Favored 'General case' 0 N--CA 1.497 1.912 0 O-C-N 121.792 -0.828 . . . . 0.0 111.612 -179.674 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 40' ' ' LEU . . . . . . . . . . . . . 1.5 mt . . . . . 0 N--CA 1.504 2.266 0 O-C-N 121.416 -0.802 . . . . 0.0 110.974 179.454 . . . . . . . . 0 0 . 1 . 019 nuclear nobuild core ' A' A ' 5' ' ' CYS . . . . . 0.438 ' SG ' ' N ' ' A' ' 8' ' ' CYS . 1.3 p . . . . . 0 N--CA 1.491 1.595 0 N-CA-C 109.941 -0.392 . . . . 0.0 109.941 . . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 6' ' ' PRO . . . . . . . . . . . . . 41.1 Cg_endo -68.2 -31.47 29.18 Favored 'Trans proline' 0 C--N 1.314 -1.246 0 O-C-N 123.637 1.335 . . . . 0.0 110.988 179.824 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -91.81 23.37 26.33 Favored Glycine 0 N--CA 1.494 2.547 0 N-CA-C 110.29 -1.124 . . . . 0.0 110.29 179.492 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 8' ' ' CYS . . . . . 0.438 ' N ' ' SG ' ' A' ' 5' ' ' CYS . 51.0 m -96.93 19.13 13.21 Favored 'General case' 0 N--CA 1.494 1.744 0 O-C-N 120.998 -1.295 . . . . 0.0 110.751 -179.904 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -79.28 -48.03 7.1 Favored Glycine 0 N--CA 1.492 2.415 0 N-CA-C 109.929 -1.268 . . . . 0.0 109.929 -179.653 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 10' ' ' GLN . . . . . . . . . . . . . 4.3 mt-30 -111.62 40.14 2.19 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 121.15 -1.206 . . . . 0.0 110.603 -179.62 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -84.43 63.39 4.43 Favored Glycine 0 N--CA 1.497 2.727 0 N-CA-C 109.861 -1.295 . . . . 0.0 109.861 179.883 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 13.3 m -134.98 48.61 0.41 Allowed 'Isoleucine or valine' 0 N--CA 1.501 2.087 0 O-C-N 121.393 -1.063 . . . . 0.0 110.652 179.923 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 13' ' ' GLN . . . . . . . . . . . . . 11.9 mt-30 -73.56 75.7 1.48 Allowed 'General case' 0 N--CA 1.498 1.936 0 O-C-N 121.074 -1.016 . . . . 0.0 110.454 179.944 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -110.13 -69.51 0.86 Allowed 'General case' 0 N--CA 1.498 1.939 0 O-C-N 121.288 -0.882 . . . . 0.0 110.563 -179.777 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -161.01 -105.1 0.2 Allowed Glycine 0 N--CA 1.493 2.445 0 N-CA-C 109.58 -1.408 . . . . 0.0 109.58 -179.674 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 0.0 OUTLIER -116.9 161.61 31.57 Favored Pre-proline 0 N--CA 1.501 2.101 0 O-C-N 121.253 -1.145 . . . . 0.0 109.61 179.438 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 42.2 Cg_endo -70.2 -59.27 0.08 OUTLIER 'Trans proline' 0 N--CA 1.489 1.225 0 O-C-N 123.825 1.434 . . . . 0.0 111.085 179.961 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . -108.05 -36.91 2.25 Favored Glycine 0 N--CA 1.495 2.602 0 N-CA-C 110.317 -1.113 . . . . 0.0 110.317 179.942 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 172.91 135.91 2.07 Favored Glycine 0 N--CA 1.492 2.426 0 N-CA-C 108.678 -1.769 . . . . 0.0 108.678 -179.923 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 4.1 m -78.57 64.83 3.7 Favored 'General case' 0 N--CA 1.5 2.03 0 O-C-N 121.413 -1.051 . . . . 0.0 110.506 -179.906 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . 0.455 HG13 ' N ' ' A' ' 22' ' ' GLU . 7.7 p -133.18 -46.06 0.6 Allowed 'Isoleucine or valine' 0 N--CA 1.498 1.956 0 O-C-N 121.468 -0.77 . . . . 0.0 109.759 179.088 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 22' ' ' GLU . . . . . 0.455 ' N ' HG13 ' A' ' 21' ' ' VAL . 23.4 mt-10 -89.18 33.86 0.8 Allowed 'General case' 0 C--N 1.306 -1.306 0 O-C-N 121.062 -1.024 . . . . 0.0 109.151 178.123 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -156.81 -75.55 0.09 Allowed 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.403 -0.81 . . . . 0.0 110.145 -179.406 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER 57.08 -165.18 0.15 Allowed 'General case' 0 N--CA 1.494 1.748 0 O-C-N 121.676 -0.64 . . . . 0.0 110.65 -179.899 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 3.3 m-20 -107.12 150.91 26.06 Favored 'General case' 0 N--CA 1.495 1.823 0 O-C-N 121.367 -0.833 . . . . 0.0 110.537 -179.666 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 88.19 -86.87 1.49 Allowed Glycine 0 N--CA 1.49 2.287 0 N-CA-C 110.194 -1.162 . . . . 0.0 110.194 179.295 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 69.86 64.16 3.04 Favored Glycine 0 N--CA 1.495 2.594 0 N-CA-C 109.127 -1.589 . . . . 0.0 109.127 -178.986 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 3.5 p -82.02 129.55 63.9 Favored Pre-proline 0 N--CA 1.499 1.987 0 O-C-N 120.859 -1.377 . . . . 0.0 110.868 -179.742 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 43.1 Cg_endo -70.42 -11.0 29.23 Favored 'Trans proline' 0 N--CA 1.489 1.238 0 O-C-N 124.086 1.571 . . . . 0.0 111.043 179.828 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -83.28 6.52 19.36 Favored 'General case' 0 N--CA 1.492 1.666 0 O-C-N 121.066 -1.022 . . . . 0.0 111.564 -179.497 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 31' ' ' GLU . . . . . 0.586 ' HG2' ' N ' ' A' ' 32' ' ' GLY . 14.6 tt0 -79.44 -75.0 0.26 Allowed 'General case' 0 N--CA 1.494 1.763 0 O-C-N 121.157 -0.965 . . . . 0.0 109.736 -179.987 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 32' ' ' GLY . . . . . 0.586 ' N ' ' HG2' ' A' ' 31' ' ' GLU . . . -136.33 22.26 3.39 Favored Glycine 0 N--CA 1.492 2.374 0 N-CA-C 109.55 -1.42 . . . . 0.0 109.55 179.563 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 33' ' ' CYS . . . . . 0.46 ' O ' ' HB2' ' A' ' 39' ' ' CYS . 0.5 OUTLIER -79.39 67.36 5.1 Favored 'General case' 0 N--CA 1.494 1.749 0 O-C-N 121.089 -1.242 . . . . 0.0 109.359 179.36 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -130.32 56.45 1.76 Allowed 'General case' 0 N--CA 1.496 1.868 0 O-C-N 121.536 -0.727 . . . . 0.0 110.319 179.763 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 5.5 mm-40 -92.88 -144.32 0.22 Allowed 'General case' 0 N--CA 1.497 1.884 0 O-C-N 121.505 -0.747 . . . . 0.0 109.74 179.713 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 36' ' ' ALA . . . . . . . . . . . . . . . -114.01 11.93 17.87 Favored 'General case' 0 N--CA 1.496 1.863 0 O-C-N 121.059 -1.026 . . . . 0.0 110.9 179.925 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 20.0 tt0 -161.2 -54.97 0.05 OUTLIER 'General case' 0 N--CA 1.496 1.862 0 O-C-N 121.261 -0.899 . . . . 0.0 110.741 179.516 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -43.6 -51.82 6.6 Favored Glycine 0 N--CA 1.5 2.938 0 N-CA-C 111.525 -0.63 . . . . 0.0 111.525 -178.74 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 39' ' ' CYS . . . . . 0.46 ' HB2' ' O ' ' A' ' 33' ' ' CYS . 56.9 m -139.94 75.68 1.52 Allowed 'General case' 0 N--CA 1.496 1.866 0 O-C-N 121.07 -1.253 . . . . 0.0 110.496 -179.234 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 40' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER . . . . . 0 N--CA 1.503 2.195 0 O-C-N 121.306 -0.872 . . . . 0.0 110.199 179.794 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 13.7 t . . . . . 0 N--CA 1.495 1.802 0 N-CA-C 109.91 -0.404 . . . . 0.0 109.91 . . . . . . . . . 0 0 . 1 . 020 nuclear nobuild core ' A' A ' 6' ' ' PRO . . . . . . . . . . . . . 50.8 Cg_endo -87.26 -24.06 1.34 Allowed 'Trans proline' 0 C--N 1.309 -1.508 0 O-C-N 123.904 1.476 . . . . 0.0 112.212 -179.515 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -109.85 68.32 0.22 Allowed Glycine 0 N--CA 1.497 2.759 0 O-C-N 120.829 -1.169 . . . . 0.0 111.332 -178.18 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 1.2 p -158.7 150.19 20.83 Favored 'General case' 0 N--CA 1.497 1.885 0 O-C-N 121.177 -1.19 . . . . 0.0 110.213 178.837 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 92.02 -110.46 3.88 Favored Glycine 0 N--CA 1.493 2.442 0 N-CA-C 108.893 -1.683 . . . . 0.0 108.893 -179.461 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 10' ' ' GLN . . . . . . . . . . . . . 5.5 pt20 -155.32 30.29 0.39 Allowed 'General case' 0 N--CA 1.494 1.745 0 O-C-N 121.272 -1.134 . . . . 0.0 110.698 179.379 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -86.58 62.69 4.23 Favored Glycine 0 N--CA 1.493 2.447 0 N-CA-C 109.461 -1.456 . . . . 0.0 109.461 179.614 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 60.2 t -126.94 -75.19 0.36 Allowed 'Isoleucine or valine' 0 N--CA 1.495 1.795 0 O-C-N 121.808 -0.819 . . . . 0.0 109.73 179.745 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 13' ' ' GLN . . . . . . . . . . . . . 1.6 mt-30 42.69 36.33 0.82 Allowed 'General case' 0 N--CA 1.495 1.82 0 O-C-N 121.652 -0.655 . . . . 0.0 111.779 179.736 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -71.5 -22.33 61.81 Favored 'General case' 0 N--CA 1.499 2.014 0 O-C-N 121.171 -0.956 . . . . 0.0 110.936 179.854 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 134.43 -53.34 0.79 Allowed Glycine 0 N--CA 1.493 2.499 0 N-CA-C 109.248 -1.541 . . . . 0.0 109.248 -179.69 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 2.6 p -88.68 121.52 69.91 Favored Pre-proline 0 N--CA 1.497 1.915 0 O-C-N 121.358 -1.083 . . . . 0.0 110.849 179.91 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 48.7 Cg_endo -76.06 79.5 2.89 Favored 'Trans proline' 0 C--N 1.309 -1.513 0 O-C-N 123.705 1.371 . . . . 0.0 110.046 179.606 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 85.79 -48.68 4.02 Favored Glycine 0 N--CA 1.493 2.461 0 N-CA-C 109.887 -1.285 . . . . 0.0 109.887 -179.512 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -72.38 68.8 1.16 Allowed Glycine 0 N--CA 1.495 2.617 0 N-CA-C 110.13 -1.188 . . . . 0.0 110.13 -179.604 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 73.2 m -105.2 119.07 38.14 Favored 'General case' 0 N--CA 1.498 1.957 0 O-C-N 121.482 -1.011 . . . . 0.0 109.511 179.627 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 12.7 t -106.71 -9.34 10.54 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.84 0 O-C-N 121.556 -0.715 . . . . 0.0 111.616 -178.95 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER -79.4 51.5 1.23 Allowed 'General case' 0 N--CA 1.493 1.695 0 O-C-N 120.855 -1.153 . . . . 0.0 110.566 179.718 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 3.2 tt0 -101.79 -24.29 14.08 Favored 'General case' 0 N--CA 1.489 1.477 0 O-C-N 121.095 -1.003 . . . . 0.0 110.139 179.539 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 2.1 pt-20 -79.89 -154.42 0.09 Allowed 'General case' 0 N--CA 1.494 1.736 0 O-C-N 121.274 -0.891 . . . . 0.0 110.575 -179.902 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -82.36 -49.16 10.32 Favored 'General case' 0 N--CA 1.5 2.06 0 O-C-N 121.456 -0.778 . . . . 0.0 110.164 179.947 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 144.09 46.64 0.04 OUTLIER Glycine 0 N--CA 1.498 2.772 0 N-CA-C 110.614 -0.995 . . . . 0.0 110.614 179.419 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 64.73 -130.92 37.06 Favored Glycine 0 N--CA 1.501 2.98 0 N-CA-C 109.685 -1.366 . . . . 0.0 109.685 -179.975 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -146.61 74.97 12.39 Favored Pre-proline 0 N--CA 1.495 1.787 0 O-C-N 121.294 -1.121 . . . . 0.0 109.926 179.691 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 43.4 Cg_endo -74.03 74.44 3.48 Favored 'Trans proline' 0 N--CA 1.488 1.172 0 O-C-N 123.632 1.333 . . . . 0.0 110.661 -179.908 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -89.87 64.84 6.5 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.111 -0.993 . . . . 0.0 110.571 179.887 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 14.8 tp10 -153.17 -67.92 0.15 Allowed 'General case' 0 N--CA 1.493 1.694 0 O-C-N 121.378 -0.826 . . . . 0.0 110.214 179.61 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 123.69 84.52 0.65 Allowed Glycine 0 N--CA 1.497 2.716 0 N-CA-C 109.406 -1.477 . . . . 0.0 109.406 -179.82 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 33' ' ' CYS . . . . . . . . . . . . . 0.4 OUTLIER -95.29 112.36 24.08 Favored 'General case' 0 N--CA 1.493 1.704 0 O-C-N 121.394 -1.062 . . . . 0.0 109.79 179.812 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -107.58 -46.13 3.9 Favored 'General case' 0 N--CA 1.497 1.875 0 O-C-N 121.564 -0.71 . . . . 0.0 110.103 179.886 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 21.8 mt-10 -79.59 -178.88 6.55 Favored 'General case' 0 N--CA 1.5 2.052 0 O-C-N 121.635 -0.665 . . . . 0.0 110.23 179.931 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 36' ' ' ALA . . . . . . . . . . . . . . . -78.66 -38.08 40.37 Favored 'General case' 0 N--CA 1.498 1.931 0 O-C-N 121.202 -0.936 . . . . 0.0 109.897 -179.634 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 7.3 tt0 -119.87 34.07 5.36 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.381 -0.825 . . . . 0.0 109.991 179.492 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -84.72 -9.45 81.13 Favored Glycine 0 N--CA 1.495 2.63 0 O-C-N 121.101 -0.999 . . . . 0.0 110.776 -179.909 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 39' ' ' CYS . . . . . . . . . . . . . 1.3 m -79.43 72.91 6.09 Favored 'General case' 0 N--CA 1.495 1.801 0 O-C-N 120.874 -1.368 . . . . 0.0 109.822 179.842 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 40' ' ' LEU . . . . . . . . . . . . . 1.0 OUTLIER . . . . . 0 N--CA 1.494 1.763 0 O-C-N 121.372 -0.83 . . . . 0.0 110.46 -179.474 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.494 1.755 0 CA-C-O 120.816 0.341 . . . . 0.0 110.127 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 17.9 mt -131.53 114.97 15.53 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.162 -0.961 . . . . 0.0 110.383 179.737 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -93.42 50.71 1.52 Allowed 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.386 -0.821 . . . . 0.0 110.546 -179.847 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 4' ' ' ARG . . . . . . . . . . . . . 26.5 ttp85 -164.24 135.59 4.5 Favored 'General case' 0 N--CA 1.493 1.68 0 O-C-N 121.269 -0.894 . . . . 0.0 110.079 179.786 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -87.74 117.77 68.91 Favored Pre-proline 0 N--CA 1.495 1.807 0 O-C-N 121.28 -0.888 . . . . 0.0 109.878 179.845 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 6' ' ' PRO . . . . . . . . . . . . . 49.5 Cg_endo -82.23 150.34 15.49 Favored 'Trans proline' 0 C--N 1.313 -1.307 0 O-C-N 123.716 1.377 . . . . 0.0 110.647 -179.822 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 88.32 -46.54 3.38 Favored Glycine 0 N--CA 1.497 2.761 0 N-CA-C 110.342 -1.103 . . . . 0.0 110.342 179.43 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 20.0 p -79.66 -174.29 4.24 Favored 'General case' 0 N--CA 1.496 1.839 0 O-C-N 121.035 -1.274 . . . . 0.0 110.493 -179.601 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 129.26 -114.43 1.73 Allowed Glycine 0 N--CA 1.494 2.545 0 N-CA-C 108.854 -1.699 . . . . 0.0 108.854 -179.433 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 10' ' ' GLN . . . . . . . . . . . . . 14.0 tp60 -164.39 -75.47 0.04 OUTLIER 'General case' 0 N--CA 1.494 1.748 0 O-C-N 121.421 -1.047 . . . . 0.0 110.542 179.222 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -56.13 -26.1 48.64 Favored Glycine 0 N--CA 1.498 2.786 0 O-C-N 121.252 -0.905 . . . . 0.0 110.986 -179.54 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 25.2 t -88.88 -53.88 8.75 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.813 0 O-C-N 121.185 -1.185 . . . . 0.0 110.241 -179.882 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 13' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -67.04 -32.08 73.04 Favored 'General case' 0 N--CA 1.501 2.113 0 O-C-N 121.375 -0.828 . . . . 0.0 112.008 -179.245 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -141.26 52.23 1.57 Allowed 'General case' 0 N--CA 1.496 1.852 0 O-C-N 120.948 -1.095 . . . . 0.0 110.615 -179.645 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -151.76 -85.36 0.05 OUTLIER Glycine 0 N--CA 1.493 2.469 0 N-CA-C 109.845 -1.302 . . . . 0.0 109.845 179.881 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 57.9 m -110.08 97.58 30.68 Favored Pre-proline 0 N--CA 1.496 1.836 0 O-C-N 121.221 -1.164 . . . . 0.0 110.442 -179.898 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 46.7 Cg_endo -72.54 66.53 3.74 Favored 'Trans proline' 0 N--CA 1.491 1.378 0 O-C-N 124.284 1.676 . . . . 0.0 110.409 179.723 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 123.29 -49.97 0.87 Allowed Glycine 0 N--CA 1.495 2.589 0 N-CA-C 109.267 -1.533 . . . . 0.0 109.267 -179.557 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 178.41 134.28 2.06 Favored Glycine 0 N--CA 1.489 2.229 0 N-CA-C 108.971 -1.652 . . . . 0.0 108.971 179.976 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 1.5 m -92.11 33.06 1.09 Allowed 'General case' 0 N--CA 1.5 2.041 0 O-C-N 121.301 -1.117 . . . . 0.0 110.634 -179.911 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 6.4 t -139.87 55.88 0.22 Allowed 'Isoleucine or valine' 0 N--CA 1.496 1.874 0 O-C-N 120.928 -1.107 . . . . 0.0 110.599 -179.89 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 5.2 tt0 -88.88 49.17 1.74 Allowed 'General case' 0 N--CA 1.496 1.863 0 O-C-N 121.135 -0.978 . . . . 0.0 109.266 178.968 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 11.1 mt-10 58.65 -168.03 0.14 Allowed 'General case' 0 N--CA 1.501 2.08 0 O-C-N 121.756 -0.59 . . . . 0.0 110.451 -179.515 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 73.0 mm-40 -69.58 -22.2 63.54 Favored 'General case' 0 N--CA 1.497 1.923 0 O-C-N 120.991 -1.068 . . . . 0.0 111.277 -179.131 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 2.8 t70 -144.34 -61.44 0.38 Allowed 'General case' 0 N--CA 1.496 1.875 0 O-C-N 121.217 -0.927 . . . . 0.0 109.807 179.879 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 172.39 82.86 0.05 OUTLIER Glycine 0 N--CA 1.495 2.567 0 N-CA-C 109.955 -1.258 . . . . 0.0 109.955 179.681 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 66.09 27.69 73.09 Favored Glycine 0 N--CA 1.496 2.658 0 N-CA-C 109.855 -1.298 . . . . 0.0 109.855 179.923 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -102.37 99.59 13.35 Favored Pre-proline 0 N--CA 1.493 1.701 0 O-C-N 121.521 -0.987 . . . . 0.0 110.068 -179.699 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 45.0 Cg_endo -70.87 66.28 2.43 Favored 'Trans proline' 0 N--CA 1.489 1.225 0 O-C-N 123.744 1.391 . . . . 0.0 110.915 -179.577 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -131.28 66.58 1.54 Allowed 'General case' 0 N--CA 1.486 1.371 0 O-C-N 121.337 -0.852 . . . . 0.0 109.974 179.664 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 8.9 tt0 -110.58 -68.75 0.91 Allowed 'General case' 0 N--CA 1.485 1.313 0 O-C-N 121.397 -0.814 . . . . 0.0 110.531 -179.539 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . -72.87 -42.71 44.55 Favored Glycine 0 N--CA 1.496 2.678 0 N-CA-C 110.088 -1.205 . . . . 0.0 110.088 -179.674 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 33' ' ' CYS . . . . . . . . . . . . . 1.7 t -113.77 79.28 1.23 Allowed 'General case' 0 N--CA 1.492 1.646 0 O-C-N 121.141 -1.211 . . . . 0.0 109.661 -179.843 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -125.23 -46.09 1.81 Allowed 'General case' 0 N--CA 1.495 1.812 0 O-C-N 121.111 -0.993 . . . . 0.0 110.992 -179.403 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 0.8 OUTLIER -97.03 -176.48 3.56 Favored 'General case' 0 N--CA 1.498 1.926 0 O-C-N 121.494 -0.754 . . . . 0.0 110.934 -179.414 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 36' ' ' ALA . . . . . 0.548 ' O ' ' HB3' ' A' ' 40' ' ' LEU . . . -79.13 -34.19 43.55 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.26 -0.9 . . . . 0.0 110.189 179.805 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -78.41 2.31 19.21 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.247 -0.908 . . . . 0.0 110.903 179.865 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -92.66 -43.81 4.12 Favored Glycine 0 N--CA 1.492 2.411 0 N-CA-C 109.432 -1.467 . . . . 0.0 109.432 179.951 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 39' ' ' CYS . . . . . . . . . . . . . 1.3 p -161.06 50.34 0.24 Allowed 'General case' 0 N--CA 1.498 1.968 0 O-C-N 121.358 -1.084 . . . . 0.0 111.215 -179.391 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 40' ' ' LEU . . . . . 0.548 ' HB3' ' O ' ' A' ' 36' ' ' ALA . 1.7 pt? -55.79 -41.09 73.6 Favored 'General case' 0 N--CA 1.504 2.234 0 O-C-N 120.801 -1.187 . . . . 0.0 112.047 -179.599 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 41' ' ' ARG . . . . . 0.529 ' H ' HD23 ' A' ' 40' ' ' LEU . 0.4 OUTLIER 48.04 -154.48 0.08 Allowed 'General case' 0 N--CA 1.502 2.168 0 O-C-N 121.184 -0.947 . . . . 0.0 110.525 -179.733 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 42' ' ' ARG . . . . . . . . . . . . . 21.5 ttt-85 -92.98 -56.21 3.07 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 120.885 -1.134 . . . . 0.0 109.482 179.539 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -116.03 136.46 53.01 Favored 'General case' 0 N--CA 1.489 1.48 0 O-C-N 121.655 -0.653 . . . . 0.0 109.838 179.301 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -114.17 -48.96 0.55 Allowed Glycine 0 N--CA 1.491 2.348 0 N-CA-C 109.736 -1.346 . . . . 0.0 109.736 -179.783 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 45' ' ' GLN . . . . . . . . . . . . . 38.9 mt-30 . . . . . 0 N--CA 1.499 2.014 0 O-C-N 121.573 -0.957 . . . . 0.0 110.338 179.879 . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.496 1.855 0 CA-C-O 121.175 0.512 . . . . 0.0 110.374 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER -137.36 20.83 2.95 Favored 'General case' 0 N--CA 1.493 1.723 0 O-C-N 120.885 -1.134 . . . . 0.0 111.177 179.832 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -76.57 85.48 3.26 Favored 'General case' 0 N--CA 1.493 1.688 0 O-C-N 121.199 -0.938 . . . . 0.0 110.443 -179.862 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 4' ' ' ARG . . . . . . . . . . . . . 0.5 OUTLIER -132.19 -167.54 1.9 Allowed 'General case' 0 N--CA 1.488 1.463 0 O-C-N 121.34 -0.85 . . . . 0.0 109.543 179.435 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 0.3 OUTLIER -79.35 125.97 82.13 Favored Pre-proline 0 N--CA 1.497 1.924 0 O-C-N 121.122 -0.986 . . . . 0.0 110.277 179.935 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 6' ' ' PRO . . . . . . . . . . . . . 45.6 Cg_endo -72.82 -86.18 0.0 OUTLIER 'Trans proline' 0 C--N 1.307 -1.656 0 O-C-N 123.944 1.497 . . . . 0.0 112.062 -179.039 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -105.6 55.8 0.54 Allowed Glycine 0 N--CA 1.49 2.246 0 N-CA-C 109.893 -1.283 . . . . 0.0 109.893 -178.99 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 0.4 OUTLIER -135.34 151.54 50.61 Favored 'General case' 0 N--CA 1.498 1.96 0 O-C-N 121.335 -1.097 . . . . 0.0 110.33 179.611 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 175.98 154.1 11.19 Favored Glycine 0 N--CA 1.495 2.605 0 N-CA-C 109.655 -1.378 . . . . 0.0 109.655 -179.809 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 10' ' ' GLN . . . . . . . . . . . . . 0.3 OUTLIER -129.89 70.56 1.43 Allowed 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.283 -1.128 . . . . 0.0 109.756 179.921 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -79.45 -61.15 2.37 Favored Glycine 0 N--CA 1.495 2.591 0 N-CA-C 110.006 -1.238 . . . . 0.0 110.006 -179.491 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 24.0 m -120.58 -31.65 1.54 Allowed 'Isoleucine or valine' 0 N--CA 1.503 2.213 0 O-C-N 121.427 -1.043 . . . . 0.0 111.491 -179.493 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 13' ' ' GLN . . . . . . . . . . . . . 1.2 tt0 56.33 50.53 13.08 Favored 'General case' 0 N--CA 1.499 1.992 0 O-C-N 121.408 -0.807 . . . . 0.0 110.616 179.93 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -104.68 -60.62 1.57 Allowed 'General case' 0 N--CA 1.495 1.815 0 O-C-N 121.269 -0.894 . . . . 0.0 110.536 179.887 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -152.12 -83.43 0.04 OUTLIER Glycine 0 N--CA 1.494 2.536 0 N-CA-C 109.876 -1.29 . . . . 0.0 109.876 179.942 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 16' ' ' CYS . . . . . 0.456 ' HB2' ' HB2' ' A' ' 20' ' ' CYS . 1.1 m -86.36 136.2 35.73 Favored Pre-proline 0 N--CA 1.496 1.831 0 O-C-N 121.338 -1.096 . . . . 0.0 109.985 179.679 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 45.3 Cg_endo -72.62 72.04 3.13 Favored 'Trans proline' 0 C--N 1.312 -1.361 0 O-C-N 123.656 1.345 . . . . 0.0 109.617 178.931 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 91.52 -49.49 2.9 Favored Glycine 0 N--CA 1.493 2.447 0 N-CA-C 109.702 -1.359 . . . . 0.0 109.702 -179.254 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -74.65 67.14 1.98 Allowed Glycine 0 N--CA 1.497 2.738 0 O-C-N 121.009 -1.289 . . . . 0.0 110.831 -179.727 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 20' ' ' CYS . . . . . 0.456 ' HB2' ' HB2' ' A' ' 16' ' ' CYS . 0.4 OUTLIER -127.77 73.14 1.43 Allowed 'General case' 0 N--CA 1.496 1.83 0 O-C-N 121.24 -1.153 . . . . 0.0 109.174 179.38 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 14.6 p -126.14 -19.66 2.68 Favored 'Isoleucine or valine' 0 N--CA 1.499 2.018 0 O-C-N 121.739 -0.601 . . . . 0.0 111.506 -179.039 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 17.7 mt-10 -79.96 50.18 1.17 Allowed 'General case' 0 N--CA 1.491 1.598 0 O-C-N 120.673 -1.267 . . . . 0.0 110.231 179.831 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 2.3 mt-10 -89.21 -172.91 3.82 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 120.864 -1.147 . . . . 0.0 110.138 -179.794 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER 56.39 59.25 3.73 Favored 'General case' 0 N--CA 1.493 1.677 0 CA-C-O 121.343 0.592 . . . . 0.0 110.4 179.976 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 1.9 p-10 -101.89 -174.45 2.59 Favored 'General case' 0 N--CA 1.496 1.83 0 O-C-N 121.223 -0.923 . . . . 0.0 109.907 179.561 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 79.35 -69.95 2.89 Favored Glycine 0 N--CA 1.495 2.628 0 N-CA-C 109.559 -1.416 . . . . 0.0 109.559 -179.807 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 144.71 115.04 0.97 Allowed Glycine 0 N--CA 1.494 2.561 0 N-CA-C 109.635 -1.386 . . . . 0.0 109.635 179.789 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 73.5 m -81.91 143.63 50.21 Favored Pre-proline 0 N--CA 1.5 2.032 0 O-C-N 121.385 -1.067 . . . . 0.0 110.187 -179.973 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 45.5 Cg_endo -73.46 91.25 0.88 Allowed 'Trans proline' 0 C--N 1.315 -1.188 0 O-C-N 123.729 1.384 . . . . 0.0 111.115 -179.078 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -94.55 -55.2 3.23 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.315 -0.865 . . . . 0.0 110.59 179.883 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 36.2 tt0 -79.05 -7.26 57.97 Favored 'General case' 0 N--CA 1.496 1.858 0 O-C-N 121.513 -0.742 . . . . 0.0 110.911 -179.8 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 90.41 -10.34 74.71 Favored Glycine 0 N--CA 1.494 2.51 0 O-C-N 120.792 -1.192 . . . . 0.0 110.182 -179.515 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 33' ' ' CYS . . . . . . . . . . . . . 59.1 m -79.73 65.71 4.97 Favored 'General case' 0 N--CA 1.494 1.741 0 O-C-N 120.925 -1.338 . . . . 0.0 110.282 -179.803 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -79.2 -38.95 34.52 Favored 'General case' 0 N--CA 1.494 1.742 0 O-C-N 121.456 -0.778 . . . . 0.0 109.573 179.576 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 47.9 mt-10 -89.91 162.59 15.36 Favored 'General case' 0 N--CA 1.493 1.716 0 O-C-N 121.381 -0.825 . . . . 0.0 109.594 179.235 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 36' ' ' ALA . . . . . . . . . . . . . . . -79.35 -46.33 17.86 Favored 'General case' 0 N--CA 1.493 1.683 0 O-C-N 121.123 -0.985 . . . . 0.0 110.412 -179.221 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 1.5 tt0 -95.3 62.41 2.47 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.191 -0.943 . . . . 0.0 110.315 -179.834 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -148.68 17.49 1.26 Allowed Glycine 0 N--CA 1.496 2.673 0 C-N-CA 119.945 -1.121 . . . . 0.0 110.958 -179.984 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 39' ' ' CYS . . . . . . . . . . . . . 57.1 m -144.23 26.87 1.45 Allowed 'General case' 0 N--CA 1.502 2.135 0 O-C-N 120.663 -1.492 . . . . 0.0 111.274 -179.837 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 40' ' ' LEU . . . . . . . . . . . . . 0.9 OUTLIER 45.69 67.3 0.76 Allowed 'General case' 0 N--CA 1.501 2.082 0 O-C-N 121.68 -0.638 . . . . 0.0 111.647 179.886 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 41' ' ' ARG . . . . . . . . . . . . . 4.5 ptp180 -173.34 118.43 0.3 Allowed 'General case' 0 N--CA 1.497 1.915 0 O-C-N 121.206 -0.934 . . . . 0.0 109.768 178.66 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 42' ' ' ARG . . . . . . . . . . . . . 2.9 ttt-85 -136.01 -42.3 0.66 Allowed 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.571 -0.706 . . . . 0.0 111.247 -179.708 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 1.3 mm-40 -57.95 131.58 50.85 Favored 'General case' 0 N--CA 1.498 1.937 0 O-C-N 121.381 -0.824 . . . . 0.0 110.462 -179.707 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -142.3 -46.7 0.05 OUTLIER Glycine 0 N--CA 1.498 2.789 0 N-CA-C 110.028 -1.229 . . . . 0.0 110.028 -179.641 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 45' ' ' GLN . . . . . . . . . . . . . 5.7 mm-40 . . . . . 0 N--CA 1.496 1.862 0 O-C-N 121.261 -1.14 . . . . 0.0 110.682 -179.985 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.494 1.73 0 N-CA-C 109.468 -0.567 . . . . 0.0 109.468 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' A' A ' 2' ' ' LEU . . . . . 0.482 HD13 ' HA ' ' A' ' 2' ' ' LEU . 0.8 OUTLIER 60.61 93.27 0.04 OUTLIER 'General case' 0 N--CA 1.505 2.284 0 O-C-N 121.688 -0.633 . . . . 0.0 110.794 179.991 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -57.8 112.73 1.57 Allowed 'General case' 0 N--CA 1.497 1.904 0 O-C-N 121.35 -0.844 . . . . 0.0 110.302 179.903 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 4' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -161.12 -56.63 0.05 Allowed 'General case' 0 N--CA 1.492 1.654 0 O-C-N 121.424 -0.797 . . . . 0.0 110.302 -179.867 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 9.5 t -135.14 90.48 21.16 Favored Pre-proline 0 N--CA 1.497 1.897 0 O-C-N 121.462 -0.774 . . . . 0.0 109.506 179.897 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 6' ' ' PRO . . . . . . . . . . . . . 48.9 Cg_endo -73.42 -21.13 20.08 Favored 'Trans proline' 0 C--N 1.312 -1.39 0 O-C-N 124.089 1.573 . . . . 0.0 111.949 -179.508 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -74.58 -40.21 39.2 Favored Glycine 0 N--CA 1.496 2.636 0 N-CA-C 110.386 -1.086 . . . . 0.0 110.386 -179.169 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 31.1 p -85.95 -174.61 5.19 Favored 'General case' 0 N--CA 1.498 1.943 0 O-C-N 121.168 -1.195 . . . . 0.0 110.881 -179.599 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -142.26 -135.11 3.05 Favored Glycine 0 N--CA 1.495 2.603 0 N-CA-C 109.854 -1.299 . . . . 0.0 109.854 -179.587 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 10' ' ' GLN . . . . . . . . . . . . . 4.2 mt-30 -80.62 41.37 0.55 Allowed 'General case' 0 N--CA 1.499 2.013 0 O-C-N 121.14 -1.212 . . . . 0.0 111.665 -179.566 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 80.49 -34.42 2.26 Favored Glycine 0 N--CA 1.497 2.714 0 O-C-N 120.718 -1.239 . . . . 0.0 111.224 179.445 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 16.9 m -130.66 60.98 0.3 Allowed 'Isoleucine or valine' 0 N--CA 1.498 1.933 0 O-C-N 121.056 -1.261 . . . . 0.0 110.867 -179.354 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 13' ' ' GLN . . . . . . . . . . . . . 0.6 OUTLIER -124.06 94.64 4.28 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.323 -0.86 . . . . 0.0 109.607 179.754 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -150.84 161.85 41.88 Favored 'General case' 0 N--CA 1.495 1.814 0 CA-C-O 121.539 0.685 . . . . 0.0 111.3 -179.553 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -144.61 -57.68 0.02 OUTLIER Glycine 0 N--CA 1.498 2.801 0 N-CA-C 108.427 -1.869 . . . . 0.0 108.427 179.378 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 0.8 OUTLIER -121.78 79.0 39.98 Favored Pre-proline 0 N--CA 1.499 1.988 0 N-CA-C 108.602 -0.888 . . . . 0.0 108.602 178.482 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 40.6 Cg_endo -66.89 -24.29 46.43 Favored 'Trans proline' 0 N--CA 1.49 1.319 0 C-N-CA 121.288 1.325 . . . . 0.0 112.246 -178.359 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . -96.06 19.43 54.5 Favored Glycine 0 N--CA 1.496 2.666 0 N-CA-C 109.973 -1.251 . . . . 0.0 109.973 179.821 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 114.94 141.56 7.55 Favored Glycine 0 N--CA 1.487 2.064 0 N-CA-C 108.528 -1.829 . . . . 0.0 108.528 179.842 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 36.3 m -109.39 167.48 10.09 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.28 -1.13 . . . . 0.0 109.792 179.889 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . 0.411 HG13 ' CB ' ' A' ' 25' ' ' ASP . 14.5 t -79.18 65.0 0.31 Allowed 'Isoleucine or valine' 0 N--CA 1.494 1.77 0 O-C-N 121.28 -0.887 . . . . 0.0 110.296 -179.801 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -96.14 -31.98 12.72 Favored 'General case' 0 N--CA 1.489 1.494 0 O-C-N 121.21 -0.931 . . . . 0.0 110.099 179.299 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 4.9 mm-40 -94.49 55.22 1.93 Allowed 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.184 -0.948 . . . . 0.0 110.437 -179.49 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 3.0 mm-40 39.09 68.36 0.36 Allowed 'General case' 0 N--CA 1.496 1.837 0 CA-C-O 121.616 0.722 . . . . 0.0 112.026 179.498 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 25' ' ' ASP . . . . . 0.411 ' CB ' HG13 ' A' ' 21' ' ' VAL . 0.7 OUTLIER -89.88 -9.94 47.12 Favored 'General case' 0 N--CA 1.497 1.909 0 O-C-N 121.155 -0.966 . . . . 0.0 110.276 178.85 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 90.25 -67.08 2.63 Favored Glycine 0 N--CA 1.494 2.51 0 N-CA-C 109.068 -1.613 . . . . 0.0 109.068 -179.053 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 67.91 176.55 10.28 Favored Glycine 0 N--CA 1.496 2.681 0 N-CA-C 110.234 -1.146 . . . . 0.0 110.234 179.516 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 1.9 t -111.37 94.41 22.19 Favored Pre-proline 0 N--CA 1.496 1.836 0 O-C-N 121.315 -1.109 . . . . 0.0 109.773 179.655 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 44.4 Cg_endo -71.91 110.1 2.83 Favored 'Trans proline' 0 C--N 1.315 -1.229 0 O-C-N 123.832 1.438 . . . . 0.0 110.728 -179.583 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -79.26 -54.15 6.25 Favored 'General case' 0 N--CA 1.492 1.646 0 O-C-N 121.264 -0.897 . . . . 0.0 110.364 -179.985 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 6.8 tt0 -90.24 16.52 8.47 Favored 'General case' 0 N--CA 1.492 1.665 0 O-C-N 121.073 -1.017 . . . . 0.0 111.002 179.702 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . -87.17 35.96 3.37 Favored Glycine 0 N--CA 1.492 2.431 0 N-CA-C 109.502 -1.439 . . . . 0.0 109.502 179.555 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 33' ' ' CYS . . . . . 0.471 ' HA ' ' O ' ' A' ' 38' ' ' GLY . 0.5 OUTLIER -114.28 22.08 14.08 Favored 'General case' 0 N--CA 1.494 1.746 0 O-C-N 121.497 -1.001 . . . . 0.0 110.646 179.328 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -152.24 46.48 0.75 Allowed 'General case' 0 N--CA 1.498 1.965 0 O-C-N 121.058 -1.026 . . . . 0.0 110.604 -179.722 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 7.6 pt-20 -128.73 -157.44 0.82 Allowed 'General case' 0 N--CA 1.499 2.002 0 O-C-N 121.51 -0.744 . . . . 0.0 110.253 179.856 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 36' ' ' ALA . . . . . . . . . . . . . . . -77.83 -23.64 48.9 Favored 'General case' 0 N--CA 1.499 1.985 0 O-C-N 121.242 -0.911 . . . . 0.0 110.448 -179.652 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER -79.5 -33.74 41.87 Favored 'General case' 0 N--CA 1.492 1.654 0 O-C-N 121.16 -0.962 . . . . 0.0 109.819 179.547 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 38' ' ' GLY . . . . . 0.471 ' O ' ' HA ' ' A' ' 33' ' ' CYS . . . 107.88 -97.09 1.1 Allowed Glycine 0 N--CA 1.492 2.421 0 N-CA-C 109.113 -1.595 . . . . 0.0 109.113 179.847 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 39' ' ' CYS . . . . . . . . . . . . . 1.8 t -160.81 115.04 2.1 Favored 'General case' 0 N--CA 1.498 1.957 0 O-C-N 121.637 -0.919 . . . . 0.0 109.687 179.435 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 40' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -89.95 117.35 28.69 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.152 -0.968 . . . . 0.0 110.908 -179.334 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 41' ' ' ARG . . . . . . . . . . . . . 4.4 tpt85 -172.24 92.7 0.13 Allowed 'General case' 0 N--CA 1.493 1.69 0 O-C-N 121.41 -0.806 . . . . 0.0 109.438 179.488 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 42' ' ' ARG . . . . . . . . . . . . . 6.8 ttt180 -174.44 -50.88 0.01 OUTLIER 'General case' 0 N--CA 1.497 1.895 0 O-C-N 121.557 -0.714 . . . . 0.0 110.844 179.955 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 1.8 tt0 57.08 -163.8 0.17 Allowed 'General case' 0 N--CA 1.497 1.896 0 CA-C-O 121.273 0.558 . . . . 0.0 110.383 -179.582 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -123.04 27.46 5.87 Favored Glycine 0 N--CA 1.495 2.63 0 N-CA-C 108.987 -1.645 . . . . 0.0 108.987 179.65 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 45' ' ' GLN . . . . . . . . . . . . . 2.9 mt-30 . . . . . 0 N--CA 1.494 1.758 0 CA-C-O 117.851 -1.071 . . . . 0.0 109.597 -179.754 . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.493 1.705 0 N-CA-C 110.013 -0.366 . . . . 0.0 110.013 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER 54.74 44.43 28.53 Favored 'General case' 0 N--CA 1.504 2.261 0 O-C-N 121.683 -0.636 . . . . 0.0 110.596 -179.987 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -134.96 117.16 15.49 Favored 'General case' 0 N--CA 1.484 1.268 0 O-C-N 121.225 -0.922 . . . . 0.0 110.529 179.899 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 4' ' ' ARG . . . . . . . . . . . . . 2.3 ptp85 -163.29 140.36 7.42 Favored 'General case' 0 N--CA 1.489 1.478 0 O-C-N 121.576 -0.703 . . . . 0.0 109.719 179.307 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -146.13 118.74 5.08 Favored Pre-proline 0 N--CA 1.496 1.854 0 O-C-N 121.249 -0.907 . . . . 0.0 110.074 -179.653 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 6' ' ' PRO . . . . . . . . . . . . . 44.6 Cg_endo -74.74 -50.99 0.13 Allowed 'Trans proline' 0 C--N 1.314 -1.268 0 O-C-N 123.665 1.35 . . . . 0.0 111.102 -179.64 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -78.03 58.38 3.94 Favored Glycine 0 N--CA 1.494 2.559 0 N-CA-C 109.736 -1.346 . . . . 0.0 109.736 179.992 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 1.1 m -114.49 3.22 14.85 Favored 'General case' 0 N--CA 1.492 1.672 0 O-C-N 121.271 -1.135 . . . . 0.0 111.349 -179.938 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 9' ' ' GLY . . . . . 0.428 ' O ' ' HB2' ' A' ' 10' ' ' GLN . . . -80.18 57.36 4.63 Favored Glycine 0 N--CA 1.494 2.534 0 N-CA-C 109.894 -1.282 . . . . 0.0 109.894 179.598 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 10' ' ' GLN . . . . . 0.428 ' HB2' ' O ' ' A' ' 9' ' ' GLY . 5.6 tt0 -178.56 -63.4 0.01 OUTLIER 'General case' 0 N--CA 1.494 1.769 0 O-C-N 121.466 -1.02 . . . . 0.0 109.994 179.787 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -85.07 62.97 4.45 Favored Glycine 0 N--CA 1.491 2.346 0 N-CA-C 110.018 -1.233 . . . . 0.0 110.018 -179.867 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 12' ' ' VAL . . . . . 0.478 HG13 ' N ' ' A' ' 13' ' ' GLN . 7.5 p -146.37 -47.24 0.11 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.652 0 O-C-N 121.467 -1.019 . . . . 0.0 110.413 179.602 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 13' ' ' GLN . . . . . 0.478 ' N ' HG13 ' A' ' 12' ' ' VAL . 20.4 tt0 -175.04 -55.07 0.01 OUTLIER 'General case' 0 N--CA 1.497 1.9 0 O-C-N 121.36 -0.838 . . . . 0.0 109.6 179.521 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -117.04 -178.26 3.4 Favored 'General case' 0 N--CA 1.496 1.825 0 O-C-N 121.788 -0.57 . . . . 0.0 110.216 179.789 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -85.03 -35.21 12.87 Favored Glycine 0 N--CA 1.496 2.65 0 N-CA-C 110.378 -1.089 . . . . 0.0 110.378 -179.581 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 0.0 OUTLIER -113.45 132.85 22.31 Favored Pre-proline 0 N--CA 1.5 2.027 0 O-C-N 121.332 -1.099 . . . . 0.0 109.67 179.702 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 47.4 Cg_endo -74.29 58.67 4.44 Favored 'Trans proline' 0 C--N 1.31 -1.488 0 O-C-N 123.72 1.379 . . . . 0.0 111.072 -179.731 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 92.9 92.85 1.48 Allowed Glycine 0 N--CA 1.495 2.579 0 N-CA-C 110.167 -1.173 . . . . 0.0 110.167 179.336 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 106.71 113.1 3.75 Favored Glycine 0 N--CA 1.49 2.298 0 N-CA-C 110.128 -1.189 . . . . 0.0 110.128 179.345 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 20' ' ' CYS . . . . . 0.477 ' O ' ' HB3' ' A' ' 25' ' ' ASP . 36.9 m -122.27 -12.99 8.18 Favored 'General case' 0 N--CA 1.502 2.166 0 O-C-N 121.521 -0.988 . . . . 0.0 111.285 179.818 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . 0.586 HG12 ' CA ' ' A' ' 27' ' ' GLY . 18.5 m -80.36 18.91 0.18 Allowed 'Isoleucine or valine' 0 N--CA 1.504 2.239 0 O-C-N 120.865 -1.147 . . . . 0.0 111.848 -179.562 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 5.0 mm-40 -79.67 -19.88 47.97 Favored 'General case' 0 N--CA 1.486 1.357 0 O-C-N 120.84 -1.163 . . . . 0.0 110.884 179.836 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -139.18 55.35 1.7 Allowed 'General case' 0 N--CA 1.491 1.591 0 O-C-N 120.891 -1.131 . . . . 0.0 110.259 179.956 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 24' ' ' GLU . . . . . 0.545 ' HG3' ' HB2' ' A' ' 28' ' ' SER . 0.8 OUTLIER 53.09 31.15 10.75 Favored 'General case' 0 N--CA 1.506 2.362 0 O-C-N 121.92 -0.487 . . . . 0.0 112.013 179.473 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 25' ' ' ASP . . . . . 0.477 ' HB3' ' O ' ' A' ' 20' ' ' CYS . 21.2 t70 -106.27 115.38 30.12 Favored 'General case' 0 N--CA 1.496 1.834 0 O-C-N 120.866 -1.146 . . . . 0.0 109.661 179.715 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 77.22 -56.07 3.63 Favored Glycine 0 N--CA 1.492 2.382 0 N-CA-C 110.559 -1.016 . . . . 0.0 110.559 179.594 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 27' ' ' GLY . . . . . 0.586 ' CA ' HG12 ' A' ' 21' ' ' VAL . . . -55.97 -54.34 35.97 Favored Glycine 0 N--CA 1.494 2.56 0 N-CA-C 110.27 -1.132 . . . . 0.0 110.27 -178.964 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 28' ' ' SER . . . . . 0.545 ' HB2' ' HG3' ' A' ' 24' ' ' GLU . 1.4 m -113.83 77.3 3.52 Favored Pre-proline 0 N--CA 1.497 1.893 0 O-C-N 121.742 -0.858 . . . . 0.0 110.696 -179.368 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 54.7 Cg_endo -79.86 114.32 3.15 Favored 'Trans proline' 0 C--N 1.314 -1.282 0 O-C-N 123.234 1.123 . . . . 0.0 110.028 179.602 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -77.2 -26.81 53.2 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 120.974 -1.079 . . . . 0.0 109.904 179.937 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 1.2 mt-10 -78.95 1.99 21.82 Favored 'General case' 0 N--CA 1.494 1.771 0 O-C-N 121.312 -0.867 . . . . 0.0 110.685 179.137 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . -99.28 35.8 4.46 Favored Glycine 0 N--CA 1.492 2.379 0 N-CA-C 110.04 -1.224 . . . . 0.0 110.04 179.904 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 33' ' ' CYS . . . . . . . . . . . . . 1.7 t -160.67 64.69 0.31 Allowed 'General case' 0 N--CA 1.494 1.764 0 O-C-N 121.268 -1.137 . . . . 0.0 110.3 179.739 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -78.64 -53.45 7.16 Favored 'General case' 0 N--CA 1.499 1.983 0 O-C-N 121.073 -1.017 . . . . 0.0 109.417 179.06 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 8.0 mt-10 -85.16 169.56 13.74 Favored 'General case' 0 N--CA 1.495 1.784 0 O-C-N 121.461 -0.774 . . . . 0.0 109.519 178.466 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 36' ' ' ALA . . . . . . . . . . . . . . . -78.18 -43.52 28.4 Favored 'General case' 0 N--CA 1.493 1.718 0 O-C-N 120.908 -1.12 . . . . 0.0 109.505 179.826 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 6.5 pt-20 -81.33 -28.22 34.64 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.309 -0.87 . . . . 0.0 110.194 179.458 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -74.3 71.17 1.53 Allowed Glycine 0 N--CA 1.491 2.324 0 N-CA-C 109.92 -1.272 . . . . 0.0 109.92 -179.881 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 39' ' ' CYS . . . . . 0.461 ' O ' ' HD3' ' A' ' 41' ' ' ARG . 0.6 OUTLIER -160.04 -47.76 0.05 Allowed 'General case' 0 C--N 1.296 -1.742 0 O-C-N 121.678 -0.895 . . . . 0.0 110.021 179.495 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 40' ' ' LEU . . . . . . . . . . . . . 17.0 mt 54.94 -124.59 2.16 Favored 'General case' 0 N--CA 1.5 2.061 0 O-C-N 121.6 -0.687 . . . . 0.0 110.595 179.368 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 41' ' ' ARG . . . . . 0.461 ' HD3' ' O ' ' A' ' 39' ' ' CYS . 2.9 mpp_? 54.44 47.73 22.17 Favored 'General case' 0 N--CA 1.501 2.119 0 O-C-N 121.408 -0.808 . . . . 0.0 110.454 -179.745 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 42' ' ' ARG . . . . . . . . . . . . . 1.2 ttp180 -160.14 41.18 0.19 Allowed 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.292 -0.88 . . . . 0.0 110.349 -179.948 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 29.7 mt-10 49.76 79.25 0.08 Allowed 'General case' 0 N--CA 1.502 2.162 0 CA-C-O 121.477 0.656 . . . . 0.0 111.172 179.841 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -122.28 78.14 0.34 Allowed Glycine 0 N--CA 1.488 2.153 0 N-CA-C 109.073 -1.611 . . . . 0.0 109.073 179.59 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 45' ' ' GLN . . . . . . . . . . . . . 4.0 mt-30 . . . . . 0 N--CA 1.503 2.186 0 CA-C-O 118.306 -0.854 . . . . 0.0 110.662 -179.333 . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.494 1.742 0 N-CA-C 109.724 -0.472 . . . . 0.0 109.724 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER -82.52 -162.5 0.58 Allowed 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.468 -0.77 . . . . 0.0 110.066 179.779 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -72.67 76.25 1.1 Allowed 'General case' 0 N--CA 1.492 1.643 0 O-C-N 121.272 -0.893 . . . . 0.0 110.729 -179.539 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 4' ' ' ARG . . . . . . . . . . . . . 3.6 mmm180 -83.75 -157.43 0.25 Allowed 'General case' 0 N--CA 1.494 1.746 0 O-C-N 121.406 -0.808 . . . . 0.0 109.483 179.394 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 2.2 t -113.62 85.73 9.58 Favored Pre-proline 0 N--CA 1.497 1.906 0 O-C-N 120.803 -1.186 . . . . 0.0 110.049 179.881 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 6' ' ' PRO . . . . . . . . . . . . . 50.5 Cg_endo -75.42 75.92 3.73 Favored 'Trans proline' 0 C--N 1.313 -1.326 0 O-C-N 123.964 1.507 . . . . 0.0 110.425 179.928 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 73.89 38.7 48.61 Favored Glycine 0 N--CA 1.498 2.798 0 N-CA-C 110.118 -1.193 . . . . 0.0 110.118 179.987 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 5.4 p -92.04 -159.84 0.69 Allowed 'General case' 0 N--CA 1.498 1.927 0 O-C-N 121.28 -1.13 . . . . 0.0 109.858 179.498 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -76.93 -93.89 0.21 Allowed Glycine 0 N--CA 1.495 2.579 0 N-CA-C 109.599 -1.4 . . . . 0.0 109.599 -179.978 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 10' ' ' GLN . . . . . . . . . . . . . 2.3 pt20 -169.58 85.72 0.14 Allowed 'General case' 0 N--CA 1.493 1.722 0 O-C-N 121.221 -1.164 . . . . 0.0 109.885 179.656 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -75.64 60.01 2.92 Favored Glycine 0 N--CA 1.497 2.7 0 N-CA-C 109.932 -1.267 . . . . 0.0 109.932 -179.809 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 12' ' ' VAL . . . . . 0.445 ' O ' HG13 ' A' ' 12' ' ' VAL . 14.2 p -146.26 52.57 0.11 Allowed 'Isoleucine or valine' 0 N--CA 1.495 1.783 0 O-C-N 121.537 -0.978 . . . . 0.0 109.537 -179.933 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 13' ' ' GLN . . . . . . . . . . . . . 4.5 tt0 -58.93 -55.4 35.57 Favored 'General case' 0 N--CA 1.5 2.027 0 O-C-N 121.125 -0.984 . . . . 0.0 110.851 -179.733 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -83.54 66.44 8.93 Favored 'General case' 0 N--CA 1.498 1.939 0 O-C-N 121.143 -0.973 . . . . 0.0 110.185 -179.775 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -72.58 -67.1 1.9 Allowed Glycine 0 N--CA 1.494 2.534 0 N-CA-C 109.78 -1.328 . . . . 0.0 109.78 -179.748 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 1.2 p -127.89 74.51 78.69 Favored Pre-proline 0 N--CA 1.497 1.88 0 O-C-N 121.788 -0.83 . . . . 0.0 110.45 179.608 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 43.8 Cg_endo -68.72 131.01 21.75 Favored 'Trans proline' 0 C--N 1.309 -1.523 0 O-C-N 123.462 1.243 . . . . 0.0 110.36 -179.978 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 100.89 -24.36 32.28 Favored Glycine 0 N--CA 1.493 2.453 0 N-CA-C 110.54 -1.024 . . . . 0.0 110.54 179.916 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 165.81 138.52 2.44 Favored Glycine 0 N--CA 1.489 2.177 0 N-CA-C 108.943 -1.663 . . . . 0.0 108.943 179.599 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 71.6 m -118.36 112.74 20.4 Favored 'General case' 0 N--CA 1.492 1.672 0 O-C-N 121.492 -1.005 . . . . 0.0 110.009 179.788 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . 0.423 ' O ' HG13 ' A' ' 21' ' ' VAL . 7.2 p -92.89 43.63 0.08 OUTLIER 'Isoleucine or valine' 0 N--CA 1.504 2.232 0 O-C-N 121.282 -0.886 . . . . 0.0 110.481 -179.608 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 2.1 mm-40 -79.45 -28.08 41.62 Favored 'General case' 0 N--CA 1.488 1.457 0 O-C-N 121.029 -1.044 . . . . 0.0 110.931 -179.908 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 1.3 tp10 -162.29 110.87 1.4 Allowed 'General case' 0 N--CA 1.493 1.685 0 O-C-N 121.018 -1.052 . . . . 0.0 110.328 179.852 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 2.3 tt0 -148.23 153.29 38.54 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 121.487 -0.758 . . . . 0.0 110.165 179.104 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -96.67 -54.41 3.24 Favored 'General case' 0 N--CA 1.497 1.888 0 O-C-N 121.75 -0.594 . . . . 0.0 110.183 -179.677 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -156.25 94.34 0.14 Allowed Glycine 0 N--CA 1.494 2.549 0 N-CA-C 108.723 -1.751 . . . . 0.0 108.723 -179.891 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -55.81 96.72 0.04 OUTLIER Glycine 0 N--CA 1.498 2.826 0 N-CA-C 110.567 -1.013 . . . . 0.0 110.567 -179.422 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 28' ' ' SER . . . . . 0.531 ' CB ' ' HD3' ' A' ' 29' ' ' PRO . 1.6 t -160.75 -65.51 0.02 OUTLIER Pre-proline 0 N--CA 1.496 1.849 0 O-C-N 121.334 -1.098 . . . . 0.0 109.586 179.615 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 29' ' ' PRO . . . . . 0.531 ' HD3' ' CB ' ' A' ' 28' ' ' SER . 51.8 Cg_endo -78.26 72.14 6.41 Favored 'Trans proline' 0 N--CA 1.486 1.048 0 O-C-N 123.205 1.108 . . . . 0.0 109.863 178.742 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 30' ' ' ALA . . . . . 0.406 ' O ' ' HB3' ' A' ' 34' ' ' ALA . . . -79.64 -64.26 1.23 Allowed 'General case' 0 N--CA 1.493 1.701 0 O-C-N 121.349 -0.844 . . . . 0.0 111.212 -179.065 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 3.5 tt0 -117.78 -22.99 7.73 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.038 -1.039 . . . . 0.0 111.381 -179.224 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . -52.04 -41.57 53.08 Favored Glycine 0 N--CA 1.498 2.821 0 O-C-N 120.99 -1.069 . . . . 0.0 110.915 -179.193 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 33' ' ' CYS . . . . . . . . . . . . . 0.8 OUTLIER -149.59 62.69 1.01 Allowed 'General case' 0 N--CA 1.496 1.858 0 O-C-N 121.159 -1.2 . . . . 0.0 110.381 179.78 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 34' ' ' ALA . . . . . 0.406 ' HB3' ' O ' ' A' ' 30' ' ' ALA . . . -141.5 34.06 1.65 Allowed 'General case' 0 N--CA 1.498 1.952 0 O-C-N 121.257 -0.902 . . . . 0.0 110.367 179.882 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -111.15 -168.7 1.34 Allowed 'General case' 0 N--CA 1.496 1.863 0 O-C-N 121.376 -0.827 . . . . 0.0 109.776 179.693 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 36' ' ' ALA . . . . . . . . . . . . . . . -78.66 -24.65 45.06 Favored 'General case' 0 N--CA 1.5 2.037 0 O-C-N 121.508 -0.745 . . . . 0.0 110.324 179.985 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 4.9 tt0 -80.06 -46.83 15.84 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.519 -0.738 . . . . 0.0 109.697 179.769 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 106.42 -112.71 3.92 Favored Glycine 0 N--CA 1.489 2.184 0 N-CA-C 109.688 -1.365 . . . . 0.0 109.688 179.792 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 39' ' ' CYS . . . . . 0.479 ' O ' ' HG3' ' A' ' 42' ' ' ARG . 1.6 m -144.81 -47.14 0.24 Allowed 'General case' 0 N--CA 1.501 2.114 0 O-C-N 121.408 -1.054 . . . . 0.0 110.715 -179.633 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 40' ' ' LEU . . . . . . . . . . . . . 0.7 OUTLIER 42.14 39.11 1.28 Allowed 'General case' 0 N--CA 1.505 2.311 0 O-C-N 121.518 -0.739 . . . . 0.0 111.892 179.731 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 41' ' ' ARG . . . . . . . . . . . . . 1.6 ttt-85 54.02 34.97 20.96 Favored 'General case' 0 N--CA 1.504 2.247 0 O-C-N 121.34 -0.85 . . . . 0.0 111.755 179.079 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 42' ' ' ARG . . . . . 0.479 ' HG3' ' O ' ' A' ' 39' ' ' CYS . 4.9 mtm180 -58.0 -33.82 69.34 Favored 'General case' 0 N--CA 1.505 2.297 0 O-C-N 121.273 -0.892 . . . . 0.0 111.01 179.845 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 1.8 tt0 63.69 -175.81 0.16 Allowed 'General case' 0 N--CA 1.499 2.021 0 O-C-N 121.712 -0.617 . . . . 0.0 110.483 -179.422 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 77.08 46.76 9.95 Favored Glycine 0 N--CA 1.498 2.777 0 N-CA-C 109.342 -1.503 . . . . 0.0 109.342 -179.577 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 45' ' ' GLN . . . . . . . . . . . . . 10.3 mt-30 . . . . . 0 N--CA 1.491 1.613 0 O-C-N 121.195 -1.179 . . . . 0.0 110.384 179.92 . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . 0.409 ' O ' ' HB2' ' A' ' 2' ' ' LEU . . . . . . . . 0 N--CA 1.491 1.583 0 N-CA-C 109.569 -0.53 . . . . 0.0 109.569 . . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 2' ' ' LEU . . . . . 0.467 HD13 ' HA ' ' A' ' 2' ' ' LEU . 3.9 mm? 59.57 -170.72 0.13 Allowed 'General case' 0 N--CA 1.504 2.25 0 O-C-N 121.939 -0.476 . . . . 0.0 110.13 -179.815 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -152.15 -84.67 0.08 Allowed 'General case' 0 N--CA 1.489 1.482 0 O-C-N 121.148 -0.97 . . . . 0.0 110.463 179.783 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 4' ' ' ARG . . . . . . . . . . . . . 14.6 mtm-85 47.05 37.31 5.0 Favored 'General case' 0 N--CA 1.503 2.194 0 O-C-N 121.372 -0.83 . . . . 0.0 111.292 -179.748 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 22.9 p -102.43 118.76 58.04 Favored Pre-proline 0 N--CA 1.494 1.763 0 O-C-N 121.048 -1.032 . . . . 0.0 109.376 178.868 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 6' ' ' PRO . . . . . . . . . . . . . 42.0 Cg_endo -70.97 -53.26 0.2 Allowed 'Trans proline' 0 C--N 1.311 -1.412 0 O-C-N 123.685 1.36 . . . . 0.0 111.778 -178.988 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -108.89 59.45 0.36 Allowed Glycine 0 N--CA 1.492 2.371 0 O-C-N 120.917 -1.114 . . . . 0.0 110.859 -179.045 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 10.5 p -110.02 -35.68 6.06 Favored 'General case' 0 N--CA 1.5 2.034 0 O-C-N 121.264 -1.139 . . . . 0.0 110.693 179.355 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 49.4 32.19 14.57 Favored Glycine 0 N--CA 1.502 3.056 0 O-C-N 121.337 -0.852 . . . . 0.0 111.478 179.441 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 10' ' ' GLN . . . . . . . . . . . . . 69.8 mt-30 49.63 43.72 24.27 Favored 'General case' 0 N--CA 1.501 2.08 0 O-C-N 121.304 -1.115 . . . . 0.0 110.904 179.691 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -48.27 -50.06 23.88 Favored Glycine 0 N--CA 1.503 3.155 0 N-CA-C 110.619 -0.992 . . . . 0.0 110.619 -179.707 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 12' ' ' VAL . . . . . 0.51 ' O ' HG13 ' A' ' 12' ' ' VAL . 11.2 p -127.82 53.75 0.37 Allowed 'Isoleucine or valine' 0 N--CA 1.494 1.728 0 O-C-N 121.312 -1.111 . . . . 0.0 109.759 179.81 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 13' ' ' GLN . . . . . . . . . . . . . 1.6 pt20 -71.02 142.76 50.91 Favored 'General case' 0 N--CA 1.495 1.795 0 O-C-N 121.01 -1.057 . . . . 0.0 110.321 -179.891 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -122.75 131.89 53.98 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.321 -0.862 . . . . 0.0 109.858 179.805 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -73.36 -54.15 7.05 Favored Glycine 0 N--CA 1.491 2.314 0 N-CA-C 109.662 -1.375 . . . . 0.0 109.662 -179.976 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 12.2 m -114.3 122.0 35.18 Favored Pre-proline 0 N--CA 1.499 1.992 0 O-C-N 121.295 -1.12 . . . . 0.0 109.996 -179.94 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 43.6 Cg_endo -72.11 75.38 2.3 Favored 'Trans proline' 0 N--CA 1.497 1.692 0 O-C-N 123.611 1.322 . . . . 0.0 110.789 -179.69 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 127.14 -46.02 1.11 Allowed Glycine 0 N--CA 1.495 2.571 0 N-CA-C 109.659 -1.376 . . . . 0.0 109.659 179.879 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 161.5 147.33 4.94 Favored Glycine 0 N--CA 1.484 1.884 0 N-CA-C 109.321 -1.512 . . . . 0.0 109.321 -179.318 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 0.9 OUTLIER -106.22 172.2 6.94 Favored 'General case' 0 C--N 1.296 -1.746 0 O-C-N 121.534 -0.98 . . . . 0.0 109.647 -179.811 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 10.5 t -78.71 61.33 0.17 Allowed 'Isoleucine or valine' 0 N--CA 1.498 1.936 0 O-C-N 121.35 -0.844 . . . . 0.0 109.781 179.527 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 3.0 mm-40 -131.24 37.49 3.72 Favored 'General case' 0 C--N 1.306 -1.305 0 O-C-N 121.585 -0.697 . . . . 0.0 109.661 -179.717 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 48.2 mt-10 -68.5 167.11 15.54 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.308 -0.87 . . . . 0.0 110.874 -179.236 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 2.8 pm0 -70.91 158.9 35.65 Favored 'General case' 0 N--CA 1.495 1.794 0 O-C-N 121.733 -0.605 . . . . 0.0 111.18 -179.014 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -80.3 -65.46 1.0 Allowed 'General case' 0 N--CA 1.491 1.597 0 N-CA-C 109.376 -0.602 . . . . 0.0 109.376 179.212 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 174.74 84.57 0.06 OUTLIER Glycine 0 N--CA 1.494 2.507 0 N-CA-C 109.535 -1.426 . . . . 0.0 109.535 179.853 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 149.16 128.3 1.66 Allowed Glycine 0 N--CA 1.493 2.464 0 N-CA-C 109.268 -1.533 . . . . 0.0 109.268 179.944 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -93.39 150.73 39.47 Favored Pre-proline 0 N--CA 1.495 1.818 0 O-C-N 121.559 -0.965 . . . . 0.0 110.444 -179.507 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 29' ' ' PRO . . . . . 0.487 ' HA ' ' HB3' ' A' ' 33' ' ' CYS . 52.4 Cg_endo -79.55 14.19 1.89 Allowed 'Trans proline' 0 N--CA 1.486 1.083 0 O-C-N 123.833 1.439 . . . . 0.0 111.784 179.81 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -127.55 15.18 7.08 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.049 -1.032 . . . . 0.0 110.394 179.585 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -159.84 -75.58 0.07 Allowed 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.458 -0.776 . . . . 0.0 109.613 -179.638 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . -66.97 -56.51 12.27 Favored Glycine 0 N--CA 1.496 2.646 0 N-CA-C 109.284 -1.526 . . . . 0.0 109.284 179.699 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 33' ' ' CYS . . . . . 0.487 ' HB3' ' HA ' ' A' ' 29' ' ' PRO . 5.5 t -87.24 73.83 9.63 Favored 'General case' 0 N--CA 1.497 1.895 0 O-C-N 121.358 -1.084 . . . . 0.0 109.891 179.766 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -147.86 49.24 1.07 Allowed 'General case' 0 N--CA 1.495 1.793 0 O-C-N 121.495 -0.753 . . . . 0.0 110.063 179.831 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 12.0 mt-10 -108.51 -174.35 2.5 Favored 'General case' 0 N--CA 1.494 1.762 0 O-C-N 121.467 -0.771 . . . . 0.0 110.69 -179.862 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 36' ' ' ALA . . . . . . . . . . . . . . . -89.97 -1.96 58.07 Favored 'General case' 0 N--CA 1.499 2.006 0 O-C-N 121.294 -0.879 . . . . 0.0 111.501 179.89 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -117.81 31.89 6.45 Favored 'General case' 0 N--CA 1.493 1.689 0 O-C-N 121.297 -0.877 . . . . 0.0 110.856 179.922 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 67.3 -118.1 9.75 Favored Glycine 0 N--CA 1.49 2.252 0 N-CA-C 109.661 -1.376 . . . . 0.0 109.661 179.607 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 39' ' ' CYS . . . . . 0.539 ' C ' HD13 ' A' ' 40' ' ' LEU . 0.1 OUTLIER -153.7 24.51 0.51 Allowed 'General case' 0 N--CA 1.499 2.006 0 O-C-N 121.522 -0.987 . . . . 0.0 111.292 -179.969 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 40' ' ' LEU . . . . . 0.76 HD22 ' H ' ' A' ' 40' ' ' LEU . 0.0 OUTLIER -140.9 172.75 12.26 Favored 'General case' 0 N--CA 1.493 1.715 0 O-C-N 120.888 -1.132 . . . . 0.0 110.496 179.083 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 41' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER 46.72 37.03 4.2 Favored 'General case' 0 N--CA 1.503 2.205 0 O-C-N 121.428 -0.795 . . . . 0.0 110.961 -179.98 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 42' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -95.19 50.16 1.25 Allowed 'General case' 0 N--CA 1.489 1.483 0 O-C-N 120.983 -1.073 . . . . 0.0 110.102 179.634 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 43' ' ' GLU . . . . . 0.402 ' H ' ' HG3' ' A' ' 43' ' ' GLU . 0.9 OUTLIER -139.13 155.66 47.71 Favored 'General case' 0 C--N 1.305 -1.348 0 O-C-N 121.865 -0.522 . . . . 0.0 109.849 179.913 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -154.43 42.05 0.61 Allowed Glycine 0 N--CA 1.5 2.914 0 N-CA-C 109.341 -1.503 . . . . 0.0 109.341 179.437 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 45' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.495 1.8 0 O-C-N 121.467 -1.019 . . . . 0.0 109.951 179.91 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.484 1.237 0 N-CA-C 109.594 -0.521 . . . . 0.0 109.594 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' A' A ' 2' ' ' LEU . . . . . 0.487 ' O ' ' HB3' ' A' ' 3' ' ' ALA . 2.1 tp 58.96 84.01 0.12 Allowed 'General case' 0 N--CA 1.507 2.397 0 CA-C-O 121.286 0.565 . . . . 0.0 111.308 179.776 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 3' ' ' ALA . . . . . 0.487 ' HB3' ' O ' ' A' ' 2' ' ' LEU . . . 61.91 177.23 0.13 Allowed 'General case' 0 N--CA 1.503 2.187 0 O-C-N 121.668 -0.645 . . . . 0.0 111.436 179.61 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 4' ' ' ARG . . . . . 0.407 ' HB2' ' O ' ' A' ' 3' ' ' ALA . 16.9 tpt180 -177.8 -57.66 0.01 OUTLIER 'General case' 0 N--CA 1.497 1.906 0 O-C-N 121.672 -0.642 . . . . 0.0 110.056 179.373 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 0.8 OUTLIER -134.56 86.98 33.07 Favored Pre-proline 0 N--CA 1.492 1.659 0 O-C-N 120.904 -1.122 . . . . 0.0 110.013 -179.964 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 6' ' ' PRO . . . . . . . . . . . . . 39.3 Cg_endo -66.93 96.46 0.37 Allowed 'Trans proline' 0 C--N 1.303 -1.823 0 O-C-N 124.835 1.966 . . . . 0.0 111.241 -179.78 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 90.35 13.17 60.44 Favored Glycine 0 N--CA 1.493 2.499 0 C-N-CA 120.292 -0.956 . . . . 0.0 111.123 179.187 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 3.7 p -143.72 171.66 13.89 Favored 'General case' 0 N--CA 1.495 1.802 0 O-C-N 120.425 -1.633 . . . . 0.0 110.134 179.614 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 97.55 122.27 4.4 Favored Glycine 0 N--CA 1.494 2.511 0 N-CA-C 108.847 -1.701 . . . . 0.0 108.847 -179.147 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 10' ' ' GLN . . . . . . . . . . . . . 2.2 mt-30 -81.7 49.44 1.34 Allowed 'General case' 0 N--CA 1.494 1.743 0 O-C-N 121.156 -1.202 . . . . 0.0 110.922 -179.483 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -92.67 58.34 2.58 Favored Glycine 0 N--CA 1.495 2.599 0 N-CA-C 108.947 -1.661 . . . . 0.0 108.947 179.453 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 10.7 t -130.21 63.08 0.3 Allowed 'Isoleucine or valine' 0 N--CA 1.496 1.873 0 O-C-N 121.551 -0.97 . . . . 0.0 109.734 -179.674 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 13' ' ' GLN . . . . . . . . . . . . . 2.2 tt0 -121.01 102.95 8.67 Favored 'General case' 0 N--CA 1.487 1.408 0 O-C-N 121.245 -0.909 . . . . 0.0 109.748 179.816 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -134.7 -73.81 0.47 Allowed 'General case' 0 N--CA 1.492 1.675 0 O-C-N 121.941 -0.475 . . . . 0.0 109.826 179.993 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 136.46 -58.47 0.66 Allowed Glycine 0 N--CA 1.495 2.608 0 N-CA-C 109.537 -1.425 . . . . 0.0 109.537 179.966 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 10.1 m -79.49 148.63 70.37 Favored Pre-proline 0 N--CA 1.5 2.043 0 O-C-N 121.387 -1.067 . . . . 0.0 109.651 179.848 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 41.1 Cg_endo -66.69 -26.57 45.68 Favored 'Trans proline' 0 N--CA 1.492 1.435 0 O-C-N 123.896 1.471 . . . . 0.0 111.414 -179.636 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 174.66 85.29 0.06 OUTLIER Glycine 0 N--CA 1.494 2.5 0 N-CA-C 109.436 -1.466 . . . . 0.0 109.436 179.802 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 94.76 142.29 12.49 Favored Glycine 0 N--CA 1.488 2.147 0 N-CA-C 109.529 -1.428 . . . . 0.0 109.529 -179.834 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 0.0 OUTLIER -142.4 110.24 5.85 Favored 'General case' 0 N--CA 1.497 1.901 0 O-C-N 121.645 -0.915 . . . . 0.0 109.62 179.602 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 3.7 t -98.51 46.7 0.11 Allowed 'Isoleucine or valine' 0 N--CA 1.497 1.901 0 O-C-N 121.645 -0.659 . . . . 0.0 110.214 -179.635 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 8.6 mt-10 -87.99 -25.62 23.05 Favored 'General case' 0 N--CA 1.488 1.459 0 O-C-N 121.307 -0.871 . . . . 0.0 110.501 179.671 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 0.9 OUTLIER 60.02 -159.96 0.3 Allowed 'General case' 0 N--CA 1.501 2.09 0 O-C-N 121.751 -0.593 . . . . 0.0 110.976 179.924 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -124.44 -154.1 0.59 Allowed 'General case' 0 N--CA 1.488 1.439 0 O-C-N 121.537 -0.727 . . . . 0.0 110.169 -179.558 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -84.96 143.98 28.62 Favored 'General case' 0 N--CA 1.494 1.765 0 O-C-N 121.282 -0.886 . . . . 0.0 110.233 -179.971 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -69.69 -16.64 72.26 Favored Glycine 0 N--CA 1.493 2.472 0 N-CA-C 109.986 -1.246 . . . . 0.0 109.986 178.926 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 115.96 -107.7 1.72 Allowed Glycine 0 N--CA 1.49 2.285 0 N-CA-C 109.286 -1.526 . . . . 0.0 109.286 179.843 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -113.01 91.7 19.04 Favored Pre-proline 0 N--CA 1.497 1.88 0 O-C-N 121.327 -1.102 . . . . 0.0 109.63 179.375 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 44.2 Cg_endo -73.42 118.22 5.41 Favored 'Trans proline' 0 N--CA 1.49 1.318 0 O-C-N 123.692 1.364 . . . . 0.0 110.955 179.959 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -121.34 34.19 5.28 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.164 -0.96 . . . . 0.0 110.716 179.664 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 31' ' ' GLU . . . . . 0.507 ' HG3' ' N ' ' A' ' 32' ' ' GLY . 0.1 OUTLIER -86.85 -32.02 20.49 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.025 -1.047 . . . . 0.0 110.168 179.873 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 32' ' ' GLY . . . . . 0.507 ' N ' ' HG3' ' A' ' 31' ' ' GLU . . . 137.41 -47.42 0.95 Allowed Glycine 0 N--CA 1.493 2.464 0 N-CA-C 110.22 -1.152 . . . . 0.0 110.22 179.623 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 33' ' ' CYS . . . . . . . . . . . . . 0.9 OUTLIER -113.72 92.21 3.9 Favored 'General case' 0 N--CA 1.493 1.675 0 O-C-N 121.582 -0.952 . . . . 0.0 110.881 -179.398 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -96.9 37.32 1.31 Allowed 'General case' 0 N--CA 1.499 1.976 0 O-C-N 121.138 -0.976 . . . . 0.0 109.863 179.211 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 10.8 mt-10 -137.48 -178.1 5.08 Favored 'General case' 0 N--CA 1.497 1.902 0 O-C-N 121.747 -0.596 . . . . 0.0 109.867 179.812 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 36' ' ' ALA . . . . . . . . . . . . . . . -88.75 35.69 0.79 Allowed 'General case' 0 N--CA 1.493 1.717 0 O-C-N 120.993 -1.067 . . . . 0.0 110.594 -179.819 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 5.6 tt0 -78.5 -26.91 46.04 Favored 'General case' 0 N--CA 1.486 1.347 0 O-C-N 121.39 -0.819 . . . . 0.0 110.076 179.666 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 70.22 70.83 1.1 Allowed Glycine 0 N--CA 1.492 2.379 0 N-CA-C 109.137 -1.585 . . . . 0.0 109.137 179.689 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 39' ' ' CYS . . . . . . . . . . . . . 1.8 m -100.89 110.08 22.11 Favored 'General case' 0 C--N 1.298 -1.665 0 O-C-N 121.733 -0.863 . . . . 0.0 109.793 -179.768 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 40' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -128.81 -64.29 0.93 Allowed 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.425 -0.797 . . . . 0.0 110.961 -179.794 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 41' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -156.62 -143.22 0.11 Allowed 'General case' 0 N--CA 1.488 1.469 0 O-C-N 121.053 -1.029 . . . . 0.0 109.878 -179.638 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 42' ' ' ARG . . . . . . . . . . . . . 1.8 mtt180 -75.13 17.46 0.24 Allowed 'General case' 0 N--CA 1.498 1.927 0 O-C-N 120.849 -1.157 . . . . 0.0 112.336 -179.767 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 3.4 mm-40 -77.95 76.44 4.48 Favored 'General case' 0 N--CA 1.494 1.773 0 O-C-N 120.499 -1.375 . . . . 0.0 109.326 179.51 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -85.96 71.55 2.83 Favored Glycine 0 N--CA 1.495 2.598 0 N-CA-C 110.397 -1.081 . . . . 0.0 110.397 -179.155 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 45' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.498 1.943 0 O-C-N 121.674 -0.898 . . . . 0.0 110.095 179.691 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.494 1.743 0 CA-C-O 120.979 0.419 . . . . 0.0 109.975 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 12.4 tp -167.09 -56.57 0.03 OUTLIER 'General case' 0 N--CA 1.493 1.712 0 O-C-N 121.455 -0.778 . . . . 0.0 110.089 179.758 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -70.25 117.91 12.4 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 121.269 -0.894 . . . . 0.0 109.517 179.342 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 4' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -158.4 76.21 0.75 Allowed 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.413 -0.804 . . . . 0.0 110.304 179.921 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 19.8 t -144.4 104.71 4.68 Favored Pre-proline 0 N--CA 1.494 1.751 0 O-C-N 121.508 -0.745 . . . . 0.0 109.579 179.836 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 6' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -80.57 -35.63 0.55 Allowed 'Trans proline' 0 C--N 1.308 -1.57 0 O-C-N 124.09 1.573 . . . . 0.0 112.171 -179.325 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -90.45 53.22 3.45 Favored Glycine 0 N--CA 1.496 2.637 0 O-C-N 120.361 -1.462 . . . . 0.0 112.007 -178.009 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 21.7 p -161.15 163.7 31.08 Favored 'General case' 0 N--CA 1.498 1.933 0 O-C-N 120.657 -1.496 . . . . 0.0 110.655 178.854 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 70.91 63.94 2.98 Favored Glycine 0 N--CA 1.494 2.535 0 N-CA-C 109.759 -1.336 . . . . 0.0 109.759 -179.951 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 10' ' ' GLN . . . . . . . . . . . . . 3.1 pt20 -145.04 27.5 1.29 Allowed 'General case' 0 N--CA 1.493 1.698 0 O-C-N 121.619 -0.93 . . . . 0.0 111.113 -179.639 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -140.53 63.31 0.53 Allowed Glycine 0 N--CA 1.491 2.35 0 N-CA-C 109.439 -1.464 . . . . 0.0 109.439 179.839 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 28.9 m -113.79 2.06 8.39 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.834 0 O-C-N 121.568 -0.96 . . . . 0.0 111.627 -179.955 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 13' ' ' GLN . . . . . . . . . . . . . 25.6 tt0 -51.41 -45.73 62.64 Favored 'General case' 0 N--CA 1.499 2.01 0 O-C-N 120.984 -1.072 . . . . 0.0 110.613 179.815 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -111.04 26.6 10.53 Favored 'General case' 0 N--CA 1.494 1.729 0 O-C-N 121.624 -0.673 . . . . 0.0 110.272 179.714 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -128.33 68.19 0.54 Allowed Glycine 0 N--CA 1.489 2.19 0 N-CA-C 108.97 -1.652 . . . . 0.0 108.97 179.753 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 17.9 m -96.0 150.27 37.06 Favored Pre-proline 0 N--CA 1.488 1.437 0 O-C-N 121.44 -1.035 . . . . 0.0 110.497 -179.745 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 43.7 Cg_endo -74.17 -39.85 1.48 Allowed 'Trans proline' 0 N--CA 1.491 1.368 0 O-C-N 123.822 1.433 . . . . 0.0 110.648 179.426 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . -167.12 59.36 0.22 Allowed Glycine 0 N--CA 1.493 2.461 0 N-CA-C 109.163 -1.575 . . . . 0.0 109.163 179.589 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 141.18 132.56 2.82 Favored Glycine 0 N--CA 1.493 2.496 0 N-CA-C 108.625 -1.79 . . . . 0.0 108.625 -179.557 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -134.32 169.38 17.31 Favored 'General case' 0 N--CA 1.496 1.851 0 O-C-N 121.512 -0.993 . . . . 0.0 109.301 -179.665 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . 0.427 HG22 ' O ' ' A' ' 21' ' ' VAL . 11.7 p -80.06 50.89 0.07 OUTLIER 'Isoleucine or valine' 0 N--CA 1.502 2.155 0 O-C-N 121.319 -0.863 . . . . 0.0 111.254 -179.736 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 2.8 mt-10 -108.58 51.76 0.73 Allowed 'General case' 0 C--N 1.305 -1.326 0 O-C-N 121.014 -1.053 . . . . 0.0 108.436 178.419 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 0.8 OUTLIER 52.55 59.41 4.52 Favored 'General case' 0 N--CA 1.495 1.806 0 CA-C-O 121.93 0.871 . . . . 0.0 109.222 -177.995 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 1.7 pm0 -61.0 -5.46 1.4 Allowed 'General case' 0 N--CA 1.5 2.034 0 O-C-N 121.432 -0.793 . . . . 0.0 112.228 -179.105 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 15.7 m-20 -77.17 -24.18 51.49 Favored 'General case' 0 N--CA 1.497 1.924 0 O-C-N 120.737 -1.227 . . . . 0.0 110.431 179.641 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 88.39 -51.96 3.99 Favored Glycine 0 N--CA 1.495 2.589 0 N-CA-C 109.726 -1.35 . . . . 0.0 109.726 -179.921 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -177.29 -140.05 3.53 Favored Glycine 0 N--CA 1.493 2.472 0 N-CA-C 109.798 -1.321 . . . . 0.0 109.798 -179.696 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 28' ' ' SER . . . . . 0.46 ' CB ' ' CD ' ' A' ' 29' ' ' PRO . 2.6 t -154.92 -64.07 0.02 OUTLIER Pre-proline 0 N--CA 1.494 1.744 0 O-C-N 121.163 -1.198 . . . . 0.0 110.665 179.835 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 29' ' ' PRO . . . . . 0.46 ' CD ' ' CB ' ' A' ' 28' ' ' SER . 41.4 Cg_endo -68.89 -31.23 25.09 Favored 'Trans proline' 0 N--CA 1.488 1.188 0 O-C-N 122.979 0.989 . . . . 0.0 111.133 -179.562 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -99.12 54.29 0.98 Allowed 'General case' 0 N--CA 1.493 1.704 0 O-C-N 121.376 -0.827 . . . . 0.0 110.827 -179.633 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 2.8 tp10 -84.48 -42.41 15.6 Favored 'General case' 0 N--CA 1.493 1.717 0 O-C-N 121.379 -0.826 . . . . 0.0 110.217 179.603 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 96.47 52.43 1.57 Allowed Glycine 0 N--CA 1.501 2.995 0 N-CA-C 109.634 -1.386 . . . . 0.0 109.634 -179.804 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 33' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -79.62 118.64 21.64 Favored 'General case' 0 N--CA 1.495 1.814 0 O-C-N 121.157 -1.202 . . . . 0.0 109.735 179.903 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -79.49 -28.5 41.47 Favored 'General case' 0 N--CA 1.497 1.918 0 O-C-N 121.259 -0.9 . . . . 0.0 110.721 -179.851 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 24.5 mp0 -78.19 153.53 31.92 Favored 'General case' 0 N--CA 1.492 1.658 0 CA-C-O 121.491 0.662 . . . . 0.0 110.556 -179.762 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 36' ' ' ALA . . . . . . . . . . . . . . . -91.88 -42.18 10.2 Favored 'General case' 0 N--CA 1.496 1.825 0 O-C-N 121.415 -0.803 . . . . 0.0 110.999 -179.668 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 16.2 tt0 -77.18 -26.12 52.57 Favored 'General case' 0 N--CA 1.494 1.757 0 O-C-N 120.796 -1.19 . . . . 0.0 111.197 -179.006 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -70.26 -32.72 68.66 Favored Glycine 0 N--CA 1.497 2.705 0 C-N-CA 120.386 -0.911 . . . . 0.0 111.203 -178.942 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 39' ' ' CYS . . . . . . . . . . . . . 90.1 m -135.36 -32.32 0.94 Allowed 'General case' 0 N--CA 1.506 2.344 0 O-C-N 120.709 -1.466 . . . . 0.0 112.872 -178.697 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 40' ' ' LEU . . . . . . . . . . . . . 1.0 OUTLIER -74.39 63.73 1.08 Allowed 'General case' 0 N--CA 1.497 1.879 0 O-C-N 120.697 -1.252 . . . . 0.0 111.606 -178.371 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 41' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -115.88 67.96 0.72 Allowed 'General case' 0 N--CA 1.487 1.409 0 O-C-N 120.995 -1.066 . . . . 0.0 110.262 179.23 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 42' ' ' ARG . . . . . . . . . . . . . 9.4 mtt180 -142.43 42.92 1.63 Allowed 'General case' 0 N--CA 1.488 1.435 0 O-C-N 121.476 -0.765 . . . . 0.0 109.712 179.041 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 3.7 pm0 -69.52 145.45 52.64 Favored 'General case' 0 N--CA 1.494 1.736 0 O-C-N 121.618 -0.676 . . . . 0.0 110.495 -179.71 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -77.48 58.86 3.73 Favored Glycine 0 N--CA 1.497 2.708 0 N-CA-C 110.118 -1.193 . . . . 0.0 110.118 -179.771 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 45' ' ' GLN . . . . . . . . . . . . . 18.9 mt-30 . . . . . 0 N--CA 1.493 1.712 0 CA-C-O 117.722 -1.133 . . . . 0.0 110.059 179.47 . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.493 1.702 0 N-CA-C 110.075 -0.342 . . . . 0.0 110.075 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 0.0 OUTLIER -151.25 57.12 0.89 Allowed 'General case' 0 N--CA 1.493 1.71 0 O-C-N 121.44 -0.788 . . . . 0.0 110.427 180.0 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -103.38 95.65 6.23 Favored 'General case' 0 N--CA 1.488 1.438 0 O-C-N 121.218 -0.926 . . . . 0.0 110.267 -179.94 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 4' ' ' ARG . . . . . . . . . . . . . 2.5 ptp85 -57.63 105.57 0.26 Allowed 'General case' 0 N--CA 1.497 1.892 0 O-C-N 121.525 -0.734 . . . . 0.0 110.463 -179.872 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 31.6 p -126.03 141.81 40.64 Favored Pre-proline 0 N--CA 1.493 1.686 0 O-C-N 121.072 -1.018 . . . . 0.0 110.599 -179.668 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 6' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -78.26 110.59 2.9 Favored 'Trans proline' 0 N--CA 1.487 1.136 0 O-C-N 123.938 1.494 . . . . 0.0 111.516 -179.416 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 47.44 54.69 10.14 Favored Glycine 0 N--CA 1.497 2.707 0 O-C-N 121.337 -0.852 . . . . 0.0 110.983 179.147 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -112.84 -171.95 1.96 Allowed 'General case' 0 N--CA 1.495 1.784 0 O-C-N 121.342 -1.093 . . . . 0.0 109.822 179.24 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 9' ' ' GLY . . . . . 0.493 ' O ' ' HG2' ' A' ' 10' ' ' GLN . . . 95.54 36.34 5.39 Favored Glycine 0 N--CA 1.495 2.608 0 N-CA-C 109.452 -1.459 . . . . 0.0 109.452 179.973 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 10' ' ' GLN . . . . . 0.493 ' HG2' ' O ' ' A' ' 9' ' ' GLY . 0.0 OUTLIER 26.87 54.81 0.05 Allowed 'General case' 0 N--CA 1.506 2.351 0 CA-C-N 117.379 0.59 . . . . 0.0 112.055 179.679 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -135.95 52.37 0.79 Allowed Glycine 0 N--CA 1.496 2.662 0 N-CA-C 109.511 -1.436 . . . . 0.0 109.511 179.586 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 6.3 p -107.97 -2.49 10.06 Favored 'Isoleucine or valine' 0 N--CA 1.499 2.017 0 O-C-N 121.12 -1.223 . . . . 0.0 110.877 -179.331 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 13' ' ' GLN . . . . . . . . . . . . . 7.0 mt-30 -76.11 79.3 2.94 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 120.884 -1.135 . . . . 0.0 110.444 -179.491 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -119.02 174.75 6.12 Favored 'General case' 0 N--CA 1.498 1.972 0 O-C-N 121.673 -0.642 . . . . 0.0 110.29 179.662 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -143.25 -94.62 0.2 Allowed Glycine 0 N--CA 1.494 2.54 0 N-CA-C 109.544 -1.422 . . . . 0.0 109.544 179.895 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 4.7 m -89.07 151.09 46.43 Favored Pre-proline 0 N--CA 1.492 1.648 0 O-C-N 121.34 -1.094 . . . . 0.0 109.975 179.655 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 50.0 Cg_endo -75.14 59.01 5.17 Favored 'Trans proline' 0 C--N 1.315 -1.205 0 O-C-N 123.847 1.446 . . . . 0.0 111.052 -179.953 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 69.93 11.3 66.3 Favored Glycine 0 N--CA 1.494 2.56 0 N-CA-C 110.609 -0.996 . . . . 0.0 110.609 179.887 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -147.74 114.52 0.7 Allowed Glycine 0 N--CA 1.488 2.141 0 N-CA-C 109.064 -1.615 . . . . 0.0 109.064 -179.507 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -153.67 142.87 21.43 Favored 'General case' 0 N--CA 1.494 1.775 0 O-C-N 121.483 -1.01 . . . . 0.0 110.125 -179.85 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 11.5 p -150.35 44.67 0.08 OUTLIER 'Isoleucine or valine' 0 N--CA 1.499 1.99 0 CA-C-O 121.559 0.695 . . . . 0.0 110.164 -179.681 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 1.8 mt-10 -112.31 -13.57 13.43 Favored 'General case' 0 N--CA 1.487 1.418 0 O-C-N 121.191 -0.943 . . . . 0.0 110.758 179.654 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 1.4 tp10 58.73 85.95 0.09 Allowed 'General case' 0 N--CA 1.504 2.253 0 O-C-N 121.355 -0.84 . . . . 0.0 110.526 179.855 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 26.1 mt-10 -79.24 50.01 1.03 Allowed 'General case' 0 N--CA 1.496 1.854 0 O-C-N 120.858 -1.151 . . . . 0.0 111.286 -179.883 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 2.5 t70 -113.97 68.98 0.7 Allowed 'General case' 0 N--CA 1.495 1.788 0 O-C-N 121.211 -0.931 . . . . 0.0 109.979 179.706 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 159.87 -87.62 0.11 Allowed Glycine 0 N--CA 1.495 2.627 0 N-CA-C 109.638 -1.385 . . . . 0.0 109.638 179.838 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 121.47 -56.92 0.61 Allowed Glycine 0 N--CA 1.494 2.526 0 N-CA-C 109.533 -1.427 . . . . 0.0 109.533 -179.853 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 58.3 m -125.42 159.75 58.71 Favored Pre-proline 0 N--CA 1.498 1.953 0 O-C-N 121.762 -0.846 . . . . 0.0 110.157 179.964 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 42.4 Cg_endo -65.76 -29.13 51.15 Favored 'Trans proline' 0 N--CA 1.492 1.411 0 O-C-N 123.883 1.465 . . . . 0.0 111.076 179.736 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -96.15 15.81 19.83 Favored 'General case' 0 N--CA 1.487 1.384 0 O-C-N 120.822 -1.174 . . . . 0.0 110.224 178.965 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 37.0 tp10 -79.65 -50.71 10.24 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.089 -1.007 . . . . 0.0 110.818 -179.103 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 131.64 88.27 0.43 Allowed Glycine 0 N--CA 1.487 2.088 0 N-CA-C 108.771 -1.732 . . . . 0.0 108.771 -179.384 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 33' ' ' CYS . . . . . . . . . . . . . 17.9 m -78.22 125.59 29.57 Favored 'General case' 0 N--CA 1.502 2.131 0 O-C-N 121.279 -1.13 . . . . 0.0 110.307 -179.811 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -79.09 -17.21 55.56 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.363 -0.836 . . . . 0.0 109.839 179.15 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 1.1 tm-20 -103.74 165.24 11.16 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.391 -0.818 . . . . 0.0 109.999 179.581 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 36' ' ' ALA . . . . . . . . . . . . . . . -102.04 -26.92 13.22 Favored 'General case' 0 N--CA 1.498 1.955 0 O-C-N 121.335 -0.853 . . . . 0.0 110.903 179.58 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 1.5 mt-10 -79.58 -31.93 41.92 Favored 'General case' 0 N--CA 1.494 1.775 0 O-C-N 120.942 -1.099 . . . . 0.0 110.604 -179.195 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -75.22 -36.96 43.76 Favored Glycine 0 N--CA 1.493 2.459 0 N-CA-C 110.392 -1.083 . . . . 0.0 110.392 -179.91 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 39' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -96.47 -27.85 14.69 Favored 'General case' 0 N--CA 1.499 2.005 0 O-C-N 120.868 -1.372 . . . . 0.0 111.477 -179.865 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 40' ' ' LEU . . . . . . . . . . . . . 0.8 OUTLIER 60.15 -170.01 0.15 Allowed 'General case' 0 N--CA 1.502 2.133 0 O-C-N 121.297 -0.877 . . . . 0.0 110.657 -179.417 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 41' ' ' ARG . . . . . . . . . . . . . 1.2 ttt-85 -125.06 82.75 2.09 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.248 -0.907 . . . . 0.0 109.875 179.707 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 42' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -100.18 -38.41 8.53 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.357 -0.839 . . . . 0.0 110.42 -179.439 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER 56.69 -167.69 0.11 Allowed 'General case' 0 N--CA 1.498 1.964 0 CA-C-O 121.506 0.67 . . . . 0.0 110.836 -179.658 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 176.1 -58.94 0.11 Allowed Glycine 0 N--CA 1.49 2.248 0 N-CA-C 109.946 -1.262 . . . . 0.0 109.946 -179.649 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 45' ' ' GLN . . . . . . . . . . . . . 2.0 pt20 . . . . . 0 N--CA 1.503 2.194 0 O-C-N 120.869 -1.371 . . . . 0.0 110.47 179.632 . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.495 1.81 0 N-CA-C 110.103 -0.332 . . . . 0.0 110.103 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -162.43 30.14 0.11 Allowed 'General case' 0 N--CA 1.498 1.938 0 O-C-N 121.689 -0.632 . . . . 0.0 110.903 179.618 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . 49.87 -154.34 0.12 Allowed 'General case' 0 N--CA 1.501 2.106 0 O-C-N 121.499 -0.751 . . . . 0.0 110.759 179.856 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 4' ' ' ARG . . . . . . . . . . . . . 4.0 mmt85 53.47 -145.94 0.57 Allowed 'General case' 0 N--CA 1.496 1.865 0 O-C-N 121.538 -0.726 . . . . 0.0 110.431 179.843 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 5.8 p -131.65 133.26 24.04 Favored Pre-proline 0 N--CA 1.497 1.923 0 O-C-N 121.083 -1.011 . . . . 0.0 110.394 -179.714 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 6' ' ' PRO . . . . . . . . . . . . . 44.1 Cg_endo -75.09 -53.49 0.1 OUTLIER 'Trans proline' 0 C--N 1.311 -1.443 0 O-C-N 123.559 1.294 . . . . 0.0 111.351 -179.577 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -85.97 59.87 4.68 Favored Glycine 0 N--CA 1.492 2.373 0 N-CA-C 110.238 -1.145 . . . . 0.0 110.238 -179.426 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 0.7 OUTLIER -106.02 18.38 22.16 Favored 'General case' 0 N--CA 1.501 2.084 0 O-C-N 121.281 -1.129 . . . . 0.0 110.56 179.325 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 106.17 55.73 0.67 Allowed Glycine 0 N--CA 1.496 2.676 0 N-CA-C 109.975 -1.25 . . . . 0.0 109.975 179.729 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 10' ' ' GLN . . . . . . . . . . . . . 3.8 pt20 -161.79 48.35 0.19 Allowed 'General case' 0 N--CA 1.492 1.633 0 O-C-N 121.383 -1.069 . . . . 0.0 110.361 179.777 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -94.79 66.36 1.37 Allowed Glycine 0 N--CA 1.495 2.588 0 N-CA-C 109.599 -1.4 . . . . 0.0 109.599 179.901 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 24.6 t -122.3 -20.06 4.05 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.029 0 O-C-N 121.393 -1.063 . . . . 0.0 111.079 -179.483 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 13' ' ' GLN . . . . . 0.427 ' O ' ' HB3' ' A' ' 14' ' ' ALA . 0.0 OUTLIER -81.38 -144.38 0.05 Allowed 'General case' 0 N--CA 1.492 1.646 0 O-C-N 121.053 -1.029 . . . . 0.0 110.393 -179.854 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 14' ' ' ALA . . . . . 0.427 ' HB3' ' O ' ' A' ' 13' ' ' GLN . . . 59.07 -155.62 0.35 Allowed 'General case' 0 N--CA 1.498 1.966 0 O-C-N 121.647 -0.658 . . . . 0.0 109.821 -179.727 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -91.28 42.93 2.81 Favored Glycine 0 N--CA 1.49 2.262 0 N-CA-C 109.371 -1.492 . . . . 0.0 109.371 179.916 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 81.1 m -119.38 67.09 9.37 Favored Pre-proline 0 N--CA 1.493 1.709 0 O-C-N 121.295 -1.12 . . . . 0.0 110.801 -179.5 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 46.6 Cg_endo -71.83 69.01 3.0 Favored 'Trans proline' 0 C--N 1.313 -1.319 0 O-C-N 123.385 1.202 . . . . 0.0 110.504 -179.892 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 105.73 -14.71 45.73 Favored Glycine 0 N--CA 1.498 2.786 0 N-CA-C 110.134 -1.186 . . . . 0.0 110.134 -179.603 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -154.2 123.95 1.47 Allowed Glycine 0 N--CA 1.489 2.213 0 N-CA-C 109.152 -1.579 . . . . 0.0 109.152 179.87 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -108.05 47.13 0.91 Allowed 'General case' 0 N--CA 1.497 1.904 0 O-C-N 121.399 -1.059 . . . . 0.0 109.699 179.706 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 9.9 p -136.4 20.97 0.9 Allowed 'Isoleucine or valine' 0 N--CA 1.502 2.167 0 O-C-N 120.915 -1.116 . . . . 0.0 111.29 -179.444 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 22' ' ' GLU . . . . . 0.401 ' C ' ' HG3' ' A' ' 23' ' ' GLU . 1.5 tp10 -101.21 -12.06 19.03 Favored 'General case' 0 C--N 1.305 -1.339 0 O-C-N 121.179 -0.951 . . . . 0.0 109.993 179.098 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 23' ' ' GLU . . . . . 0.401 ' HG3' ' C ' ' A' ' 22' ' ' GLU . 0.0 OUTLIER -146.06 74.86 1.39 Allowed 'General case' 0 N--CA 1.488 1.446 0 O-C-N 121.429 -0.794 . . . . 0.0 109.436 -179.582 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER -56.05 -58.54 7.47 Favored 'General case' 0 N--CA 1.5 2.037 0 O-C-N 121.207 -0.933 . . . . 0.0 110.79 -179.421 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -149.28 -61.86 0.22 Allowed 'General case' 0 N--CA 1.495 1.811 0 O-C-N 121.332 -0.855 . . . . 0.0 110.06 179.964 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 134.04 86.03 0.25 Allowed Glycine 0 N--CA 1.497 2.708 0 N-CA-C 109.504 -1.438 . . . . 0.0 109.504 -179.716 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 165.45 95.95 0.11 Allowed Glycine 0 N--CA 1.494 2.557 0 N-CA-C 109.147 -1.581 . . . . 0.0 109.147 -179.702 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 28' ' ' SER . . . . . 0.484 ' HB2' ' HD3' ' A' ' 29' ' ' PRO . 0.0 OUTLIER -154.72 -62.6 0.02 OUTLIER Pre-proline 0 N--CA 1.497 1.909 0 O-C-N 121.263 -1.14 . . . . 0.0 110.777 179.85 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 29' ' ' PRO . . . . . 0.484 ' HD3' ' HB2' ' A' ' 28' ' ' SER . 44.8 Cg_endo -75.44 123.82 7.91 Favored 'Trans proline' 0 C--N 1.318 -1.062 0 O-C-N 122.922 0.959 . . . . 0.0 110.405 -179.744 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -78.54 -9.39 59.32 Favored 'General case' 0 N--CA 1.498 1.943 0 O-C-N 121.148 -0.97 . . . . 0.0 111.154 -179.665 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 4.1 tp10 -79.76 -56.92 3.94 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.253 -0.905 . . . . 0.0 109.556 179.742 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 171.88 -64.85 0.14 Allowed Glycine 0 N--CA 1.492 2.418 0 N-CA-C 109.181 -1.568 . . . . 0.0 109.181 -179.999 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 33' ' ' CYS . . . . . . . . . . . . . 12.7 p -148.29 88.33 1.64 Allowed 'General case' 0 N--CA 1.493 1.715 0 O-C-N 121.495 -1.003 . . . . 0.0 109.521 179.648 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -86.28 39.42 0.82 Allowed 'General case' 0 N--CA 1.495 1.808 0 O-C-N 121.342 -0.849 . . . . 0.0 110.82 -179.479 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER -113.8 163.26 15.28 Favored 'General case' 0 N--CA 1.495 1.793 0 O-C-N 121.218 -0.926 . . . . 0.0 110.214 179.812 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 36' ' ' ALA . . . . . 1.066 ' HB1' HD12 ' A' ' 40' ' ' LEU . . . -102.61 0.1 32.78 Favored 'General case' 0 N--CA 1.498 1.97 0 O-C-N 121.515 -0.741 . . . . 0.0 112.148 -178.706 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 2.7 pm0 -79.59 -27.24 41.13 Favored 'General case' 0 N--CA 1.498 1.94 0 O-C-N 120.582 -1.324 . . . . 0.0 111.556 -179.132 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -133.34 -47.41 0.1 Allowed Glycine 0 N--CA 1.498 2.799 0 C-N-CA 118.894 -1.622 . . . . 0.0 111.825 -178.77 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 39' ' ' CYS . . . . . . . . . . . . . 4.3 m -79.53 0.94 27.68 Favored 'General case' 0 N--CA 1.499 2.022 0 O-C-N 120.889 -1.359 . . . . 0.0 112.304 -178.451 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 40' ' ' LEU . . . . . 1.066 HD12 ' HB1' ' A' ' 36' ' ' ALA . 0.5 OUTLIER -75.87 56.68 0.98 Allowed 'General case' 0 N--CA 1.497 1.923 0 O-C-N 120.851 -1.156 . . . . 0.0 109.797 179.07 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 41' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -177.91 42.49 0.01 OUTLIER 'General case' 0 N--CA 1.498 1.944 0 O-C-N 121.606 -0.684 . . . . 0.0 110.873 -179.846 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 42' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -123.56 7.6 8.91 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.27 -0.894 . . . . 0.0 110.894 179.745 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER -79.99 63.79 4.63 Favored 'General case' 0 N--CA 1.493 1.709 0 O-C-N 120.63 -1.294 . . . . 0.0 109.96 179.33 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -159.65 72.03 0.23 Allowed Glycine 0 N--CA 1.489 2.193 0 N-CA-C 109.266 -1.533 . . . . 0.0 109.266 -179.908 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 45' ' ' GLN . . . . . . . . . . . . . 0.6 OUTLIER . . . . . 0 N--CA 1.495 1.786 0 CA-C-O 117.889 -1.053 . . . . 0.0 110.628 -179.708 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.494 1.726 0 CA-C-O 120.86 0.362 . . . . 0.0 110.231 . . . . . . . . . 0 0 . 1 . 011 nuclear nobuild full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -170.65 90.8 0.16 Allowed 'General case' 0 N--CA 1.494 1.747 0 O-C-N 121.358 -0.839 . . . . 0.0 110.131 179.828 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -163.61 121.73 1.91 Allowed 'General case' 0 N--CA 1.494 1.729 0 O-C-N 121.315 -0.866 . . . . 0.0 110.114 179.945 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 4' ' ' ARG . . . . . . . . . . . . . 1.7 tmm_? -89.25 88.42 7.51 Favored 'General case' 0 N--CA 1.492 1.633 0 O-C-N 121.502 -0.749 . . . . 0.0 110.043 -179.916 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -142.32 158.89 60.01 Favored Pre-proline 0 N--CA 1.491 1.614 0 O-C-N 121.463 -0.773 . . . . 0.0 110.264 -179.757 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 6' ' ' PRO . . . . . . . . . . . . . 43.6 Cg_endo -75.11 -53.21 0.1 OUTLIER 'Trans proline' 0 C--N 1.315 -1.233 0 O-C-N 123.691 1.364 . . . . 0.0 110.619 179.608 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -85.17 60.73 4.74 Favored Glycine 0 N--CA 1.496 2.654 0 N-CA-C 109.465 -1.454 . . . . 0.0 109.465 179.522 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 1.5 m -96.74 24.31 6.19 Favored 'General case' 0 N--CA 1.497 1.923 0 O-C-N 121.271 -1.135 . . . . 0.0 110.678 -179.952 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -144.02 -144.46 4.22 Favored Glycine 0 N--CA 1.495 2.579 0 N-CA-C 109.354 -1.498 . . . . 0.0 109.354 179.841 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 10' ' ' GLN . . . . . 0.491 ' HB2' ' HB3' ' A' ' 14' ' ' ALA . 3.5 mt-30 -54.12 -49.02 70.12 Favored 'General case' 0 N--CA 1.499 2.006 0 O-C-N 121.423 -1.045 . . . . 0.0 110.959 179.953 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 109.15 -25.17 19.19 Favored Glycine 0 N--CA 1.494 2.539 0 N-CA-C 109.874 -1.29 . . . . 0.0 109.874 -179.654 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 12' ' ' VAL . . . . . 0.438 ' H ' HG22 ' A' ' 12' ' ' VAL . 27.4 m -95.9 46.76 0.1 OUTLIER 'Isoleucine or valine' 0 N--CA 1.497 1.908 0 O-C-N 121.015 -1.285 . . . . 0.0 110.26 179.879 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 13' ' ' GLN . . . . . . . . . . . . . 1.1 mt-30 52.11 49.38 20.76 Favored 'General case' 0 N--CA 1.498 1.93 0 O-C-N 121.705 -0.622 . . . . 0.0 111.006 179.779 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 14' ' ' ALA . . . . . 0.491 ' HB3' ' HB2' ' A' ' 10' ' ' GLN . . . -103.87 161.65 13.78 Favored 'General case' 0 N--CA 1.497 1.917 0 O-C-N 121.263 -0.898 . . . . 0.0 110.137 179.512 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 75.58 72.06 1.1 Allowed Glycine 0 N--CA 1.495 2.625 0 N-CA-C 109.461 -1.455 . . . . 0.0 109.461 179.908 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 16' ' ' CYS . . . . . 0.44 ' HB2' ' HD2' ' A' ' 17' ' ' PRO . 17.7 p -79.8 167.23 35.42 Favored Pre-proline 0 N--CA 1.497 1.924 0 O-C-N 121.428 -1.042 . . . . 0.0 110.215 -179.922 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 17' ' ' PRO . . . . . 0.44 ' HD2' ' HB2' ' A' ' 16' ' ' CYS . 49.7 Cg_endo -77.33 53.19 4.17 Favored 'Trans proline' 0 C--N 1.311 -1.437 0 O-C-N 123.499 1.263 . . . . 0.0 110.217 178.927 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 92.7 -43.09 2.63 Favored Glycine 0 N--CA 1.496 2.64 0 N-CA-C 110.392 -1.083 . . . . 0.0 110.392 -179.89 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -74.89 83.38 0.82 Allowed Glycine 0 N--CA 1.492 2.376 0 O-C-N 121.189 -1.183 . . . . 0.0 110.495 -179.176 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 1.3 m -117.45 118.93 33.54 Favored 'General case' 0 N--CA 1.497 1.9 0 O-C-N 121.407 -1.054 . . . . 0.0 109.974 179.427 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 14.0 t -83.33 75.36 1.03 Allowed 'Isoleucine or valine' 0 N--CA 1.497 1.876 0 O-C-N 121.639 -0.663 . . . . 0.0 109.573 179.851 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 31.4 mt-10 -95.34 40.96 1.1 Allowed 'General case' 0 C--N 1.304 -1.391 0 O-C-N 121.356 -0.84 . . . . 0.0 110.115 -179.587 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 3.4 pt-20 -157.52 60.03 0.49 Allowed 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.372 -0.83 . . . . 0.0 110.164 -179.801 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -112.27 147.53 36.07 Favored 'General case' 0 N--CA 1.493 1.718 0 O-C-N 121.224 -0.922 . . . . 0.0 110.281 -179.574 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 3.1 p-10 -96.78 176.73 5.88 Favored 'General case' 0 N--CA 1.495 1.801 0 O-C-N 121.37 -0.831 . . . . 0.0 109.538 178.99 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -126.36 27.86 4.91 Favored Glycine 0 N--CA 1.493 2.487 0 N-CA-C 110.134 -1.186 . . . . 0.0 110.134 179.921 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 71.75 -68.77 1.0 Allowed Glycine 0 N--CA 1.499 2.88 0 N-CA-C 109.782 -1.327 . . . . 0.0 109.782 -179.934 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 64.4 m -83.5 116.9 66.87 Favored Pre-proline 0 N--CA 1.499 1.992 0 O-C-N 121.273 -1.134 . . . . 0.0 110.378 179.788 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 44.1 Cg_endo -71.16 154.39 62.07 Favored 'Trans proline' 0 N--CA 1.491 1.333 0 O-C-N 124.016 1.535 . . . . 0.0 111.485 -179.493 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -112.43 -50.26 2.91 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.398 -0.814 . . . . 0.0 110.625 179.84 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -102.54 -63.84 1.12 Allowed 'General case' 0 N--CA 1.495 1.79 0 O-C-N 121.485 -0.759 . . . . 0.0 110.233 -179.956 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 152.96 -59.2 0.41 Allowed Glycine 0 N--CA 1.495 2.587 0 N-CA-C 109.626 -1.39 . . . . 0.0 109.626 -179.907 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 33' ' ' CYS . . . . . . . . . . . . . 17.3 m -133.17 61.24 1.68 Allowed 'General case' 0 N--CA 1.496 1.87 0 O-C-N 121.32 -1.106 . . . . 0.0 110.075 179.87 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -122.62 26.63 8.2 Favored 'General case' 0 N--CA 1.497 1.911 0 O-C-N 121.274 -0.891 . . . . 0.0 109.876 179.528 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 22.7 mp0 -116.5 -171.88 2.09 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.732 -0.605 . . . . 0.0 110.612 -179.186 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 36' ' ' ALA . . . . . . . . . . . . . . . -92.07 -24.97 18.99 Favored 'General case' 0 N--CA 1.499 2.022 0 O-C-N 121.244 -0.91 . . . . 0.0 111.151 -179.597 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER -79.71 52.46 1.45 Allowed 'General case' 0 N--CA 1.499 2.006 0 O-C-N 120.836 -1.165 . . . . 0.0 110.739 -179.608 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 47.42 -111.5 0.79 Allowed Glycine 0 N--CA 1.501 3.013 0 N-CA-C 110.126 -1.189 . . . . 0.0 110.126 179.5 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 39' ' ' CYS . . . . . . . . . . . . . 90.0 m -143.4 141.4 30.86 Favored 'General case' 0 N--CA 1.495 1.794 0 O-C-N 121.485 -1.009 . . . . 0.0 109.26 179.462 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 40' ' ' LEU . . . . . 0.584 ' HB2' ' HG3' ' A' ' 43' ' ' GLU . 2.9 mt -69.87 -172.26 0.5 Allowed 'General case' 0 N--CA 1.495 1.778 0 O-C-N 121.351 -0.843 . . . . 0.0 110.938 -179.499 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 41' ' ' ARG . . . . . . . . . . . . . 13.9 mtp180 -105.9 117.59 34.43 Favored 'General case' 0 N--CA 1.489 1.477 0 O-C-N 121.096 -1.002 . . . . 0.0 111.317 -179.098 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 42' ' ' ARG . . . . . . . . . . . . . 38.0 ttp180 60.93 52.42 4.17 Favored 'General case' 0 N--CA 1.501 2.091 0 CA-C-O 121.044 0.45 . . . . 0.0 111.789 178.885 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 43' ' ' GLU . . . . . 0.584 ' HG3' ' HB2' ' A' ' 40' ' ' LEU . 69.2 mm-40 -96.34 136.97 36.1 Favored 'General case' 0 N--CA 1.487 1.424 0 O-C-N 120.93 -1.106 . . . . 0.0 109.473 178.442 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 109.64 -46.24 1.2 Allowed Glycine 0 N--CA 1.493 2.472 0 N-CA-C 109.211 -1.555 . . . . 0.0 109.211 -179.392 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 45' ' ' GLN . . . . . . . . . . . . . 2.2 mp0 . . . . . 0 N--CA 1.497 1.915 0 O-C-N 121.726 -0.867 . . . . 0.0 110.168 179.316 . . . . . . . . 0 0 . 1 . 012 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 1.497 0 N-CA-C 109.877 -0.416 . . . . 0.0 109.877 . . . . . . . . . 0 0 . 1 . 012 nuclear nobuild full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 0.9 OUTLIER -75.84 -178.47 4.29 Favored 'General case' 0 N--CA 1.492 1.672 0 O-C-N 121.6 -0.687 . . . . 0.0 110.689 179.913 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -163.84 -161.98 0.67 Allowed 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.18 -0.95 . . . . 0.0 109.971 179.79 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 4' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -61.22 133.73 56.24 Favored 'General case' 0 N--CA 1.494 1.73 0 O-C-N 121.515 -0.74 . . . . 0.0 110.003 179.871 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 5' ' ' CYS . . . . . 0.507 ' SG ' ' N ' ' A' ' 8' ' ' CYS . 0.8 OUTLIER -86.35 150.89 52.74 Favored Pre-proline 0 N--CA 1.496 1.858 0 O-C-N 121.512 -0.743 . . . . 0.0 109.716 179.864 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 6' ' ' PRO . . . . . . . . . . . . . 51.6 Cg_endo -81.0 45.36 1.98 Allowed 'Trans proline' 0 C--N 1.314 -1.271 0 O-C-N 123.755 1.397 . . . . 0.0 111.627 -179.092 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 165.1 41.73 0.02 OUTLIER Glycine 0 N--CA 1.497 2.702 0 N-CA-C 109.925 -1.27 . . . . 0.0 109.925 179.838 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 8' ' ' CYS . . . . . 0.507 ' N ' ' SG ' ' A' ' 5' ' ' CYS . 14.3 m -79.84 -177.2 5.82 Favored 'General case' 0 N--CA 1.499 1.993 0 O-C-N 121.404 -1.056 . . . . 0.0 110.132 -179.842 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -86.5 -79.72 1.19 Allowed Glycine 0 N--CA 1.495 2.631 0 N-CA-C 109.886 -1.286 . . . . 0.0 109.886 -179.885 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 10' ' ' GLN . . . . . . . . . . . . . 0.1 OUTLIER -67.05 -71.73 0.19 Allowed 'General case' 0 N--CA 1.496 1.868 0 O-C-N 121.434 -1.039 . . . . 0.0 110.648 -179.677 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 72.05 8.35 69.06 Favored Glycine 0 N--CA 1.497 2.758 0 N-CA-C 110.426 -1.07 . . . . 0.0 110.426 -179.595 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 12' ' ' VAL . . . . . 0.451 ' O ' HG13 ' A' ' 12' ' ' VAL . 4.3 p -160.64 82.41 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.493 1.675 0 O-C-N 121.209 -1.171 . . . . 0.0 108.767 179.954 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 13' ' ' GLN . . . . . . . . . . . . . 1.3 tt0 -53.22 101.16 0.04 OUTLIER 'General case' 0 N--CA 1.498 1.953 0 O-C-N 121.567 -0.708 . . . . 0.0 111.089 -178.897 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -108.72 31.55 5.56 Favored 'General case' 0 N--CA 1.497 1.894 0 O-C-N 121.643 -0.661 . . . . 0.0 109.547 179.209 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 143.95 -86.24 0.18 Allowed Glycine 0 N--CA 1.49 2.278 0 N-CA-C 108.548 -1.821 . . . . 0.0 108.548 -179.45 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 28.4 m -106.93 100.66 33.11 Favored Pre-proline 0 N--CA 1.494 1.764 0 O-C-N 121.331 -1.099 . . . . 0.0 109.544 179.133 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 47.2 Cg_endo -72.66 55.4 2.66 Favored 'Trans proline' 0 C--N 1.312 -1.382 0 O-C-N 123.817 1.43 . . . . 0.0 111.826 -178.955 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 152.62 36.56 0.03 OUTLIER Glycine 0 N--CA 1.496 2.684 0 O-C-N 120.836 -1.165 . . . . 0.0 111.097 179.444 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 82.38 137.24 2.6 Favored Glycine 0 N--CA 1.492 2.37 0 O-C-N 121.013 -1.287 . . . . 0.0 109.909 179.46 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -116.37 27.36 9.27 Favored 'General case' 0 N--CA 1.5 2.035 0 O-C-N 121.265 -1.138 . . . . 0.0 110.323 179.671 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 8.4 p -132.26 8.45 1.63 Allowed 'Isoleucine or valine' 0 N--CA 1.494 1.765 0 O-C-N 121.01 -1.056 . . . . 0.0 110.926 179.945 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 8.3 mm-40 -98.81 14.99 26.88 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 120.657 -1.277 . . . . 0.0 111.145 179.965 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 4.6 tt0 -146.4 -54.92 0.26 Allowed 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.202 -0.936 . . . . 0.0 109.507 179.404 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER -124.41 101.77 7.32 Favored 'General case' 0 C--N 1.307 -1.24 0 O-C-N 121.443 -0.785 . . . . 0.0 110.129 179.61 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 3.5 p-10 -115.43 23.76 12.15 Favored 'General case' 0 N--CA 1.496 1.841 0 O-C-N 121.236 -0.915 . . . . 0.0 110.542 179.926 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 129.52 -95.69 0.37 Allowed Glycine 0 N--CA 1.493 2.451 0 N-CA-C 109.209 -1.556 . . . . 0.0 109.209 179.914 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 80.29 -95.52 1.56 Allowed Glycine 0 N--CA 1.495 2.573 0 N-CA-C 109.701 -1.36 . . . . 0.0 109.701 179.752 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -79.29 165.77 46.2 Favored Pre-proline 0 N--CA 1.5 2.062 0 O-C-N 121.39 -1.065 . . . . 0.0 110.267 -179.919 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 45.6 Cg_endo -73.68 64.73 4.79 Favored 'Trans proline' 0 C--N 1.317 -1.116 0 O-C-N 123.868 1.457 . . . . 0.0 110.579 -179.975 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -127.63 76.62 1.69 Allowed 'General case' 0 N--CA 1.485 1.314 0 O-C-N 121.449 -0.782 . . . . 0.0 110.388 179.935 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 31' ' ' GLU . . . . . 0.42 ' HG3' ' N ' ' A' ' 32' ' ' GLY . 12.9 pt-20 -79.2 -43.22 24.3 Favored 'General case' 0 N--CA 1.494 1.744 0 O-C-N 121.152 -0.967 . . . . 0.0 110.243 -179.797 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 32' ' ' GLY . . . . . 0.42 ' N ' ' HG3' ' A' ' 31' ' ' GLU . . . 111.54 80.15 1.06 Allowed Glycine 0 N--CA 1.492 2.433 0 N-CA-C 109.582 -1.407 . . . . 0.0 109.582 179.739 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 33' ' ' CYS . . . . . . . . . . . . . 0.7 OUTLIER -79.68 133.22 36.37 Favored 'General case' 0 N--CA 1.497 1.894 0 O-C-N 121.264 -1.139 . . . . 0.0 109.362 179.66 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -78.5 -22.48 47.37 Favored 'General case' 0 N--CA 1.501 2.096 0 O-C-N 121.325 -0.859 . . . . 0.0 110.445 179.886 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 0.8 OUTLIER -130.68 165.51 22.7 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.381 -0.824 . . . . 0.0 109.814 179.554 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 36' ' ' ALA . . . . . . . . . . . . . . . -93.28 -39.91 10.72 Favored 'General case' 0 N--CA 1.493 1.679 0 O-C-N 121.462 -0.774 . . . . 0.0 109.644 179.403 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 6.2 tt0 -79.27 -53.85 6.54 Favored 'General case' 0 N--CA 1.495 1.81 0 O-C-N 121.525 -0.735 . . . . 0.0 109.844 179.713 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -75.87 63.09 2.8 Favored Glycine 0 N--CA 1.498 2.792 0 N-CA-C 109.557 -1.417 . . . . 0.0 109.557 179.887 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 39' ' ' CYS . . . . . 0.435 ' HB3' HD23 ' A' ' 40' ' ' LEU . 2.6 t -122.4 -63.49 1.28 Allowed 'General case' 0 N--CA 1.496 1.831 0 O-C-N 121.549 -0.971 . . . . 0.0 110.181 179.497 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 40' ' ' LEU . . . . . 0.435 HD23 ' HB3' ' A' ' 39' ' ' CYS . 1.9 pt? -169.86 -164.98 0.45 Allowed 'General case' 0 N--CA 1.497 1.898 0 O-C-N 121.196 -0.94 . . . . 0.0 110.547 179.139 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 41' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER 64.14 179.95 0.17 Allowed 'General case' 0 N--CA 1.503 2.203 0 O-C-N 121.768 -0.583 . . . . 0.0 110.445 179.938 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 42' ' ' ARG . . . . . . . . . . . . . 15.4 mtm180 -131.87 -70.9 0.56 Allowed 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.111 -0.993 . . . . 0.0 109.792 179.812 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 5.9 mp0 -128.74 88.51 2.74 Favored 'General case' 0 N--CA 1.487 1.391 0 O-C-N 121.423 -0.798 . . . . 0.0 109.335 -179.861 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 157.9 65.72 0.01 OUTLIER Glycine 0 N--CA 1.492 2.373 0 N-CA-C 109.279 -1.528 . . . . 0.0 109.279 -179.589 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 45' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.493 1.695 0 O-C-N 121.441 -1.035 . . . . 0.0 110.217 179.837 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.499 1.996 0 N-CA-C 109.816 -0.438 . . . . 0.0 109.816 . . . . . . . . . 0 0 . 1 . 013 nuclear nobuild full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 0.7 OUTLIER -174.0 154.31 2.29 Favored 'General case' 0 N--CA 1.499 1.987 0 O-C-N 121.359 -0.838 . . . . 0.0 109.697 179.575 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -110.13 162.71 14.31 Favored 'General case' 0 N--CA 1.492 1.666 0 O-C-N 121.492 -0.755 . . . . 0.0 110.325 -179.923 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 4' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -168.05 89.51 0.27 Allowed 'General case' 0 N--CA 1.495 1.817 0 O-C-N 121.418 -0.801 . . . . 0.0 110.39 -179.992 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 9.3 t -160.43 103.4 1.35 Allowed Pre-proline 0 N--CA 1.497 1.925 0 O-C-N 120.945 -1.097 . . . . 0.0 110.023 179.955 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 6' ' ' PRO . . . . . . . . . . . . . 52.7 Cg_endo -77.57 155.0 31.5 Favored 'Trans proline' 0 C--N 1.314 -1.28 0 O-C-N 123.666 1.351 . . . . 0.0 110.335 179.796 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 82.82 -50.47 4.39 Favored Glycine 0 N--CA 1.497 2.762 0 C-N-CA 120.118 -1.039 . . . . 0.0 110.601 179.717 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 8' ' ' CYS . . . . . 0.443 ' SG ' ' N ' ' A' ' 9' ' ' GLY . 12.0 p -78.71 -33.09 47.07 Favored 'General case' 0 N--CA 1.497 1.905 0 O-C-N 120.967 -1.314 . . . . 0.0 111.062 -179.36 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 9' ' ' GLY . . . . . 0.443 ' N ' ' SG ' ' A' ' 8' ' ' CYS . . . -79.76 -60.63 2.42 Favored Glycine 0 N--CA 1.497 2.708 0 N-CA-C 109.631 -1.387 . . . . 0.0 109.631 -179.486 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 10' ' ' GLN . . . . . . . . . . . . . 34.2 mt-30 -143.91 -62.6 0.39 Allowed 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.438 -1.037 . . . . 0.0 110.754 -179.813 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 89.25 -68.56 2.7 Favored Glycine 0 N--CA 1.495 2.598 0 N-CA-C 108.962 -1.655 . . . . 0.0 108.962 -179.271 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 41.0 t -136.51 -94.06 0.04 OUTLIER 'Isoleucine or valine' 0 N--CA 1.496 1.85 0 O-C-N 121.657 -0.908 . . . . 0.0 109.715 179.287 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 13' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -166.86 30.76 0.04 OUTLIER 'General case' 0 N--CA 1.499 1.977 0 O-C-N 120.825 -1.172 . . . . 0.0 110.875 179.824 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -154.02 136.44 15.01 Favored 'General case' 0 N--CA 1.496 1.843 0 O-C-N 121.107 -0.996 . . . . 0.0 110.459 179.986 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -108.2 65.52 0.25 Allowed Glycine 0 N--CA 1.495 2.592 0 N-CA-C 109.788 -1.325 . . . . 0.0 109.788 179.881 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 60.6 m -80.51 114.01 44.12 Favored Pre-proline 0 N--CA 1.499 2.019 0 O-C-N 121.719 -0.871 . . . . 0.0 109.975 179.641 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 45.0 Cg_endo -70.07 89.22 0.56 Allowed 'Trans proline' 0 N--CA 1.49 1.318 0 O-C-N 123.722 1.38 . . . . 0.0 110.767 -179.931 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 108.58 -16.83 34.03 Favored Glycine 0 N--CA 1.495 2.582 0 N-CA-C 110.361 -1.096 . . . . 0.0 110.361 179.886 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 117.92 138.41 5.99 Favored Glycine 0 N--CA 1.489 2.231 0 N-CA-C 108.675 -1.77 . . . . 0.0 108.675 -179.314 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 6.0 p -124.65 -2.66 7.86 Favored 'General case' 0 N--CA 1.497 1.911 0 O-C-N 121.435 -1.038 . . . . 0.0 112.076 -179.622 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . 0.459 HG22 ' O ' ' A' ' 21' ' ' VAL . 12.1 p -160.07 39.81 0.02 OUTLIER 'Isoleucine or valine' 0 N--CA 1.497 1.894 0 O-C-N 120.581 -1.324 . . . . 0.0 110.353 -179.803 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 13.4 mm-40 -98.94 46.23 0.99 Allowed 'General case' 0 N--CA 1.487 1.408 0 O-C-N 120.84 -1.162 . . . . 0.0 111.089 -179.621 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER 43.02 68.4 0.51 Allowed 'General case' 0 N--CA 1.505 2.294 0 CA-C-O 121.409 0.623 . . . . 0.0 111.528 179.617 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 2.7 tt0 -80.6 -57.38 3.6 Favored 'General case' 0 N--CA 1.494 1.761 0 O-C-N 120.983 -1.073 . . . . 0.0 109.904 179.987 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 3.1 t70 -160.25 176.72 11.41 Favored 'General case' 0 N--CA 1.489 1.522 0 N-CA-C 108.838 -0.801 . . . . 0.0 108.838 179.136 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 62.06 39.75 98.02 Favored Glycine 0 N--CA 1.493 2.484 0 N-CA-C 109.658 -1.377 . . . . 0.0 109.658 179.683 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -58.16 -29.96 63.39 Favored Glycine 0 N--CA 1.497 2.738 0 N-CA-C 110.076 -1.21 . . . . 0.0 110.076 179.962 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 1.1 m -79.19 163.58 59.0 Favored Pre-proline 0 N--CA 1.5 2.035 0 O-C-N 121.338 -1.096 . . . . 0.0 109.515 179.467 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 44.1 Cg_endo -69.89 68.88 1.75 Allowed 'Trans proline' 0 C--N 1.308 -1.578 0 O-C-N 123.268 1.141 . . . . 0.0 110.937 -179.747 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -99.5 -40.25 7.94 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.245 -0.909 . . . . 0.0 110.537 -179.958 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 4.4 tt0 -78.98 -9.61 59.58 Favored 'General case' 0 N--CA 1.494 1.74 0 O-C-N 121.503 -0.748 . . . . 0.0 111.12 -179.754 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . -73.23 -38.59 53.87 Favored Glycine 0 N--CA 1.497 2.76 0 N-CA-C 110.198 -1.161 . . . . 0.0 110.198 -179.839 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 33' ' ' CYS . . . . . 0.421 ' HB2' ' O ' ' A' ' 38' ' ' GLY . 0.8 OUTLIER -127.22 94.0 3.89 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.544 -0.974 . . . . 0.0 109.976 179.684 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -123.04 35.29 4.91 Favored 'General case' 0 N--CA 1.495 1.78 0 O-C-N 121.699 -0.626 . . . . 0.0 109.681 179.552 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 2.2 mp0 -78.5 -144.57 0.03 OUTLIER 'General case' 0 N--CA 1.502 2.126 0 O-C-N 121.814 -0.554 . . . . 0.0 109.824 -179.782 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 36' ' ' ALA . . . . . . . . . . . . . . . -76.95 -25.89 53.37 Favored 'General case' 0 N--CA 1.492 1.634 0 O-C-N 121.022 -1.048 . . . . 0.0 109.795 -179.822 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 6.0 tt0 -99.81 -40.04 7.92 Favored 'General case' 0 N--CA 1.497 1.884 0 O-C-N 121.321 -0.862 . . . . 0.0 110.131 179.111 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 38' ' ' GLY . . . . . 0.421 ' O ' ' HB2' ' A' ' 33' ' ' CYS . . . 81.37 -119.5 4.88 Favored Glycine 0 N--CA 1.487 2.079 0 N-CA-C 109.355 -1.498 . . . . 0.0 109.355 -179.881 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 39' ' ' CYS . . . . . . . . . . . . . 1.0 OUTLIER -152.67 43.81 0.66 Allowed 'General case' 0 N--CA 1.495 1.804 0 O-C-N 121.548 -0.972 . . . . 0.0 110.23 179.605 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 40' ' ' LEU . . . . . . . . . . . . . 71.4 mt -92.85 138.99 31.0 Favored 'General case' 0 N--CA 1.493 1.684 0 O-C-N 121.085 -1.01 . . . . 0.0 110.735 -179.502 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 41' ' ' ARG . . . . . . . . . . . . . 29.7 mmt85 -116.23 151.99 34.67 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.515 -0.741 . . . . 0.0 109.955 179.406 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 42' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -88.27 41.58 1.02 Allowed 'General case' 0 N--CA 1.496 1.835 0 O-C-N 121.235 -0.916 . . . . 0.0 111.461 -179.381 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 10.3 mt-10 -93.05 -36.28 12.79 Favored 'General case' 0 N--CA 1.492 1.643 0 O-C-N 121.149 -0.97 . . . . 0.0 110.54 179.333 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -84.8 69.94 3.23 Favored Glycine 0 N--CA 1.496 2.684 0 N-CA-C 109.957 -1.257 . . . . 0.0 109.957 -179.674 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 45' ' ' GLN . . . . . . . . . . . . . 2.2 pt20 . . . . . 0 N--CA 1.5 2.053 0 O-C-N 121.662 -0.905 . . . . 0.0 110.187 179.714 . . . . . . . . 0 0 . 1 . 014 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.492 1.632 0 CA-C-O 120.825 0.345 . . . . 0.0 110.315 . . . . . . . . . 0 0 . 1 . 014 nuclear nobuild full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER 50.76 34.2 9.69 Favored 'General case' 0 N--CA 1.504 2.253 0 O-C-N 121.773 -0.579 . . . . 0.0 112.191 179.371 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -168.89 31.93 0.02 OUTLIER 'General case' 0 N--CA 1.498 1.94 0 O-C-N 120.893 -1.129 . . . . 0.0 111.426 179.52 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 4' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER 42.19 31.86 0.28 Allowed 'General case' 0 N--CA 1.506 2.332 0 O-C-N 121.229 -0.919 . . . . 0.0 111.334 -179.911 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 8.7 t -124.98 114.96 26.39 Favored Pre-proline 0 N--CA 1.492 1.668 0 O-C-N 121.02 -1.05 . . . . 0.0 109.472 -179.935 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 6' ' ' PRO . . . . . . . . . . . . . 44.2 Cg_endo -75.97 -58.27 0.05 OUTLIER 'Trans proline' 0 C--N 1.314 -1.284 0 O-C-N 124.195 1.629 . . . . 0.0 111.161 -179.704 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -76.02 57.02 3.15 Favored Glycine 0 N--CA 1.498 2.811 0 N-CA-C 110.111 -1.196 . . . . 0.0 110.111 -179.77 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 0.8 OUTLIER -113.91 12.66 18.17 Favored 'General case' 0 N--CA 1.495 1.794 0 O-C-N 121.11 -1.229 . . . . 0.0 110.335 179.131 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -116.61 160.37 13.47 Favored Glycine 0 N--CA 1.494 2.534 0 N-CA-C 108.26 -1.936 . . . . 0.0 108.26 179.195 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 10' ' ' GLN . . . . . . . . . . . . . 4.8 mt-30 55.05 31.43 16.17 Favored 'General case' 0 N--CA 1.502 2.16 0 O-C-N 121.574 -0.957 . . . . 0.0 110.639 -179.635 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -76.58 53.04 3.2 Favored Glycine 0 N--CA 1.496 2.699 0 N-CA-C 110.064 -1.214 . . . . 0.0 110.064 -179.822 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 10.0 p -98.89 36.11 0.18 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.722 0 O-C-N 121.351 -1.088 . . . . 0.0 110.32 -179.8 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 13' ' ' GLN . . . . . . . . . . . . . 2.0 tt0 56.48 15.42 2.03 Favored 'General case' 0 N--CA 1.502 2.174 0 O-C-N 121.316 -0.865 . . . . 0.0 111.796 179.814 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . 46.15 36.26 3.08 Favored 'General case' 0 N--CA 1.502 2.172 0 O-C-N 121.274 -0.891 . . . . 0.0 110.663 -179.496 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -95.46 -50.22 2.05 Favored Glycine 0 N--CA 1.493 2.463 0 N-CA-C 109.961 -1.256 . . . . 0.0 109.961 -179.353 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 96.6 m -111.57 80.83 2.93 Favored Pre-proline 0 N--CA 1.497 1.922 0 O-C-N 121.126 -1.22 . . . . 0.0 110.406 -179.629 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 43.5 Cg_endo -74.48 100.9 1.37 Allowed 'Trans proline' 0 C--N 1.312 -1.358 0 O-C-N 123.769 1.405 . . . . 0.0 109.993 179.808 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 114.94 -38.68 3.04 Favored Glycine 0 N--CA 1.496 2.663 0 N-CA-C 110.184 -1.167 . . . . 0.0 110.184 -179.798 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 179.07 144.92 5.95 Favored Glycine 0 N--CA 1.487 2.055 0 N-CA-C 108.973 -1.651 . . . . 0.0 108.973 -179.742 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -108.64 43.58 1.23 Allowed 'General case' 0 N--CA 1.496 1.86 0 O-C-N 121.625 -0.927 . . . . 0.0 110.125 -179.935 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 0.1 OUTLIER -146.09 52.8 0.12 Allowed 'Isoleucine or valine' 0 N--CA 1.496 1.869 0 O-C-N 121.547 -0.721 . . . . 0.0 109.19 179.656 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 2.2 mp0 -79.32 -30.07 42.66 Favored 'General case' 0 N--CA 1.488 1.472 0 O-C-N 121.602 -0.686 . . . . 0.0 111.233 -178.842 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 10.9 tt0 -161.44 108.8 1.44 Allowed 'General case' 0 N--CA 1.493 1.693 0 O-C-N 121.178 -0.951 . . . . 0.0 110.51 -179.709 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 0.8 OUTLIER -89.73 155.26 19.32 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.223 -0.923 . . . . 0.0 109.909 179.438 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 8.8 p-10 -79.05 -33.95 44.24 Favored 'General case' 0 N--CA 1.498 1.96 0 O-C-N 121.359 -0.838 . . . . 0.0 110.7 -179.953 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -55.19 -46.87 77.32 Favored Glycine 0 N--CA 1.495 2.632 0 N-CA-C 110.36 -1.096 . . . . 0.0 110.36 -179.91 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -98.47 61.79 0.86 Allowed Glycine 0 N--CA 1.495 2.619 0 N-CA-C 109.904 -1.279 . . . . 0.0 109.904 -179.743 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 1.6 m -112.57 92.63 20.4 Favored Pre-proline 0 N--CA 1.497 1.918 0 O-C-N 121.318 -1.107 . . . . 0.0 110.578 179.998 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 52.1 Cg_endo -78.8 133.92 11.7 Favored 'Trans proline' 0 C--N 1.316 -1.181 0 O-C-N 123.817 1.43 . . . . 0.0 110.475 179.723 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -127.11 56.99 1.49 Allowed 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.357 -0.84 . . . . 0.0 110.436 179.761 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 10.0 tt0 -160.75 -48.55 0.05 OUTLIER 'General case' 0 N--CA 1.495 1.808 0 O-C-N 121.338 -0.851 . . . . 0.0 110.733 179.557 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . -59.23 -27.15 62.43 Favored Glycine 0 N--CA 1.497 2.713 0 O-C-N 121.514 -0.741 . . . . 0.0 111.524 -179.394 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 33' ' ' CYS . . . . . 0.43 ' O ' ' HB3' ' A' ' 39' ' ' CYS . 26.0 p -79.12 68.55 5.12 Favored 'General case' 0 N--CA 1.498 1.961 0 O-C-N 120.821 -1.399 . . . . 0.0 110.315 -179.556 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -92.39 33.28 1.11 Allowed 'General case' 0 N--CA 1.496 1.855 0 O-C-N 120.888 -1.133 . . . . 0.0 110.626 179.771 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 4.8 mp0 -97.4 -178.5 4.17 Favored 'General case' 0 N--CA 1.492 1.648 0 O-C-N 121.16 -0.963 . . . . 0.0 110.351 -179.968 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 36' ' ' ALA . . . . . . . . . . . . . . . -87.86 28.66 1.0 Allowed 'General case' 0 N--CA 1.498 1.957 0 O-C-N 121.045 -1.034 . . . . 0.0 111.227 -179.807 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 13.6 pt-20 -78.91 -17.57 55.31 Favored 'General case' 0 N--CA 1.493 1.721 0 O-C-N 121.046 -1.033 . . . . 0.0 110.895 179.329 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 122.45 10.22 6.14 Favored Glycine 0 N--CA 1.496 2.673 0 N-CA-C 110.148 -1.181 . . . . 0.0 110.148 -179.533 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 39' ' ' CYS . . . . . 0.43 ' HB3' ' O ' ' A' ' 33' ' ' CYS . 0.1 OUTLIER -79.35 -25.26 42.3 Favored 'General case' 0 N--CA 1.501 2.08 0 O-C-N 120.876 -1.367 . . . . 0.0 110.369 179.78 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 40' ' ' LEU . . . . . 0.44 ' CD2' ' HB3' ' A' ' 42' ' ' ARG . 0.9 OUTLIER -86.95 -69.8 0.65 Allowed 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.024 -1.047 . . . . 0.0 110.851 -179.721 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 41' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER 53.12 67.51 0.99 Allowed 'General case' 0 N--CA 1.502 2.158 0 O-C-N 121.506 -0.746 . . . . 0.0 110.77 -179.917 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 42' ' ' ARG . . . . . 0.44 ' HB3' ' CD2' ' A' ' 40' ' ' LEU . 5.0 ptm180 -110.23 17.56 20.81 Favored 'General case' 0 N--CA 1.496 1.867 0 O-C-N 121.392 -0.818 . . . . 0.0 111.15 -179.906 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 46.2 mt-10 47.33 -123.1 1.44 Allowed 'General case' 0 N--CA 1.497 1.925 0 O-C-N 121.477 -0.764 . . . . 0.0 109.959 -179.623 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -113.45 27.81 9.11 Favored Glycine 0 N--CA 1.492 2.409 0 N-CA-C 108.547 -1.821 . . . . 0.0 108.547 179.223 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 45' ' ' GLN . . . . . . . . . . . . . 0.3 OUTLIER . . . . . 0 N--CA 1.493 1.715 0 O-C-N 121.61 -0.936 . . . . 0.0 110.237 -179.392 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.492 1.671 0 CA-C-O 120.966 0.412 . . . . 0.0 109.9 . . . . . . . . . 0 0 . 1 . 015 nuclear nobuild full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 28.4 mt -80.17 79.31 6.75 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.359 -0.838 . . . . 0.0 110.33 -179.748 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -142.4 173.79 11.21 Favored 'General case' 0 N--CA 1.488 1.472 0 O-C-N 121.366 -0.834 . . . . 0.0 110.431 -179.961 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 4' ' ' ARG . . . . . . . . . . . . . 1.3 mmp_? -74.11 -20.7 60.17 Favored 'General case' 0 N--CA 1.496 1.874 0 O-C-N 121.184 -0.947 . . . . 0.0 111.371 -179.701 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 31.2 p -129.56 146.17 59.98 Favored Pre-proline 0 N--CA 1.494 1.763 0 O-C-N 120.753 -1.217 . . . . 0.0 110.652 -179.914 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 6' ' ' PRO . . . . . . . . . . . . . 47.3 Cg_endo -77.95 121.49 5.43 Favored 'Trans proline' 0 C--N 1.315 -1.189 0 O-C-N 123.899 1.473 . . . . 0.0 110.903 -179.549 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 96.64 12.64 50.06 Favored Glycine 0 N--CA 1.496 2.68 0 N-CA-C 110.734 -0.946 . . . . 0.0 110.734 179.536 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 0.8 OUTLIER -160.5 172.32 17.42 Favored 'General case' 0 N--CA 1.496 1.852 0 O-C-N 120.75 -1.441 . . . . 0.0 110.171 -179.47 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 115.75 -173.26 14.64 Favored Glycine 0 N--CA 1.494 2.55 0 N-CA-C 109.599 -1.4 . . . . 0.0 109.599 -179.871 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 10' ' ' GLN . . . . . . . . . . . . . 4.4 mt-30 -89.14 50.29 1.92 Allowed 'General case' 0 N--CA 1.492 1.659 0 O-C-N 121.279 -1.13 . . . . 0.0 110.381 179.939 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -83.19 60.66 4.87 Favored Glycine 0 N--CA 1.495 2.573 0 N-CA-C 109.744 -1.342 . . . . 0.0 109.744 179.974 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 9.0 p -135.43 25.33 0.93 Allowed 'Isoleucine or valine' 0 N--CA 1.496 1.851 0 O-C-N 121.334 -1.097 . . . . 0.0 110.805 179.904 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 13' ' ' GLN . . . . . 0.45 ' O ' ' HB3' ' A' ' 14' ' ' ALA . 0.2 OUTLIER -71.73 -14.64 62.07 Favored 'General case' 0 N--CA 1.498 1.96 0 O-C-N 120.938 -1.101 . . . . 0.0 111.461 -179.782 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 14' ' ' ALA . . . . . 0.45 ' HB3' ' O ' ' A' ' 13' ' ' GLN . . . 59.63 82.85 0.14 Allowed 'General case' 0 N--CA 1.502 2.165 0 O-C-N 121.17 -0.957 . . . . 0.0 110.583 -179.915 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -125.36 75.95 0.4 Allowed Glycine 0 N--CA 1.492 2.424 0 N-CA-C 109.045 -1.622 . . . . 0.0 109.045 179.665 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 10.7 m -78.4 118.32 71.62 Favored Pre-proline 0 N--CA 1.496 1.866 0 O-C-N 121.29 -1.124 . . . . 0.0 109.709 -179.863 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 40.7 Cg_endo -68.25 -41.2 7.3 Favored 'Trans proline' 0 C--N 1.316 -1.139 0 O-C-N 123.855 1.45 . . . . 0.0 111.32 -179.498 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . -176.22 60.87 0.1 Allowed Glycine 0 N--CA 1.496 2.66 0 N-CA-C 109.796 -1.322 . . . . 0.0 109.796 179.994 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 162.61 75.19 0.02 OUTLIER Glycine 0 N--CA 1.493 2.495 0 N-CA-C 109.539 -1.424 . . . . 0.0 109.539 179.72 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 0.3 OUTLIER -105.86 -40.09 5.82 Favored 'General case' 0 N--CA 1.495 1.803 0 O-C-N 121.191 -1.182 . . . . 0.0 110.647 -179.516 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 3.6 t -107.7 56.27 0.14 Allowed 'Isoleucine or valine' 0 N--CA 1.497 1.903 0 O-C-N 121.319 -0.863 . . . . 0.0 110.186 179.923 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER -79.72 46.2 0.75 Allowed 'General case' 0 N--CA 1.495 1.823 0 O-C-N 120.979 -1.075 . . . . 0.0 110.479 179.827 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 23' ' ' GLU . . . . . 0.488 ' HG3' ' N ' ' A' ' 24' ' ' GLU . 6.7 pt-20 -128.0 -29.41 2.55 Favored 'General case' 0 N--CA 1.493 1.676 0 O-C-N 121.06 -1.025 . . . . 0.0 110.964 179.318 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 24' ' ' GLU . . . . . 0.488 ' N ' ' HG3' ' A' ' 23' ' ' GLU . 10.7 mt-10 57.76 177.38 0.05 Allowed 'General case' 0 N--CA 1.498 1.952 0 O-C-N 121.513 -0.742 . . . . 0.0 111.8 179.401 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 1.2 p-10 -102.81 -36.53 8.23 Favored 'General case' 0 N--CA 1.495 1.802 0 O-C-N 121.122 -0.986 . . . . 0.0 110.433 -179.302 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 118.55 92.03 1.47 Allowed Glycine 0 N--CA 1.49 2.27 0 N-CA-C 108.891 -1.684 . . . . 0.0 108.891 -179.484 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -59.01 105.85 0.77 Allowed Glycine 0 N--CA 1.494 2.545 0 N-CA-C 109.636 -1.386 . . . . 0.0 109.636 -179.564 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 28' ' ' SER . . . . . 0.508 ' N ' ' HD2' ' A' ' 29' ' ' PRO . 0.0 OUTLIER -79.5 -49.3 1.4 Allowed Pre-proline 0 N--CA 1.496 1.837 0 O-C-N 121.536 -0.979 . . . . 0.0 111.769 -179.007 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 29' ' ' PRO . . . . . 0.508 ' HD2' ' N ' ' A' ' 28' ' ' SER . 44.2 Cg_endo -72.21 60.83 3.24 Favored 'Trans proline' 0 N--CA 1.49 1.292 0 O-C-N 123.159 1.083 . . . . 0.0 111.478 -179.197 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -121.74 47.62 1.84 Allowed 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.148 -0.97 . . . . 0.0 110.096 179.421 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 1.2 tp10 -80.46 -68.65 0.66 Allowed 'General case' 0 N--CA 1.493 1.706 0 O-C-N 121.494 -0.754 . . . . 0.0 109.885 -179.664 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 116.56 76.2 0.6 Allowed Glycine 0 N--CA 1.494 2.53 0 N-CA-C 109.766 -1.334 . . . . 0.0 109.766 179.943 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 33' ' ' CYS . . . . . . . . . . . . . 10.4 p -79.09 127.5 32.09 Favored 'General case' 0 N--CA 1.496 1.85 0 O-C-N 121.632 -0.922 . . . . 0.0 109.687 179.462 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -144.77 17.72 1.63 Allowed 'General case' 0 N--CA 1.499 1.989 0 O-C-N 121.385 -0.822 . . . . 0.0 110.543 -179.904 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 1.5 mp0 -90.8 -163.8 1.08 Allowed 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.395 -0.816 . . . . 0.0 110.472 -179.566 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 36' ' ' ALA . . . . . . . . . . . . . . . -88.15 43.05 1.1 Allowed 'General case' 0 N--CA 1.499 1.988 0 O-C-N 121.123 -0.986 . . . . 0.0 111.44 -179.275 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 1.9 pt-20 -138.39 9.73 2.71 Favored 'General case' 0 N--CA 1.494 1.759 0 O-C-N 121.261 -0.9 . . . . 0.0 110.956 179.254 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 68.39 -108.63 2.53 Favored Glycine 0 N--CA 1.495 2.615 0 N-CA-C 108.869 -1.692 . . . . 0.0 108.869 -179.657 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 39' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -160.64 -54.86 0.05 Allowed 'General case' 0 N--CA 1.498 1.96 0 O-C-N 121.154 -1.204 . . . . 0.0 110.376 179.321 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 40' ' ' LEU . . . . . . . . . . . . . 6.3 tt -67.35 -17.74 64.87 Favored 'General case' 0 N--CA 1.494 1.764 0 O-C-N 121.271 -0.893 . . . . 0.0 111.104 -179.888 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 41' ' ' ARG . . . . . . . . . . . . . 6.1 mtp180 64.07 75.61 0.38 Allowed 'General case' 0 N--CA 1.499 1.98 0 CA-C-O 121.869 0.842 . . . . 0.0 110.011 -179.804 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 42' ' ' ARG . . . . . 0.691 ' HG3' ' HG3' ' A' ' 45' ' ' GLN . 10.6 ttm180 -128.46 68.45 1.37 Allowed 'General case' 0 N--CA 1.485 1.298 0 O-C-N 121.353 -0.842 . . . . 0.0 109.334 -179.951 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 8.4 mt-10 -65.18 82.67 0.05 OUTLIER 'General case' 0 N--CA 1.496 1.851 0 O-C-N 121.538 -0.726 . . . . 0.0 112.386 -178.372 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 58.07 46.89 92.08 Favored Glycine 0 N--CA 1.494 2.508 0 N-CA-C 110.566 -1.014 . . . . 0.0 110.566 179.122 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 45' ' ' GLN . . . . . 0.691 ' HG3' ' HG3' ' A' ' 42' ' ' ARG . 0.0 OUTLIER . . . . . 0 N--CA 1.497 1.917 0 CA-C-O 117.996 -1.002 . . . . 0.0 109.885 179.055 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.495 1.777 0 CA-C-O 120.991 0.424 . . . . 0.0 110.1 . . . . . . . . . 0 0 . 1 . 016 nuclear nobuild full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER -100.95 -3.27 29.86 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.167 -0.958 . . . . 0.0 111.918 -179.722 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -57.74 -37.97 74.52 Favored 'General case' 0 N--CA 1.5 2.051 0 O-C-N 121.117 -0.99 . . . . 0.0 111.549 -179.179 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 4' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -131.46 133.59 45.32 Favored 'General case' 0 N--CA 1.489 1.482 0 O-C-N 120.924 -1.11 . . . . 0.0 110.492 -179.64 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 8.5 t -109.09 118.66 50.76 Favored Pre-proline 0 N--CA 1.496 1.828 0 O-C-N 121.403 -0.811 . . . . 0.0 109.475 179.656 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 6' ' ' PRO . . . . . . . . . . . . . 44.1 Cg_endo -73.14 106.86 2.24 Favored 'Trans proline' 0 C--N 1.312 -1.356 0 O-C-N 123.891 1.469 . . . . 0.0 111.162 -179.267 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 66.69 49.07 58.0 Favored Glycine 0 N--CA 1.496 2.659 0 N-CA-C 110.515 -1.034 . . . . 0.0 110.515 179.154 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -84.93 178.57 7.55 Favored 'General case' 0 N--CA 1.5 2.038 0 O-C-N 121.212 -1.17 . . . . 0.0 110.47 179.676 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -74.34 150.97 42.83 Favored Glycine 0 N--CA 1.491 2.311 0 N-CA-C 109.763 -1.335 . . . . 0.0 109.763 179.961 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 10' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -79.23 50.08 1.03 Allowed 'General case' 0 N--CA 1.496 1.875 0 O-C-N 121.591 -0.946 . . . . 0.0 110.773 -179.953 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -79.7 -57.06 3.17 Favored Glycine 0 N--CA 1.492 2.41 0 N-CA-C 109.612 -1.395 . . . . 0.0 109.612 179.929 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 12' ' ' VAL . . . . . 0.456 HG22 ' O ' ' A' ' 12' ' ' VAL . 7.4 p -137.17 65.69 0.25 Allowed 'Isoleucine or valine' 0 N--CA 1.496 1.85 0 O-C-N 121.466 -1.02 . . . . 0.0 110.35 -179.99 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 13' ' ' GLN . . . . . . . . . . . . . 2.6 tp-100 -80.22 -36.87 34.16 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.226 -0.921 . . . . 0.0 110.404 179.712 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -94.83 167.07 11.66 Favored 'General case' 0 N--CA 1.494 1.75 0 O-C-N 121.593 -0.692 . . . . 0.0 110.256 179.976 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -60.12 -34.19 82.92 Favored Glycine 0 N--CA 1.497 2.76 0 N-CA-C 110.228 -1.149 . . . . 0.0 110.228 179.608 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 16' ' ' CYS . . . . . 0.446 ' HB2' ' HB2' ' A' ' 20' ' ' CYS . 0.0 OUTLIER -110.01 96.86 26.98 Favored Pre-proline 0 N--CA 1.496 1.851 0 O-C-N 120.714 -1.462 . . . . 0.0 109.614 179.403 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 41.2 Cg_endo -68.43 111.26 2.48 Favored 'Trans proline' 0 C--N 1.311 -1.424 0 O-C-N 123.837 1.44 . . . . 0.0 111.079 -179.59 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 62.68 20.02 61.26 Favored Glycine 0 N--CA 1.496 2.685 0 N-CA-C 110.654 -0.978 . . . . 0.0 110.654 179.857 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -157.93 54.2 0.38 Allowed Glycine 0 N--CA 1.498 2.771 0 N-CA-C 109.741 -1.344 . . . . 0.0 109.741 -179.808 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 20' ' ' CYS . . . . . 0.446 ' HB2' ' HB2' ' A' ' 16' ' ' CYS . 0.8 OUTLIER -125.95 93.87 3.95 Favored 'General case' 0 N--CA 1.497 1.914 0 O-C-N 121.362 -1.081 . . . . 0.0 109.527 179.686 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 22.5 m -122.27 41.04 0.77 Allowed 'Isoleucine or valine' 0 N--CA 1.494 1.745 0 CA-C-O 121.268 0.556 . . . . 0.0 110.879 -179.211 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 2.8 mt-10 -110.6 44.99 1.18 Allowed 'General case' 0 C--N 1.307 -1.275 0 O-C-N 121.371 -0.83 . . . . 0.0 109.865 179.374 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 1.3 tp10 -101.2 -57.3 2.12 Favored 'General case' 0 N--CA 1.492 1.671 0 O-C-N 121.32 -0.863 . . . . 0.0 110.225 -179.824 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 1.0 OUTLIER -72.77 154.4 40.67 Favored 'General case' 0 N--CA 1.499 1.99 0 O-C-N 121.523 -0.735 . . . . 0.0 110.466 -179.744 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 4.1 p-10 -95.25 36.84 1.2 Allowed 'General case' 0 N--CA 1.502 2.134 0 O-C-N 121.353 -0.842 . . . . 0.0 111.357 179.956 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 154.96 -90.47 0.12 Allowed Glycine 0 N--CA 1.492 2.426 0 N-CA-C 109.719 -1.353 . . . . 0.0 109.719 178.922 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -138.15 141.81 12.51 Favored Glycine 0 N--CA 1.498 2.817 0 N-CA-C 109.799 -1.32 . . . . 0.0 109.799 -179.803 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 28' ' ' SER . . . . . 0.452 ' OG ' ' HD2' ' A' ' 29' ' ' PRO . 23.0 t -84.94 154.43 60.92 Favored Pre-proline 0 C--N 1.301 -1.535 0 O-C-N 121.285 -1.126 . . . . 0.0 109.854 179.759 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 29' ' ' PRO . . . . . 0.452 ' HD2' ' OG ' ' A' ' 28' ' ' SER . 37.9 Cg_endo -65.51 -26.87 54.41 Favored 'Trans proline' 0 C--N 1.308 -1.584 0 O-C-N 123.353 1.186 . . . . 0.0 109.819 179.03 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -93.59 24.2 4.19 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.592 -0.693 . . . . 0.0 110.446 179.182 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 31' ' ' GLU . . . . . 0.413 ' HB2' ' O ' ' A' ' 28' ' ' SER . 1.7 tp10 -83.26 -7.99 59.52 Favored 'General case' 0 N--CA 1.495 1.822 0 O-C-N 121.376 -0.827 . . . . 0.0 111.106 -179.883 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 77.62 29.0 56.28 Favored Glycine 0 N--CA 1.494 2.542 0 N-CA-C 109.404 -1.478 . . . . 0.0 109.404 -179.481 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 33' ' ' CYS . . . . . . . . . . . . . 0.0 OUTLIER -161.64 43.86 0.16 Allowed 'General case' 0 N--CA 1.498 1.929 0 O-C-N 121.411 -1.052 . . . . 0.0 109.861 179.842 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -109.39 -49.44 3.11 Favored 'General case' 0 N--CA 1.498 1.943 0 O-C-N 120.919 -1.113 . . . . 0.0 111.21 -179.342 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 35.1 mt-10 -95.02 -167.45 1.63 Allowed 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.051 -1.031 . . . . 0.0 110.369 -179.217 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 36' ' ' ALA . . . . . . . . . . . . . . . -82.27 44.07 0.84 Allowed 'General case' 0 N--CA 1.497 1.89 0 O-C-N 121.299 -0.876 . . . . 0.0 110.316 179.563 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 3.2 pt-20 -79.67 -13.29 59.58 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.43 -0.794 . . . . 0.0 110.327 179.297 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 132.34 38.12 0.26 Allowed Glycine 0 N--CA 1.502 3.074 0 C-N-CA 120.159 -1.02 . . . . 0.0 111.103 179.389 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 39' ' ' CYS . . . . . . . . . . . . . 13.5 t -93.51 -47.41 6.86 Favored 'General case' 0 N--CA 1.493 1.715 0 O-C-N 121.357 -1.084 . . . . 0.0 110.196 179.76 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 40' ' ' LEU . . . . . . . . . . . . . 7.9 mt -90.31 -100.69 0.1 Allowed 'General case' 0 N--CA 1.488 1.465 0 O-C-N 121.136 -0.977 . . . . 0.0 110.314 179.952 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 41' ' ' ARG . . . . . . . . . . . . . 25.9 ptt180 -165.58 179.87 5.82 Favored 'General case' 0 N--CA 1.494 1.765 0 O-C-N 121.061 -1.025 . . . . 0.0 110.543 179.955 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 42' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -160.92 78.66 0.6 Allowed 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.386 -0.821 . . . . 0.0 110.088 179.93 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -140.05 137.5 34.64 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.381 -0.824 . . . . 0.0 110.92 -179.857 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 91.28 29.28 12.69 Favored Glycine 0 N--CA 1.495 2.599 0 N-CA-C 110.378 -1.089 . . . . 0.0 110.378 179.216 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 45' ' ' GLN . . . . . . . . . . . . . 2.5 mt-30 . . . . . 0 N--CA 1.494 1.755 0 O-C-N 121.275 -1.132 . . . . 0.0 110.106 179.551 . . . . . . . . 0 0 . 1 . 017 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.5 2.05 0 CA-C-O 120.906 0.384 . . . . 0.0 110.257 . . . . . . . . . 0 0 . 1 . 017 nuclear nobuild full ' A' A ' 2' ' ' LEU . . . . . 0.507 HD22 ' HA ' ' A' ' 2' ' ' LEU . 0.3 OUTLIER -147.96 111.78 5.09 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.394 -0.816 . . . . 0.0 110.0 179.926 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -119.26 165.35 14.36 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.584 -0.697 . . . . 0.0 110.345 179.786 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 4' ' ' ARG . . . . . . . . . . . . . 17.4 ttt85 -114.93 158.29 22.2 Favored 'General case' 0 N--CA 1.489 1.481 0 O-C-N 121.251 -0.906 . . . . 0.0 109.935 179.503 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 5' ' ' CYS . . . . . 0.487 ' O ' ' SG ' ' A' ' 8' ' ' CYS . 1.3 p -127.65 163.01 45.65 Favored Pre-proline 0 N--CA 1.496 1.859 0 O-C-N 121.54 -0.725 . . . . 0.0 110.41 179.724 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 6' ' ' PRO . . . . . . . . . . . . . 49.6 Cg_endo -77.54 -50.43 0.09 OUTLIER 'Trans proline' 0 C--N 1.311 -1.396 0 O-C-N 123.552 1.29 . . . . 0.0 111.173 179.488 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -105.2 67.31 0.27 Allowed Glycine 0 N--CA 1.494 2.54 0 N-CA-C 110.239 -1.144 . . . . 0.0 110.239 -179.545 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 8' ' ' CYS . . . . . 0.487 ' SG ' ' O ' ' A' ' 5' ' ' CYS . 3.5 m -86.56 138.04 32.03 Favored 'General case' 0 N--CA 1.494 1.766 0 O-C-N 121.308 -1.113 . . . . 0.0 109.404 179.107 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 114.18 88.51 1.62 Allowed Glycine 0 N--CA 1.492 2.416 0 N-CA-C 109.165 -1.574 . . . . 0.0 109.165 -179.486 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 10' ' ' GLN . . . . . . . . . . . . . 4.1 mt-30 51.62 33.38 10.65 Favored 'General case' 0 N--CA 1.507 2.383 0 O-C-N 121.647 -0.913 . . . . 0.0 111.161 -179.558 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -110.27 -40.36 1.39 Allowed Glycine 0 N--CA 1.496 2.693 0 N-CA-C 109.659 -1.377 . . . . 0.0 109.659 179.761 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 43.6 t -79.16 -47.71 22.23 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.822 0 O-C-N 121.39 -1.065 . . . . 0.0 110.485 179.905 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 13' ' ' GLN . . . . . . . . . . . . . 7.1 tt0 -72.86 133.84 44.59 Favored 'General case' 0 N--CA 1.494 1.735 0 O-C-N 121.054 -1.029 . . . . 0.0 110.244 179.887 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -102.76 -164.08 1.05 Allowed 'General case' 0 N--CA 1.495 1.784 0 O-C-N 121.524 -0.735 . . . . 0.0 109.697 179.602 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -168.71 -105.33 0.18 Allowed Glycine 0 N--CA 1.496 2.649 0 N-CA-C 109.348 -1.501 . . . . 0.0 109.348 179.886 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 16' ' ' CYS . . . . . 0.52 ' SG ' ' N ' ' A' ' 20' ' ' CYS . 0.0 OUTLIER -115.03 98.26 49.91 Favored Pre-proline 0 N--CA 1.49 1.538 0 O-C-N 121.328 -1.101 . . . . 0.0 109.8 179.855 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 48.0 Cg_endo -77.36 60.92 7.2 Favored 'Trans proline' 0 C--N 1.31 -1.458 0 O-C-N 123.572 1.301 . . . . 0.0 109.559 179.251 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 91.4 -20.61 39.87 Favored Glycine 0 N--CA 1.493 2.447 0 N-CA-C 109.605 -1.398 . . . . 0.0 109.605 -178.471 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -99.24 68.8 0.58 Allowed Glycine 0 N--CA 1.496 2.636 0 O-C-N 120.606 -1.526 . . . . 0.0 109.677 -179.901 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 20' ' ' CYS . . . . . 0.52 ' N ' ' SG ' ' A' ' 16' ' ' CYS . 16.3 m -82.17 143.35 31.48 Favored 'General case' 0 N--CA 1.488 1.473 0 O-C-N 121.308 -1.113 . . . . 0.0 109.262 179.803 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 35.7 m -77.88 -21.18 13.72 Favored 'Isoleucine or valine' 0 N--CA 1.503 2.176 0 O-C-N 121.888 -0.508 . . . . 0.0 111.685 -179.137 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 4.1 pt-20 -88.36 15.09 8.26 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.127 -0.983 . . . . 0.0 111.141 179.494 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 3.0 mm-40 -134.21 24.63 3.85 Favored 'General case' 0 N--CA 1.494 1.744 0 O-C-N 120.975 -1.078 . . . . 0.0 110.549 179.482 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 13.9 mm-40 -85.38 -2.83 58.52 Favored 'General case' 0 N--CA 1.494 1.759 0 O-C-N 121.093 -1.004 . . . . 0.0 111.563 -179.717 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 3.8 p-10 -104.98 19.69 20.15 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 120.68 -1.263 . . . . 0.0 109.999 179.972 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -72.45 56.28 1.6 Allowed Glycine 0 N--CA 1.489 2.174 0 N-CA-C 109.31 -1.516 . . . . 0.0 109.31 179.386 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 115.98 9.37 12.25 Favored Glycine 0 N--CA 1.501 3.004 0 O-C-N 121.32 -1.106 . . . . 0.0 110.378 -179.61 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -108.47 92.89 10.66 Favored Pre-proline 0 N--CA 1.493 1.718 0 O-C-N 120.899 -1.354 . . . . 0.0 109.822 179.683 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 43.9 Cg_endo -72.87 71.5 3.38 Favored 'Trans proline' 0 N--CA 1.489 1.238 0 O-C-N 123.472 1.249 . . . . 0.0 110.483 -179.751 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -108.18 61.3 0.61 Allowed 'General case' 0 N--CA 1.488 1.437 0 O-C-N 121.272 -0.893 . . . . 0.0 110.219 -179.86 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 2.1 tt0 -78.76 -28.14 44.79 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.369 -0.832 . . . . 0.0 110.569 -179.749 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 74.57 46.9 17.38 Favored Glycine 0 N--CA 1.489 2.178 0 N-CA-C 110.377 -1.089 . . . . 0.0 110.377 179.255 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 33' ' ' CYS . . . . . . . . . . . . . 14.1 m -79.84 87.56 5.3 Favored 'General case' 0 N--CA 1.497 1.921 0 O-C-N 120.931 -1.335 . . . . 0.0 109.782 179.624 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -102.87 -61.19 1.43 Allowed 'General case' 0 N--CA 1.493 1.689 0 O-C-N 121.503 -0.748 . . . . 0.0 110.201 -179.787 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 1.3 pm0 -85.18 -169.5 2.68 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.445 -0.784 . . . . 0.0 110.533 -179.747 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 36' ' ' ALA . . . . . . . . . . . . . . . -107.93 35.5 3.1 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.013 -1.055 . . . . 0.0 110.232 179.849 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -110.64 -55.36 2.49 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.181 -0.949 . . . . 0.0 110.26 179.948 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -68.38 -41.32 85.71 Favored Glycine 0 N--CA 1.497 2.713 0 N-CA-C 109.546 -1.421 . . . . 0.0 109.546 179.859 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 39' ' ' CYS . . . . . . . . . . . . . 1.6 p -156.82 84.67 0.96 Allowed 'General case' 0 N--CA 1.497 1.915 0 O-C-N 121.412 -1.052 . . . . 0.0 110.119 -179.766 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 40' ' ' LEU . . . . . 0.503 HD12 ' N ' ' A' ' 41' ' ' ARG . 1.4 pp -69.83 -156.36 0.02 OUTLIER 'General case' 0 N--CA 1.498 1.958 0 O-C-N 121.312 -0.868 . . . . 0.0 110.611 -179.751 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 41' ' ' ARG . . . . . 0.503 ' N ' HD12 ' A' ' 40' ' ' LEU . 0.0 OUTLIER -165.13 -35.09 0.03 OUTLIER 'General case' 0 N--CA 1.498 1.946 0 O-C-N 120.854 -1.154 . . . . 0.0 111.93 179.85 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 42' ' ' ARG . . . . . 0.46 ' HG3' ' CD1' ' A' ' 40' ' ' LEU . 34.2 mtt-85 57.9 49.98 11.1 Favored 'General case' 0 N--CA 1.498 1.972 0 O-C-N 121.13 -0.981 . . . . 0.0 110.312 -179.231 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER 53.45 71.53 0.49 Allowed 'General case' 0 N--CA 1.499 1.993 0 O-C-N 121.518 -0.739 . . . . 0.0 110.888 179.857 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -177.83 66.77 0.08 OUTLIER Glycine 0 N--CA 1.494 2.523 0 N-CA-C 109.319 -1.512 . . . . 0.0 109.319 179.903 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 45' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.497 1.893 0 O-C-N 121.735 -0.862 . . . . 0.0 110.64 -179.918 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.497 1.918 0 N-CA-C 109.998 -0.371 . . . . 0.0 109.998 . . . . . . . . . 0 0 . 1 . 018 nuclear nobuild full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER 67.17 94.59 0.07 Allowed 'General case' 0 N--CA 1.505 2.297 0 CA-C-O 121.458 0.647 . . . . 0.0 110.476 -179.991 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -130.06 113.45 14.55 Favored 'General case' 0 N--CA 1.488 1.47 0 O-C-N 121.447 -0.783 . . . . 0.0 110.027 179.774 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 4' ' ' ARG . . . . . . . . . . . . . 2.9 ptm180 -153.65 75.95 1.06 Allowed 'General case' 0 N--CA 1.492 1.675 0 O-C-N 121.198 -0.939 . . . . 0.0 110.49 -179.881 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 3.3 p -131.82 128.85 21.76 Favored Pre-proline 0 N--CA 1.495 1.802 0 O-C-N 121.494 -0.754 . . . . 0.0 109.475 179.463 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 6' ' ' PRO . . . . . . . . . . . . . 42.1 Cg_endo -69.06 -43.98 2.87 Favored 'Trans proline' 0 C--N 1.312 -1.364 0 O-C-N 123.588 1.309 . . . . 0.0 111.534 -179.367 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -82.75 50.81 4.44 Favored Glycine 0 N--CA 1.495 2.624 0 N-CA-C 109.946 -1.262 . . . . 0.0 109.946 -179.975 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 1.7 m -119.06 -30.25 5.04 Favored 'General case' 0 N--CA 1.499 1.995 0 O-C-N 121.257 -1.143 . . . . 0.0 111.001 179.945 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 109.34 133.51 6.76 Favored Glycine 0 N--CA 1.493 2.483 0 N-CA-C 109.73 -1.348 . . . . 0.0 109.73 -179.802 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 10' ' ' GLN . . . . . . . . . . . . . 0.7 OUTLIER 45.39 49.71 10.33 Favored 'General case' 0 N--CA 1.501 2.125 0 O-C-N 121.953 -0.734 . . . . 0.0 111.053 179.499 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -86.93 -54.7 2.55 Favored Glycine 0 N--CA 1.496 2.675 0 N-CA-C 110.092 -1.203 . . . . 0.0 110.092 -179.848 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 12' ' ' VAL . . . . . 0.458 ' O ' HG13 ' A' ' 12' ' ' VAL . 9.0 p -138.03 48.08 0.35 Allowed 'Isoleucine or valine' 0 N--CA 1.495 1.784 0 O-C-N 121.275 -1.132 . . . . 0.0 110.413 179.93 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 13' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -81.82 -7.38 59.6 Favored 'General case' 0 N--CA 1.495 1.78 0 O-C-N 120.946 -1.096 . . . . 0.0 111.159 179.919 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -125.6 141.72 51.88 Favored 'General case' 0 N--CA 1.495 1.821 0 O-C-N 121.303 -0.873 . . . . 0.0 109.767 179.943 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -161.05 90.98 0.11 Allowed Glycine 0 N--CA 1.492 2.406 0 N-CA-C 109.372 -1.491 . . . . 0.0 109.372 179.697 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 13.4 m -94.69 152.71 40.02 Favored Pre-proline 0 N--CA 1.5 2.04 0 O-C-N 121.233 -1.157 . . . . 0.0 110.456 -179.95 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 48.2 Cg_endo -76.38 -147.81 0.03 OUTLIER 'Trans proline' 0 C--N 1.308 -1.554 0 O-C-N 123.779 1.41 . . . . 0.0 108.773 178.454 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . -62.92 -12.39 42.44 Favored Glycine 0 N--CA 1.498 2.767 0 O-C-N 120.878 -1.139 . . . . 0.0 110.898 179.574 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -151.18 115.4 0.7 Allowed Glycine 0 N--CA 1.494 2.536 0 N-CA-C 109.175 -1.57 . . . . 0.0 109.175 -179.705 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 4.8 t -84.56 -10.3 57.53 Favored 'General case' 0 N--CA 1.499 2.01 0 O-C-N 121.179 -1.189 . . . . 0.0 111.459 -179.834 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 8.6 p -129.36 26.21 1.9 Allowed 'Isoleucine or valine' 0 N--CA 1.499 1.997 0 O-C-N 121.045 -1.034 . . . . 0.0 111.027 -179.81 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 1.4 tp10 -105.72 -4.44 20.94 Favored 'General case' 0 N--CA 1.493 1.692 0 O-C-N 120.479 -1.388 . . . . 0.0 110.952 179.56 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 0.8 OUTLIER -138.14 -47.09 0.52 Allowed 'General case' 0 N--CA 1.492 1.673 0 O-C-N 121.064 -1.023 . . . . 0.0 110.712 179.697 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 1.1 mt-10 -59.95 115.84 3.71 Favored 'General case' 0 N--CA 1.494 1.747 0 O-C-N 121.482 -0.761 . . . . 0.0 110.079 -179.423 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 6.4 t0 -104.5 91.37 3.86 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.371 -0.831 . . . . 0.0 109.37 179.297 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -79.32 60.22 4.29 Favored Glycine 0 N--CA 1.496 2.676 0 N-CA-C 109.52 -1.432 . . . . 0.0 109.52 -179.296 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 177.45 -179.24 48.24 Favored Glycine 0 N--CA 1.493 2.49 0 N-CA-C 109.956 -1.258 . . . . 0.0 109.956 179.753 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -160.07 155.56 22.09 Favored Pre-proline 0 N--CA 1.494 1.73 0 O-C-N 121.381 -1.07 . . . . 0.0 110.187 179.854 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 40.2 Cg_endo -67.74 -40.72 9.35 Favored 'Trans proline' 0 N--CA 1.492 1.438 0 O-C-N 123.549 1.289 . . . . 0.0 110.17 179.484 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -92.97 47.95 1.31 Allowed 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.403 -0.811 . . . . 0.0 110.191 179.369 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 12.5 tt0 -77.85 -11.38 59.88 Favored 'General case' 0 N--CA 1.494 1.747 0 O-C-N 121.487 -0.758 . . . . 0.0 111.034 -179.87 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 98.16 84.44 1.76 Allowed Glycine 0 N--CA 1.489 2.22 0 N-CA-C 108.675 -1.77 . . . . 0.0 108.675 -179.668 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 33' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -79.02 65.45 4.2 Favored 'General case' 0 N--CA 1.493 1.714 0 O-C-N 121.166 -1.196 . . . . 0.0 110.051 -179.341 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -115.75 56.38 0.77 Allowed 'General case' 0 N--CA 1.496 1.832 0 O-C-N 121.469 -0.769 . . . . 0.0 109.75 179.697 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 1.1 tt0 -147.59 -162.3 1.52 Allowed 'General case' 0 N--CA 1.494 1.765 0 O-C-N 121.457 -0.777 . . . . 0.0 110.081 -179.363 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 36' ' ' ALA . . . . . . . . . . . . . . . -78.65 -30.85 46.57 Favored 'General case' 0 N--CA 1.494 1.727 0 O-C-N 121.464 -0.772 . . . . 0.0 109.108 179.029 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER -134.74 -74.32 0.47 Allowed 'General case' 0 N--CA 1.487 1.395 0 O-C-N 121.6 -0.687 . . . . 0.0 109.723 179.079 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 56.97 -99.27 0.09 OUTLIER Glycine 0 N--CA 1.496 2.685 0 N-CA-C 110.319 -1.113 . . . . 0.0 110.319 179.291 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 39' ' ' CYS . . . . . . . . . . . . . 2.5 p -99.49 6.56 45.88 Favored 'General case' 0 N--CA 1.497 1.912 0 O-C-N 121.792 -0.828 . . . . 0.0 111.612 -179.674 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 40' ' ' LEU . . . . . . . . . . . . . 1.5 mt 59.25 -165.94 0.18 Allowed 'General case' 0 N--CA 1.504 2.266 0 O-C-N 121.416 -0.802 . . . . 0.0 110.974 179.454 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 41' ' ' ARG . . . . . . . . . . . . . 2.7 mtm180 -134.0 122.16 22.64 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.423 -0.798 . . . . 0.0 109.68 -179.48 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 42' ' ' ARG . . . . . 0.402 HH11 ' HD3' ' A' ' 42' ' ' ARG . 27.8 ttp-105 -135.08 53.58 1.98 Allowed 'General case' 0 N--CA 1.497 1.92 0 O-C-N 121.387 -0.821 . . . . 0.0 110.525 -179.703 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 2.5 pm0 -77.74 76.78 4.27 Favored 'General case' 0 N--CA 1.496 1.828 0 O-C-N 121.216 -0.928 . . . . 0.0 110.944 -179.467 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 114.25 -43.15 1.76 Allowed Glycine 0 N--CA 1.494 2.518 0 N-CA-C 110.184 -1.166 . . . . 0.0 110.184 179.228 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 45' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.494 1.747 0 O-C-N 121.402 -1.057 . . . . 0.0 110.408 -179.991 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.493 1.699 0 CA-C-O 121.264 0.554 . . . . 0.0 110.013 . . . . . . . . . 0 0 . 1 . 019 nuclear nobuild full ' A' A ' 2' ' ' LEU . . . . . 0.548 ' O ' ' HB3' ' A' ' 3' ' ' ALA . 0.9 OUTLIER -85.04 -164.48 1.0 Allowed 'General case' 0 N--CA 1.494 1.742 0 O-C-N 121.099 -1.001 . . . . 0.0 110.32 179.832 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 3' ' ' ALA . . . . . 0.548 ' HB3' ' O ' ' A' ' 2' ' ' LEU . . . 66.73 9.9 7.07 Favored 'General case' 0 N--CA 1.508 2.464 0 O-C-N 121.671 -0.643 . . . . 0.0 111.618 -179.988 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 4' ' ' ARG . . . . . 0.435 ' HB2' ' O ' ' A' ' 3' ' ' ALA . 3.4 mmt180 60.85 -179.76 0.1 Allowed 'General case' 0 N--CA 1.502 2.13 0 O-C-N 121.411 -0.806 . . . . 0.0 111.141 179.734 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 5' ' ' CYS . . . . . 0.438 ' SG ' ' N ' ' A' ' 8' ' ' CYS . 1.3 p -148.13 161.76 33.24 Favored Pre-proline 0 N--CA 1.491 1.595 0 O-C-N 121.572 -0.705 . . . . 0.0 109.941 -179.627 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 6' ' ' PRO . . . . . . . . . . . . . 41.1 Cg_endo -68.2 -31.47 29.18 Favored 'Trans proline' 0 C--N 1.314 -1.246 0 O-C-N 123.637 1.335 . . . . 0.0 110.988 179.824 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -91.81 23.37 26.33 Favored Glycine 0 N--CA 1.494 2.547 0 N-CA-C 110.29 -1.124 . . . . 0.0 110.29 179.492 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 8' ' ' CYS . . . . . 0.438 ' N ' ' SG ' ' A' ' 5' ' ' CYS . 51.0 m -96.93 19.13 13.21 Favored 'General case' 0 N--CA 1.494 1.744 0 O-C-N 120.998 -1.295 . . . . 0.0 110.751 -179.904 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -79.28 -48.03 7.1 Favored Glycine 0 N--CA 1.492 2.415 0 N-CA-C 109.929 -1.268 . . . . 0.0 109.929 -179.653 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 10' ' ' GLN . . . . . . . . . . . . . 4.3 mt-30 -111.62 40.14 2.19 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 121.15 -1.206 . . . . 0.0 110.603 -179.62 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -84.43 63.39 4.43 Favored Glycine 0 N--CA 1.497 2.727 0 N-CA-C 109.861 -1.295 . . . . 0.0 109.861 179.883 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 13.3 m -134.98 48.61 0.41 Allowed 'Isoleucine or valine' 0 N--CA 1.501 2.087 0 O-C-N 121.393 -1.063 . . . . 0.0 110.652 179.923 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 13' ' ' GLN . . . . . . . . . . . . . 11.9 mt-30 -73.56 75.7 1.48 Allowed 'General case' 0 N--CA 1.498 1.936 0 O-C-N 121.074 -1.016 . . . . 0.0 110.454 179.944 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -110.13 -69.51 0.86 Allowed 'General case' 0 N--CA 1.498 1.939 0 O-C-N 121.288 -0.882 . . . . 0.0 110.563 -179.777 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -161.01 -105.1 0.2 Allowed Glycine 0 N--CA 1.493 2.445 0 N-CA-C 109.58 -1.408 . . . . 0.0 109.58 -179.674 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 0.0 OUTLIER -116.9 161.61 31.57 Favored Pre-proline 0 N--CA 1.501 2.101 0 O-C-N 121.253 -1.145 . . . . 0.0 109.61 179.438 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 42.2 Cg_endo -70.2 -59.27 0.08 OUTLIER 'Trans proline' 0 N--CA 1.489 1.225 0 O-C-N 123.825 1.434 . . . . 0.0 111.085 179.961 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . -108.05 -36.91 2.25 Favored Glycine 0 N--CA 1.495 2.602 0 N-CA-C 110.317 -1.113 . . . . 0.0 110.317 179.942 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 172.91 135.91 2.07 Favored Glycine 0 N--CA 1.492 2.426 0 N-CA-C 108.678 -1.769 . . . . 0.0 108.678 -179.923 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 4.1 m -78.57 64.83 3.7 Favored 'General case' 0 N--CA 1.5 2.03 0 O-C-N 121.413 -1.051 . . . . 0.0 110.506 -179.906 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . 0.455 HG13 ' N ' ' A' ' 22' ' ' GLU . 7.7 p -133.18 -46.06 0.6 Allowed 'Isoleucine or valine' 0 N--CA 1.498 1.956 0 O-C-N 121.468 -0.77 . . . . 0.0 109.759 179.088 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 22' ' ' GLU . . . . . 0.455 ' N ' HG13 ' A' ' 21' ' ' VAL . 23.4 mt-10 -89.18 33.86 0.8 Allowed 'General case' 0 C--N 1.306 -1.306 0 O-C-N 121.062 -1.024 . . . . 0.0 109.151 178.123 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -156.81 -75.55 0.09 Allowed 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.403 -0.81 . . . . 0.0 110.145 -179.406 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER 57.08 -165.18 0.15 Allowed 'General case' 0 N--CA 1.494 1.748 0 O-C-N 121.676 -0.64 . . . . 0.0 110.65 -179.899 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 3.3 m-20 -107.12 150.91 26.06 Favored 'General case' 0 N--CA 1.495 1.823 0 O-C-N 121.367 -0.833 . . . . 0.0 110.537 -179.666 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 88.19 -86.87 1.49 Allowed Glycine 0 N--CA 1.49 2.287 0 N-CA-C 110.194 -1.162 . . . . 0.0 110.194 179.295 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 69.86 64.16 3.04 Favored Glycine 0 N--CA 1.495 2.594 0 N-CA-C 109.127 -1.589 . . . . 0.0 109.127 -178.986 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 3.5 p -82.02 129.55 63.9 Favored Pre-proline 0 N--CA 1.499 1.987 0 O-C-N 120.859 -1.377 . . . . 0.0 110.868 -179.742 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 43.1 Cg_endo -70.42 -11.0 29.23 Favored 'Trans proline' 0 N--CA 1.489 1.238 0 O-C-N 124.086 1.571 . . . . 0.0 111.043 179.828 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -83.28 6.52 19.36 Favored 'General case' 0 N--CA 1.492 1.666 0 O-C-N 121.066 -1.022 . . . . 0.0 111.564 -179.497 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 31' ' ' GLU . . . . . 0.586 ' HG2' ' N ' ' A' ' 32' ' ' GLY . 14.6 tt0 -79.44 -75.0 0.26 Allowed 'General case' 0 N--CA 1.494 1.763 0 O-C-N 121.157 -0.965 . . . . 0.0 109.736 -179.987 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 32' ' ' GLY . . . . . 0.586 ' N ' ' HG2' ' A' ' 31' ' ' GLU . . . -136.33 22.26 3.39 Favored Glycine 0 N--CA 1.492 2.374 0 N-CA-C 109.55 -1.42 . . . . 0.0 109.55 179.563 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 33' ' ' CYS . . . . . 0.46 ' O ' ' HB2' ' A' ' 39' ' ' CYS . 0.5 OUTLIER -79.39 67.36 5.1 Favored 'General case' 0 N--CA 1.494 1.749 0 O-C-N 121.089 -1.242 . . . . 0.0 109.359 179.36 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 34' ' ' ALA . . . . . 0.498 ' HB1' ' HB2' ' A' ' 42' ' ' ARG . . . -130.32 56.45 1.76 Allowed 'General case' 0 N--CA 1.496 1.868 0 O-C-N 121.536 -0.727 . . . . 0.0 110.319 179.763 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 5.5 mm-40 -92.88 -144.32 0.22 Allowed 'General case' 0 N--CA 1.497 1.884 0 O-C-N 121.505 -0.747 . . . . 0.0 109.74 179.713 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 36' ' ' ALA . . . . . . . . . . . . . . . -114.01 11.93 17.87 Favored 'General case' 0 N--CA 1.496 1.863 0 O-C-N 121.059 -1.026 . . . . 0.0 110.9 179.925 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 20.0 tt0 -161.2 -54.97 0.05 OUTLIER 'General case' 0 N--CA 1.496 1.862 0 O-C-N 121.261 -0.899 . . . . 0.0 110.741 179.516 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -43.6 -51.82 6.6 Favored Glycine 0 N--CA 1.5 2.938 0 N-CA-C 111.525 -0.63 . . . . 0.0 111.525 -178.74 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 39' ' ' CYS . . . . . 0.46 ' HB2' ' O ' ' A' ' 33' ' ' CYS . 56.9 m -139.94 75.68 1.52 Allowed 'General case' 0 N--CA 1.496 1.866 0 O-C-N 121.07 -1.253 . . . . 0.0 110.496 -179.234 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 40' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER 52.28 -148.89 0.39 Allowed 'General case' 0 N--CA 1.503 2.195 0 O-C-N 121.306 -0.872 . . . . 0.0 110.199 179.794 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 41' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -141.32 156.99 45.79 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.069 -1.019 . . . . 0.0 110.664 179.762 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 42' ' ' ARG . . . . . 0.498 ' HB2' ' HB1' ' A' ' 34' ' ' ALA . 0.0 OUTLIER -92.85 -44.48 8.46 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.27 -0.894 . . . . 0.0 110.499 179.888 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -83.86 145.06 28.84 Favored 'General case' 0 N--CA 1.487 1.425 0 O-C-N 121.476 -0.765 . . . . 0.0 110.302 179.941 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -77.58 62.51 3.49 Favored Glycine 0 N--CA 1.492 2.416 0 N-CA-C 110.033 -1.227 . . . . 0.0 110.033 -179.159 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 45' ' ' GLN . . . . . . . . . . . . . 0.4 OUTLIER . . . . . 0 N--CA 1.5 2.039 0 O-C-N 121.475 -1.015 . . . . 0.0 110.401 179.986 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 1.517 0 N-CA-C 109.936 -0.394 . . . . 0.0 109.936 . . . . . . . . . 0 0 . 1 . 020 nuclear nobuild full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 5.0 mp -68.85 156.19 38.87 Favored 'General case' 0 N--CA 1.492 1.652 0 O-C-N 121.404 -0.81 . . . . 0.0 110.406 -179.873 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -75.7 70.51 2.5 Favored 'General case' 0 N--CA 1.491 1.623 0 O-C-N 121.484 -0.76 . . . . 0.0 110.424 179.981 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 4' ' ' ARG . . . . . . . . . . . . . 0.3 OUTLIER -114.67 106.73 14.57 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.261 -0.9 . . . . 0.0 110.422 179.882 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 13.7 t -148.26 115.12 3.92 Favored Pre-proline 0 N--CA 1.495 1.802 0 O-C-N 121.452 -0.78 . . . . 0.0 109.91 -179.939 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 6' ' ' PRO . . . . . . . . . . . . . 50.8 Cg_endo -87.26 -24.06 1.34 Allowed 'Trans proline' 0 C--N 1.309 -1.508 0 O-C-N 123.904 1.476 . . . . 0.0 112.212 -179.515 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -109.85 68.32 0.22 Allowed Glycine 0 N--CA 1.497 2.759 0 O-C-N 120.829 -1.169 . . . . 0.0 111.332 -178.18 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 1.2 p -158.7 150.19 20.83 Favored 'General case' 0 N--CA 1.497 1.885 0 O-C-N 121.177 -1.19 . . . . 0.0 110.213 178.837 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 92.02 -110.46 3.88 Favored Glycine 0 N--CA 1.493 2.442 0 N-CA-C 108.893 -1.683 . . . . 0.0 108.893 -179.461 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 10' ' ' GLN . . . . . . . . . . . . . 5.5 pt20 -155.32 30.29 0.39 Allowed 'General case' 0 N--CA 1.494 1.745 0 O-C-N 121.272 -1.134 . . . . 0.0 110.698 179.379 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -86.58 62.69 4.23 Favored Glycine 0 N--CA 1.493 2.447 0 N-CA-C 109.461 -1.456 . . . . 0.0 109.461 179.614 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 60.2 t -126.94 -75.19 0.36 Allowed 'Isoleucine or valine' 0 N--CA 1.495 1.795 0 O-C-N 121.808 -0.819 . . . . 0.0 109.73 179.745 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 13' ' ' GLN . . . . . . . . . . . . . 1.6 mt-30 42.69 36.33 0.82 Allowed 'General case' 0 N--CA 1.495 1.82 0 O-C-N 121.652 -0.655 . . . . 0.0 111.779 179.736 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -71.5 -22.33 61.81 Favored 'General case' 0 N--CA 1.499 2.014 0 O-C-N 121.171 -0.956 . . . . 0.0 110.936 179.854 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 134.43 -53.34 0.79 Allowed Glycine 0 N--CA 1.493 2.499 0 N-CA-C 109.248 -1.541 . . . . 0.0 109.248 -179.69 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 2.6 p -88.68 121.52 69.91 Favored Pre-proline 0 N--CA 1.497 1.915 0 O-C-N 121.358 -1.083 . . . . 0.0 110.849 179.91 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 48.7 Cg_endo -76.06 79.5 2.89 Favored 'Trans proline' 0 C--N 1.309 -1.513 0 O-C-N 123.705 1.371 . . . . 0.0 110.046 179.606 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 85.79 -48.68 4.02 Favored Glycine 0 N--CA 1.493 2.461 0 N-CA-C 109.887 -1.285 . . . . 0.0 109.887 -179.512 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -72.38 68.8 1.16 Allowed Glycine 0 N--CA 1.495 2.617 0 N-CA-C 110.13 -1.188 . . . . 0.0 110.13 -179.604 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 73.2 m -105.2 119.07 38.14 Favored 'General case' 0 N--CA 1.498 1.957 0 O-C-N 121.482 -1.011 . . . . 0.0 109.511 179.627 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 12.7 t -106.71 -9.34 10.54 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.84 0 O-C-N 121.556 -0.715 . . . . 0.0 111.616 -178.95 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER -79.4 51.5 1.23 Allowed 'General case' 0 N--CA 1.493 1.695 0 O-C-N 120.855 -1.153 . . . . 0.0 110.566 179.718 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 3.2 tt0 -101.79 -24.29 14.08 Favored 'General case' 0 N--CA 1.489 1.477 0 O-C-N 121.095 -1.003 . . . . 0.0 110.139 179.539 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 2.1 pt-20 -79.89 -154.42 0.09 Allowed 'General case' 0 N--CA 1.494 1.736 0 O-C-N 121.274 -0.891 . . . . 0.0 110.575 -179.902 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -82.36 -49.16 10.32 Favored 'General case' 0 N--CA 1.5 2.06 0 O-C-N 121.456 -0.778 . . . . 0.0 110.164 179.947 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 144.09 46.64 0.04 OUTLIER Glycine 0 N--CA 1.498 2.772 0 N-CA-C 110.614 -0.995 . . . . 0.0 110.614 179.419 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 64.73 -130.92 37.06 Favored Glycine 0 N--CA 1.501 2.98 0 N-CA-C 109.685 -1.366 . . . . 0.0 109.685 -179.975 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -146.61 74.97 12.39 Favored Pre-proline 0 N--CA 1.495 1.787 0 O-C-N 121.294 -1.121 . . . . 0.0 109.926 179.691 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 43.4 Cg_endo -74.03 74.44 3.48 Favored 'Trans proline' 0 N--CA 1.488 1.172 0 O-C-N 123.632 1.333 . . . . 0.0 110.661 -179.908 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -89.87 64.84 6.5 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.111 -0.993 . . . . 0.0 110.571 179.887 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 14.8 tp10 -153.17 -67.92 0.15 Allowed 'General case' 0 N--CA 1.493 1.694 0 O-C-N 121.378 -0.826 . . . . 0.0 110.214 179.61 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 123.69 84.52 0.65 Allowed Glycine 0 N--CA 1.497 2.716 0 N-CA-C 109.406 -1.477 . . . . 0.0 109.406 -179.82 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 33' ' ' CYS . . . . . . . . . . . . . 0.4 OUTLIER -95.29 112.36 24.08 Favored 'General case' 0 N--CA 1.493 1.704 0 O-C-N 121.394 -1.062 . . . . 0.0 109.79 179.812 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -107.58 -46.13 3.9 Favored 'General case' 0 N--CA 1.497 1.875 0 O-C-N 121.564 -0.71 . . . . 0.0 110.103 179.886 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 21.8 mt-10 -79.59 -178.88 6.55 Favored 'General case' 0 N--CA 1.5 2.052 0 O-C-N 121.635 -0.665 . . . . 0.0 110.23 179.931 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 36' ' ' ALA . . . . . . . . . . . . . . . -78.66 -38.08 40.37 Favored 'General case' 0 N--CA 1.498 1.931 0 O-C-N 121.202 -0.936 . . . . 0.0 109.897 -179.634 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 7.3 tt0 -119.87 34.07 5.36 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.381 -0.825 . . . . 0.0 109.991 179.492 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -84.72 -9.45 81.13 Favored Glycine 0 N--CA 1.495 2.63 0 O-C-N 121.101 -0.999 . . . . 0.0 110.776 -179.909 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 39' ' ' CYS . . . . . . . . . . . . . 1.3 m -79.43 72.91 6.09 Favored 'General case' 0 N--CA 1.495 1.801 0 O-C-N 120.874 -1.368 . . . . 0.0 109.822 179.842 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 40' ' ' LEU . . . . . 0.489 ' C ' ' HG2' ' A' ' 41' ' ' ARG . 1.0 OUTLIER -75.5 -164.72 0.36 Allowed 'General case' 0 N--CA 1.494 1.763 0 O-C-N 121.372 -0.83 . . . . 0.0 110.46 -179.474 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 41' ' ' ARG . . . . . 0.489 ' HG2' ' C ' ' A' ' 40' ' ' LEU . 4.4 mmt180 66.47 -3.92 0.79 Allowed 'General case' 0 N--CA 1.51 2.543 0 O-C-N 121.743 -0.598 . . . . 0.0 111.933 179.656 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 42' ' ' ARG . . . . . . . . . . . . . 2.7 ttt85 56.4 22.89 6.82 Favored 'General case' 0 N--CA 1.5 2.039 0 O-C-N 120.922 -1.111 . . . . 0.0 111.53 -179.932 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 48.0 mm-40 -90.09 95.18 10.09 Favored 'General case' 0 N--CA 1.488 1.431 0 O-C-N 121.153 -0.967 . . . . 0.0 109.606 179.236 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -155.7 71.62 0.26 Allowed Glycine 0 N--CA 1.492 2.411 0 N-CA-C 109.26 -1.536 . . . . 0.0 109.26 -179.249 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 45' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.499 1.994 0 O-C-N 121.757 -0.849 . . . . 0.0 110.255 -179.822 . . . . . . . . 1 1 . 1 stop_ save_